tenofovir has been researched along with HIV Coinfection in 3002 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 11 (0.37) | 18.2507 |
| 2000's | 610 (20.32) | 29.6817 |
| 2010's | 1655 (55.13) | 24.3611 |
| 2020's | 726 (24.18) | 2.80 |
| Authors | Studies |
|---|---|
| Aldern, KA; Almond, MR; Beadle, JR; De Clercq, E; Hostetler, KY; Korba, BE; Lampert, BM; Neyts, J; Painter, GR; Trost, LC | 1 |
| Bachmann, MH; Fessel, WJ; Kagan, RM; Mitsuya, Y; Shafer, RW; Shahriar, R; Varghese, V | 1 |
| Anton, P; Cranage, M; Herrera, C; McGowan, I; Shattock, RJ | 1 |
| Almond, MR; Buckheit, RW; Hartman, T; Keilholz, L; Lampert, BM; Lanier, ER; Mankowski, MK; Osterling, MC; Painter, GR; Ptak, RG | 1 |
| Balzarini, J; Flynn, ÁS; Hinsinger, K; McGuigan, C; Pertusati, F; Powell, N; Tristram, A | 1 |
| Bartsch, PW; Basson, AE; Burton, SL; Bushnev, A; D'Erasmo, M; Dasari, M; Derdeyn, CA; Giesler, KE; Hwang, SS; Iskandar, S; Liotta, DC; Miller, EJ; Pribut, N; Raghuram, A; Sharma, SK | 1 |
| Boyd, A; Chas, J; Delaugerre, C; Dezanet, LNC; Gabassi, A; Lacombe, K; Lascoux-Combe, C; Maylin, S; Miailhes, P; Rougier, H | 1 |
| Hughes, C | 1 |
| Anderson, PL; Brooks, KM; Bushman, L; Castillo-Mancilla, JR; Ibrahim, M; Kiser, JJ; MaWhinney, S; Morrow, M; Nemkov, C; Peterson, S; Yager, JL | 1 |
| Darcis, G; Fombellida, K; Frippiat, F; Lecomte, M; Léonard, P; Maes, N; Meuris, C; Moutschen, M; Paquot, N; Plum, PE; Sauvage, AS; Uurlings, F; Vaira, D | 1 |
| Baxi, SM; Choden, T; Desai, M; Dorjee, K; Hubbard, AE; Reingold, AL | 1 |
| Ajana, F; Brainard, D; Chuck, SK; Collins, SE; Gandhi-Patel, B; Kityo, C; Koenig, E; Liu, Y; Makadzange, T; McNicholl, I; Natukunda, E; Orkin, C; Pikora, C; Wang, H; Wei, X; White, K | 1 |
| Barbini, B; Burling, K; Campbell, L; Cromarty, B; Hamzah, L; Johnson, M; Jones, R; Post, FA; Samarawickrama, A; Williams, D; Winston, A | 1 |
| Barrail-Tran, A; Becker, PH; Castro Gordon, A; Catalan, P; Chéret, A; Furlan, V; Gasnault, J; Gelé, T; Gouget, H; Goujard, C; Nkam, L; Pallier, C; Taburet, AM | 1 |
| Alnouti, Y; Bade, AN; Cobb, DA; Cohen, SM; Deodhar, S; Edagwa, B; Gautam, N; Gendelman, HE; McMillan, J; Shetty, BLD; Smith, N | 1 |
| Brand, RM; Chitwarakorn, A; Cranston, RD; Curlin, ME; Doncel, G; Hendrix, CW; Holtz, TH; Johnson, S; Kunjara Na Ayudhya, RP; Marzinke, MA; McGowan, IM; Piper, J; Raengsakulrach, B; Rooney, JF; Schwartz, JL | 1 |
| Beyer, A; Brunet, L; Fusco, GP; Fusco, JS; Mallon, P; Prajapati, G; Wohlfeiler, MB | 1 |
| Adamson, J; Cele, S; Derache, A; Gosnell, BI; Govender, K; Gupta, RK; Harrichandparsad, R; Jeena, PM; Karim, F; Khan, K; Kløverpris, H; Lustig, G; Marais, S; Moosa, MS; Ngoepe, A; Ntshuba, N; Patel, VB; Sigal, A | 1 |
| Cruz, D; DeJesus, E; Hinestrosa, F; Nguyen, V; Patel, K; Rolle, CP | 1 |
| Araujo, V; Arauz, AB; Bakolis, I; Beltrán, C; Calanni, L; Chaverri, J; Contarelli, J; Cuini, R; Hojman, M; Moncada, W; Morales, M; Parenti, P; Sabato, S; Teran, R; Thormann, M; Zitko, P | 1 |
| Abdool Karim, S; Bardon, AR; Celum, C; Cressey, TR; Dorward, J; Drain, PK; Feutz, E; Gandhi, M; Garrett, N; Lessells, R; Moodley, P; Naicker, N; Naidoo, K; Ngobese, H; Pillay, C; Quame-Amaglo, J; Sayed, F; Sharma, M; Simoni, JM; Sookrajh, Y; Thomas, K | 1 |
| Gao, LY; Hu, Y; Huang, XJ; Ma, P; Wu, H; Wu, Y; Xia, H; Yan, ZF | 1 |
| Ho, RJY; Perazzolo, S; Shen, DD; Shireman, LM | 1 |
| Ho, RJY; Perazzolo, S; Shen, DD | 1 |
| Lyu, J; Pan, L; Teng, J; Wu, H; Zhang, F; Zhang, M; Zhu, C | 1 |
| Ahmed, K; Bekker, LG; Brumskine, W; Chersich, MF; Delany-Moretlwe, S; Doncel, GF; Gray, G; Kotze, P; Lombard, C; Mabude, Z; Mogodiri, T; Munthali, RJ; Myer, L; Naidoo, I; Nchabeleng, M; Nkala, B; Palanee-Phillips, T; Panchia, R; Rees, H; Sebe, M | 1 |
| Affram, Y; Benedetti, F; Bryant, J; Denaro, F; Heredia, A; Latinovic, OS; Munawwar, A; Ramadhani, HO; Reitz, M; Rikhtegaran-Tehrani, Z; Romerio, F; Sajadi, MM; Tagaya, Y; Weichseldorfer, M; Williams, SP; Zella, D | 1 |
| Cogill, D; Decloedt, E; Gandhi, M; Jennings, L; Kellermann, T; Nkantsu, Z; Orrell, C; Spinelli, M; van Schalkwyk, M; van Zyl, G | 2 |
| Bazzi, R; Roa, PE | 1 |
| Brown, TT; Chege, W; Chen, YQ; Gulick, RM; Hendrix, CW; Klingman, KL; Landovitz, RJ; Marzinke, MA; Mayer, KH; Mccauley, MB; Wilkin, TJ; Yuhas, K | 1 |
| Baeten, JM; Bukusi, EA; Donnell, D; Irungu, EM; Morton, JF; Mugambi, M; Mugo, NR; Mugwanya, KK; Mukui, I; Ngure, K; O'Malley, G; Odoyo, J; Peacock, S; Wamoni, E | 1 |
| Cheng, CN; Chuang, YC; Hung, CC; Kuo, CH; Lin, KY; Lin, SW; Lin, YJ; Lin, YT; Liou, BH; Liu, WC; Sun, HY | 1 |
| Hill, A; Pilkington, V; Shah, S | 1 |
| Dokmetas, I; Gunduz, A; Kuran, B; Oncul, A; Ozcan, SN; Pehlivan, O; Sevgi, DY; Terlemez, R | 1 |
| Antoniak, S; Begovac, J; Dragovic, G; Fleischhans, L; Gokengin, D; Harxhi, A; Hofman, S; Jilich, D; Kase, K; Kowalska, J; Lakatos, B; Matulionyte, R; Oprea, C; Papadopoulus, A; Rukhadze, N; Vassilenko, A; Vasyliev, M; Verhaz, A; Wasilewski, P; Yancheva, N | 1 |
| Alba Alejandre, I; Bukkems, VE; Burger, D; Colbers, A; Garcia, C; Hidalgo Tenorio, C; Konopnicki, D; Lambert, JS; Necsoi, C; Richel, O; Te Brake, LHM; van der Meulen, E; van Hulzen, A; Weiss, F | 1 |
| Barbini, B; Campbell, L; Fox, J; Gilleece, Y; Ibrahim, F; Orkin, C; Post, FA; Samarawickrama, A; Tariq, S; Waters, L | 1 |
| Antinori, S; Baldelli, S; Bisinella, GC; Cattaneo, D; Cossu, MV; Fusi, M; Gervasoni, C; Meraviglia, P; Micheli, V; Resnati, C; Vimercati, S | 1 |
| Bon, I; Borderi, M; Calza, L; Colangeli, V; Lazzarotto, T; Miani, T; Nuti, B; Viale, P | 1 |
| Abe, K; Goto, T; Imamura, J; Ito, T; Kamio, S; Kondo, A; Obara, T; Sato, H; Takahashi, N | 1 |
| Blake, K; Cottrell, M; Doncel, GF; Fang, X; Jacot, TA; Ju, S; Ouattara, LA; Schwartz, J; Sykes, C; Thurman, AR; Vann, NC | 1 |
| Migliorati, JM; Zhong, XB | 1 |
| Chang, SY; Chen, GJ; Hsieh, SM; Huang, SH; Huang, YC; Hung, CC; Liu, WC; Liu, WD; Sheng, WH; Su, LH; Su, YC; Sun, HY | 1 |
| Hideta, K; Higasa, S; Hikasa, S; Kimura, T; Sawada, A; Shimabukuro, S; Tanaka, K; Tokugawa, T; Yanai, M | 1 |
| Acosta, R; Andreatta, K; Chang, S; D'Antoni, ML; Martin, H; Martin, R; White, KL | 1 |
| Aidara, M; Alleyo, A; Diallo, K; Manga, NM; Wembulua, BS | 1 |
| Bowen, N; Inzaule, SC; Jordan, MR; Kiiru, JN; Kingwara, L; Momanyi, L; Ngugi, C; Nyanya, W; Oramisi, V | 1 |
| Baum, MM; Clark, MR; Moss, JA; Nuttall, J; Palanee-Phillips, T; Romano, JW | 1 |
| De Clercq, E | 10 |
| Allerton, J; Castillo-Mancilla, J; Hsiao, NY; Hu, NC; Kabanda, S; Lesosky, M; Malaba, TR; Myer, L; Odayar, J; Orrell, C; Phillips, TK; Wiesner, L | 1 |
| Chen, P; Deng, L; Hong, Z; Li, C; Luo, X; Xia, J; Zheng, X; Zhou, L; Zhou, Y | 1 |
| Gelman, M; Holmes, J; Kraft, J; Mayer, KH; Melbourne, K; Mimiaga, MJ | 1 |
| Abdool Karim, Q; Abdool Karim, S; Baum, MM; Baxter, C; Gengiah, TN; Hankins, C; Harkoo, I; Maharaj, B; Mansoor, L; Moss, JA; Pozzetto, B; Radebe, P; Samsunder, N; Zuma, NY | 1 |
| Golub, SA; Guerra, A; Harris, AB; Klein, A; Radix, AE; Rincon, C; Starbuck, L | 1 |
| Barrail-Tran, A; Benzemrane, MS; Bourgeois, C; Gelé, T; Gouget, H; Labarthe, L; Lambotte, O; Le Calvez, P; Le Grand, R; Legrand, N | 1 |
| Hasan, SS; Kow, CS; Ramachandram, DS | 1 |
| Cressey, TR; Dossantos, S; Drain, PK; Niu, X; Sandlin, RD; Sevenler, D; Toner, M | 1 |
| Ambrosioni, J; Berrocal, L; Blanco, JL; Chivite, I; de la Mora, L; de Lazzari, E; González-Cordón, A; Inciarte, A; Laguno, M; Leal, L; Mallolas, J; Martinez, E; Martínez-Rebollar, M; Miró, JM; Rojas Liévano, J; Torres, B; Ugarte, A | 1 |
| Alejos, B; Arribas, JR; Bernardino, JI; Cadiñanos, J; Castro-Alvarez, JM; De Miguel, R; Esteban-Cantos, A; Jiménez-González, M; Mena-Garay, B; Montejano, R; Rodés, B; Rodríguez-Centeno, J; Saiz-Medrano, G; Stella-Ascariz, N | 1 |
| Aboud, M; Ait-Khaled, M; Ajana, F; Bisshop, F; De Wit, S; George, N; Leone, P; Osiyemi, O; Pappa, KA; Portilla, J; Routy, JP; Smith, KY; van Wyk, J; Wang, R; Wright, J; Wyen, C; Wynne, B | 1 |
| Alcaraz, A; Alejos, B; Alonso Socas, MDM; Belza, MJ; Espacio, R; Garaialde, A; García-Yubero, C; Gómez-Ayerbe, C; Gutiérrez Cuéllar, I; Hernández, J; Jarrín, I; Martínez Madrid, OJ; Muñoz Sánchez, J; Olalla, J; Pierola Ruiz de Galarreta, B; Ruiz-Algueró, M; Suárez-García, I | 1 |
| Bekker, LG; Bukusi, EA; Chi, BH; Delany-Moretlwe, S; Goga, A; Joseph Davey, DL; Lyerly, AD; Mgodi, NM; Mugo, N; Myer, L; Noguchi, LM; Pintye, J; Slack, C; Stranix-Chibanda, L | 1 |
| Ciaranello, AL; Clement, ME; Cohen, MS; Freedberg, KA; Grinsztejn, B; Hyle, EP; Landovitz, RJ; Le, MH; McCauley, M; Neilan, AM; Paltiel, AD; Reddy, KP; Walensky, RP; Wattananimitgul, N | 1 |
| Bamford, L; Burkholder, GA; Cachay, ER; Christopoulos, K; Crane, HM; Delaney, JAC; Eron, JJ; Gravett, RM; Jacobson, JM; Keruly, J; Kitahata, MM; Ma, J; Martin, J; Mayer, KH; Moore, RD; Nance, RM; Napravnik, S; Saag, MS; Whitney, BM | 1 |
| Barday, Z; Geragotellis, A; Naicker, V; Patel, S; Sanglay, L; Sonderup, M; Spearman, CW; Wearne, N | 1 |
| Abdool Karim, Q; Abdool Karim, SS; Archary, D; Garcia-Lerma, JG; Heneine, W; Holder, A; Jewanraj, J; Liebenberg, LJP; Mansoor, LE; McKinnon, LR; Mtshali, A; Ngcapu, S; Osman, F; Passmore, JAS; Sivro, A | 1 |
| Abdool Karim, Q; Abdool Karim, SS; Garrett, NJ; McKinnon, LR; Molatlhegi, RP; Ngcapu, S; Ngcobo, S; Osman, F; Samsunder, N; Sivro, A | 1 |
| Distenhreft, JIQ; Fioroti, CEA; Lacchine, K; Luchi, WM; Paulino, BB; Ramos, DR; Seguro, AC | 1 |
| Bassetti, M; Beltramini, S; Briano, F; Bruno, SR; Di Biagio, A; Ferrara, S; Giacomini, M; Lo Caputo, S; Magnasco, L; Mora, S; Pincino, R; Poliseno, M; Sarteschi, G; Sasso, E; Taramasso, L | 1 |
| Browne, EN; Chen, BA; Gundacker, HM; Hawley, I; Hoesley, C; Liu, A; Piper, J; Scheckter, R; Singh, D; Song, M; Stoner, MCD; van der Straten, A | 1 |
| Egger, M; Goldstein, F; Hauser, A; Kouyos, RD; Reichmuth, ML; Riou, J; Wandeler, G | 1 |
| Fidler, S; Fox, J; Kulasegaram, R; Lee, MJ; Nori, A; Smith, C | 1 |
| Barr, E; Best, BM; Brooks, KM; Browning, R; Capparelli, EV; Chakhtoura, N; Deville, JG; Febo, IL; George, K; Knowles, K; Mirochnick, M; Paul, ME; Pinilla, M; Rungruengthanakit, K; Shapiro, DE; Stek, AM | 1 |
| Anderson, PL; Blumenthal, J; Chaillon, A; Chow, K; Cottrell, M; Gianella, S; Karris, M; Kay, A; Morris, S; Pacheco, D; Peterson, S; Rawlings, SA | 1 |
| Abdool Karim, Q; Akolo, C; Amparo da Costa Leite, PH; Azwa, I; Baggaley, R; Cáceres, CF; Dalal, S; Dourado, I; Green, K; Hettema, A; Hoornenborg, E; Jana, S; Kerschberger, B; Mahler, H; Matse, S; McManus, H; Molina, JM; Reza-Paul, S; Schaefer, R; Shahmanesh, M; Silva, R; Taylor, D; Vega-Ramirez, H; Veloso, VG | 1 |
| Burns, CM; Wyatt, C | 1 |
| Aydin, OA; Bilge, B; Bolukcu, S; Dokmetas, I; Gumuser, F; Gunduz, A; Karaosmanoglu, HK; Mete, B; Tabak, F; Yildiz, DS | 1 |
| Bakshi, RP; Chaturvedula, A; Fuchs, EJ; Hendrix, CW; Marzinke, MA; Shieh, E; Tanaudommongkon, A | 1 |
| Hackett, C; Murray, G; Roche, D; Tobin, AM | 1 |
| Bender, AT; Boyle, D; Drain, PK; Lillis, L; Olanrewaju, AO; Posner, JD; Sullivan, BP; Zhang, JY; Zhang, Y | 1 |
| Diggins, CE; Lo, J; Russo, SC | 1 |
| Adeyeye, A; Agyei, Y; Anderson, PL; Bushman, LR; Chau, G; Cohen, MS; Cummings, V; Delany-Moretlwe, S; Eshleman, SH; Farrior, J; Fogel, JM; Ford, S; Haines, CD; Hanscom, B; Hendrix, CW; Hosseinipour, M; Hughes, JP; Hunidzarira, P; Kofron, R; Marzinke, MA; Mathew, CA; Mellors, J; Mpendo, J; Nair, G; Persaud, D; Petropoulos, C; Piwowar-Manning, E; Richardson, P; Rinehart, A; Rooney, JF; Spooner, E; St Clair, M; Sullivan, P | 1 |
| Chen, M; Meng, W; Song, Y; Xie, R; Zhang, F; Zhang, H | 1 |
| Balogh, A; Jaeger, H; Jonsson-Oldenbuettel, C; Noe, S; Schoenitzer, V; Wolf, E | 1 |
| Fentie Wendie, T; Mengistu, G | 1 |
| Azu, OO; Dare, A; Lawal, SK; Naidu, ECS; Olojede, SO; Rennie, CO | 1 |
| de la Court, F; de Vries, HJ; Hoornenborg, E; Jurriaans, S; Koole, JC; Op de Coul, EL; Prins, M; Stalenhoef, JE; Welkers, MR; Yap, K | 1 |
| Ake, JA; Bahemana, E; Chang, D; Crowell, TA; Dear, NF; Esber, AL; Iroezindu, M; Kibuuka, H; Maswai, J; Owuoth, J; Polyak, CS; Singoei, V | 1 |
| Beksinska, ME; Brown, TT; Glenn Fowler, M; Kiwanuka, N; Kiweewa Matovu, F; Musoke, P; Nabwana, M; Pettifor, JM; Scholes, D | 1 |
| Jones, J; Pampati, S; Siegler, AJ | 1 |
| Blanco, JR; Calzado Isbert, S; López Cortés, LF; Martínez-Sanz, J; Mena, Á; Moreno, E; Moreno, S; Muriel, A; Pineda, JA; Ron, R; Sánchez-Conde, M; Serrano-Villar, S | 1 |
| Joob, B; Wiwanikit, V | 1 |
| Asienzo, J; Ategeka, G; Balyegisawa, A; Borok, M; Castelnuovo, B; Hoppe, A; Kaimal, A; Kambugu, A; Kiragga, A; Kityo, C; Lugemwa, A; Mirembe, G; Mugerwa, H; Musaazi, J; Odongpiny, ELA; Paton, NI; Siika, A; Walimbwa, S | 1 |
| Acosta, R; Andreatta, K; Blair, C; Chang, S; Collins, SE; D'Antoni, ML; Daar, ES; Gallant, J; Hagins, D; Liu, H; Martin, H; Martin, R; McNicholl, I; Molina, JM; Sax, PE; White, KL | 1 |
| Anderson, P; Baeten, JM; Celum, CL; Choopanya, K; Garcia-Cremades, M; Glidden, DV; Grant, R; Hendrix, CW; Jarlsberg, L; Jayachandran, P; Marrazzo, J; Martin, M; Savic, RM; Vanichseni, S; Vučićević, K | 1 |
| Alessandri-Gradt, E; Martin, C; Plantier, JC; Unal, G | 1 |
| Ehteshami, M; Patel, D; Schinazi, RF | 1 |
| Carrozzo, G; Cattaneo, D; Gervasoni, C; Poloni, A; Riva, A | 1 |
| Abdool Karim, Q; Abdool Karim, SS; Baxter, C | 1 |
| Cheng, AK; Lee, WA | 1 |
| Bookstaver, PB; Clary, JC; Derrick, C; Drummond, M; Rowe, SM; Sanasi, K | 1 |
| Blanco, JL; Callau, P; de la Mora, L; de Lazzari, E; Gonzalez-Cordón, A; Inciarte, A; Laguno, M; Mallolas, J; Martinez, E; Martinez-Rebollar, M; Rojas, J; Subirana, M; Torres, B | 1 |
| Berenguer, J; Blair, C; Chuck, SK; D'Antoni, ML; De Wit, S; Gallant, J; Haubrich, R; Maggiolo, F; Martin, H; McNicholl, IR; Molina, JM; Piontkowsky, D; Pulido, F; Rizzardini, G; Vandekerckhove, L | 1 |
| Buzibye, A; Chinyenze, K; Kaleebu, P; Kamacooko, O; Kuteesa, M; Lunkuse, JF; Mayanja, Y; Muturi-Kioi, V; Omali, D; Price, MA | 1 |
| Harrington, P; Hayes, C; Marshall, L; Moran, P; O Murchu, E; Ryan, M; Teljeur, C | 1 |
| Baum, MM; Beliveau, M; Buser, C; Caprioli, RM; Castonguay, AE; Gallay, PA; Gunawardana, M; Hendrix, CW; Kuo, J; Marzinke, MA; Moss, JA; Remedios-Chan, M; Reyzer, ML; Sanchez, D; Trinh, M; Tuck, M; Webster, P; Webster, S | 1 |
| Cottrell, M; Crane, H; Di Girolamo, J; Dumond, J; Gane, E; Kashuba, A; Kayes, T; Levy, MT; Lim, TH; Manandhar, S; Symonds, A | 1 |
| Jordan, MR; Marryshow, TA; Matta, R; Molulela, MMM; Muhairwe, J; Tang, A | 1 |
| Drak, D; Gowers, A; Gracey, DM; Lin, J | 1 |
| Bernardino, JI; de Gea Grela, A; Martín Carbonero, L; Micán, R; Ramos, L; Valencia, ME | 1 |
| Bhattacharya, D; Butler, K; Chakhtoura, N; Currier, JS; Dula, D; Fowler, MG; George, K; Govender, V; Kiweewa, FM; Mohtashemi, N; Moodley, D; Musoke, P; Peters, MG; Ship, H; Tierney, C; Vhembo, T | 1 |
| Afonso Reis, E; Almeida-Brasil, CC; Ceccato, MDGB; de Oliveira Costa, J; Rodrigues, VA; Silveira, MR | 1 |
| Chew, SA; Garcia, CR; Manojkumar, A; Nieh, MP; Rad, AT; Rahman, Z; Rodrigo, H; Roy, D; Roy, U; Saeedinejad, F | 1 |
| Post, FA; Sinxadi, P | 1 |
| Chadwick, DR; Durrani, M; Hardy, Y; Hunt, M; Mitchelmore, R; Owusu, DO; Payne, BAI; Phillips, R | 1 |
| Cerankowski, J; Keith, SW; Schafer, JJ; Shimada, A; Walshe, C; Zimmerman, M | 1 |
| Fernandez, G; Imaz, A; Navarro, A; Piatti, C; Podzamczer, D; Prieto, P; Saumoy, M; Scevola, S; Silva, A; Tiraboschi, J | 1 |
| Aceiton, J; Bruguera, A; Casabona, J; Deig, E; Díaz, Y; Domingo, P; Imaz, A; Llibre, JM; Miro, JM; Moreno, S; Navarro, G; Navarro, J; Nomah, DK; Reyes-Urueña, J; Vivanco-Hidalgo, RM | 1 |
| Amico, KR; Andrew, P; Chege, W; Chen, YQ; Cottle, LM; Eshleman, SH; Farley, JE; Frank, I; Gulick, RM; Hendrix, CW; Ho, K; Landovitz, RJ; Liu, AY; Magnus, M; Marcus, C; Marzinke, MA; Mayer, KH; McCauley, M; Richardson, P; Rinehart, AR; Rooney, JF; Salata, RA; Santana, J; Stekler, JD; Wilkin, T; Yuhas, K | 1 |
| Aladeyelu, OS; Azu, OO; Dare, A; Faborode, OS; Lawal, SK; Moodley, R; Naidu, EC; Olojede, SO; Rennie, CO | 1 |
| Aguilar, G; Ávila-Ríos, S; De Arias, AR; García-Morales, C; Giron, A; Lopez, G; López-Sánchez, DM; McFarland, W; Ovelar, P; Rios-Gonzalez, C; Samudio, T; Tapia-Trejo, D; Truong, HM | 1 |
| Anderson, PL; Bushman, LR; Castillo-Mancilla, JR; Coleman, SS; Coyle, RP; Ellison, L; Kiser, JJ; MaWhinney, S; Morrow, M; Zheng, JH | 2 |
| Czarnogorski, M; Evans, TM; Pilgrim, NA | 1 |
| Bonnichsen, MH; Bye, W; Post, JJ; Tschuchnigg, M | 1 |
| Aho, I; Kauppinen, KJ; Sutinen, J | 1 |
| Amstutz, A; Belus, JM; Brown, JA; Glass, TR; Klimkait, T; Labhardt, ND; Mokhele, K; Muhairwe, J; Nsakala, BL; Rakuoane, I; Tschumi, N | 1 |
| Agorastou, P; Dalekos, GN; Deutsch, M; Elefsiniotis, I; Gatselis, N; Goulis, J; Kapatais, A; Karaoulani, T; Karatapanis, S; Kranidioti, H; Kyriazidou, A; Manesis, E; Manolakopoulos, S; Mimidis, K; Mylopoulou, T; Papatheodoridi, M; Papatheodoridis, GV; Samonakis, D; Sevastianos, V; Triantos, C; Vasiliadis, T; Zisimopoulos, K | 1 |
| Audo, I; Joharjy, H; Le-Lez, ML; Pisella, PJ | 1 |
| Flexner, C | 1 |
| Liegeon, G | 1 |
| Mellors, JW; Parikh, UM | 2 |
| Abel, S; Ajana, F; Avettand-Fenoel, V; Bauer, R; Calin, R; Chéret, A; Goujard, C; Lacombe, K; Lascoux, C; Lopez, P; Meiffrédy, V; Meyer, L; Morlat, P; Reynes, J; Rouzioux, C | 1 |
| Algarte-Genin, M; Assoumou, L; Ben-Mechlia, M; Beniguel, L; Costagliola, D; Delaugerre, C; Ghosn, J; Goldwirt, L; Katlama, C; Le Mestre, S; Liegeon, G; Lourenco, J; Loze, B; Molina, JM; Mouhim, H; Ohayon, M; Pavie, J; Pialoux, G; Rojas-Castro, D; Slama, L; Spire, B; Surgers, L | 1 |
| Ferrara, P; Gianfredi, V | 1 |
| Chahine, EB; Durham, SH; Milam, A; Waer, D | 1 |
| Bossolasco, S; Bruzzesi, E; Carini, E; Castagna, A; Chiurlo, M; Galli, L; Gianotti, N; Lazzarin, A; Mancusi, D; Mastrangelo, A; Nozza, S; Poli, A; Ranzenigo, M; Spagnuolo, V; Termini, R | 1 |
| Chang, HY; Chang, SF; Chang, SY; Chen, GJ; Chen, LY; Chuang, YC; Hsieh, SM; Huang, YS; Hung, CC; Lin, KY; Liu, WC; Liu, WD; Luo, YZ; Sheng, WH; Su, YC; Sun, HY; Wu, PY | 1 |
| Parveen, S; Shah, A; Singh, J; Tiwari, A | 1 |
| Andreoni, M; Antinori, A; Armenia, D; Berno, G; Bertoli, A; Borghi, V; Buonomini, A; Ceccherini-Silberstein, F; Cicalini, S; Forbici, F; Gagliardini, R; Gennari, W; Lanini, S; Latini, A; Malagnino, V; Mussini, C; Perno, CF; Santoro, MM; Sarmati, L; Teti, E | 1 |
| Cleary, S; Coates, TJ; Dovel, K; Joseph Davey, DL; Khadka, N; Mashele, N; Mvududu, R; Myer, L; Nyemba, DC; Silliman, M | 1 |
| Lee, MH | 1 |
| Babusis, D; Bilello, JP; Chan, J; Cihlar, T; Cohen, C; Du Pont, V; Duong, V; Feng, JY; Gordon, CJ; Götte, M; Juneja, K; Perry, JK; Tchesnokov, EP; Vijjapurapu, A; Zhao, X | 1 |
| Barry, S; Chopra, A; Ibrahim, A; Pokhrel, K; Smith, T | 1 |
| Anderson, P; Bushman, L; Cardoso, SW; Castro, CRV; Cattani, VB; Eksterman, L; Estrela, R; Grinsztejn, B; Jalil, EM; Monteiro, L; Torres, T; Veloso, VG; Wilson, E | 1 |
| Boyd, A; Coffie, PA; Freedberg, KA; Hyle, EP; Kim, AY; Kouamé, MG; Larmarange, J; Mohareb, AM | 1 |
| Bezenchek, A; Callegaro, AP; Carlo, DD; Celani, L; Francisci, D; Gennari, W; Lombardi, F; Maggiolo, F; Micheli, V; Piermatteo, L; Rossetti, B; Santoro, MM; Stella, G; Vicenti, I; Volpicelli, L | 1 |
| Allen, SA; Dabee, S; Doncel, GF; Feng, C; Gasper, M; Haugen, HS; Heffron, R; Jaspan, HB; McLellan-Lemal, E; Mudhune, V; Mugo, N; Njoroge, B; Nyagol, B; O'Connor, S; Ouma, E; Peacock, S; Ridzon, R; Thurman, AR; Wiener, J | 1 |
| Arribas, JR; Bernardino, JI; Busca, C; Cadiñanos, J; de Gea Grela, A; de Miguel, R; González-García, J; Martín-Carbonero, L; Micán, R; Montejano, R; Montes, ML; Moreno, V; Pérez Valero, I; Serrano, L; Valencia, E | 1 |
| Aoun-Barakat, L; Cartwright, EJ; Casas, JP; Dickerman, BA; Hernán, MA; Justice, AC; Li, G; Lodi, S; Logan, RW; Park, LS; Rentsch, CT | 1 |
| Baltrusaitis, K; Browning, R; Fairlie, L; Fowler, MG; George, K; Heckman, B; Knowles, K; Makanani, B; Moodley, D; Nyakudya, LH; Siberry, GK; Stranix-Chibanda, L; Taha, TE; Theron, G; Tierney, C; Tomu, M | 1 |
| Bedimo, RJ; Guaraldi, G; Stapleton, JT | 1 |
| Evans, D; Hans, L; Levin, L; Steegen, K; Technau, KG | 1 |
| Campins, AA; García Fraile, LJ; Martínez-Sanz, J; Mena de Cea, Á; Moreno, S; Muriel, A; Orviz, E; Serrano-Villar, S | 1 |
| Abdi, B; Bitilinyu-Bangoh, JE; Calvez, V; Descamps, D; Jahn, A; Kalua, T; Lê, MP; Marcelin, AG; Nicholas, S; Ousley, J; Peytavin, G; Schramm, B; Storto, A; Szumilin, E; Temfack, E | 1 |
| Alhassan, Y; Bokako, S; Burger, D; Byamugisha, J; Byrne, K; Chen, T; Chiong, J; Colbers, A; Hodel, EM; Hu, NC; Khoo, S; Kintu, K; Lamorde, M; Malaba, TR; Mrubata, M; Myer, L; Nakatudde, I; Orrell, C; Read, J; Read, L; Reynolds, H; Seden, K; Stemmet, LA; Taegtmeyer, M; Theunissen, H; Twimukye, A; Waitt, C; Wang, D | 1 |
| Arribas, JR; Borobia, AM; Carcas, AJ; Ciudad, M; de la Calle-Prieto, F; de Miguel, M; Del Álamo, M; Díaz-Brasero, A; Díez, C; Estrada, V; Goikoetxea, AJ; González-Ruano, P; Guijarro, C; Gutiérrez, Á; Ibarra, S; Ibarrola, M; Jiménez-González, M; Marcelo, C; Marcos, J; Martínez, P; Merino, E; Montejano, R; Moreno, S; Novella, M; Queiruga-Parada, J; Rivera, MA; Ruiz-Muñoz, M; Ryan, P; Soler, L; Torralba, M; Velasco, M | 1 |
| Dobard, C; García-Lerma, JG; Gary, J; Gatto, G; Heneine, W; Holder, A; Johnson, L; Khalil, G; Krovi, A; Li, L; Luecke, E; Massud, I; Mills, P; Mitchell, J; Nishiura, K; Pan, Y; Ruone, S; van der Straten, A | 1 |
| Figueredo, CC; Gomes, MP; Juneau, P; Kitamura, RSA; Kubis, GC; Navarro-Silva, MA; Nogueira, KDS; Vieira, F | 1 |
| Brunet, L; Fusco, GP; Fusco, JS; Hsu, RK; Lamori, JC; Mounzer, K | 1 |
| Alfaro, EM; Arazo, P; Arellano, JP; Arribas, JR; Bachiller, P; Buzón, L; Del Amo, J; Díaz de Santiago, A; Díaz-Brito, V; García Del Toro, M; García-Albéniz, X; Garcinuño, MA; Gómez-Sirvent, JL; Guerra, JM; Hernán, MA; Hernández-Torres, A; Hita, C; Martínez de Salazar, P; Masiá, M; Morales, M; Moreno, S; Muñoz, L; Polo, R; Rial-Crestelo, D; Santos, J; Sanz, J; Terán, C | 1 |
| Anderson, PL; Brooks, KM; Brothers, J; Glenny, C; Hosek, S; Landovitz, R; Malhotra, M; Mulligan, K; Reirden, D; Yager, J | 1 |
| Bacchetti, P; Chanaiwa, VM; Chipato, T; Gandhi, M; Louie, A; Murnane, PM; Mutambanengwe-Jacob, MT; Nematadzira, TG; Odiase, OJ; Okochi, H; Stranix-Chibanda, L; Tallerico, R; Vhembo, T | 1 |
| Katzenstein, D; Kouamou, V; Machekano, R; Manasa, J; Mapangisana, T; Maposhere, C; McCarty, K; Munyati, S; Mutsvangwa, J; Shamu, T | 1 |
| He, W; Lin, B; Liu, J; Ma, Y; Pan, H; Zhong, X | 1 |
| Ahmed, K; Baeten, JM; Beesham, I; Beksinska, M; Heffron, R; Joseph Davey, DL; Kotze, P; Louw, C; Mansoor, LE; Palanee-Phillips, T; Parikh, UM; Rees, H; Selepe, P; Singata-Madliki, M; Smit, J; Wiesner, L | 1 |
| Afani Saud, A; Bettacchi, C; Chahin Anania, C; Correll, T; Eves, K; Grandhi, A; Hanna, GJ; Hepler, D; Hwang, C; Klopfer, SO; Molina, JM; Robertson, MN; Yazdanpanah, Y | 1 |
| Decloedt, EH; Esterhuizen, T; Joska, JA; Kamau, F; Kellermann, T; Khoo, S; Maartens, G; Solanke, T; Strijdom, H | 1 |
| Cattaneo, D; Cinausero, M; Fusi, M; Gervasoni, C; Londero, A; Tascini, C | 1 |
| Allahna, E; Christina S, P; Emmanuel, B; Hannah, K; John, O; Jonah, M; Joseph S, C; Julie A, A; Michael, I; Neha, S; Nicole, D; Trevor A, C; Valentine, S | 1 |
| Anderson, PL; Buchbinder, SP; Christie, RH; Coleman, K; Laborde, N; Liu, AY; Lockard, A; Marlborough, M; Scott, H; Siegler, AJ; van der Straten, A; Vittinghoff, E; Wilde, G | 1 |
| Alvarez, E; Brady, JJ; Burling, K; Campbell, L; Garcia-Leon, A; Graham, H; Jamshidian, F; Jouret, F; Mallon, PW; Neuville, MF; Noe, S; Post, FA; Rhee, M; Tinago, W; Walsh, I | 1 |
| Liu, W; Yan, B; Yu, S | 1 |
| Asawanonda, P; Boontaveeyuwat, E; Pemcharoen, J; Sriaram, A; Wongjirattikarn, R | 1 |
| Hsiao, NY; Hu, NC; Joseph Davey, D; Mashele, N; Mvududu, R; Myer, L; Sonderup, M; Wendy Spearman, C | 1 |
| Adebisi, SA; Adedeji, NO; Adedeji, TA; Ajeigbe, AK; Ajose, AO; Akande, AA; Fawale, MB; Jeje, OA; Okesina, BA; Smith, OS | 1 |
| Anderson, PL; Bekker, LG; Celum, C; Chirenje, ZM; Delany-Moretlwe, S; Donnell, D; Hosek, S; Marzinke, MA; Mgodi, N; Velloza, J | 1 |
| Cao, T; He, Y; Jia, X; Ju, B; Liu, J; Liu, X; Peng, Q; Rao, M; Song, Y; Sun, L; Wang, H; Wang, S; Xu, L; Zhang, H; Zhang, L; Zhang, Q; Zhao, F; Zhou, J; Zhou, Y | 1 |
| Cai, L; Guo, Z; He, S; Wang, Y; Wang, Z; Yan, D; Yang, X; Zheng, Y | 1 |
| Babu, AS; Henny, KD; Pyra, M; Schneider, J; Smith, DK; Townes, A; Wiener, J; Williams, T | 1 |
| Brady, M; Chen, YQ; Cover, J; Cressey, TR; Drain, P; Duerr, A; Kariithi, E; Mori, K; Obanda, R; Obong'o, C; Okomo, G; Oluoch-Madiang, D; Tapsoba, JD | 1 |
| Abdusalaamu, K; Boulware, DR; Collins, L; Lukande, R; Meya, DB; Mishra, U; Namuju, OC; Nicol, MR; Pastick, KA; Wang, F | 1 |
| Bogoch, II; Nhean, S; Sheehan, NL; Tseng, A | 1 |
| Anderson, PL; Brothers, J; Hosek, S; Huhn, G; Keckler, K; Liu, H; Xiong, D | 1 |
| Karoney, MJ; Koech, MK; Njiru, EW; Owino Ong'or, WD | 1 |
| Granade, TC; Heneine, W; Pau, CP; Pohl, J; Reed, MS; Switzer, WM; Vanderford, TH; Youngpairoj, AS | 1 |
| Alcantarini, C; Bono, V; Bonora, S; Calcagno, A; Cannizzo, ES; Cusato, J; D'Avolio, A; De Nicolò, A; De Vivo, E; Di Perri, G; Ferrara, M; Ianniello, A; Marchetti, G; Nozza, S; Salvador, E; Trentalange, A; Trunfio, M | 1 |
| Hebel, SK; Hermans, LE; Lalla-Edward, ST; Nijhuis, M; Tempelman, HA; Umunnakwe, CN; Venter, WDF; Wensing, AMJ | 1 |
| Dave, M; Gonchikar, NT; Goyal, A; Sareen, M; Shah, Y | 1 |
| Chen, T; Gui, F; Tan, J; Wei, G; Yang, J; Zhao, Y | 1 |
| Baxter, C; Beyer, A; Derkach, E; Lobodina, A; Pyadushkina, E; Rozenberg, V; Ugrekhelidze, D | 1 |
| Barham, L; Dzinamarira, T; Mhango, M; Moyo, E; Musuka, G | 1 |
| Allen, SA; Betts, JE; Deaton, SR; Doncel, GF; Heffron, R; McLellan-Lemal, E; Mudhune, V; Mugo, NR; Nyagol, B; O'Connor, SM; Ondenge, K; Thurman, AR | 1 |
| Abdool Karim, Q; Abdool Karim, SS; Archary, D; Elsherbini, JA; Kwon, DS; Lewis, L; Mansoor, LE; Mazibuko-Motau, N; Mtshali, A; Mzobe, G; Ngcapu, S; Ntuli, L; San, JE; Sobia, P; Xu, J | 1 |
| Dickson, S; Gabriel, N; Hernandez, I | 1 |
| Crockett, KB; Turan, B; Van Gerwen, OT; Yigit, I | 1 |
| Brache, V; Chandra, N; Clark, MR; Cochon, L; Doncel, GF; Erikson, DW; Fichorova, RN; Hanif, H; Herold, BC; Jacot, T; Ju, S; Marzinke, MA; Ouattara, LA; Parikh, U; Peet, M; Schwartz, JL; Thurman, AR; Tolley, E; Yousefieh, N | 1 |
| Aurpibul, L; Best, BM; Campbell, H; Cassim, H; Cooper, E; Flynn, P; Gray, KP; Krotje, C; McCarthy, K; McFarland, E; Melvin, AJ; Moye, J; Ounchanum, P; Rungmaitree, S; Scheckter, R; Teppler, H; Tobin, NH; Townley, E; Wan, H; Yedla, M; Yee, KL | 1 |
| Amico, KR; Bailey, RC; Graham, SM; Harper, GW; Jadwin-Cakmak, L; Mehta, SD; Ng'ety, G; Obondi, E; Ochieng, E; Okall, DO; Otieno, FO | 1 |
| Bulterys, M; Chen, L; Fan, B; Kourtis, AP; Liu, W; Shepherd, J; Wang, L; Wiener, J | 1 |
| Chang, J; Delgado, H; Do, D; Huynh, A; Kanimian, N | 1 |
| Ishii, T; Onoda, T; Tanaka, H | 1 |
| Ailincai, D; Bercea, M; Marin, L; Mititelu Tartau, L | 1 |
| Béguelin, C; Bernasconi, E; Boillat-Blanco, N; Calmy, A; Günthard, HF; Hofmann, E; Rauch, A; Schmid, P; Stöckle, M; Surial, B; Suter-Riniker, F; Wandeler, G | 1 |
| Arreguin, M; Chattopadhyay, A; Gandhi, M; Glidden, DV; Hickey, MD; Imbert, E; Johnson, KA; Okochi, H; Spinelli, M; Watabe, J | 1 |
| Brandão, LAC; Coelho, AVC; De Araújo, PSR; De Melo, HRL; Lima, K; Soares, RCA | 1 |
| Chen, D; Du, Y; Huang, Z; Li, J; Wang, Y; Wen, Z; Yin, S; Zhong, H | 1 |
| Derkach, EV; Pyadushkina, EA | 1 |
| Coffin, CS; Conway, B; Cooper, C; Doucette, K; Fung, S; Hansen, BE; Haylock-Jacobs, S; Janssen, HLA; Ramji, A; Sarowar, A; Truong, D; Wong, A | 1 |
| Brakenhoff, SM; de Knegt, RJ; de Man, RA; Katwaroe, WK; Sonneveld, MJ; van der Meer, AJP; van der Spek, DPC; van Kleef, LA | 1 |
| Abdul Massih, S; Andrade, A; Beselman, S; Breakey, J; Fuchs, EJ; Hendrix, CW; Marzinke, MA; McNicholl, I | 1 |
| Aung, W; Bakshi, RP; Bream, JH; Bumpus, NN; Coleman, JS; Diniz, CP; Farzadegan, H; Fuchs, EJ; Hendrix, CW; Hudson, S; Marzinke, MA; Nilles, TL; Rooney, JF; Rosenblum, MA; Schwartz, GJ | 1 |
| Arribas, JR; Cahn, P; Daar, ES; Gibas, KM; Kelly, SG; Orkin, C; Sax, PE; Taiwo, BO | 1 |
| Alix, A; Bois, J; Brucato, S; Dargere, S; Fournel, F; Fournier, A; Got, L; Gregoire, N; Hocqueloux, L; Lefeuvre, S; McNicholl, I; Parienti, JJ; Peyro-Saint-Paul, L; Prazuck, T; Valentin, C | 1 |
| Agrahari, V; Clark, MR; Dinh, C; Doncel, GF; García-Lerma, JG; Heneine, W; Holder, A; Makarova, N; Mendoza, M; Mitchell, J; Pan, Y; Peet, MM; Singletary, T; Smith, JM | 1 |
| Bavinton, BR; Bazaale, JM; Grulich, AE; Jin, J; Nakiganda, LJ; Poynten, IM; Serwadda, D | 1 |
| Delany-Moretlwe, S; Hosseinipour, MC; Jamieson, L; Johnson, LF; Meyer-Rath, G; Nichols, BE; Russell, C | 1 |
| Aubert, A; Bani-Sadr, F; Berger, JL; Hittinger Roux, A; N'Guyen, Y | 1 |
| Johnson, TM; Rivera, CG | 1 |
| Arribas, JR; Cabello, A; Curran, A; de la Cámara, SP; Del Amo, J; Díaz, A; Dueñas, C; Hernán, MA; Iribarren, JA; Jarrín, I; Macías, J; Mariño, AI; Martínez, E; Montero, M; Moreno, S; Polo, R | 1 |
| Andreoni, M; Barchi, V; De Simone, G; Iannazzo, R; Iannetta, M; Massa, B; Rindi, LV; Sarmati, L | 1 |
| Chen, CP; Hung, CC; Hung, TC; Lee, CH; Lee, CY; Lee, YT; Li, CW; Liou, BH; Liu, CE; Sun, HY; Tang, HJ; Tsai, MS; Yang, CJ | 1 |
| Seneviratne, HK | 1 |
| Abdel Alem, S; Abdelbary, MS; Cordie, A; El Garhy, N; El Khateeb, E; Elsharkawy, A; Esmat, G; Fouad, R; Khalil, M | 1 |
| Blades, C; Blair, CS; Clark, JL; Gandhi, M; Shoptaw, S | 1 |
| Baum, MM; Beliveau, M; Fanter, R; Gallay, PA; Gunawardana, M; Kuo, J; Marzinke, MA; Moss, JA; Ramirez, CM; Remedios-Chan, M; Sanchez, D; Trinh, M; Webster, P; Webster, S | 1 |
| Agrahari, V; Clark, MR; Dinh, C; Dobard, CW; Doncel, GF; García-Lerma, JG; Gupta, P; Heneine, W; Holder, A; Jonnalagadda, S; Khalil, G; McCormick, TJ; Mitchell, J; Nishiura, K; Pan, Y; Peet, MM; Singh, ON | 1 |
| Kanie, N; Katoh, S; Takahashi, K; Yamauchi, M | 1 |
| To, EE | 1 |
| Cone, R; Date, AA; Ensign, LM; Fuchs, EJ; Gumber, S; Hanes, J; Hendrix, CW; Hoang, T; Marzinke, MA; Myers, R; Rohan, LC; Villinger, F; Wang, L; Xiao, P | 1 |
| Bhrusundi, M; Dravid, A; K R, R; Kulkarni, V; Madhukarrao, KM; Morkar, DN; Nageswaramma, S; Naik, KS; Pilawan, AS; Ramapuram, JT; S, A | 1 |
| Baldi, A; Carleo, MA; Contieri, M; De Blasiis, P; De Luca, A; Esposito, V; Guerra, G; Guida, A; Hay, E; Lucariello, A; Maggi, P; Mascolo, S; Perna, A; Sellitto, C | 1 |
| Cheung, AM; Clarke, R; De Pokomandy, A; Guaraldi, G; Lee, T; Messina, E; Singer, J; Smaill, F; Trottier, S; Walmsley, S | 1 |
| Akpomiemie, G; Bosch, B; Chandiwana, N; Hill, A; McCann, K; Mirchandani, M; Qavi, A; Sokhela, S; Venter, WDF | 1 |
| Canidate, SS; Cook, RL; Gebru, NM; Leeman, RF; Liu, Y; Pavila, E; Schaefer, SE | 1 |
| Burger, DM; Colbers, A; Grintjes, K; Jacobs, TG; Nieuwenstein, T; Zino, L | 1 |
| Baeten, JM; Benson, P; Berhe, M; Crofoot, G; Dvory-Sobol, H; Gupta, SK; Koenig, E; Liu, SY; McDonald, C; Ramgopal, M; Rhee, MS; Ruane, P; Sanchez, WE; Scribner, A; Sims, J; VanderVeen, LA | 1 |
| Greenberg, L; Mocroft, A; Neesgaard, B; Peters, L; Ryom, L | 1 |
| Ayers, C; Bedimo, R; Drechsler, H | 1 |
| Liu, QZ; Qin, QQ; Tang, HL; Xu, P; Yang, X | 1 |
| Fan, L; Gao, L; Hu, Y; Huang, R; Li, L; Ma, P; Qiu, C; Wu, Y; Yu, A; Zhang, D | 1 |
| Godman, B; Kalemeera, F; Rennie, T; Stergachis, A | 2 |
| Bouldouyre, MA; Brun, A; Caraux-Paz, P; Chabrol, A; De Castro, N; Delaugerre, C; Froguel, E; Garrait, V; Hamet, G; Mechaï, F; Molina, JM; Rozenbaum, W; Sellier, P; Troisvallets, D | 1 |
| Anderson, DJC; Cottrell, ML; Devanathan, AS; Dumond, JB; Gay, CL; Kashuba, ADM; Moody, K; Poliseno, AJ; Rosen, EP; Schauer, AP; Sykes, C | 1 |
| Byun, KS; Choi, J; Kim, JH; Lim, YS; Yoo, BC | 1 |
| Griesel, R; Hill, A; Keene, C; Maartens, G; Meintjes, G; Omar, Z; Simmons, B; van Zyl, G; Zhao, Y | 1 |
| Anderson, PL; Glidden, DV; Marzinke, MA | 1 |
| Fotooh Abadi, L; Gajbhiye, V; Kulkarni, S; Kumar, P; Paknikar, K | 1 |
| Aristegui, I; Cahn, P; Cardozo, N; Cesar, C; Figueroa, MI; Fink, V; Frola, CE; Gun, A; Patterson, P; Radusky, PD; Sued, O; Zalazar, V | 1 |
| Abba, A; Beloumou, GA; Billong, SC; Bouba, NP; Ceccherini-Silberstein, F; Chenwi, CA; Colizzi, V; Dambaya, B; Djupsa Ndjeyep, SC; Eben-Moussi, E; Etame, NK; Fokam, J; Ka'e, AC; Kengni, AMN; Kouanfack, C; Meledie, AP; Molimbou, E; Mossiang, L; Ndjolo, A; Nka, AD; Perno, CF; Santoro, MM; Semengue, ENJ; Sosso, SM; Takou, D; Teto, G; Tommo Tchouaket, MC; Yagai, B; Zoung-Kanyi Bissek, AC | 1 |
| Abgrall, S; Allavena, C; Bernard, L; Bregigeon, S; Caby, F; Capeau, J; Costagliola, D; de Truchis, P; Duvivier, C; Enel, P; Grabar, S; Katlama, C; Khuong, MA; Launay, O; Matheron, S; Melica, G; Melliez, H; Meynard, JL; Pavie, J; Piroth, L; Potard, V; Slama, L; Tattevin, P | 1 |
| Berzigotti, A; Bonnet, F; Günthard, HF; Leleux, O; Limacher, A; Mocroft, A; Peters, L; Ramírez Mena, A; Rauch, A; Rockstroh, JK; Roumet, M; Smit, C; Surial, B; van der Valk, M; Wandeler, G | 1 |
| Cassidy, T; Flowers, T; Goemaere, E; Griesel, R; Hill, A; Jackson, A; Keene, CM; Maartens, G; Meintjes, G; Ngwenya, O; Omar, Z; Sayed, K; Van Zyl, G; Zhao, Y | 1 |
| Lunn, G | 1 |
| Fowler, MG; Hamill, MM; Kekitiinwa, A; Nabwire, F; Prentice, A | 1 |
| Antinori, S; Bonora, S; Cattaneo, D; Gervasoni, C; Meraviglia, P; Vimercati, S | 1 |
| Ake, JA; Bahemana, E; Cavanaugh, JS; Crowell, TA; Dear, N; Esber, AL; Ganesan, K; Iroezindu, M; Kibuuka, H; Maswai, J; Mwesigwa, R; Owuoth, J; Parikh, AP; Polyak, CS; Reed, D; Shah, N; Singoei, V | 1 |
| Donald, JL; Gift, TL; Salas, SB; Schmidt, MA; Tao, G | 1 |
| Boileau, M; Lambotte, O; Pouvelle, A; Robert, C; Routier, E | 1 |
| Clark, R; Desmond, AC; Govender, V; Gray, G; Lombard, C; Mhlongo, O; Moodley, D; Naidoo, K; Naidoo, M; Newell, ML; Rooney, JF; Sebitloane, M | 1 |
| Decloedt, E; Gandhi, M; Hoddinott, G; Jennings, L; Mcinziba, A; Myburgh, H; Orrell, C; van Schalkwyk, M; van Zyl, G; Viljoen, L; Wademan, D | 1 |
| Adede, RO; Ayieko, J; Balzer, LB; Garraza, LG; Havlir, DV; Hickey, MD; Ogachi, SM; Ojwando, H; Orori, G; Petersen, ML; Wafula, E | 1 |
| Brunet, L; Dunbar, M; Fusco, GP; Fusco, JS; McCurdy, LH; McNicholl, IR; Mounzer, K; Sension, M | 1 |
| Anderson, PL; Atukunda, EC; Bangsberg, DR; Bennett, K; Bwana, MB; Chitneni, P; Haberer, JE; Hendrix, CW; Hurwitz, KE; Isehunwa, OO; Kalyebera, KP; Marrazzo, JM; Marzinke, MA; Matthews, LT; Muyindike, W; Owembabazi, M; Psaros, C | 1 |
| Chang, HY; Chen, LY; Chuang, YC; Huang, YS; Hung, CC; Lin, KY; Liu, WC; Liu, WD; Luo, YZ; Su, YC; Sun, HY; Wu, PY | 1 |
| Castro, H; Collins, IJ; Jesson, J; Judd, A; Leroy, V; Milanzi, E; O'Rourke, J; Penazzato, M; Renaud, F; Townsend, CL; Vicari, M | 1 |
| Fan, X; Huang, H; Jiao, Y; Li, J; Wang, FS; Yu, XD; Zhang, D | 1 |
| Asselin, J; Carter, A; Chen, M; Donovan, B; Gracey, DM; Grulich, A; Guy, R; Heron, JE; Lewis, DA; McManus, H; O'Connor, CC; Ryan, K; Ryder, N; Stoove, M; Templeton, DJ; Varma, R; Vickers, T; Wright, E | 1 |
| Daskou, M; Kelesidis, T; Murakami, E; Petcherski, A; Ritou, E; Satta, S; Sharma, M; Shirihai, OS; Vasilopoulos, H | 1 |
| Nguyen, TK; Van Le, D | 1 |
| Del Amo, J | 1 |
| Agil, D; Althoff, KN; Augenbraun, M; Bastarache, L; Benning, L; Coburn, SB; Gangireddy, S; Gebo, KA; Gordon, KS; Horberg, MA; Jefferson, C; Lang, R; Lea, AN; Leyden, WA; Marafino, BJ; Marconi, VC; Napravnik, S; Park, LS; Silverberg, MJ; Skarbinski, J; Sofrygin, O; Williams, C | 1 |
| Che, X; Jiang, J; Qian, Y; Suo, J; Wang, L; Wang, Z; Xing, Y; Yin, L; Zhang, L | 1 |
| Adamson, J; Chen, G; Gandhi, M; Govender, K; Hedt-Gauthier, B; Marconi, VC; Masette, G; McCluskey, SM; Moodley, P; Moosa, MY; Muyindike, W; Pillay, M; Pillay, S; Siedner, MJ; Spinelli, MA; Sunpath, H | 1 |
| Adebajo, S; Adeyemi, OA; Baral, S; Charurat, ME; Craddock, J; Crowell, TA; Marzinke, M; Morgan, D; Ndembi, N; Nowak, RG; Sam-Agudu, N; Zhan, M | 1 |
| Baum, MM; Gallay, PA; Ramirez, CM | 1 |
| Galindo, MJ; González, CS; Lillo, IS; Rodríguez, AP | 1 |
| Barreiro, P; Corral, O; Mendoza, C; Moreno-Torres, V; Soriano, V | 1 |
| Ando, N; Aoki, T; Gatanaga, H; Kikuchi, Y; Mizushima, D; Oka, S; Takano, M; Uemura, H; Watanabe, K; Yanagawa, Y | 1 |
| Burns, JA; Hull, SJ; Inuwa, A; Moriarty, P; Scott, RK | 1 |
| Biello, KB; Chan, PA; Gandhi, M; Holcomb, R; Mayer, KH; Maynard, M; Mimiaga, MJ; Ndoye, CD; Valente, PK | 1 |
| Adeyeye, A; Anderson, PL; Arduino, RC; Bhandari, P; Bushman, LR; Chariyalertsak, S; Cohen, MS; Eshleman, SH; Fogel, JM; Ford, SL; Gollings, R; Grinsztejn, B; Halvas, EK; Hanscom, B; Hendrix, CW; Kofron, R; Landovitz, RJ; Marzinke, MA; Mayer, K; McCauley, M; Mellors, J; Moser, A; Persaud, D; Piwowar-Manning, E; Rinehart, AR; Rooney, JF; St Clair, M; Wang, Z; Weng, L | 1 |
| Chandiwana, N; Denti, P; Kawuma, AN; Maartens, G; Sinxadi, P; Sokhela, SM; Venter, WDF; Wasmann, RE; Wiesner, L | 1 |
| Allavena, C; Arvieux, C; Becker, A; Cabié, A; Chéret, A; Delpierre, C; Duvivier, C; Hocqueloux, L; Joly, V; Menard, A | 1 |
| Guan, W; Li, T; Li, Y; Lin, Q; Song, X; Xu, Y; Yu, W; Zhang, Y; Zhang, Z | 1 |
| Alves Saldanha, S; Andre, P; Buclin, T; Cavassini, M; Courlet, P; Decosterd, LA; Desfontaine, V; Guidi, M; Kusejko, K; Thoueille, P | 1 |
| Arrieta-Aldea, I; Cañas-Ruano, E; Garcia-Giralt, N; Gonzále-Mena, A; Güerri-Fernández, R; Knobel, H; Rins-Lozano, O; Soldado-Folgado, J | 1 |
| Coltart, H; Dominguez, L; Fitzgerald, N; Flanagan, K; Gilleece, Y | 1 |
| Surial, B; Wandeler, G | 1 |
| Bradford, Y; Chandiwana, N; Cindi, Z; Denti, P; Haas, DW; Kawuma, AN; Maartens, G; Ritchie, MD; Sinxadi, P; Sokhela, S; Venter, WDF; Wasmann, RE; Wiesner, L | 1 |
| Bradford, Y; Chandiwana, NC; Haas, DW; Maartens, G; Mateza, S; Post, FA; Ritchie, MD; Sinxadi, P; Sokhela, S; Venter, WDF | 1 |
| Anderson, PL; Arduino, RC; Bushman, LR; Capuani, S; Chua, CYX; Di Trani, N; Grattoni, A; Hernandez, N; Ittmann, MM; Kezar, S; Nehete, B; Nehete, PN; Nichols, JE; Niles, J; Pons-Faudoa, FP; Shelton, KA; Wood, AM | 1 |
| Avorn, J; Barenie, RE; Kesselheim, AS; Tessema, FA | 1 |
| Chen, F; Hou, Y; Lyu, F; Niu, D; Tang, H; Wang, S; Zhao, D; Zhao, H | 1 |
| Hao, X; Li, B; Li, L; Ni, J; Tian, Z; Wu, L; Xiao, Y; Zhang, W; Zhao, D; Zhao, X | 1 |
| Conway, B; Niyongabo, B; Zaccarelli, M | 1 |
| Anderson, PL; Bushman, LR; Clark, M; Doncel, GF; Fang, X; Hanif, H; Ouattara, LA; Singh, O; Thurman, AR; Yousefieh, N | 1 |
| Batey, DS; Crockett, KB; Turan, B | 1 |
| Amico, KR; Boyce, C; Brummel, S; Cassim, H; Chakhtoura, N; Chinula, L; Coletti, A; Currier, JS; Fairlie, L; Frenkel, LM; Hoffman, R; Jean-Philippe, P; Johnston, B; Knowles, K; Korutaro, V; Krotje, C; Lockman, S; Masheto, G; McCarthy, K; Mmbaga, BT; Moyo, S; Patel, F; Purdue, L; Rooney, JF; Sax, PE; Shapiro, R; Stranix-Chibanda, L; Stringer, J; van Wyk, J; Ziemba, L | 1 |
| Callebaut, C; Cox, S; Margot, N | 1 |
| Chen, X; Kou, L; Li, J; Li, Y; Wei, D; Xie, X | 1 |
| Baltrusaitis, K; Browning, R; Dadabhai, S; Fowler, MG; George, K; Moodley, D; Mukwasi-Kahari, C; Owor, M; Shepherd, J; Siberry, GK; Stranix-Chibanda, L; Theron, G; Tierney, C; Vhembo, T; Violari, A | 1 |
| Han, M; Liu, H; Liu, J; Shan, D; Xue, H; Yu, F; Zan, X; Zhang, D | 1 |
| Bernasconi, E; Burkhalter, F; Calmy, A; Fellay, J; Günthard, HF; Hasse, B; Kahlert, CR; Kouyos, RD; Lamy, O; Ledergerber, B; Marzolini, C; Ryom, L; Schoepf, IC; Schwenke, JM; Tarr, PE; Thorball, CW; Wandeler, G | 1 |
| Caldeira, DB; Camargo, M; de Lima, IB; Dias, D; Diaz, RS; Galinskas, J; Hunter, JR; Nassar, I; Schechter, M; Sucupira, MC | 1 |
| Griesel, R; Hill, AM; Keene, CM; Maartens, G; Meintjes, G; Omar, Z; Simmons, B; Wiesner, L; Zhao, Y | 1 |
| Calanni, L; Cassetti, I; Cecchini, D; Cuini, R; Diana Menendez, S; El Kozah, Y; Greco, MM; Migazzi, C; Morales, F; Morganti, L; Obieta, E; Parenti, P; Rombini, MF | 1 |
| Lima, WDS; Mol, MPG; Pereira, CAJ; Silveira, MR; Souza, CR; Souza-Silva, G | 1 |
| Adebajo, S; Baral, SD; Charurat, ME; Crowell, TA; Kayode, BO; Ndembi, N; Nowak, RG; Ononaku, U; Ramadhani, HO | 1 |
| Daharwal, SJ; Singh, VD; Singh, VK | 1 |
| Eleje, GU; Ikechebelu, JI; Nwagha, UI; Okafor, HU; Ugwu, AO; Ugwu, EO; Umeh, UA | 1 |
| Fang, Z; Gang, X; Guoqiang, Z; Jing, C; Min, W; Ning, W; Wei, T; Xingzhi, W | 1 |
| Chagomerana, MB; DiPrete, BL; Harrington, BJ; Hosseinipour, MC; Jumbe, A; Kumwenda, W; Maliwichi, M; Phulusa, JN; Wallie, S; Wesevich, A | 1 |
| Hachey, D; Shiluama, R; Singu, BS; van Woerden, I | 1 |
| Bamford, A; Burger, DM; Bwakura-Dangarembizi, M; Chabala, C; Colbers, A; Denti, P; Doerholt, K; Gibb, DM; Griffiths, AL; Makumbi, S; McIlleron, HM; Monkiewicz, LN; Mulenga, V; Mumbiro, V; Musiime, V; Nangiya, J; Szubert, AJ; Waalewijn, H; Wasmann, RE; Wiesner, L | 1 |
| Brumme, CJ; DeKoven, S; Naccarato, M; Tan, DHS | 1 |
| Akello, C; Babirye, JA; Biira, F; Celum, C; Etima, J; Gandhi, M; Ggita, J; Heffron, R; Kataike, H; Kizito, S; Kuteesa, CN; Lukyamuzi, Z; Maena, J; Mawanda, D; Menge, R; Mirembe, BG; Mujugira, A; Mukiza, N; Mulumba, E; Nabukeera, J; Nabunya, HK; Nagawa, C; Nakalega, R; Nakanjako, L; Nakaye, C | 1 |
| Kitazawa, T; Wakabayashi, Y; Yoshino, Y | 1 |
| Álvarez-Díaz, AM; Esteban-Cartelle, B; Gramage-Caro, T; Montero-Llorente, B; Parro-Martín, MLÁ; Rodríguez-Sagrado, MÁ; Vélez-Díaz-Pallarés, M | 1 |
| Ambe Chenwi, C; Billong, SC; Bouba, Y; Colizzi, V; Ebiama Lifanda, L; Efakika Gabisa, J; Fainguem, N; Flore Yimga, J; Fokam, J; Hadja, H; Halle, EG; Ka'e, AC; Kamgaing, N; Kembou, E; Kengni Ngueko, AM; Kesseng, D; Ketchaji, A; Mamgue Dzukam, FY; Moudourou, S; Nayang Mundo, RA; Ndiang Tetang, S; Ndjolo, A; Ndombo Koki, P; Ngoufack Jagni Semengue, E; Njom-Nlend, AE; Nka, AD; Nnomo Zam, MK; Pabo, W; Pamen, B; Perno, CF; Saounde Temgoua, E; Simo Kamgaing, R; Sosso, SM; Takou, D; Tangimpundu, C; Tommo Tchouaket, MC; Zoung-Kanyi Bissek, AC | 1 |
| Bhagani, S; Mburu, M; Nkuranga, J; Ombajo, LA; Otieno, D; Penner, J; Pozniak, A; Wahome, S | 1 |
| Abad-Fuentes, A; Abad-Somovilla, A; Anfossi, L; Baggiani, C; Cavalera, S; Chiarello, M; D'Avolio, A; De Nicolò, A; Mercader, JV; Nardo, FD; Serra, T; Testa, V | 1 |
| Gill, S; Kalinoski, T; Mehboob, G; Mpejane, O; Zilwa, N | 1 |
| Liu, Z; Luo, S; Wang, N; Wu, X; Xiong, X; Zhang, H; Zhang, R | 1 |
| Reiss, P; Rijnders, BJA; van der Valk, M; Verburgh, ML; Wit, FWNM | 1 |
| Chaweza, T; Chiwoko, J; de Forest, A; Heller, T; Kasper, P; Mahanani, MR; Neuhann, F; Nhlema, A; Phiri, S; Steffen, HM; Tweya, H; Winkler, V | 1 |
| Avedissian, SN; Fletcher, CV; Mykris, TM; Podany, AT; Scarsi, KK; Weinhold, J; Winchester, LC | 1 |
| Boyd, A; Reiss, P; Van der Valk, M; Verburgh, ML; Wit, FWNM | 1 |
| Barnabas, R; Boily, MC; Dimitrov, DT; Donnell, DJ; Doyle, CM; Hanscom, B; Heitner, J; Maheu-Giroux, M; Milwid, RM; Mitchell, KM; Moore, M; Stansfield, SE; Vijver, DV; Wang, H; Xia, Y | 1 |
| Amole, C; Jenkins, SY; Panos, Z; Resar, D; Ripin, D; Staple, A; Watkins, M | 1 |
| Cohen, CE; Garvey, L; Heskin, J; Leung, S; Naous, N; Oddie, PD | 1 |
| Ishikawa, K; Kawai, F; Mori, N | 1 |
| Burger, D; Chen, RQ; Colbers, A; Geerlings, S; Zino, L | 1 |
| Abbasian, L; Alavian, G; Alinaghi, SAS; Ashtiani, MF; Hasannezhad, M; Khalili, H; Manshadi, SAD | 1 |
| Benfield, T; de Magalhães, JP; Escos, A; Gelpi, M; Høgh, J; Knudsen, AD; Mikaeloff, F; Neogi, U; Nielsen, SD | 1 |
| Daniels, A; Kriegel, D; Seehusen, DA | 1 |
| Gatanaga, H; Mizushima, D; Oka, S | 1 |
| Cardoso, SW; Castro, T; Estrela, R; Grinsztejn, B; Oliveira, VG; Toledo, T; Torres, TS; Veloso, VG | 1 |
| Berni, A; Castagna, A; Cazanave, C; Chounta, V; D'Amico, R; Di Perri, G; Diaz-Brito, V; Dretler, R; Garges, HP; Latham, CL; Oka, S; Osiyemi, O; Pascual Bernáldez, M; Patel, P; Ramgopal, MN; Sims, J; Smith, K; Spreen, WR; Sutherland-Phillips, D; Sutton, K; Van Eygen, V; Van Solingen-Ristea, R; van Wyk, J; Walmsley, S; Zhang, F | 1 |
| Almangour, TA; Chang, PP; Corbett, A; Farel, CE; Rodgers, JE; Skersick, PT | 1 |
| Chang, SY; Chen, GJ; Chuang, YC; Hsieh, SM; Huang, YS; Hung, CC; Lin, KY; Liu, WC; Sheng, WH; Su, YC; Sun, HY | 1 |
| Amano, K; Bingo, M; Chikasawa, Y; Hagiwara, T; Ichiki, A; Kinai, E; Muramatsu, T; Sekiya, R; Yotsumoto, M | 1 |
| Cecka, F; Cerveny, L; Dusek, T; Halodova, V; Huliciak, M; Kocova-Vlckova, H; Lhotska, I; Staud, F; Vokral, I | 1 |
| Ahmed, A; Blazina, I; Bougatsos, C; Chou, R; Selph, S; Spencer, H | 1 |
| Collier, AC; Delle Fratte, R; Eguchi, M; Ho, RJY; Melvin, AJ; Perazzolo, S; Stephen, ZR; Xu, X | 1 |
| Althoff, KN; Cachay, ER; Carbonari, DM; Chew, K; Coburn, SB; Gebo, KA; Gill, MJ; Horberg, MA; Hull, M; Kim, HN; Kim, J; Kirk, GD; Kitahata, MM; Klein, MB; Lang, R; Lim, JK; Lo Re, V; Mayor, AM; McGinnis, KA; Moore, RD; Napravnik, S; Newcomb, CW; Reddy, KR; Seaberg, EC; Silverberg, MJ; Sterling, TR; Torgersen, J | 1 |
| Avlani, D; H N, S; Kumar, A | 1 |
| Chiarabini, T; Devred, I; Kayembe, K; Lacombe, K; Lambert-Niclot, S; Meyohas, MC; Rougier, H; Shinga, BW; Valin, N | 1 |
| Hechter, RC; Mefford, MT; Pak, KJ; Rivera, AS | 1 |
| Ripamonti, D; Zazzi, M | 1 |
| Bansi-Matharu, L; Cambiano, V; Cowan, F; Ehrenkranz, P; Gilks, CF; Godfrey, C; Hargreaves, JR; Lundgren, JD; Phillips, AN; Revill, P; Rodger, A; Shahmanesh, M; Sibanda, E; Sikwese, K; Smith, J | 1 |
| Butler, CC; Dorward, J; Drain, PK; Gandhi, M; Garrett, N; Govender, K; Hayward, G; Lessells, R; Moodley, P; Samsunder, N; Sookrajh, Y; Turner, P | 1 |
| Hsu, SJ; Hung, CT; Liu, CJ | 1 |
| Buteaue, J; Dos Santos, G; Duval, N; Francois, K; Geffrard, H; Giron, A; Inzaule, SC; Jordan, MR; Journel, I; Pierre, E; Sued, O; Van Onacker, JD | 1 |
| Adeyeye, A; Cardozo, N; Cohen, MS; Coutinho, C; Donnell, D; Eshleman, SH; Feliciano, KG; Ford, S; Franks, J; Grinsztejn, B; Hanscom, B; Jalil, E; Jennings, A; Khan, T; Landovitz, RJ; Lucas, J; Maia, B; Marzinke, MA; McCauley, M; Middelkoop, K; Psaros, C; Richardson, PA; Rinehart, AR; Rooney, JF; Safren, SA; Sanchez, N; Singh, Y; Sullivan, P; Valencia, J; Wang, Z | 1 |
| Bruns, C; Chapwanya, G; Chatora, K; Harris, EL; Mawoyo, T; Ncube, G; Nhamo, D; Shelley, KD; Sisimayi, T | 1 |
| Bonvillain, A; Cottrell, M; Davies, M; Degrange, P; Di Mascio, M; Ho, RJY; Jang, H; Kaplan, J; Perazzolo, S; Srinivasula, S; Tobery, A; Turnier, R | 1 |
| Anderson, PL; Bekker, LG; Boily, MC; Celum, CL; Delany-Moretlwe, S; Dimitrov, D; Donnell, DJ; Mgodi, NM; Mitchell, KM; Moore, M; Stansfield, S | 1 |
| Moncayo, JE; Pérez-Arizabaleta, MDM; Rodríguez-Ortiz, A; Villegas-Trujillo, LM | 1 |
| Alagaratnam, J; Ambrosioni, J; Bamford, A; Boesecke, C; Calmy, A; Cinque, P; Guaraldi, G; Koval, A; Levi, L; Martínez, E; Marzolini, C; Mastrangelo, A; Mendao, L; Molina, JM; Oprea, C; Rockstroh, JK; Van Bremen, K; Waalewijn, H; Welch, S; Winston, A | 1 |
| Ait-Khaled, M; Espinosa, N; Fernvik, E; Grove, R; Gulminetti, R; Hagins, D; Man, C; Sierra Madero, J; Sievers, J; Tsai, HC; van Wyk, J; Wynne, B; Zolopa, A | 1 |
| De Clercq, E; Huang, J; Li, G; Zhang, M; Zhang, Z | 1 |
| Ambrosioni, J; Berrocal, L; Blanch, J; Blanco, JL; Borjabad, B; Chivite, I; De La Mora, L; De Lazzari, E; Foncillas, A; Gonzalez-Cordon, A; Inciarte, A; Laguno, M; Llobet, R; Mallolas, J; Martinez, E; Martinez-Rebollar, M; Miro, JM; Rocabert, A; Rodriguez, A; Sempere, A; Solbes, E; Torres, B | 1 |
| Chinula, L; Corbett, AH; Cottrell, ML; Gajer, P; Haddad, LB; Hurst, S; Kourtis, AP; Lantz, AM; Nelson, JAE; Nicol, MR; Ravel, J; Tang, JH; Tegha, G | 1 |
| Cai, W; Gu, F; Guo, P; He, Y; Hu, F; Lan, Y; Li, H; Li, L; Li, Y; Lin, W; Tang, X; Zhong, H | 1 |
| Cao, X; Peng, Y; Wang, M; Wang, Y; Yu, W; Zeng, Z | 1 |
| Adams, AL; Alexeeff, S; Hechter, RC; Horberg, MA; Hu, H; Lam, JO; Lea, A; Leyden, WA; Lo, JC; Marcus, JL; Pak, KJ; Rivera, AS; Silverberg, MJ; Towner, WJ; Yuan, Q; Zhou, H | 1 |
| Chandiwana, P; Duri, K; Gumbo, FZ; Marere, T; Mataramvura, H; Mazengera, LR; Mazhandu, AJ; Munjoma, PT | 1 |
| Carrillo, CM; Cilento, ME; Edwards, K; Kitzler, DR; Kodama, EN; Mitsuya, H; Parniak, MA; Reeve, AB; Sarafianos, SG; Smith, CP; Snyder, AA; Tedbury, PR; Ukah, OB; Wahoski, CC; Wen, X | 1 |
| Martin, VO; Sunguya, BF; Tesha, NA | 1 |
| Akello, CA; Anderson, P; Baeten, JM; Bekker, LG; Brown, ER; Bunge, K; Celum, C; Garcia, M; Hendrix, C; Hillier, SL; Hosek, S; Jacobson, C; Johnson, S; Levy, L; Livant, E; Macdonald, P; McClure, T; Milan, G; Muhlanga, F; Nair, G; Nakabiito, C; Nakalega, R; Ngure, K; Palanee-Phillips, T; Parikh, U; Reddy, K; Rooney, JF; Siziba, B; Soto-Torres, L; Steytler, J; Szydlo, D; Tahuringana, E; van der Straten, A | 1 |
| He, K; Liu, M; Lu, Y; Qi, W; Tan, Q; Yang, H; Zhou, Y | 1 |
| Beghetto, B; Borella, R; Borghi, V; Cossarizza, A; Cozzi-Lepri, A; Cuomo, G; De Biasi, S; Digaetano, M; Fidanza, L; Gibellini, L; Guaraldi, G; Mattioli, M; Menozzi, M; Milic, J; Mussini, C; Nardini, G; Neroni, A; Orlando, G; Paolini, A; Roncaglia, E; Tartaro, DL | 1 |
| Isoda, A; Matsumoto, M; Mihara, M; Sawamura, M | 1 |
| Anuradha, S; Bhrusundi, M; Dravid, AN; Kulkarni, V; Madhukarrao, KM; Morkar, DN; Nageswaramma, S; Naik, KS; Pilawan, AS; Ramapuram, JT; Raveendra, KR | 1 |
| Fuller, B; Killelea, A; McManus, KA; Powers, SD; Rogawski McQuade, ET; Strumpf, A | 1 |
| Allan-Blitz, LT; Mayer, KH | 2 |
| Adeyeye, A; Anderson, PL; Berman, R; Clement, ME; Cohen, MS; Del Rio, C; Donnell, D; Eron, JJ; Eshleman, SH; Fields, SD; Grinsztejn, B; Hanscom, BS; Hendrix, CW; Kallas, EG; Kofron, RM; Landovitz, RJ; Lucas, JP; Magnus, M; Marzinke, MA; McCauley, M; Piwowar-Manning, EM; Richardson, PA; Rinehart, AR; Rooney, JF; Sanchez, J; Scott, H; Spinelli, MA; Sued, O; Sullivan, PA; Tran, HV | 1 |
| Bruxvoort, K; Dourado, I; Grangeiro, A; Greco, D; Magno, L; Pinto, JA; Soares, F | 1 |
| Chaturvedula, A; Haberer, JE; Hendrix, CW; Iannuzzi, S; Irungu, E; von Kleist, M; Zhang, L | 1 |
| Gusmão, MBF; Melo, LC; Oliveira, VV; Santos, NMDS | 1 |
| Gandhi, M; Herbertson, EC; Lahiri, CD; Olugbake, OA; Soremekun, RO; Spinelli, MA | 1 |
| Ackerman, ME; Anderson, PL; Andrew, P; Angier, H; Azzam, Y; Cohen, MS; Corey, L; Donnell, D; Edupuganti, S; Gama, L; Gilbert, PB; Huang, Y; Hural, J; Juraska, M; Karuna, S; Koup, RA; Lemos, MP; McElrath, MJ; Mgodi, NM; Morgan, E; Swann, E; Weiner, JA; Zhang, L | 1 |
| Balkus, JE; Bunge, K; Chakhtoura, N; Chappell, CA; Fairlie, L; Gadama, L; Hillier, SL; Matrimbira, M; Mayo, AJ; Mgodi, N; Nakabiito, C; Piper, J; Richardson, B; Szydlo, DW | 1 |
| Althaus, T; Banchongkit, S; Halue, G; Harrison, L; Jourdain, G; Lallemant, M; Lertkoonalak, R; Liegeon, G; Mary, JY; Nechba, A; Nilmanat, A; Pathipvanich, P; Thongpaen, S; Yutthakasemsunt, N | 1 |
| Chu, Z; Ding, H; Geng, W; Jia, Y; Jiang, Y; Leuba, SI; Mei, Z; Shang, H; Wang, H; Xu, J; Zhang, J; Zhang, Y | 1 |
| Allavena, C; Chauveau, M; Raffi, F | 1 |
| Badshah, C; DeJesus, E; Goldstein, D; Hanna, GJ; Hepler, D; Hwang, C; Johnson, M; Kumar, S; Mallolas, J; Molina, JM; Pozniak, A; Rodgers, A; Sklar, P; Teal, V; Teppler, H; Wong, A | 1 |
| Andreatta, K; Chang, S; Graham, H; Liu, H; Liu, YP; Martin, H; Martin, R; Quirk, E; Wei, L; White, KL; Willkom, M | 1 |
| Bedoya, LM; Cazorla-Luna, R; Martín-Illana, A; Notario-Pérez, F; Peña, J; Ruiz-Caro, R; Veiga, MD | 1 |
| Brown, K; DeJesus, E; Eron, JJ; Girard, PM; Huhn, GD; Lathouwers, E; Luo, D; Molina, JM; Nettles, RE; Orkin, C; Petrovic, R; Van Landuyt, E; Wong, EY | 1 |
| Brown, TT; Landay, A; Masters, MC; Miyahara, S; Robertson, K; Taiwo, BO; Vecchio, A | 1 |
| Shang, H; Tang, W; Xu, J; Zhang, F | 1 |
| Bale, MJ; Boltz, VF; Coffin, JM; Currier, JS; Halvas, EK; Hogg, E; Hughes, MD; Kearney, MF; Lockman, S; Luke, B; McIntyre, JA; Mellors, JW; Sawe, F; Schooley, RT; Shao, W | 1 |
| Amico, KR; Chitwarakorn, A; Curlin, ME; Grant, RM; Holtz, TH; Hughes, JP; Li, M; Mock, PA; Varangrat, A | 1 |
| Bani-Sadr, F; Berger, JL; Brunet, A; Favarel-Garrigues, M; Hentzien, M | 1 |
| Abdool Karim, Q; Baxter, C; Dawood, H; Doncel, GF; Gengiah, TN; Mansoor, LE; Mngadi, KT; Samsunder, N; Schwartz, JL; Yende-Zuma, N | 1 |
| Alejos, B; Arribas, JR; Bernardino, JI; De Miguel, R; Esser, S; Esteban-Cantos, A; Goujard, C; Montejano, R; Raffi, F; Rodes, B; Rodriguez-Centeno, J; Sarmento-Castro, R; Schwimmer, C; Stella-Ascariz, N; Wallet, C | 1 |
| Coelho, LE; Grinsztejn, B; Landovitz, RJ; Torres, TS; Veloso, VG | 1 |
| Burgi, A; Letendre, SL; Little, SJ; Ma, Q; Morse, GD; Ocque, AJ; Sanders, C | 1 |
| Bai, F; Bandera, A; Bernasconi, DP; Bonora, S; Castelli, F; Di Biagio, A; Focà, E; Gori, A; Lapadula, G; Migliorino, GM; Monforte, AD; Squillace, N | 1 |
| Dunn, DT; Geng, EH; Glidden, DV; Mehrotra, ML | 1 |
| Gao, S; Gui, X; Ke, H; Xiong, Y; Yang, R | 1 |
| Castagna, A; Gianotti, N | 1 |
| Das, M; Haubrich, R; Maggiolo, F; Mateo-Garcia, MG; McNicholl, I; Molina, JM; Ong, E; Piontkowsky, D; Pulido, F; Raffi, F; Rizzardini, G; Shao, Y | 1 |
| Cherry, CL; Kamerman, PR; Karstaedt, AS; Pillay, P; Wadley, AL | 1 |
| Bernasconi, E; Calmy, A; Cavassini, M; Fehr, J; Furrer, H; Fux, CA; Kovari, H; Rauch, A; Roth, B; Stöckle, M; Surial, B; Wandeler, G | 1 |
| Briano, F; Comi, L; Di Biagio, A; Di Filippo, E; Giacomini, M; Gori, A; Maggiolo, F; Mora, S; Riccardi, N; Taramasso, L | 1 |
| Brainard, DM; Brown, TT; Carter, CC; Das, M; Erlandson, KM; Esser, S; Koethe, JR; Lake, JE; Mccomsey, GA; Melbourne, K; Orkin, C; Post, FA; Rockstroh, JK; Sax, PE; Stellbrink, HJ; Waters, L; Wei, X; Zhong, L | 1 |
| Acosta, RK; Avihingsanon, A; Cao, H; Chetchotisakd, P; DeJesus, E; Gankina, N; Hagins, D; Kityo, C; Koenig, E; Makadzange, T; Martin, H; Pokrovsky, V; Quirk, E; Stephens, JL; Supparatpinyo, K; Voronin, E; Wang, H | 1 |
| Adamson, L; Akkina, R; Blake, K; Burgunder, EM; Devanathan, AS; Garcia, JV; Kashuba, ADM; Kovarova, M; Luciw, P; Pirone, JR; Remling-Mulder, L; Rosen, EP; Schauer, AP; Srinivas, N; Sykes, C; White, NR | 1 |
| Hollenbeck, BL; Kishore, S; Lee, MSL; Padival, S | 1 |
| Bhattacharya, D; Chihota, BV; Chilengi, R; Chung, RT; Egger, M; Mulenga, L; Vinikoor, MJ; Wandeler, G | 1 |
| Avataneo, V; Bonora, S; Calcagno, A; Cusato, J; Di Perri, G; DʹAvolio, A; Marinaro, L | 1 |
| Borghi, V; Di Giambenedetto, S; Francisci, D; Franzetti, M; Giacomelli, A; Lai, A; Lepore, L; Lombardi, F; Maggiolo, F; Magnani, G; Monno, L; Paolucci, S; Pecorari, M; Rusconi, S; Vicenti, I | 1 |
| Bacchetti, P; Baeten, JM; Cressey, TR; Drain, PK; Gandhi, M; Glidden, DV; King, R; Klinbuayaem, V; Mugo, NR; Ngure, K; Okochi, H; Rodrigues, WC; Siriprakaisil, O; Spinelli, MA; Vincent, M; Wang, G | 1 |
| Batey, DS; Beyrer, C; Cummings, V; Del Rio, C; Eshleman, SH; Farley, JE; Fernandez, RE; Fogel, JM; Gamble, T; Hart, S; Hughes, JP; Laeyendecker, O; Mayer, KH; McKinstry, L; Remien, RH; Sivay, MV; Wilson, EA | 1 |
| Saag, MS | 2 |
| Bührer, C; Feiterna-Sperling, C; Henrich, W; Krüger, R; Rancourt, RC; Seidel, V; Weizsäcker, K | 1 |
| Goldstein, RH; Walensky, RP | 1 |
| Bailey, AC; Barbini, B; Burling, K; Campbell, L; Hamzah, L; Ibrahim, F; Jones, R; Musso, CG; Post, FA; Williams, D | 1 |
| Aung, W; Bakshi, R; Breakey, J; Brown, T; Bumpus, NN; Fuchs, EJ; Hamlin, A; Hendrix, CW; Marzinke, MA; Poteat, T; Shieh, E | 1 |
| Bela, B; Ibrahim, F; Kusumaningrum, A; Yunihastuti, E | 1 |
| Huang, YS; Hung, CC; Ko, WC; Lee, YC; Lee, YT; Li, CW; Lin, JJ; Lin, KY; Lin, SP; Liu, CE; Tang, HJ; Wang, NC; Yang, HJ | 1 |
| Koenig, HC; Lalley-Chareczko, L; Moorthy, GS; Zuppa, AF | 1 |
| Hideta, K; Higasa, S; Hikasa, S; Kimura, T; Nishida, S; Sawada, A; Shimabukuro, S; Tanaka, K; Tokugawa, T; Yanai, M | 1 |
| Chadwick, EG; Correia, KF; Crowell, CS; DiPerna, A; Hazra, R; Seage, GR; Smith, R; Van Dyke, RB; Williams, PL; Yildirim, C | 1 |
| Cottrell, M; Dellon, ES; Gonzalez, D; Kashuba, ADM; Madanick, RD; Maffuid, K; Nelson, JAE; Prince, HA; Shaheen, NJ; Srinivas, N; Sykes, C; White, N | 1 |
| Desta, Z; Gufford, BT; Liu, SN | 1 |
| Kerkemeyer, KLS; Lai, FYX; Mar, A | 1 |
| Boffito, M; Bonora, S; Cursley, A; D'Avolio, A; Di Perri, G; Dickinson, L; Fäetkenheuer, G; Gurjar, R; Molina, JM; Owen, A; Pozniak, A; Raffi, F; Richert, L; Stöhr, W; Vandekerckhove, L | 1 |
| Balakasi, K; Bardon, AR; Dovel, K; Fox, M; Haambokoma, M; Hoffman, RM; Hubbard, J; Kakwesa, G; Kalua, T; Moyo, C; Pisa, P; Rosen, S; Sanne, I; Siwale, Z; Xulu, T | 1 |
| Anekvorapong, R; Cherdtrakulkiat, T; Choopanya, K; Council, OD; Curlin, ME; García-Lerma, JG; Heneine, W; Khalil, G; Leelawiwat, W; Martin, A; Martin, M; McNicholl, JM; Mock, PA; Ruone, S; Vanichseni, S | 1 |
| Arenas-Pinto, A; Berger, F; Mauss, S; Milinkovic, A | 1 |
| Chi, BH; Fairlie, L; Farhad, M; Fenton, T; Fowler, MG; Moodley, D; Naik, S; Nakabiito, C; Stringer, JSA; Venkatesh, KK | 1 |
| Harrigan, PR; Lapointe, HR | 1 |
| Fulco, PP; Gomes, D; Leibrand Kaczmar, CR; Smith, T | 1 |
| Datir, R; Derache, A; Gregson, J; Gupta, RK; Perno, CF; Pillay, D; Rhee, SY; Shafer, RS | 1 |
| Parienti, JJ | 4 |
| Antoni, G; Capitant, C; Charreau, I; Chas, J; Cotte, L; Cua, E; Delaugerre, C; Huleux, T; Meyer, L; Molina, JM; Raffi, F; Rojas Castro, D; Spire, B; Tremblay, C | 1 |
| Ascher, SB; Defechereux, P; Estrella, MM; Gandhi, M; Glidden, DV; Grant, RM; Jotwani, V; Mehrotra, ML; Scherzer, R; Shigenaga, J; Shlipak, MG; Spaulding, KA | 1 |
| Jewsbury, S; Ward, C | 1 |
| Ajana, F; Bani-Sadr, F; Bouvet, E; Cotte, L; Galempoix, JM; Gantner, P; Hessamfar, M; Hustache-Mathieu, L; Lebrette, MG; Muret, P; Pellissier, G; Piroth, L; Rey, D; Rouveix, E; Simon, A; Souala, MF; Truchetet, F; Valin, N | 1 |
| Drak, D; Gracey, DM; O'Connor, CC; Templeton, DJ; Turner, D | 1 |
| Blennow, K; Das, M; Gisslen, M; Hermansson, L; Makadzange, T; McCallister, S; Nilsson, S; Price, RW; Yilmaz, A; Zetterberg, H | 1 |
| Eron, JJ; Esser, S; Hufkens, V; Jezorwski, J; Lathouwers, E; Opsomer, M; Orkin, C; Podzamczer, D; Rockstroh, J; Van Landuyt, E; Vandekerckhove, L | 1 |
| Bhatia, R; Rizza, S; Temesgen, Z; Zeuli, J | 1 |
| Di Perri, G | 2 |
| Slogrove, AL | 1 |
| Di Perri, G; Shafran, SD | 1 |
| Fischer, A; Gumede, SB; Lalla-Edward, ST; Venter, WDF | 1 |
| Cain, CM; Dobek, G; Grasperge, B; Hope, T; Karunakaran, D; Kiser, PF; Marzinke, M; Pearson, E; Peet, MM; Qiu, J; Simpson, SM; Su, JT; Sung, S; Tfaily, EB; Veazey, R; Watrous, D; Widanapathirana, L | 1 |
| Baeten, JM; Dettinger, JC; John-Stewart, G; Kinuthia, J; Pintye, J | 1 |
| Benson, C; Bolan, R; Crofoot, G; Dunn, K; Gathe, J; Huhn, GD; Luo, D; Nettles, RE; Ramgopal, M; Simonson, RB | 1 |
| Nabih, MF; Nur, AM; Puteh, SEW | 1 |
| Jaeger, H; Jonsson-Oldenbuettel, C; Noe, S | 1 |
| Baker, D; Bloch, M; Carr, M; Hoy, JF; Richardson, R; Tong, W | 1 |
| Aboud, M; Ait-Khaled, M; Ajana, F; Bisshop, F; De Wit, S; Gartland, MJ; Nascimento, MC; Osiyemi, O; Pappa, KA; Portilla Sogorb, J; Routy, JP; Smith, KY; Tenorio, AR; van Wyk, J; Wang, R; Wright, J; Wyen, C; Wynne, B | 1 |
| Aldrovandi, G; Baeten, JM; Baggaley, R; Bekker, LG; Celum, C; Chi, BH; Coates, TJ; Haberer, JE; Heffron, R; John-Stewart, G; Joseph Davey, DL; Kinuthia, J; Matthews, LT; McIntyre, J; Mofenson, LM; Moodley, D; Mugo, N; Mujugira, A; Myer, L; Pintye, J; Shoptaw, S; Stranix-Chibanda, L | 1 |
| Asboe, D; Dunn, DT; Gilson, R; Hill, T; Mackie, NE; Pozniak, A; Sabin, CA; Stirrup, OT; Tostevin, A | 1 |
| Aizire, J; Brooks, KM; Butler, K; Cababasay, M; Fenton, T; Flynn, PM; Fowler, MG; Kiser, JJ; Mirochnick, M; Siberry, GK | 1 |
| Daskalakis, DC; Feinberg, J; Krakower, DS; Marcus, JL | 2 |
| Bedoya, LM; Cazorla-Luna, R; Martín-Illana, A; Notario-Pérez, F; Rubio, J; Ruiz-Caro, R; Tamayo, A; Veiga, MD | 3 |
| Foresto, RD; Kirsztajn, GM; Reghine, ÉL | 1 |
| Arpadi, SM; Shiau, S; Yin, MT | 1 |
| Li, A; Li, C; Li, H; Li, W; Li, X; Xia, W | 1 |
| Boyd, A; Chas, J; Delaugerre, C; Dezanet, LNC; Gabassi, A; Girard, PM; Lacombe, K; Lascoux-Combe, C; Maylin, S; Miailhes, P; Rougier, H | 1 |
| Saberi, P; Scott, HM | 1 |
| Lodi, VJC; Monteiro, JCMS; Pires, CAA; Rego, RM | 1 |
| Aschenbrenner, DS | 1 |
| Aboud, M; Baril, JG; Bogner, J; Eron, J; Falcó, V; Gartland, M; Hung, CC; Koteff, J; Maggiolo, F; Man, CY; Mills, A; Pappa, KA; Sievers, J; Slim, J; Smith, KY; Tenorio, AR; Underwood, M; Urbaityte, R; Wynne, B | 1 |
| Bajpai, P; Jain, A; Maheshwari, PK | 1 |
| Álvarez, M; Chueca, N; Collado, A; de Salazar, A; Fernández, JM; Fernández-Fuertes, E; García, F; Lozano, AB | 1 |
| Adoua Doukaga, T; Axel Aloumba, G; Bienvenue Ossibi Ibara, R; Boumandoki, P; Diafouka, M; Herbas Ekat, M; Mahambou-Nsonde, D; Obengui, P; Roger Nzounza, P; Seydi, M; Tidiane Ndour, C | 1 |
| Chen, Y; Lu, Y; Tao, X; Zhang, L; Zhou, Y | 1 |
| Applin, S; Asmuth, DM; Cox, S; Das, M; Goldstein, D; Guyer, B; Haubrich, RH; Hinestrosa, F; Huhn, GD; Jain, MK; Jiang, S; Nguyen-Cleary, T; Piontkowsky, D; Ramgopal, M; Rossaro, L; Ryu, JH; Slim, J | 1 |
| Begum, I; Nandakrishna, B; Rajesh, R; Salimi, R; Varma, DM; Vidyasagar, S | 1 |
| Ainembabazi, P; Ayitewala, A; Kato, CD; Kyeyune, F; Nabulime, E; Nankya, I | 1 |
| Bailey, AC; Mackie, N; Muir, D; Ring, K | 1 |
| Lazzarin, A; Llibre, JM; Stellbrink, HJ; Woolley, I | 1 |
| Caldwell, A; Cuppone, AM; Dereuddre-Bosquet, N; Desjardins, D; Frank, B; Grand, RL; Gwozdz, G; Hijazi, K; Iannelli, F; Kelly, C; Mukhopadya, I; Pozzi, G; Santoro, F; Scala, C; Smith, KA | 1 |
| Howe, Z; Huesgen, E; Moore, SE | 1 |
| Badowski, ME; Biagi, MJ; Chiampas, TD; Michienzi, SM; Patel, MC; Schriever, CA; Young, JD | 1 |
| An, M; Ding, H; Han, X; Li, S; Ouyang, J; Wang, L; Zhang, M; Zhao, B | 1 |
| Chadwick, D; Moss, D; Neary, M; Olagunju, A; Owen, A; Phillips, R; Sarfo, F | 1 |
| DiBenedetto, A; Fackler, P; Fan, L; Iwamoto, M; Khalilieh, S; Stoch, SA; Triantafyllou, I; Vallee, MH; Yee, KL | 1 |
| Amoura, NJ; Bares, SH; Cirrincione, LR; Dyavar, SR; Fletcher, CV; Gwon, Y; Havens, JP; Johnson, TM; Podany, AT; Scarsi, KK | 1 |
| Boesecke, C; Piduhn, H; Rockstroh, JK; Schlabe, S; Schwarze-Zander, C; Stoffel-Wagner, B; Strassburg, CP; Wasmuth, JC | 1 |
| Alejandria, M; Arcangel, L; Arevalo, GM; Ching, PR; Destura, R; Dungca, NT; Leyritana, K; Lim, J; Mendoza, KAR; Palaypayon, NS; Peñalosa-Ramos, C; Salvana, EMT; Samonte, GMJ; Schwem, BE; Solante, R; Tactacan-Abrenica, RJ; Telan, E; Tonga, AD; Trinidad, LF | 1 |
| Atukunda, M; Ayieko, J; Balzer, LB; Black, D; Brown, LB; Bukusi, EA; Camlin, CS; Chamie, G; Charlebois, ED; Clark, TD; Cohen, CR; Gandhi, M; Havlir, DV; Jain, V; Kabami, J; Kamya, MR; Koss, CA; Kwarisiima, D; Marquez, C; Mwangwa, F; Mwinike, Y; Olilo, W; Owaraganise, A; Peng, J; Petersen, ML; Rooney, JF; Ruel, TD; Sang, N; Zhang, K | 1 |
| Abuna, F; Anderson, PL; Baeten, JM; Dettinger, JC; John-Stewart, G; Kinuthia, J; Lagat, H; Mugwanya, K; Odinga, D; Pintye, J; Sila, J | 1 |
| Li, X; Qiao, S; Shen, Z; Zhang, Q; Zhou, Y | 1 |
| Brooks, KM; Dooley, KE; Eke, AC; Gebreyohannes, RD; Mirochnick, M; Sheffield, JS | 1 |
| Freedberg, KA; Horn, T; McCann, NC; Paltiel, AD; Walensky, RP | 2 |
| Armstrong, WS; Del Rio, C | 1 |
| Baeten, JM; Defechereux, P; Deutsch, M; Gandhi, M; Glidden, DV; Grant, RM; Mugo, NR; Ngure, K; Okochi, H; Rodrigues, WC; Spinelli, MA; Stalter, R; Vincent, M; Wang, G | 1 |
| Ahamed, J; Choi, ME; Elhadad, S; Fung, KM; Gostynska, S; Laurence, J; Terry, H; Varshney, R; Yu, Z | 1 |
| Anderson, PL; Chan, DPC; Kwan, TH; Lam, TTN; Lee, KCK; Lee, SS; Lui, GCY; Wong, NS | 1 |
| Bernasconi, E; Calmy, A; Cavassini, M; Furrer, H; Fux, CA; Günthard, HF; Kovari, H; Ledergerber, B; Rauch, A; Schmid, P; Stöckle, M; Surial, B; Wandeler, G | 1 |
| Ajibola, G; Batlang, O; Bennett, K; Davey, S; Diseko, M; Hughes, MD; Isaacson, A; Kuritzkes, DR; Lichterfeld, M; Lockman, S; Makhema, J; Maswabi, K; Moyo, S; Sakoi, M; Shapiro, R; Zash, R | 1 |
| Fulco, PP | 1 |
| Cantor, R; Clark, D; DiFlavis, L; Koenig, HC; Lalley-Chareczko, L; Nahan, RA; Ramos, MT; Troutman, GS; Young, LB | 1 |
| Baeten, JM; Begnel, ER; Beima-Sofie, K; Dettinger, JC; Escudero, J; John-Stewart, G; Kinuthia, J; Mugambi, M; Mugwanya, K; Pintye, J | 1 |
| Apornpong, T; Avihingsanon, A; Buranasupkajorn, P; Chaiwatanarat, T; Han, WM; Jadwattanakul, T; Jantrapakde, J; Kerr, SJ; Phanuphak, N; Phanuphak, P; Ramautarsing, R; Ruxrungtham, K; Sunthornyothin, S; Teeratakulpisarn, N; Wattanachanya, L | 1 |
| Anderson, PL; Bushman, LR; Castillo-Mancilla, JR; Coleman, SS; Coyle, RP; Ellison, L; Gardner, EM; Kiser, JJ; MaWhinney, S; Morrow, M; Zheng, JH | 3 |
| Adam, A; Buhk, T; Fenske, S; Hansen, S; Hoffmann, C; Sabranski, M; Schewe, K; Stellbrink, HJ | 1 |
| Chen, J; Chen, R; Hu, Z; Huang, Q; Liu, L; Lu, H; Qi, T; Shen, Y; Song, W; Sun, J; Tang, Y; Wang, J; Wang, X; Wang, Z; Wei, H; Xie, R; Zhang, R | 1 |
| Berruti, M; Briano, F; Di Biagio, A; Taramasso, L | 1 |
| Baeten, J; Celum, C | 2 |
| Chan, PA; Crowley, C; Galárraga, O; Marak, T; Napoleon, S; Nocka, K; Raifman, J; Tao, J; Wilson, IB | 1 |
| Azmi, M; Baber, ZU; Badlani, S; Dodani, SK; Nasim, A; Sheerani, M | 1 |
| Barco, EA; Cotter, AG; Feeney, E; Lacey, A; Lambert, JS; Macken, A; Mallon, PW; Muldoon, E; Savinelli, S; Sheehan, G; Tinago, W | 1 |
| Abrams, EJ; Bartilol, K; Batuka, J; Gitonga, M; Imbuki, E; Kimani, M; Lahuerta, M; Odhiambo, J; Odhiambo, S; Sugandhi, N; Syowai, M; Vakil, S; Wamicwe, J | 1 |
| Bouazza, N; Bregigeon, S; Descamps, D; Dhiver, C; Gattacceca, F; Lacarelle, B; Lê, MP; Mokhtari, S; Néant, N; Peytavin, G; Solas, C; Tamalet, C; Yazdanpanah, Y | 1 |
| Abboussi, O; Daniels, WMU; Mabandla, MV; Simola, N; Zulu, SS | 1 |
| Baker, J; Rolls, J | 1 |
| Anderson, J; Baker, JV; Fletcher, CV; Jorstad, S; Mykris, T; Podany, AT; Schacker, TW; Thorkelson, A; Winchester, LC | 1 |
| He, J; Ma, R; Sun, S; Xu, B; Zhang, Q; Zhang, Y; Zhao, CS | 1 |
| Agwu, AL; Arrington-Sanders, R; Fields, E; Griffith, D; Yusuf, H | 1 |
| Bardon, A; Drain, PK; Fernandez Suarez, M; Marshall, L; Sandlin, RD; Sevenler, D; Toner, M | 1 |
| Bickel, M; Gillor, D; Grunwald, S; Härter, G; Hoffmann, C; Krznaric, I; Mueller, MC; Müller, M; Postel, N; Roider, J; Römer, K; Schabaz, F; Schewe, K; Spinner, CD | 1 |
| Anderson, PL; Castillo-Mancilla, J; Chai, PR; Gandhi, M; Haberer, JE; Spinelli, MA | 1 |
| de Leuw, P; Haberl, A; Herrmann, E; Höfler, S; Kann, G; Königs, C; Schüttfort, G; Stephan, C | 1 |
| El Kamari, V; Hileman, CO; Kosco, J; Mccomsey, GA | 1 |
| Atencio, P; Cabello, A; Conesa-Buendía, FM; Górgolas, M; Herrero-Beaumont, G; Largo, R; Llamas-Granda, P; Mediero, A | 1 |
| Danziger, J; Morales, A | 1 |
| Bermejo-Vicedo, T; Gramage-Caro, T; Montero-Llorente, B; Rodríguez-Sagrado, MÁ; Vélez-Díaz-Pallarés, M | 1 |
| Casado, JL; Dronda, F; Moreno, A; Pérez-Elías, MJ; Quereda, C; Vivancos, MJ; Vizcarra, P | 1 |
| André-Garnier, E; Charpentier, C; Ferré, V; Hingrat, QL; Leducq, V; Malet, I; Marcelin, AG; Peytavin, G; Raffi, F; Reliquet, V; Rodallec, A | 1 |
| Affolabi, D; Alary, M; Bachabi, M; Béhanzin, L; Diabaté, S; Gangbo, F; Geraldo, N; Giguère, K; Guédou, F; Hendrix, C; Kêkê, RK; Marzinke, MA; Mboup, A; Zannou, DM | 1 |
| Killelea, A; McManus, KA; Powers, S; Rogawski McQuade, E; Tello-Trillo, S | 1 |
| Alagaratnam, J; Boffito, M; Bozzali, M; Cercignani, M; Mora-Peris, B; Nelson, M; Toniolo, S; Underwood, J; Vera, JH; Winston, A | 1 |
| Coleman, H; Douthwaite, ST; Lee, MJ; Simons, R; Snell, LB | 1 |
| Hill, A; Venter, WDF | 1 |
| Acosta, R; Arribas, JR; Brainard, DM; Brinson, C; Clarke, A; Collins, SE; DeJesus, E; Flamm, JA; Gupta, SK; Hagins, D; Huang, H; Maggiolo, F; Martin, H; Martorell, C; Orkin, C; Podzamczer, D; Sax, PE; Stellbrink, HJ; Stephens, JL; Thompson, MA; Wohl, D | 1 |
| Anderson, KS; Blanco, L; Cosme, M; Duong, VN; He, L; Martínez-Jiménez, MI; Paintsil, E; Zhou, L | 1 |
| Panagopoulos, P; Papachristou, S; Papanas, N; Papazoglou, D; Petrakis, V; Terzi, I; Trypsianis, G | 1 |
| Anderson, PL; Brooks, KM; Bushman, LR; Castillo-Mancilla, J; Ibrahim, ME; Kiser, JJ; MaWhinney, S; McCallister, S; McHugh, C; Morrow, M; Yager, J | 1 |
| Gwenden, KN; Marzinke, MA; Parsons, TL | 1 |
| Amponsah-Dacosta, E; Blackard, JT; Burnett, RJ; Gededzha, MP; Kyaw, T; Lukhwareni, A; Mphahlele, MJ; Selabe, SG | 1 |
| Baeten, JM; Cressey, R; Cressey, TR; Drain, PK; Gandhi, M; Klinbuayaem, V; Kubiak, RW; Okochi, H; Quame-Amaglo, J; Siriprakaisil, O; Sukrakanchana, PO; Tawon, Y | 1 |
| Bogner, JR; Hilge, R; Schrader, SY; Seybold, U; Zeder, AJ | 1 |
| Allavena, C; Bregigeon, S; Cabie, A; Cotte, L; Duvivier, C; Gantner, P; Makinson, A; Ravaux, I; Rey, D; Reynes, J | 1 |
| Chen, H; Hu, XL; Huang, XS; Luo, RH; Shen, XN; Tang, CR; Xiang, SY; Zhang, CT; Zheng, YT | 1 |
| Achilles, SL; Chen, BA; Hendrix, CW; Marzinke, MA; Meyn, LA; Tarleton, J | 1 |
| Byakika-Kibwika, P; Kalyesubula, R; Nyende, L; Sekasanvu, E | 1 |
| Byamugisha, J; Fowler, MG; Goldberg, GR; Hamill, MM; Kekitiinwa, A; Nabwire, F; Prentice, A | 1 |
| Amin, J; Boyd, MA; Center, JR; Kelleher, A; Mwasakifwa, GE; White, CP | 1 |
| Arribas, JR; Del Amo, J; Díaz, A; Hernán, MA; Jarrín, I; Martínez, E; Moreno, S; Polo, R | 1 |
| Adachi, E; Hoshina, T; Ikeuchi, K; Saito, M; Yotsuyanagi, H | 1 |
| Goffard, JC; Henrard, S; Noure, L; Simeni Njonnou, SR | 1 |
| Gandhi, M; Huo, Y; Kacanek, D; Kuncze, K; Okochi, H; Pintye, J; Zhang, K | 2 |
| Anderson, P; Bardon, AR; Celum, C; Cressey, TR; Drain, PK; Gandhi, M; Olanrewaju, AO; Sevenler, D; Simoni, JM | 1 |
| Brainard, D; McCallister, S | 1 |
| Adimora, AA; Anastos, K; Bay, CP; Davalos, A; De Paris, K; Dumond, JB; Edmonds, A; Fischl, MA; French, AL; Gange, S; Kassaye, S; Nelson, JAE; Ofotokun, I; Sharma, R; Sykes, C; Tamraz, B; Vance, DE | 1 |
| Bwakura-Dangarembizi, MF; Maponga, CC; Mashingaidze-Mano, R; Monera-Penduka, TG; Morse, GD; Mtisi, TJ; Mudzviti, T; Mujuru, HA | 1 |
| Anderson, SA; Busch, MP; Custer, B; Glick, S; Glynn, SA; Haaland, R; Kessler, D; Martin, A; McFarland, W; Melton, CD; Quiner, C; Raymond, HF; Reik, R; Robinson, WT; Sey, K; Steele, WR; Stone, M; Stramer, SL; Williams, AE; Williamson, PC | 1 |
| Aberg, JA; Cardoso, SW; de Lacerda, MVG; Douglas, PS; Fitch, KV; Grinspoon, SK; Kantor, A; McComsey, G; Mohapi, L; Mosepele, M; Muntner, P; Overton, ET; Patil, S; Ribaudo, H; Supparatpinyo, K; Wyatt, CM | 1 |
| Acosta, R; Brainard, DM; Collins, SE; Liu, H; Luetkemeyer, AF; Martin, H; Rieger, A; Rockstroh, JK; Sax, PE; Trottier, B; Ward, D; Yazdanpanah, Y | 1 |
| Chang, SY; Chen, YT; Chen, YW; Huang, CK; Huang, SH; Huang, WC; Hung, CC; Lin, SW; Liu, WC; Ou, ST; Sun, HY | 1 |
| Alonso-Castro, AJ; Alvarez-Alvarez, RM; Del Carmen Preciado-Puga, M; Del Rocio Ibarra-Reynoso, L; Lazo-de-la-Vega-Monroy, ML; Ruiz-Noa, Y; Ruiz-Padilla, AJ; Sánchez-Barajas, M | 1 |
| Anderson, PL; Defechereux, P; Gandhi, M; Grant, RM; Jee, K; Johannessen, D; Kearney, MF; Kuncze, K; Lowery, B; McDonald, C; McFarlane, JR; Okochi, H; Phung, N; Shuford, JA; Smith, DK; Spindler, J; Spinelli, MA | 1 |
| Bremner, S; Bruce, C; Churchill, D; Geretti, AM; Iwuji, CC; Lambert, D; Orkin, C; Perry, N; To, Y; Waters, L | 1 |
| Amador, C; de Zárraga, MA; Díez Martínez, M; Górgolas, M; Jarrín, I; Moreno, C; Navarro, M; Pérez-Elías, MJ; Pérez-Martínez, L; Ruiz-Algueró, M; Suárez-García, I; Viciana, P | 1 |
| Audsley, J; Avihingsanon, A; Bowden, S; Fairley, CK; Lewin, SR; Littlejohn, M; Matthews, GV; Sasadeusz, J | 1 |
| Cattaneo, D; Filice, C; Gervasoni, C; Riva, A | 1 |
| Aghokeng, AF; Asio, J; Avila-Rios, S; Bertagnolio, S; Billong, S; Cham, F; Cournil, A; Dat, VQ; Diop-Ndiaye, H; Doherty, M; Girón-Callejas, A; Inzaule, SC; Jordan, MR; Mulenga, L; Nhan, DT; Niasse-Traore, F; Ssemwanga, D | 1 |
| Ancona, G; Baldelli, S; Bossolasco, S; Cattaneo, D; Cernuschi, M; De Bona, A; Fusi, M; Gervasoni, C; Rossotti, R; Suardi, E; Vinti, P; Zagato, D | 2 |
| Foreman, RM; Zappas, MP | 1 |
| Acosta, RK; Andreatta, K; Collins, S; Liu, H; Martin, H; Martin, R; Parvangada, A; White, KL; Willkom, M | 1 |
| Cong, ME; Dinh, C; García-Lerma, JG; Haaland, R; Heneine, W; Holder, A; Johnson, R; Kelley, CF; Kelley, K; Khalil, G; Massud, I; Mills, P; Pan, Y; Ruone, S; Sanchez, T; Zlotorzynska, M | 1 |
| Bao, R; Chen, Y; Chu, Z; Ding, H; Geng, W; He, X; Hu, Q; Hu, Z; Huang, X; Jiang, Y; Jin, X; Li, H; Li, S; Lv, W; Shang, H; Wang, H; Xu, J; Zhang, J; Zhang, L | 1 |
| Spiegel, HML | 1 |
| Anderson, PL; Brainard, DM; Brinson, C; Callebaut, C; Clarke, A; Coll, P; Collins, SE; Das, M; De Wet, JJ; DeJesus, E; Ebrahimi, R; Grant, RM; Hare, CB; Jessen, H; Mathias, A; Mayer, KH; McCallister, S; Molina, JM; Mounzer, KC; Post, FA; Ruane, PJ; Thompson, MA; Wong, P; Zhong, L | 1 |
| D'Angelo, AB; Daskalakis, DC; Grov, C; Johnson, J; Nash, D; Westmoreland, DA | 1 |
| Abdool Karim, Q; Abdool Karim, SS; Archary, D; Baxter, C; Chung, AW; Fisher, KL; Mabuka, JM; Ndlovu, B; Ngcapu, S; Osman, F; Passmore, JS; Sivro, A | 1 |
| Cai, WP; Deng, XZ; Hu, FY; Lan, Y; Li, F; Li, LH; Nie, Y | 1 |
| Chang, SF; Chang, SY; Chen, GJ; Cheng, CY; Chuang, YC; Hsieh, MH; Huang, SH; Hung, CC; Lee, CH; Lee, YC; Lee, YL; Su, LS; Sun, HY; Tang, HJ; Tsai, HC | 1 |
| Alhassan, Y; Kambugu, A; Khoo, S; Lamorde, M; Malaba, T; Myer, L; Orrell, C; Reynolds, H; Taegtmeyer, M; Twimukye, A; Waitt, C | 1 |
| Baum, MM; Bobardt, M; Gallay, PA; Gunawardana, M; Moss, JA; Ramirez, CM | 1 |
| Bardon, AR; Drain, PK; Layman, LM; Simoni, JM; Stekler, JD | 1 |
| Anderson, PL; Blum, J; Brooks, KM; Bushman, LR; Castillo-Mancilla, JR; Cendali, F; Choi, YJ; Gomez, J; Haas, H; Ibrahim, ME; Johnson, B; Kiser, JJ; MaWhinney, S; Morrow, M; Roon, L; Rowan, SE; Wyles, DL; Zheng, JH | 1 |
| Adams-Huet, B; Bedimo, RJ; Maalouf, NM; Moore-Matthews, D; Nguyen, V; Poindexter, J | 1 |
| Bloch, M; Gracey, DM; Heron, JE; Saunders, J; Vanguru, V | 1 |
| Ahouada, C; Alary, M; Batona, G; Béhanzin, L; Diabaté, S; Gning, NN; Guédou, FA; Hessou, S; Mondor, M; Zannou, DM | 1 |
| Abbasi, S; Abd El-Wahab, A; Abdallah, M; Abebe, G; Aca-Aca, G; Adama, S; Adefegha, SA; Adidigue-Ndiome, R; Adiseshaiah, P; Adrario, E; Aghajanian, C; Agnese, W; Ahmad, A; Ahmad, I; Ahmed, MFE; Akcay, OF; Akinmoladun, AC; Akutagawa, T; Alakavuklar, MA; Álava-Rabasa, S; Albaladejo-Florín, MJ; Alexandra, AJE; Alfawares, R; Alferiev, IS; Alghamdi, HS; Ali, I; Allard, B; Allen, JD; Almada, E; Alobaid, A; Alonso, GL; Alqahtani, YS; Alqarawi, W; Alsaleh, H; Alyami, BA; Amaral, BPD; Amaro, JT; Amin, SAW; Amodio, E; Amoo, ZA; Andia Biraro, I; Angiolella, L; Anheyer, D; Anlay, DZ; Annex, BH; Antonio-Aguirre, B; Apple, S; Arbuznikov, AV; Arinsoy, T; Armstrong, DK; Ash, S; Aslam, M; Asrie, F; Astur, DC; Atzrodt, J; Au, DW; Aucoin, M; Auerbach, EJ; Azarian, S; Ba, D; Bai, Z; Baisch, PRM; Balkissou, AD; Baltzopoulos, V; Banaszewski, M; Banerjee, S; Bao, Y; Baradwan, A; Barandika, JF; Barger, PM; Barion, MRL; Barrett, CD; Basudan, AM; Baur, LE; Baz-Rodríguez, SA; Beamer, P; Beaulant, A; Becker, DF; Beckers, C; Bedel, J; Bedlack, R; Bermúdez de Castro, JM; Berry, JD; Berthier, C; Bhattacharya, D; Biadgo, B; Bianco, G; Bianco, M; Bibi, S; Bigliardi, AP; Billheimer, D; Birnie, DH; Biswas, K; Blair, HC; Bognetti, P; Bolan, PJ; Bolla, JR; Bolze, A; Bonnaillie, P; Borlimi, R; Bórquez, J; Bottari, NB; Boulleys-Nana, JR; Brighetti, G; Brodeur, GM; Budnyak, T; Budnyk, S; Bukirwa, VD; Bulman, DM; Burm, R; Busman-Sahay, K; Butcher, TW; Cai, C; Cai, H; Cai, L; Cairati, M; Calvano, CD; Camacho-Ordóñez, A; Camela, E; Cameron, T; Campbell, BS; Cansian, RL; Cao, Y; Caporale, AS; Carciofi, AC; Cardozo, V; Carè, J; Carlos, AF; Carozza, R; Carroll, CJW; Carsetti, A; Carubelli, V; Casarotta, E; Casas, M; Caselli, G; Castillo-Lora, J; Cataldi, TRI; Cavalcante, ELB; Cavaleiro, A; Cayci, Z; Cebrián-Tarancón, C; Cedrone, E; Cella, D; Cereda, C; Ceretti, A; Ceroni, M; Cha, YH; Chai, X; Chang, EF; Chang, TS; Chanteux, H; Chao, M; Chaplin, BP; Chaturvedi, S; Chaturvedi, V; Chaudhary, DK; Chen, A; Chen, C; Chen, HY; Chen, J; Chen, JJ; Chen, K; Chen, L; Chen, Q; Chen, R; Chen, SY; Chen, TY; Chen, WM; Chen, X; Chen, Y; Cheng, G; Cheng, GJ; Cheng, J; Cheng, YH; Cheon, HG; Chew, KW; Chhoker, S; Chiu, WN; Choi, ES; Choi, MJ; Choi, SD; Chokshi, S; Chorny, M; Chu, KI; Chu, WJ; Church, AL; Cirrincione, A; Clamp, AR; Cleff, MB; Cohen, M; Coleman, RL; Collins, SL; Colombo, N; Conduit, N; Cong, WL; Connelly, MA; Connor, J; Cooley, K; Correa Ramos Leal, I; Cose, S; Costantino, C; Cottrell, M; Cui, L; Cundall, J; Cutaia, C; Cutler, CW; Cuypers, ML; da Silva Júnior, FMR; Dahal, RH; Damiani, E; Damtie, D; Dan-Li, W; Dang, Z; Dasa, SSK; Davin, A; Davis, DR; de Andrade, CM; de Jong, PL; de Oliveira, D; de Paula Dorigam, JC; Dean, A; Deepa, M; Delatour, C; Dell'Aiera, S; Delley, MF; den Boer, RB; Deng, L; Deng, Q; Depner, RM; Derdau, V; Derici, U; DeSantis, AJ; Desmarini, D; Diffo-Sonkoue, L; Divizia, M; Djenabou, A; Djordjevic, JT; Dobrovolskaia, MA; Domizi, R; Donati, A; Dong, Y; Dos Santos, M; Dos Santos, MP; Douglas, RG; Duarte, PF; Dullaart, RPF; Duscha, BD; Edwards, LA; Edwards, TE; Eichenwald, EC; El-Baba, TJ; Elashiry, M; Elashiry, MM; Elashry, SH; Elliott, A; Elsayed, R; Emerson, MS; Emmanuel, YO; Emory, TH; Endale-Mangamba, LM; Enten, GA; Estefanía-Fernández, K; Estes, JD; Estrada-Mena, FJ; Evans, S; Ezra, L; Faria de, RO; Farraj, AK; Favre, C; Feng, B; Feng, J; Feng, L; Feng, W; Feng, X; Feng, Z; Fernandes, CLF; Fernández-Cuadros, ME; Fernie, AR; Ferrari, D; Florindo, PR; Fong, PC; Fontes, EPB; Fontinha, D; Fornari, VJ; Fox, NP; Fu, Q; Fujitaka, Y; Fukuhara, K; Fumeaux, T; Fuqua, C; Fustinoni, S; Gabbanelli, V; Gaikwad, S; Gall, ET; Galli, A; Gancedo, MA; Gandhi, MM; Gao, D; Gao, K; Gao, M; Gao, Q; Gao, X; Gao, Y; Gaponenko, V; Garber, A; Garcia, EM; García-Campos, C; García-Donas, J; García-Pérez, AL; Gasparri, F; Ge, C; Ge, D; Ge, JB; Ge, X; George, I; George, LA; Germani, G; Ghassemi Tabrizi, S; Gibon, Y; Gillent, E; Gillies, RS; Gilmour, MI; Goble, S; Goh, JC; Goiri, F; Goldfinger, LE; Golian, M; Gómez, MA; Gonçalves, J; Góngora-García, OR; Gonul, I; González, MA; Govers, TM; Grant, PC; Gray, EH; Gray, JE; Green, MS; Greenwald, I; Gregory, MJ; Gretzke, D; Griffin-Nolan, RJ; Griffith, DC; Gruppen, EG; Guaita, A; Guan, P; Guan, X; Guerci, P; Guerrero, DT; Guo, M; Guo, P; Guo, R; Guo, X; Gupta, J; Guz, G; Hajizadeh, N; Hamada, H; Haman-Wabi, AB; Han, TT; Hannan, N; Hao, S; Harjola, VP; Harmon, M; Hartmann, MSM; Hartwig, JF; Hasani, M; Hawthorne, WJ; Haykal-Coates, N; Hazari, MS; He, DL; He, P; He, SG; Héau, C; Hebbar Kannur, K; Helvaci, O; Heuberger, DM; Hidalgo, F; Hilty, MP; Hirata, K; Hirsch, A; Hoffman, AM; Hoffmann, JF; Holloway, RW; Holmes, RK; Hong, S; Hongisto, M; Hopf, NB; Hörlein, R; Hoshino, N; Hou, Y; Hoven, NF; Hsieh, YY; Hsu, CT; Hu, CW; Hu, JH; Hu, MY; Hu, Y; Hu, Z; Huang, C; Huang, D; Huang, DQ; Huang, L; Huang, Q; Huang, R; Huang, S; Huang, SC; Huang, W; Huang, Y; Huffman, KM; Hung, CH; Hung, CT; Huurman, R; Hwang, SM; Hyun, S; Ibrahim, AM; Iddi-Faical, A; Immordino, P; Isla, MI; Jacquemond, V; Jacques, T; Jankowska, E; Jansen, JA; Jäntti, T; Jaque-Fernandez, F; Jarvis, GA; Jatt, LP; Jeon, JW; Jeong, SH; Jhunjhunwala, R; Ji, F; Jia, X; Jia, Y; Jian-Bo, Z; Jiang, GD; Jiang, L; Jiang, W; Jiang, WD; Jiang, Z; Jiménez-Hoyos, CA; Jin, S; Jobling, MG; John, CM; John, T; Johnson, CB; Jones, KI; Jones, WS; Joseph, OO; Ju, C; Judeinstein, P; Junges, A; Junnarkar, M; Jurkko, R; Kaleka, CC; Kamath, AV; Kang, X; Kantsadi, AL; Kapoor, M; Karim, Z; Kashuba, ADM; Kassa, E; Kasztura, M; Kataja, A; Katoh, T; Kaufman, JS; Kaupp, M; Kehinde, O; Kehrenberg, C; Kemper, N; Kerr, CW; Khan, AU; Khan, MF; Khan, ZUH; Khojasteh, SC; Kilburn, S; Kim, CG; Kim, DU; Kim, DY; Kim, HJ; Kim, J; Kim, OH; Kim, YH; King, C; Klein, A; Klingler, L; Knapp, AK; Ko, TK; Kodavanti, UP; Kolla, V; Kong, L; Kong, RY; Kong, X; Kore, S; Kortz, U; Korucu, B; Kovacs, A; Krahnert, I; Kraus, WE; Kuang, SY; Kuehn-Hajder, JE; Kurz, M; Kuśtrowski, P; Kwak, YD; Kyttaris, VC; Laga, SM; Laguerre, A; Laloo, A; Langaro, MC; Langham, MC; Lao, X; Larocca, MC; Lassus, J; Lattimer, TA; Lazar, S; Le, MH; Leal, DB; Leal, M; Leary, A; Ledermann, JA; Lee, JF; Lee, MV; Lee, NH; Leeds, CM; Leeds, JS; Lefrandt, JD; Leicht, AS; Leonard, M; Lev, S; Levy, K; Li, B; Li, C; Li, CM; Li, DH; Li, H; Li, J; Li, L; Li, LJ; Li, N; Li, P; Li, T; Li, X; Li, XH; Li, XQ; Li, XX; Li, Y; Li, Z; Li, ZY; Liao, YF; Lin, CC; Lin, MH; Lin, Y; Ling, Y; Links, TP; Lira-Romero, E; Liu, C; Liu, D; Liu, H; Liu, J; Liu, L; Liu, LP; Liu, M; Liu, T; Liu, W; Liu, X; Liu, XH; Liu, Y; Liuwantara, D; Ljumanovic, N; Lobo, L; Lokhande, K; Lopes, A; Lopes, RMRM; López-Gutiérrez, JC; López-Muñoz, MJ; López-Santamaría, M; Lorenzo, C; Lorusso, D; Losito, I; Lu, C; Lu, H; Lu, HZ; Lu, SH; Lu, SN; Lu, Y; Lu, ZY; Luboga, F; Luo, JJ; Luo, KL; Luo, Y; Lutomski, CA; Lv, W; M Piedade, MF; Ma, J; Ma, JQ; Ma, JX; Ma, N; Ma, P; Ma, S; Maciel, M; Madureira, M; Maganaris, C; Maginn, EJ; Mahnashi, MH; Maierhofer, M; Majetschak, M; Malla, TR; Maloney, L; Mann, DL; Mansuri, A; Marelli, E; Margulis, CJ; Marrella, A; Martin, BL; Martín-Francés, L; Martínez de Pinillos, M; Martínez-Navarro, EM; Martinez-Quintanilla Jimenez, D; Martínez-Velasco, A; Martínez-Villaseñor, L; Martinón-Torres, M; Martins, BA; Massongo, M; Mathew, AP; Mathews, D; Matsui, J; Matsumoto, KI; Mau, T; Maves, RC; Mayclin, SJ; Mayer, JM; Maynard, ND; Mayr, T; Mboowa, MG; McEvoy, MP; McIntyre, RC; McKay, JA; McPhail, MJW; McVeigh, AL; Mebazaa, A; Medici, V; Medina, DN; Mehmood, T; Mei-Li, C; Melku, M; Meloncelli, S; Mendes, GC; Mendoza-Velásquez, C; Mercadante, R; Mercado, MI; Merenda, MEZ; Meunier, J; Mi, SL; Michels, M; Mijatovic, V; Mikhailov, V; Milheiro, SA; Miller, DC; Ming, F; Mitsuishi, M; Miyashita, T; Mo, J; Mo, S; Modesto-Mata, M; Moeller, S; Monte, A; Monteiro, L; Montomoli, J; Moore, EE; Moore, HB; Moore, PK; Mor, MK; Moratalla-López, N; Moratilla Lapeña, L; Moreira, R; Moreno, MA; Mörk, AC; Morton, M; Mosier, JM; Mou, LH; Mougharbel, AS; Muccillo-Baisch, AL; Muñoz-Serrano, AJ; Mustafa, B; Nair, GM; Nakanishi, I; Nakanjako, D; Naraparaju, K; Nawani, N; Neffati, R; Neil, EC; Neilipovitz, D; Neira-Borrajo, I; Nelson, MT; Nery, PB; Nese, M; Nguyen, F; Nguyen, MH; Niazy, AA; Nicolaï, J; Nogueira, F; Norbäck, D; Novaretti, JV; O'Donnell, T; O'Dowd, A; O'Malley, DM; Oaknin, A; Ogata, K; Ohkubo, K; Ojha, M; Olaleye, MT; Olawande, B; Olomo, EJ; Ong, EWY; Ono, A; Onwumere, J; Ortiz Bibriesca, DM; Ou, X; Oza, AM; Ozturk, K; Özütemiz, C; Palacio-Pastrana, C; Palaparthi, A; Palevsky, PM; Pan, K; Pantanetti, S; Papachristou, DJ; Pariani, A; Parikh, CR; Parissis, J; Paroul, N; Parry, S; Patel, N; Patel, SM; Patel, VC; Pawar, S; Pefura-Yone, EW; Peixoto Andrade, BCO; Pelepenko, LE; Peña-Lora, D; Peng, S; Pérez-Moro, OS; Perez-Ortiz, AC; Perry, LM; Peter, CM; Phillips, NJ; Phillips, P; Pia Tek, J; Piner, LW; Pinto, EA; Pinto, SN; Piyachaturawat, P; Poka-Mayap, V; Polledri, E; Poloni, TE; Ponessa, G; Poole, ST; Post, AK; Potter, TM; Pressly, BB; Prouty, MG; Prudêncio, M; Pulkki, K; Pupier, C; Qian, H; Qian, ZP; Qiu, Y; Qu, G; Rahimi, S; Rahman, AU; Ramadan, H; Ramanna, S; Ramirez, I; Randolph, GJ; Rasheed, A; Rault, J; Raviprakash, V; Reale, E; Redpath, C; Rema, V; Remucal, CK; Remy, D; Ren, T; Ribeiro, LB; Riboli, G; Richards, J; Rieger, V; Rieusset, J; Riva, A; Rivabella Maknis, T; Robbins, JL; Robinson, CV; Roche-Campo, F; Rodriguez, R; Rodríguez-de-Cía, J; Rollenhagen, JE; Rosen, EP; Rub, D; Rubin, N; Rubin, NT; Ruurda, JP; Saad, O; Sabell, T; Saber, SE; Sabet, M; Sadek, MM; Saejio, A; Salinas, RM; Saliu, IO; Sande, D; Sang, D; Sangenito, LS; Santos, ALSD; Sarmiento Caldas, MC; Sassaroli, S; Sassi, V; Sato, J; Sauaia, A; Saunders, K; Saunders, PR; Savarino, SJ; Scambia, G; Scanlon, N; Schetinger, MR; Schinkel, AFL; Schladweiler, MC; Schofield, CJ; Schuepbach, RA; Schulz, J; Schwartz, N; Scorcella, C; Seeley, J; Seemann, F; Seinige, D; Sengoku, T; Seravalli, J; Sgromo, B; Shaheen, MY; Shan, L; Shanmugam, S; Shao, H; Sharma, S; Shaw, KJ; Shen, BQ; Shen, CH; Shen, P; Shen, S; Shen, Y; Shen, Z; Shi, J; Shi-Li, L; Shimoda, K; Shoji, Y; Shun, C; Silva, MA; Silva-Cardoso, J; Simas, NK; Simirgiotis, MJ; Sincock, SA; Singh, MP; Sionis, A; Siu, J; Sivieri, EM; Sjerps, MJ; Skoczen, SL; Slabon, A; Slette, IJ; Smith, MD; Smith, S; Smith, TG; Snapp, KS; Snow, SJ; Soares, MCF; Soberman, D; Solares, MD; Soliman, I; Song, J; Sorooshian, A; Sorrell, TC; Spinar, J; Staudt, A; Steinhart, C; Stern, ST; Stevens, DM; Stiers, KM; Stimming, U; Su, YG; Subbian, V; Suga, H; Sukhija-Cohen, A; Suksamrarn, A; Suksen, K; Sun, J; Sun, M; Sun, P; Sun, W; Sun, XF; Sun, Y; Sundell, J; Susan, LF; Sutjarit, N; Swamy, KV; Swisher, EM; Sykes, C; Takahashi, JA; Talmor, DS; Tan, B; Tan, ZK; Tang, L; Tang, S; Tanner, JJ; Tanwar, M; Tarazi, Z; Tarvasmäki, T; Tay, FR; Teketel, A; Temitayo, GI; Thersleff, T; Thiessen Philbrook, H; Thompson, LC; Thongon, N; Tian, B; Tian, F; Tian, Q; Timothy, AT; Tingle, MD; Titze, IR; Tolppanen, H; Tong, W; Toyoda, H; Tronconi, L; Tseng, CH; Tu, H; Tu, YJ; Tung, SY; Turpault, S; Tuynman, JB; Uemoto, AT; Ugurlu, M; Ullah, S; Underwood, RS; Ungell, AL; Usandizaga-Elio, I; Vakonakis, I; van Boxel, GI; van den Beucken, JJJP; van der Boom, T; van Slegtenhorst, MA; Vanni, JR; Vaquera, A; Vasconcellos, RS; Velayos, M; Vena, R; Ventura, G; Verso, MG; Vincent, RP; Vitale, F; Vitali, S; Vlek, SL; Vleugels, MPH; Volkmann, N; Vukelic, M; Wagner Mackenzie, B; Wairagala, P; Waller, SB; Wan, J; Wan, MT; Wan, Y; Wang, CC; Wang, H; Wang, J; Wang, JF; Wang, K; Wang, L; Wang, M; Wang, S; Wang, WM; Wang, X; Wang, Y; Wang, YD; Wang, YF; Wang, Z; Wang, ZG; Warriner, K; Weberpals, JI; Weerachayaphorn, J; Wehrli, FW; Wei, J; Wei, KL; Weinheimer, CJ; Weisbord, SD; Wen, S; Wendel Garcia, PD; Williams, JW; Williams, R; Winkler, C; Wirman, AP; Wong, S; Woods, CM; Wu, B; Wu, C; Wu, F; Wu, P; Wu, S; Wu, Y; Wu, YN; Wu, ZH; Wurtzel, JGT; Xia, L; Xia, Z; Xia, ZZ; Xiao, H; Xie, C; Xin, ZM; Xing, Y; Xing, Z; Xu, S; Xu, SB; Xu, T; Xu, X; Xu, Y; Xue, L; Xun, J; Yaffe, MB; Yalew, A; Yamamoto, S; Yan, D; Yan, H; Yan, S; Yan, X; Yang, AD; Yang, E; Yang, H; Yang, J; Yang, JL; Yang, K; Yang, M; Yang, P; Yang, Q; Yang, S; Yang, W; Yang, X; Yang, Y; Yao, JC; Yao, WL; Yao, Y; Yaqub, TB; Ye, J; Ye, W; Yen, CW; Yeter, HH; Yin, C; Yip, V; Yong-Yi, J; Yu, HJ; Yu, MF; Yu, S; Yu, W; Yu, WW; Yu, X; Yuan, P; Yuan, Q; Yue, XY; Zaia, AA; Zakhary, SY; Zalwango, F; Zamalloa, A; Zamparo, P; Zampini, IC; Zani, JL; Zeitoun, R; Zeng, N; Zenteno, JC; Zepeda-Palacio, C; Zhai, C; Zhang, B; Zhang, G; Zhang, J; Zhang, K; Zhang, Q; Zhang, R; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, B; Zhao, D; Zhao, G; Zhao, H; Zhao, Q; Zhao, R; Zhao, S; Zhao, T; Zhao, X; Zhao, XA; Zhao, Y; Zhao, Z; Zheng, Z; Zhi-Min, G; Zhou, CL; Zhou, HD; Zhou, J; Zhou, W; Zhou, XQ; Zhou, Z; Zhu, C; Zhu, H; Zhu, L; Zhu, Y; Zitzmann, N; Zou, L; Zou, Y | 1 |
| Beck-Wirth, G; Bozon, F; Brunel, AS; Chirouze, C; Davani, S; Drobacheff-Thiebaut, MC; Flammang, M; Foltzer, A; Hustache-Mathieu, L; Kowalczyk, J; Lagoutte-Renosi, J; Michel, C; Muret, P | 1 |
| Beaubrun, A; Cummings, TH; Hardin, JW; Hsu, LI; Magagnoli, J; Majethia, S; Sutton, SS | 1 |
| Alonso-Vega, GG; Ferrández, JS; García, AL; García, TM; González, AO | 1 |
| Kandala, B; Vaddady, P; Yee, KL | 1 |
| Chinbunchorn, T; Cressey, TR; Janyam, S; Kawichai, S; Linjongrat, D; Phanuphak, N; Puthanakit, T; Saisaengjan, C; Songtaweesin, WN; Wongharn, P | 1 |
| Boffito, M; Girometti, N; Lander, F; McOwan, A; Nwokolo, N; Whitlock, G | 1 |
| Béguelin, C; Bernasconi, E; Boillat-Blanco, N; Chave, JP; Doco-Lecompte, T; Fehr, J; Furrer, H; Günthard, HF; Rauch, A; Schmid, P; Stöckle, M; Surial, B; Walti, LN; Wandeler, G | 1 |
| Bush, S; Das, M; Shreay, S; Ting, J | 1 |
| Kumar, B; Prabhakar, R; Thangavelu, S | 1 |
| Chivite, I; Cottrell, ML; Domingo, P; Garcia, B; Imaz, A; Kashuba, ADM; Martinez-Picado, J; Morenilla, S; Negredo, E; Niubó, J; Podzamczer, D; Scévola, S; Schauer, A; Silva-Klug, A; Tiraboschi, JM; Urrea, V; Van Horne, B | 1 |
| Castel, AD; Hoffman, HJ; Jones, JS; Kramer, MR; Kuo, I; McGuinness, P; Mera Giler, R; Mouhanna, F; Siegler, AJ; Sullivan, PS | 1 |
| Bukkems, VE; Burger, DM; Colbers, AP; Cressey, TR; Jourdain, G; Smolders, EJ | 1 |
| Agrati, C; Antinori, A; Capobianchi, MR; Casetti, R; Castilletti, C; Cicalini, S; Cimini, E; Colavita, F; De Zottis, F; Gagliardini, R; Girardi, E; Ippolito, G; Maeurer, M; Matusali, G; Mazzotta, V; Mondi, A; Pinnetti, C; Puro, V; Schininà, V; Vaia, F; Vergori, A | 1 |
| Balcombe, SM; Hill, LA; Martin, TCS; Tang, ME | 1 |
| Djan, K; Dorsey, HG; Jnr, DA; Li, M; Musoff, C; Paintsil, E; Schoen, N; Zhou, L | 1 |
| Barbini, B; Campbell, L; Gilleece, Y; Hamzah, L; Ibrahim, F; Kegg, S; Post, FA; Samarawickrama, A; Vincent, R; Waters, L | 1 |
| Burger, DM; Mollema, FP; Roelofsen, EE; Wildenbeest, S | 1 |
| Abrams, E; Akpomiemie, G; Arulappan, N; Chandiwana, N; Chersich, M; Clayden, P; Fairlie, L; Hill, A; Lalla-Edward, S; Maartens, G; Masenya, M; Mashabane, N; McCann, K; Moorhouse, M; Norris, S; Qavi, A; Serenata, C; Simmons, B; Sokhela, S; Venter, WDF; Vos, A | 1 |
| Avenant, C; Dlamini, S; Enfield, K; Hapgood, JP; Kuipa, M | 1 |
| Baeten, JM; Berard, AR; Birse, K; Burgener, A; Calienes, FL; Cameron, MJ; Cartwright, M; Collier, AC; Cranston, RD; Curlin, ME; Golden, JB; Hladik, F; Holtz, TH; Hughes, SM; Irungu, E; Katabira, E; Lama, JR; Levy, CN; Lingappa, JR; Mackelprang, R; McElrath, MJ; McGowan, I; Mugo, N; Muwonge, T; Noël-Romas, L; Pandey, U; Richardson, B; Stekler, JD; Stevens, CE; Vojtech, L | 1 |
| Ward, KA | 1 |
| Aho, I; Alexiev, I; Balayan, T; Begovac, J; Bukovinova, P; Gokengin, D; Harxhi, A; Holban, T; Horban, A; Jevtovic, D; Kase, K; Kowalska, JD; Lakatos, B; Latysheva, I; Matulionyte, R; Oprea, C; Papadopoulos, A; Rukhadze, N; Salemovic, D; Sedlacek, D; Skrzat-Klapaczyńska, A; Tomazic, J; Vassilenko, A; Vasylyev, M; Verhaz, A; Yancheva, N; Yurin, O | 1 |
| Betha, TP; Dravid, A; Dravid, M; Gawali, R; Kore, S; Kulkarni, M; Mahajan, U; Rathod, N; Saraf, C; Sharma, AK | 1 |
| Bauleni, A; Corbett, A; Dube, Q; Hosseinipour, MC; Kapito-Tembo, AP; Mwale, P; Mwapasa, V; Ongubo, D; Phiri, S; Wesevich, A | 1 |
| Baeten, JM; Haberer, JE; Hodges-Mameletzis, I; Mujugira, A | 1 |
| Anugulruengkitt, S; Kawichai, S; Pornpaisalsakul, K; Puthanakit, T; Songtaweesin, WN; Suponsilchai, V; Tepmongkol, S; Wongharn, P | 1 |
| Bakhshandeh, H; Bolhassani, A; Khoobi, M; Milani, A; Vahabpour, R; Yadavar-Nikravesh, MS | 1 |
| Gotham, D; Hill, A; Hughes, SL; McCann, K; Pepperrell, T; Pilkington, V; Pozniak, AL | 1 |
| Bjørnevik, K; Myhr, KM; Skogen, V; Steffensen, LH; Torkildsen, Ø | 1 |
| Devitt, E; Hegarty, D; Loy, A; Lyons, F; Mulcahy, F; Quinn, L; Quirke, S | 1 |
| Mc Mullan, K; McIntyre, M; Quah, SP; Rafferty, P; Wood, A | 1 |
| Bini, T; Borsino, C; d'Arminio Monforte, A; De Bona, A; Gazzola, L; Marchetti, G; Mondatore, D; Tagliaferri, G | 1 |
| Baeten, JM; Beesham, I; Beksinska, M; Evans, S; Heffron, R; Mansoor, LE; Smit, J | 1 |
| Baeten, JM; Bagaya, M; Bambia, F; Brown, C; Celum, C; Haberer, JE; Heffron, R; Katabira, E; Kyambadde, P; Mujugira, A; Muwonge, TR; Nakyanzi, A; Nsubuga, R | 1 |
| Abad-Fuentes, A; Abad-Somovilla, A; Agulló, C; Anfossi, L; Baggiani, C; Cavalera, S; Chiarello, M; D'Avolio, A; Di Nardo, F; Mercader, JV | 1 |
| Patel, RR; Rowan, SE; Schneider, JA; Smith, DK | 1 |
| Dunn, DT; Glidden, DV; Stirrup, OT | 1 |
| Abdel Alem, S; Atef, M; Hamed, M; Saber, M; Salama, R; Yosry, A; Yousof, H; Zayed, N | 1 |
| Lee, SS; To, KW | 1 |
| Abraham, P; Isaac, B; Ramamoorthy, H | 1 |
| Burkholder, GA; Collier, AC; Crane, HM; Curtis, L; Delaney, JAC; Eron, JJ; Geng, E; Harding, BN; Henegar, C; Kitahata, MM; Lindström, S; Mathews, WC; Mayer, KH; Moore, RD; Nance, RM; Rodriguez, B; Ruderman, SA; Saag, MS; Van Wyk, J; Vannappagari, V; Whitney, BM; Willig, AL; Wood, BR | 1 |
| DeMarais, P; Max, B | 1 |
| Aweeka, FT; Currier, JS; Deitchman, AN; Gingrich, D; Hsue, PY; Huang, L; Kantor, A; Ribaudo, HJ; Stein, JH | 1 |
| Atrio, JM; Barnett, R; Dobkin, A; Espinoza, L; Keller, MJ; McGinn, AP; McWalters, J; Ray, LL | 1 |
| Wood, BR | 1 |
| Babusis, D; Barouch, DH; Bekerman, E; Callebaut, C; Campigotto, F; Cihlar, T; Cox, S; Das, M | 1 |
| Gandhi, M; Robles, G; Sauermilch, D; Starks, TJ | 1 |
| Achterfeld, A; Herzer, K; Rashidi-Alavijeh, J; Straub, K; Wedemeyer, H; Willuweit, K | 1 |
| Chavas, TEJ; Chiefari, J; Ho, DK; LeGuyader, C; Lopez, CL; Postma, A; Roy, D; Snyder, JM; Srinivasan, S; Stayton, PS; Vlaskin, V | 1 |
| Archary, M; Mngqibisa, R | 1 |
| Bekker, LG; Dietrich, J; Fynn, L; Gill, K; Gray, G; Hosek, S; Johnson, L; Jones, K; Marcus, R; Mendel, E; Myer, L; Pidwell, T; Rooney, J; Slack, C; Spiegel, H; Strode, A; Wallace, M; Wiesner, L | 1 |
| Ostankova, YV; Semenov, AV; Serikova, EN; Totolian, AA; Zueva, EB | 1 |
| Edmonston, D; Hemmersbach-Miller, M; Hung, A; Sinclair, M; Wyatt, C | 1 |
| Barr, E; Best, BM; Brooks, KM; Capparelli, EV; Chakhtoura, N; Cielo, M; Denson, K; Deville, JG; Espina, R; Febo, IL; George, K; Haubrich, R; Mirochnick, M; Momper, JD; Pinilla, M; Rooney, JF; Rungruengthanakit, K; Shapiro, DE; Smith, E; Stek, AM; Weinberg, A | 1 |
| Cheng, CY; Cheng, SH; Ho, MW; Huang, SH; Huang, YS; Hung, CC; Lee, CH; Lee, YT; Lin, SP; Liou, BH; Liu, CE; Lu, PL; Sun, HY; Tang, HJ; Tsai, HC; Yang, CJ | 1 |
| Ma, R; Tong, ZW; Xu, B; Zhang, Q; Zhang, YS; Zhao, CS; Zhao, RG | 1 |
| Hill, A; Shah, S | 2 |
| Baugh, B; De Meyer, S; Ghys, A; Jezorwski, J; Lathouwers, E; Mohsine, EG; Van Landuyt, E; Weinsteiger, S | 1 |
| Anderson, PL; Burke, LA; Bushman, L; Caffrey, M; Ellison, L; Ellsworth, GB; Gulick, RM; Liddle, D; Madhava, M; Mishra, S; O'Neal, C; Stein, J; Wells, MT | 1 |
| Castagna, A; Esser, S; Haubrich, R; Llibre, JM; Margot, N; McNicholl, IR; Molina, JM; Perez-Valero, I; Piontkowsky, D; Pulido, F; Shao, Y; Temme, L | 1 |
| Ambrosioni, J; Laguno, M; Liegeon, G; Miró, JM; Petit, E | 1 |
| Hanna, GJ; Hwang, C; Kumar, S; Lin, G; Martin, E; Molina, JM; Orkin, C; Sax, PE; Squires, KE; Sussmann, O; Teppler, H | 1 |
| Amin, J; Bavinton, B; Cabrera Quichua, G; Grulich, AE; Guy, R; Holden, J; Jin, F; McManus, H; McNulty, A; Ogilvie, E; Price, K; Selvey, C; Smith, D; Vaccher, S; Vickers, T; Yeung, B; Zablotska, I | 1 |
| Galvani, AP; Goedel, WC; Marshall, BDL | 1 |
| Conway-Washington, C; Dinh, C; Fountain, J; Haaland, RE; Hall, L; Kelley, CF; Lupo, LD; Martin, A; Mengesha, M | 1 |
| Chirro, O; de Wit, TFR; Graham, SM; Ibrahim, F; Kimani, M; Mukuria, N; Operario, D; Sanders, EJ; van der Elst, EM; Wahome, E | 1 |
| Arnold, T; Brown, LK; Craker, L; Haubrick, KK; Mena, L; Olsen, E; Whiteley, L | 1 |
| Chawana, T; Gandhi, M; Katzenstein, D; Kuncze, K; Louie, A; Metcalfe, J; Nathoo, K; Ngara, B; Nhachi, C; Okochi, H | 1 |
| Bacon, O; Chen, MJ; Cohen, SE; Johnson, KA; Kohn, R; Lee, S; Sachdev, D | 1 |
| Baeten, JM; Donnell, D; Gandhi, M; Glidden, DV; Hendrix, C; Marzinke, M; Mugo, N; Mujugira, A; Rodrigues, WC; Spinelli, MA; Stalter, RM; Vincent, M; Wang, G | 1 |
| Baugh, B; Brown, K; El Ghazi, M; Huhn, GD; Jezorwski, J; Lathouwers, E; Mussini, C; Spinner, CD; Van Landuyt, E; Wilkin, A | 1 |
| Bekker, LG; Carter, A; Craig, C; Devlin, B; Gill, K; Gwetu, T; Kotze, P; Kusemererwa, S; Louw, C; Mabude, Z; Malherbe, M; Mans, W; Moraba, R; Nel, A; Rosenberg, Z; Steytler, J; Tempelman, H; Van Baelen, B; van der Ryst, E; van Niekerk, N | 1 |
| Baeten, JM; Balán, IC; Brown, ER; Bunge, K; Chinula, L; Chirenje, ZM; Garcia, M; Gati Mirembe, B; Govender, V; Hendrix, CW; Hillier, SL; Hunidzarira, P; Jacobson, C; Jiao, Y; Jones, J; Livant, E; Makanani, B; Mansoor, LE; Mayo, AJ; Mellors, JW; Mgodi, NM; Mhlanga, F; Naidoo, L; Nair, G; Nakabiito, C; Nel, A; Ngure, K; Palanee-Phillips, T; Parikh, UM; Patterson, K; Peda, M; Ramjee, G; Rosenberg, Z; Scheckter, R; Singh, D; Singh, N; Siva, S; Soto-Torres, LE; Szydlo, DW; Taha, TE; Torjesen, K; van der Straten, A | 1 |
| Aizire, J; Browning, R; Dadabhai, S; Fan, B; Fowler, MG; George, K; Mofenson, LM; Moodley, D; Mukwasi-Kahari, C; Nelson, B; Sebikari, D; Shepherd, J; Siberry, GK; Sommer, MJ; Stranix-Chibanda, L; Theron, G; Tierney, C; Vhembo, T; Violari, A; Zanga, A | 1 |
| Anton, P; Bumpus, NN; Garcia-Cremades, M; Hendrix, C; Jayachandran, P; Savić, R; Vučićević, K | 1 |
| Atukunda, M; Awuonda, B; Ayieko, J; Balzer, LB; Black, D; Brown, LB; Bukusi, EA; Camlin, CS; Chamie, G; Charlebois, ED; Clark, TD; Cohen, CR; Gandhi, M; Havlir, DV; Jain, V; Kabami, J; Kamya, MR; Koss, CA; Kwarisiima, D; Marquez, C; Mwangwa, F; Mwinike, Y; Nugent, J; Okochi, H; Olilo, W; Owaraganise, A; Peng, J; Petersen, ML; Snyman, K; Zhang, K | 1 |
| Bao, RT; Chen, YK; Chu, ZX; Ding, HB; Geng, WQ; He, XQ; Hu, QH; Hu, ZL; Huang, XJ; Jiang, YJ; Li, H; Li, SC; Li, Y; Shang, H; Sylvia, S; Wang, H; Wang, HY; Xu, JJ; Zhang, J; Zhang, LK | 1 |
| Bassa, A; Hill, A; Kumar, S; Mngqibisa, R; Nelson, M; Orkin, C; Rassool, M; Rodgers, A; Teal, V; Teppler, H; Winston, A | 1 |
| Bast, AC; Butler, CC; Dorward, J; Jones, NR; Matthews, PC; Mellor, MM; Ordóñez-Mena, JM; Reith, AJM; Roberts, NW | 1 |
| Ait-Khaled, M; Ajana, F; Jones, B; Nascimento, MC; Santos, J; Scholten, S; Smith, DE; Tenorio, AR; van Wyk, J; Wohlfeiler, M; Wright, J; Wynne, B | 1 |
| Anderson, M; Andrew, P; Baepanye, K; Burns, D; Cohen, MS; Corey, L; Donnell, D; Edupuganti, S; Garnett, P; Gomez Lorenzo, MM; Greene, E; Hural, J; Juraska, M; Karg, C; Karuna, S; Kochar, N; Lazarus, E; Ledgerwood, J; Luthuli, N; Marshall, K; Mascola, JR; Mgodi, NM; Miner, MD; Mukwekwerere, PG; Rudnicki, E; Shava, E; Takuva, S; Tindale, I | 1 |
| Chang, SF; Chang, SY; Hsiao, YY; Huang, YC; Hung, CC; Kuo, CH; Lee, YL; Lin, YT; Luo, YZ | 1 |
| Fried, JR; Fuqua, JL; Minooei, F; Palmer, KE; Steinbach-Rankins, JM | 1 |
| Bradford, Y; Chandiwana, NC; Cindi, Z; Haas, DW; Maartens, G; Sinxadi, P; Sokhela, S; Venter, WDF | 1 |
| Bickel, M; Cahn, P; Greaves, W; Johnson, M; Kumar, P; Molina, JM; Morais, C; Rizzardini, G; Sklar, P; Wan, H; Xu, ZJ | 1 |
| Duan, L; Li, XF; Lin, W; Liu, JZ; Ren, DC; Song, M; Zhan, ZR | 1 |
| Deepa, S; Kondapi, AK; Kumar, P; Yeruva, SL | 1 |
| Harris, P; Henderson, R | 1 |
| Anderson, PL; Baeten, JM; Bukusi, EA; Garrison, LE; Haberer, JE; Kiptinness, C; Morrison, S; Mugo, NR; Musinguzi, N; Ngure, K; Oware, K; Pyra, M; Thomas, KK | 1 |
| Anderson, PL; Bangdiwala, AS; Boulware, DR; Castillo-Mancilla, J; Hullsiek, KH; Kandole, TK; Lofgren, SM; Meya, DB; Mpoza, E; Nicol, MR; Rhein, J; Ssebambulidde, K; Tugume, L | 1 |
| Mesplède, T | 1 |
| Baeten, JM; Barasch, J; Branch, AD; Celum, C; Donnell, D; Heffron, R; Mugo, NR; Mugwanya, KK; Nickolas, TL; Ronald, A; Wanga, V; Wyatt, CM | 1 |
| DeJong, C; Gandhi, M; Okochi, H; Spinelli, MA | 1 |
| Eke, AC; Thimm, MA | 1 |
| Mwethera, PG; Obiero, J; Ogongo, P; Wiysonge, CS | 1 |
| Hatakeyama, S; Kanda, N; Mieno, M; Okamoto, K; Okumura, H; Sakashita, K; Sasahara, T | 1 |
| Bernasconi, E; Calmy, A; Cavassini, M; Furrer, H; Günthard, HF; Ledergerber, B; Mugglin, C; Rauch, A; Schmid, P; Stöckle, M; Surial, B; Tarr, PE; Wandeler, G | 1 |
| Ajana, F; Avettand-Fènoël, V; Bernard, L; Darasteanu, I; de la Blanchardière, A; Etienne, M; Hocqueloux, L; Le Moal, G; Parienti, JJ; Pasdeloup, T; Pialoux, G; Ponscarme, D; Prazuck, T; Roncato-Saberan, M; Sunder, S; Verdon, R; Viard, JP | 1 |
| Benet, LZ; Gandhi, M; Koss, CA; Kuncze, K; Louie, A; Okochi, H; Phung, N; Spinelli, MA; Tallerico, RM; Zhang, K | 1 |
| Bhan, AK; Chung, RT; Ghany, MG; Hinerman, AS; Jain, MK; Khalili, M; King, WC; Kleiner, DE; Lisker-Melman, M; Sterling, RK; Sulkowski, M; Wahed, AS; Wong, DK | 1 |
| Bonomini, M; Di Liberato, L; Piscitani, L; Pontolillo, M; Ucciferri, C; Vecchiet, J | 1 |
| Butcher, L; Davidson, AM; Johnson, M; Joshi, SR; Lataillade, M; Min, S; Pene Dumitrescu, T; Webster, L; Xu, J; Zhan, J; Zimmerman, E | 1 |
| Lake, JE; Trevillyan, J | 1 |
| Amico, KR; Brummel, SS; Cassim, H; Chakhtoura, N; Chinula, L; Coletti, A; Currier, J; Fairlie, L; Frenkel, LM; Hanley, S; Hoffman, RM; Holmes, LB; Jean-Philippe, P; João, E; Johnston, B; Korutaro, V; Krotje, C; Lockman, S; Masheto, G; McCarthy, K; Mmbaga, BT; Momper, JD; Moyo, S; Purdue, L; Rooney, JF; Sax, PE; Shapiro, RL; Stranix-Chibanda, L; Stringer, JS; Thoofer, NK; Ziemba, L | 1 |
| Behrens, GMN; Sandmann, L; Stoll, M | 1 |
| Beyer, AP; Brunet, L; Fusco, GP; Fusco, JS; Hsu, RK; Mallon, PW; Mounzer, KC; Prajapati, G; Wohlfeiler, MB | 1 |
| Alvarez-Barco, E; Mallon, PWG | 1 |
| Bowen, AC; Campbell, AJ; Yeoh, DK | 1 |
| Bateman, BT; Fischer, M; Hernández-Díaz, S; Huybrechts, KF; Mogun, H; Straub, L; Zhu, Y | 1 |
| Amico, KR; Anderson, PL; Blumenthal, J; Chow, K; Corado, K; Ellorin, E; Haubrich, R; He, F; Jain, S; Kofron, R; Landovitz, RJ; Moore, DJ; Morris, S; Ntim, GM; Psaros, C; Stockman, JK | 1 |
| Acosta, RK; Brainard, D; Chang, S; Chen, GQ; Collins, SE; Huang, H; Martin, H; Martin, R; Wang, X; White, KL | 1 |
| Bernasconi, E; Calmy, A; Cavassini, M; Kovari, H; Ledergerber, B; Rauch, A; Schmid, P; Surial, B; Tarr, PE; Wandeler, G | 1 |
| Amico, KR; Chatterhee, P; Gandhi, M; Leddy, AM; Ngure, K; Polay, M; Thuo, N | 1 |
| Baum, MM; Demkovich, ZR; Diana, F; Dobard, C; Feldman, PL; Garcia-Lerma, JG; Grattoni, A; Gunawardana, M; Ho, DK; Hope, TJ; Massud, I; Milad, M; Moss, JA; Pons-Faudoa, FP; Roller, S; Romano, JW; Srinivasan, S; van der Straten, A; Veazey, RS; Zane, D | 1 |
| Anderson, DM; Beck, IA; Frenkel, LM; Hu, SL; Joy, JP; Kuller, L; Montefiori, DC; Mulvania, TM; Tsai, CC | 1 |
| Do, HQ; Kinai, E; Matsumoto, S; Nagai, M; Nguyen, HDT; Nguyen, KV; Oka, S; Pham, TN; Tanuma, J | 1 |
| Bogas, S; das Neves, J; Faria, MJ; Gonçalves, H; Lúcio, M; Nunes, R; Sarmento, B; Viseu, T | 1 |
| Cassidy, T; Flowers, T; Gcwabe, Z; Goemaere, E; Goliath, R; Griesel, R; Hill, A; Jackson, A; Keene, CM; Maartens, G; Meintjes, G; Ngwenya, O; Sayed, K; Schutz, C; Simmons, B; van Zyl, G; Wiesner, L; Zhao, Y | 1 |
| Brown, TT; Carter, CC; Cohen, C; Das, M; Erlandson, KM; Esser, S; Huang, H; Koethe, JR; Lake, JE; Martin, H; McComsey, GA; Melbourne, K; Orkin, C; Post, FA; Rockstroh, JK; Sax, PE; Stellbrink, HJ; Waters, L; Wei, X | 1 |
| Gandhi, M; Glidden, DV; Johnson, KA; Okochi, H; Spinelli, M | 1 |
| Dunn, K; Hardy, H; Kassam, PT; Luo, D; Rogers, R; Seyedkazemi, S; Sheng, S; Simonson, RB | 1 |
| Anderson, PL; Ibrahim, M; MaWhinney, S; Moore, CM; Peterson, S | 1 |
| Anderson, PL; Baeten, JM; Das, M; Dunn, DT; Ebrahimi, R; Glidden, DV; Stirrup, OT; Zhao, Y | 1 |
| Chawana, TD; Ngara, B; Nhachi, CFB; Rusakaniko, S; Zvada, S | 1 |
| Iatan, I; Lee, TC; McDonald, EG | 1 |
| Gutiérrez-Lorenzo, M; Rubio-Calvo, D; Urda-Romacho, J | 1 |
| Ikeda, M; Moriya, K; Okamoto, K; Okugawa, S; Wakabayashi, Y; Yanagimoto, S | 1 |
| Agboyibor, MK; Anoma, C; Coulibaly, A; Dagnra, CA; Dah, TTE; De Baetselier, I; Dembélé Keita, B; Diallo, F; Diandé, S; Eubanks, A; Fayé-Ketté, H; Koné, A; Laurent, C; Le Guicher, G; Malan, JB; Mensah, E; Riegel, L; Rojas Castro, D; Sagaon-Teyssier, L; Serrano, L; Spire, B; Traoré, I; Vuylsteke, B; Yaya, I | 1 |
| Araújo, PMM; Martins, J; Osório, NS; Poveda, E; Santos-Pereira, A; Soares, H; Souto, B; Triunfante, V | 1 |
| Avelino-Silva, VI; Carvalhanas, T; Costa, AF; Domingues, CSB; Ferreira, PM; Ferreira, PRA; Furtado, JJD; Gianna, MC; Gomes E Costa, DA; Jamal, LF; Kalichman, AO; Leite, OHM; Rocha, SQ; Souza, RA; Souza, TNL; Tancredi, MV; Tayra, A | 1 |
| Alrubayyi, A; Burns, F; Fisher-Pearson, N; Gilson, R; Griffith, SA; Gupta, RK; Kinloch, S; McCoy, LE; Muir, L; Pellegrino, P; Peppa, D; Rees-Spear, C; Rowland-Jones, S; Touizer, E; Waters, L | 1 |
| Bachelard, A; Chalal, L; Damond, F; Descamps, D; Ghosn, J; Isernia, V; Landman, R; Le Gac, S; Peytavin, G; Vallois, D; Yazdanpanah, Y | 1 |
| Aydin, E; Celen, MK; Demir, Y; Yildirim, Y; Yilmaz Aydin, F | 1 |
| Chipanga, J; Ferrand, RA; Filteau, S; Gregson, CL; Kowo-Nyakoko, F; Madanhire, T; McHugh, G; Mujuru, H; Mukwasi-Kahari, C; Rehman, AM; Rukuni, R; Simms, V; Ward, KA | 1 |
| Malisheni, M; Murewanhema, G; Takah, NF | 1 |
| Bamoulid, J; Clairet, AL; Davani, S; Ducloux, D; Flammang, M; Lagoutte-Renosi, J; Lepiller, Q; Muret, P; Royer, PY | 1 |
| Marukutira, T; Wood, BR | 1 |
| Arribas, JR; Asensi, V; Berenguer, J; Del Romero, J; Díez, C; Galera, C; García-Fraile, LJ; González-García, J; Gutiérrez, F; Iribarren, JA; Izquierdo, R; Jarrín, I; López, JC; Martín-Vicente, M; Micán, R; Moreno, S; Pérez-Elías, MJ; Podzamczer, D; Portilla, J; Poveda, E; Pulido, F; Resino, S; Suárez-García, I; Vidal, F | 1 |
| Alessi, T; Feldman, PL; Felx, M; Jain, R; Roller, S; Shelton, J; Singh, R; Wang, Y; Yang, B; Zane, D | 1 |
| Asmuth, DM; Baeten, JM; Brainard, DM; Brunetta, JM; Carter, C; Cox, S; Das, M; Ebrahimi, R; Gilson, R; Henry, K; Kintu, A; Kronborg, G; Ogbuagu, O; Podzamczer, D; Ruane, PJ; Salazar, LC; Shao, Y; Spinner, CD; Whitlock, G; Wohl, D | 1 |
| Yazie, TS | 1 |
| An, M; Ding, H; Dong, X; Han, X; Li, X; Song, W; Tian, W; Wang, L; Wang, Z; Zhao, B | 1 |
| Aliyu, MH; Banda, N; Chabala, FW; Goma, F; Heimburger, DC; Kaonga, P; Mulenga, L; Munkombwe, D; Mutale, W; Mweemba, A; Siew, ED; Wester, WC | 1 |
| Boffito, M; Lei, JJH; Milinkovic, A; Moyle, G; Pereira, B | 1 |
| Asif, S; Baxevanidi, E; Chandiwana, N; Fairlie, L; Hill, A; Masenya, M; Serenata, C; Sokhela, S; Venter, WDF | 1 |
| Busca Arenzana, C; Daroca, G; Martin-Carbonero, L; Mican, R; Perez-Valero, I; Vasquez, J | 1 |
| Anderson, PL; Bauer, R; Buschman, L; Charreau, I; Cotte, L; Cua, E; Delaugerre, C; Goldwirt, L; Laghzal, A; Liegeon, G; Meyer, L; Molina, JM; Mourah, S; Pialou, G | 1 |
| Best, BM; Hill, L; Momper, JD; Patel, N; Salama, E | 1 |
| Asienzo, J; Ategeka, G; Balyegisawa, A; Castelnuovo, B; Hakim, J; Hoppe, A; Kaimal, A; Kambugu, A; Kiragga, A; Kityo, C; Mirembe, G; Mugerwa, H; Musaazi, J; Paton, NI; Siika, A; Tukamushabe, P; Walimbwa, S | 1 |
| Iannuzzi, S; von Kleist, M | 1 |
| Cao, Y; Kashuba, ADM; Scholz, EMB | 1 |
| Carneiro, PB; D'Angelo, AB; Grov, C; Johnson, J; Westmoreland, DA | 1 |
| Adeyeye, A; Anderson, P; Asmelash, A; Blanchette, C; Brown, TT; Bryan, M; Cabello, R; Chariyalertsak, S; Clement, ME; Coelho, L; Cohen, MS; Cottle, L; Daar, E; Del Rio, C; Donnell, D; Dunne, EF; Eron, JJ; Eshleman, SH; Fields, SD; Frank, I; Gallardo-Cartagena, JA; Gaur, AH; Gomez-Feliciano, K; Gonzales, P; Grinsztejn, B; Gulick, RM; Hanscom, B; Hendrix, C; Hinojosa, JC; Holtz, TH; Jennings, A; Kallas, EG; Kelley, CF; Kofron, RM; Landovitz, RJ; Li, M; Losso, MH; Lucas, J; Madruga, JV; Margolis, D; Marrazzo, J; Marzinke, M; McCauley, M; Middelkoop, K; Overton, ET; Phanuphak, N; Piwowar-Manning, E; Psaros, C; Richardson, P; Rinehart, A; Rooney, JF; Safren, S; Santos, B; Scott, H; Shin, K; Sista, ND; Smith, KY; Spreen, W; Sued, O; Sugarman, J; Sullivan, P; Swaminathan, S; Tran, HV; Valencia Huamaní, J; Wang, Z | 1 |
| Alnajebi, B; Huang, A; Ma, Q; Shang, J; Tan, R; Yan, B; Yang, J; Zhang, Y; Zhong, X | 1 |
| Chaudhary, NS; Funderburg, N; Irvin, MR; Kind, T; Overton, ET; Saag, MS; Shrestha, S; Wiener, HW; Willig, AL | 1 |
| Andreatta, K; Berger, D; Blair, C; Brainard, DM; Brar, I; Collins, SE; Hagins, D; Hileman, CO; Kumar, P; Martin, H; McDonald, C; Osiyemi, O; Ramgopal, MN; Saag, M; Wurapa, AK | 1 |
| Avihingsanon, A; Avihingsanon, Y; Gatechompol, S; Iampenkhae, K; Surintrspanont, J; Udomkarnjananun, S; Ueaphongsukkit, T | 1 |
| Babaoglu, MO; Cho, YS; Ghim, JL; Jung, JA; Kalkisim, S; Kim, EY; Nguyen, PTT; Park, JK; Parvez, MM; Shin, JG | 1 |
| Bernstein, A; Saber, S; Siegel, M; Sjaarda, A; Sparks, A | 1 |
| Darnell, J; Hill, LA; Jain, S; Karris, MY; Qin, H; Reynolds, T; Sun, X | 1 |
| Agrati, C; Antinori, A; Cicalini, S; D'Avolio, A; De Nicolò, A; Tempestilli, M | 1 |
| Khamadi, SA; Lihana, RW; Mabeya, SN; Ngugi, C; Nyamache, AK | 1 |
| Gupta, R; Kalabalik, J; Özdener, AE; Park, TE | 1 |
| Bayerri, CR; Payne, BAI; Price, DA; Samuels, R; Sayer, JA | 1 |
| Borges, ÁH; Flamholc, L; Florence, E; Gargalianos-Kakolyris, P; Hoy, J; Kyselyova, G; Leen, C; Lundgren, JD; Maltez, F; Mocroft, A; Mulcahy, F; Orkin, C; Pedersen, C; Pradier, C; Ridolfo, AL; Schmid, P; Sedlacek, D; Staub, T; Stellbrink, HJ; Tomazic, J; Uzdaviniene, V; Weber, R | 1 |
| Collier, AC; Daar, ES; Freedberg, KA; Losina, E; Parker, RA; Rabideau, DJ; Sax, PE; Tierney, C | 1 |
| Castagna, A; Chiappetta, S; Galli, L; Lazzarin, A; Nozza, S; Poli, A; Ripa, M; Rovelli, C; Spagnuolo, V; Tambussi, G | 2 |
| Ehmer, J; Hatz, C; Hobbins, MA; Labhardt, ND; Motlatsi, MM; Muhairwe, JA; Müller, UF; Muser, J; Pfeiffer, K; Ringera, I | 1 |
| Agingu, W; Ahmed, K; Crucitti, T; de Baetselier, I; Deese, J; Fransen, K; Owino, F; Rammutla, E; Van Damme, L; Venter, G | 1 |
| Cohan, D; Seidman, DL; Weber, S | 1 |
| Callebaut, C; Cox, S; Johnson, A; Margot, N; Miller, M; Ram, R | 1 |
| Boyd, MA; Carmona, S; Charpentier, C; Cooper, DA; D'amour Ndahimana, J; de Oliveira, T; Etiebet, MA; Garcia, F; Goedhals, D; Gomes, P; Günthard, HF; Gupta, RK; Hamers, RL; Hoffmann, CJ; Holmes, SP; Hunt, G; Jiamsakul, A; Kaleebu, P; Kanki, P; Kantor, R; Kerschberger, B; Marconi, VC; Ndembi, N; Ngo-Giang-Huong, N; Nsanzimana, S; Rhee, SY; Rokx, C; Santoro, MM; Saravanan, S; Schapiro, JM; Schmidt, D; Seu, L; Shafer, RW; Sigaloff, KCE; Sirivichayakul, S; Skhosana, L; Steegen, K; Sunpath, H; Tang, M; Van Zyl, GU; Varghese, V; Yang, C | 1 |
| Bodwell, J; Patel, MV; Rodriguez-Garcia, M; Rossoll, RM; Shen, Z; Wira, CR | 1 |
| Brown, TT; Gupta, SK; Ha, B; Kitch, DW; McComsey, GA; Melbourne, K; Morse, GD; Venuto, CS; Yeh, E | 1 |
| Churchill, D; Clark, D; Collins, S; Dunn, DT; Jose, S; Nelson, M; Pillay, D; Sabin, C; Smit, E; Tostevin, A; White, E; Winston, A; Zhang, H | 1 |
| Prabhu, VR; Ripin, D | 1 |
| Adimora, AA; Cole, SR; Eron, JJ | 1 |
| Baum, MM; Cox, DM; Easley, JT; Moss, JA; Smith, TJ | 1 |
| Ashworth, A; Barker, J; Davies, A; Feddy, L; Fedor, I; Ghazi Suliman, MA; Hayes, T; Kosmidis, C; Malagon, I; Ogungbenro, K; Stirling, S; Szabo-Barnes, A | 1 |
| Gotham, D; Hill, A; Pozniak, AL | 1 |
| Boffito, M; Flexner, CW; Maartens, G | 1 |
| Badal-Faesen, S; Brown, TT; Campbell, TB; Cardoso, SW; Erlandson, KM; Fiorillo, SP; Hakim, J; Kumarasamy, N; Kumwenda, J; Lalloo, U; Riviere, C; Sanchez, J | 1 |
| Karris, MY | 1 |
| Arcondo, F; Cordova, E; Morganti, L; Odzak, A; Rodriguez, C; Silva, M; Zylberman, M | 1 |
| Brouwer, WP | 1 |
| Boulle, A; Cohen, K; Davies, MA; De Waal, R; Fox, MP; Igumbor, EU; Maartens, G; Stinson, K | 1 |
| Anderson, PL; Costa Leite, ID; De Boni, RB; Goulart, S; Grinsztejn, B; Hoagland, B; Kallas, EG; Liu, AY; Luz, PM; Madruga, JV; Marins, LMS; Moreira, RI; Torres, TS; Vasconcelos, R; Veloso, VG | 1 |
| Arnalich, F; Arribas, JR; Bernardino, JI; González-García, J; Martín-Carbonero, L; Mingorance, J; Monge, S; Montejano, R; Montes, ML; Moreno, V; Pérez-Valero, I; Perona, R; Pintado Berniches, L; Stella-Ascariz, N; Valencia, E | 1 |
| Díez-Pérez, A; González-Mena, A; Guelar, A; Güerri-Fernández, R; Herrera, S; Knobel, H; Molina-Morant, D; Trenchs-Rodríguez, M; Villar-García, J | 1 |
| Fujiwara, H; Hasegawa, N; Kato, S; Takagi, R; Tanabe, Y; Yamada, E | 1 |
| Conrad, F; Govender, M; Maartens, G; Manning, K; Papavarnavas, NS | 1 |
| Chen, R; Estrella, MM; Grunfeld, C; Horberg, MA; Hsue, PY; Jotwani, V; Scherzer, R; Shlipak, MG | 1 |
| Beauchamp, G; Breaud, A; Clarke, W; Cloherty, GA; Emel, L; Eshleman, SH; Fields, SD; Hendrix, CW; Hightow-Weidman, L; Marzinke, MA; Piwowar-Manning, E; Rose, S; Shoptaw, S; Siegel, M; Wheeler, D; Zhang, Y | 1 |
| Conyngham, SC; Daughtridge, GW; Koenig, HC; Lalley-Chareczko, L; Montaner, LJ; Moorthy, GS; Mounzer, K; Sloan, CE; Tebas, P; Zuppa, AF | 1 |
| Bonnet, F; Boucquemont, J; Dabis, F; Dauchy, FA; Dupon, M; Greib, C; Lawson-Ayayi, S; Miremont-Salamé, G; Neau, D; Proust-Lima, C; Rigothier, C | 1 |
| Baeten, JM; Campbell, TB; Celum, C; Cent, A; Donnell, D; Firnhaber, C; Grinsztejn, B; Hakim, J; Hong, T; Hosseinipour, MC; Kumarasamy, N; Lalloo, U; Morrow, R; Nyirenda, M; Riviere, C; Sanchez, J; Santos, B; Supparatpinyo, K | 1 |
| Abram, ME; Callebaut, C; Kulkarni, R; Margot, NA; Miller, MD; Porter, D; White, K; Wong, P | 1 |
| Anastos, K; Aouizerat, BE; Bacchetti, P; Baxi, SM; Cohen, M; DeHovitz, JA; Gange, SJ; Greenblatt, RM; Young, MA | 1 |
| Tobin, SC | 1 |
| Collins, S; Fox, J | 1 |
| Esser, S; Streeck, H | 1 |
| Brookhart, MA; Cole, SR; Crane, HM; Edwards, JK; Eron, JJ; Hall, HI; Kitahata, MM; Mathews, WC; Moore, RD; Mugavero, MJ; Saag, MS | 1 |
| Aytekin, E; Çalış, S; Gürsoy, RN; Öztürk, N; Polat, KH; Şahin, A; Tezel, N; Timur, SS | 1 |
| Kurmi, M; Singh, S | 1 |
| Bias, TE; Boyle, SM; Doyle, AM; Harhay, MN; Lee, DH; Malat, G; Pang, L; Ranganna, K; Sharma, A; Talluri, S | 1 |
| Maartens, G; Martinson, NA; Mochan, A; Muchichwa, P; Norman, J; Rakgokong, M; Sigauke, FR; Variava, E | 1 |
| Hadigan, CM; Hazra, R; Jones, SE; Kopp, JB; Mattingly, AS; Purdy, JB; Reynolds, JC; Unsal, AB | 1 |
| Clayden, P; Serenata, C; Venter, WDF | 1 |
| Choi, JY; Han, SH; Jeong, SJ; Kim, JM; Ku, NS; Lee, JU; Lee, KH; Song, YG | 1 |
| Beigi, R; Biggio, J; Dai, JY; Hendrix, C; Isaacs, K; Montgomery, ET; Noguchi, LM; Pan, J; Piper, J; Schwartz, JL; Watts, DH | 1 |
| Anderson, M; Bailey, B; Balba, G; Brooks, KM; Garrett, KL; George, JM; Kuriakose, SS; Lane, HC; Maldarelli, F; Pau, AK | 1 |
| Li, J; Mesplède, T; Nekka, F; Sanche, S; Sheehan, N; Wainberg, MA | 1 |
| Angione, SA; Cherian, SM; Özdener, AE | 1 |
| Boffito, M; Lamorde, M; Pozniak, A; Watkins, M | 1 |
| Baeten, J; John-Stewart, G; Mugwanya, KK | 1 |
| Abdool Karim, Q; Abdool Karim, SS; Birse, K; Burgener, AD; Butler, J; Cheu, R; Grobler, A; Klatt, NR; Mansoor, L; McKinnon, LR; Noël-Romas, L; Passmore, JS; Perner, M; Westmacott, G; Xie, IY; Zevin, AS | 1 |
| Incardona, F; Meini, G; Mloka, D; Mugusi, F; Mugusi, S; Neogi, U; Sönnerborg, A; Svärd, J; Zazzi, M | 1 |
| Avettand-Fenoel, V; Bellecave, P; Bonnet, F; Caldato, S; Hessamfar, M; Morlat, P; Ngo Bell, EC; Saunier, A; Tumiotto, C; Vandenhende, MA | 1 |
| Atzori, C; Clementi, EGI; Falvella, FS; Galli, M; Giacomelli, A; Meraviglia, P; Oreni, ML; Rusconi, S; Salvaggio, SE | 1 |
| Calcagno, A; Cattelan, AM; Celesia, BM; De Socio, G; Focà, E; Gervasi, E; Guaraldi, G; Maia, L; Malagoli, A; Nozza, S; Orofino, G; Piconi, S | 1 |
| Savage, N | 1 |
| Gore, ML; Jatta, A; Lemoine, M; Ndow, G; Njie, R; Sabally, S; Sadiq, F; Shimakawa, Y; Sow, A; Suso, P; Tamba, S; Thursz, MR; Touré-Kane, C | 1 |
| Avihingsanon, A; Burger, DM; Gatechompol, S; Maek-A-Nantawat, W; Ruxrungtham, K; Sapsirisavat, V; Sophonphan, J; Thammajaruk, N; Thiansanguankul, W; Ubolyam, S | 1 |
| Bandera, A; Bonfanti, P; Calza, L; Carenzi, L; Celesia, BM; Cordier, L; De Socio, GV; Di Biagio, A; Falasca, K; Gori, A; Madeddu, G; Maggi, P; Martinelli, C; Orofino, G; Pellicanò, GF; Quirino, T; Ricci, E; Rusconi, S; Squillace, N; Vichi, F | 1 |
| Anderson, PL; Bekker, LG; Buchbinder, SP; Chariyalertsak, S; Glidden, DV; Grant, RM; Grinsztejn, B; Guanira, J; McMahan, V; Mulligan, K; Schechter, M | 2 |
| Awoke, T; Birlie, B; Braekers, R; Kasim, A; Shkedy, Z | 1 |
| Boffito, M; Day-Weber, I; Hill, A; Korologou-Linden, R; McClure, MO; Nwokolo, N; Wang, X; Whitlock, G | 1 |
| Fountain, JJ; Haaland, RE; Hall, L; Heeke, S; Holder, A; Kelley, CF; Martin, A; Pescatore, NA | 1 |
| Balkus, J; Elharrar, V; Husnik, M; Jeenarain, N; Kabwigu, S; Levy, L; Livant, E; Mhlanga, F; Nair, G; Palanee-Phillips, T; Panchia, R; Pather, A; Patterson, K; Premrajh, A; Ramjee, G; Riddler, SA; Selepe, P; Siva, S; Tutshana, BO | 1 |
| Kaufman, B; Zehtabchi, S | 1 |
| Darcis, G; Moutschen, M; Sauvage, AS | 1 |
| Gallagher, A; Gracey, DM; Quan, D | 1 |
| Battegay, M; Bernasconi, E; Calmy, A; Cavassini, M; Fehr, J; Gayet-Ageron, A; Hirzel, C; Schmid, P; Sculier, D | 1 |
| Andreatta, K; Antinori, A; Berenguer, J; Bloch, M; Cote, P; Flamm, J; Garner, W; McColl, DJ; Nguyen-Cleary, T; Piontkowsky, D; Pozniak, A; Szwarcberg, J; Ward, D | 1 |
| Lau, JSY; Ratnam, D; Woolley, I | 1 |
| Anugulruengkitt, S; Bunupuradah, T; Chanakul, A; Jantarabenjakul, W; Phupitakphol, T; Prasitsuebsai, W; Puthanakit, T; Ruxrungtham, K; Sopa, B; Sophonphan, J | 1 |
| Arrabal-Durán, P; Chamorro-de-Vega, E; Gijón-Vidaurreta, P; Herranz-Alonso, A; Rodríguez-González, CG; Sanjurjo-Sáez, M | 1 |
| Aboud, M; Aylott, A; Belonosova, E; Buchanan, AM; Falcó, V; Hagins, DP; Man, CY; Orrell, C; Porteiro, N; Smith, KY; Vavro, C; Walmsley, S; Wynne, B | 1 |
| Baeten, JM; Balkus, JE; Bukusi, E; Celum, C; Cohen, CR; Donnell, D; Fiedler, T; Fredricks, DN; Heffron, R; Kiarie, J; Lingappa, J; McClelland, RS; Mugo, N; Munch, M | 1 |
| Bernaud, C; Capitant, C; Charreau, I; Chas, J; Chidiac, C; Cotte, L; Cua, E; Delaugerre, C; Doré, V; Fonsart, J; Mestre, SL; Meyer, L; Molina, JM; Pasquet, A; Pialoux, G; Pintado, C; Ponscarme, D; Rojas-Castro, D; Sagaon-Teyssier, L; Spire, B; Thompson, D; Tremblay, C; Wainberg, MA | 1 |
| Balán, IC; Bekker, LG; Brown, W; Carballo-Diéguez, A; Chariyalertsak, S; Chitwarakorn, A; Cranston, RD; Dolezal, C; Giguere, R; Gomez, K; Gonzales, P; Grossman, C; Hendrix, CW; Holtz, TH; Horn, S; Jacobson, C; Johnson, S; Kunjara Na Ayudhya, RP; Lama, J; Leu, CS; Liu, A; Marzinke, MA; Mayer, KH; McGowan, I; Patterson, K; Piper, JM; Richardson, BA; Zorrilla, C | 1 |
| Di Nicola, M; Falasca, K; Francisci, D; Gabrielli, C; Porfilio, I; Schiaroli, E; Ucciferri, C; Vecchiet, J | 1 |
| Chen, M; Chow, EP; Fairley, CK; Medland, NA; Read, TR; Walker, RG | 1 |
| Bulut, N; Yılmaz, B | 1 |
| Ahoua, L; Baggaley, R; DiMattei, P; El-Sadr, WM; Falcao, J; Lahuerta, M; Morales, F; Ramiro, I; Zerbe, A | 1 |
| Atta, MG; Estrella, MM; Jotwani, V | 1 |
| Arduino, RC; Luque, A; Ma, Q; Mapstone, M; Miller, E; Qiu, X; Schifitto, G; Tivarus, M; Wang, L; Weber, M; Zhong, J; Zhuang, Y | 1 |
| Abdool Karim, Q; Abdool Karim, S; Carlson, JM; Chopera, DR; Ndabambi, N; Ngandu, NK; Williamson, C | 1 |
| Heffron, R; Velloza, J | 1 |
| Ayon, NJ; Coulibaly, FS; Ezoulin, MJM; Oyler, NA; Purohit, SS; Youan, BC | 1 |
| Akpomiemie, G; Arulappan, N; Chersich, MF; Majam, M; Mashabane, N; Moorhouse, M; Venter, WDF | 1 |
| Anderson, PL; Bacchetti, P; Buchbinder, S; Cohen, SE; Elion, R; Gandhi, M; Horng, H; Kolber, MA; Koss, CA; Kuncze, K; Liu, A; Louie, A; Murnane, PM | 1 |
| Ding, Y; Gao, M; He, N; Liu, C; Liu, X; Ning, Z; Wong, FY | 1 |
| Murphy, RA; Valentovic, MA | 1 |
| Brar, I; Cheng, A; Custodio, J; Daar, ES; Gallant, J; Girard, PM; Lazzarin, A; Martin, H; Mills, A; Orkin, C; Podzamczer, D; Quirk, E; Rockstroh, J; Tebas, P; Wei, X; White, K; Wohl, D | 1 |
| Antinori, A; Cheng, A; Custodio, J; DeJesus, E; Garner, W; Koenig, E; Montes, ML; Pozniak, A; Quirk, E; Reynes, J; Sax, PE; SenGupta, D; Slim, J; Stellbrink, HJ; White, K; Workowski, K | 1 |
| Brambilla, D; Ceffa, S; De Luca, A; Liotta, G; Luhanga, R; Magid, NA; Mancinelli, S; Marazzi, MC; Palombi, L; Sidumo, ZJ; Zanelli, G | 1 |
| Baum, MM; Chatterji, U; Gallay, PA; Gandarilla, A; Gunawardana, M; Kirchhoff, A; Marzinke, MA; Moss, JA; Pyles, RB | 1 |
| Chen, Q; Jin, X; Ouyang, B; Peng, Y; Sun, J; Wang, G; Zhang, J; Zhen, L; Zhou, F | 1 |
| Atta, MG; Choi, MJ; Fine, D; McMahon, BA; Novick, TK; Rosenberg, AZ | 1 |
| Cao, H; Chang, S; Hodder, SL; Kulkarni, R; Miller, MD; White, KL | 1 |
| Agarwal, A; Alexander, PE; Chang, Y; Foroutan, F; Guyatt, GH; Hepworth, E; Lee, Y; Lesi, O; Mah Ming, J; Merglen, A; Mir, H; Mirza, R; Siemieniuk, RA; Zeraatkar, D; Zhang, Y | 1 |
| Amico, KR; Anderson, PL; Beymer, M; Bolan, RK; Bushman, L; Dierst-Davies, R; Flynn, R; Jordan, WC; Kofron, R; Landovitz, RJ; Lee, DP; Psaros, C; Rooney, J; Tseng, CH; Wohl, AR | 1 |
| Cotarelo, M; Macías, J; Mancebo, M; Merchante, N; Merino, D; Montes-Ramírez, ML; Pérez-Pérez, M; Pineda, JA; Pulido, F; Raffo, M; Rivero-Juárez, A; Téllez, F | 1 |
| Avihingsanon, A; Bloch, M; Cahn, P; East, L; Homony, B; Kaplan, R; Katlama, C; Leavitt, R; Molina, JM; Nguyen, BY; Rassool, M; Ratanasuwan, W; Rawlins, S; Rodgers, A; Rojas, E; Ruane, P; Sax, PE; Sklar, P; Squires, K; Teppler, H; Vandekerckhove, L; Wenning, L; Xu, X; Yazdanpanah, Y | 1 |
| Achterbergh, RCA; Anderson, PL; Cornelissen, M; de Bree, GJ; de Vries, HJC; Hoornenborg, E; Jurriaans, S; Kootstra, NA; Prins, JM; Prins, M; Reiss, P; Woittiez, LR | 1 |
| Goorhuis, A; Kooij, KW; Post, FA; Prins, M; Reiss, P; van der Valk, M; van Zoest, RA; Vogt, L; Wit, FWNM | 1 |
| Abbai, NS; Naidoo, S; Nyirenda, M; Ramjee, G | 1 |
| Baldelli, S; Cattaneo, D; Clementi, E; Galli, M; Gervasoni, C; Giacomelli, A; Mazzali, C; Meraviglia, P; Milazzo, L; Minisci, D; Resnati, C; Rizzardini, G | 1 |
| Bonito, A; Bonora, S; Calcagno, A; Casari, S; Castelli, F; D'Avolio, A; Di Perri, G; Domenighini, E; Focà, E; Quiros Roldan, E; Simiele, M; Trentini, L | 1 |
| Ankrah, DNA; Lartey, M; Leufkens, HGM; Mantel-Teeuwisse, AK | 1 |
| Amico, KR; Anderson, PL; Bekker, LG; Dye, BJ; Elharrar, V; Eshleman, SH; Grant, RM; Hendrix, CW; Hughes, JP; Li, M; Marzinke, MA; McKinstry, L; Piwowar-Manning, E; Rooney, JF; Roux, S; Sebastien, E; Stirratt, M; Yola, N | 1 |
| Ferrara, SM; Santantonio, T; Sica, S; Tartaglia, A | 1 |
| Anderson, PL; Bacon, O; Buchbinder, SP; Chege, W; Cohen, SE; Coleman, ME; Doblecki-Lewis, S; Elion, R; Kolber, MA; Liu, AY; Shlipak, M; Tang, EC; Vittinghoff, E | 1 |
| Arribas, JR; Eron, JJ; Gathe, J; Hufkens, V; Lathouwers, E; Molina, JM; Negredo, E; Opsomer, M; Orkin, C; Petrovic, R; Van Landuyt, E; Vanveggel, S | 1 |
| Anderson, PL; Bacchetti, P; Benet, LZ; Gandhi, M; Horng, H; Hosek, SG; Koss, CA; Kuncze, K; Liu, AY; Louie, A; Saberi, P; Wilson, CM | 1 |
| Alejos, B; Arribas, JR; Barrufet, P; Cervero, M; Curran, A; Domingo, P; Iribarren, JA; Knobel, H; Lagarde, M; Palacios, R; Payeras, A; Pérez-Valero, I; Pulido, F; Ribera, E; Rivero, A; Rodríguez-Gómez, FJ; Ryan, P; Sanz, J; Téllez, MJ; Yllescas, M | 1 |
| Baker, A; Flynn, PM; Gordon, CM; Harris, DR; Havens, PL; Hazra, R; Kapogiannis, BG; Meyer, WA; Mulligan, K; Pan, CG; Price, G; Rutledge, B; Schuster, GU; Stephensen, CB; Van Loan, MD; Wilson, CM; Woodhouse, LR | 1 |
| Kwak, IS; Lee, JE; Lee, S; Lee, SH; Song, SH | 1 |
| Bregigeon, S; Faucher-Zaegel, O; Lacarelle, B; Obry-Roguet, V; Poizot-Martin, I; Quaranta, S; Solas, C; Tamalet, C | 1 |
| Gatanaga, H; Kawasaki, Y; Kikuchi, Y; Mutoh, Y; Nishijima, T; Oka, S; Tomonari, K | 1 |
| Donahue Carlson, R; Frisch, MB; Haaland, RE; Kraft, CS; Martin, A; Mehta, CC; Ofotokun, I; Patel, AS; Pau, CP; Read, TD; Sheth, AN | 1 |
| Guaraldi, G | 1 |
| Baeten, JM; Bukusi, EA; Celum, C; Heffron, RA; John-Stewart, G; Mugo, N; Ngure, K; Pintye, J; Were, E | 1 |
| Cairns, G; Cambiano, V; Delpech, V; Desai, M; Dunn, D; Field, N; Gill, ON; Hart, G; McCormack, S; Miners, A; Nardone, A; Ong, KJ; Phillips, AN; Rodger, A | 1 |
| Arudo, J; Barry, M; Hodgkinson, LM; Makori, J; Okwiri, J; Tsisiche, C | 1 |
| Abdool Karim, SS; Baxter, C; Passmore, JS | 1 |
| Avihingsanon, A; Burger, DM; Mitruk, S; Punyawudho, B; Rungtivasuwan, K; Ruxrungtham, K; Sukasem, C; Thammajaruk, N | 1 |
| Reinke, T | 1 |
| Janabi, M; Kabeho, A; Mayala, H; Nicholaus, P; Nkinda, A; Pallangyo, P | 1 |
| Deeks, ED | 4 |
| Ayudhya, RPKN; Balán, IC; Brown, W; Carballo-Diéguez, A; Cranston, RD; Giguere, R; Hendrix, CW; Horn, S; Lama, JR; Marzinke, MA; McGowan, I; Patterson, K; Piper, JM | 1 |
| Coppola, N; Macera, M; Pisaturo, M; Sagnelli, C; Sagnelli, E | 1 |
| Agbaji, O; Audu, R; Chaplin, B; Ezechi, O; Idigbe, E; Imade, G; Kanki, PJ; Meloni, S; Muazu, M; Musa, AZ; Odaibo, G; Okpokwu, J; Olaleye, D; Onwuamah, C; Rawizza, H; Samuel, J | 1 |
| Abaasa, A; Anderson, P; Bumpus, NN; Gandhi, M; Haberer, JE; Hendrix, C; Kamali, A; Kibengo, F; Mutua, G; Priddy, F; Sanders, EJ | 1 |
| Arnaiz, JA; Cruceta, A; García, F; Gatell, JM; González, E; González-Cordón, A; Inciarte, A; Laguno, M; Leal, L; León, A; Lucero, C; Mallolas, J; Martínez-Rebollar, M; Rojas, J; Torres, B | 1 |
| Ganase, B; Harrigan, PR; Harris, M; Hull, MW; Montaner, JSG; Watson, B | 1 |
| Cottrell, ML; Kashuba, ADM; Prince, H; Schauer, AP; Sykes, C | 1 |
| Cazorla-Luna, R; Martín-Illana, A; Notario-Pérez, F; Rubio, J; Ruiz-Caro, R; Tamayo, A; Veiga, MD | 1 |
| Badiou, S; Bado, G; Ciaffi, L; Cournil, A; Delaporte, E; Diouf, A; Eymard-Duvernay, S; Héma, A; Kabore, FN; Koulla-Shiro, S; Zoungrana, J | 1 |
| Balán, IC; Bekker, LG; Brown, W; Carballo-Diéguez, A; Chariyalertsak, S; Chitwarakorn, A; Cranston, RD; Dolezal, C; Giguere, R; Gonzales, P; Holtz, TH; Lama, JR; Leu, CS; Liu, A; Mayer, KH; McGowan, I; Piper, JM; Rael, C; Richardson, BA; Zorrilla, CD | 1 |
| Kimani, J; Ndakala, FN; Norbert Behrens, GM; Oluka, MN; Oyugi, JO | 1 |
| Adams-Huet, B; Bedimo, RJ; Brown, G; Castanon, R; Farukhi, I; Maalouf, NM; Moore, T; Poindexter, J; Tebas, P; Turner, D | 1 |
| Carbone, A; Castagna, A; Galizzi, N; Galli, L; Gianotti, N; Lazzarin, A; Merli, M; Nozza, S; Poli, A; Ripa, M; Spagnuolo, V | 1 |
| Bauman, LJ; Keller, MJ; Stein, K; Watnick, D | 1 |
| Bruzzone, B; D'Ambrosio, B; Del Puente, F; Di Biagio, A; Riccardi, N; Ripamonti, D; Taramasso, L; Viscoli, C | 1 |
| Akunuri, S; Kallampallil, J; Leong, S; Maweni, R | 1 |
| Chan, PA; Harrison, LC; Patel, RR; Powderly, WG; Presti, R | 1 |
| Grace, D; Jollimore, J; MacPherson, P; Strang, MJP; Tan, DHS | 1 |
| Anderson, PL; Bushman, LR; Castillo-Mancilla, JR; Erlandson, K; Gandhi, M; Horng, H; Kiser, JJ; Kuncze, K; MaWhinney, S; Morrow, M; Seifert, SM; Zheng, JH | 1 |
| Balestre, E; Bärnighausen, T; Bazin, B; Boyer, S; Dabis, F; De Oliveira, T; Dreyer, J; Herbst, K; Iwuji, CC; Larmarange, J; Makowa, T; McGrath, N; Newell, ML; Okesola, N; Orne-Gliemann, J; Pillay, D; Rekacewicz, C; Tanser, F; Thiebaut, R | 1 |
| Arami, H; Cai, Y; Febo, M; Huang, Z; Nair, M; Raymond, A; Rodriguez, E; Takemura, Y; Tomitaka, A | 1 |
| Bedimo, R; Bress, AP; Crook, J; Esker, S; Knippenberg, K; LaFleur, J; Nyman, H; Rosenblatt, L; Tebas, P | 1 |
| Beck, B; Beste, L; Howren, MB; Lund, B; Maier, M; Ohl, ME; Skolnik, A; van Epps, P; Vaughan-Sarrazin, M | 1 |
| Aboud, M; Angelis, K; Cupo, M; De Wet, J; Gartland, M; Kahl, LP; Lupo, S; McComsey, GA; Parks, D; Poggio, MC; Vandermeulen, K; Wynne, B | 1 |
| Bodwell, J; Kashuba, ADM; Patel, MV; Rodriguez-Garcia, M; Shen, Z; Wira, CR | 1 |
| Bakshi, RP; Breakey, J; Fuchs, EJ; Jois, B; Manohar, M; Marzinke, MA | 1 |
| Dorward, J; Drain, PK; Garrett, N; Karim, QA; Samsunder, N; Yende-Zuma, N | 1 |
| Asriel, B; Chan, L; Eaton, EF; Wyatt, CM | 1 |
| de Bree, GJ; Hoornenborg, E; Prins, JM; Prins, M | 1 |
| Darcis, G; Moutschen, M | 1 |
| Olalla, J | 1 |
| Dayyab, FM; Habib, AG; Iliyasu, G | 1 |
| Leufkens, HGM; Mantel-Teeuwisse, AK; Mavhunga, F; Mekonen, TT; Mengistu, A; Rennie, T; Ruswa, N; Sagwa, EL | 1 |
| Aboud, M; Angelis, K; Blair, EA; Brinson, C; Castelli, F; Gartland, M; Girard, PM; Hung, CC; Kahl, LP; Llibre, JM; Smith, K; Underwood, M; Vandermeulen, K; Wynne, B | 1 |
| Bares, SH; Dyavar, SR; Fletcher, CV; Havens, J; Lee, S; O'Neill, J; Podany, AT; Scarsi, KK; Swindells, S | 1 |
| Chikwapulo, B; Evans, R; Ngwira, B; Sagno, JB | 1 |
| Barth, A; Lai, MT; Ma, B; McHale, CM | 1 |
| Jhaveri, R; Meshnick, SR; Parr, JB; Wilson, P | 1 |
| Heldwein, S; Jaeger, H; Noe, S; Oldenbuettel, C; Pascucci, R; Ruecker, K; von Krosigk, A; Wiese, C; Wolf, E | 1 |
| DeJesus, E; Haas, B; Liu, YP; Makadzange, T; Margot, N; McCallister, S; Mills, A; Ramgopal, MN; Segal-Maurer, S | 1 |
| Cadinha, S; Malheiro, D; Moreira da Silva, JP; Mota, M; Sousa, MJ; Teixeira, T | 1 |
| Dalzero, S; Degli Antoni, A; Floridia, M; Guaraldi, G; Liuzzi, G; Masuelli, G; Personeni, C; Pinnetti, C; Ravizza, M; Sansone, M; Spinillo, A; Tamburrini, E; Tassis, B | 1 |
| Carlson, K; Seidman, D; Weber, S; Witt, J | 1 |
| Cautela, MP; das Neves, J; Moshe, H; Sarmento, B; Sosnik, A | 1 |
| Amico, KR; Anderson, PL; Chitwarakorn, A; Curlin, ME; Dye, BJ; Elharrar, V; Eshleman, SH; Grant, RM; Hendrix, CW; Hirsch-Moverman, Y; Holtz, TH; Hughes, JP; Li, M; Loquere, A; Mannheimer, S; Marzinke, MA; McKinstry, L; McNicholl, JM; Piwowar-Manning, E; Rooney, JF; Stirratt, M; van Griensven, F | 1 |
| Amico, KR; Bekker, LG; Boily, MC; Bokoch, K; Chitwarakorn, A; Dimitrov, D; Donnell, D; Grant, RM; Holtz, TH; Hughes, JP; Mannheimer, S; Mitchell, KM; Xia, F | 1 |
| Brown, TT; Díez-Pérez, A; Fernandez Marron, A; García-Giralt, N; González-Mena, A; Guelar, A; Güerri-Fernández, R; Knobel, H; Lerma-Chippirraz, E; Soldado-Folgado, J; Trenchs-Rodríguez, M; Villar-García, J | 1 |
| Anderson, SM; Chandra, N; Cottrell, M; Doncel, GF; Kashuba, A; Kimble, T; Schwartz, JL; Sykes, C; Thurman, AR; Yousefieh, N | 1 |
| Innes, S; Patel, K | 1 |
| Denieffe, S; Dunne, E; Kenny, D; Mallon, PWG; O'Halloran, JA; Tinago, W | 1 |
| Awodele, O; Oshikoya, KA; Popoola, TD | 1 |
| Anderson, PL; De Boni, RB; Freitas, L; Goulart, S; Grinsztejn, B; Hoagland, B; Kallas, EG; Leite, IC; Liu, A; Luz, PM; Madruga, JV; Martins, LMS; Moreira, RI; Torres, TS; Vasconcelos, R; Veloso, VG | 1 |
| Chetty, T; Coutsoudis, A; Thorne, C | 1 |
| Castelli, F; Cheng, A; Cox, S; Crofoot, G; Das, M; DeJesus, E; Di Perri, G; Estrada, V; Mallon, PWG; Peyrani, P; Podzamczer, D; Post, FA; Raffi, F; Rhee, MS; Ruane, P; Winston, A; Yan, M | 1 |
| Archary, D; Garcia Lerma, JG; Karim, QA; Karim, SSA; Kashuba, AD; Liebenberg, LJ; Mansoor, LE; Masson, L; McKinnon, LR; Nagelkerke, N; Ngcapu, S; Passmore, JS; Sivro, A; Yende-Zuma, N | 1 |
| Frieboes, HB; Halwes, ME; Steinbach-Rankins, JM; Tyo, KM | 1 |
| Avihingsanon, A; Cao, H; Cheng, A; Hagins, D; Hodder, S; Jiang, S; Kido, A; Kityo, C; Kulkarni, R; Squires, K | 1 |
| Amet, S; Deray, G; Isnard-Bagnis, C; Loens, C; Tourret, J | 1 |
| Farcasanu, M; Kwon, DS | 1 |
| Cevik, M; Orkin, C | 1 |
| Chang, HH; Choi, JY; Jung, H; Kim, S; Kim, SW; Lee, JM; Lee, SA; Park, HK | 1 |
| Becquet, V; Danel, C; Eholié, S; Larmarange, J; Masumbuko, JM; Nouaman, M; Plazy, M | 1 |
| Collier, AC; Ho, RJY; Kinman, LM; Koehn, J; Kraft, JC; Lane, S; Lee, W; McConnachie, LA | 1 |
| Amico, KR; Mayer, KH; Riddell, J | 1 |
| Besseghir, A; Blum, L; Brun-Vezinet, F; Charpentier, C; Chene, G; Collin, F; Damond, F; Descamps, D; Gallien, S; Matheron, S; Mortier, E; Peytavin, G; Ponscarme, D; Sellier, P; Tubiana, R | 1 |
| Gatanaga, H; Matsumoto, S; Mizushima, D; Nguyen, DT; Nguyen, DTH; Oka, S; Tanuma, J; Trung, NV; van Kinh, N | 1 |
| Freedberg, KA; Grinsztejn, B; Losina, E; Luz, PM; Maclean, RL; Mesquita, F; Osher, B; Paltiel, AD; Parker, RA; Stern, ME; Struchiner, CJ; Veloso, VG; Walensky, RP | 1 |
| Achterbergh, RC; Davidovich, U; de Vries, HJ; Hogewoning, A; Hoornenborg, E; Prins, M; Sonder, GJ; van der Helm, JJ; van der Loeff, MFS; van Duijnhoven, YT | 1 |
| Eron, JJ; Hoffman, E; Hudgens, M; Marcus, C; Menezes, P; Mollan, K; Rublein, J; Wills, J; Xie, Z | 1 |
| Callebaut, C; Cox, S; Margot, N; Miller, M | 1 |
| Bowden, BH; Smith, DE; Tom, M | 1 |
| Ikeda, A; Kikuchi, A; Komatsu, A; Matsushita, S; Minami, C; Tan, M | 1 |
| Agarwal, N; Balasubramanyam, A; Couturier, J; Fletcher, CV; Grattoni, A; Lake, JE; Lewis, DE; Nehete, BP; Nehete, PN; Podany, AT; Sastry, KJ; Suliburk, JW; Wilkerson, GK; Winchester, LC; Xuan Chua, CY | 1 |
| Hope, TJ | 1 |
| Manosuthi, W; Pinthong, D; Puangpetch, A; Sukasem, C; Tomongkon, S; Wiriyakosol, N | 1 |
| Bekker, LG; Bokoch, K; Bumpus, NN; Figueroa, DB; Grant, RM; Hendrix, CW; Holtz, TH; Hughes, JP; Li, M; Mannheimer, S; Piwowar-Manning, E; Tillotson, J; van Griensven, F | 1 |
| Choonara, YE; du Toit, LC; Kondiah, PPPD; Kumar, P; Pillay, V; Siyawamwaya, M | 1 |
| Bonawitz, R; Brennan, AT; Fox, MP; Heeren, T; Long, L; Maskew, M; Sanne, I | 1 |
| Gandhi, M; Hurt, CB; McKellar, MS; Okochi, H; Thaden, JT | 1 |
| Abdelghani, N; Dawood, H; Naidoo, K; Naidu, N; Padayatchi, N; Perumal, R; Singh, N; Yende-Zuma, N | 1 |
| Diseko, M; Essex, M; Jacobson, DL; Lockman, S; Makhema, J; Mayondi, G; Mmalane, M; Petlo, C; Rough, K; Shapiro, RL; Zash, R | 1 |
| Buchbinder, SP | 1 |
| Barr, E; Chadwick, EG; Currier, JS; Hernandez-Diaz, S; Hoffman, RM; Huo, Y; Patel, K; Rough, K; Seage, GR; Shapiro, DE; Williams, PL | 1 |
| Satsangi, S | 1 |
| Appiah, LT; Beloukas, A; Chadwick, D; Geretti, AM; Phillips, RO; Post, F; Ruggiero, A; Sarfo, FS; Smith, C; Stockdale, AJ; Villa, G | 1 |
| Garofalo, R; Kuhns, L; Mimiaga, MJ; Ogunbajo, A; Reisner, SL; Restar, AJ | 1 |
| Hsieh, E; Yin, MT | 1 |
| Andrews, E; Bay, C; De Paris, K; Dellon, ES; Gay, CL; Kashuba, AD; Madanick, RD; Nelson, JA; Prince, HA; Rosen, EP; Shaheen, NJ; Sykes, C; Weber, MD | 1 |
| Amiel, C; Chaix, ML; Charpentier, C; Delaugerre, C; Descamps, D; Dufayard, J; Flandre, P; Grude, M; Guinard, J; Lambert-Niclot, S; Le Guillou-Guillemette, H; Maillard, A; Marcelin, AG; Mirand, A; Montes, B; Morand-Joubert, L; Mourez, T; Reigadas, S; Rodallec, A; Vallet, S | 1 |
| Jones, J; Taylor, BS; Tieu, HV; Wilkin, TJ | 1 |
| Carpp, LN; Cohen, MS; Corey, L; Gilbert, PB; Gray, GE; Janes, H; Lombard, C; Ramjee, G | 1 |
| Franconi, I; Guaraldi, G | 1 |
| Andersson, MI; Arends, JE; Glashoff, RH; Maponga, TG; Preiser, W; Taljaard, J; van Rensburg, CJ | 1 |
| Bonolo, PF; Ceccato, MDGB; Costa, JO; Dos Santos, H; Mendes, JC; Reis, AMM; Silveira, MR | 1 |
| Castagna, A; Lazzarin, A; Spagnuolo, V | 2 |
| Anderson, PL; Brainard, DM; Bushman, LR; Castillo-Mancilla, JR; Chung, RT; Fierer, DS; Hughes, MD; Kim, AY; Kiser, JJ; MacBrayne, CE; Marks, KM; Naggie, S; Peters, MG; Seifert, SM | 1 |
| Fulco, PP; Higginson, RT | 1 |
| Easley, KA; Kalapila, AG; Kyle, AW; Michal, JL; Miller, LS; Patel, M; Rab, S | 1 |
| Clotet, B; Negredo, E | 1 |
| Bennett, M; Coca, SG; Defechereux, P; Gandhi, M; Glidden, DV; Grant, RM; Jotwani, V; Liu, A; Mehrotra, M; Parikh, CR; Scherzer, R; Shlipak, MG | 1 |
| Balar, B; Dai, JY; Dezzutti, CS; Galaska, B; Hendrix, CW; Justman, JE; Kunjara Na Ayudhya, RP; Levy, L; Marzinke, MA; McGowan, I; Mushamiri, I; Nair, GL; Pan, Z; Piper, JM; Schwartz, JL | 1 |
| Bärnighausen, T; Bor, J; Boulle, A; Brennan, AT; Davies, MA; Fatti, G; Fox, MP; Prozesky, H; Sikazwe, I; Stinson, K; Tanser, F; Wandeler, G; Wood, R; Zanolini, A | 1 |
| Bacon, O; Cardenas, G; Cohen, SE; Coleman, M; Doblecki-Lewis, S; Elion, R; Feaster, DJ; Kolber, MA; Liu, AY | 1 |
| Casado, JL; Fontecha, M; Monsalvo, M; Rodriguez-Sagrado, MA; Rojo, AM | 1 |
| Degen, O; Ebert, J; Schröder, AS; Sperhake, JP | 1 |
| Bachiller, P; Bahamonde, A; Barberá, JR; Casado, A; Diz, J; Domingo, P; Fernández, P; Lorenzo, JF; Martínez, E; Mayorga, MI; Muñoz, A; Ocampo, A; Podzamczer, D; Rodriguez, M; Rozas, N; Salgado, X; Santos, J; Sepúlveda, MA; Torres, C; Yzusqui, M | 1 |
| Bensouda, S; Cone, RA; Date, AA; Ensign, LM; Fuchs, EJ; Gumber, S; Hanes, J; Hendrix, C; Hoang, T; Marzinke, M; Ortiz, JO; Rohan, L; Villinger, F; Xiao, P; Young, TW | 1 |
| Antinori, A; Cossarizza, A; Cozzi-Lepri, A; d'Arminio Monforte, A; Gori, A; Lichtner, M; Lorenzini, P; Marchetti, G; Mussini, C; Nozza, S; Rusconi, S | 1 |
| Calinas, F; Costa, MN; Germano, I; Loureiro, RV | 1 |
| Dunn, DT; Glidden, DV; McCormack, S; Stirrup, OT | 1 |
| Corbino, JA; Cottrell, ML; Nicol, MR | 1 |
| Baron, D; Delany-Moretlwe, S; Gray, G; Ikaneng, T; Ju, S; Mabude, Z; Makgopa, S; Malefo, MA; Manenzhe, KN; Mazibuko, T; Nkala, B; Ntjana, H; Palanee-Phillips, T; Rees, H; Scorgie, F; Stadler, J | 1 |
| Alejos, B; Arnalich, F; Arribas, JR; Bernardino, JI; Cantos, AE; de Miguel, R; González-Garcia, J; Martín-Carbonero, L; Monge, S; Montejano, R; Montes, ML; Moreno, V; Pérez-Valero, I; Perona, R; Rodes, B; Rodriguez-Centeno, J; Stella-Ascariz, N; Valencia, E | 1 |
| Harris, M | 1 |
| Andreatta, K; Brar, I; Brinson, C; Cheng, A; Custodio, J; Liu, H; López-Cortés, L; Martin, H; Mills, A; Molina, JM; Podzamczer, D; Quirk, E; Ruane, P; Stellbrink, HJ; Ward, D | 1 |
| Andreatta, K; Cheng, A; Creticos, C; Crofoot, G; Custodio, J; Daar, ES; DeJesus, E; Graham, H; Koenig, E; Liu, YP; Martin, H; Molina, JM; Oguchi, G; Quirk, E; Rockstroh, JK; Ruane, P | 1 |
| Carr, A; Ebeling, PR; Hoy, JF; Kerr, SJ; Martinez, E; Pocock, N; Richardson, R; Rojas, J | 1 |
| Butini, L; Costantini, A; Martini, M; Rocchi, M; Tontini, C | 1 |
| Borghetti, A; Castelli, F; Izzo, I; Lombardi, F; Maggiolo, F; Magro, P; Quiros-Roldan, E; Raffetti, E; Saracino, A | 1 |
| Asin, SN; Brache, V; Chandra, N; Clark, MR; Dezzutti, CS; Doncel, GF; Fichorova, R; Herold, BC; Hillier, SL; Kiser, P; Marzinke, MA; McCormick, T; Rollenhagen, C; Schwartz, JL; Stanczyk, FZ; Thurman, AR; Weiner, D | 1 |
| Clarke, A; Garner, W; Laouri, M; Maggiolo, F; Martin, H; Quirk, E; Wohl, D | 1 |
| Höring, S; Löffler, B; Pletz, MW; Rößler, S; Schleenvoigt, BT; Weis, S | 1 |
| Ananworanich, J; Colby, DJ; Gandhi, M; Grant, RM; Kroon, E; Phanuphak, N; Phanuphak, P; Robb, ML; Sacdalan, C | 1 |
| Aung, WS; Bakshi, RP; Breakey, J; Fuchs, EJ; Hendrix, CW; Johnson, JE; Marzinke, MA; Weld, E | 1 |
| Bradshaw, CS; Chen, MY; Chow, EPF; Cornelisse, VJ; Fairley, CK; Fortune, R; Needleman, R; Towns, JM; Yang, TZT | 1 |
| Alsunaid, SR; Ashraf, H; Soubani, AO | 1 |
| Bares, SH; Havens, JP; Lee, SS; O'Neill, JL; Podany, AT; Sayles, HR; Scarsi, KK; Swindells, S | 1 |
| Alejos, B; Allavena, C; Arribas, JR; Bernardino, JI; de Miguel, R; Esteban-Cantos, A; Gisslén, M; Hoffmann, C; Montejano, R; Raffi, F; Rodes, B; Rodriguez-Centeno, J; Schwimmer, C; Stella-Ascariz, N; Wallet, C | 1 |
| Dubrocq, G; Rakhmanina, N | 1 |
| Antonyak, S; Bukovinowa, P; Bursa, D; Gökengin, D; Horban, A; Jilich, D; Kowalska, JD; Mulabdic, V; Tomazic, J; Vasylyev, M | 1 |
| Cameron, SA; Cheshenko, N; Frank, B; Fredricks, D; Herold, BC; Keller, MJ; Mesquita, PM; Reagle, K; Sinclair, S; Srinivasan, S; Taneva, E; Weinrick, B | 1 |
| Asiimwe, S; Baeten, JM; Bukusi, EA; Bulya, N; Celum, C; Heffron, R; Hong, T; Katabira, E; Marzinke, MA; Mugo, N; Ngure, K; Odoyo, J; Tindimwebwa, E | 1 |
| Li, J; Mesplède, T; Nekka, F; Sanche, S; Sheehan, NL | 1 |
| Appiah, LT; Beloukas, A; Chadwick, D; Geretti, AM; Phillips, RO; Ruggiero, A; Sarfo, FS; Smith, C; Stockdale, AJ; Villa, G | 1 |
| Bumpus, NN; Fuchs, EJ; Hendrix, CW; Seneviratne, HK | 1 |
| Baettig, V; Battegay, M; Courlet, P; Delko, T; Marzolini, C | 1 |
| Aralaguppe, SG; Neogi, U; Njenda, DT; Rao, R; Sarafianos, SG; Singh, K; Sönnerborg, A | 1 |
| Bulterys, M; Chen, L; Fan, B; Kourtis, AP; Liu, W; Shepard, C; Shepherd, JA; Wang, A; Wang, L; Wiener, J | 1 |
| Bunge, KE; Dezzutti, CS; Hendrix, CW; Hillier, SL; Marzinke, MA; Meyn, LA; Moncla, BJ; Richardson-Harman, N; Rohan, LC; Schwartz, JL; Spiegel, HML | 1 |
| Ho, RJY; Koehn, J; Kraft, JC; McConnachie, LA; Perazzolo, S; Shen, DD; Shireman, LM | 1 |
| Dai, J; Huang, A; Liang, H; Qu, D; Xiao, G; Zhong, X | 1 |
| Álvarez, H; Díaz-Cambre, H; García-González, J; Llibre, JM; Mariño, A; Valcarce, N | 1 |
| Chen, J; Cottrell, ML; Dumond, JB; Garrett, KL; Maas, BM; Prince, HA; Schauer, AP; Sykes, C; White, N | 1 |
| Azariah, S; Coughlan, E; Giola, M; Ludlam, A; Myers, J; O'Toole, C; Pohl, M; Rich, J; Saxton, P | 1 |
| Folayan, MO; Peterson, K | 1 |
| Jiang, X; Luo, A; Ren, H | 1 |
| Brache, V; Chandra, N; Chen, BA; Doncel, GF; Kashuba, ADM; Mauck, C; Schwartz, JL; Thurman, AR; Weiner, DH | 1 |
| Aslan, A; Balavoine, S; Bauer, R; Brun, A; Delaugerre, C; Leplatois, A; Loze, B; Molina, JM; Moudachirou, K; Noret, M; Pintado, C; Rozenbaum, W; Siguier, M | 1 |
| Anderson, PL; Bacchetti, P; Castillo-Mancilla, J; Gandhi, M; Koss, CA; Kuncze, K; Liu, AY; Louie, A; MaWhinney, S; McHugh, C; Morrow, M; Okochi, H; Seifert, S | 1 |
| Lee, FJ | 1 |
| Firląg-Burkacka, E; Grycner, E; Horban, A; Kowalska, JD; Matłosz, B; Pietraszkiewicz, E | 1 |
| Agyei, NA; Cotton, M; Frigati, L; Machemedze, T; Mahtab, S; Myer, L; Nourse, P; Perrazzo, S; Ray, P; Zar, H | 1 |
| Burgess, JF; Christiansen, CL; Drainoni, ML; Horný, M; Kuohung, W; Leech, AA; Linas, BP; Sullivan, M | 1 |
| Gordon, CM; Havens, PL; Kapogiannis, BG; Long, D; Mulligan, K; Price, G; Schuster, GU; Stephensen, CB; Wilson, CM | 1 |
| Domingo, P; Gutierrez, MDM; Mateo, MG; Vidal, F | 1 |
| Anton, PA; Baum, MM; Butkyavichene, I; Churchman, SA; Cortez, JM; Dawson, L; Fanter, R; Gunawardana, M; Guthrie, KM; Hendrix, CW; Marzinke, MA; Miller, CS; Moss, JA; Olive, TJ; Pyles, RB; Rosen, RK; Vargas, SE; Vincent, KL; Yang, F | 1 |
| Abdool Karim, Q; Abdool Karim, SS; Bekker, V; Bhiman, JN; Eren, K; Garrett, N; Marais, J; Moore, PL; Morris, L; Murrell, B; Nonyane, M; Sheward, DJ; Williamson, C; Woodman, ZL | 1 |
| Anderson, PL; Gordon, CM; Havens, PL; Hosek, SG; Kapogiannis, BG; Liu, N; Mulligan, K; Schuster, GU; Stephensen, CB; Tamhane, A; Wilson, CM | 1 |
| Edelstein, H; Maruff, P; Robertson, K; Ross, LL; Shaefer, MS; Small, CB; Wohl, D | 1 |
| Andrinopoulou, ER; Bakker, JA; Bierau, J; Leers, MPG; Lowe, SH; Paulussen, ADC; Peltenburg, NC; Schippers, JA; van den Bosch, BJC; Verbon, A | 1 |
| Kingdon, E; Richardson, D; Scott, J; Williams, D | 1 |
| Blumenthal, J; Corado, K; Daar, ES; Dubé, MP; Ellorin, E; Haubrich, R; Jain, S; Milam, J; Moore, DJ; Morris, SR; Sun, X | 1 |
| Bedoya, LM; Cazorla-Luna, R; Martín-Illana, A; Notario-Pérez, F; Ruiz-Caro, R; Veiga, MD | 1 |
| Bogner, JR; DeGrosky, M; Dicker, IB; Gartland, M; Joshi, SR; Lataillade, M; Llamoso, C; Lombaard, J; Min, S; Molina, JM; Morales-Ramirez, J; Pene Dumitrescu, T; Stock, DA | 1 |
| Chen, QY; Fang, ZL; Harrison, TJ; Hu, LP; Jia, HH; Li, KW; Liang, SJ; Ren, CC; Wang, C; Wang, XY; Yang, QL | 1 |
| Kabwigu, S; Kamira, B; Kemigisha, D; Kiweewa Matovu, F; Mubiru, MC; Muwawu, R; Nakabiito, C; Nakyanzi, T; Wynne, J | 1 |
| Blake, KH; Chen, J; Cohen, MS; Dumond, JB; Gay, CL; Greene, SA; Kashuba, ADM; Maas, BM; Nelson, JAE; Prince, HMA; Schauer, AP; Sykes, C | 1 |
| Cattaneo, D; Perno, CF; Rizzardini, G | 1 |
| Tartaglia, A | 1 |
| Calvez, V; Dabis, F; Danaviah, S; de Oliveira, T; Derache, A; Giandhari, J; Gupta, RK; Iwuji, CC; Marcelin, AG; Pillay, D | 1 |
| Balboa-Barreiro, V; Castro-Iglesias, Á; Cid-Silva, P; Fernández-Bargiela, N; López-Calvo, S; Margusino-Framiñán, L; Martín-Herranz, I; Mena-De-Cea, Á; Míguez-Rey, E; Poveda, E; Vázquez-Rodríguez, P | 1 |
| Eichner, A; Shalit, P; Thomas, A; Tung, EL | 1 |
| Bonora, S; Calcagno, A; Cusato, J; D'Avolio, A; Di Perri, G; Ferrara, M; Fiumanò, M; Marinaro, L; Montrucchio, C; Pizzi, C; Trentini, L; Zugna, D | 1 |
| Carballo-Dieguez, A; Dolezal, C; Fuchs, EJ; Giguere, R; Hendrix, CW; Lentz, C | 1 |
| Eberle, J; Kroidl, A | 1 |
| Aboud, M; Antinori, A; Arribas, JR; Cahn, P; Clarke, AE; Currie, A; Fettiplace, A; Gartland, M; Girard, PM; Hung, CC; Madero, JS; Man, C; Ortiz, R; Pappa, K; Rockstroh, JK; Sievers, J; Smith, K; Tenorio, AR; Underwood, M; Wynne, B | 1 |
| Abgrall, S; Costagliola, D; Duvivier, C; Fischer, H; Joly, V; Lacombe, JM; Lang, S; Mary-Krause, M; Potard, V; Rozenberg, S; Valantin, MA | 1 |
| Naing, C; Poovorawan, Y; Tong, KS | 1 |
| Dai, JH; Hu, Y; Huang, AL; Liang, H; Peng, B; Zhang, JY; Zhang, Y; Zhong, XN | 1 |
| Davies, N; Heffron, R | 1 |
| Castro, L; Chow, DC; Duerler, T; Gangcuangco, LMA; Kallianpur, KJ; Kohorn, L; Nagamine, L; Nakamoto, BK; Paul, R; Pien, FD; Shikuma, CM; Soll, B; Souza, S; Walker, M | 1 |
| Baptiste, SL; Etya'ale, HM; Taro, TB | 1 |
| Bagella, P; Baldin, G; Capetti, A; Ciccullo, A; Cossu, MV; De Luca, A; Di Giambenedetto, S; Giacomelli, A; Lagi, F; Latini, A; Madeddu, G; Rusconi, S; Sterrantino, G | 1 |
| Bandera, A; Bozzi, G; Colella, E; Gori, A; Squillace, N | 1 |
| Siegler, AJ; Sullivan, PS | 1 |
| Andreoni, M; Cerva, C; Maffongelli, G; Malagnino, V; Sarmati, L; Teti, E | 1 |
| Baggaley, R; Dalal, S; Hodges-Mameletzis, I; Msimanga-Radebe, B; Rodolph, M | 1 |
| Geng, EH; Glidden, DV; Padian, N | 1 |
| Ahmed, K; Baron, D; Bekker, LG; Brown, ER; Brumskine, W; Delany-Moretlwe, S; Doncel, GF; Gray, G; Lombard, C; Marzinke, M; Morris, L; Myer, L; Nchabeleng, M; Nkala, B; Ntshangase, J; Palanee-Philips, T; Panchia, R; Rees, H; Schwartz, JL; Sebe, M; Sibiya, S; Smith, E | 1 |
| Coulibaly, FS; Dim, DC; Ezoulin, MJM; Molteni, A; Youan, BC | 1 |
| Martìnez, E; Pulido, F | 1 |
| Gómez Ayerbe, C; Palacios Muñoz, R; Santos González, J | 1 |
| Galindo Puerto, MJ | 1 |
| Fontecha, M; Luis Casado, J; Monsalvo, M; Vizcarra, P | 1 |
| Barth, RE; Chersich, MF; Grobbee, DE; Kambugu, A; Klipstein-Grobusch, K; Kumarasamy, N; Lalla-Edward, ST; Moorhouse, MA; Venter, WD; Vos, AG; Zuithoff, P | 1 |
| Kan, W; Leng, X; Liao, L; Liu, P; Ruan, Y; Shao, Y; Wang, J; Xing, H; Xu, W; Yan, J; You, Y; Zuo, Z | 1 |
| Cottrell, ML; Garcia, B; Imaz, A; Kashuba, ADM; Morenilla, S; Niubó, J; Perez, E; Podzamczer, D; Tiraboschi, JM | 1 |
| Hamers, RL; Inzaule, SC; Rinke de Wit, TF | 1 |
| Destache, CJ; Fan, W; Kang, G; Li, Q; Mandal, S; Prathipati, PK; Zhou, Y | 1 |
| Capetti, AF; Cossu, MV; Giacomet, V; Rizzardini, G; Zuccotti, G | 1 |
| Amico, KR; Andrade, A; Chege, W; Chen, YQ; Gulick, RM; Kapadia, SN; Landovitz, RJ; Mayer, KH; McCauley, M; Schackman, BR; Wilkin, TJ; Wu, C | 1 |
| Anderson, PL; Blumenthal, J; Dawson, M; Ellorin, EE; Franklin, D; Hanashiro, M; Heaton, R; Hoenigl, M; Moore, DJ; Morgan, E; Morris, SR; Pasipanodya, E | 1 |
| Arendt, G; Orhan, E; Schlonies, S; Stüve, O | 1 |
| Bumpus, NN; Hamlin, AN; Tillotson, J | 1 |
| Heldwein, S; Jaeger, H; Noe, S; Page, M; Wolf, E | 1 |
| Akpomiemie, G; Arulappan, N; Becker, S; Chersich, MF; Duncombe, C; Feldman, C; Hill, A; Kambugu, A; Kumarasamy, N; Majam, M; Moorhouse, M; Poongulali, S; Ripin, DHB; Sokhela, S; Venter, WDF; Vos, A | 1 |
| Buchbinder, SP; Defechereux, P; Gandhi, M; Glidden, DV; Grant, RM; Kuncze, K; Mehrotra, M; Okochi, H; Rodrigues, WC; Spinelli, MA; Vincent, M; Wang, G | 1 |
| Baldin, G; Belmonti, S; Borghetti, A; Ciccullo, A; De Luca, A; Di Giambenedetto, S; Emiliozzi, A; Gagliardini, R; Lamonica, S; Lombardi, F; Montagnani, F; Moschese, D; Visconti, E | 1 |
| Antinori, A; Calcagno, A; Ceccherini-Silberstein, F; Cozzi-Lepri, A; d'Arminio Monforte, A; De Luca, A; Maggiolo, F; Marchetti, G; Mondi, A; Rusconi, S; Tavelli, A; Vichi, F | 1 |
| Bacchetti, P; Baeten, JM; Cressey, TR; Drain, PK; Gandhi, M; Klinbuayaem, V; Okochi, H; Rodrigues, WC; Siriprakaisil, O; Spinelli, MA; Vincent, M; Wang, G | 1 |
| Allavena, C; Billaud, E; Bonnet, B; Bouchez, S; Chauveau, M; Hall, N; Hitoto, H; Merrien, D; Michau, C; Perez, L; Raffi, F; Sécher, S | 1 |
| Bahr, NC; Yarlagadda, SG | 1 |
| Boyer, EW; Carrico, AW; Chai, PR; Jambaulikar, GD; Mayer, KH; O'Cleirigh, C; Pereira, LM | 1 |
| Mesplède, T; Pham, HT | 1 |
| Touger, R; Wood, BR | 1 |
| Ammassari, A; Angeletti, C; Antinori, A; Bellagamba, R; Gallo, AL; Giancola, ML; Narciso, P; Nicastri, E; Pinnetti, C; Piselli, P; Tempestilli, M; Tommasi, C; Zaccarelli, M | 1 |
| Chirenje, ZM; Deal, C; Hendrix, CW; Hillier, SL; Kelly, C; Marrazzo, JM; Marzinke, MA; Morrow, RA; Piper, J; Rabe, L; Richardson, B; Schwartz, JL | 1 |
| Bodwell, J; Patel, MV; Rodriguez-Garcia, M; Shen, Z; Wira, CR | 1 |
| Dickinson, L; Else, LJ; Gini, J; Khoo, S; Neary, M; Olagunju, A; Siccardi, M; Waitt, C | 1 |
| Brown, TT; Díez-Pérez, A; García-Giralt, N; González-Mena, A; Güerri-Fernández, R; Knobel, H; Lerma-Chippirraz, E; Pineda-Moncusí, M; Soldado-Folgado, J; Trenchs-Rodríguez, M | 1 |
| Beauchamp, G; Chen, YQ; Emel, LM; Fields, SD; Hendrix, CW; Hightow-Weidman, L; Hucks-Ortiz, C; Kuo, I; Lucas, J; Magnus, M; Mayer, KH; Nelson, LE; Piwowar-Manning, E; Shoptaw, S; Watkins, P; Watson, CC; Wheeler, DP; Wilton, L | 1 |
| Coy, KC; Delpino, A; Hazen, RJ; Kirkham, HS; Siegler, AJ | 1 |
| Acosta, RK; Chang, S; Garner, W; Lutz, J; Majeed, S; Martin, H; Martin, R; Quirk, E; SenGupta, D; Wei, X; White, KL; Willkom, M | 1 |
| Chendi, BH; Eyoh, A; Ikomey, GM; Jacobs, GB; Lyonga, E; Mesembe, M; Okomo Assoumou, MC; Yekwa, EL | 1 |
| Bugnon, S; Godinho, R; Gracin, T; Tataw, J | 1 |
| Daughtridge, G; Hunt, T; Koenig, H; Lalley-Chareczko, L; Swyryn, M | 1 |
| Ascher, SB; Cohen, M; Estrella, MM; Grunfeld, C; Gustafson, D; Ho, K; Jotwani, V; Kassaye, S; Muiru, A; Ng, DK; Palella, FJ; Parikh, CR; Scherzer, R; Sharma, A; Shlipak, MG; Tien, PC; Witt, MD; Zhang, WR | 1 |
| Lelièvre, JD | 1 |
| Billong, SC; Cappelli, G; Ceccherini-Silberstein, F; Colizzi, V; Dambaya, B; Fokam, J; Fokunang, CN; Gori, C; Nanfack, AJ; Ndjolo, A; Perno, CF; Salpini, R; Santoro, MM; Sosso, SM; Takou, D; Teto, G | 1 |
| Abrams, EJ; Brittain, K; Gomba, Y; Hu, NC; Maartens, G; Myer, L; Norman, J; Orrell, C; Phillips, TK; Sinxadi, P; Wiesner, L; Zerbe, A | 1 |
| Amico, KR; Anderson, PL; Beymer, MR; Bolan, R; Bushman, LR; Goodman-Meza, D; Jordan, WC; Kofron, RM; Landovitz, RJ; Psaros, C; Rooney, JF; Wohl, AR | 1 |
| Baidoobonso, S; Husbands, W; Kaul, R; Nelson, LE; Sa, T; Tharao, W; Thomas-Pavanel, J; Zhabokritsky, A; Zhang, N | 1 |
| Huang, JP; Huang, WH; Luo, SD; Luo, XL; Mo, LD; Ni, ZY; Su, GS; Su, HZ; Wu, JY | 1 |
| Althoff, KN; Brown, TT; Estrella, MM; Gonciulea, A; Kingsley, LA; Lake, JE; Palella, FJ; Sellmeyer, DE; Wang, R | 1 |
| Chen, J; Ji, Y; Liu, L; Lu, H; Qi, T; Shen, Y; Song, W; Tang, Q; Tang, Y; Wang, Z; Xun, J; Yang, J; Zhang, R | 1 |
| Gibas, KM; Krakower, DS; Powell, VE; van den Berg, P | 1 |
| Armishaw, J; Asselin, J; Batrouney, C; Chang, CC; Cornelisse, VJ; Cundill, P; El-Hayek, C; Fairley, CK; Forgan-Smith, G; Gall, J; Hellard, ME; Hoy, JF; Lal, L; Lockwood, JT; Mak, A; Murphy, DA; Nguyen, L; Penn, M; Pickett, C; Price, B; Roth, NJ; Ruth, S; Ryan, KE; Spelman, TD; Stoové, MA; Tee, BK; Traeger, MW; Vujovic, O; West, M; Willcox, J; Wright, EJ | 1 |
| Aguilera, A; Barea, L; Corral, O; Gomez-Gallego, F; Gonzalez, R; Soriano, V; Treviño, M | 1 |
| Gandhi, RT; Rosales, IA; Wojciechowski, D | 1 |
| Laroche, H; Lions, C; Poizot-Martin, I; Tamalet, C; Zaegel-Faucher, O | 1 |
| Borsa, A; Carnevale, C; Cohall, A; Gordon, P; Gottlieb, F; Hyden, C; Olender, S; Richards, P; Slowikowski, J; Sobieszczyk, ME; Vakkur, I; Zucker, J | 1 |
| Bauermeister, JA; Dowshen, N; Franklin, J; Gross, R; Koenig, HC; Lalley-Chareczko, L; Petsis, D; Shea, JA; Swyryn, M; Wood, S | 1 |
| Allavena, C; Bani-Sadr, F; Cabié, A; Chéret, A; Cotte, L; Delobel, P; Duvivier, C; Gantner, P; Huleux, T; Jacomet, C; Joly, V; Pugliese, P; Rey, D; Valantin, MA | 1 |
| Blake, K; Chen, J; Cohen, MS; Dumond, JB; Gay, CL; Greene, SA; Nelson, JAE; Prince, HMA; Schauer, AP; Sykes, C | 1 |
| Bacchetti, P; Brummel, S; Currier, JS; Flynn, PM; Fowler, MG; Gandhi, M; Hoffman, RM; Kuncze, K; Louie, A; Murnane, PM; Nematadzira, T; Okochi, H; Owor, M; Phung, N; Saidi, F; Soko, DK | 1 |
| Blumenthal, J; Corado, K; Dube, M; Ellorin, E; Haubrich, R; Hoenigl, M; Jain, S; Moore, DJ; Morris, SR; Sun, X | 1 |
| Kacin, A; Moll, AP; Ndlovu, NE; Shenoi, SV; Vazquez, L | 1 |
| Acosta, R; Antinori, A; Baumgarten, A; Brainard, D; Brinson, C; Clarke, A; Collins, SE; Hagins, D; Martin, H; Ramgopal, MN; Thompson, MA; Wei, X; Wohl, DA; Yazdanpanah, Y | 1 |
| Barber, TJ | 1 |
| Acosta, R; Albrecht, H; Arribas, JR; Brainard, D; Collins, SE; Creticos, C; Maggiolo, F; Martin, H; Martorell, CT; Sax, PE; Stellbrink, HJ; Stephens, JL; Wei, X | 1 |
| Bastard, JP; Capeau, J; Costagliola, D; Eme, AL; Esteve, E; Fellahi, S; Guiard-Schmid, JB; Lebrette, MG; Lescure, FX; Pialoux, G; Plaisier, E; Ronco, P | 1 |
| Boffito, M; Brady, M; Green, I; McClure, M; Nutland, W; Wang, X | 1 |
| Alexander, K; Anderson, PL; Blum, J; Brooks, KM; Bushman, LR; Castillo-Mancilla, JR; Ellison, L; Huntley, R; Kerr, BJ; Kiser, JJ; MacBrayne, CE; MaWhinney, S | 1 |
| Anderson, PL; Bacon, O; Buchbinder, SP; Cohen, S; Coleman, ME; Elion, R; Gandhi, M; Glidden, DV; Kolber, MA; Liu, AY; Scott, H; Spinelli, MA; Vittinghoff, E | 1 |
| Di Perri, G; Esser, S; Lelièvre, JD; Parczewski, M; Shafran, SD | 1 |
| Anderson, SM; Doncel, GF; Gajer, P; Marzinke, MA; Ravel, J; Schwartz, JL; Thurman, AR; Yousefieh, N | 1 |
| Aldrovandi, G; Chan, C; Fischer, B; Goodenow, MM; Kim-Chang, JJ; Sleasman, JW; Venturi, G; Weber, TJ; Wilson, L | 1 |
| Anderson, PL; Bekker, LG; Buchbinder, SP; Chariyalertsak, S; Defechereux, P; Gandhi, M; Glidden, DV; Grant, RM; Guanira, JV; McMahan, VM; Schechter, M; Spinelli, MA; Veloso, VG | 1 |
| Cahn, P; Hanna, G; Hwang, C; Kumar, S; Martin, E; Molina, JM; Orkin, C; Rodgers, A; Sax, P; Squires, K; Teppler, H; Thompson, M; Xu, X | 1 |
| Beksinska, M; Brown, TT; Eneh, P; Fowler, MG; Isingel, E; Kabwigu, S; Kaiser, T; Kiweewa Matovu, F; Nakalega, R; Nicol, MR; Staley, C; Sykes, C | 1 |
| Chellappan, DK; Chellian, J; Collet, T; Dua, K; Gupta, G; Liew, YK; Loo Xin, GL; Tan, YY; Yap, PK | 1 |
| Amico, KR; Bekker, LG; Chitwarakorn, A; Dye, BJ; Grant, RM; Hendrix, CW; Holtz, TH; Hughes, JP; Li, M; Mannheimer, S; Marzinke, M; Ojeda, VD; Wilson, E | 1 |
| Maponga, CC; Morse, GD; Mtisi, TJ; Ndhlovu, CE | 1 |
| Elopre, L; Mena, L; Siegler, AJ; Sullivan, PS | 1 |
| Chang, SY; Chen, GJ; Cheng, A; Chuang, YC; Huang, SH; Huang, YC; Huang, YS; Hung, CC; Lin, KY; Liu, WC; Su, YC; Sun, HY | 1 |
| Anderson, PL; Cofield, SS; Havens, PL; Hosek, SG; Kapogiannis, BG; Landovitz, RJ; Liu, N; Mulligan, K; Patki, A; Perumean-Chaney, SE; Wilson, CM | 1 |
| Bumpus, NN; Chaturvedula, A; Fossler, MJ; Goti, V; Haberer, JE; Hendrix, CW; Mallayasamy, S; Marzinke, MA; Sale, M | 1 |
| Bougatsos, C; Chou, R; Dana, T; Evans, C; Grusing, S; Hoverman, A; Korthuis, PT; Sun, C | 1 |
| Barry, MJ; Cabana, M; Caughey, AB; Curry, SJ; Davidson, KW; Doubeni, CA; Epling, JW; Krist, AH; Kubik, M; Landefeld, CS; Mangione, CM; Owens, DK; Pbert, L; Silverstein, M; Simon, MA; Tseng, CW; Wong, JB | 1 |
| Geng, E; Glidden, DV; Glymour, MM; Grant, RM; McMahan, VM; Mehrotra, ML; Westreich, D | 1 |
| Barriere, G; Chas, J; Cotte, L; Cua, E; Durand, F; Ghosn, J; Mera, R; Molina, JM; Ohayon, M; Pialoux, G; Pintado, C; Siguier, M; Valin, N | 1 |
| Beymer, MR; Holloway, IW; Landovitz, RJ; Pulsipher, C | 1 |
| Abdool Karim, SS; Baxter, C; Blackard, JT; Ngcapu, S; Penton, PK; Powell, EA | 1 |
| Azariah, S; Forster, R; Franklin, R; Jenkins, R; Saxton, P; Werder, S | 1 |
| Bopitiya, S; Das, S; Dhother, J; Taha, H | 1 |
| Boyer, L; Citerne, Q; Garon, J; Gillet, P; Moreau, E; Petitpain, N | 1 |
| Fekade, D; Gebre-Selassie, S; Grossmann, S; Kalu, AW; Marrone, G; Neogi, U; Sönnerborg, A; Tegbaru, B; Telele, NF | 1 |
| Wyles, DL | 1 |
| Abbas, UL; Ding, Y; Glaubius, RL; Hood, G | 1 |
| Domingues, WV; Dos Reis, LM; Eira, M; Furukawa, LN; Galvão, J; Jorgetti, V; Martins, CSW; Moyses, RM; Nickolas, TL; Oliveira, IB; Pereira, RM; Ramalho, J; Yin, MT | 1 |
| Kim, WR; Kwo, PY; Mannalithara, A; Sripongpun, P | 1 |
| Barabona, G; Hachiya, A; Iwatani, Y; Lyamuya, E; Mahiti, M; Masoud, S; Matsuda, M; Mbelele, P; Mgunya, AS; Minja, L; Shigemi, U; Sunguya, B; Ueno, T | 1 |
| Brown, K; Cunningham, D; De Wit, S; Eron, JJ; Hufkens, V; Jezorwski, J; Lathouwers, E; Opsomer, M; Orkin, C; Petrovic, R; Post, FA; Pulido, F; Van Landuyt, E | 1 |
| Gatanaga, H; Oka, S | 1 |
| Kaplun, O; Psevdos, G | 1 |
| Affolabi, D; Alary, M; Aza-Gnandji, M; Bachabi, M; Béhanzin, L; Boily, MC; Cianci, F; Diabaté, S; Diallo, M; Dramane, K; Gagnon, MP; Gangbo, F; Geidelberg, L; Geraldo, N; Giguère, K; Goma-Matsétsé, E; Guédou, FA; Kêkê, RK; Kessou, L; Lafrance, C; Mboup, A; Vickerman, P; Zannou, DM | 1 |
| Bekker, LG; Buchbinder, S; Carballo-Diéguez, A; Chariyalertsak, S; Chitwarakorn, A; Cranston, RD; Gonzales, P; Gundacker, H; Holtz, TH; Johnson, S; Lama, JR; Liu, AY; Mayer, KH; Norwood, A; Patterson, K; Piper, JM; Zorrilla, C | 1 |
| Brieva, J; Kosche, C; Nardone, B; Palella, FJ; Para, A; West, DP | 1 |
| Baggaley, R; Dalal, S; Fonner, VA; Hodges-Mameletzis, I; Msimanga-Radebe, B; Mugo, N | 1 |
| Castillo-Mancilla, JR | 1 |
| Bacchetti, P; Baeten, JM; Cressey, R; Cressey, TR; Drain, PK; Gandhi, M; Klinbuayaem, V; Kubiak, RW; Okochi, H; Punyati, P; Quame-Amaglo, J; Siriprakaisil, O; Sirirungsi, W; Sukrakanchana, PO; Tanasri, S | 1 |
| Masson, L; McKinnon, LR | 1 |
| Baeten, JM; Barnabas, RV; Bekker, LG; Bukusi, EA; Celum, CL; Delany-Moretlwe, S; Hosek, S; McConnell, M; van der Straten, A | 1 |
| Chen, Y; Huang, Y; Lu, Y; Tao, X; Zhou, Y | 1 |
| Dodoo, ANO; Lartey, M; Leufkens, HGM; Mantel-Teeuwisse, AK; Nartey, ET; Tetteh, RA; Yankey, BA | 1 |
| Amico, KR; Bacchetti, P; Curlin, ME; Dye, BJ; Eshleman, SH; Gandhi, M; Grant, RM; Hendrix, CW; Holtz, TH; Hughes, JP; Li, M; Liu, A; Mannheimer, S; Marzinke, MA; Murnane, P; Piwowar-Manning, E; Velloza, J | 1 |
| Conway-Washington, C; Dinh, C; Fountain, J; Haaland, RE; Hall, L; Holder, A; Kelley, CF; Livermont, T; Lupo, LD; Martin, A | 1 |
| Archampong, T; Bears, K; Chen, Y; Gong, Y; Kwara, A; Langaee, T; Lartey, M; Obo-Akwa, A; Ojewale, O; Sagoe, KW | 1 |
| Baeten, JM; Celum, C; Irungu, E; Katabira, E; Lingappa, JR; Lund, JM; Meyers, AFA; Mugo, N; Muwonge, TR; Pattacini, L; Plews, M; Richert-Spuhler, LE | 1 |
| Boyer, S; Calmy, A; Delaporte, E; Eymard-Duvernay, S; Kouanfack, C; Leroy, S; Mpoudi-Etame, M; Omgba Bassega, P; Peeters, M | 1 |
| Baeten, JM; Bangsberg, DR; Haberer, JE; Hendrix, C; Jaggernath, M; Kriel, Y; Matthews, LT; O'Neil, K; Psaros, C; Smit, JA; Smith, PM; Ware, NC; Wirth, K | 1 |
| Asano, T; Fujiki, K; Furumoto, Y; Hayakawa, Y; Horiuchi, T; Kobayashi, K; Matsumoto, T; Matsuoka, M; Misumi, Y; Miura, N; Nozaka, T; Sakamoto, N | 1 |
| Hu, X; Wang, L; Xu, F | 1 |
| Katzenstein, D; Kouamou, V; Makadzange, AT; Manasa, J; McGregor, AM; Ndhlovu, CE | 1 |
| Carr, A; Ebeling, P; Hoy, J; Kerr, SJ; Martinez, E; Pocock, N; Richardson, R; Rojas, J | 1 |
| Babusis, D; Callebaut, C; Cong, ME; Deyounks, F; Dinh, C; García-Lerma, JG; Heneine, W; Holder, A; Johnson, R; Khalil, G; Lipscomb, J; Massud, I; McCallister, S; Nishiura, K; Pan, Y; Park, Y; Rooney, JF; Ruone, S | 1 |
| Avihingsanon, A; Bukuru, A; Cardoso, SW; Collier, AC; Faesen, S; Godfrey, C; Grinsztejn, B; Gross, R; Hogg, E; Hughes, MD; Kanyama, C; Kumarasamy, N; Makanga, M; Mave, V; Mellors, JW; Mngqibisa, R; Mohapi, L; Montalban, E; Mugyenyi, P; Nerette Fontain, S; Ritz, J; Salata, R; Samaneka, W; Santos, BR; Schooley, RT; Secours, R; Sugandhavesa, P; Valencia, J; van Schalkwyk, M; Wallis, CL; Wangari Ndege, B; Wieclaw, L | 1 |
| Chagomerana, MB; DiPrete, BL; Harrington, BJ; Hosseinipour, MC; Jumbe, AN; Limarzi, L; Ngongondo, M; Wallie, SD | 1 |
| Bąkowska, E; Firląg-Burkacka, E; Horban, A; Kowalska, JD; Matłosz, B; Vassilenko, A | 1 |
| Adebisi, SA; Adedeji, NO; Adedeji, TA | 1 |
| DeJesus, E; DiNubile, MJ; Leavitt, R; Lennox, JL; Miller, M; Nguyen, BY; Rockstroh, JK; Rodgers, AJ; Saag, MS; Sklar, P; Teppler, H; Walker, ML; Wan, H; Yazdanpanah, Y | 1 |
| Adams, JL; Corbett, AH; Dumond, JB; Forrest, A; Jennings, SH; Kashuba, AD; Kendrick, RL; Malone, S; Patterson, KB; Prince, HM; Sykes, C; Wang, R; White, N | 1 |
| Bayonne Kombo, ES; Gathse, A | 1 |
| Brady, JJ; Brinkman, K; Cotter, AG; Furrer, H; Fux, CA; Mallon, PW; Reiss, P; Sabin, CA; Vrouenraets, SM; Wit, FW | 1 |
| Plosker, GL | 1 |
| Barrail-Tran, A; Descamps, D; Duval, X; Goujard, C; Mentré, F; Nembot, G; Panhard, X; Parienti, JJ; Taburet, AM; Vigan, M; Vrijens, B | 1 |
| Ackers, ML; Buchbinder, SP; Chillag, KL; Collins, BM; Grant, RM; Grohskopf, LA; Gvetadze, R; Liu, AY; Mayer, KH; Oʼhara, B; Pathak, SR; Paxton, LA; Rose, CE; Thompson, M | 1 |
| Gatanaga, H; Kikuchi, Y; Komatsu, H; Nishijima, T; Oka, S; Shimbo, T; Takano, M; Tanuma, J; Teruya, K; Tsukada, K | 1 |
| Bangsberg, DR; Karim, QA; Mansoor, LE; Matthews, LT; Sibeko, S; Yende-Zuma, N | 1 |
| Abdool Karim, Q; Abdool Karim, SS; Altfeld, M; Carr, WH; Douek, DC; Naranbhai, V; Ndungʼu, T; Roque, A; Samsunder, N; Sandler, NG | 1 |
| Ackers, M; Buchbinder, SP; Chillag, K; Colfax, G; Collins, B; Grohskopf, L; Gvetadze, R; Liu, AY; Mayer, K; Oʼhara, B; Pathak, S; Paxton, L; Thompson, M; Vittinghoff, E | 1 |
| Gatanaga, H; Hayashida, T; Oka, S; Tanuma, J | 1 |
| de la Torre, J; del Arco, A; Olalla, J; Pombo, M; Prada, JL; Urdiales, D | 1 |
| Baeten, JM; Grant, R | 1 |
| Broderick, E; Hotta, MT; Wyatt, CM | 1 |
| Baltussen, R; Boucher, CA; Nichols, BE; Nouwen, JL; Sloot, PM; Thuma, PE; van de Vijver, DA; van de Wijgert, J; van Dijk, JH | 1 |
| Chateau, ML; Denton, PW; Garcia, JV; McGowan, I; Swanson, MD | 1 |
| Cahn, P; Sued, O | 1 |
| Andrade-Villanueva, J; Antunes, F; Arastéh, K; Callebaut, C; Cheng, AK; Chetchotisakd, P; DeJesus, E; Fehr, J; Gallant, JE; Koenig, E; Liu, Y; Moyle, G; Rhee, MS; Rizzardini, G; Szwarcberg, J; Zhong, L | 1 |
| Endo, T; Fujii, T; Gatanaga, H; Higasa, S; Horiba, M; Ishisaka, M; Kaneda, S; Kikuchi, Y; Koibuchi, T; Komatsu, H; Matsushita, S; Mitsuya, H; Naito, T; Nishijima, T; Oka, S; Tachikawa, N; Takada, K; Takano, M; Tanabe, Y; Tateyama, M; Uchiumi, H; Ueda, M; Yamamoto, M; Yokomaku, Y; Yoshida, M | 1 |
| Choo, HW; Davis, J; Fang, J; Hansson, AG; Langdon, G; Layton, G; Tawadrous, M; Vourvahis, M | 1 |
| Andrew, P; Ayudhya, RK; Carballo-Dieguez, A; Cranston, RD; Dai, JY; Hladik, F; Hoesley, C; Janocko, L; Mayer, K; McGowan, I; Piper, J | 1 |
| Arnett, DK; Bagchi, S; Chi, BH; Heimburger, DC; Kabagambe, EK; Kiage, JN; Koethe, JR; Nyirenda, CK; Wellons, MF | 1 |
| Angeletti, C; Antonucci, G; Armignacco, O; Cassola, G; De Stefano, G; Girardi, E; Grossi, P; Mazzotta, F; Orani, A; Pagano, G; Petrosillo, N; Puoti, M; Sagnelli, C; Sagnelli, E | 1 |
| Andrasik, M; Broder, G; Fuchs, JD; Grove, D; Hammer, S; Karuna, ST; Koblin, B; Madenwald, T; Mayer, K; Sherwat, A; Sobieszczyk, ME | 1 |
| Ball, C; Chaowanachan, T; Krogstad, E; Woodrow, KA | 1 |
| Bedogni, G; Cococcioni, L; Fabiano, V; Giacomet, V; Mora, S; Stucchi, S; Viganò, A; Zuccotti, GV | 1 |
| Anglaret, X; Bohoussou, F; Carrou, JL; Danel, C; Eholie, SP; Gabillard, D; Konan, R; Moh, R; Ouattara, E; Peytavin, G | 1 |
| Aguilar, A; De La Torre, J; Del Arco, A; García-Alegría, J; Olalla, J; Pombo, M; Prada, JL; Ruiz-Mateas, F; Urdiales, D | 1 |
| Antinori, A; Bansi, L; Boumis, E; Callegaro, A; Ceccherini-Silberstein, F; Dunn, D; Fearnhill, E; Forbici, F; Francisci, D; Maggiolo, F; Mussini, C; Nicastri, E; Palamara, G; Perno, CF; Sabin, C; Santoro, MM; Zazzi, M; Zoncada, A | 1 |
| Aguilera, A; Barreiro, P; del Romero, J; Mena, A; Pedreira, J; Plaza, Z; Poveda, E; Rodriguez, C; Sierra-Enguita, R; Soriano, V; Tomé, S; Vispo, E | 1 |
| Mayer, KH; Morrow, KM; Operario, D; Underhill, K | 1 |
| Brache, V; Callahan, M; Cochon, L; Cohen, JA; Foster, J; Schwartz, J | 1 |
| Albert, J; Brun-Vezinet, F; Gatell, JM; Gupta, RK; Nachega, JB; Sönnerborg, A; Wainberg, MA | 1 |
| Aghokeng, A; Belec, L; Bertagnolio, S; Bunupuradah, T; Burda, S; Cane, P; Cappelli, G; Charpentier, C; Dagnra, AY; de Wit, TF; Deshpande, AK; El-Katib, Z; Eshleman, SH; Fleury, HJ; Fokam, J; Ford, N; Gody, JC; Hamers, RL; Hawkins, CA; Holmes, S; Hosseinipour, MC; Jordan, MR; Kanki, PJ; Katzenstein, D; Koyalta, DD; Kumwenda, JJ; Lallemant, M; Lynen, L; Manosuthi, W; Marconi, VC; Margot, NA; Moussa, S; Ndung'u, T; Ngo-Giang-Huong, N; Nyambi, PN; Orrell, C; Peeters, M; Rhee, SY; Ruxrungtham, K; Schapiro, JM; Schuurman, R; Shafer, RW; Sigaloff, KC; Sirivichayakul, S; Smith, D; Stevens, W; Tang, MW; van Zyl, GU; Wallis, CL; Zolfo, M | 1 |
| Charalambous, S; Churchyard, GJ; Grant, AD; Hoffmann, CJ; Lewis, JJ; Velen, K | 1 |
| Kanjanabuch, T; Suankratay, C; Woratanarat, K | 1 |
| Funk, EK; Heytens, L; Kohli, A; Kottilil, S; Kwan, R; Masur, H; Nelson, A; Polis, MA; Shaffer, A; Shivakumar, B; Sneller, M | 1 |
| Baldelli, F; Belfiori, B; Bonora, S; Conti, V; Falcinelli, E; Francisci, D; Giannini, S; Gresele, P; Guglielmini, G; Malincarne, L; Mezzasoma, A; Petito, E; Sebastiano, M | 1 |
| Bekker, LG; Kaplan, R; Lawn, SD; Njuguna, C; Orrell, C; Wood, R | 1 |
| Dodds, S; Lange, MM; Rogers, W | 1 |
| Abgrall, S; Antinori, A; Cavassini, M; Costagliola, D; Crane, HM; Gill, MJ; Gomez Sirvent, JL; Guest, JL; Ingle, SM; Manzardo, C; May, MT; Mercie, P; Mugavero, MJ; Phillips, A; Reekie, J; Reiss, P; Saag, MS; Samji, H; Stephan, C; Sterling, TR; Sterne, JA; Tate, J; Wasmuth, JC | 1 |
| Gatanaga, H; Kikuchi, Y; Komatsu, H; Nishijima, T; Oka, S; Tanuma, J; Teruya, K; Tsukada, K | 1 |
| Folayan, MO; Haire, B; Hankins, C; McCormack, S; Ramjee, G; Sugarman, J; Warren, M | 1 |
| Fowler, S; Senn, H; Sharma, M; Tan, DH; Wilton, J | 1 |
| Arends, JE; Feuth, T; Hoepelman, AI; van Baarle, D | 1 |
| Casado, JL; Del Palacio, M; Moreno, A; Moreno, S; Safont, P; Wikman, P | 1 |
| Chaisson, RE; Charalambous, S; Churchyard, GJ; Fielding, KL; Grant, AD; Hoffmann, CJ; Hunt, G; Johnson, JA; Johnston, V; Ledwaba, J; Li, JF; Morris, L | 1 |
| Baeten, JM; Haberer, JE; Liu, AY; Sista, N | 1 |
| Chen, YQ; Donnell, D; Fleming, TR; Hughes, JP; Wang, L | 1 |
| Mayer, KH; Sugarman, J | 1 |
| Baxter, C; Karim, QA; Karim, SA | 2 |
| Karim, SS | 1 |
| Chiamwongpaet, S; Choopanya, K; Chuachoowong, R; Curlin, ME; Gvetadze, RJ; Hendrix, CW; Kitisin, P; Kittimunkong, S; Leethochawalit, M; Martin, M; McNicholl, JM; Mock, PA; Natrujirote, P; Paxton, LA; Sangkum, U; Suntharasamai, P; Vanichseni, S | 1 |
| Asselineau, J; Bonnet, F; Chêne, G; Dauchy, FA; Déti, E; Duffau, P; Gerard, Y; Lazaro, E; Morlat, P; Neau, D; Vandenhende, MA; Vivot, A | 1 |
| Puthanakit, T; Siberry, GK | 1 |
| Mendes-Correa, MC; Núñez, M | 1 |
| Acosta, EP; Andrade, A; Campbell, T; Cillo, AR; Daar, ES; Feinberg, J; Flexner, C; Jacobson, JM; Kuritzkes, DR; Lederman, M; Lu, D; Mellors, JW; Rosenkranz, SL | 1 |
| Berger, D; Bredeek, UF; Callebaut, C; DeJesus, E; Fordyce, MW; Markowitz, M; Ramanathan, S; Rhee, MS; Ruane, PJ; Yale, K; Zhong, L | 1 |
| Cao, Y; Cui, Q; Han, Y; Li, T; Li, Y; Song, X; Xie, J; Zhang, L; Zhu, T | 1 |
| Allavena, C; Bach-Ngohou, K; Billaud, E; Dejoie, T; Fakhouri, F; Raffi, F; Reliquet, V; Sécher, S | 1 |
| Boot, J; Boucher, CA; Burger, DM; Fanoy, EB; Op de Coul, EL; Rump, BO; van Agtmael, MA; van de Vijver, DA | 1 |
| Boeke, AJ; Heijnen, AM | 1 |
| Hsu, P; Lucey, JM; Ziegler, JB | 1 |
| Hassoun, G; Kedem, E; Mugrabi, F; Pollack, S; Shahar, E | 1 |
| Benko, E; Blazkova, J; Casazza, JP; Chun, TW; Costiniuk, CT; Fauci, AS; Hallahan, CW; Kandel, G; Kaul, R; Kim, CJ; Koup, RA; Kovacs, C; Moir, S; Murray, D; Ostrowski, M; Shawn Justement, J | 1 |
| Foisy, MM; Hills-Nieminen, C; Hughes, C; Joffe, AM; Singh, AE | 1 |
| Bani-Sadr, F; de Vries-Sluijs, T; Dunn, D; Gilson, R; Jain, MK; Kuzushita, N; Mauss, S; Nüesch, R; Núñez, M; Peters, M; Pillay, D; Price, H; Reiberger, T; Stephan, C; Tan, L | 1 |
| Schrier, PB; Shah, HH; Spiegel, LR | 1 |
| Cauda, R; Digiambenedetto, S; Fabbiani, M; Fortuna, S; Lisi, L; Navarra, P; Ragazzoni, E | 1 |
| Botes, ME; Hamers, RL; Hoepelman, AI; Ive, P; Rinke de Wit, TF; Sigaloff, KC; Siwale, M; Stevens, WS; Wallis, CL; Zaaijer, HL | 1 |
| Arribas, JR; Compston, J; Domingo, P; Gartland, M; Granier, C; Moyle, GJ; Orkin, C; Pearce, H; Sedani, S; Stellbrink, HJ | 1 |
| Coombes, AG; Dang, NT; Harrich, D; Sivakumaran, H | 1 |
| Barreiro, P; Poveda, E; Soriano, V; Vispo, E | 1 |
| Bailly, F; Brochier, C; Cotte, L; Le Pogam, MA; Maynard, M; Miailhes, P; Okon, JB; Pradat, P; Trolliet, P; Zoulim, F | 1 |
| Badiou, S; Chatron, M; Cournil, A; Cristol, JP; Guiller, E; Peyriere, H; Psomas, C; Reynes, J | 1 |
| Echenique, IA; Rich, JD | 1 |
| Abbas, UL; Boucher, CA; Cambiano, V; Eaton, JW; Glaubius, R; Hallett, TB; Lythgoe, K; Mellors, J; Nichols, BE; Phillips, A; Sigaloff, KC; van de Vijver, DA | 1 |
| Berhanu, R; Fox, MP; Long, L; Maskew, M; Sanne, I; Shearer, K | 1 |
| Feucht, N; Hadeler, J; Lanzl, I; Loos, D; Schmid, RM; Schwerdtfeger, C; Spinner, CD | 1 |
| Endo, T; Fujii, T; Gatanaga, H; Horiba, M; Itoda, I; Koga, M; Komatsu, H; Mitsuya, H; Miyakawa, T; Naito, T; Nishijima, T; Oka, S; Shimbo, T; Takada, K; Tanabe, Y; Tei, M; Yamamoto, M | 1 |
| Ahmed-Jushuf, I; Arumainayagam, J; Carlin, EM; Chandramani, S; Das, S; Ghanem, M; Kumari, B; Pammi, M; Riddell, L | 1 |
| Gulholm, T; Jamani, S; Poynten, IM; Templeton, DJ | 1 |
| Bertz, R; Bifano, M; Grasela, D; Hartstra, J; Hwang, C; Kandoussi, H; Oosterhuis, B; Sevinsky, H; Tiessen, R; Velinova-Donga, M | 1 |
| Benalycherif, A; Charpentier, C; Delaporte, E; Diallo, MB; Eymard-Duvernay, S; Girard, PM; Guèye, NF; Koulla-Shiro, S; Landman, R; Le Moing, V; Ngolle, M; Peytavin, G; Sow, PS | 1 |
| Dorrell, L; Duncan, S; Sherrard, J; Shine, B; Wainwright, E | 1 |
| Boyd, A; Brichler, S; Chevallier-Queyron, P; Delaugerre, C; Girard, PM; Gordien, E; Lacombe, K; Maylin, S; Miailhes, P; Scholtès, C | 1 |
| Feldt-Rasmussen, B; Gerstoft, J; Helleberg, M; Kronborg, G; Larsen, CS; Obel, N; Pedersen, C; Pedersen, G; Rasch, MG | 1 |
| Emel, L; Eshleman, SH; Fowler, MG; George, K; Herron, C; Hudelson, SE; Joao, E; Kearney, B; Kreitchmann, R; Kumwenda, N; Mirochnick, M; Mofenson, L; Nielsen-Saines, K; Parsons, T; Pinto, J; Richardson, P; Santos, B; Sato, P; Taha, T | 1 |
| Amann, K; Bickel, M; Brodt, HR; Buettner, M; Geiger, H; Gute, P; Haberl, A; Jung, O; Khaykin, P; Lutz, T; Schmidt, K; Stephan, C | 1 |
| Rosenberg, K | 1 |
| Arnoczy, G; Campbell, T; Fichtenbaum, CJ; Ha, B; Hicks, C; Koletar, S; Massengale, K; McComsey, GA; Sax, P; Stein, JH; Taiwo, B; Tebas, P; Walsh, K; Wohl, DA | 1 |
| Baker, A; Bethel, J; Flynn, PM; Gordon, CM; Havens, PL; Hazra, R; Kapogiannis, BG; Kiser, JJ; Liu, N; Lujan-Zilbermann, J; Mulligan, K; Pan, CG; Rutledge, B; Stephensen, CB; Van Loan, MD; Wilson, CM; Woodhouse, LR | 2 |
| Carr, A; Ingersoll, A; McAllister, J; McNulty, A; Read, P; Tong, WW | 1 |
| Brockman, MA; Brumme, ZL; Chopera, DR; Goodier, S; Karim, QA; Karim, SA; Kuang, XT; Mann, JK; Martin, E; Mwimanzi, P; Naranbhai, V; Ndabambi, N; Ndung'u, T; Omarjee, S; Williamson, C | 1 |
| Arai, M; Satoh, M; Tanaka, H; Tomoda, Y; Wada, T; Yago, K | 1 |
| Assoumou, L; Bentata, M; Costagliola, D; Katlama, C; Kolta, S; Roux, C; Rozenberg, S; Simon, A; Viard, JP | 1 |
| Gao, Y; Katz, DF | 1 |
| Aldir, I; Horta, A; Serrado, M | 1 |
| Bulterys, M; Ellington, S; Kourtis, AP; Legardy-Williams, J; Wang, L | 1 |
| Churchill, DR; Fitzgerald, N; Gilleece, Y; Hughes, DJ; Konig, M; Moore-Moffatt, R; Sran, H; Webb, A | 1 |
| Bansi-Matharu, L; Bibby, D; Bulteel, N; Churchill, D; Dunn, D; Hill, T; Nelson, M; Sabin, C | 1 |
| Baeten, JM; Bangsberg, DR; Campbell, J; Celum, C; Donnell, D; Haberer, JE; Katabira, E; Kidoguchi, L; Krows, M; Psaros, C; Ronald, A; Safren, SA; Thomas, KK; Tumwesigye, E; Wangisi, J; Ware, NC | 1 |
| Danjuma, MI; Khoo, S; Mohamad-Fadzillah, NH | 1 |
| Cattaneo, D; Clementi, E; Giacomet, V; Manfredini, V; Nannini, P; Ramponi, G; Viganò, A; Zuccotti, GV | 1 |
| Albrecht, H; Almond, S; Baril, JG; Belonosova, E; Brennan, C; Domingo, P; Gatell, JM; Jaeger, H; Min, S; Quiros-Roldan, E; Raffi, F | 1 |
| Bahemuka, U; Bangsberg, DR; Barin, B; Bwanika, AN; Chetty, P; Fast, P; Haberer, JE; Kamali, A; Katende, D; Kibengo, FM; Mark, D; Priddy, FH; Rooney, JF; Ruzagira, E | 1 |
| Amico, KR; Buchbinder, S; Gilmore, HJ; Goicochea, P; Grant, R; Koester, KA; Liu, A; Lubensky, D; McMahan, V; Vargas, L | 1 |
| Bekker, LG; Kamkuemah, M; Kaplan, R; Myer, L | 1 |
| Beyrer, C; Chariyalertsak, C; Chariyalertsak, S; Guadamuz, T; Kawichai, S; Saokhieo, P; Suwanvanichkij, V; Wongthanee, A; Yang, D; Yotruean, K | 1 |
| Buyze, J; Lynen, L; Phirum, L; Thai, S; van Griensven, J | 1 |
| Cheng, A; Custodio, JM; Hepner, M; Kearney, BP; Ling, KH; Ramanathan, S; Yin, X | 1 |
| Graber, P; Kalbermatter, S; Kiss, D; Koenig, KF; Menter, T | 1 |
| Aoki, M; Desai, DV; Kodama, EN; Maeda, K; Mitsuya, H; Nakata, H | 1 |
| Jabłonowska, E; Piekarska, A; Wójcik, K | 1 |
| Lundgren, JD; Mocroft, A; Ryom, L | 1 |
| Estrada, V; Portilla, J | 1 |
| Brennan, AT; Fox, MP; Ive, P; Long, L; Maskew, M; Sanne, I; Shearer, K | 1 |
| Anastos, K; Bacchetti, P; Baxi, SM; Cohen, M; Gandhi, M; Gange, SJ; Greenblatt, RM; Huang, Y; Minkoff, H; Scherzer, R; Shlipak, MG; Young, M | 1 |
| Boulle, A; Chi, BH; Chimbetete, C; Egger, M; Fox, MP; Gerber, F; Gsponer, T; Hoffmann, CJ; Orrell, C; Prozesky, H; Rohr, J; Wandeler, G; Zwahlen, M | 1 |
| Calvez, V; Charpentier, C; Descamps, D; Flandre, P; Fofana, D; Fourati, S; Lambert-Niclot, S; Marcelin, AG; Masquelier, B; Morand-Joubert, L; Soulie, C; Storto, A; Wirden, M | 1 |
| Baldelli, S; Castagnoli, L; Cattaneo, D; Clementi, E; Fucile, S; Galli, M; Gervasoni, C; Landonio, S; Meraviglia, P; Riva, A; Rizzardini, G | 1 |
| Brooks, JT; Chirwa, LI; Henderson, FL; Johnson, JA; Li, JF; Matlhaba, O; Niska, RW; Paxton, LA; Rose, CE; Segolodi, TM; Thigpen, MC | 1 |
| Amico, KR; Buchbinder, SP; Glidden, DV; Grant, RM; Kallas, EG; Liu, AY; Marcus, JL; Mayer, KH; McMahan, V; Montoya-Herrera, O; Pilotto, J | 1 |
| Andrade, A; Chan, ES; Clagett, B; Daar, E; Feinberg, J; Funderburg, NT; Jacobson, JM; Kuritzkes, D; Lederman, MM; Lu, D; Mellors, J; Pilch-Cooper, HA; Rodriguez, B; Rosenkranz, SL | 1 |
| Abdool Karim, Q; Abdool Karim, SS; Bruno, D; Garrett, NJ; Martens, C; Mullis, CE; Porcella, SF; Quinn, TC; Redd, AD; Sheward, D; Wendel, SK; Werner, L; Williamson, C | 1 |
| Rahman, SM; Vaidya, NK; Zou, X | 1 |
| Baeten, JM; Bukusi, E; Campbell, JD; Celum, C; Donnell, D; Kahle, EM; Mugo, N; Mujugira, A; Murnane, PM; Tappero, J; Thomas, KK | 1 |
| Agrahari, V; Ezoulin, MJ; Meng, J; Youan, BB; Zhang, T | 1 |
| Cox, AP; Delany-Moretlwe, S; Foss, AM; Heise, L; Mertenskoetter, T; Meyer-Rath, G; Rees, H; Terris-Prestholt, F; Vickerman, P; Watts, CH | 1 |
| Cattaneo, D; Fucile, S; Gervasoni, C; Milazzo, L; Pezzani, D | 1 |
| Anderson, PL; Bacchetti, P; Buchbinder, SP; Gandhi, M; Goggin, K; Grant, R; Greenblatt, RM; Huang, Y; Jin, C; Liu, AY; Stojanovski, K; Yang, Q | 1 |
| Abdool Karim, Q; Abdool Karim, SS; Heneine, W; Hunt, G; Johnson, JA; Kashuba, AD; Li, JF; Morris, L; Naranbhai, V; Passmore, JA; Sibeko, S; Wei, X; Werner, L | 1 |
| Currier, J; Hogg, E; Hosseinipour, M; Hughes, MD; Lockman, S; Mulenga, L; Mwafongo, A; Nkanaunena, K; Samaneka, W; Siika, A; Zheng, Y | 1 |
| Ananworanich, J; Bowonwattanuwong, C; Bunupuradah, T; Hirschel, B; Jirajariyavej, S; Klinbuayaem, V; Mahanontharit, A; Munsakul, W; Ruxrungtham, K; Sophonphan, J | 1 |
| Dufrene, SL; Li, J; Okulicz, JF | 1 |
| Chamnanphon, M; Jantararoungtong, T; Koomdee, N; Manosuthi, W; Prommas, S; Puangpetch, A; Santon, S; Sukasem, C | 1 |
| Asin, SN; Doncel, GF; Lathrop, MJ; Macura, SL; Rollenhagen, C | 1 |
| Bekker, LG; Burns, DN; Chariyalertsak, S; Glidden, DV; Grant, RM; Guanira, JV; Kallás, EG; Lama, JR; Liu, AY; Mayer, KH; McMahan, V; Mulligan, K; Schechter, M; Solomon, MM; Veloso, VG | 1 |
| Boswell, S; Crane, HM; Eron, JJ; Geng, E; Kim, HN; Kitahata, MM; Martin, J; Mathews, WC; Moore, R; Mugavero, M; Overton, ET; Rodriguez, B; Rodriguez, CV; Saag, MS; Thio, CL; Van Rompaey, S | 1 |
| Coakley, D; Kearney, B; Lee, WA; Markowitz, M; Miller, MD; Ruane, P; Squires, K; Wulfsohn, M; Zhong, L; Zolopa, A | 1 |
| Anderson, S; Doncel, GF; Thurman, AR | 1 |
| DeGrosky, M; Farajallah, A; Hardy, H; McGrath, D; Moyle, GJ | 1 |
| Bao, Y; Currier, J; Hogg, E; Hughes, MD; Lockman, S; Moses, A; Sawe, F; Shaffer, D | 1 |
| Alam, S; Dinello, D; Israr, M; Jia, R; Kishel, J; Meyers, C; Mitchell, D | 1 |
| Bosch, ME; Burger, DM; Ezinga, M; van der Ven, AJ; Wetzels, JF | 1 |
| Calmy, A; Chi, BH; Davies, MA; Keiser, O; Mulenga, L; Musonda, P; Mwango, A; Mweemba, A; Stringer, JS; Vinikoor, MJ; Wandeler, G | 1 |
| Campbell, LJ; Chadwick, D; Fisher, M; Gilson, R; Hamzah, L; Hay, P; Hill, T; Johnson, M; Jones, R; Jose, S; Leen, C; Nelson, M; Nitsch, D; Post, FA; Sabin, CA; Walsh, J | 1 |
| Brennan, AT; Fox, MP; Long, L; Maskew, M; Sanne, I; Shearer, K | 1 |
| Buchbinder, S; Cohan, D; Cohen, S; Follansbee, S; Liu, A; Sachdev, D; Weber, S | 1 |
| Amorosa, VK; Chang, KM; De La Torre, P; Frank, I; Gross, R; Hafkin, JS; Kostman, JR; Lo Re, V; Localio, AR; Mounzer, K; Osborn, MK; Stern, JJ | 1 |
| Bandera, A; Crivellaro, C; Gori, A; Guerra, L; Mangioni, D; Messa, C; Muscatello, A; Squillace, N | 1 |
| Boyd, A; Delaugerre, C; Girard, PM; Gozlan, J; Lacombe, K; Maylin, S; Simon, F | 1 |
| Blum, JD; Kiser, JJ; MacBrayne, CE | 1 |
| Gengiah, TN; Karim, QA; Karim, SS; Kashuba, AD; Mansoor, LE; Naidoo, A; Upfold, M; Yende-Zuma, N | 1 |
| Dunn, DT; Gibb, DM; Gilks, CF; Goodall, RL; Kaleebu, P; Kasirye, R; Kityo, C; Mambule, I; Mugyenyi, P; Pillay, D; Walker, AS | 1 |
| Henderson, FL; Kasonde, M; Niska, RW; Paxton, LA; Rose, C; Segolodi, TM; Smith, DK; Thigpen, MC; Turner, K | 1 |
| Awio, P; Dunn, DT; Gilks, CF; Goodall, RL; Kaleebu, P; Kityo, C; Munderi, P; Ndembi, N; Nkurunziza, P; Pattery, T; Pillay, D; van Cauwenberge, A | 1 |
| Abdool Karim, Q; Abdool Karim, SS; Frohlich, JA; Grobler, AC; Maarschalk, S; Madlala, B; Mansoor, LE; Mngadi, KT; Ngcobo, N | 1 |
| Amico, KR; Cornman, DH; Fisher, J; Fisher, WA; Karim, QA; Karim, SS; Macqueen, KM; Madlala, B; Mansoor, LE; Ngcobo, N; Werner, L | 1 |
| McGowan, I | 2 |
| Battegay, M; Bernasconi, E; Bucher, HC; Calmy, A; Cavassini, M; Furrer, H; Fux, CA; Vernazza, P; Wang, Q; Weber, R; Young, J | 1 |
| Adesoye, A; Chen, CY; Danavall, D; Easley, K; Evans-Strickfaden, T; Gatcliffe, C; Haaland, R; Hart, C; Lupo, LD; Martin, A; Ofotokun, I; Omondi, MW; Pau, CP; Sheth, AN | 1 |
| Abdool Karim, Q; Abdool Karim, SS; Baxter, C; Grobler, A; MacQueen, KM; Madlala, BT; Mansoor, LE; Yende-Zuma, N | 1 |
| Moyo, C; Vinikoor, MJ | 1 |
| Karim, QA; Karim, SA; MacQueen, KM; Majola, N; Succop, S; Taylor, D; van Loggerenberg, F; Weaver, MA | 1 |
| Anderson, AM; Ebrahimi, R; Flaherty, JF; Fortin, C; Fralich, T; Graham, H; Gupta, SK; Kalayjian, RC; Rachlis, A; Scharen-Guivel, V; Wyatt, CM | 1 |
| Behrens, G; Bosse, M; Chuck, SK; Cohen, C; DeMorin, J; Elion, RA; Mills, A; Nelson, M; Orkin, C; Rijnders, B; Rimsky, L; Stevens, M; Thorpe, D; Vanveggel, S; White, K; Zhong, L | 1 |
| Betancor, G; Gómez-Puertas, P; Martínez, MA; Mendieta, J; Menéndez-Arias, L; Nevot, M | 1 |
| Chiamwongpaet, S; Choopanya, K; Curlin, ME; Gvetadze, RJ; Kittimunkong, S; Leethochawalit, M; Martin, M; McNicholl, JM; Mock, PA; Paxton, LA; Sangkum, U; Suntharasamai, P; Vanichseni, S; Worrajittanon, D | 1 |
| Hsiao, CB; Ma, Q; Sawyer, JR | 1 |
| Bele, V; Bhagani, S; Dabhade, D; Johnson, M; Joshi, K; Makane, A; Pujari, SN; Smith, C; Youle, M | 1 |
| Amin, J; Cooper, DA; Cordery, DV; Emery, S; Haskelberg, H; Kelleher, AD | 1 |
| Iyer, HS; Larson, BA; Long, L; McCoy, K; Moyo, C; Rosen, S; Scott, CA | 1 |
| Akil, A; Cost, M; Devlin, B; Rohan, LC | 1 |
| Aberg, JA; Hollabaugh, K; Kang, M; Koletar, SL; Pham, V; Smurzynski, M; Wu, K | 1 |
| Holmes, DT; Jiang, SY; Kendler, DL; Saeedi, R | 1 |
| Fonjungo, PN; Hart, C; Henderson, FL; Niska, R; Paxton, LA; Rose, CE; Segolodi, TM; Turner, KT; Zeh, C | 1 |
| Chimbwandira, FM; Chirwa, Z; Crampin, AC; Dasgupta, AN; Glynn, JR; Jahn, A; Katundu, C; Kayange, M; Koole, O; Price, AJ; Saul, JL; Zaba, B | 1 |
| Abdool Karim, Q; Abdool Karim, SS; Dellar, RC; Grobler, A; Humphries, H; Luthuli, L; Mansoor, LE; Ntombela, F; Werner, L | 1 |
| Allworth, A; Amin, J; Carr, A; Ebeling, PR; Emery, S; Haskelberg, H; Pocock, N | 1 |
| Arnold, V; Barcellos, NT; Brites, C; Chêne, G; De Castro, N; Delaugerre, C; Fagard, C; Grinsztejn, B; Madruga, JV; Molina, JM; Morgado, M; Patey, O; Pilotto, JH; Santini-Oliveira, M; Santos, BR; Veloso, VG; Vorsatz, C | 1 |
| Arribas, J; Deckx, H; Duiculescu, D; Florence, E; Hung, CC; Sension, M; Stevens, M; Tebas, P; Vanveggel, S; Wilkin, T | 1 |
| Rijnders, BJ; Rokx, C; Verbon, A | 1 |
| Abdel-Mohsen, M; Anderson, PL; Atchison, R; Bentley, LG; Buchbinder, S; Eden, C; Glidden, DV; Grant, RM; Guanira, JV; Javier, J; Li, P; Liegler, T; McMahan, V; Mehrotra, M; Schmidt, T; Wong, JK | 1 |
| Boyd, A; Delaugerre, C; Girard, PM; Gozlan, J; Lacombe, K; Maylin, S; Peytavin, G; Zoulim, F | 1 |
| Cardoso, SW; Demeter, LM; Godfrey, C; Infante, R; Johnson, VA; Moran, LE; Sanchez, J; Smeaton, LM; Vogler, MA; Wright, RL | 1 |
| Coppola, N; Filippini, P; Martini, S; Pisaturo, M; Sagnelli, C; Sagnelli, E | 1 |
| Ayala-Sims, VA; Fulco, PP | 1 |
| Baeten, JM; Bangsberg, DR; Brantley, J; Bumpus, NN; Celum, C; Donnell, D; Haberer, JE; Hendrix, C; Mugo, N; Mujugira, A; Ndase, P | 1 |
| Manosuthi, W; Nilkamhang, S; Sukasem, C; Sungkanuparph, S; Thongyen, S | 1 |
| Bonjoch, A; Holgado, S; Mariñoso, ML; Mateo, L; Olivé, A; Pérez-Andrés, R; Romeu, J | 1 |
| Domingo, JC; Domingo, P; Gallego-Escuredo, JM; Giralt, M; Gutierrez, Mdel M; Lamarca, K; Mateo, MG; Torres, F; Vidal, F; Villarroya, F; Villarroya, J | 1 |
| Anekvorapong, R; Chantharojwong, N; Cherdtrakulkiat, T; Chiamwongpaet, S; Choopanya, K; Curlin, ME; Gvetadze, RJ; Kittimunkong, S; Leelawiwat, W; Leethochawalit, M; Martin, M; McNicholl, JM; Mock, PA; Paxton, LA; Sangkum, U; Suntharasamai, P; Vanichseni, S | 1 |
| Chima-Okereke, C; Sivaprakasam, V | 1 |
| Henderson, H; Kruse, L; Stover, K | 1 |
| Boucherie, C; Breton, G; Bugault, F; Chakrabarti, LA; Chêne, G; Cumont, MC; Lortholary, O; Patey, O; Richert, L; Roussillon, C | 1 |
| Brar, I; Callebaut, C; Elion, R; Fordyce, MW; Martin, H; McCallister, S; Ortiz, R; Post, F; Sax, PE; Wang, H; Zolopa, A | 1 |
| Barthe, Y; Bouix, C; Cacoub, P; Carrat, F; Lascoux-Combe, C; Lebossé, F; Maynard-Muet, M; Miailhes, P; Piroth, L; Pol, S; Rey, D; Sogni, P; Zoulim, F | 1 |
| Antonopoulou, S; Chini, M; Demopoulos, CA; Fragopoulou, E; Gargalianos, P; Lazanas, MC; Mangafas, N; Papakonstantinou, VD; Psarra, K; Stamatakis, GM; Tsogas, N; Tsoupras, AB | 1 |
| Coombes, AG; Dang, NT; Davis-Poynter, N; Harrich, D; Shaw, PN; Sivakumaran, H | 1 |
| Allavena, C; André-Garnier, E; Billaud, E; Bonnet, B; Bouchez, S; Bouquié, R; Boutoille, D; Dailly, E; Pineau, S; Raffi, F; Raveleau, A; Reliquet, V | 1 |
| Debyser, Z; Schrijvers, R | 2 |
| Arribas, JR; Di Perri, G; Ebrahimi, R; Gathe, J; Nguyen, T; Pialoux, G; Piontkowsky, D; Reynes, J; Tebas, P; White, K | 1 |
| Antela, A; Domingo, P; Garner, W; Girard, PM; Guyer, B; Henry, K; Markowitz, M; Mills, A; Nguyen, T; Piontkowsky, D; Pozniak, A; Stellbrink, HJ; White, K | 1 |
| Deeks, SG; Estrella, MM; Gandhi, M; Grunfeld, C; Peralta, CA; Scherzer, R; Shlipak, MG; Tien, PC | 1 |
| Chariyalertsak, S; Fernandez, T; Glidden, DV; Grant, RM; Guanira, JV; Liu, AY; Mayer, KH; McMahan, VM; Solomon, MM | 1 |
| Abe, M; Hiasa, Y; Hirooka, M; Ikeda, Y; Koizumi, Y; Kumagi, T; Matsuura, B; Ochi, H; Tada, F; Takada, K; Tokumoto, Y; Watanabe, T | 1 |
| Baum, MM; Brooks, AA; Butkyavichene, I; Dinh, CT; Lopez, G; Martin, A; Moss, JA; Smith, JM; Smith, TJ; Srinivasan, P | 1 |
| Asmelash, A; Currier, J; Hughes, MD; Kaloustian, KW; Lockman, S; Ogwu, A; Salata, R; Sawe, F; Shaffer, D; Zheng, Y | 1 |
| Dashti-Khavidaki, S; Jafari, A; Khalili, H | 1 |
| Baeten, JM; Celum, C; Donnell, D; Fife, KH; Hendrix, CW; Hong, T; Morrow, RA; Mujugira, A; Nakku-Joloba, E; Thomas, KK | 1 |
| Ananworanich, J; Bunupuradah, T; Keadpudsa, S; Prasitsuebsai, W; Puthanakit, T; Sahakijpicharn, T; Srimuan, A; Techasaensiri, C; Thammajaruk, N | 1 |
| Burger, D; Colbers, A; Giaquinto, C; Gingelmaier, A; Hawkins, D; Hidalgo-Tenorio, C; Ivanovic, J; Kabeya, K; Lambert, J; Moltó, J; Rockstroh, J; Sadiq, ST; Taylor, G; van der Ende, M; Weizsäcker, K; Wyen, C | 1 |
| Chau, JJ; Giancola, MA; Keller, SB; King, HL; Little, SJ; Rodriguez, DA; Smith, DM; Young, JA | 1 |
| Abebe, KZ; Dezzutti, CS; Friend, DR; Li, J; McGowan, IM; Rohan, LC; Russo, J; Wang, L | 1 |
| Clumeck, N; Delforge, M; Ilunga, J; Kabeya, K; Kadiebwe, D; Kapend, L; Kasamba, E; Matanda, S; Milolo, C; Mwamba, C; Necsoi, C; Vaira, D | 1 |
| Gürtler, LG | 1 |
| Haire, B | 1 |
| De Castro, N; Delaugerre, C; Flandre, P; Gallien, S; Molina, JM; Nguyen, N | 1 |
| Bosco, O; Cruciani, M; Malena, M; Mengoli, C; Moyle, G; Parisi, SG; Serpelloni, G | 1 |
| Babu, GR; Detels, R; Han, N; Mahapatra, S; Mahapatra, T; Tang, W; Wang, L; Yu, W; Zhang, X; Zhao, J | 1 |
| Agashe, H; Akil, A; Devlin, B; Dezzutti, CS; Hillier, SL; Moncla, BJ; Rohan, LC; Shi, Y; Uranker, K | 1 |
| Ballow, C; Battegay, M; Elgadi, M; Feifel, U; Fuhr, R; Girlich, B; Haschke, M; Kort, J; Lang, B; Li, Y; Sabo, JP; Schobelock, M | 1 |
| Agot, K; Ambia, J; Corneli, AL; Kashuba, AD; Lemons, A; Lombaard, J; Malahleha, M; Parker, C; Taylor, D; Van Damme, L; Wang, M | 1 |
| Andrade-Fuentes, K; Gaytan-Martínez, J; López-De León, JI; Manjarrez-Téllez, B; Mata-Marín, JA; Ramírez, JL | 1 |
| Allavena, C; Antinori, A; Arribas, JR; Babiker, AG; Chêne, G; Delfraissy, JF; George, EC; Grarup, J; Hudson, F; Jansson, PO; Molina, JM; Pozniak, A; Raffi, F; Richert, L; Saillard, J; Schwimmer, C; Van Leeuwen, R; Vella, S; Wallet, C | 1 |
| Akkina, R; Kashuba, ADM; LeCureux, J; Remling-Mulder, L; Sykes, C; Veselinovic, M; Yang, KH | 1 |
| Barreiro, P; Fernández-Montero, JV; Labarga, P; Mendoza, Cd; Sierra-Enguita, R; Soriano, V; Vispo, E | 1 |
| Amiel, C; Chas, J; Guessant, S; Hamidi, M; Kherallah, K; Lebrette, MG; Lependeven, C; Pialoux, G; Schneider, V | 1 |
| Daar, ES; Gupta, SK; Ha, B; Kitch, D; McComsey, GA; Melbourne, K; Sax, PE; Tierney, C; Wyatt, CM | 1 |
| Baeten, JM; Bangsberg, DR; Celum, C; Cohen, CR; Heffron, R; Hendrix, CW; Matthews, LT; Mugo, NR | 1 |
| Baldeyrou, M; Batard, ML; Bernard-Henry, C; Cheneau, C; de Mautort, E; Fafi-Kremer, S; Gantner, P; Muret, P; Partisani, M; Priester, M; Reinhart, S; Rey, D | 1 |
| Bonjoch, A; Clotet, B; Domingo, P; Echeverría, P; Escrig, R; Gutiérrez, M; Mateo, G; Negredo, E; Pérez-Álvarez, N; Puig, J | 1 |
| Agot, K; Ahmed, K; Corneli, AL; Deese, J; Kapiga, S; Kashuba, A; Lombaard, J; Manongi, R; Taylor, D; Van Damme, L; Wang, M | 1 |
| Bedimo, RJ; Castanon, R; Cutrell, J; Drechsler, H; Farukhi, I; Jain, M; Li, X; Maalouf, NM; Tebas, P; Zhang, S | 1 |
| Becker, A; Desprez, S; Froidure, M; Gagneux, M; Huguet, D; Leduc, D; Legout, L; Sifaoui, F; Vignoli, P | 1 |
| Gray, SC; Henderson, FL; Kebaabetswe, PM; McLellan-Lemal, E; Paxton, LA; Rose, CE; Stirratt, MJ; Williams, T | 1 |
| Camejo, RR; Cuffe, R; Gilchrist, KA; Lim, JW; Nichols, G; Patel, DA; Pulgar, S; Snedecor, SJ; Stephens, J; Sudharshan, L; Tang, WY | 1 |
| Greeff, OB; Hurrell, T; Khwitshana, AK | 1 |
| Fraenkel, L; Han, Y; Hsieh, E; Hu, YY; Insogna, K; Li, T; Xia, W; Xie, J; Yin, MT; Zhu, T | 1 |
| Aiestarán, A; Bonet, J; Bonjoch, A; Clotet, B; Echeverría, P; Juega, J; Negredo, E; Pérez, V; Pérez-Alvarez, N; Puig, J; Romero, R | 1 |
| Abdool-Karim, Q; Abdool-Karim, SS; Garrett, NJ; Gray, C; Morris, L; Naicker, N; Naranbhai, V; Samsunder, N; Sibeko, S; Werner, L; Williamson, C | 1 |
| Aurpibul, L; Puthanakit, T | 1 |
| Aoki, T; Gatanaga, H; Honda, H; Kawasaki, Y; Kikuchi, Y; Kinai, E; Mizushima, D; Nishijima, T; Oka, S; Tanaka, N; Tanuma, J; Teruya, K; Tsukada, K; Watanabe, K; Yazaki, H | 1 |
| Baeten, JM; Bukusi, EA; Celum, C; Heffron, R; Mugo, NR; Mujugira, A; Were, EO | 1 |
| Boucher, CA; Langebeek, N; Mudrikova, T; Nijhuis, M; Pingen, M; Richter, C; van Laarhoven, A; Wensing, AM | 1 |
| Brun-Vezinet, F; Costagliola, D; Mokhtari, S; Poizot-Martin, I; Potard, V; Pradier, C; Rey, D; Rozenbaum, W | 1 |
| Aweeka, F; Baugh, BP; Benson, CA; Brown, TT; Cohn, SE; Currier, JS; Fichtenbaum, CJ; Godfrey, C; Haas, DW; Koletar, SL; Kuritzkes, DR; Landovitz, RJ; Leavitt, RY; Lennox, JL; McComsey, GA; Na, LH; Ofotokun, I; Patterson, KB; Presti, RM; Ribaudo, HJ; Rooney, JF; Sagar, M; Seekins, D | 1 |
| Karim, QA; Karim, SS; MacQueen, KM; Majola, N; Succop, SM; van Loggerenberg, F | 1 |
| Buchbinder, S | 1 |
| Baeten, JM; Bangsberg, D; Bukusi, EA; Campbell, JD; Celum, C; Cohen, CR; Coombs, RW; Donnell, D; Farquhar, C; Fife, KH; Frenkel, L; Haberer, JE; Hendrix, C; John-Stewart, G; Katabira, E; Kiarie, J; Kidoguchi, L; Marzinke, MA; Mugo, NR; Ndase, P; Ronald, A; Tappero, JW; Thomas, KK; Tumwesigye, E; Wangisi, J; Were, E | 1 |
| Boyd, A; Fonquernie, L; Girard, PM; Meynard, JL; Morand-Joubert, L; Surgers, L; Valin, N; Viala, C | 1 |
| Cheng, AK; Kulkarni, R; McColl, DJ; Miller, MD; Rhee, MS; Szwarcberg, J; White, KL | 1 |
| Anton, PA; Bumpus, NN; Cranston, RD; Elliott, J; Hendrix, CW; Kashuba, A; Mauck, C; McGowan, I; Richardson-Harman, N; Tanner, K; Yang, K | 1 |
| Guo, F; Li, T; Lin, Q; Shao, H; Sun, P; Tian, J; Xu, Y; Yu, W; Zhou, X | 1 |
| Avihingsanon, A; Burger, DM; Chaiyahong, P; Colbers, A; Kerr, SJ; Phonphithak, S; Punyawudho, B; Ruxrungtham, K; Sapsirisavat, V; Thammajaruk, N | 1 |
| Amico, KR; Brown, ER; Cheng, H; Laborde, N; Marrazzo, J; Mayo, A; Torjesen, K; van der Straten, A | 1 |
| Almond, S; Arasteh, K; Brennan, C; Brinson, C; Cuffe, RL; Eron, J; Górgolas, M; Granier, C; Nichols, WG; Pappa, K; Rachlis, A; Raffi, F; Walmsley, S | 1 |
| Baker, J; OʼHara, KM | 1 |
| Agot, K; Ahmed, K; Corneli, A; Lombaard, J; Van Damme, L; Wang, M | 1 |
| Freeling, JP; Ho, RJ; Koehn, J; Shu, C; Sun, J | 1 |
| Anderson, PL; Bushman, LR; Castillo-Mancilla, JR; Gardner, EM; Glidden, DV; Guida, LA; Kerr, BJ; Klein, B; Meditz, AL; Predhomme, JA; Rower, C; Seifert, SM; Zheng, JH | 1 |
| Carta, M; D'Angelo, A; Frassetti, N; Innico, G; Lai, C; Lai, S; Mangiulli, M; Mariotti, A; Russo, GE; Testorio, M | 1 |
| Ferrada, MA; Nuermberger, E; Xie, Y | 1 |
| Anzala, O; Bangsberg, DR; Barin, B; Haberer, JE; Mugo, PM; Mutua, G; Priddy, FH; Sanders, EJ; van der Elst, E | 1 |
| Bekker, LG; Kamkuemah, M; Kaplan, R; Little, F; Myer, L | 1 |
| Deese, J; Hubacher, D; Otunga, S; Steiner, MJ; Todd, CS; Van Damme, L; Wang, M | 1 |
| Abram, ME; Andrade-Villanueva, JF; Beraud, C; Cheng, AK; Fisher, M; Graham, H; Liu, Y; Post, FA; Rhee, MS; Szwarcberg, J; Winston, J | 1 |
| Bam, R; Cihlar, T; Dahlin, A; de la Cruz, M; Flaherty, J; Giacomini, KM; Gupta, SK; Ray, AS; Scharen-Guivel, V; Wittwer, M; Woo, JM | 1 |
| Archer, DF; Doncel, GF; Jacot, TA; Kashuba, AD; Nelson, A; Thurman, A | 1 |
| Álvarez, ML; Arterburn, S; Berenguer, J; Clotet, B; Curran, A; Estrada, V; Ferrer, P; Larrousse, M; Martínez, E; Negredo, E; Pulido, F; Ribera, E; Rubio, R; Sanz, J | 2 |
| Bacon, O; Blue, RW; Buchbinder, S; Castro, JG; Chege, W; Cohen, SE; Coleman, ME; Doblecki-Lewis, S; Elion, R; Estrada, Y; Feaster, DJ; Kolber, MA; Liu, AY; Matheson, T; Philip, SS; Postle, BS; Trainor, N; Vittinghoff, E | 1 |
| Cohen, MS; Emerson, CW; Fedoriw, Y; Geller, EJ; Kashuba, AD; Nelson, JA; Nicol, MR; Patterson, KB; Prince, HM; Sykes, C | 1 |
| Abdel-Mohsen, M; Agingu, W; Ahmed, K; Bentley, G; Crucitti, T; Damme, LV; De Baetselier, I; Deese, J; Defechereux, P; Fransen, K; Grant, RM; Kashuba, AD; Liegler, T; Taylor, D | 1 |
| Bonino, B; Di Biagio, A; Grignolo, S; Gustinetti, G; Maggi, P; Tatarelli, P; Viazzi, F; Viscoli, C | 1 |
| André-Schmutz, I; Azria, E; Blanche, S; Cavazzana, M; Cordier, AG; Cuccuini, W; Lechenadec, J; Luce, S; Mandelbrot, L; Soheili, TS; Soulier, J; Vivanti, A | 1 |
| Huang, J; Huang, S; Lassman, C; Lum, EL | 1 |
| Abdool Karim, Q; Abdool Karim, SS; Baxter, C; Dawood, H; Dlamini, S; Frohlich, JA; Gengiah, TN; Grobler, A; Mansoor, LE; Mngadi, KT; Montague, C; Mvandaba, N; Nkomonde, N; Samsunder, N | 1 |
| Katz, MH | 1 |
| Baeten, JM; Celum, C; Donnell, D; Kiarie, J; Mugo, NR; Mugwanya, KK; Ronald, A; Tappero, J; Wyatt, C | 1 |
| De Baetselier, I; Deese, J; Lombaard, J; Malahleha, M; Mandala, J; Manongi, R; Nanda, K; Owino, F; Taylor, D; Van Damme, L; Wang, M | 1 |
| Cressey, TR; Harrison, L; Jourdain, G; Kamkon, J; Lallemant, M; Le Coeur, S; Luekamlung, N; Ngo-Giang-Huong, N; Nilmanat, A; Owen, A; Sirirungsi, W; Tawon, Y; Thongpaen, S; Urien, S | 1 |
| Borsa-Lebas, F; Cacoub, P; Carrat, F; Fillion, A; Lacombe, K; Lopes, A; Loustaud-Ratti, V; Miailhes, P; Piroth, L; Pol, S; Rosenthal, E; Salmon, D | 1 |
| Back, DJ; Burger, D; Lamorde, M; Schapiro, JM | 1 |
| Benalycherif, A; Charpentier, C; Delaporte, E; Diallo, MB; Eymard-Duvernay, S; Girard, PM; Koulla-Shiro, S; Landman, R; Le Moing, V; Lê, MP; Ngolle, M; Ngom Gueye, NF; Peytavin, G; Sow, PS | 1 |
| Baeten, JM; Celum, C; Donnell, D; Frenkel, L; Hendrix, CW; Lehman, DA; Marzinke, MA; Matsen, FA; Mbara, G; McCoy, CO; Mugo, NR; Ndase, P; Overbaugh, J; Peterson, D; Thomas, KK; Weis, JF | 1 |
| Callahan, R; Kapiga, S; Malahleha, M; Mandala, J; Nanda, K; Ogada, T; Taylor, D; Van Damme, L | 1 |
| Furusyo, N; Hayashi, J; Hiramine, S; Mitsumoto, F; Murata, M; Ogawa, E; Shimizu, M; Takayama, K; Toyoda, K; Ura, K | 1 |
| Andreatta, KN; Da Silva, MT; De Aquino, MZ; De Carvalho, AP; Della Negra, M; Graham, B; Liu, YP; Pinto, JA; Quirk, EK | 1 |
| Badiou, S; Bargnoux, AS; Cournil, A; Cristol, JP; Dupuy, AM; Fernandez, C; Peyriere, H; Reynes, J; Toubal, S | 1 |
| Barth, RE; Bauer, MP; Hoepelman, AI; Reiss, P; Schoffelen, AF; Smit, C; van Lelyveld, SF; Vogt, L | 1 |
| Calvez, V; Desire, N; Girard, PM; Katlama, C; Marcelin, AG; Mercier-Darty, M; Morand-Joubert, L; Rodriguez, C; Todesco, E; Wirden, M | 1 |
| Chirenje, ZM; Dai, JY; Ganesh, S; Gomez, K; Grossman, C; Hendrix, CW; Hillier, SL; Marrazzo, JM; Marzinke, MA; Mâsse, B; McGowan, IM; Mgodi, N; Mkhize, B; Nair, G; Nakabiito, C; Noguchi, L; Palanee, T; Parikh, UM; Piper, J; Ramjee, G; Richardson, BA; Rooney, J; Schwartz, JL; Taljaard, M; van der Straten, A; Watts, H | 1 |
| Back, DJ; Byakika-Kibwika, P; Else, L; Katwere, M; Khoo, SH; Lamorde, M; Merry, C; Mukisa, L; Sempa, JB; Walimbwa, S | 1 |
| Anderson, J; Dhar, J; Ebrahimi, R; Ewan, J; Fisher, M; Moyle, GJ; Orkin, C; Wang, H; Wilkins, E | 1 |
| Bronze, M; Carmona, SC; Letsoalo, E; Lukhwareni, A; Papathanasopoulos, MA; Skhosana, L; Steegen, K; Stevens, WS | 1 |
| Cherian, AO; Mitra, S; Priscilla, R; Rajeev, K; Rajkumar, S; Sauradeep, S | 1 |
| Krakower, DS; Mayer, KH | 2 |
| Abdool Karim, SS; Eshleman, SH; Garrett, N; Karim, QA; Laeyendecker, O; Longosz, AF; Naranbhai, V; Nason, M; Quinn, TC; Redd, AD | 1 |
| Alonso-Villaverde, C; Ferrer, E; Martinez-Picado, J; Maso, M; Muñoz-Moreno, JA; Ouchi, D; Podzamczer, D; Prats, A; Puertas, MC; Rozas, N; Tiraboschi, JM | 1 |
| Arribas, JR; Bernardino, JI; Estébanez, M; González-García, JJ; Montes-Ramírez, ML; Pérez-Valero, I; Serrano, L; Zamora, FX | 1 |
| Rowniak, S | 1 |
| Aurpibul, L; Chokephaibulkit, K; Cressey, TR; Phongsamart, W; Sirisanthana, V; Sricharoenchai, S; Sudjaritruk, T; Wittawatmongkol, O | 1 |
| Arterburn, S; Castaño, E; Cheng, AK; Chuck, SL; Church, J; Deville, J; Enejosa, JV; Estripeaut, D; Gaur, A; Rathore, M; Rhee, MS; Saez-Llorens, X; White, K | 1 |
| Agot, K; Ahmed, K; Corneli, AL; Malamatsho, F; McKenna, K; Odhiambo, J; Perry, B; Skhosana, J; Van Damme, L | 1 |
| Bonjoch, A; Clotet, B; Diez-Pérez, A; Domingo, P; Echeverría, P; Escrig, R; Gutierrez, M; Mateo, G; Negredo, E; Pérez-Álvarez, N; Puig, J | 1 |
| Mayer, KH | 2 |
| Clarance, P; Cohen, JT; George, L; Kang, G; Karthik, R; Muliyil, J; Mwamburi, M; Noubary, F; Ooriapdickal, AC; Peter, D; Pulimood, SA; Rupali, P; Sathasivam, R; Thuppal, SV; Varghese, GM; Wanke, CA | 1 |
| Bader, J; Glass, TR; Klimkait, T; Labhardt, ND; Lejone, TI; Puga, D; Ringera, I | 1 |
| Canetta, PA; Herlitz, L; Hirsch, JS; Mohan, S; Sise, ME | 1 |
| Bae-Harboe, YS; Mahalingam, M; Marszalek, RM; Masterpol, K | 1 |
| Avihingsanon, A; Burger, DM; Mitruk, S; Pengsuparp, T; Punyawudho, B; Rungtivasuwan, K; Ruxrungtham, K; Thammajaruk, N | 1 |
| Achan, J; Burstein, R; Dansereau, E; DeCenso, B; Duber, HC; Gakidou, E; Gasasira, A; Ikilezi, G; Kisia, C; Masiye, F; Masters, SH; Njuguna, P; Odeny, T; Okiro, E; Roberts, DA | 1 |
| Antinori, A; Brunetta, J; De-Oertel, S; Ebrahimi, R; Johnson, B; Johnson, M; Moreno Guillén, S; Shalit, P; Wade, B; Walker, I; Yeni, P | 1 |
| Han, Y; Li, T; Li, Y; Qiu, Z; Song, X; Xie, J; Zhu, T | 1 |
| Cameron, D; Dias, N; Dreier, P; Holding, J; Holt, JD; Muntendam, A; Nuttall, J; Oostebring, F; Rohan, L | 1 |
| Amiel, C; Caseris, M; Charpentier, C; Descamps, D; Desnoyer, A; Farnoux, C; Lassel, L; Lê, MP; Pain, JB; Peytavin, G; Pialoux, G | 1 |
| Duim, AR; Rijnders, BJ; Rokx, C; van Gorp, EC | 1 |
| Anglaret, X; Boyd, A; Danel, C; Delaugerre, C; Eholié, SP; Gabillard, D; Girard, PM; Lacombe, K; le Carrou, J; Maylin, S; Moh, R; Zoulim, F | 1 |
| Foster, C; Lim, Y; Lyall, H | 1 |
| De La Mata, FJ; Gómez, R; Jiménez, JL; Muñoz-Fernández, MÁ; Sánchez-Rodríguez, J; Sepúlveda-Crespo, D; Serramía, MJ | 1 |
| Callebaut, C; Cao, H; Cheng, A; Crofoot, G; Custodio, J; Das, M; Flamm, JA; Gathe, J; Liu, HC; Martin, H; McCallister, S; McDonald, C; Mills, A; Saag, M; Scribner, A; Shalit, P; Shamblaw, D; Thomas, A; Yan, M | 1 |
| Bravo, I; Clotet, B; Curran, A; Estany, C; Llibre, JM; Navarro, J; Negredo, E; Paredes, R; Podzamczer, D; Ribera, E; Santos, JR; Saumoy, M | 1 |
| Amin, J; Belloso, W; Carey, D; Cooper, DA; Crabtree-Ramirez, B; Emery, S; Foulkes, S; Jessen, H; Kumar, S; Lee, MP; Losso, M; Mohapi, L; Phanupak, P; Puls, R; Winston, A | 1 |
| Chaipung, B; Chiamwongpaet, S; Choopanya, K; Curlin, ME; Gvetadze, RJ; Kittimunkong, S; Leethochawalit, M; Martin, M; McNicholl, JM; Mock, PA; Paxton, LA; Sangkum, U; Suntharasamai, P; Vanichseni, S | 1 |
| Baeten, JM; Wyatt, C | 1 |
| Andrade-Villanueva, J; Callebaut, C; Cao, H; Cheng, AK; Crofoot, G; Custodio, JM; DeJesus, E; Fordyce, MW; Koenig, E; Martin, H; McCallister, S; Molina, JM; Oka, S; Plummer, A; Podzamczer, D; Post, F; Pozniak, A; Saag, M; Sax, PE; Thompson, M; Trottier, B; Wohl, D; Yin, MT; Zhong, L | 1 |
| Baum, MM; Beliveau, M; Fanter, R; Gunawardana, M; Hendrix, CW; Marzinke, MA; Miller, CS; Moss, JA; Remedios-Chan, M; Smith, TJ; Yang, F | 1 |
| Falutz, J | 1 |
| Anderson, PL; Bekker, LG; Buchbinder, S; Chariyalertsak, S; Chodacki, P; de Mendonca, LM; Glidden, DV; Gonzales, P; Grant, RM; Guanira, JV; Lama, JR; Liu, A; McMahan, V; Mulligan, K; Namwongprom, S; Ramirez-Cardich, ME; Schechter, M; Veloso, VG; Wang, F | 1 |
| Avihingsanon, A; Bowonwatanuwong, C; Cressey, TR; Fletcher, CV; Halue, G; Jaisieng, N; Jourdain, G; Klinbuayaem, V; Leenasirimakul, P; Podany, AT; Sukrakanchana, PO; Tawon, Y | 1 |
| Kathwate, J; Shah, I | 1 |
| Barré-Sinoussi, F; Bekker, LG; Beyrer, C; Pozniak, A | 1 |
| Gordon, M; Moodley, P; Naidoo, A; Parboosing, R; Paredes, R; Samuel, R; Singh, L | 1 |
| Balasubramanian, R; Bangsberg, DR; Ertel, K; Haberer, JE; Hankinson, SE; Kintu, A; Tumwesigye, E | 1 |
| Abebe, K; Anton, PA; Cranston, RD; Dezzutti, CS; Duffill, K; Elliott, J; Engstrom, JC; Hendrix, CW; Hiruy, H; Jacobson, C; Khanukhova, E; Marzinke, MA; Mauck, C; Mcgowan, I; Nikiforov, A; Rehman, KK; Richardson-Harman, N; Rohan, LC; Siegel, A; Spiegel, HM | 1 |
| Brown, TT; Currier, JS; Dubé, MP; Kelesidis, T; McComsey, GA; Moser, C; Murphy, RL; Ribaudo, HJ; Rothenberg, J; Stein, JH; Yang, O | 1 |
| Best, BM; Burchett, S; Byroads, M; Capparelli, EV; Fletcher, CV; Hawkins, E; Hu, C; Li, H; Mirochnick, M; Smith, E; Stek, A; Wang, J; Watts, DH | 1 |
| Hazra, R; Himes, SK; Huestis, MA; Jacobson, DL; Kacanek, D; Rich, KC; Siberry, GK; Tassiopoulos, K; Van Dyke, RB; Wu, JW | 1 |
| Hendrix, CW; Minnis, AM; Salee, P; van der Straten, A | 1 |
| Ajose, O; Beanland, RL; Calmy, A; Doherty, M; Ford, N; Irvine, C; Mayer, KH; Rapparini, C; Shubber, Z; Vitoria, M | 1 |
| Epelboin, S; Flores, J; Luton, D; Mabileau, G; Mandelbrot, L; Matheron, S; Patrat, C; Schwarzinger, M; Yazdanpanah, Y | 1 |
| Chiamwongpaet, S; Choopanya, K; Curlin, ME; Gvetadze, RJ; Kittimunkong, S; Leethochawalit, M; Martin, M; McNicholl, JM; Mock, PA; Na-Pompet, S; Paxton, LA; Sangkum, U; Suntharasamai, P; Vanichseni, S; Warapronmongkholkul, A | 1 |
| Ariaudo, A; Bonora, S; Calcagno, A; Carcieri, C; D'Avolio, A; De Nicolò, A; Di Perri, G; Sciandra, M; Simiele, M | 1 |
| Amico, KR; Eden, C; Goicochea, P; Grant, RM; Hosek, S; Koester, KA; Liu, A; Mayer, KH; McMahan, V | 1 |
| Ananworanich, J; Bennett, K; Chomchey, N; DeGruttola, V; Ebenezer, G; Gerschenson, M; Hauer, P; Hongchookiat, P; Jadwattanakul, T; Mathajittiphun, P; McArthur, JC; Nakamoto, B; Phanuphak, N; Phanuphak, P; Praihirunkit, P; Shikuma, CM; Teeratakulpisarn, N | 1 |
| Alonso-Vega, GG; Esteban, LL; Ferrández, JS; García, JR; García, TM; Quesada, PR; Sánchez, RV | 1 |
| Bedogni, G; Benincaso, A; Cattaneo, D; Erba, P; Falvella, FS; Giacomet, V; Nannini, P; Vigano, A; Zuccotti, GV | 1 |
| Appiah, LT; Beloukas, A; Bhagani, S; Bonnett, L; Chadwick, D; Dusheiko, G; Geretti, AM; Phillips, RO; Sarfo, FS; Stockdale, AJ | 1 |
| Battegay, M; Burkhalter, F; Dickenmann, M; Elzi, L; Hopfer, H; Kurz, M; Mayr, M | 1 |
| Bender, R; Berenguer, J; Garner, W; Mills, A; Nguyen, T; Pozniak, A; Speck, RM | 1 |
| Walter, M | 1 |
| Barr, E; Butler, L; Davtyan, M; DiMeglio, LA; Hazra, R; Jacobson, DL; Kalkwarf, HJ; Knapp, KM; Miller, TL; Mofenson, LM; Rich, KC; Seage, GR; Siberry, GK; Van Dyke, RB; Wheeler, JJ; Wu, JW; Yogev, R | 1 |
| Berzins, B; Brown, T; Chan, ES; Eron, JJ; Fichtenbaum, CJ; Klingman, KL; Landay, A; Ofotokun, I; Ribaudo, H; Robertson, K; Taiwo, BO; Tsibris, A | 1 |
| Antela, A; Esteban, H; Estébanez, M; Mariño, A; Moreno, S; Navarro, J; Pasquau, J; Perez-Molina, JA; Riera, M; Rivero, A; Rubio, R; Santos, J; Sanz-Moreno, J; Suárez-Lozano, I; Troya, J | 1 |
| Boettiger, DC; Chaiwarith, R; Choi, JY; Ditangco, R; Durier, N; Kamarulzaman, A; Kantipong, P; Kerr, S; Kiertiburanakul, S; Kumarasamy, N; Law, M; Lee, CK; Li, PC; Merati, TP; Mustafa, M; Ng, OT; Oka, S; Pham, TT; Pujari, S; Ratanasuwan, W; Van Kinh, N; Vonthanak, S; Wong, WW; Yunihastuti, E; Zhang, F | 1 |
| Amico, KR; Avelino-Silva, VI; Burns, D; Chodacki, P; Defechereux, PA; Fernandez, T; Glidden, DV; Grant, RM; Liu, AY; Mayer, KH; McMahan, VM; Mehrotra, M; Vargas, L | 1 |
| Assuied, A; De Castro, N; Fagard, C; Grinsztejn, B; Grondin, C; Molina, JM; Pilotto, JH; Sauvageon, H; Taburet, AM; Veloso, V | 1 |
| Brown, ER; Chirenje, ZM; Dai, JY; Hendrix, CW; Kelly, C; Marrazzo, JM; Marzinke, M; Richardson, BA | 1 |
| Vermund, SH; Walker, AS | 1 |
| Battegay, M; Bernasconi, E; Bihl, F; Calmy, A; Caminada, AP; Cavassini, M; Ledergeber, B; Martinetti, G; Rickenbach, M; Vernazza, P; Wandeler, G; Weber, R | 1 |
| Baeten, JM; Balkus, JE; Bunge, K; Chirenje, ZM; Gomez, K; Hillier, SL; Marrazzo, JM; Nair, G; Noguchi, LM; Palanee-Phillips, T; Parikh, UM; Piper, JM; Ramjee, G; Richardson, BA; Selepe, P; van der Straten, A; Watts, DH | 1 |
| Destache, CJ; Fan, W; Kang, G; Li, Q; Li, Y; Lu, W; Tso, FY; Wood, C; Yuan, Z | 1 |
| Abdool Karim, SS; Gengiah, TN; Karim, QA; Kashuba, AD; Werner, L; White, NR; Yang, KH | 1 |
| Abram, ME; Andrade-Villanueva, JF; Antunes, F; Arastéh, K; Cao, H; Chetchotisakd, P; DeJesus, E; Fehr, J; Gallant, JE; Koenig, E; Liu, HC; Rizzardini, G; Szwarcberg, J | 1 |
| Amara, A; Back, D; Boffito, M; Dickinson, L; Else, L; Higgs, C; Jackson, A; Karolia, Z; Khoo, S; Moyle, G; Yapa, HM | 1 |
| Cáceres, CF; Godfrey-Faussett, P; Goicochea, P; Koechlin, F; Mayer, KH; O'Reilly, KR; Sow, PS | 1 |
| Charpentier, C; Descamps, D; Joly, V; Landman, R; Lariven, S; Lê, MP; Peytavin, G; Phung, B; Visseaux, B; Yazdanpanah, Y; Yéni, P | 1 |
| Abebe, KZ; Aung, WS; Bakshi, RP; Breakey, JC; Caffo, BS; Du, Y; Fuchs, EJ; Hendrix, CW; Hiruy, H; Manohar, M; Marzinke, MA; McGowan, I; Rohan, LC; Spiegel, HM; Yue, C | 1 |
| Bossolasco, S; Castagna, A; Cernuschi, M; Cinque, P; Galli, L; Gianotti, N; Lazzarin, A; Maillard, M; Nozza, S; Poli, A; Spagnuolo, V; Tambussi, G | 1 |
| Zhang, XQ | 1 |
| Abdool Karim, Q; Abdool Karim, SS; Baxter, C; Gengiah, TN; Grobler, AC; Kashuba, A; Kharsany, AB; Mansoor, LE; Mindel, A; Samsunder, N; Werner, L | 1 |
| Aleman, J; de Fijter, CW; Franssen, EJ; van den Berk, GE | 1 |
| Ding, Y; Duan, J; Freeling, J; Ho, RJ; Koehn, J | 1 |
| Hyslop, WB; Lee, YZ; Napravnik, S; Wilkin, A; Wohl, DA; Young, L | 1 |
| Cong, ME; Dobard, CW; Garcia-Lerma, JG; Hanson, DL; Heneine, W; Holder, A; Makarova, N; Novembre, FJ; Pau, CP; Sharma, S; West, R | 1 |
| Craig, IK; du Toit, EF | 1 |
| Arribas, JR; Bender, R; Garner, W; Gathe, J; Nguyen, T; Shreay, S; Speck, RM; Van Lunzen, J | 1 |
| Antierens, A; Chinnakali, P; Das, M; Fernandez, M; Harries, AD; Htwe, PS; Kyaw, NT; Shetty, S; Soe, KP; Woodman, M; Zuu, MK | 1 |
| Klein, MB; Mucsi, I; Rollet-Kurhajec, KC; Young, J | 1 |
| Avihingsanon, A; Burger, D; Lewin, SR; Matthews, G; Punyawudho, B; Ruxrungtham, K; Thammajaruk, N; Thongpeang, P | 1 |
| Anglaret, X; Boyd, A; Danel, C; Delaugerre, C; Eholié, SP; Gabillard, D; Girard, PM; Lacombefor, K; Mahjoub, N; Maylin, S; Moh, R; Zoulim, F | 1 |
| Doll, M; Kleinberg, M; Kokh, D; Riedel, DJ | 1 |
| Abassi, M; Bahr, NC; Boulware, DR; Hullsiek, KH; Kiggundu, R; Meya, DB; Morawski, BM; Musubire, AK; Nabeta, HW; Rhein, J; Williams, DA | 1 |
| Boyd, A; Lacombe, K | 1 |
| Geretti, AM; Stockdale, AJ | 1 |
| Mayor, S | 1 |
| Brooks, JT; Bush, T; Conley, L; Escota, GV; Hammer, J; Henry, K; Kojic, EM; Lichtenstein, KA; Mondy, K; Önen, N; Overton, ET; Patel, P; Wood, KC | 1 |
| Burling, K; Campbell, L; Fisher, M; Gilleece, Y; Hamzah, L; Pope, M; Post, FA; Samarawickrama, A; Walker-Bone, K | 1 |
| Badowski, M; Biagi, M; Chiampas, T; Patel, M; Shicker, L; Vaughn, P; Young, J | 1 |
| Binda, K; Chen, JY; Dryden-Peterson, S; Essex, M; Lockman, S; Makhema, J; Mmalane, M; Shapiro, R; Souda, S; Zash, R | 1 |
| Baum, MM; Butkyavichene, I; Churchman, SA; Lopez, G; Miller, CS; Moss, JA; Smith, TJ | 1 |
| Briel, M; Bucher, HC; Bühler, JE; Ewald, H; Hemkens, LG; Santini-Oliveira, M; Schandelmaier, S; Stöckle, M; Vuichard, D | 2 |
| Alshangi, H; Hoorn, EJ; Rijnders, BJ; Rokx, C; Verbon, A; Zietse, R | 1 |
| Anderson, PL; Andrade, A; Bakshi, RP; Bumpus, NN; Bushman, LR; Donnell, D; Elharrar, V; Fuchs, EJ; Hendrix, CW; Kashuba, AD; Li, X; Marzinke, MA; Mayer, KH; McKinstry, L; Moore, A; Patterson, KB; Prince, HA; Radebaugh, C; Richardson, P; Shieh, E; Wang, R; Wiggins, I | 1 |
| Baeten, JM; Bekker, LG; Celum, CL; Heffron, R; Mugo, NR; Thomson, KA | 1 |
| Grome, H; Jenkins, CA; Kalams, SA; Koethe, JR; Sterling, TR | 1 |
| Amin, J; Boyd, MA; Cooper, DA; Emery, S; Kelleher, AD; Losso, M; Madero, JS; Molina, JM; Moore, CL; Renjifo, B; Ruxrungtham, K; Teppler, H; Wolff, M; Wood, R | 1 |
| He, C; Huang, H; Liao, L; Liu, J; Ruan, Y; Shao, Y; Wang, J; Wang, Z; Xing, H; Yang, S; Yue, Y | 1 |
| Baeten, JM; Bii, DK; Bukusi, EA; Bulya, N; Campbell, JD; Celum, C; Egessa, JJ; John-Stewart, G; Kusemererwa, S; Morrison, S; Mubezi, S; Mugume, F; Wangisi, J | 1 |
| Deshpande, S; Horne, K; Kiss, C; Ko, T; Lau, JS; Ratnam, D; Roberts, E; Williams, J; Woolley, I | 1 |
| Andrei, G; Snoeck, R; Topalis, D | 1 |
| Bumpus, NN; Hendrix, CW; Lade, JM; To, EE | 1 |
| Chen, BA; Dezzutti, CS; Galaska, B; Hendrix, CW; Herold, BC; Hillier, S; Kelly, CW; Levy, L; Marzinke, MA; McGowan, I; Piper, JM; Salata, RA | 1 |
| Manosuthi, S; Manosuthi, W; Nilkamhang, S; Sungkanuparph, S; Thongyen, S | 1 |
| Kuhn, L; Stein, Z; Susser, I | 1 |
| Arribas, JR; Babiker, A; Bernardino, JI; Buño, A; Castagna, A; Chene, G; De Wit, S; Gerstoft, J; Girard, PM; Katlama, C; Mallon, PW; Mocroft, A; Raffi, F; Reiss, P; Richert, L; Russell, C; Wallet, C | 1 |
| Bon, I; Borderi, M; Calza, L; Colangeli, V; Conti, M; Danese, I; Magistrelli, E; Mancini, R; Motta, R; Re, MC; Viale, P | 1 |
| Gatanaga, H; Hayashida, T; Kurosawa, T; Nishijima, T; Oka, S; Tanaka, N | 1 |
| Arends, J; Chene, G; Cosin, J; Dabis, F; Daikos, G; de Wit, S; Mallolas, J; Montforte, Ad; Mussini, C; Peters, L; Raben, D; Rockstroh, J; Smit, C; Zangerle, R; Zinkernagel, A | 1 |
| Baeten, JM; Dhanireddy, S | 1 |
| Andrade-Villanueva, J; Arribas, JR; Brar, I; Brunetta, J; Cavassini, M; Cheng, AK; DeJesus, E; DiPerri, G; Elion, R; Girard, PM; Huhn, G; Koenig, E; Liu, YP; Madruga, JV; McCallister, S; Mills, A; Orkin, C; Plummer, A; Shamblaw, D; Stephens, JL; Van Lunzen, J; Wohl, DA | 1 |
| Bennie, T; Cheng, H; Etima, J; Grossman, CI; Hartmann, M; Laborde, N; Levy, L; Marrazzo, J; Mensch, B; Montgomery, ET; Musara, P; Naidoo, S; Piper, J; van der Straten, A | 1 |
| Abraham, AG; Baxi, SM; Cohen, M; Greenblatt, RM; Minkoff, H; Scherzer, R; Sharma, A; Shlipak, MG; Young, MA | 1 |
| Bedimo, R; Brown, G; Castanon, R; Cutrell, J; Drechsler, H; Farukhi, I; Gao, A; Maalouf, NM; Tebas, P; Zhang, S | 1 |
| Boissonnault, M; Charest, L; Galanakis, C; Huchet, E; Longpré, D; Machouf, N; Murphy, D; Thomas, R; Trottier, B; Vézina, S | 1 |
| Agbaji, OO; Darin, KM; Eisen, G; Gashau, W; Kanki, PJ; Meloni, ST; Murphy, RL; Nkado, R; Okonkwo, P; Onwujekwe, DI; Rawizza, HE; Scarsi, KK; Tchetgen Tchetgen, EJ | 1 |
| Grant, RM; Koester, KA | 1 |
| Badiou, S; Casanova, ML; Cournil, A; Cristol, JP; Peyriere, H; Reynes, J | 1 |
| Landovitz, RJ | 1 |
| Green, K; Khanna, AS; Michaels, S; Morgan, E; Schneider, JA; Skaathun, B; Young, L | 1 |
| Amico, KR; Anderson, PL; Bacon, O; Blue, RW; Buchbinder, S; Cardenas, G; Chege, W; Cohen, SE; Coleman, ME; Doblecki-Lewis, S; Elion, R; Estrada, Y; Feaster, DJ; Grant, R; Kolber, MA; Liegler, T; Liu, AY; Matheson, T; Philip, SS; Postle, BS; Rawlings, MK; Trainor, N; Vittinghoff, E | 1 |
| Antonello, IC; Antonello, VS; Herrmann, S; Tovo, CV | 1 |
| Cairns, G; McCormack, S; Molina, JM | 1 |
| Anderson, PL; Atrio, JM; Espinoza, L; Frank, B; Fredricks, DN; Hendrix, CW; Herold, BC; Keller, MJ; Kiser, PF; Lo, Y; Marzinke, MA; Mesquita, PM; Rabe, L; Srinivasan, S; Teller, R | 1 |
| Chariyalertsak, S; Deutsch, MB; Glidden, DV; Grant, RM; Guanira, J; Kallas, EG; Keatley, J; McMahan, V; Sevelius, J | 1 |
| Booth, JW; Post, FA | 1 |
| Aboulker, JP; Capitant, C; Charbonneau, P; Charreau, I; Chas, J; Cheret, A; Chidiac, C; Cotte, L; Cua, E; Delaugerre, C; Delfraissy, JF; Doré, V; Etien, N; Fonsart, J; Girard, G; Le Gall, JM; Lorente, N; Loze, B; Marchand, L; Meyer, L; Molina, JM; Pasquet, A; Peytavin, G; Pialoux, G; Pintado, C; Préau, M; Raffi, F; Rooney, JF; Rozenbaum, W; Simon, MC; Spire, B; Suzan-Monti, M; Thompson, D; Timsit, J; Tremblay, C; Wainberg, MA | 1 |
| Baeten, JM; Boueilh, A; Grant, RM; Konstantinidis, I; Mugwanya, KK; Nadkarni, GN; Weikum, D; Wyatt, CM; Yacoub, R | 1 |
| Abram, ME; Arribas, JR; Avihingsanon, A; Benson, P; Bloch, M; Cheng, A; Chetchotisakd, P; Crofoot, G; Custodio, JM; Fordyce, MW; Gathe, J; Gupta, SK; Lichtenstein, K; McCallister, S; Post, FA; Pozniak, A; Ramgopal, M; SenGupta, D; Wei, X | 1 |
| Bedu-Addo, G; Chadwick, DR; Kirk, ES; Owusu, AL; Owusu, D; Parris, V; Phillips, R; Sarfo, FS | 1 |
| McCarthy, M | 1 |
| Baeten, J; McCormack, S | 1 |
| Haberer, JE | 1 |
| Anderson, PL; García-Lerma, JG; Heneine, W | 1 |
| Baeten, JM; Mugwanya, KK | 1 |
| Alcantarini, C; Bonora, S; Calcagno, A; Cusato, J; D'Avolio, A; Di Perri, G; Lucchiari, M; Marinaro, L; Mengozzi, G; Simiele, M; Tettoni, MC; Trentini, L | 1 |
| McHenry, MS; Nyandiko, WM; Scanlon, ML; Vreeman, RC | 1 |
| Fordyce, MW; Hitchcock, MJ; Ray, AS | 1 |
| Bonora, S; Calcagno, A; Di Perri, G; Trentalange, A | 1 |
| Baeten, JM; Bukusi, E; Celum, C; Donnell, D; Fluharty, TR; Lingappa, JR; Lund, JM; McElrath, MJ; Mugo, N; Murnane, PM; Pattacini, L; Ronald, A; Thomas, KK | 1 |
| Horn, TH; Paltiel, AD; Walensky, RP | 1 |
| Anderson, PH; Ebeling, PR; Emery, S; Fairley, CK; Kimlin, MG; Klassen, KM | 1 |
| Andreotti, M; Floridia, M; Galluzzo, CM; Giuliano, M; Jere, H; Liotta, G; Luhanga, R; Mancinelli, S; Marazzi, MC; Marchei, E; Mwenda, R; Palombi, L; Pichini, S; Pirillo, MF; Sagno, JB; Vella, S | 1 |
| Boucherie, C; Breton, G; Caumes, E; Chaix, ML; Chêne, G; Fagard, C; Lortholary, O; May, T; Molina, JM; Padoin, C; Patey, O; Rami, A; Robert, J; Roussillon, C; Tod, M; Veziris, N | 1 |
| Bañón, S; Casado, JL; del Rey, JM; Guzman, P; Liaño, F; Santiuste, C; Serna, J; Tenorio, M | 1 |
| Bugnon, O; Cavassini, M; Fayet Mello, A; Locatelli, I; Parienti, JJ; Rotzinger, A; Schneider, MP | 1 |
| Brooks, JT; García-Lerma, JG; Hanson, D; Heneine, W; McLaurin, T; Paxton, L; Ruone, S; Taylor, A | 1 |
| Effa, EE; Okonkwo, RI; Weidmann, AE | 1 |
| Bendle, M; Boffito, M; Bower, M; Dalla Pria, A; Ramaswami, R | 1 |
| Barchiesi, F; Castelletti, S; Cirioni, O; Di Campli, FM; Falasca, K; Giacometti, A; Mazzocato, S; Orsetti, E; Ucciferri, C; Valeriani, C; Vecchiet, J | 1 |
| Cheshenko, N; Crooker, K; Frank, B; Herold, BC; Kiser, PF; Mesquita, PM; Ott, A; Park, SH; Su, JT; Szleifer, I; Taneva, E | 1 |
| Anekvorapong, R; Cherdtrakulkiat, T; Chiamwongpaet, S; Choopanya, K; Curlin, ME; Gvetadze, RJ; Kittimunkong, S; Leelawiwat, W; Leethochawalit, M; Martin, M; McNicholl, JM; Mock, PA; Paxton, LA; Sangkum, U; Suntharasamai, P; Tararut, P; Vanichseni, S | 1 |
| Arastéh, K; Bergmann, F; Chaves, RL; Cooper, DA; Cordery, DV; Neto, JL; Robinson, P; Ruxrungtham, K; Scherer, J; Zajdenverg, R | 1 |
| Cottrell, M; Dumond, JB; Forrest, A; Francis, O; Hudgens, MG; Malone, S; Mollan, K; Patterson, KB; Prince, HM; Sharpless, NE; Sykes, C; Torrice, C; Trezza, C; Van Dam, C; Wang, R; White, N | 1 |
| Baeten, JM; Celum, C; Donnell, D; Hendrix, CW; Lehman, DA; Marzinke, MA; Matsen, FA; McCoy, CO; Mugo, N; Thomas, KK; Warth, C; Weis, JF | 1 |
| Du, S; Guo, F; Han, Y; Li, T; Li, Y; Lv, W; Qiu, Z; Song, X; Thio, CL; Wang, H; Wang, N; Xie, J; Zhu, T | 1 |
| Doerr, HW; Herrmann, E; Keppler, OT; Reinheimer, C; Stephan, C; Stürmer, M; Wesner, A | 1 |
| Archampong, TN; Boamah, I; Flanigan, T; Gillani, FS; Kenu, E; Kwara, A; Lartey, M; Obo-Akwa, A; Sagoe, KW; Yang, H | 1 |
| Béguelin, C; Moradpour, D; Rauch, A; Sahli, R; Suter, F; Vazquez, M; Wandeler, G | 1 |
| Estrella, MM; Ix, JH; Kim, JE; Scherzer, R; Shlipak, MG | 1 |
| Fux, CA; Kirk, O; Lundgren, JD; Mocroft, A; Monforte, Ad; Moranne, O; Morlat, P; Reiss, P; Ross, M; Ryom, L | 1 |
| Andreotti, M; Buonomo, E; Floridia, M; Giuliano, M; Jere, H; Liotta, G; Mancinelli, S; Marazzi, MC; Palombi, L; Sagno, JB; Scarcella, P; Vella, S | 1 |
| Baeten, JM; Bangsberg, DR; Haberer, JE; Musinguzi, N; Muwonge, T; Thomas, K | 1 |
| Baeten, JM; Bangsberg, DR; Boum, Y; Celum, C; Haberer, JE; Hendrix, CW; Marzinke, MA; Muganzi, CD; Musinguzi, N; Ronald, A | 1 |
| Duwal, S; von Kleist, M | 1 |
| Amico, KR; Anderson, PL; Buchbinder, SP; David, B; Glidden, DV; Grant, RM; Grinsztejn, B; Guanira, J; Hosek, SG; Liu, AY; Mayer, KH; McMahan, V; Schechter, M | 1 |
| Anderson, PL; Kiser, JJ; Lan, A; Naggie, S; Patel, K; Tillman, H; Wong, TC | 1 |
| Likanonsakul, S; Nakayama, EE; Nitiyanontakij, R; Prasithsirikul, W; Sangsajja, C; Shioda, T; Suntisuklappon, B | 1 |
| Casadellà, M; Gordon, M; Kuritzkes, DR; Marconi, VC; Noguera-Julian, M; Paredes, R; Parera, M; Rodriguez, C; Sunpath, H | 1 |
| Altfeld, M; Archary, D; Arnold, KB; Bergin, P; Deal, A; Dunphy, LJ; Garrett, N; Karim, QA; Karim, SA; Lauffenburger, DA; Liebenberg, LJ; Morris, L; Mureithi, MW; Passmore, JS; Samsunder, N; Seaton, KE; Tomaras, GD; Werner, L; Yates, NL | 1 |
| Calvez, V; Marcelin, AG; Meynard, JL; Morand-Joubert, L; Surgers, L; Todesco, E | 1 |
| John-Stewart, G; Katana, A; Kinuthia, J; Langat, A; McGrath, CJ; Nganga, L; Odeny, B; Pintye, J; Singa, B | 1 |
| Botelho-Nevers, E; Frésard, A; Gagneux-Brunon, A; Lucht, F | 1 |
| Arribas, JR; Brinson, C; Brunetta, J; Callebaut, C; Cheng, A; Cheret, A; Clarke, A; Clumeck, N; Das, M; Fordyce, M; Mussini, C; Oka, S; Rashbaum, B; Sax, PE; Stephens, J; Tashima, K; Tebas, P; Wohl, D; Zhong, L | 1 |
| Cai, WP; He, HL; Huang, SB; Ling, XM; Liu, YF; Wang, H; Wang, M; Wang, XC; Wei, FL; Wu, H; Wu, YS; Wu, ZY; Yang, L; Zhang, FJ; Zhang, WW | 1 |
| Estrella, MM; Machekano, R; Moosa, MR; Nachega, JB; Taljaard, JJ; Uthman, OA; Veldkamp, PJ; Zachor, H; Zeier, MD | 1 |
| Brown, ER; Chirenje, MZ; Gomez, K; Hendrix, CW; Liu, K; Marrazzo, JM; Marzinke, MA; Piper, JM; van der Straten, A | 1 |
| Gavegnano, C; Haile, WB; Jiang, Y; Schinazi, RF; Tao, S; Tyor, WR | 1 |
| Chateau, M; Denton, PW; Garcia, JV; Honeycutt, JB; Hudgens, MG; Kovarova, M; Long, JM; Nochi, T; Olesen, R; Richardson, A; Swanson, MD; Tolstrup, M; Wahl, A; Østergaard, L | 1 |
| Chang, SC; Chang, SY; Hung, CC; Kuo, CH; Lin, SW; Liu, WC; Su, YC; Sun, HY; Tang, SY; Tsai, MS; Wu, BR | 1 |
| Cotter, AG; Grant, PM | 1 |
| Akello, CA; Chirenje, ZM; Dai, JY; Greenspan, S; Kelly, CW; Kiweewa, FM; Magure, T; Marrazzo, JM; Mayo, A; Mgodi, N; Mirembe, BG; Nakabiito, C; Piper, J; Riddler, SA | 1 |
| Amer, H; Berg, ML; Cummins, NW; Marcelin, JR; Rizza, SA; Tan, EM | 1 |
| Capitant, C; Chas, J; Chidiac, C; Demoulin, B; Lorente, N; Meyer, L; Molina, JM; Mora, M; Préau, M; Rojas Castro, D; Sagaon-Teyssier, L; Spire, B; Suzan-Monti, M | 1 |
| Callebaut, C; Fordyce, M; Kitrinos, KM; Margot, NA; McCallister, S; Miller, MD | 1 |
| Bacon, O; Cohen, SE; Hare, CB; Liu, AY; Marcus, JL; Pinder, J; Volk, JE | 1 |
| Brown, ER; Chirenje, ZM; Gomez, K; Liu, K; Marrazzo, J; Mensch, BS; Patterson, K; Piper, J; van der Straten, A | 1 |
| Cottrell, ML; Dellon, ES; Hudgens, MG; Kashuba, AD; Madanick, RD; Malone, S; Nelson, JA; Patterson, KB; Prince, HM; Shaheen, NJ; Sykes, C; White, N; Wulff, J; Yang, KH | 1 |
| Bañón, S; Caballero, C; Casado, JL; Gomez, A; Moreno, S; Perez-Elías, MJ; Rey, JM; Rosillo, M; Santiuste, C; Vazquez, M | 1 |
| Gatanaga, H; Kawasaki, Y; Kikuchi, Y; Kurosawa, T; Nishijima, T; Oka, S; Tanaka, N | 1 |
| Dlamini, S; Jerome, S; Karim, QA; Karim, SA; MacQueen, KM; Majors, A; Mansoor, LE; Okumu, E; Perry, B; Pillay, D; Singh, C; Sortijas, S; Watson, S | 1 |
| Audsley, J; Avihingsanon, A; Bayliss, J; Bent, SJ; Bowden, S; Fairley, CK; Lewin, SR; Littlejohn, M; Locarnini, S; Luciani, F; Matthews, G; Sasadeusz, J; Yuen, L | 1 |
| Aguiar, C; Antela, A; Boffito, M; Compston, J; Di Perri, G; Hendry, BM; Mallon, P; Pourcher-Martinez, V | 1 |
| Dewar, RL; Kopp, JB; Lane, HC; Maldarelli, F; Manion, MM; Mikula, JM; Norman-Wheeler, JF; Ober, AG; Pau, AK; Suarez, LM | 1 |
| Warpakowski, A | 1 |
| Bañón, S; Casado, JL; Del Rey, JM; Liaño, F; Moreno, A; Moreno, S; Perez-Elías, MJ; Rodriguez, M; Santiuste, C | 1 |
| Agot, K; Callahan, R; Dorflinger, L; Jenkins, D; Nanda, K; Taylor, D; Van Damme, L; Wang, M | 1 |
| Bertucci, R; Bonora, S; Calcagno, A; D'Avolio, A; Di Perri, G; Mornese Pinna, S; Motta, I; Simiele, M | 1 |
| Maki, DG | 1 |
| Bowman, VQ; Daar, ES; Diamond, C; Dube, MP; Goicoechea, M; Haubrich, RH; Jain, S; Karris, MY; Kemper, C; Kerkar, S; Morris, S; Rieg, G; Sun, X | 1 |
| Ebell, MH | 1 |
| Dimitrov, DT; Donnell, D; Mâsse, BR | 1 |
| Amico, KR; Anderson, P; Avelino-Silva, VI; Grant, R; Guanira, J; McMahan, V; Mehrotra, M; Veloso, VG | 1 |
| Heffron, R; Matthews, LT; Mugo, N; Pintye, J; Weber, S | 1 |
| Abrams, EJ; Jao, J; Myer, L; Petro, G; Phillips, T; Zerbe, A | 1 |
| Barnett, SW; Cope, A; Dereuddre-Bosquet, N; Desjardins, D; Dispinseri, S; Gosse, L; Le Grand, R; Ochsenbauer, C; Prague, M; Saidi, H; Scarlatti, G; Shattock, RJ; Shen, X; Thiebaut, R; Tolazzi, M; Tomaras, G | 1 |
| Díez-García, LF; Gálvez-Contreras, MC; Romero-León, JM | 1 |
| Baeten, J; Branch, A; Celum, C; Donnell, D; Kiarie, J; Mugo, N; Mugwanya, K; Nickolas, T; Ronald, A; Tappero, J; Wyatt, C; Yin, M | 1 |
| Boyd, MA; Cooper, DA | 1 |
| Anoma, C; Aranda, JF; Bernier, A; Dah, E; Gapiya, J; Himmich, H; Somda, M; Sylla, A | 1 |
| Abram, ME; Brinson, C; Cheng, AK; Clumeck, N; Daar, ES; DeJesus, E; Gallant, JE; Johnson, M; Morales-Ramirez, J; Osiyemi, O; Plummer, A; Raffi, F; Rhee, MS; Ruane, P; Ward, D; Yan, M | 1 |
| Bonora, S; Calcagno, A; Di Perri, G | 1 |
| Bruck, P; Date, AA; Destache, CJ; Fletcher, CV; Kang, G; Li, Q; Lu, W; Mandal, S; Pham, R; Rezich, M; Shibata, A; Vivekanandan, R; Yuan, Z; Zhou, Y | 1 |
| Cai, X; Ding, Y; Gao, M; He, N; Ning, Z; Pan, R; Rou, K; Wu, Z; Yan, H; Yang, Y; Zheng, H; Zhou, Y | 1 |
| Gazzard, B | 1 |
| Baum, MM; Butkyavichene, I; Churchman, SA; Easley, JT; Fanter, R; Gunawardana, M; Hendrix, CW; Marzinke, MA; Miller, CS; Moss, JA; Smith, TJ; Yang, F | 1 |
| Bennett, M; Estrella, MM; Ix, JH; Jacobson, LP; Jotwani, V; Macatangay, B; Palella, F; Parikh, CR; Scherzer, R; Shlipak, M; Witt, MD | 1 |
| Bolduc, P; Cheeseman, SH; Colgate, E; Roder, N | 1 |
| Allavena, C; Bani-Sadr, F; Cabié, A; Cheret, A; Chirouze, C; Cotte, L; Cuzin, L; Flandre, P; Katlama, C; Pugliese, P; Rey, D | 1 |
| Emanuel, EJ; Persad, GC | 1 |
| Cheng, X; Fraenkel, L; Han, Y; Hsieh, E; Insogna, KL; Li, T; Xia, W; Yin, MT; Zhu, T | 1 |
| Forrest, JI; Jagodzinski, LL; Kanters, S; Kirk, C; Kubwimana, M; Mugabo, J; Mulindabigwi, A; Mwumvaneza, M; Ndahimana, Jd; Nsanzimana, S; Peel, SA; Redfield, RR; Ribakare, M; Riedel, DJ; Sebuhoro, D; Uwimbabazi, JC | 1 |
| Gosset, C; Molina, JM; Penot, P; Verine, J | 1 |
| Achhra, AC; Mocroft, A; Nugent, M; Ryom, L; Wyatt, CM | 1 |
| Moodley, J; Naidoo, S; Ramjee, G | 1 |
| Baggaley, R; Dalglish, SL; Fonner, VA; Grant, RM; Hodges-Mameletzis, I; Kennedy, CE; Koechlin, FM; O'Reilly, KR; Rodolph, M | 1 |
| Beraud, G; Chagneau-Derrode, C; Garcia, M; Godet, C; Le Moal, G; Roblot, F | 1 |
| Benson, P; Brinson, C; Brunetta, J; Cheng, A; Crofoot, G; Das, M; Fordyce, M; Gallant, J; Garner, W; McCallister, S; Mills, A; Oka, S | 1 |
| Bergmann, JF; Champion, K; Clevenbergh, P; Collet, C; de Vernejoul, MC; Evans, J; Fernandez, S; Lopes, A; Morgand, M; Ostertag, A; Sellier, P; Souak, S; Trout, H | 1 |
| Deeks, ED; Greig, SL | 1 |
| Battegay, M; Bernasconi, E; Braun, DL; Darling, K; Günthard, HF; Hirzel, C; Hoffmann, M; Kouyos, RD; Kovari, H; Marzel, A; Rougemont, M; Scherrer, AU; Shilaih, M | 1 |
| Jones, R; Levy, JB; Milburn, J | 1 |
| Carrero, A; Collado, A; de Lagarde-Sebastián, M; Delgado-Fernández, M; Espinosa, N; Gómez-Berrocal, A; Hernández-Quero, J; Hontañón-Antoñana, V; Jiménez-Aguilar, P; Macías, J; Merino, D; Neukam, K; Pérez-Camacho, I; Pineda, JA; Ríos, MJ; Rivero-Juárez, A; Ruiz-Morales, J; Téllez, F; Vera-Méndez, F | 1 |
| Behrens, G; Borg, P; Bouee, S; M Llibre, J; Moyle, G; Piontkowsky, D; Raffi, F; Reilly, G; Rogatto, F | 1 |
| Callebaut, C; Liu, Y; Margot, NA; Miller, MD | 1 |
| Boyd, A; Delaugerre, C; Girard, PM; Lacombe, K; Lascoux-Combe, C; Lavocat, F; Maylin, S; Miailhes, P; Zoulim, F | 1 |
| Custodio, JM; Fordyce, M; Garner, W; Kearney, BP; Ling, KH; Ramanathan, S; Vimal, M | 1 |
| Barber, TJ; Girometti, N; Jones, R; Levy, J; McCormack, S; Sullivan, A | 1 |
| Balamane, M; Brooks, K; Coetzer, M; DeLong, A; Diero, L; Emonyi, W; Hogan, J; Kantor, R; Kemboi, E; Orido, M; Reitsma, M | 1 |
| Allavena, C; Andre, E; Calvez, V; Flandre, P; Grude, M; Jovelin, T; Katlama, C; Lambert-Niclot, S; Marcelin, AG; Raffi, F; Rodallec, A; Sayon, S; Wirden, M | 1 |
| Baldelli, S; Cattaneo, D; Clementi, E; Gervasoni, C; Meraviglia, P; Minisci, D; Rizzardini, G | 1 |
| Cavadas, C; Costa, S; do Céu Sousa, M; Machado, M | 1 |
| Bogner, JR; Hilge, R; Schrader, S; Seybold, U; Zeder, AJ | 1 |
| Carbone, A; Castagna, A; Galli, L; Gianotti, N; Lazzarin, A; Merli, M; Nozza, S; Poli, A; Ripa, M; Salpietro, S | 1 |
| Bischoff, M | 1 |
| Seidman, D; Weber, S | 1 |
| Brown, TT; Chan, ES; Eron, JJ; Fichtenbaum, CJ; Klingman, KL; Landay, AL; Martinson, J; Mirmonsef, P; Ofotokun, I; Plants, J; Ribaudo, HJ; Taiwo, BO; Weitzmann, MN | 1 |
| Atta, MG; Decker, BS; Gupta, SK; Kashuba, ADM; Slaven, JE; Wyatt, CM | 1 |
| Bennett, M; Estrella, MM; Ix, JH; Jacobson, LP; Jotwani, V; Macatangay, B; Palella, FJ; Parikh, CR; Scherzer, R; Shlipak, MG; Witt, MD | 1 |
| Briz, V; De Ory, SJ; Falcon-Neyra, L; Fortuny, C; Frick, MA; González-Tomé, MI; López-Cortés, LF; Moreno, EB; Navarro Gómez, ML; Neth, O; Noguera-Julian, A; Olbrich, P; Palladino, C; Santos, JL; Soler-Palacín, P | 1 |
| Bloch, M; Grulich, A; Holden, J; McAllister, J; McNulty, A; Poynten, IM; Prestage, G; Templeton, DJ; Vaccher, S; Zablotska, I | 1 |
| Gordon, M; Julian, MN; Moodley, P; Naidoo, A; Parboosing, R; Paredes, R; Samuel, R; Singh, L | 1 |
| Almonte, A; Anderson, P; Chan, PA; Liegler, T; Mayer, KH; Mena, L; Montgomery, MC; Nunn, AS; Oldenburg, CE; Patel, R | 1 |
| Berzins, B; Brown, TT; Chan, ES; Eron, JJ; Lee, A; Miyahara, S; Robertson, KR; Rusin, D; Taiwo, BO | 1 |
| Balakrishnan, P; Boobalan, J; Dinesha, TR; Gomathi, S; Poongulali, S; Pradeep, A; Saravanan, S; Sivamalar, S; Solomon, S; Solomon, SS | 1 |
| Anderson, PL; Bushman, LR; Castillo-Mancilla, JR; Chen, X; MaWhinney, S; McAllister, KB; Seifert, SM; Zheng, JH | 1 |
| Baeten, JM; Bangsberg, D; Celum, CL; Chaturvedula, A; Fossler, MJ; Goti, V; Haberer, JE; Hendrix, CW; Lu, Y; Sale, ME | 1 |
| Grobler, A; Mansoor, LE; Suleman, F; Upfold, M | 1 |
| Brand, RM; Carballo-Diéguez, A; Cranston, RD; Dolezal, C; Duffill, K; Engstrom, JC; Febo, I; Frasca, T; Giguere, R; Jacobson, C; Leu, CS; Mayer, KH; McGowan, I; Nikiforov, A; Park, SY; Schwartz, JL; Siegel, A | 1 |
| Beigi, RH; Biggio, JR; Bogen, DL; Dai, JY; Dezzutti, CS; Hendrix, CW; Hillier, SL; Isaacs, SK; Marzinke, MA; Montgomery, ET; Noguchi, LM; Piper, JM; Schwartz, JL; Watts, DH | 1 |
| Cohn, JA; Riddell, J | 1 |
| Asiimwe, S; Baeten, JM; Carroll, JJ; Celum, C; Heffron, R; Mugo, N; Ndase, P; Ngure, K | 1 |
| Dong, Y; Gedmintas, L; Katz, JN; Lehmann, E; Losina, E; Solomon, DH; Wright, EA | 1 |
| Anderson, PL; Castillo-Mancilla, J; Reirden, D | 1 |
| Brochier, C; Cottalorda-Dufayard, J; Cotte, L; Dellamonica, P; Durant, J; Gagnieu, MC; Gatey, C; Izopet, J; Jacomet, C; Lucht, F; Pradat, P; Raffi, F; Trabaud, MA; Vassallo, M | 1 |
| Buscemi, L | 1 |
| Bunnell, KL; Gallagher, MA; Glowacki, RC; Huhn, G; Osei, AM; Vibhakar, S | 1 |
| Bunders, MJ; Cohen, S; Denneman, L; Godfried, MH; Kuijpers, TW; Nellen, JF; Pajkrt, D; Scherpbier, HJ; Smit, C; van de Plas, A; van Leeuwen, E; Weijsenfeld, AM | 2 |
| Gibson, AK; Nambiar, PH; Schafer, JJ; Shah, BM | 1 |
| Bertagnolio, S; Doherty, M; Ford, N; Vitoria, M | 1 |
| Abraham, P; Mancama, D; Martinson, N; Motlhaoleng, K; Naicker, S; Seedat, F; Variava, E | 1 |
| Amici, R; Andreotti, M; Buonomo, E; Floridia, M; Galluzzo, CM; Giuliano, M; Jere, H; Liotta, G; Mancinelli, S; Marazzi, MC; Palombi, L; Sagno, JB; Scarcella, P; Vella, S | 1 |
| Destache, CJ; Mandal, S; Prathipati, PK | 1 |
| Cohen, K; Maartens, G; Mouton, JP | 1 |
| Babin, FX; Balathandan, TP; Chinnakali, P; Clevenbergh, PA; Das, M; Harries, AD; Lwin, TT; Shwe, M; Thein Than Tun, S; Thiha, N; Tin, HH; Yi, Y | 1 |
| Ammassari, A; Antinori, A; Bellagamba, R; Borghi, V; Colafigli, M; D'Ettorre, G; Di Giambenedetto, S; Fabbiani, M; Giannetti, A; Latini, A; Loiacono, L; Lorenzini, P; Sterrantino, G; Zaccarelli, M | 1 |
| Alcaro, S; Alteri, C; Andreoni, M; Antinori, A; Artese, A; Bellagamba, R; Bertoli, A; Carta, S; Ceccherini-Silberstein, F; Continenza, F; Costa, G; Di Maio, VC; Di Santo, F; Fedele, V; Girardi, E; Giuliani, M; Gori, C; Latini, A; Liuzzi, G; Monforte, AD; Orchi, N; Parrotta, L; Perno, CF; Petrosillo, N; Pinnetti, C; Romeo, I; Santoro, MM; Surdo, M; Svicher, V | 1 |
| Amici, R; Andreotti, M; Floridia, M; Galluzzo, CM; Giuliano, M; Jere, H; Liotta, G; Mancinelli, S; Marazzi, MC; Palombi, L; Sagno, JB; Vella, S | 1 |
| Avihingsanon, A; Chaiwarith, R; Choi, JY; Ditangco, R; Jiamsakul, A; Kamarulzaman, A; Kantipong, P; Kiertiburanakul, S; Kumarasamy, N; Lee, MP; Makane, A; Merati, TP; Mustafa, M; Ng, OT; Nguyen, KV; Pham, TT; Pujari, S; Ratanasuwan, W; Saphonn, V; Sim, BL; Sohn, AH; Tanuma, J; Wong, WW; Yunihastuti, E; Zhang, F | 1 |
| Avihingsanon, A; Cao, H; Cheng, A; Hagins, D; Hodder, S; Jiang, S; Johnson, M; Kityo, C; Koenig, E; Squires, K; Szwarcberg, J; Voronin, E; White, K | 1 |
| Terrault, NA | 1 |
| Anderson, PL; Bushman, LR; Campbell, K; Castillo-Mancilla, J; Coleman, S; Gardner, EM; Glidden, DV; Grant, R; Hosek, S; Liu, A; MaWhinney, S; McAllister, K; Seifert, S; Wilson, CM; Zheng, JH | 1 |
| Kaleebu, P; Kasamba, I; Kazooba, P; Mayanja, BN; Munderi, P; Salome, T; Were, J | 1 |
| Borghi, V; Bruzzone, B; Callegaro, AP; Colao, G; Gismondo, MR; Micheli, V; Penco, G; Rossotti, R; Rusconi, S; Vicenti, I; Zazzi, M | 1 |
| Chang, SY; Cheng, CY; Cheng, SH; Ku, SY; Lin, MH; Sun, NL | 1 |
| Chen, H; Guo, W; Huang, J; Jiang, J; Liang, B; Liang, H; Liao, Y; Su, J; Xu, X; Ye, L; Zang, N | 1 |
| Dahlby, JS; Guillemi, SA; Harris, M; Hogg, RS; Hull, MW; Lima, VD; Ling, SH; Montaner, JS; Werb, R; Yip, B; Zhang, W | 1 |
| De Swardt, G; Egan, JE; Hugo, JM; McIntyre, JA; Rebe, K; Stall, RD; Struthers, H | 1 |
| Bernasconi, DP; Casari, S; Cauda, R; Costarelli, S; Dal Zoppo, S; Di Pietro, M; Gori, A; Ladisa, N; Lapadula, G; Maggiolo, F; Mondi, A; Pezzoli, C; Sabbatini, F; Sighinolfi, L; Soria, A; Torti, C; Valsecchi, MG | 1 |
| García-Arieta, A; Gordon, J; Gwaza, L; Leufkens, H; Potthast, H; Stahl, M; Welink, J | 1 |
| Hongzhou, LU; Yinzhong, S | 1 |
| Justesen, K; Prasad, S | 1 |
| Brown, TT; Currier, JS; Dube, MP; Kelesidis, T; McComsey, GA; Moser, C; Ribaudo, HJ; Stein, JH; Tran, TTT; Yang, OO | 1 |
| Cope, AB; Crooks, AM; Eron, JJ; Ferrari, G; Fiscus, SA; Gay, CL; Hicks, CB; Kuruc, JD; Margolis, DM; McGee, KS; McKellar, MS; Sebastian, J; Willis, SJ | 1 |
| Boucher, CAB; Nichols, BE; Rijnders, BJA; van de Vijver, DAMC; van der Valk, M | 1 |
| Baeten, JM; Celum, CL; Hendrix, CW; John-Stewart, G; Katabira, ET; Marzinke, M; Mugo, NR; Mugwanya, KK; Muthuri, G; Muwonge, TR; Ngure, K; Semiyaga, NB; Stergachis, A | 1 |
| Birbal, S; Dheda, M; Ojewole, E; Oosthuizen, F | 1 |
| Antinori, A; Bonora, S; Costarelli, S; Cozzi-Lepri, A; d'Arminio Monforte, A; Di Perri, G; Galli, M; Gori, A; Lapadula, G; Madeddu, G; Maggiolo, F; Viale, P | 1 |
| Booth, C; Churchill, D; Collins, S; Dunn, DT; Pillay, D; Sabin, C; Smit, E; Tostevin, A; White, E | 1 |
| Andrade, A; Funderburg, NT; Joshi, AA; Kuritzkes, DR; Lederman, MM; Mehta, NN; Playford, MP; Xu, D | 1 |
| Lu, X; Wang, H; Xu, N; Yang, X | 1 |
| Bannerman, T; Cheng, A; Das, M; Dinoso, J; Fang, L; Fordyce, MW; Funderburg, NT; Kulkarni, M; Liu, HC; Mantini, J; McCallister, S; McComsey, GA; Song, Q; Thornton, B; Zhang, Y | 1 |
| Battle, S; Closson, EF; Denson, D; Herbst, JH; Holman, J; Landers, S; Mansergh, G; Mimiaga, MJ; Pitts, N | 1 |
| Banigbe, B; Chang, CA; Eisen, G; Jolayemi, T; Kanki, PJ; Meloni, ST; Okonkwo, PI | 1 |
| Batra, J; Chakraborty, R; Gaur, AH; Kizito, H; Kosalaraksa, P; Luesomboon, W; Myers, M; Porter, D; Prasitsueubsai, W; Quirk, E; Rakhmanina, N; Rassool, M; Rhee, MS; SenGupta, D; Shao, Y; Ting, L | 1 |
| Bor, J; Boulle, A; Brennan, AT; Davies, MA; de Rekeneire, N; Fatti, G; Fox, MP; Leroy, V; Prozesky, H; Sikazwe, I; Stinson, K; Tanser, F; Wandeler, G; Wood, R; Wool-Kaloustian, K; Yuannoutsos, C | 1 |
| Agrahari, V; Christenson, LK; Dim, DC; Ezoulin, MJ; Hung, WT; Meng, J; Molteni, A; Youan, BC; Youm, I | 1 |
| Ananworanich, J; Aurpibul, L; Bunupuradah, T; Kosalaraksa, P; Kurniati, N; Puthanakit, T; Sophonphan, J; Sudjaritruk, T | 1 |
| Alioni, S; Izudi, J; Kerukadho, E; Ndungutse, D | 1 |
| Boechat, MI; Emel, L; George, K; Joao, E; Kreitchmann, R; Kumwenda, N; Mirochnick, M; Mofenson, L; Nielsen-Saines, K; Osorio, LE; Pinto, J; Santos, B; Sato, P; Swenson, M | 1 |
| Abdool Karim, Q; Govender, EM; Mansoor, LE | 1 |
| Albert, J; Blaxhult, A; Carlander, C; Eriksen, J; Flamholc, L; Gisslén, M; Josephson, F; Karlström, O; Navér, L; Sönnerborg, A; Svedhem, V; Yilmaz, A | 1 |
| Basar, M; Bhosale, R; Bobat, R; Browning, R; Chi, BH; Chipato, T; Coletti, AS; Currier, JS; Fenton, T; Fiscus, SA; Flynn, PM; Fowler, MG; Gnanashanmugam, D; Klingman, KL; Loftis, AJ; Martinson, FE; McIntyre, J; Mlay, P; Mofenson, LM; Moodley, D; Owor, M; Purdue, L; Qin, M; Shapiro, DE; Siberry, GK; Strehlau, R; Taha, TE; Theron, GB; Violari, A | 1 |
| Antinori, S; Binda, F; Cattaneo, D; Cheli, S; Falvella, FS; Gervasoni, C; Mazzali, C; Milazzo, L; Ronzi, P; Sollima, S | 1 |
| Bedimo, R; Myers, J; Rosenblatt, L | 1 |
| Akula, SM; Artola, RT; Barone Gibbs, B; Bielke, LR; Bironaitė, D; Bogomolovas, J; Bukelskienė, V; Burke, LE; Chen, B; Chen, D; Chen, WJ; Cook, FJ; Cook, PP; Cotutiu, P; Cui, Y; Davis, KK; Dumitras, DE; El-Sayed, MA; Grabauskienė, V; Gretz, N; Gupta, R; Hargis, BM; Heck, C; Hernandez-Velasco, X; Huang, W; Huete-Ortega, M; Jakicic, JM; Jian, J; Jiang, K; Jiang, M; Jiang, Q; Jin, T; Kiuchi, M; Kovacs, SJ; Labeit, D; Labeit, S; Lang, W; Lang, XY; Latorre, JD; Li, HF; Li, J; Li, YQ; Lin, H; Lin, X; Liu, BT; Liu, M; Longworth, J; Lu, JB; Luo, C; Mahmoud, MA; Marx, A; Menconi, A; Mihos, CG; Muresan, D; Notter, RH; Pant, B; Petrisor, FM; Podkopajev, A; Popp, RA; Portzer, LA; Pradhan, S; Qian, G; Ranjit, M; Regmi, T; Rinkūnaitė, I; Rogers, RJ; Rotar, IC; Sakurai, H; Santana, O; Schwan, AL; Shi, XM; Shkoor, MG; Šimoliūnas, E; Smalinskaitė, L; Stamatian, F; Stang, AT; Tellez, G; Vaidyanathan, S; Vicente, JL; Walker, LR; Walther, FJ; Wan, Y; Wang, H; Wang, X; Wang, Z; Weis, CA; Wen, Z; Wolfenden, AD; Wolfenden, RE; Wright, PC; Wu, D; Xing, H; Xiong, X; Yang, H; Yang, Y; Yu, Q; Yue, D; Zang, Q; Zhang, L; Zhao, B; Zheng, Y; Zhou, L; Zhou, M; Zhuge, F | 1 |
| Amin, J; Azwa, I; Belloso, WH; Boyd, MA; Chetchotisakd, P; Cooper, DA; Emery, S; Hoy, J; Kumarasamy, N; Lombaard, J; Mallon, PW; Mohapi, L; Molina, JM; Moore, CL; Phanuphak, P; Wood, R | 1 |
| Post, FA | 2 |
| Baggaley, RC; Mameletzis, I; Mofenson, LM | 1 |
| Anderson, PL; Bushman, LR; Castillo-Mancilla, JR; Chen, X; Kiser, JJ; MaWhinney, S; Seifert, SM; Zheng, JH | 1 |
| Asari, V; Baxter, C; Garrett, N; Grobler, A; Karim, QA; Karim, SSA; Majola, N; Naicker, N; Naidoo, A; Werner, L | 1 |
| Clarke, W; Elsesser, SA; Haberer, J; Hendrix, C; Marzinke, M; Mayer, KH; Mimiaga, MJ; Psaros, C; Safren, SA; Tinsley, JP; Wade Taylor, S | 1 |
| Etima, J; Hartmann, M; Mensch, B; Montgomery, ET; Musara, P; van der Straten, A; Woeber, K | 1 |
| Bor, J; Brennan, AT; Conradie, F; Davies, MA; Fox, MP; Long, L; Maskew, M; Sanne, I | 1 |
| Iwata, K; Nagata, M; Nishi, S; Watanabe, S | 1 |
| Chaipung, B; Chiamwongpaet, S; Choopanya, K; Curlin, ME; Gvetadze, RJ; Holtz, TH; Kittimunkong, S; Leethochawalit, M; Martin, M; McNicholl, JM; Mock, PA; Paxton, LA; Samandari, T; Sangkum, U; Suntharasamai, P; Vanichseni, S; Worrajittanon, D | 1 |
| Günthard, HF; Scherrer, AU | 1 |
| Gilson, R; Nugent, D | 1 |
| Hoornenborg, E; Laga, M; Reyniers, T; Vuylsteke, B; Wouters, K | 1 |
| Abrams, EJ; Brittain, K; Jao, J; M le Roux, S; Myer, L; Olatunbosun, S; Phillips, TK; Ronan, A; Zerbe, A | 1 |
| Dittmer, U; Esser, S; Jochum, C; Storim, J; Streeck, H; Timm, J; Verheyen, J | 1 |
| Fox, J; Hamzah, L; Post, FA | 1 |
| Havlíčková, K; Husa, P; Snopková, S | 1 |
| Clumeck, N; de Oliveira, T; Gregson, J; Gupta, RK; Hamers, RL; Hoffmann, CJ; Hunt, G; Kaleebu, P; Kanki, P; Kantor, R; Kerschberger, B; Lockman, S; Marconi, VC; Ndembi, N; Pillay, D; Raizes, E; Shafer, RW; van Vuuren, C; Yang, C | 1 |
| Baeten, JM; Bangsberg, D; Celum, C; Chaturvedula, A; Fossler, MJ; Haberer, JE; Hendrix, CW; Madrasi, K; Sale, M | 1 |
| Harrison, M; Matjila, M; Riemer, L; Tooke, L | 1 |
| Coumbis, J; Myers, J; Nkhoma, ET; Rosenblatt, L; Villasis-Keever, A | 1 |
| Assoumou, L; Benaboud, S; Bouazza, N; Chenevier-Gobeaux, C; Cobat, A; De Sousa Mendes, M; Foissac, F; Ghosn, J; Hirt, D; Illamola, SM; Lui, G; Rouzioux, C; Suzan-Monti, M; Treluyer, JM; Urien, S; Valade, E; Viard, JP | 1 |
| Bekker, LG; Carballo-Diéguez, A; Chariyalertsak, S; Chitwarakorn, A; Cranston, RD; Galaska, B; Gonzales, P; Grossman, C; Hendrix, CW; Ho, KS; Holtz, TH; Jacobson, CE; Johnson, S; Kunjara Na Ayudhya, RP; Lama, JR; Leu, CS; Liu, AY; Liu, K; Lucas, J; Marzinke, MA; Mayer, KH; McGowan, I; Parikh, UM; Patterson, KB; Pickett, J; Piper, JM; Richardson, BA; Rooney, J; Schwartz, JL; Zorrilla, C | 1 |
| Ammassari, A; Andreoni, M; Antinori, A; Armenia, D; Bellagamba, R; Berno, G; Bertoli, A; Bonora, S; Calcagno, A; Carta, S; Ceccherini-Silberstein, F; Cicalini, S; Continenza, F; Di Carlo, D; Di Perri, G; Fedele, V; Forbici, F; Ghisetti, V; Libertone, R; Perno, CF; Santoro, MM; Vendemiati, G; Zaccarelli, M | 1 |
| Aurpibul, L; Bunupuradah, T; Hansudewechakul, R; Kanjanavanit, S; Kosalaraksa, P; Lumbiganon, P; Puthanakit, T; Taeprasert, P | 1 |
| Anderson, PL; Flynn, PM; Gordon, CM; Havens, PL; Hazra, R; Hosek, SG; Kapogiannis, BG; Liu, N; Mulligan, K; Pan, CG; Rutledge, B; Schuster, GU; Seifert, SM; Stephensen, CB; Van Loan, MD; Wilson, CM; Woodhouse, LR | 1 |
| Borghetti, A; Cauda, R; Colafigli, M; D'Avino, A; De Luca, A; Di Giambenedetto, S; Fabbiani, M; Gagliardini, R; Lamonica, S; Mondi, A | 1 |
| Chang, SC; Chang, SY; Chuang, YC; Huang, YS; Hung, CC; Lee, KY; Liu, WC; Sheng, WH; Su, YC; Sun, HY | 1 |
| Cottrell, ML; Dumond, JB; Francis, O; Hudgens, MG; Lee, C; Maas, BM; Malone, S; Mollan, KR; Prince, HM; Sharpless, NE; Sykes, C; Torrice, C; Trezza, C; White, N | 1 |
| Flamant, M; Joseph, A; Vidal-Petiot, E; Yazdanpanah, Y | 1 |
| Ganase, B; Guillemi, SA; Harrigan, PR; Harris, M; Hull, MW; Saeedi, R; Watson, B; Zhang, W | 1 |
| Callebaut, C; Cox, S; Das, M; Margot, N; McCallister, S; Miller, MD | 1 |
| Koh, HM; Suresh, K | 1 |
| Portman, M | 1 |
| Humphreys, WG; Lai, Y; Li, W; Shen, H | 1 |
| Albert, C; Koepsell, H; Martinez-Picado, J; Minuesa, G; Pastor-Anglada, M | 1 |
| Rizza, S; Sampath, R; Temesgen, Z; Zeuli, J | 1 |
| Imaz, A; Podzamczer, D | 1 |
| Abrams, EJ; Jao, J; le Roux, SM; Malaba, T; Myer, L | 1 |
| Destache, CJ; Fan, W; Kang, G; Li, Q; Mandal, S; Prathipati, PK; Yuan, Z; Zhou, Y | 1 |
| Bailey, A; Booth, JW; Chadwick, DR; Hamzah, L; Hay, P; Hegazi, A; Hendry, BM; Johnson, M; Jones, R; Jose, S; Levy, JB; Post, FA; Rayment, M; Sabin, CA; Williams, DI | 1 |
| Dodoo, AN; Lartey, M; Leufkens, HG; Nartey, ET; Tetteh, RA; Yankey, BA | 1 |
| Babusis, D; Callebaut, C; Cihlar, T; Park, Y; Perron, M; Ray, AS; Stray, KM | 1 |
| Kransdorf, LN; Ntim, GJ | 1 |
| Ahmad, S; Brima, N; Chaponda, M; Davies, C; Hay, P; Johnson, M; Kingston, M; Lewis, JM; Marshall, N; Mulka, L; Muqbill, G; Nelson, M; Shaw, J; Smith, C; Tomkins, A; Torkington, A; Waters, L; Williams, D | 1 |
| Denton, PW; Garcia, JV; Garrett, KL; Ho, PT; Hudgens, MG; Kashuba, AD; O'Neill, C; Swartz, G; Veronese, F; Wahl, A | 1 |
| Corado, KC; Daar, ES | 1 |
| Atta, MG; Estrella, MM; Fine, DM; Lucas, GM; Mcfall, AM; Schwartz, GJ; Sheets, KM; Zook, K | 1 |
| Behrens, GM; Jablonka, A; Kimani, J; Ndakala, FN; Oluka, MN; Oyugi, JO | 1 |
| Naidoo, P; Soorju, V | 1 |
| Deray, G; Isnard-Bagnis, C; Rouvier, P; Simon-Tillaux, N; Tourret, J | 1 |
| Ambrosioni, J; Miró, JM; Mosquera, MM | 1 |
| Decloedt, EH; Joska, JA; Lesosky, M; Maartens, G | 1 |
| Blondel, L; Charpentier, C; Descamps, D; Joly, V; Landman, R; Lê, M; Matheron, S; Perrier, M; Peytavin, G; Pinto, A; Visseaux, B; Yazdanpanah, Y | 1 |
| Bregigeon, S; Faucher, O; Obry-Roguet, V; Poizot-Martin, I; Solas, C; Tamalet, C | 1 |
| Atkinson, A; Battegay, M; Béguelin, C; Bernasconi, E; Calmy, A; Cavassini, M; Friolet, N; Günthard, HF; Lüthi, A; Moradpour, D; Rauch, A; Sahli, R; Schmid, P; Suter-Riniker, F; Wandeler, G | 1 |
| Benson, P; Brinson, C; Cheng, A; Crofoot, G; DeJesus, E; Dretler, R; Martin, H; Mills, A; Peloquin, J; Quirk, E; Sax, PE; Ward, D; Wei, X; White, K | 1 |
| Burger, D; Havenith, T; Oude Lashof, A; Schippers, J; Visschers, MJ | 1 |
| Bruggemans, A; Debyser, Z | 1 |
| Cao, H; Cheng, A; Crofoot, G; de Wet, J; DeJesus, E; LaMarca, A; Liu, Y; Martorell, CT; Mills, A; Molina, JM; Porter, D; Post, FA; Quirk, E; Ramgopal, M; Ruane, P; SenGupta, D; Stellbrink, HJ; Valero, IP | 1 |
| Cao, H; Cheng, A; Crofoot, G; de Wet, J; DeJesus, E; LaMarca, A; Lazzarin, A; Liu, HC; Mills, A; Orkin, C; Podzamczer, D; Porter, D; Quirk, E; Ramgopal, M; Rijnders, B; Rockstroh, J; Ruane, P; SenGupta, D; Stoeckle, M; Thalme, A; Vandercam, B | 1 |
| Cattaneo, D; Gervasoni, C; Pezzani, D; Resnati, C; Riva, A | 1 |
| Abram, ME; Bellos, N; Cheng, A; Clarke, A; Daar, E; Gallant, J; Henry, K; Orkin, C; Raffi, F; Rhee, MS; Santana-Bagur, J; Scarsella, A; Slama, L; Stein, DK; Yan, M | 1 |
| Arribas, JR; Callebaut, C; Cheng, A; Clarke, AE; Das, M; DeJesus, E; Guo, S; Haas, B; McCallister, S; McDonald, C; Plummer, A; Sax, PE; Thompson, M; Wang, H; Wohl, DA | 1 |
| Balboa, P; Galaz, MI; Galindo, A; Romero, P; Torrejón, C; Vivanco, M; Zúñiga, M | 1 |
| Blaylock, JM; Hartzell, JD; Morgan, MK | 1 |
| Anderson, JR; Doherty, MC; Essajee, S; Ford, N; Kanters, S; Mills, EJ; Mofenson, LM; Nachega, JB; Renaud, F; Uthman, OA | 1 |
| Carr, A; Foster, R; McAllister, JW; Mcnulty, A; Pierce, AB; Richardson, R; Towns, JM | 1 |
| Barreiro, P; García-Gascó, P; González-Pardo, G; Jiménez-Nácher, I; Maida, I; Morello, J; Parra, A; Rodríguez-Nóvoa, S; Soriano, V; Vispo, E | 1 |
| Cantrell, RA; Chi, BH; Chintu, N; Kankasa, C; Kruse, G; Mbewe, F; Sinkala, M; Smith, PJ; Stringer, EM; Stringer, JS | 1 |
| Brown, AJ; Lewis, FI; Miller, MD; Murray, RJ | 1 |
| de Groot-Mijnes, JD; Rothova, A; Schneider, M | 1 |
| Calabresi, A; Carosi, G; Cologni, G; Costarelli, S; Lapadula, G; Puoti, M; Quiros-Roldan, E; Tirelli, V; Torti, C; Zaltron, S | 1 |
| Abel, K; Bischofberger, N; Brignolo, LL; Cihlar, T; Durand-Gasselin, L; Jerome, C; Kearney, BP; Marthas, ML; Moore, J; Ray, AS; Reiser, H; Spinner, A; Van Rompay, KK | 1 |
| Bläckberg, J; Duberg, AS; Fischler, B; Friman, S; Karlström, O; Lindh, M; Norkrans, G; Reichard, O; Sangfeldt, P; Söderström, A; Sönnerborg, A; Uhnoo, I; Weiland, O; Wejstål, R; Wiström, J | 1 |
| Borroto-Esoda, K; Feng, JY; Goodman, D; Kutty, N; Ly, JK; Margot, NA; Miller, MD; Myrick, F; Svarovskaia, ES; Wang, R; White, KL | 1 |
| Ray, AS; Rhodes, GR; Wright, MR | 1 |
| Breidinger, SA; Chen, J; Friedman, EJ; Gottesdiener, KM; Iwamoto, M; Kost, JT; Lasseter, KC; Stek, JE; Stone, JA; Teppler, H; Wagner, JA; Wenning, LA | 1 |
| Baietto, L; Bonora, S; D'Avolio, A; Di Perri, G; Gonzalez de Requena, D; Sciandra, M; Siccardi, M | 1 |
| Cortes, C; Domingo, P; Ferrer, E; Gatell, JM; Gutierrez, M; Leon, A; Niubo, J; Pedrol, E; Podzamczer, D; Puig, T; Sanchez, P; Veloso, S | 1 |
| Dezzutti, CS; Hladik, F | 1 |
| Cotter, BR; Currier, JS; Dubé, MP; Fichtenbaum, CJ; Gerschenson, M; Komarow, L; Mitchell, CK; Murphy, RL; Parker, RA; Squires, K; Stein, JH; Torriani, FJ | 1 |
| Amin, J; Avihingsanon, A; Bowden, S; Cooper, DA; Dore, GJ; Lewin, SR; Locarnini, S; Marks, P; Matthews, GV; Petcharapirat, P; Rerknimitr, R; Ruxrungtham, K; Sasadeusz, J | 1 |
| Pozniak, A | 1 |
| Crane, HM; Harrington, RD; Kestenbaum, B; Kitahata, MM | 2 |
| Carrington, M; Davis, B; Duh, FM; Jean-Pierre, P; La Roche, M; Markowitz, M; Mehandru, S; Mohri, H; Poles, M; Prada, N | 1 |
| Boelle, PY; Bonnard, P; Boyd, A; Girard, PM; Gozlan, J; Lacombe, K; Lascoux-Combe, C; Miailhes, P; Molina, JM; Serfaty, L; Zoulim, F | 1 |
| Hsu, R; Lanier, ER; Oie, KL; Pappa, KA; Ross, LL; Rouse, EG | 1 |
| Morrow, JS; Redfield, RR | 1 |
| Freedberg, KA; Losina, E; Sax, PE; Schackman, BR; Scott, CA; Walensky, RP | 1 |
| Chen, SS; Cheng, AK; DeJesus, E; Enejosa, JV; Gallant, JE; Pozniak, AL; Winston, JA | 1 |
| del Arco, A; Gálvez, MC; Gutiérrez-Ravé, V; Hidalgo, C; Lozano, F; Muñoz, L; Palacios, R; Ríos, MJ; Rivero, A; Santos, J | 1 |
| Barreiro, P; Collado, A; de Los Santos Gil, I; González-Serrano, M; Hernández-Burruezo, JJ; López-Cortés, LF; López-Ruz, MA; Macías, J; Martín-Rico, P; Merino, D; Mira, JA; Muñoz, L; Pineda, JA; Ríos-Villegas, MJ; Rivero, A; Soriano, V; Torres-Tortosa, M; Tural, C; Viciana, P | 1 |
| Bele, V; Dravid, A; Gupte, N; Joshi, K; Pujari, S | 1 |
| Hogben, M; Liddon, N | 1 |
| Deray, G; Hawkins, T; Szczech, L; Winston, J; Wyatt, C; Young, B | 1 |
| Hayes, E; Mondy, K; Nurutdinova, D; Onen, NF; Overton, ET | 1 |
| Amani-Bosse, C; Arrivé, E; Blanche, S; Dabis, F; Ekouévi, DK; Gray, G; Hirt, D; Kone, M; Leang, SK; McIntyre, J; Nerrienet, E; Rey, E; Tréluyer, JM; Urien, S | 1 |
| Guhl, C; Heinz, W; Klinker, H; Langmann, P; Leyh, M; Schirmer, D; Weissbrich, B; Winzer, R | 1 |
| Gerondelis, P; Irlbeck, DM; Lanier, E; Parkin, N; Ross, LL; Rouse, E; St Clair, MH; Trinh, L; Underwood, MR | 1 |
| Allavena, C; Calvez, V; Chavanet, P; Diemer, M; Duong, M; Hoen, B; Hoizey, G; Lang, JM; May, T; Meyer, P; Peytavin, G; Rey, D; Schmit, JL; Schmitt, MP; Spire, B | 1 |
| Abecasis, AB; Camacho, R; Deforche, K; Libin, P; Theys, K; Vandamme, AM; Vercauteren, J | 1 |
| Calza, L; Manfredi, R | 2 |
| Akumatey, B; Chen, PL; Clarke, EE; Guest, G; Johnson, L; MacQueen, KM; Shattuck, D | 1 |
| Kasahara, K; Konishi, M; Maeda, K; Mikasa, K; Nakagawa, C; Uno, K; Yonekawa, S; Yoshimoto, E | 1 |
| Burgisser, P; Cavassini, M; Giulieri, SG; Günthard, HF; Knoepfel, SA; Metzner, KJ; Rauch, P; Yerly, S | 1 |
| Cappelli, G; Esposito, R; Giovanardi, C; Guaraldi, G; Orlando, G; Palella, F; Ravera, F; Roverato, A; Squillace, N | 1 |
| Chatelut, E; Jaafar, A; Malard, L; Massip, P; Séronie-Vivien, S; Tack, I | 1 |
| Amini-Bavil-Olyaee, S; Lutz, T; Sheldon, J; Tacke, F; Trautwein, C | 1 |
| Barreiro, P; García-Samaniego, J; Martín-Carbonero, L | 1 |
| Arrivé, E; Avit, D; Blanche, S; Coffié, P; Dabis, F; Ekouévi, DK; Hirt, D; Lalsab, S; Leang, SK; McIntyre, J; Nerrienet, E; Rey, E; Tréluyer, JM; Urien, S | 1 |
| Barry, SM; Fischetti, L; Hope, TJ; Shattock, RJ | 1 |
| Avihingsanon, A; Bowden, S; Dore, GJ; Lewin, SR; Locarnini, SA; Marks, P; Matthews, G; Perelson, AS; Ribeiro, RM; Ruxrungtham, K | 1 |
| Okoromah, CA; Okwundu, CI | 1 |
| Arrifin, N; Audsley, J; Ayres, A; Bartholomeusz, A; Crowe, SM; Lewin, SR; Locarnini, SA; Mijch, A; Sasadeusz, J; Yuen, LK | 1 |
| Kaplan, BS; Meyers, KE; Rutstein, RM; Shah, SS; Steenhoff, AP; Wood, SM | 1 |
| Freedberg, KA; Losina, E; Paltiel, AD; Sax, PE; Schackman, BR; Scott, CA; Seage, GR; Sloan, CE; Walensky, RP; Wang, B | 1 |
| Bernasconi, E; Bucher, HC; Cavassini, M; Elzi, L; Furrer, H; Fux, CA; Hirschel, B; Opravil, M; Rauch, A; Simcock, M; Vernazza, P | 1 |
| Azanza, JR; García Quetglas, E; Gómez-Giu, A; Sádaba, B | 1 |
| Mallolas, J | 2 |
| Fiorante, S; Pulido, F | 1 |
| Arribas López, JR; Bernardino de la Serna, JI; Mora Rillo, M | 1 |
| Portilla, J | 1 |
| López Bernaldo de Quirós, JC | 1 |
| Barreiro, P; Soriano, V; Tuma, P; Vispo, E | 1 |
| Barril Cuadrado, G; de Los Santos Gil, I | 1 |
| Miralles Alvarez, C | 1 |
| Willyard, C | 1 |
| Aharchi, F; Beets, G; De Smedt, G; Hoetelmans, RM; Kakuda, TN; Peeters, MP; Schöller-Gyüre, M; Vandermeulen, K; Woodfall, BJ | 1 |
| Boyd, K; Butler, K; Cliff, D; Doerholt, K; Gibb, D; Judd, A; Lyall, H; Menson, E; Riordan, A | 1 |
| Alvarez-Uria, G; Ratcliffe, L; Vilar, J | 1 |
| Moreno, V; Valencia, ME | 1 |
| Albalater, M; Barreiro, P; Blanco, F; Labarga, P; Martin-Carbonero, L; Medrano, J; Moreno, V; Rivas, P; Rodriguez-Novoa, S; Solera, C; Soriano, V; Vispo, E | 1 |
| Aslangul, E; Caillat-Vigneron, N; Le Jeunne, C; Perrot, S; Szwebel, T | 1 |
| Albrecht, H | 1 |
| Ayen, R; Clotet, B; Grassi, J; Levi, M; Negredo, E; Pruvost, A; Puig, J; Théodoro, F | 1 |
| Gills Ray, VL; Lee, H; Silkiss, RZ | 1 |
| Arrivé, E; Avit, D; Blanche, S; Chaix, ML; Coffie, PA; Dabis, F; Diallo, A; Ekouévi, DK; Gray, G; Kruy Leang, S; McIntyre, J; N'Dri-Yoman, T; Nerrienet, E; Rouzioux, C; Srey, VH | 1 |
| Belsey, E; Berzins, B; Chen, D; Choi, J; da Silva, B; Gerschenson, M; Kim, C; Libutti, DE; McComsey, GA; Murphy, RL; Shore, J; Taiwo, B; Weinstein, J | 1 |
| Alvarez, S; Brumble, LM; Dwyer, JP; Irizarry-Alvarado, JM; Mendez, JC | 1 |
| Atta, MG; Fine, DM | 1 |
| Curran, A; Ribera Pascuet, E | 1 |
| Levenson, E | 1 |
| Dejesus, E; Ebrahimi, R; Ecker, J; Farajallah, A; Flaherty, JF; Maa, JF; McColl, D; Morales-Ramirez, JO; Reilly, K; Seekins, D; Sloan, L; Ward, DJ; Young, B | 1 |
| Hanabusa, H; Kinai, E | 2 |
| Arnaiz, JA; Arranz, JA; Arribas, JR; Barragán, P; Barrufet, P; Blanco, JL; Casas, E; Clotet, B; Cosín, J; Cruceta, A; Curran, A; Dalmau, D; Ferrer, E; Gatell, JM; González, A; Gutiérrez, F; Knobel, H; Llibre, JM; Loncá, M; Mallolas, J; Martínez, E; Miró, JM; Pich, J; Podzamczer, D; Ribera, E; Roca, V; Sanz, J; Segura, F | 1 |
| Albalater, M; Back, D; Cuenca, L; Egan, D; González-Pardo, G; Khoo, S; Labarga, P; Morello, J; Owen, A; Rodríguez-Nóvoa, S; Soriano, V | 1 |
| Cabié, A; Chêne, G; Girard, PM; Katlama, C; Mercié, P; Michelet, C; Monchecourt, F; Morand-Joubert, L; Pétour, P; Trylesinski, A; Verdon, R | 1 |
| Calmy, A; Ford, N; Mills, E | 1 |
| Colebunders, R; Lynen, L; van Griensven, J | 1 |
| Brenchley, J; Buckler-White, A; Igarashi, T; Kubo, M; Lafont, B; Lee, W; Martin, MA; Nishimura, Y; Shingai, M | 1 |
| Borroto-Esoda, K; Harris, J; Lansdon, EB; Miller, MD; O'Neal, W; Svarovskaia, ES; Wakeford, C; Waters, JM; White, KL | 1 |
| Beijnen, JH; Huitema, AD; Jansen, RS; Mulder, JW; Smits, PH; Ter Heine, R; van Gorp, EC; Wagenaar, JF | 1 |
| Perry, CM | 1 |
| Cope, D; Iskander, E; Mikhail, N | 1 |
| Dauer, B; Gute, P; Khaykin, P; Klauke, S; Staszewski, S; Stephan, C; Stuermer, M | 1 |
| Callahan, MM; Mauck, CK; Poindexter, A; Schwartz, JL; Wheeless, A | 1 |
| Yoganathan, K | 1 |
| Atkins, M; Fisher, M; Gilleece, Y; Grover, D; Mandalia, S; Murungi, A; Nelson, M; Tan, LK | 1 |
| Foster, C; Gibb, DM; Lyall, H; Olmscheid, B; Pearce, G; Zhang, S | 1 |
| Connolly, JO; Copas, A; Edwards, SG; Hall, AM; Johnson, MA; Madge, S; Nair, D; Williams, IG; Woodward, CL | 1 |
| Benn, P; Cartledge, J; Edwards, SG; Linney, A; Moyle, G; Reilly, G; Ruff, C; Sabin, CA; Sauret-Jackson, V | 1 |
| Arasteh, K; Ebrahimi, R; Fenske, S; Freiwald, M; Gallo, L; Kuhlmann, B; Mertenskoetter, T; Ranneberg, R; Weitner, L | 1 |
| Bellos, N; Fine, D; Kumar, PN; Lackey, P; Patel, P; Shaefer, MS; Sloan, L; Smith, KY; Sutherland-Phillips, DH; Vavro, C; Wannamaker, P; Yau, L | 1 |
| Ebrahimi, R; Ewan, J; Fisher, M; Kingston, M; Liu, H; Moyle, GJ; Orkin, C; Reilly, G; Shahmanesh, M; Wilkins, E | 1 |
| Cohen, C; Dejesus, E; Elion, R; Gathe, JC; Ha, B; Hsu, RK; Lanier, R; Paulsen, D; Redfield, RR; Ross, L; Yau, L | 1 |
| Brooks, JT; Buchacz, K; Moorman, A; Wood, KC; Young, B | 1 |
| Andrade, A; Eshleman, SH; Flanigan, T; Flexner, C; Gross, R; Hogg, E; Lalama, C; Mildvan, D; Reisler, R; Rosenkranz, S; Salomon, N; Santana, J; Tierney, C; Wiggins, I | 1 |
| Roehr, B | 2 |
| Andreotti, M; Antonelli, G; Ceccarelli, G; d'Ettorre, G; Massetti, P; Mastroianni, CM; Rizza, C; Turriziani, O; Vella, S; Vullo, V | 1 |
| Ainsworth, J; Anderson, J; Bansi, L; Dunn, D; Easterbrook, P; Fisher, M; Gazzard, B; Gilson, R; Gompels, M; Hill, T; Johnson, M; Leen, C; Orkin, C; Phillips, A; Pillay, D; Sabin, C; Walsh, J | 1 |
| Carballo-Diéguez, A; Gai, F; Hoffman, S; Mantell, JE; Morrow, KM; Rosen, RK | 1 |
| Cheng, AK; Enejosa, J; Margot, NA; McColl, DJ; Miller, MD | 1 |
| Barnard, RJ; Berger, DS; DeJesus, E; DiNubile, MJ; Lazzarin, A; Leavitt, R; Lennox, JL; Madruga, JV; Miller, MD; Nguyen, BY; Pollard, RB; Rodgers, AJ; Sklar, P; Williams-Diaz, A; Xu, X; Zhao, J | 1 |
| Bourgeois, A; Calmy, A; Ciaffi, L; Delaporte, E; Ducos, J; Kouanfack, C; Koulla-Shiro, S; Laurent, C; Mougnutou, R; Mpoudi-Ngolé, E; Nkoué, N | 1 |
| Cauda, R; Cicconi, P; Corsi, P; De Luca, A; Di Giambenedetto, S; Ladisa, N; Lapadula, G; Manca, N; Nasta, P; Paraninfo, G; Prosperi, M; Torti, C; Trezzi, M; Zazzi, M | 1 |
| Abeli, C; Bonfanti, P; Gianelli, E; Giuntini, R; Grosso, C; Madeddu, G; Marconi, P; Martinelli, C; Palvarini, L; Pellicano, G; Penco, G; Quirino, T; Ricci, E; Vichi, F | 1 |
| Gallant, JE; Moore, RD | 1 |
| Barreiro, P; Fernández, JV; Labarga, P; Medrano, J; Soriano, V; Tuma, P; Vispo, E | 1 |
| Chetchotisakd, P | 1 |
| Beltrame, A; Bozzano, F; Cenderello, G; Costa, P; De Maria, A; Di Biagio, A; Fenoglio, D; Ferrea, G; Pagano, G | 1 |
| Bickel, M; Bodtländer, A; Gute, P; Klauke, S; Knecht, GK; Kurowski, M; Lutz, T; Stephan, C; von Hentig, N | 1 |
| Chetty, K; Connolly, JO; Edwards, SG; Hall, AM; Lapsley, M; O'Farrell, S; Unwin, RJ; Williams, IG | 1 |
| Hill, A; Sawyer, W | 1 |
| Cavassini, M; Hayoz, D; Mazzolai, L; Periard, D; Widmeier, A; Yerly, P | 1 |
| Boccafoglio, F; Concia, E; Gottardi, M; Lanzafame, M; Lattuada, E; Soldani, F | 1 |
| Bersoff-Matcha, S; Blank, J; Chang, J; Horberg, M; Hurley, L; Klein, D; Quesenberry, C; Silverberg, M; Tang, B; Towner, W | 1 |
| Labarga, P; Rodriguez-Novoa, S; Soriano, V | 1 |
| Amin, J; Baker, D; Bloch, M; Carr, A; Cooper, DA; Emery, S; Martin, A | 2 |
| Reiss, P | 1 |
| Bangsberg, DR | 1 |
| Bonora, S; Calcagno, A; D'Avolio, A; Lanzafame, M; Penco, G; Perri, GD; Tettoni, MC | 1 |
| Andrews, M; Condoluci, DV; Luber, AD; Olson, K; Pakes, GE; Pappa, KA; Peloquin, CA; Slowinski, PD | 1 |
| Aldrovandi, GM; Cantrell, RA; Chi, BH; Chintu, N; Ellis, GM; Frenkel, LM; Mbewe, F; Nakamura, K; Sinkala, M; Stringer, EM; Stringer, JS; Warrier, R | 1 |
| Battegay, M; Calmy, A; de Wolf, F; Hirschel, B; Hogg, RS; Lange, JM; Lima, VD; Montaner, JS; Nguyen, A; Reiss, P; Vallier, N; Wit, FW; Yip, B | 1 |
| Amuron, B; Birungi, J; Bunnell, R; Coutinho, A; Foster, S; Grosskurth, H; Jaffar, S; Kyomuhangi, R; Levin, J; Mermin, J; Nabiryo, C; Namara, G; Ndembi, N; Opio, A; Tappero, JW | 1 |
| Collier, AC; Daar, ES; Farajallah, A; Fischl, MA; Geiseler, PJ; Godfrey, C; Ha, B; Jahed, NC; Johnson, VA; Katzenstein, D; Koletar, SL; Mollan, K; Myers, L; Peeples, L; Rooney, JF; Sax, PE; Tierney, C; Woodward, WC | 1 |
| Bonnet, F; Dabis, F; Déti, EK; Dupon, M; Lawson-Ayayi, S; Malvy, D; Morlat, P; Neau, D; Pellegrin, JL; Tchamgoué, S; Thiébaut, R | 1 |
| Abaine, D; Aber, M; Ahimbisibwe, F; Akao, J; Akuma, S; Amuron, B; Amurwon, J; Angweng, E; Anywar, W; Atwiine, D; Atwiine, S; Awio, P; Babiker, A; Babiker, AG; Bafana, T; Bagaya, L; Bahendeka, S; Bakeinyaga, GT; Barungi, G; Bassett, M; Bohannon, J; Boocock, K; Borok, M; Bray, D; Breckenridge, A; Bulaya-Tembo, R; Buluma, E; Burke, A; Burke, C; Byakwaga, H; Byamukama, A; Byaruhanga, R; Chakonza, L; Chidziva, E; Chigwedere, E; Chimanzi, J; Chimbetete, C; Chirairo, H; Chirara, M; Chirema, O; Chitsungo, S; Chivhunga, T; Coutinho, A; Darbyshire, JH; Drasiku, A; Dunn, D; Enzama, R; Etukoit, B; Fadhiru, K; Ferrier, A; Florence, A; Foster, S; Gazzard, B; Generous, L; Gibb, DM; Gilks, C; Gilks, CF; Goodall, R; Grosskurth, H; Grundy, C; Haguma, W; Hakim, J; Hill, C; Hughes, P; Jamu, A; Jangano, M; Jones, S; Kabanda, J; Kabuye, G; Kagina, G; Kajungu, D; Kaleebu, P; Kambungu, A; Kankunda, R; Karungi, J; Kasirye, R; Katabira, E; Katabira, H; Katundu, P; Khauka, P; Kigozi, J; Kikaire, B; Kityo, C; Komugyena, J; Kulume, R; Kusiima, A; Kyomugisha, H; Labeja, O; Lara, AM; Latif, A; Levin, J; Lubwama, E; Lutwama, F; Lyagoba, F; Machingura, I; Machingura, J; Makota, S; Mambule, I; Mapinge, F; Mapuchere, C; Massa, R; Matenga, J; Matongo, M; Maweni, C; Mawora, A; McCormick, A; McLaren, A; Mdege, N; Moyo, K; Muchabaiwa, L; Mudzingwa, S; Mufuka-Kapuya, C; Muganzi, A; Mugisha, A; Mugurungi, O; Mugyenyi, P; Muhweezi, D; Muhwezi, A; Mukiibi, S; Mukose, A; Mulindwa, G; Mulindwa, M; Munderi, P; Murungi, S; Musana, H; Musoro, G; Mutowo, J; Mutsai, S; Muvirimi, C; Muyingo, S; Muzambi, M; Mwebesa, D; Mwesigwa, P; Nabankema, E; Nabongo, P; Naidoo, B; Nairuba, R; Nakahima, W; Nakazibwe, M; Nakiyingi, J; Nalumenya, R; Namale, L; Namara, W; Namata, I; Namazzi, A; Namuli, T; Namyalo, M; Nanfuka, A; Nanfuka, R; Nassuna, G; Ndembi, N; Newland, C; Ngorima, N; Nimwesiga, E; Nsibambi, D; Nyachwo, L; Nyiraguhirwa, D; Ochai, R; Ojiambo, H; Ojiambo, W; Oketta, F; Omony, W; Otim, T; Oyugi, J; Palfreeman, A; Pascoe, M; Pearce, G; Peto, L; Peto, T; Phiri, M; Pillay, D; Pozniak, A; Puddephatt, C; Rahim, S; Rauchenberger, M; Reid, A; Robertson, V; Ronald, A; Rooney, J; Ruberantwari, A; Rutikarayo, N; Sabiiti, J; Sadik, F; Sematala, F; Serwadda, D; Sheehan, S; Simango, M; Smith, M; Snowden, W; Spencer-Drake, C; Spyer, M; Ssali, F; Steens, JM; Svovanapasis, P; Takubwa, J; Taylor, K; Taziwa, F; Tinago, G; Todd, J; Tugume, S; Tukamushaba, J; Tumukunde, D; Tumusiime, C; Twijukye, C; Vere, L; Waita, R; Wakholi, BN; Walker, AS; Walusimbi, J; Wangati, K; Wanyama, J; Wapakhabulo, AC; Warambwa, C; Warara, R; Wavamunno, P; Weller, I; Whitworth, J; Wilkes, H; Winogron, D; Yirrell, D; Zalwango, A; Zalwango, E; Zawedde, C; Zengeza, E | 1 |
| Cohen, C; DeJesus, E; Elion, R; Gerondelis, P; Ha, B; Horton, J; Lanier, ER; Ross, LL; Rouse, E | 1 |
| Bolton-Moore, C; Chi, BH; Chintu, N; Giganti, M; Mulenga, LB; Mulenga, PL; Mwaba, P; Mwango, A; Reid, SE; Sheneberger, R; Stringer, EM; Stringer, JS; Tambatamba-Chapula, B | 1 |
| Barragán, P; Casamitjana, R; Deulofeu, R; Gatell, JM; Gutiérrez, F; Larrousse, M; Loncá, M; Mallolas, J; Martínez, E; Pérez, I; Pich, J; Podzamczer, D | 1 |
| Moore, K; Radzio, J; Sluis-Cremer, N; Sonza, S; Tachedjian, G | 1 |
| Gervain, J; Horváth, G; Hunyady, B; Makara, M; Pár, A; Szalay, F; Telegdy, L; Tornai, I | 1 |
| Boothby, M; Gathercole, LL; McGee, KC; McTernan, PG; Nightingale, P; Shahmanesh, M; Shojaee-Moradie, F; Tomlinson, JW; Umpleby, AM | 1 |
| Cheshenko, N; Fakioglu, E; Herold, BC; Keller, MJ; Mesquita, PM; Wilson, SS | 1 |
| Absalon, J; Andrade-Villanueva, J; Chetchotisakd, P; Corral, J; David, N; Echevarria, J; Lataillade, M; Mancini, M; McGrath, D; Molina, JM; Moyle, G; Percival, L; Wirtz, V; Yang, R | 1 |
| Bender, MA; Flanigan, T; Freedberg, KA; Kumarasamy, N; Lu, Z; Mayer, KH; Schackman, BR; Scott, CA; Walensky, RP; Wang, B | 1 |
| Aubron-Olivier, C; Bittar, R; Bollens, D; Bonnefont-Rousselot, D; Costagliola, D; de Truchis, P; Giral, P; Katlama, C; Pétour, P; Slama, L; Valantin, MA | 1 |
| Battegay, M; Bernasconi, E; Cavassini, M; Elzi, L; Furrer, H; Hirschel, B; Ledergerber, B; Marzolini, C; Vernazza, P; Weber, R | 1 |
| Altice, FL; Springer, SA | 1 |
| Bateman, C | 3 |
| Bi, L; Daar, ES; Diamond, C; Flaherty, J; Goicoechea, M; Ha, B; Haubrich, R; Jain, S; Kemper, C; Louie, S; Richman, D; Sun, S | 1 |
| Baraboutis, IG; Georgiou, O; Kotsianopoulou, M; Papastamopoulos, V; Samarkos, M; Skoutelis, AT; Vrionis, E | 1 |
| Dinsmore, WW; Donnelly, CM; Emerson, CR; Quinn, KJ | 1 |
| Burty, C; Christian, B; May, T; Penalba, C; Prazuck, T; Rabaud, C; Salmon-Ceron, D; Truchetet, F; Yazdanpanah, Y | 1 |
| Denton, PW; Estes, JD; Garcia, JV; Krisko, JF; Kwak, YT; Martinez-Torres, F; Mathias, M; Payne, DA; Powell, DA; Zou, W | 1 |
| Calvez, V; Grant, PM; Marcelin, AG; Nevins, AB; Taylor, J; Wirden, M; Zolopa, AR | 1 |
| Bruzzone, B; Colao, G; De Silvestri, A; Di Biagio, A; Di Pietro, M; Maserati, R; Re, MC; Tinelli, C; Uglietti, A; Zazzi, M | 1 |
| Boyd, KL; Butler, K; Dunn, D; Gibb, DM; Judd, A; Lyall, H; Riordan, A; Sharland, M; Shingadia, D; Stöhr, W | 1 |
| Flux, K; Gholam, P; Hartmann, M; Hueter, E; Weberschock, T | 1 |
| Dejesus, E; Ebrahimi, R; Ecker, J; Esker, S; Farajallah, A; Flaherty, JF; Grimm, K; Hodder, SL; Mounzer, K | 1 |
| Airoldi, M; Cossarizza, A; De Biasi, S; Gibellini, L; Maggiolo, F; Mussini, C; Nasi, M; Pinti, M; Ravasio, V; Roat, E; Suter, F | 1 |
| de Mendoza, C; Labarga, P; Medrano, J; Morello, J; Poveda, E; Rodriguez-Novoa, S; Seclen, E; Soriano, V; Vispo, E | 1 |
| Carr, A; van Agtmael, MA; Wever, K | 1 |
| Flandre, P | 1 |
| Landman, GW; Soonawala, D | 1 |
| Albalate, M; Barreiro, P; Bonora, S; D'avolio, A; Di Perri, G; Labarga, P; Rodríguez-Nóvoa, S; Siccardi, M; Solera, C; Soriano, V; Vispo, E | 1 |
| Brown, LB; Eron, JJ; Hosseinipour, MC; Kumwenda, JJ; Mhango, B; Mzinganjira, D; Phiri, S; van Oosterhout, JJ; Weigel, R | 1 |
| DeJesus, E; Fischl, MA; Horton, JH; Lancaster, CT; Pakes, GE; Pappa, KA; Ross, LL; Smith, KY; Weinberg, WG | 1 |
| Alvarez, E; Labarga, P; Rodriguez-Nóvoa, S; Soriano, V | 1 |
| Back, D; Dickinson, L; Erlwein, OW; Garvey, L; Latch, N; Mackie, NE; McClure, MO; Scullard, G; Walsh, J; Winston, A | 1 |
| Benhamou, Y; Izzedine, H; Peytavin, G; Schneider, L; Thibault, V; Valantin, MA | 1 |
| Branco, T; Cavassini, M; Domingo, P; Fisher, M; Givens, N; Khuong-Josses, MA; Lim, ML; Moyle, GJ; Norden, AG; Pearce, HC; Podzamczer, D; Post, FA; Rieger, A; Stellbrink, HJ; Vavro, C | 1 |
| Floridia, M; Manconi, PE; Ortu, F; Weimer, LE | 1 |
| Absalon, J; Malan, N; Mancini, M; McGrath, D; Su, J; Wirtz, V; Yang, R | 1 |
| Sax, PE | 4 |
| Aberg, JA; Alston-Smith, B; Glesby, MJ; Gupta, SK; Jones, L; Kitch, D; Mellors, JW; Moran, L; Rooney, JF; Tungsiripat, M | 1 |
| Behrens, G; Ho, NA; Schmidt, RE | 1 |
| Barahona, I; Brodine, S; Crum-Cianflone, N; Ganesan, A; Medina, S; Riddle, M; Teneza-Mora, N | 1 |
| Barnas, D; Bazmi, H; Bixby, C; Jemsek, J; Koontz, D; Mellors, JW | 1 |
| Freedberg, KA; Loubiere, S; Meiners, C; Sloan, C; Yazdanpanah, Y | 1 |
| Galau, NH; Moore, S; Myint, MM | 1 |
| Johnson, LM; Mack, N; MacQueen, KM; Moffett, J; Robinson, ET | 1 |
| Chambers, MG; Earnshaw, SR; Farkouh, RA; Kauf, TL; Maroudas, P; Watson, ME | 1 |
| Anzidei, G; Baroncelli, S; Cauda, R; Cusato, M; De Luca, A; Fantoni, M; Floridia, M; Pinnetti, C; Regazzi, M; Tamburrini, E; Tozzi, V; Villani, P | 1 |
| Bansi, L; Campbell, LJ; Cheserem, E; Hendry, BM; Ibrahim, F; Naftalin, C; Post, FA; Roe, J; Sabin, C | 1 |
| Cohen, J | 7 |
| Abdool Karim, Q; Abdool Karim, SS; Arulappan, N; Baxter, C; Frohlich, JA; Gengiah, TN; Grobler, AC; Kharsany, AB; Maarschalk, S; Mansoor, LE; Mlisana, KP; Mlotshwa, M; Morris, L; Omar, Z; Sibeko, S; Taylor, D | 1 |
| Carr, A; Richardson, R; Sinn, K | 1 |
| Gianini, RJ; Gomes-Gouvêa, MS; Leite, OM; Locarnini, S; Martins, LG; Mendes-Correa, MC; Pinho, JR; Santana, RA; Silva, MH; Sitnik, R; Uip, DE; Yuen, L | 1 |
| Li, JZ; Sax, PE | 1 |
| Bacchetti, P; Biggs, ML; Currier, JS; Delaney, JA; Grunfeld, C; Kronmal, RA; O'leary, D; Polak, JF; Scherzer, R; Shliplak, MG; Tien, PC; Wanke, C | 1 |
| Bano, G; Copas, AJ; Gedela, K; Hay, PE; Pakianathan, MR; Rosenvinge, MM; Sadiq, ST; Sheehy, CA; Wilkinson, A | 1 |
| Branch, AD; Childs, KE; Constable, C; Dieterich, DT; Fishman, SL; Gutierrez, JA; Mullen, MP; Wyatt, CM | 1 |
| Bernstein, B; Cohen, D; da Silva, B; Fredrick, L; González-García, J; Johnson, M; Naylor, C; Sloan, L | 1 |
| Cooper, RD; Keiser, P; Naicker, S; Smith, N; Tonelli, M; Wiebe, N | 1 |
| Baleta, A | 2 |
| German, P; Hui, J; Kearney, BP; Warren, D; West, S | 1 |
| Curto, J; Niubo, J; Podzamczer, D; Tiraboschi, JM | 1 |
| Cates, W | 1 |
| DeJesus, E; Kakuda, TN; Lalezari, JP; Osiyemi, OO; Ruane, PJ; Ryan, R; Witek, J | 1 |
| Benabdelmoumen, G; Bouvet, E; Christian, B; Muller, P; Peyrouse, E; Prazuck, T; Quertainmont, Y; Rabaud, C; Tosini, W | 1 |
| Alcaro, S; Alteri, C; Antinori, A; Artese, A; Balzarini, J; Ceccherini-Silberstein, F; Costa, G; Forbici, F; Narciso, P; Perno, CF; Santoro, MM; Schols, D; Svicher, V; Tommasi, C; Van Laethem, K; Zaccarelli, M | 1 |
| Cacoub, P; Carrat, F; Goderel, I; Lacombe, K; Loustau-Ratti, V; Miailhes, P; Morlat, P; Piroth, L; Pol, S; Rami, A; Rey, D; Rosenthal, E; Sene, D | 1 |
| de Man, RA; de Vries-Sluijs, TE; Hansen, BE; Hoepelman, AI; Janssen, HL; Mulder, JW; Pas, SD; Prins, JM; Reijnders, JG; Richter, C; Schutten, M; van der Ende, ME; Zaaijer, HL | 1 |
| D'Agati, VD; Herlitz, LC; Markowitz, GS; Mohan, S; Radhakrishnan, J; Stokes, MB | 1 |
| Mohammadi, D | 1 |
| Arrivé, E; Avit, D; Blanche, S; Chaix, ML; Dabis, F; Ekouévi, DK; Gray, G; Kruy, LS; McIntyre, J; Nerrienet, E; Rouzioux, C; Say, L | 1 |
| Carr, A; Hoy, J | 1 |
| Arribas, JR; Compston, J; Gerstoft, J; Hughes, S; Lambert, J; Lazzarin, A; Leather, D; Orkin, C; Pearce, H; Rizzardini, G; Sprenger, HG; Stellbrink, HJ; Sture, G; Van Wijngaerden, E; Zucchi, P | 1 |
| Aba, YT; Aoussi, EF; Bissagnene, E; Eholié, SP; Ehui, E; Kadio, A; Kakou, AR; Kassi, A; Ondounda, M; Ouattara, I; Tanon, A | 1 |
| Avihingsanon, A; Bowden, S; Chang, JJ; Dore, GJ; Kerr, S; Lange, J; Lewin, SR; Matthews, GV; Napissanant, N; Piyawat, K; Ruxrungtham, K | 1 |
| Boucher, CA; van de Vijver, DA | 1 |
| McCoy, SI; Padian, NS; Watts, CH | 1 |
| De Beaudrap, P; Delaporte, E; Diallo, MB; Diouf, A; Etard, JF; Girard, PM; Guèye, NF; Kane, CT; Landman, R; Ndiaye, I; Sow, PS | 1 |
| Allegri, R; Amadasi, S; Carosi, G; Cristini, G; Gatti, F; Izzo, I; Mendeni, M; Motta, D; Paraninfo, G; Quiros-Roldan, E; Torti, C | 1 |
| Murphy, B; Romanelli, F | 1 |
| De Terlizzi, F; Parodi, A; Rosso, R; Torrisi, C; Vignolo, M; Viscoli, C | 1 |
| Corbett, C; De Smedt, G; Hoetelmans, RM; Kakuda, TN; Leopold, L; Nijs, S; Peeters, MP; Schöller-Gyüre, M; Snoeck, E; Vingerhoets, J; Vis, P; Wade, JR; Woodfall, BJ | 1 |
| Addad, N; Ariën, KK; Augustijns, P; Bourlet, T; Brouwers, J; Delezay, O; Gali, Y; Hamzeh-Cognasse, H; Pozzetto, B; Vanham, G | 1 |
| Rutherford, GW; Siegfried, N; Spaulding, A | 1 |
| Alston-Smith, B; Asmelash, A; Atwine, D; Chipato, T; Conradie, F; Currier, JS; Eshleman, S; Hakim, J; Hogg, E; Hosseinipour, MC; Hughes, MD; Kanyama, C; Lockman, S; McIntyre, J; Mellors, JW; Mngqibisa, R; Mohapi, L; Purcelle-Smith, E; Rahim, S; Rooney, J; Salata, RA; Sawe, F; Schooley, RT; Shaffer, D; Siika, A; Stringer, E; Walawander, A; Wools-Kaloustian, K; Zheng, Y | 1 |
| Arrivé, E; Avit, D; Benaboud, S; Blanche, S; Dabis, F; Ekouévi, DK; Gray, G; Hirt, D; McIntyre, J; Nerrienet, E; Rey, E; Sim, KL; Tréluyer, JM; Urien, S | 1 |
| Anton, P; Becker, S; Burns, D; DeGruttola, V; Fletcher, CV; McGowan, I; Veronese, F; Zwerski, S | 1 |
| Bonacini, M | 1 |
| Asensi, V; Miró, JM; Rodríguez-Guardado, A; Tuset, M | 1 |
| Bonnard, P; Boyd, A; Girard, PM; Lacombe, K; Lascoux-Combe, C; Lasnier, E; Meynard, JL; Miailhes, P; Molina, JM; Wendum, D | 1 |
| Anglaret, X; Attia, A; Chenal, H; Danel, C; Eholié, S; Gabillard, D; Messou, E; N'Dri-Yoman, T; Polneau, S; Seyler, C; Toni, T; Wakasugi, N | 1 |
| Cerini, C; Fabiano, V; Giacomet, V; Mora, S; Pivetti, V; Puzzovio, M; Viganò, A; Zamproni, I; Zuccotti, GV | 1 |
| Bonjoch, A; Clotet, B; del Rio, L; di Gregorio, S; Estany, C; Figueras, M; Gómez, G; Negredo, E; Perez-Alvarez, N; Puig, J; Rosales, J | 1 |
| Bangsberg, DR; Deeks, SG; Monk, A; Ragland, K | 1 |
| Batard, ML; Martinot, M; Roth, B; Springinsfeld, G; Tortel, MC | 1 |
| Bénet, T; Billioud, C; Boibieux, A; Brochier, C; Chevallier, M; Cotte, L; Ferry, T; Miailhes, P; Scoazec, JY; Vanhems, P; Zoulim, F | 1 |
| Bowonwatanuwong, C; Chaisiri, K; Kasettratat, N; Kiertiburanakul, S | 1 |
| Figueras, C; Fortuny, C; Garcia, L; Martín-Nalda, A; Melendo, S; Mellado, MJ; Navarro, ML; Noguera-Julian, A; Soler-Palacín, P; Uriona, S | 1 |
| Perazella, MA | 1 |
| Michael, NL | 1 |
| Amico, KR; Anderson, PL; Bekker, LG; Buchbinder, SP; Burns, DN; Bushman, LR; Casapía, M; Chariyalertsak, S; Defechereux, P; Fernández, T; Ganoza, C; Glidden, DV; Goicochea, P; Grant, RM; Guanira-Carranza, JV; Hance, RJ; Jaffe, HS; Kallás, EG; Lama, JR; Lee, J; Liu, AY; Martinez, AI; Mayer, KH; McConnell, JJ; McMahan, V; Montoya-Herrera, O; Mulligan, K; Postle, B; Ramirez-Cardich, ME; Rooney, JF; Schechter, M; Vargas, L; Veloso, VG; Wang, F; Zheng, JH | 1 |
| Benhamou, Y; Pais, R | 1 |
| Anderson, PL; Gardner, EM; Grant, RM; Kiser, JJ; Meditz, A; Rower, JE | 1 |
| Bracciale, L; Cauda, R; De Luca, A; Di Cristo, V; Di Giambenedetto, S; Doino, M; Fabbiani, M; Farina, S; Sidella, L | 1 |
| Ariën, KK; Vanham, G | 1 |
| Back, DJ; Boffito, M; Jackson, AG; Mandalia, S; Moyle, GJ; Randell, PA; Taylor, J; Tjia, JF | 1 |
| Kaul, R; Raboud, JM; Tan, DH; Walmsley, SL | 1 |
| Borroto-Esoda, K; Goodman, DD; Margot, NA; McColl, DJ; Miller, MD; Svarovskaia, ES; Zhong, L; Zhou, Y | 1 |
| Bygrave, H; Ford, N; Goemaere, E; Hilderbrand, K; Jouquet, G; Kranzer, K; Makakole, L; Triviño, L; van Cutsem, G; Vlahakis, N | 1 |
| Burleson, D; Gayton, JC; Laughlin, RT; Polenakovik, H | 1 |
| Martin, L | 1 |
| Mallet, V; Pol, S; Vallet-Pichard, A | 1 |
| Cooper, RD; Tonelli, M | 1 |
| Abdool Karim, SS; Baxter, C | 2 |
| de Silva, T; Weiss, RA | 1 |
| Wainberg, MA | 1 |
| Van Damme, L; Vermund, SH | 1 |
| Arulappan, N; Gengiah, T; Karim, QA; Karim, SS; Kharsany, AB; Luthuli, LR; Mlisana, KP; Naidoo, K; Omar, Z; Yende, N | 1 |
| Babusis, D; Durand-Gasselin, L; Flaherty, JF; Hawkins, T; Ray, AS; Reddy, YS; Veikley, W | 1 |
| Basar, M; Best, BM; Burchett, SK; Capparelli, EV; Hawkins, E; Hu, C; Mirochnick, M; Read, JS; Rossi, SS; Smith, E; Stek, AM | 1 |
| Chen, J; Cho, S; Cohen, HW; Diament, EC; Fazzari, MJ; Hendrix, CW; Herold, BC; Kalyoussef, S; Keller, MJ; Lee, AC; Louissaint, N; Madan, RP; Mesquita, PM; Shust, G; Soto-Torres, L; Torres, NM | 1 |
| Mayer, KH; Myers, GM | 1 |
| Bentley, TG; Broder, MS; Chang, EY; Juday, T; Uy, J | 1 |
| Alivanis, P; Aperis, G; Arvanitis, A; Paliouras, C; Zervos, A | 1 |
| García, N; Gutiérrez, F; Jarrin, I; Masiá, M; Padilla, S; Tormo, C | 1 |
| Arribas, JR; Hill, A; Moecklinghoff, C; Pulido, F; Van Delft, Y | 1 |
| de Béthune, MP; De Meyer, S; Dierynck, I; Lathouwers, E; Lavreys, L; Picchio, G; Van de Casteele, T | 1 |
| Campbell, LJ; Hamzah, L; Post, FA | 1 |
| Bracciale, L; Cauda, R; D'Avino, A; De Luca, A; Di Giambenedetto, S; Doino, M; Fabbiani, M; Marzocchetti, A; Navarra, P | 1 |
| León, E; Lozano de León-Naranjo, F; Pérez-Rivera, AÁ; Sáez, P | 1 |
| Baldelli, F; Floridia, M; Francisci, D; Martinelli, L; Masini, G; Weimer, LE; Zazzi, M | 1 |
| Kaptur, PE; Mertenskoetter, T | 1 |
| Beadsworth, MB; Pennell, A; Phillips, M; Ratcliffe, L; Vilar, FJ | 1 |
| Aboh, S; Bosivert, N; Duke, N | 1 |
| Chimsuntorn, S; Lueangniyomkul, A; Mankatitham, W; Manosuthi, W; Nilkamhang, S; Sungkanuparph, S; Suntisuklappon, B; Tantanathip, P; Thongyen, S | 1 |
| Arulappan, N; Baxter, C; Frohlich, JA; Gengiah, TN; Grobler, A; Karim, QA; Karim, SS; Kharsany, AB; Maarschalk, S; Mansoor, LE; Mlisana, KP; Mlotshwa, M; Omar, Z; Samsunder, N; Sibeko, S; Yende, N | 1 |
| Darin, KM; Gerzenshtein, L; O'Donnell, EP; Palella, FJ; Postelnick, MJ; Scarsi, KK | 1 |
| Gruters, RA; Luider, TM; Meesters, RJ; Scheuer, RD; van der Ende, ME; van Kampen, JJ | 1 |
| Calmy, A; Hirschel, B; Schiffer, V | 1 |
| Chuck, SL; Cohen, C; DeJesus, E; Elion, R; Kearney, BP; Liu, HC; Ramanathan, S; Rashbaum, B; Ruane, P; Shamblaw, D; Warren, DR; Yale, K | 1 |
| Kuijper, A; Mudrikova, T; Rookmaker, MB | 1 |
| Connolly, JO; Hall, AM; Hendry, BM; Nitsch, D | 1 |
| Alukda, D; Sturgis, T; Youan, BC | 1 |
| Desire, N; Katlama, C; Stitou, H; Thibault, V; Tubiana, R; Valantin, MA | 1 |
| Calza, L; Colangeli, V; Manfredi, R; Piergentili, B; Tedeschi, S; Trapani, F; Viale, P | 1 |
| French, P; Pittrof, R; Sauer, U | 1 |
| Underhill, K | 1 |
| Malgarini, RB; Pimpinella, G | 1 |
| Lafuente-Lafuente, C; Roques, P; Sellier, PO | 1 |
| Lee, DH; Vielemeyer, O | 1 |
| Cooper, V; Ewan, J; Fisher, M; Horne, R; Liu, HC; Moyle, GJ; Reilly, G | 1 |
| Barry, AC; Chu, H; Eron, JJ; Ferrari, G; Fiscus, SA; Gay, CL; Hicks, CB; Kerkau, M; Kuruc, JD; Margolis, DM; Mayo, AJ; McGee, KS; Mfalila, CK; Sebastian, J | 1 |
| Balzarini, J; Dittmann, E; Férir, G; Huskens, D; Kehr, JC; Markovitz, DM; Schols, D; Swanson, MD; Van Damme, EJ; Vermeire, K | 1 |
| Chan, DJ; Jeganathan, S; Maruszak, H; Smith, DE | 1 |
| Choi, AI; Deeks, SG; Li, Y; Shlipak, MG; Vittinghoff, E; Weekley, CC | 1 |
| Gracey, D; MacLeod, C; McKenzie, P; Post, J | 1 |
| Andrade-Villanueva, J; Cairns, V; Clotet, B; de Rossi, L; Domingo, P; Gellermann, HJ; Podzamczer, D; Reiss, P; Rockstroh, JK; Soriano, V; Taylor, S | 1 |
| Aung, W; Cong, ME; García-Lerma, JG; Hanson, DL; Heneine, W; Holder, A; Kersh, E; Kuklenyik, S; Lee, WA; Lin, CY; Luo, W; Martin, A; Mitchell, J; Pau, CP; Ray, AS; Rooney, JF; Youngpairoj, AS; Zheng, Q | 1 |
| Bedogni, G; Caprio, C; Cerini, C; di Nello, F; Giacomet, V; Manfredini, V; Penagini, F; Viganò, A; Zuccotti, GV | 1 |
| Bonnet, F; Cazanave, C; Dabis, F; Dauchy, FA; de La Faille, R; Dupon, M; Greib, C; Lawson-Ayayi, S; Mehsen, N; Miremont-Salamé, G; Rigothier, C | 1 |
| Andrade-Villanueva, J; Antunes, F; Arastéh, K; de Rossi, L; Di Perri, G; Domingo, P; Gellermann, H; Lutz, T; Migrone, H; Opravil, M; Podzamczer, D; Soriano, V; Taylor, S | 1 |
| Bronsveld, W; Haverkort, ME; Huitema, AD; Lips, P; Slieker, WA; ter Heine, R; van der Spek, BW | 1 |
| Stephenson, J | 1 |
| Appella, E; Denton, PW; Estes, JD; Fleming, E; Gallay, P; Garcia, JV; Kay, MS; Krisko, JF; Kwak, YT; Lu, M; Martinez-Torres, F; Othieno, F; Payne, DA; Powell, DA; Wahl, A; Welch, BD; Zein, S; Zou, W | 1 |
| Wepner, U | 1 |
| Daar, ES; Ha, B; Jahed, NC; Kitch, D; McComsey, GA; Melbourne, K; Myers, L; Sax, PE; Tebas, P; Tierney, C | 1 |
| Albalater, M; Back, DJ; Bonora, S; Di Perri, G; Hopper-Borge, E; Khoo, S; Labarga, P; Liptrott, NJ; Owen, A; Pirmohamed, M; Pushpakom, SP; Rodríguez-Nóvoa, S; Soriano, V | 1 |
| Colby-Germinario, SP; Schachter, JR; Schader, SM; Wainberg, MA; Xu, H | 1 |
| Brennan, A; Evans, D; Fox, M; Ive, P; Maotoe, T; Maskew, M; Naicker, S; Sanne, I | 1 |
| Blanche, S; Dollfus, C; Firtion, G; Foissac, F; Hirt, D; Laurent, C; Treluyer, JM; Urien, S | 1 |
| Bedimo, RJ; Drechsler, H; Tebas, P; Vidiella, G; Westfall, AO | 1 |
| Abdool Karim, SS; Gouws, E; Karim, QA; Williams, BG | 1 |
| Cotter, AG; Powderly, WG | 1 |
| Hakim, JG; Katsidzira, L | 1 |
| Acosta, EP; Britto, P; Carey, V; Graham, B; Hazra, R; Jean-Philippe, P; King, JR; Wiznia, A; Yogev, R | 1 |
| Barragán, P; Bonet, R; Curran, A; Gatell, JM; Knobel, H; Loncá, M; Martínez, E; Negredo, E; Ordoñez-Llanos, J; Podzamczer, D; Ribera, E; Saumoy, M | 1 |
| Athmann, C; Berger, F; Filmann, N; Hegener, P; Henke, J; Herrmann, E; Hueppe, D; Mauss, S; Schmutz, G | 1 |
| Meng, J; Sturgis, TF; Youan, BB | 1 |
| Chimsuntorn, S; Manosuthi, W; Nilkamhang, S; Prasithsirikul, W; Sungkanuparph, S; Tantanathip, P | 1 |
| Koole, O; Lynen, L; Sopheak, T; van Griensven, J; Verpooten, GA | 1 |
| Chan, K; Cooper, C; Hogg, RS; Klein, MB; Loutfy, MR; Machouf, N; Montaner, JS; Raboud, J; Rourke, SB; Tan, DH; Tsoukas, C; Walmsley, S | 1 |
| Bonasso, M; Bonora, S; Calcagno, A; D'Avolio, A; Di Perri, G; Imperiale, D; Romito, A; Rostagno, R; Simiele, M; Tettoni, MC | 1 |
| Akimoto, T; Hamano, Y; Iwazu, Y; Kusano, E; Miki, T; Muto, S; Numata, A; Otani, N; Saito, O; Sugase, T; Takemoto, F; Toshima, M; Ueda, Y | 1 |
| Farajallah, A; McGrath, D; Sheppard, L; Uy, J; Wirtz, V; Yang, R | 1 |
| Sturgis, TF; Youan, BB; Zhang, T | 1 |
| Bouldouyre, MA; Molina, JM; Pavie, J; Pillebout, E; Scemla, A; Verine, J | 1 |
| Hosseini, SH; Kohler, JJ | 1 |
| Debyser, Z; Desimmie, BA; Schrijvers, R | 1 |
| Karim, QA; Karim, SS; Kashuba, AD; Werner, L | 1 |
| Bygrave, H; Cleary, S; Ford, N; Gadot, L; Goemaere, E; Hilderbrand, K; Jouquet, G; Kranzer, K; Lee, J; Makakole, L; Trivino, L; Vlahakis, N | 1 |
| Bertz, R; Boffito, M; Child, M; Chung, E; Kashuba, A; Mahnke, L; Patterson, K; Tebas, P; Wang, X; Wu, Y; Zhang, J; Zhu, L | 1 |
| Karim, QA; Karim, SS | 2 |
| Chau, Q; Fessel, WJ; Leong, D | 1 |
| Burlacu, R; de Lastours, V; Fonsart, J; Gourmel, B; Molina, JM | 1 |
| Lane, JM; Rebolledo, BJ; Unnanuntana, A | 1 |
| Aoki, T; Gatanaga, H; Honda, H; Honda, M; Kikuchi, Y; Kinai, E; Komatsu, H; Nishijima, T; Oka, S; Tanuma, J; Teruya, K; Tsukada, K; Watanabe, K; Yazaki, H | 1 |
| Bruzzone, B; Callegaro, AP; Di Biagio, A; Maggiolo, F; Nulvesu, L; Rosso, R; Taramasso, L; Viscoli, C | 1 |
| Gatanaga, H; Kikuchi, Y; Nagata, N; Nishijima, T; Oka, S; Teruya, K; Tsukada, K; Watanabe, K | 1 |
| Chuck, SL; Cohen, C; Elion, R; Gathe, J; Hawkins, T; Kearney, BP; Liu, HC; Mathias, AA; Shalit, P; Warren, DR | 1 |
| Allavena, C; Dejesus, E; Fernandez Garcia, E; Fisher, M; Hardy, WD; Jackson, AG; Jayaweera, DT; Katlama, C; Mauss, S; Moyle, GJ; Raffi, F; Reiss, P; Slama, L; van Eeden, A; Vrouenraets, SM; Wit, FW | 1 |
| Ammassari, A; Castagna, A; Delaugerre, C; Ghosn, J; Medrano, J; Molina, JM; Pavie, J; Porcher, R; Rusconi, S; Torti, C; Valin, N | 1 |
| Cocohoba, J; Gruta, C; John, MD; Lao, CK | 1 |
| Holodniy, M; Schirmer, P; Winters, M | 1 |
| Balazs, AB; Baltimore, D; Dekel, E; Kim, JT; Mayo, A; Milo, R; Sigal, A | 1 |
| Baldelli, F; Belfiori, B; Falcinelli, E; Fierro, T; Francisci, D; Gresele, P; Petito, E | 1 |
| Bolton-Moore, C; Chi, BH; Chintu, NT; Giganti, MJ; Moyo, C; Mulenga, LB; Mwango, A; Schuttner, L; Sheneberger, R; Sikazwe, I; Stringer, EM; Stringer, JS | 1 |
| Benaboud, S; Blanche, S; Bouazza, N; Foissac, F; Frange, P; Hirt, D; Rey, E; Tréluyer, JM; Urien, S | 1 |
| Vermund, SH | 1 |
| Abeling, NG; Brinkman, K; Furrer, H; Fux, CA; Garcia, EF; Hoek, FJ; Krediet, RT; Reiss, P; Vrouenraets, SM; Wit, FW | 1 |
| Kohli, R; Mehendale, S; Tolley, EE; Tsui, S; Weaver, MA | 1 |
| Bardeguez, A; Cotter, A; Fiscus, SA; Flynn, PM; Heckman, B; Huang, S; Jean-Philippe, P; Kearney, B; Mirochnick, M; Mofenson, LM; Purswani, M; Robbins, B; Rodman, J; Rooney, JF; Shapiro, DE; Thorpe, E; Van Rompay, KK; Watts, DH | 1 |
| Hull, MW; Montaner, JS | 1 |
| Budhathoki, C; Collier, AC; Daar, ES; Farajallah, A; Feinberg, J; Fischl, MA; Godfrey, C; Ha, B; Jahed, NC; Katzenstein, D; Mollan, K; Murphy, RL; Myers, L; Rooney, JF; Sax, PE; Tashima, K; Tierney, C; Woodward, WC | 1 |
| Hitomi, S; Kiyasu, Y; Koganemaru, H | 1 |
| Dejesus, E; Dinubile, MJ; Lazzarin, A; Leavitt, R; Lennox, JL; Nguyen, BY; Rockstroh, JK; Rodgers, AJ; Saag, MS; Sklar, P; Teppler, H; Walker, ML; Wan, H; Xu, X; Zhao, J | 1 |
| da Silva, AC; Gianini, RJ; Gomes-Gouvea, MS; Guastini, CF; Leite, AG; Martins, LG; Mendes-Correa, MC; Pinho, JR; Silva, MH; Uip, DE | 1 |
| Abraham, B; Bélec, L; Charpentier, C; Dandy, M; De Dieu Longo, J; Grésenguet, G; Matta, M; Mbelesso, P; Moussa, S; Péré, H | 1 |
| Bando, H; Kasai, D; Kushida, H; Kuwahara, T; Nishida, Y; Ogawa, Y; Shirasaka, T; Taniguchi, T; Uehira, T; Watanabe, D; Yagura, H; Yajima, K; Yonemoto, H; Yoshino, M | 1 |
| Chiamwongpaet, S; Choopanya, K; Chuachoowong, R; Kittimunkong, S; Leethochawalit, M; Martin, M; McNicholl, JM; Mock, PA; Paxton, L; Sangkum, U; Suntharasamai, P; van Griensven, F; Vanichseni, S | 1 |
| Frederiksen, CA; Langdahl, BL; Laursen, AL; Melchjorsen, J; Nielsen, US; Rasmussen, TA; Tolstrup, M; Østergaard, L | 1 |
| Allen, P; Kashuba, A; Nuttall, J; Roberts, J; Romano, J; Wang, R; White, N | 1 |
| Albini, L; Bellagamba, R; Calabresi, A; Cesana, BM; Fezza, R; Focà, E; Gotti, D; Guaraldi, G; Izzo, I; Lapadula, G; Maggi, P; Manili, L; Motta, D; Narciso, P; Quiros-Roldan, E; Sighinolfi, L; Torti, C | 1 |
| Baeten, JM; Barnes, L; Bukusi, E; Campbell, JD; Celum, C; Cohen, CR; Coombs, RW; Donnell, D; Farquhar, C; Fife, KH; Ingram, C; John-Stewart, G; Katabira, E; Kiarie, J; Kidoguchi, L; Krows, M; Lingappa, JR; Morrison, S; Mugo, NR; Mujugira, A; Ndase, P; Ondrejcek, L; Panteleeff, D; Revall, J; Ronald, A; Shah, H; Tappero, JW; Tumwesigye, E; Wangisi, J; Were, E | 1 |
| Krakower, D; Mayer, KH | 2 |
| Agarwal, R; Dubé, MP; Gupta, SK; Mather, KJ; Shen, C | 1 |
| Esser, S; Gölz, J; Haberl, A; Körber, A; Lazzarin, A; Mulcahy, F; Staszewski, S; Teofilo, E; Vera, J | 1 |
| Gibb, DM; Gilks, CF; Grosskurth, H; Hakim, J; Kityo, C; Mambule, I; Munderi, P; Reid, A; Ssali, F; Stöhr, W; Walker, AS | 1 |
| Brown, TT; Labbato, D; McComsey, GA; Ross, AC; Storer, N | 1 |
| Clercq, ED | 1 |
| Furrer, H; Rauch, A; Wandeler, G | 1 |
| Keller, SB; Smith, DM | 1 |
| Dobard, C; García-Lerma, JG; Hanson, DL; Heneine, W; Holder, A; Kuklenyik, Z; Lipscomb, J; Martin, A; Novembre, FJ; Pau, CP; Sharma, S; Smith, J | 1 |
| Aboulker, JP; Andreo, C; Capitant, C; Carrieri, MP; Cook, E; Fugon, L; Le Gall, JM; Lorente, N; Molina, JM; Spire, B | 1 |
| Kohli, R; Marlow, HM; Mehendale, S; Tolley, EE; Weaver, MA | 1 |
| Branger, M; Collin, G; Fraqueiro, G; Gervais, A; Hamet, G; Lada, O; Marcellin, P; Martinot-Peignoux, M; Matheron, S; Moucari, R; Peytavin, G; Roquebert, B | 1 |
| Caro-Vega, Y; Crabtree-Ramírez, B; López-Martínez, A; O'Brien, NM; Sierra-Madero, J | 1 |
| Pletz, MW; Schleenvoigt, BT; Stallmach, A | 1 |
| Bertz, R; Child, M; Eley, T; Farajallah, A; Krystal, M; Liao, S; McGrath, D; Molina, JM; Persson, A; Sevinsky, H; Xu, X; Zhang, J; Zhu, L | 1 |
| Chipato, T; Cole, SR; Currier, JS; D'Amico, R; Eron, JJ; Hosseinipour, M; Hughes, MD; Lockman, S; McCarthy, JS; Meshnick, SR; Poole, C; Porter, KA; Salata, R; Sawe, FK; Shaffer, D; Siika, A; Skinner-Adams, TS; Stringer, E; Zheng, Y | 1 |
| Benaboud, S; Bouazza, N; Chappuy, H; Firtion, G; Foissac, F; Hirt, D; Launay, O; Pannier, E; Rey, E; Tréluyer, JM; Urien, S | 1 |
| Baum, MM; Butkyavichene, I; Clark, MR; Friend, DR; Gilman, J; Kennedy, S; Kopin, E; Malone, AM; Moss, JA; Motamedi, M; Nguyen, C; Smith, TJ; Vincent, KL | 1 |
| Colby-Germinario, SP; Ibanescu, RI; Moisi, D; Oliveira, M; Schader, SM; Wainberg, MA | 1 |
| Angarano, G; Bellacosa, C; Graziano, G; Maggi, P; Montinaro, V; Pietanza, S; Strippoli, GF; Volpe, A | 1 |
| Cooper, DA; Duncombe, C; Emery, S; Gill, JM; Kerr, SJ; Li, PC; Puls, R; Taylor-Robinson, SD; Winston, A | 1 |
| Cane, PA; Crook, AM; Delpech, V; Dolling, D; Dunn, D; Fearnhill, E; Hill, T; Phillips, AN; Pillay, D; Shepherd, J | 1 |
| Back, DJ; Else, LJ; Khoo, SH; Taylor, S | 1 |
| Cellini, M; Gabiano, C; Giacomet, V; Manfredini, V; Mora, S; Puzzovio, M; Salvini, F; Stucchi, S; Tamburrini, E; Viganò, A; Zuccotti, GV | 1 |
| Clauss, M; Desta, Z; Deuter-Reinhard, M; Green, L; Gupta, SK; Kim, C; Taylor, BM | 1 |
| Baeten, JM; Celum, C | 1 |
| Cohen, MS; Jenkins, AJ; Kashuba, AD; Kraft, E; Patterson, KB; Prince, HA; Rooney, JF; Shaheen, NJ | 1 |
| Camp, R; Connick, E; Daar, ES; Degruttola, V; Del Rio, C; Fiscus, SA; Hare, CB; Hogan, CM; Kallungal, B; Little, S; Macatangay, B; Markowitz, M; Morton, T; Sun, X; Tashima, KT | 1 |
| Conway, B; Tossonian, H | 1 |
| Boyd, A; Delaugerre, C; Girard, PM; Lacombe, K; Lavocat, F; Maylin, S; Simon, F; Zoulim, F | 1 |
| Bugeja, A; Gupta, A; Kirpalani, D | 1 |
| Aoki, T; Gatanaga, H; Honda, H; Honda, M; Kikuchi, Y; Kinai, E; Komatsu, H; Nishijima, T; Oka, S; Shimbo, T; Tanuma, J; Teruya, K; Tsukada, K; Watanabe, K; Yazaki, H | 1 |
| Balzarini, J; Schols, D | 1 |
| Gelman, M; Grasso, C; Mayer, KH; Mimiaga, MJ | 1 |
| Baeten, JM; Bangsberg, DR; Celum, CL; Haberer, JE; Kintu, A; Psaros, C; Safren, S; Tumwesigye, E; Ware, NC; Wyatt, MA | 1 |
| Branger, M; Collin, G; Fraqueiro, G; Gervais, A; Lada, O; Leclerc, L; Marcellin, P; Martinot-Peignoux, M; Matheron, S; Moucari, R; Peytavin, G; Roquebert, B | 1 |
| Baker, A; Bethel, J; Flynn, PM; Havens, PL; Hazra, R; Kapogiannis, BG; Liu, N; Lujan-Zilbermann, J; Mulligan, K; Pan, CG; Rutledge, B; Stephensen, CB; Van Loan, MD; Wilson, CM; Woodhouse, LR | 1 |
| Amodio, D; Baldassari, S; Bernardi, S; Cotugno, N; Palma, P; Pontrelli, G; Tchidjou, HK; Zangari, P | 1 |
| Choi, J; Gerschenson, M; Harrill, D; Libutti, D; McComsey, GA; O'Riordan, M; Rowe, D; Storer, N | 1 |
| Ando, M; Nitta, K; Tsuchiya, K | 1 |
| Celum, CL | 1 |
| Al-Daghri, NM; Boothby, M; Das, S; Gathercole, LL; Harte, AL; McGee, KC; McTernan, PG; Nightingale, P; Shahmanesh, M; Shojaee-Moradie, F; Tomlinson, JW; Tripathi, G; Umpleby, AM | 1 |
| Baker, J; Brooks, JT; Bush, T; Conley, L; Hammer, J; Henry, K; Kojic, E; Overton, T; Patel, P | 1 |
| Bedimo, R; Drechsler, H; Maalouf, NM; Tebas, P; Zhang, S | 1 |
| Arterburn, S; Cheng, AK; Chuck, SL; da Silva, MT; de Aquino, MZ; de Carvalho, AP; Della Negra, M; Enejosa, JV; Liu, YP; Pinto, J; Rhee, MS; White, K | 1 |
| Fernando, M; Gracey, DM; Post, JJ; White, CP; Ziegler, J | 1 |
| Adams, JL; Kashuba, AD | 1 |
| Ramjee, G | 1 |
| Choi, AI; Deeks, SG; Estrella, M; Grunfeld, C; Li, Y; Scherzer, R; Shlipak, MG | 1 |
| Fessel, WJ; Israelski, D; Kagan, R; Kaufman, D; Melikian, GL; Rhee, SY; Robbins, GK; Shafer, RW; Taylor, J; Towner, W; Troia-Cancio, PV; Zolopa, A | 1 |
| Boyd, A; Delaugerre, C; Girard, PM; Gozlan, J; Lacombe, K; Lascoux-Combe, C; Lassel, L; Lavocat, F; Maylin, S; Miailhes, P; Zoulim, F | 1 |
| Bangsberg, DR; Haberer, JE; Van Damme, L; van der Straten, A | 1 |
| Amoroso, A; Edozien, A; Etienne-Mesubi, M; Hossain, MB; Obiefune, M; Ojoo, S; Redfield, RR; Sheneberger, R; Stafford, K | 1 |
| Bando, H; Hirota, K; Koizumi, Y; Kuwahara, T; Nishida, Y; Otera, H; Shirasaka, T; Tominari, S; Uehira, T; Watanabe, D; Yagura, H; Yajima, K; Yonemoto, H; Yoshino, M | 1 |
| Hakim, JG; Kuritzkes, DR; Sanne, I | 1 |
| Kanki, PJ; Shafer, RW; Tang, MW | 1 |
| Bork, K; Cames, C; Cournil, A; Coutherut, J; Delaporte, E; Diouf, A; Eymard-Duvernay, S; Moquet, C; Ngom Gueye, NF; Sow, PS; Taverne, B | 1 |
| Abdool Karim, Q; Abdool Karim, S; Altfeld, M; Mkhwanazi, NP; Mureithi, MW; Naranbhai, V; Ndung'u, T; Poole, D; Reddy, S; Sibeko, S; Werner, L | 1 |
| Fidler, S; Fisher, M; McCormack, S | 1 |
| Fernandez, VA; Reiser, IW; Spitalewitz, S; Thomas, DB | 1 |
| Agu, KA; Akpoigbe, KJ; Badru, T; Chabikuli, O; Eluwa, GI; Hamelmann, C | 1 |
| Aubron-Olivier, C; Calvez, V; Charpentier, C; Descamps, D; Katlama, C; Landman, R; Marcelin, AG; Simon, A; Valantin, MA; Wirden, M; Yeni, P | 1 |
| Barragan, P; Crespo, M; Curran, A; Falco, V; Gatell, JM; Imaz, A; Lonca, M; Martinez, E; Martinez, M; Podzamczer, D; Ribera, E; Vidal-Sicart, S | 1 |
| DiMeglio, LA; Griner, R; Hazra, R; Jacobson, DL; Kacanek, D; Mendez, H; Miller, T; Mofenson, LM; Rich, KC; Seage, GR; Siberry, GK; Tassiopoulos, K; Watts, DH; Williams, PL | 1 |
| Friend, DR | 1 |
| Bao, R; Cao, Y; Chen, Y; Han, C; He, B; Jiang, S; Li, L; Li, Y; Shi, W; Sun, Y; Yan, H; Yang, J; Yang, Y; Zhang, X; Zhang, Y; Zhong, M; Zhou, D | 1 |
| Heneine, W; Kashuba, A | 1 |
| Abdool Karim, SS; Baxter, C; Gengiah, TN; Kharsany, AB; Mansoor, LE | 1 |
| Clark, MR; Friend, DR | 1 |
| Battegay, M; Bernasconi, E; Bucher, HC; Calmy, A; Cavassini, M; Furrer, H; Fux, CA; Schäfer, J; Vernazza, P; Weber, R; Young, J | 1 |
| Akil, A; Clark, MR; Cost, M; Dezzutti, CS; Friend, DR; Rohan, LC | 1 |
| Clark, MR; Friend, DR; Major, I; Malcolm, RK; Mc Conville, C; Woolfson, AD | 1 |
| Islam, FM; Jansson, J; Wilson, DP; Wu, J | 1 |
| Brinkman, K; Furrer, H; Fux, CA; Garcia, EF; Hoek, FJ; Krediet, RT; Reiss, P; van Straalen, JP; Vrouenraets, SM; Wit, FW | 1 |
| Lee, WM; Tujios, SR | 1 |
| Herold, BC; Huber, AM; Kiser, PF; Mesquita, PM; Rastogi, R; Segarra, TJ; Teller, RS; Torres, NM | 1 |
| Bekker, LG; Freedberg, KA; Losina, E; Mayer, KH; Paltiel, AD; Park, JE; Scott, CA; Seage, GR; Walensky, RP; Wood, R | 1 |
| Birn, H; Erlandsen, EJ; Jensen, D; Langdahl, BL; Laursen, AL; Nielsen, US; Rasmussen, TA; Tolstrup, M; Østergaard, L | 1 |
| Aguilar-Bernier, M; Del Boz, J; Fernández-Morano, T; Fúnez-Liébana, R | 1 |
| Bookstaver, PB; Bryant, JE; Millisor, VE; Rokas, KE; Shamroe, CL; Sutton, SS; Weissman, SB | 1 |
| Anzala, O; Bangsberg, D; Barin, B; Chetty, P; Fast, P; Haberer, JE; Mark, D; Mugo, P; Mutua, G; Priddy, FH; Rooney, JF; Sanders, E | 1 |
| Naggie, S; Sulkowski, MS | 1 |
| Bräu, N; Chang, MH; Fung, HB; Monteagudo-Chu, MO | 1 |
| Abrahams, MR; Anderson, J; Arney, L; Bandawe, G; Goodier, S; Karim, QA; Karim, SS; Naranbhai, V; Sibeko, S; Swanstrom, R; Treurnicht, F; Valley-Omar, Z; Werner, L; Williamson, C | 1 |
| Cost, M; Dezzutti, CS; Friend, D; Lynam, JD; Rohan, LC; Shetler, C; Uranker, K; Wang, L | 1 |
| Bulterys, M; Kuhn, L | 1 |
| Ang, BC; Teoh, SC | 1 |
| Edelman, EJ; Gordon, K; Justice, AC; Rodriguez-Barradas, MC | 1 |
| Chidziva, E; Gibb, DM; Gilks, CF; Grosskurth, H; Hakim, J; Kizito, H; Kyomugisha, H; Munderi, P; Musoke, P; Nalumenya, R; Nathoo, K; Russell, EC; Spyer, M; Tumukunde, D; Walker, AS; Zalwango, E | 1 |
| Baum, MM; Butkyavichene, I; Clark, MR; Friend, DR; Gilman, J; Kennedy, S; Kopin, E; Malone, AM; Moss, JA; Nguyen, C; Smith, TJ | 1 |
| Alonso-Villaverde, C; Aragonès, G; Beltrán-Debón, R; Camps, J; Fernández-Sender, L; Joven, J; Pardo-Reche, P; Rodríguez-Gallego, E; Rull, A | 1 |
| Buscher, A; Giordano, TP; Hartman, C; Kallen, MA | 1 |
| Haire, B; Jordens, CF; Kaldor, J | 1 |
| Engsig, FN; Feldt-Rasmussen, B; Gerstoft, J; Kirk, O; Kronborg, G; Obel, N; Pedersen, C; Rasch, MG | 1 |
| Mwethera, PG; Obiero, J; Wiysonge, CS | 1 |
| Grabczewska, E; Olczak, A | 1 |
| Amin, J; Carr, A; Ebeling, PR; Emery, S; Haskelberg, H; Hoy, JF | 1 |
| Bobardt, MD; Dezzutti, CS; Esch, T; Gallay, PA; Gunaseelan, S; Maskiewicz, R | 1 |
| Fang, J; Jadhav, PR | 1 |
| Boulle, A; Brennan, A; Chaweza, T; Chimbetete, C; Egger, M; Garone, D; Giddy, J; Hoffmann, CJ; Keiser, O; Mulenga, L; Prozesky, H; Wandeler, G; Wood, R | 1 |
| Cheng, AK; DeJesus, E; Gathe, J; Henry, K; Kearney, BP; Molina, JM; Ramanathan, S; Rockstroh, JK; Szwarcberg, J; Wei, X; White, K; Yale, K | 1 |
| Cheng, AK; Cohen, C; DeJesus, E; Gallant, JE; Kearney, BP; Liu, HC; Mills, A; Quirk, E; Sax, PE; Szwarcberg, J; White, K; Wohl, D; Yale, K; Zhong, L; Zolopa, A | 1 |
| Ducos, J; Kania, D; Kuster, N; Lozano, C; Mondain, AM; Nagot, N; Pageaux, GP; Poinso, A; Reynes, J; Tuaillon, E; Van de Perre, P | 1 |
| Baden, LR; Cohen, MS | 1 |
| Abdool Karim, SS; Gray, GE; Martinson, N | 1 |
| Abebe, D; Brooks, JT; Buliva, E; Chillag, KL; Chirwa, LI; Gvetadze, RJ; Hart, C; Henderson, FL; Hendrix, CW; Johnson, JA; Johnson, S; Kasonde, M; Kebaabetswe, PM; Malotte, CK; Mutanhaurwa, R; Pathak, SR; Paxton, LA; Rose, CE; Segolodi, TM; Smith, DK; Soud, FA; Sukalac, T; Thigpen, MC; Thomas, VT | 1 |
| Agot, K; Ahmed, K; Corneli, A; Crucitti, T; Deese, J; Fransen, K; Grant, R; Kapiga, S; Kashuba, A; Kiernan, H; Kirkendale, S; Lombaard, J; Mak'Oketch, P; Makanda, M; Makatu, SE; Malahleha, M; Mandala, J; Manongi, R; Mastro, TD; Monedi, MC; Nanda, K; Onyango, J; Owino, F; Reblin, I; Saylor, L; Taylor, D; Temu, L; Van Damme, L; Wong, C | 1 |
| Apaka, C; Baeten, JM; Bangsberg, D; Bukusi, EA; Bumpus, NN; Campbell, JD; Celum, C; Cohen, CR; Coombs, RW; Donnell, D; Emmanuel-Ogier, M; Farquhar, C; Fife, KH; Frenkel, L; Gabona, F; Haberer, JE; Haugen, H; Hendrix, C; John-Stewart, G; Kakia, A; Katabira, E; Kiarie, J; Kidoguchi, L; Krows, M; Lingappa, JR; Morrison, S; Mucunguzi, A; Mugo, NR; Mujugira, A; Nakku-Joloba, E; Ndase, P; Ngure, K; Odoyo, J; Ondrejcek, L; Panteleeff, D; Revall, J; Ronald, A; Stevens, WS; Tamooh, H; Tappero, JW; Thomas, KK; Tumwesigye, E; Twesigye, R; Wangisi, J; Were, E | 1 |
| Okoromah, CA; Okwundu, CI; Uthman, OA | 1 |
| Kim, JH; Psevdos, G; Sharp, V | 1 |
| Daly, F | 1 |
| Chianura, L; Errante, I; Moioli, MC; Orcese, C; Orso, M; Puoti, M; Rossotti, R; Schiantarelli, C; Schlacht, I; Travi, G; Vigo, B; Villa, MR; Volonterio, A | 1 |
| Duwal, S; Schütte, C; von Kleist, M | 1 |
| Bruzzone, B; Caligiuri, P; Di Biagio, A; Giacobbe, DR; Mikulska, M; Taramasso, L; Viscoli, C | 1 |
| Abdool Karim, Q; Abdool Karim, SS; Altfeld, M; Carr, WH; Durgiah, R; Naranbhai, V; Samsunder, N; Sibeko, S | 1 |
| Gibbs, C; Guyer, B; Haddad, M; McColl, DJ; Miller, MD; Su, C | 1 |
| Akinkuotu, A; Chasela, C; Hosseinipour, MC; Jamieson, DJ; Johnson, DC; King, CC; Kourtis, AP; Maliwichi, M; Moses, A; Mwafongo, A; van der Horst, C | 1 |
| Holmes, D | 2 |
| Bartlett, H; Gibson, A; Kelly, MD; Patten, J; Rowling, D | 1 |
| Hall, AM | 1 |
| Aguilera, A; Alcamí, J; Álvarez, M; Anta, L; Betancor, G; Blanco, JL; Caballero, E; Cañizares, A; Clotet, B; Córdoba, J; Dalmau, D; de Mendoza, C; del Romero, J; Galindo, MJ; García, F; Garrido, C; Garriga, C; Gatel, JM; Gómez Sirvent, JL; Gutiérrez, C; Gutiérrez, F; Iribarren, JA; Jaén, A; Leal, M; Llibre, JM; López Aldeguer, J; Manuzza, G; Martínez, MA; Martinez-Picado, J; Menéndez-Arias, L; Miralles, C; Morano, L; Moreno, S; Nevot, M; Ocampo, A; Palomares, JC; Pedreira, J; Peraire, J; Pérez-Elías, MJ; Pérez-Olmeda, M; Pérez-Romero, P; Pineda, JA; Poveda, E; Puertas, MC; Ribera, E; Riera, M; Rodríguez, C; Rodríguez, P; Santos, J; Soriano, V; Viciana, I; Viciana, P; Vidal, C; Vidal, F | 1 |
| Bonjoch, A; Clotet, B; Echeverría, P; Estany, C; Negredo, E; Perez-Alvarez, N; Puig, J | 1 |
| Pommer, P | 1 |
| Attia, S; Bogner, JR; Füeßl, B; Goebel, FD; Kay, L; Lederer, SR; Röder, M; Schlattner, U; Schmid, H; Tokarska-Schlattner, M | 1 |
| Bertagnolio, S; Cambiano, V; Jordan, MR; Lundgren, J; Miners, A; Phillips, AN; Pillay, D; von Wyl, V | 1 |
| Baxter, C; Frolich, J; Grobler, A; Karim, QA; Karim, SS; Kharsany, AB; Maarshalk, S; Mansoor, LE; Miya, N; Mlisana, K; Sibeko, S; Sokal, DC; Yende-Zuma, N | 1 |
| Aaron, E; Cohan, D | 1 |
| Borghi, V; Capetti, A; Cicconi, P; Di Biagio, A; Di Giambenedetto, S; Francisci, D; Giacometti, A; Giannarelli, D; Maggiolo, F; Monno, L; Penco, G; Prinapori, R; Sterrantino, G; Zoncada, A | 1 |
| Grulich, AE; Poynten, IM; Zablotska, I | 1 |
| Szpir, M; Van Damme, L | 1 |
| Lyseng-Williamson, KA; Scott, LJ | 1 |
| Anderson, PL; Bushman, LR; Castillo-Mancilla, JR; Fernandez, C; Gardner, EM; Kiser, JJ; Langness, J; Meditz, A; Predhomme, J; Rower, JE; Zheng, JH | 1 |
| Buckheit, KW; Buckheit, RW; Dezzutti, CS; Gwozdz, G; Mahalingam, A; Shetler, C; Ugaonkar, SR | 1 |
| Gnarini, M; Maserati, R; Uglietti, A; Zanaboni, D | 1 |
| Anton, PA; Bumpus, NN; Carballo-Diéguez, A; Cranston, RD; Cumberland, WG; Dennis, R; Elliott, J; Hendrix, CW; Janocko, L; Ju, C; Kashuba, A; Khanukhova, E; Mauck, C; McGowan, I; Richardson-Harman, N | 1 |
| Henry, K | 1 |
| Alvarez, A; Calatayud, S; De Pablo, C; Esplugues, JV; Martí-Cabrera, M; Orden, S | 1 |
| Gatanaga, H; Hayashida, T; Higasa, K; Komatsu, H; Nishijima, T; Oka, S; Takano, M; Tsuchiya, K | 1 |
| Du, X; Fu, Q; Kou, H; Li, T; Li, Y; Zhu, Z | 1 |
| Bonovas, S; Hatzakis, A; Nikolopoulos, G; Tsiodras, S | 1 |
| Hendrix, CW | 1 |
| Herold, BC; Kiser, PF; Mesquita, PM | 1 |
| Hansen, BE; Janssen, HL; Koëter, T; Komuta, M; Rossing, HH; Schouten, JN; Van der Ende, ME; van der Valk, M; Verheij, J | 1 |
| Anderson, PL; Bekker, LG; Buchbinder, S; Bushman, LR; Casapía, M; Chariyalertsak, S; Glidden, DV; Grant, RM; Guanira, JV; Kallás, EG; Lama, JR; Liu, A; Mayer, KH; McMahan, V; Montoya-Herrera, O; Schechter, M; Veloso, VG | 1 |
| Gatanaga, H; Hinoshita, F; Hoshimoto, K; Kikuchi, Y; Nishijima, T; Oka, S; Tasato, D; Teruya, K; Yazaki, H | 1 |
| Cooke, G; Courtney, AP; Hickson, M; Klassen, K; Martineau, AR; Wilkinson, RJ | 1 |
| Borderi, M; Calza, L; Colangeli, V; Di Bari, MA; Magistrelli, E; Manfredi, R; Salvadori, C; Trapani, F; Viale, P | 1 |
| Ananworanich, J; Bhakeecheep, S; Bowonwattanuwong, C; Bunupuradah, T; Chetchotisakd, P; Hirschel, B; Jirajariyavej, S; Klinbuayaem, V; Mahanontharit, A; Munsakul, W; Prasithsirikul, W; Ruxrungtham, K; Sophonphan, J; Valcour, V | 1 |
| Albright, TH; Chandra, N; Clark, JT; Clark, MR; Doncel, GF; Fabian, J; Friend, DR; Johnson, TJ; Kiser, PF; McCabe, RT; Nebeker, JS; Tuitupou, AL | 1 |
| Abecasis, AB; Camacho, RJ; Snoeck, J; Theys, K; Vandamme, AM; Vercauteren, J | 1 |
| Bonfanti, P; Carenzi, L; di Biagio, A; Madeddu, G; Martinelli, C; Menzaghi, B; Mura, MS; Orofino, G; Parruti, G; Ricci, E | 1 |
| Acosta, EP; Baheti, G; Fletcher, CV; King, JR | 1 |
| Amin, J; Cooper, DA; Cordery, DV; Emery, S; Kelleher, AD; Martin, A | 1 |
| Barrail-Tran, A; Descamps, D; Duval, X; Goujard, C; Mentré, F; Nembot, G; Panhard, X; Savic, RM; Taburet, AM; Verstuyft, C; Vrijens, B | 1 |
| Crowther, NJ; Dickens, C; Dix-Peek, T; Duarte, R; Fox, MP; Ive, P; John, MA; Macphail, P; Maskew, M; Menezes, CN; Raal, F; Sanne, I; Van Amsterdam, D | 1 |
| Ceppi, C; Cua, E; De Salvador, F; Dellamonica, P; Durant, J; Esnault, V; Fafin, C; Mondain, V; Moranne, O; Perbost, I; Pradier, C; Pugliese, P; Rahelinirina, V; Roger, PM; Rosenthal, E | 1 |
| Grabmeier-Pfistershammer, K; Kosi, L; Payer, BA; Peck-Radosavljevic, M; Reiberger, T; Rieger, A; Strassl, R | 1 |
| Cohen, MS; Dumond, JB; Forrest, A; Garonzik, SM; Kashuba, AD; Kendrick, RN; Nicol, MR; Patterson, KB | 1 |
| Hayashi, T; Ikeda, H; Ishida, T; Kunimoto, Y; Miyamoto, A; Nakata, H; Noda, N; Okazaki, M; Shinomura, Y; Takahashi, S; Touda, N; Yasui, H | 1 |
| Raphael, MC | 1 |
| Chen, BA; Gandham, S; Gomez, K; Guddera, V; Hendrix, CW; Hoesley, C; Justman, J; Minnis, AM; Nakabiito, C; Patterson, K; Richardson, BA; Salata, R; Soto-Torres, L | 1 |
| Ananworanich, J; Bhakeecheep, S; Bowonwatanuwong, C; Bunupuradah, T; Chetchotisakd, P; Hirschel, B; Jirajariyavej, S; Kantipong, P; Kerr, SJ; Klinbuayaem, V; Munsakul, W; Prasithsirikul, W; Ruxrungtham, K; Sophonphan, J; Sungkanuparph, S | 1 |
| Fätkenheuer, G; Kümmerle, T | 1 |
| Adams, JL; Crucitti, T; De Baetselier, I; Fransen, K; Kashuba, AD; Menezes, P; Patterson, KB; Prince, HM; Sykes, C; Van Damme, L | 1 |
| Chateau, M; Garcia, JV; Swanson, MD | 1 |
| Baril, JG; Dufresne, S; Laprise, C; Trottier, H | 1 |
| Cabie, A; Charpentier, C; Chene, G; Colin de Verdiere, N; Descamps, D; Fagard, C; Grondin, C; Joly, V; Raffi, F; Tabuteau, S; Yazdanpanah, Y; Yeni, P | 1 |
| Burger, DM; Colbers, AP; Giaquinto, C; Gingelmaier, A; Hawkins, DA; Ivanovic, J; Kabeya, K; Moltó, J; Rockstroh, JK; Sadiq, ST; Taylor, GP; Weizsäcker, K; Wyen, C | 1 |
| Abecasis, AB; Camacho, RJ; Clotet, B; De Luca, A; Grossman, Z; Schülter, E; Snoeck, J; Sönnerborg, A; Struck, D; Theys, K; Torti, C; Vandamme, AM; Vercauteren, J; Zazzi, M | 1 |
| Blevins, S; Dumond, JB; Eron, JJ; Floris-Moore, M; Hudgens, MG; Kashuba, AD; Massengale, K; Pittard, D; Ragan, D; Richardson, A; Walsh, K; Wang, R; Wohl, DA | 1 |
| Craig, C; Fätkenheuer, G; Heera, J; Leal, M; McFadyen, L; Mildvan, D; Mills, A; Podzamczer, D; Portsmouth, S; Rinehart, AR; Than, S; Valdez, H; Valluri, SR; Vourvahis, M | 1 |
| Collier, AC; Daar, ES; Fichtenbaum, CJ; Fink, H; Gerschenson, M; Kosmiski, L; Libutti, DE; McComsey, GA; O'Riordan, M; Santana, JL; Sax, PE | 1 |
| Ananworanich, J; Chomchey, N; Gerschenson, M; Hongchookiat, P; Jadwattanakul, T; Kerr, SJ; Kim, JH; Mathajittiphun, P; Phanuphak, N; Phanuphak, P; Pinyakorn, S; Praihirunyakit, P; Rungrojrat, P; Shikuma, C; Teeratakulpisarn, N; Valcour, V | 1 |
| Bisi, L; Borghi, V; Cossarizza, A; Manzini, L; Mussini, C | 1 |
| Basse, CD; Dia, NM; Dieng, AB; Diop, BM; Diop, SA; Fortes-Déguénonvo, L; Manga, NM; Ndaw, G; Ndour, CT; Seydi, M; Soumaré, M; Sow, PS | 1 |
| Chernoff, MC; Hazra, R; Kopp, JB; Mofenson, LM; Patel, K; Purswani, M; Scott, GB; Seage, GR; Siberry, GK; Van Dyke, RB | 1 |
| Abraham, AG; Anastos, K; Benning, L; Burian, P; Cohen, M; Gandhi, M; Oboho, I; Sharma, A; Szczech, L; Young, M | 1 |
| Lueangniyomkul, A; Mankatitham, W; Manosuthi, S; Manosuthi, W; Nilkamhang, S; Sukasem, C; Sungkanuparph, S; Thongyen, S | 1 |
| Aral, SO; Cates, W | 1 |
| Agrahari, V; Murowchick, JB; Oyler, NA; Youan, BB; Zhang, C; Zhang, T | 1 |
| Ammara, A; Back, D; Boffito, M; Gazzard, B; Jackson, A; Mohabeer, M; Moyle, G; Tjia, J; Watson, V | 1 |
| Cannizzaro, MV; Chimenti, S; Chiricozzi, A; Giunta, A; Nisticò, SP; Saraceno, R | 1 |
| Cattaneo, D; Galli, M; Gervasoni, C; Landonio, S; Meraviglia, P; Riva, A; Rizzardini, G | 1 |
| Armishaw, J; Cameron, PU; Chuah, J; Cooper, DA; Crowe, SM; Fairley, C; Gouillou, M; Hearps, A; Koelsch, KK; Leeansyah, E; Lewin, SR; Liu, JP; Pierce, AB; Smit, de V; Solomon, A; Spelman, T; Tennakoon, S; Velayudham, P | 1 |
| Chan, PA; Huang, A; Kantor, R | 1 |
| Avihingsanon, A; Bowden, S; Dore, GJ; Finlayson, R; Hoy, JF; Lewin, SR; Littlejohn, M; Locarnini, S; Matthews, GV; Revill, PA; Ruxrungtham, K; Sasadeusz, J; Saulynas, M; Seaberg, EC; Thio, CL | 1 |
| Freedberg, KA; Nakamura, YM; Paltiel, AD; Pei, PP; Sax, PE; Schackman, BR; Walensky, RP; Weinstein, MC | 1 |
| Cooper, DA; Craig, C; Goodrich, J; Kaplan, R; Lazzarin, A; Mori, J; Pozniak, A; Pulik, P; Tawadrous, M; Valdez, H; Vernazza, P; Wang, C; Weil, E | 1 |
| Abram, M; Cheng, AK; DeJesus, E; Fordyce, MW; Gathe, J; Henry, K; Molina, JM; Plummer, A; Ramanathan, S; Rockstroh, JK; Szwarcberg, J; Wei, X | 1 |
| Parks, L | 1 |
| Calvez, V; Charpentier, C; Descamps, D; Flandre, P; Fofana, DB; Fourati, S; Lambert-Niclot, S; Marcelin, AG; Masquelier, B; Morand-Joubert, L; Soulié, C; Storto, A; Visseaux, B; Wirden, M | 1 |
| Benson, P; Bredeek, UF; Brinson, C; Campo, R; Dau, L; DeJesus, E; Flaherty, J; Fralich, T; Guyer, B; Henry, K; Khanlou, H; Logue, K; Piontkowsky, D; Wang, H; White, K | 1 |
| Atta, MG; Stokes, MB | 1 |
| Bershteyn, A; Eckhoff, PA | 1 |
| Bigliano, P; Bonora, S; Bramato, C; Calcagno, A; D'Avolio, A; Di Perri, G; Gonzalez de Requena, D; Libanore, V; Motta, I; Orofino, G; Orsucci, E; Salassa, B; Simiele, M; Tettoni, MC | 1 |
| Bumpus, NN; Chen, BA; Gandham, S; Gomez, K; Guddera, V; Hendrix, CW; Hoesley, C; Justman, J; Minnis, AM; Nakabiito, C; Patterson, K; Richardson, BA; Salata, R; Soto-Torres, L | 1 |
| Best, BM; Burchett, SK; Byroads, M; Caparelli, E; Cressey, TR; Hawkins, E; Kreitchmann, R; Mirochnick, M; Rossi, S; Shapiro, DE; Smith, E; Stek, A; Wang, J; Watts, DH | 1 |
| Feinberg, J | 3 |
| Gallant, JE | 1 |
| Prescott, LM | 1 |
| Gazzard, B; Mandalia, S; Pillay, D; Pozniak, A; Winston, A | 1 |
| Shere-Wolfe, KD; Verley, JR | 1 |
| Bates, M; Chappey, C; Hellmann, NS; Maroldo, L; Parkin, N; Petropoulos, CJ | 1 |
| Dieterich, DT | 1 |
| Alcaide, ML; Jayaweera, D; Kolber, M | 1 |
| Díaz, B; González-Lahoz, J; Núñez, M; Pérez-Olmeda, M; Ríos, P; Soriano, V | 1 |
| Aberg, JA; Crippin, J; Kessels, L; Lisker-Melman, M; Powderly, WG; Ristig, MB; Tebas, P | 1 |
| Fung, HB; Piacenti, FJ; Stone, EA | 1 |
| Atkins, M; Barr, A; Bower, M; Fisher, M; Gazzard, B; Matthews, G; Nelson, M; Pillay, D; Portsmouth, S; Stebbing, J | 1 |
| Eagan, L | 1 |
| James, JS | 6 |
| Coca, S; Perazella, MA | 1 |
| Benhamou, Y; Thibault, V; Tubiana, R | 1 |
| Antoniou, T; Park-Wyllie, LY; Tseng, AL | 1 |
| Bruno, R; Ciappina, V; Filice, G; Puoti, M; Sacchi, P; Zocchetti, C | 1 |
| Créput, C; Gonzalez-Canali, G; Hill, G; Kazatchkine, M; Nochy, D; Piketty, C | 1 |
| Brun, S; Di Mascio, M; Ho, DD; Hogan, C; Hurley, A; Louie, M; Markowitz, M; Perelson, AS; Rooney, J; Ruiz, N; Simon, V; Sun, E | 1 |
| Bourgarit, A; Droz, D; Furco, A; Karras, A; Lafaurie, M; Legendre, C; Martinez, F; Molina, JM; Sereni, D | 1 |
| Grim, SA; Romanelli, F | 1 |
| Cheng, A; Isaacson, E; Margot, NA; McGowan, I; Miller, MD | 1 |
| Beijnen, JH; Crommentuyn, KM; Schellens, JH; Sparidans, RW | 1 |
| Chung, C; Coakley, D; Di Mascio, M; Flaherty, J; Hogan, C; Hurley, A; Lamy, P; Louie, M; Markowitz, M; Padte, N; Perelson, AS; Simon, V | 1 |
| Mallal, S; Nolan, D | 1 |
| Callens, S; Colebunders, R; De Schacht, C; Huyst, V | 1 |
| Vere Hodge, A | 1 |
| Chadapaud, S; Hittinger, G; Jolly, P; Lafeuillade, A; Lambry, V; Philip, G | 1 |
| Bassetti, D; Bassetti, M; Ciravegna, BW; Di Biagio, A; Ferrazin, A; Rosso, R | 1 |
| Chapman, T; McGavin, J; Noble, S | 1 |
| Antoniou, T | 1 |
| Kumar, A | 1 |
| Gross, M | 1 |
| Aymard, G; Fernandez, C; Lechat, P; Sentenac, S; Thuillier, A | 1 |
| Kirian, MA; Pecora Fulco, P | 1 |
| Blanchard, JN; Canas, A; King, K; Lonergan, JT; Wohlfeiler, M | 1 |
| Asensi, V; Barrios, A; Dalmau, D; de Mendoza, C; Domingo, P; Estrada, V; Galindo, MJ; Gálvez, J; Martín-Carbonero, L; Ribera, E; Soriano, V | 1 |
| Becker, SL; Bellos, NC; Berger, D; Cheng, A; Coakley, DF; Miller, MD; Pierone, G; Pozniak, AL; Squires, K; Steinhart, CR; Toole, JJ; Wulfsohn, M | 1 |
| Deresinski, S; Gallant, JE | 1 |
| Crippin, J; Drechsler, H; Lisker-Melman, M; Ristig, M; Tebas, P | 1 |
| Lee, JC; Marosok, RD | 1 |
| Dixit, NM; Perelson, AS | 1 |
| Becker, S; Feinberg, J | 1 |
| Brinkman, K; Frissen, PH; Hoogewerf, M; Regez, RM; Schouten, WE; Weigel, HM | 1 |
| Camino, N; Núñez, M; Puoti, M; Soriano, V | 1 |
| Balis, FM; Blanche, S; Bresson, JL; Coakley, DF; DeCarlo, E; Flaherty, JF; Hazra, R; Kearney, BP; Poblenz, M; Steinberg, SM; Tullio, AN; Worrell, CJ; Yale, K; Zeichner, SL; Zhong, L; Zuckerman, JA | 1 |
| DeChristoforo, R; Penzak, SR | 1 |
| Cunningham, CK; McKinney, RE | 1 |
| Boyle, BA | 1 |
| Chen, SS; Cheng, A; Lu, B; Margot, N; Miller, MD; Wulfsohn, M; Zhong, L | 1 |
| Chen, JM; Margot, NA; Miller, MD; Naeger, LK; Petropoulos, CJ; Swaminathan, S; White, KL; Wrin, T | 1 |
| Benhamou, Y | 1 |
| Cheng, AK; Cooper, DA; DeJesus, E; Dore, GJ; Lu, B; Miller, MD; Pozniak, AL; Zhong, L | 1 |
| Lamba, H; Richardson, D | 1 |
| Carter, M | 1 |
| Gazzard, B; Mandalia, S; Nelson, M; Pillay, D; Pozniak, A; Winston, A | 1 |
| Barrios, A; García-Benayas, T; González-Lahoz, J; Soriano, V | 1 |
| Thio, CL | 1 |
| Ala, A; Dieterich, DT | 1 |
| Earle, KE; Seneviratne, T; Shaker, J; Shoback, D | 1 |
| Burger, D; Clotet, B; Grassi, J; Juan, M; Masmitjà, E; Moltó, J; Negredo, E; Paredes, R; Pruvost, A; Puig, J; Ribera, E; Ruiz, L; Viciana, P | 1 |
| Cheng, A; Deray, G; Hulot, JS; Isnard-Bagnis, C; Izzedine, H; Jais, CK; Launay-Vacher, V; Vittecoq, D | 1 |
| Gutiérrez, F; Masiá, M; Padilla, S; Pascual, J; Ramos, JM | 2 |
| Aboulker, JP; Calvez, V; Chazallon, C; Clavel, F; Gérard, L; Girard, PM; Piketty, C; Taburet, AM; Vincent, I | 1 |
| Almond, MR; Liotta, DC; Mao, S; Painter, GR | 1 |
| Gerstoft, J; Katzenstein, TL; Kristiansen, TB; Larsen, K; Laursen, AL; Lerbaek, A; Mathiesen, L; Nielsen, C; Nielsen, JO; Nielsen, SD; Obel, N | 1 |
| Domingo, P; Elías, MJ; Guerro, MF; Labarga, P; Llibre, JM; Palacios, R; Ruiz, MI; Santos, J; Terrón, JA | 1 |
| Agher, R; Calvez, V; Dominguez, S; Duvivier, C; Ghosn, J; Katlama, C; Marcelin, AG; Paris, L; Peytavin, G; Tubiana, R; Valantin, MA; Wirden, M | 1 |
| Flaherty, JF; Kearney, BP; Shah, J | 1 |
| Berger, A; Brodt, HR; Lennemann, TS; Lutz, T; Mösch, M; Staszewski, S; Stephan, C; Stürmer, M | 1 |
| Stebbing, J; Winston, A | 1 |
| Cheng, AK; Coakley, DF; DeJesus, E; Gallant, JE; Lu, B; Miller, MD; Pozniak, AL; Staszewski, S; Suleiman, JM; Toole, JJ | 1 |
| Bocket, L; Brun-Vézinet, F; Costagliola, D; Descamps, D; Ferré, V; Izopet, J; Masquelier, B; Miller, M; Montès, B; Palmer, P; Peytavin, G; Ruffault, A; Schneider, V; Tamalet, C; Trylesinski, A; Wirden, M | 1 |
| Burger, D; Clotet, B; Galindos, MJ; Gel, S; Miralles, C; Moltó, J; Muñoz-Moreno, JA; Negredo, E; Pedrol, E; Puig, J; Ribera, E; Rodriguez Fumaz, C; Rodríguez, E; Ruiz, L; Viciana, P; Videla, S | 1 |
| Benhamou, Y; Cahour, A; Katlama, C; Lada, O; Poynard, T; Thibault, V | 1 |
| Luber, AD; Ruane, PJ | 1 |
| Bates, M; Chappey, C; Clair, MS; Fisher, R; Lanier, ER; Parkin, N; Ross, L; Tisdale, M | 1 |
| Peraire, J; Ribera, E; Richart, C; Sauleda, S; Saumoy, M; Vea, AM; Vidal, F; Viladés, C | 1 |
| Gerstoft, J; Hansen, AB; Mathiesen, S | 1 |
| Alexandre, M; Breton, G; Duval, X; Leport, C; Peytavin, G; Prie, D; Vildei, JL | 1 |
| Harangozo, CS; Korman, TM; Moyle, M; Veitch, AJ; Woolley, IJ | 1 |
| Benhamou, Y; Bonyhay, L | 1 |
| Bini, T; Bongiovanni, M; Cicconi, P; d'Arminio Monforte, A; Melzi, S; Tordato, F | 1 |
| Fung, HB; Guo, Y | 1 |
| Fulco, PP; Higginson, RT; Kirian, MA | 1 |
| Aguero, J; Corral, A; de Mendoza, C; Gallego, O; Martin-Carbonero, L; Soriano, V | 1 |
| Bresson, JL; Chaix, ML; Ghosn, J; Goujard, C; Katlama, C; Peytavin, G; Rey, E; Rouzioux, C; Tréluyer, JM; Viard, JP | 1 |
| Brun-Vézinet, F; Campa, P; Chêne, G; Collin, G; Damond, F; Delaunay, C; Descamps, D; Matheron, S; Peytavin, G; Taieb, A | 1 |
| Ahmad, K | 1 |
| Blum, MR; Kearney, BP; Rousseau, FS; Stevens, RC | 1 |
| Bani-Sadr, F; Molina, JM; Palmer, P; Scieux, C | 1 |
| Gallant, JE; Pham, PA | 2 |
| Cheng, AK; Coakley, DF; Margot, NA; McColl, DJ; Miller, MD; Wulfsohn, M | 1 |
| Heseltine, PN; Kagan, RM; Merigan, TC; Winters, MA | 1 |
| Bassetti, D; Bassetti, M; Briozzo, A; Cruciani, M; Di Biagio, A; Ferrazin, A; Gatti, G; Rosso, R | 1 |
| Berg, T; Bergk, A; Mauss, S; Reinke, P; Schürmann, D; van Bömmel, F; Wiedenmann, B; Wünsche, T | 1 |
| Däumer, M; Kaiser, R; Matz, B; Rockstroh, JK; Schewe, CK; Schildgen, O; Vogel, M; Weitner, L | 1 |
| Corral, A; de Mendoza, C; Martín-Carbonero, L; Soriano, V; Valer, L | 1 |
| Boeri, E; Castagna, A; Clementi, M; Fusetti, G; Galli, A; Gianotti, N; Lazzarin, A; Salpietro, S; Seminari, E | 1 |
| Bower, M; Gazzard, B; Jones, R; Mandalia, S; Moyle, G; Nelson, M; Stebbing, J | 1 |
| Back, D; Boffito, M; Di Perri, G; Gazzard, B; Hill, A; Moyle, G; Nelson, M; Pozniak, A; Stainsby-Tron, M; Tomkins, J | 1 |
| Montes, B; Segondy, M | 1 |
| Anderson, PL; Becker, SL; Kakuda, TN | 1 |
| Berger, F; Mauss, S; Schmutz, G | 1 |
| Berger, F; Gatell, J; Hoffmann, C; Holm, S; Kuhlmann, B; Martínez, E; Mauss, S; Milinkovic, A; Schmutz, G | 1 |
| Ananworanich, J; Hill, A; Hirschel, B; Mahanontharit, A; Ruxrungtham, K; Siangphoe, U | 1 |
| Thompson, M | 1 |
| Blanco, JL; Gatell, JM; Laguno, M; León, A; Mallolas, J; Martinez, E; Pumarola, T | 1 |
| Lyseng-Williamson, KA; Plosker, GL; Reynolds, NA | 1 |
| Frantzen, L; Hannedouche, T; Krummel, T; Lalanne, H; Marcellin, L; Moulin, B; Parvez-Braun, L | 1 |
| Bonn, D | 1 |
| Benhamou, Y; Bonacini, M; Brook, G; Cargnel, A; Puoti, M; Rockstroh, J; Soriano, V; Thio, C | 1 |
| Chaix, ML; Delaugerre, C; Peytavin, G; Roudiere, L; Rouzioux, C; Viard, JP | 1 |
| Bannister, A; Day, SL; Fisher, M; Hankins, M; Leake Date, HA | 1 |
| Cheng, A; Deray, G; Gallant, JE; Hulot, JS; Izzedine, H; Launay-Vacher, V; Staszewski, S; Vittecoq, D | 1 |
| Havlir, DV; Ignacio, CC; Koelsch, KK; Lu, B; Margot, N; Miller, MD; Strain, MC; Wong, JK | 1 |
| Dalmau, D; Ferrer, E; Gatell, JM; Iniguez, D; Knobel, H; Leon, A; Niubo, J; Podzamczer, D; Polo, C; Ruiz, I | 1 |
| Gallant, JE; Keruly, JC; Moore, RD; Parish, MA | 1 |
| Mallal, S; Nolan, D; Reiss, P | 1 |
| Farthing, C; Guyer, B; Khanlou, H; Yeh, V | 1 |
| Barreiro, P; Barrios, A; Blanco, F; Clotet, B; Cooper, D; Domingo, P; Garcia-Benayas, T; Gil, P; Gonzalez-Lahoz, J; Labarga, P; Maida, I; Martín-Carbonero, L; Negredo, E; Núñez, M; Rendón, A; Sambeat, MA; Sánchez-Conde, M; Santos, J; Soriano, V | 1 |
| Coco, J; DeJesus, E; Grinsztejn, B; Johnson, M; Lazzarin, A; Lichtenstein, K; Rightmire, A; Rodriguez, C; Sankoh, S; Wilber, R | 1 |
| Benech, H; Clotet, B; García, E; Grassi, J; Grau, E; Moltó, J; Negredo, E; Pruvost, A; Puig, J; Theodoro, F | 1 |
| Becker, M; Breske, A; Esser, S; Hill, A; Koerber, A; Kopperman, M; Kruse, G; Kurowski, M; Möcklinghoff, C; Ross, B; Stocker, H; Wiehler, H | 1 |
| D'Agostino, C; d'Ettorre, G; Lichtner, M; Massetti, AP; Mastroianni, CM; Vullo, V | 1 |
| Bower, M; Gazzard, B; Mandalia, S; Nelson, M; Tung, MY | 1 |
| Amin, J; Carr, A; Cooper, DA; McAllister, J; Winston, A | 1 |
| Bonmarchand, M; Calvez, V; Conan, F; Kalkias, L; Katlama, C; Kirstetter, M; Marcelin, AG; Paris, L; Simon, A; Tubiana, R; Valantin, MA; Wirden, M | 1 |
| Boelle, PY; Girard, PM; Gozlan, J; Lacombe, K; Serfaty, L; Valleron, AJ; Zoulim, F | 1 |
| Basilico, C; Giola, M; Grossi, P | 1 |
| Bignani, O; Delfraissy, JF; Goujard, C; Harmouche, H; Le Bras, P | 1 |
| Girard, PM; Lacombe, K; Meynard, JL; Pacanowski, J; Trylesinski, A | 1 |
| Boffito, M; Gazzard, B; Hand, J; Maitland, D; Mandalia, S; Moyle, G; Nelson, M | 1 |
| Angel-Moreno-Maroto, A; Hernández-Cabrera, M; Pérez-Arellano, JL; Suárez-Castellano, L | 1 |
| Lange, JM | 1 |
| Mills, EJ; Singh, JA | 1 |
| Clark, N; Guyer, B; Hawkins, T; Kearney, BP; St Claire, RL; Veikley, W | 1 |
| Antoniou, T; Chirhin, S; Gough, K; Govan, V; Loutfy, M; Raboud, J; Rachlis, A; Yoong, D | 1 |
| Brun-Vézinet, F; Collin, G; Delaunay, C; Descamps, D; Flandre, P; Landman, R; Miller, M; Peytavin, G; Trylesinski, A | 1 |
| Gupta, SK | 2 |
| Fine, DM | 1 |
| Brito, MO; Quimby, D | 1 |
| Dupin, N; Jaffray, P; Jullien, V; Krivine, A; Lescoat, A; Lillo-Le Louet, A; Moachon, L; Pons, G; Rey, E; Salmon, D; Tréluyer, JM; Urien, S | 1 |
| Bogner, JR; Crispin, A; Goebel, FD; Jülg, BD | 1 |
| Cánovas, V; Gutiérrez, F; Masiá, M; Orozco, C; Padilla, S | 1 |
| Harris, M; Montaner, JS | 1 |
| Bonjoch, A; Clotet, B; Negredo, E; Paredes, R; Puig, J | 1 |
| Maitland, D; Moyle, GJ; Waters, L | 1 |
| Chadwick, DR; Williams, J | 1 |
| Issa, BG; Parsonage, MJ; Savage, MW; Snowden, N; Wilkins, EG | 1 |
| Barrail, A; Goujard, C; Le Tiec, C; Taburet, AM | 1 |
| Badiou, S; Baillat, V; Cristol, JP; De Boever, CM; Reynes, J; Terrier, N | 1 |
| Biglia, A; Blanco, JL; De Lazzari, E; Gatell, JM; Laguno, M; Larrousse, M; León, A; Lonca, M; Mallolas, J; Martinez, E; Milincovic, A; Pumarola, T | 1 |
| Geerlings, SE; Lange, JM; Prins, JM; van Leth, F | 1 |
| Bulgheroni, E; Cicconi, P; Galli, M; Lo Cicero, M; Rusconi, S; Soster, F; Viganò, O | 1 |
| Buchbinder, S; Cates, W; Clarke, E; Coates, T; Cohen, MS; Delaney, M; Flores, G; Goicochea, P; Gonsalves, G; Grant, RM; Harrington, M; Lama, JR; MacQueen, KM; Moore, JP; Peterson, L; Sanchez, J; Thompson, M; Wainberg, MA | 1 |
| Bartholomeusz, A; Camino, N; Klausen, G; Kuiper, M; Locarnini, S; Lutz, T; Mauss, S; Núñez, M; Rodés, B; Sheldon, J; Soriano, V; Tacke, F | 1 |
| Cawthorne, P; Chua, A; Ford, N; Wilson, D | 1 |
| Ditmore, M | 1 |
| Susman, E | 1 |
| Battegay, M; Cavassini, M; Elzi, L; Furrer, H; Gayet-Ageron, A; Hirschel, B; Karrer, U; Ledergerber, B; Russotti, M; Schmid, P; Speck, RF; Weber, R | 1 |
| Kuritzkes, DR | 1 |
| Berger, DS; Gallant, JE; Johnson, J; Liao, Q; Lim, ML; Rodriguez, AE; Ross, L; Shaefer, MS; Weinberg, WG; Young, B | 1 |
| Bushman, L; Delahunty, T; Fletcher, CV | 1 |
| Berger, A; Bickel, M; Carlebach, A; Klauke, S; Lutz, T; Staszewski, S; Stephan, C; Stuermer, M | 1 |
| Collins, C; Halima, Y | 1 |
| Giacomet, V; Martelli, L; Merlo, M; Mora, S; Sciannamblo, M; Viganò, A | 1 |
| Balis, FM; DeCarlo, E; Flaherty, J; Gafni, RI; Hazra, R; Kearney, BP; Maldarelli, F; Steinberg, SM; Tullio, AN; Worrell, CJ; Yale, K; Zeichner, SL | 1 |
| Asensi, V; Barrios, A; Clotet, B; Domingo, P; Estrada, V; Labarga, P; Morales, D; Negredo, E; Santos, J; Soriano, V | 1 |
| Adam, A; Maserati, R; Schewe, CK; Wassmer, G; Weitner, L | 1 |
| Girault, V | 1 |
| Burger, DM; Droste, JA; Hekster, YA; Kearney, BP | 1 |
| Mills, E | 1 |
| Diaz, RS | 1 |
| de Man, RA; de Vries-Sluijs, TE; Hansen, BE; Osterhaus, AD; van der Eijk, AA; van der Ende, ME | 1 |
| Amin, J; Carr, A; Cooper, DA; Emery, S; Mallon, P; Marriott, D; Winston, A | 1 |
| Arribas, JR; Campo, RE; Cheng, AK; Chuck, S; DeJesus, E; Enejosa, J; Gallant, JE; Gazzard, B; Lu, B; McColl, D; Pozniak, AL; Toole, JJ | 1 |
| Aldrovandi, GM; Beretta, S; Giacomet, V; Luraschi, P; Martelli, L; Merlo, M; Mora, S; Rombolà, G; Viganò, A | 1 |
| Cardellach, F; Casademont, J; Clotet, B; Garrabou, G; Infante, AB; López, S; Miró, O; Negredo, E; Puig, J; Ramos, X; Ruiz, L; Sanjurjo, E | 1 |
| El-Sadr, WM; Eshleman, SH; Gai, F; Hendrix, C; Justman, J; Kwiecien, A; Maslankowski, LA; Mâsse, B; Mayer, KH; Morrow, K; Rooney, JF; Soto-Torres, L | 1 |
| Benhamou, Y; Fleury, H; Katlama, C; Le Teuff, G; Pellegrin, I; Piketty, C; Rozenbaum, W; Trimoulet, P; Trylesinski, A; Urbinelli, R | 1 |
| Coco, J; DeJesus, E; Grinsztejn, B; Johnson, M; Lazzarin, A; Lichtenstein, K; McLaren, C; Odeshoo, L; Rightmire, A; Rodriguez, C; Wirtz, V | 1 |
| Andrade, RA; El Sahly, HM; Hunter, R; Munoz, C; Nnabuife, C; Teeter, L; Zerai, T | 1 |
| Bonjoch, A; Bravo, I; Clotet, B; Heilek-Sneider, GM; Martinez-Picado, J; Moltó, J; Negredo, E; Ruiz, L; Valle, M | 1 |
| Fisher, M; Gazzard, B; Higgs, C; Johnson, M; Mandalia, S; Moyle, G; Nelson, M; Teague, A | 1 |
| Côté, HC; Gadawski, I; Harrigan, PR; Harris, M; Hogg, R; Magil, AB; Montaner, JS; Scarth, BJ; Wang, N; Werb, R; Yip, B; Yu, E; Zalunardo, N | 1 |
| Darder, M; Ford, N | 1 |
| Barreiro, P; Soriano, V | 1 |
| Antinori, A; Bellagamba, R; Bonfigli, S; Boumis, E; Ceccherini-Silberstein, F; Comandini, UV; Concetta Bellocchi, M; D'Arrigo, R; Federico Perno, C; Forbici, F; Lorenzini, P; Marconi, P; Narciso, P; Soldani, F; Tozzi, V; Trotta, MP; Zaccarelli, M | 1 |
| Gazzard, BG | 2 |
| Balestre, E; Boucher, S; Capdepont, S; Dabis, F; Dupon, M; Fleury, H; Masquelier, B; Thiébaut, R | 1 |
| Manfredi, R | 1 |
| Butt, AA | 1 |
| Armon, C; Baker, RK; Holmberg, SD; Moorman, AC; Weidle, PJ; Wood, KC; Young, B | 1 |
| Barreiro, P; Barrios, A; Blanco, F; García-Benayas, T; González-Lahoz, J; Maida, I; Rendón, AL; Rivas, P; Rodríguez-Novóa, S; Soriano, V | 1 |
| Cheng, A; Ebrahimi, R; Kearney, BP; Mittan, A; Ramanathan, S | 1 |
| Aboulker, JP; Calvez, V; Chazallon, C; Clavel, F; Gérard, L; Girard, PM; Madelaine-Chambrin, I; Marcelin, AG; Molina, JM; Piketty, C; Taburet, AM | 1 |
| Andreoni, M; Antinori, A; Bini, T; Bonora, S; Carosi, G; Castagna, A; Di Perri, G; Landonio, S; Merli, S; Nasta, P; Perno, CF; Quirino, T; Tozzi, V; Trotta, MP; Zaccarelli, M | 1 |
| Gottardi, M; Lanzafame, M; Lattuada, E; Rapagna, F; Vento, S | 1 |
| Shepp, DH; Winston, JA | 1 |
| Antunes, F; Chiesi, A; Goebel, FD; Katlama, C; Knysz, B; Ledergerber, B; Lundgren, JD; Mocroft, A; Phillips, AN; Reiss, P | 1 |
| Carr, A | 1 |
| Anderson, PL; Kakuda, TN | 1 |
| Nagy, GS | 1 |
| Hammerstrom, TS; Laessig, KA; Lewis, LL | 1 |
| Alvarez, ML; Domingo, P; Ena, J; Estrada, V; Falcó, V; Moreno, S; Murillas, J; Palacios, R; Santos, J | 1 |
| Amiel, C; Guessant, S; Kara, A; Lebrette, MG; Marechal, Eda S; Pialoux, G; Quercia, R; Renaud, S; Schneider, V; Thevenet, S | 1 |
| Arvieux, C; Dailly, E; Jolliet, P; Perré, P; Raffi, F; Tattevin, P; Tribut, O | 1 |
| Jenny-Avital, ER | 1 |
| Hussain, S; Khayat, A; Rathore, MH; Tolaymat, A | 1 |
| Antela, A; Domingo, P; Llibre, JM; Miralles, C; Moreno, S; Palacios, R; Pérez-Elías, MJ; Sánchez-de la Rosa, R; Santos, J | 1 |
| Forbes, A | 1 |
| Mentré, F; Panhard, X; Piketti, C; Taburet, AM | 1 |
| Lee, WA; Martin, JC | 1 |
| Cha, AE | 1 |
| Piacenti, FJ | 1 |
| Cirino, CM; Kan, VL | 1 |
| Fätkenheuer, G; Lehmann, C; Wyen, C | 1 |
| Croom, KF; Frampton, JE | 1 |
| Gatanaga, H; Genka, I; Honda, M; Kikuchi, Y; Kimura, S; Oka, S; Tachikawa, N; Tanuma, J; Teruya, K; Ueda, A; Yazaki, H | 1 |
| DeCarlo, E; Flaherty, JF; Gafni, RI; Hazra, R; Kearney, BP; Maldarelli, F; Reynolds, JC; Tullio, AN; Worrell, CJ; Yale, K; Zeichner, SL | 1 |
| Cheng, A; Lu, B; Margot, NA; Miller, MD | 1 |
| Baker, RK; Brooks, JT; Buchacz, K; Greenberg, A; Holmberg, SD; Moorman, AC; Tong, T | 1 |
| Shepp, DH; Winston, J | 1 |
| Blaas, S; Glück, T; Salzberger, B; Schneidewind, A | 1 |
| Blanche, S; Delaugerre, C; Jullien, V; Macassa, E; Rouzioux, C; Teglas, JP; Tréluyer, JM; Veber, F | 1 |
| Grant, RM; Levy, V | 1 |
| Alloui, C; Bouhassoune, K; Calboreanu, A; Dény, P; Gordien, E; Legal, F; Podevin, P; Rico-Garcia, M; Salmon-Céron, D; Sogni, P | 1 |
| Grant, RM; Wainberg, MA | 1 |
| Adams, DR; Bashirian, S; Butera, S; Folks, TM; Greenberg, AE; Hudgens, MG; Jackson, E; Janssen, R; Johnson, J; Kim, C; Monsour, M; Otten, RA; Paxton, L; Ramos, A; Rendon, A; Soriano, V; Subbarao, S | 1 |
| Cardellach, F; Casademont, J; Deig, E; Garrabou, G; Infante, AB; López, S; Miró, O; Pedrol, E; Vidal, I | 1 |
| Farthing, C; Khanlou, H | 1 |
| Berg, T; Berger, F; Bruno, R; Carlebach, A; Hoffmann, C; Jaeger, H; Lutz, T; Mauss, S; Nelson, M; Rockstroh, J; Schmutz, G; Schürmann, D; Schwarze-Zander, C; Sheldon, J; Soriano, V; Stoehr, A; von Boemmel, F; Wolf, E | 1 |
| Barreiro, P; Camino, N; Díaz-Pollán, B; González-Lahoz, J; Martín-Carbonero, L; Núñez, M; Ramos, B; Soriano, V | 1 |
| Arribas López, JR; Muñoz de Benito, RM | 1 |
| Laurence, J | 1 |
| Cartledge, J; Churchill, D; Fakoya, A; Hay, P; Johnson, M; Leen, C; Moyle, GJ; Murphy, M; Reilly, G; Sabin, CA; Scullard, G; Wilkins, E | 1 |
| Bernard-Henry, C; Cheneau, C; de Mautort, E; Hess, G; Krebs, M; Lang, JM; Partisani, M; Priester, M; Rey, D | 1 |
| Arribas, JR; Campo, RE; Chen, SS; Cheng, AK; DeJesus, E; Enejosa, J; Gallant, JE; Gazzard, B; McColl, D; Pozniak, AL; Toole, JJ | 1 |
| Alston-Smith, B; Andersen, J; Brosgart, CL; Jacobson, JM; Johnson, VA; Liu, T; Lynch, P; Peters, MG; Pollard, RB; Polsky, B; Rooney, JF; Sherman, KE; Swindells, S | 1 |
| d'Ettorre, G; Mastroianni, CM; Vullo, V | 1 |
| Bongiovanni, M; Tordato, F | 1 |
| Haas, DW; Hulgan, T | 1 |
| Deray, AG; Dominguez, S; Ghosn, J; Goyenvalle, C; Hulot, JS; Izzedine, H; Lechat, P; Valantin, MA; Villard, E | 1 |
| Durantel, S; Girard, PM; Gozlan, J; Lacombe, K; Ollivet, A; Tran, N; Zoulim, F | 1 |
| Bonfanti, P; Carradori, S; De Socio, G; Grosso, C; Madeddu, G; Marconi, P; Melzi, S; Mura, MS; Palvarini, L; Penco, G; Quirino, T; Ricci, E; Rossella, E | 1 |
| Baker, RK; Brooks, JT; Buchacz, K; Chmiel, JS; Moorman, A; Wood, KC; Young, B | 1 |
| Aubron-Olivier, C; Calvez, V; Deray, G; Dominguez, S; Ghosn, J; Izzedine, H; Katlama, C; Ktorza, N; Miller, M; Peytavin, G; Trylesinski, A; Wirden, M | 1 |
| Hester, J; Jain, MK; Lee, WM; Parekh, NK | 1 |
| Cheng, AK; Margot, N; McColl, D; Miller, MD | 1 |
| Barreiro, P; Blanco, F; de Mendoza, C; García-Benayas, T; Gil, P; González-Lahoz, J; Maida, I; Martín-Carbonero, L; Soriano, V | 1 |
| Halima, Y | 1 |
| Best, B; Goicoechea, M | 1 |
| Bogner, JR; Goebel, FD; Jülg, B; Mühlbayer, D; Nelson, PJ; Röling, J; Schlattner, U; Schmid, H; Sternfeld, T; Wallimann, T | 1 |
| Attar, N; Comanor, L; Elkin, C; Jain, MK; Keiser, P; Kipnis, P; Lee, WM; Leung, K; Ocampo, A; White, C | 1 |
| Boucher, S; Fleury, H; Lavignolle-Aurillac, V; Masquelier, B; Neau, D; Ragnaud, JM; Recordon-Pinson, P; Schrive, MH | 1 |
| Gallant, JE; Klotman, PE; Sax, PE | 1 |
| Amoroso, A; Chan-Tack, KM; Kopack, AM; Polk, C | 1 |
| De Munter, P; Schrooten, Y; Van Laethem, K; Van Ranst, M; Van Wijngaerden, E; Vandamme, AM; Verbesselt, R | 1 |
| Bogner, J; Claas, GJ; Goebel, FD; Jülg, B | 1 |
| Ananworanich, J; Chetchotisakd, P; Gayet-Ageron, A; Hirschel, B; Jupimai, T; Le Braz, M; Prasithsirikul, W; Rooney, JF; Ruxrungtham, K; Ubolyam, S | 1 |
| Cihlar, T; Ray, AS | 1 |
| Chappell, BJ; Margot, NA; Miller, MD | 1 |
| Dore, GJ; Matthews, GV | 1 |
| Mertenskoetter, T; Pearce, G; Ranneberg, B | 1 |
| Gulick, RM; Klingman, KL; Koletar, SL; Kuritzkes, DR; Lalama, CM; Pilcher, CD; Reichman, RC; Ribaudo, HJ; Schackman, BR; Schouten, J; Shikuma, CM; Squires, KE | 1 |
| Antinori, A; Antonucci, F; Barreiro, P; Carosi, G; De Silvestri, A; El Hamad, I; Ladisa, N; Lapadula, G; Maggiolo, F; Mandalia, S; Maserati, R; Migliorino, G; Pierotti, P; Sighinolfi, L; Soriano, V; Suter, F; Torti, C | 1 |
| Benech, H; Da Silva, D; Durand-Gasselin, L; Grassi, J; Pruvost, A | 1 |
| Kagan, RM; Lee, TS; Lewinski, MA; Lloyd, RM; Potts, SJ; Ross, L | 1 |
| Maggiolo, F; Ripamonti, D; Suter, F | 1 |
| Anastos, K; Cohen, M; Cole, S; Hessol, NA; Justman, J; Kaplan, RC; Lu, D; Shi, Q; Tien, PC; Vigen, C; Young, M | 1 |
| Ambuhl, P; Huber, M; Keusch, G; Moch, H; Moddel, M; Opravil, M; Pfammatter, R; Schmid, S; Varga, Z; Wuthrich, RP | 1 |
| Gripshover, B; Gupta, S; Hammond, SP; Hatano, H; Hu, Z; Kalayjian, RC; Kuritzkes, DR; Smith, D; Whitcomb, J; Wild, M | 1 |
| El Barkil, M; Gagnieu, MC; Guitton, J | 1 |
| Beniowski, M; Gargalianos, P; Gatell, J; Kirk, O; Lundgren, JD; Mocroft, A; Reiss, P; Staszewski, S; Viard, JP; Zilmer, K | 1 |
| Birnkrant, DB; Chan-Tack, KM; Struble, KA; Truffa, MM | 1 |
| Chaix, ML; Correas, JM; Dhalluin-Venier, V; Mallet, VO; Pol, S; Verkarre, V; Viard, JP | 1 |
| Aboulker, JP; Chazallon, C; Gérard, L; Girard, PM; Piketty, C; Taburet, AM | 1 |
| Buclin, T; Colombo, S; Décosterd, L; Furrer, H; Rotger, M; Telenti, A | 1 |
| Cooper, DA; Dore, GJ; Matthews, GV | 1 |
| Antenozzi, S; Hulse, S; Luque, A; Shahzad, U; Smith, B; Tanzman, E; Wang, D | 1 |
| Bischofberger, N; Chen, SS; Clotet, B; Cooper, DA; Curtis, S; Gazzard, B; Katlama, C; Lange, J; Lazzarin, A; Montaner, JS; Nelson, MR; Rooney, JF; Schewe, K; Smith, S; Wyatt, C | 1 |
| Calvez, V; Chaix, ML; Delaugerre, C; Girard, PM; Katlama, C; Marcelin, AG; Morand-Joubert, L; Soulié, C | 1 |
| Baker, DL; Drevets, DA; Greenfield, RA; Lockhart, SM; Rathbun, RC; Salvaggio, MR; Stephens, JR; Vincent, S | 1 |
| Acosta, EP; Jennings, HC; Parks, DA; Taylor, CW | 1 |
| Bonfanti, P; Carradori, S; De Socio, GV; Grosso, C; Landonio, S; Madeddu, G; Marconi, P; Melzi, S; Miccolis, S; Mura, MS; Penco, G; Quirino, T; Ricci, E; Rosella, E | 1 |
| Baker, RK; Brooks, JT; Buchacz, K; Chmiel, J; Moorman, AC; Wood, KC; Young, B | 1 |
| Mellors, JW; Parikh, UM; Sluis-Cremer, N; Zelina, S | 1 |
| Curtis, S; Rooney, JF; Shepp, DH | 1 |
| Christen, A; Furrer, H; Fux, CA; Mohaupt, MG; Zgraggen, S | 1 |
| Celesia, BM; Massimino, SD; Mavilla, S; Mughini, MT; Nunnari, G; Onorante, A; Russo, R | 1 |
| Garcia-Gasco, P; Sheldon, J; Soriano, V | 1 |
| Arnaiz, JA; Blanco, JL; de Lazzari, E; Garrabou, G; Gatell, JM; Laguno, M; Larrousse, M; Leon, A; Lonca, M; López, S; Mallolas, J; Martinez, E; Milinkovic, A; Miró, O; Vidal, S | 1 |
| Anderson, PL; Aquilante, CL; Bushman, LR; Carten, ML; Delahunty, T; Fletcher, CV; King, TM; Kiser, JJ; Wolfe, P | 1 |
| Cascone, A; Colella, G; Di Martino, F; Filippini, A; Filippini, P; Lanza, A; Martini, S; Masiello, A; Pisapia, R | 1 |
| Acosta, EP; Binongo, JN; Chuck, SK; Lennox, JL; Ofotokun, I; Palau, M | 1 |
| Hope, T; Jaffe, HW; Paxton, LA | 1 |
| Clotet, B; Girard, PM; Negredo, E; Neubacher, D; Youle, M | 1 |
| Brim, NM; Cu-Uvin, S; Hu, SL; O'Bell, JW | 1 |
| Beretta, S; Borgonovo, S; Cafarelli, L; Giacomet, V; Martelli, L; Mora, S; Rombolà, G; Viganò, A; Zuccotti, GV | 1 |
| Ahya, SN; Kanwar, YS; Palella, F; Patel, SM; Zembower, TR | 1 |
| Ball, C; Hawkins, S | 1 |
| Dauer, B; Haberl, A; Harder, S; Klauke, S; Lutz, T; Staszewski, S; von Hentig, N | 1 |
| Bae, AS; Borroto-Esoda, K; Goodman, D; Margot, NA; Miller, MD; Svarovskaia, ES; Waters, JM; Zhong, L | 1 |
| Akumatey, B; Alleman, P; Johnson, L; Lawoyin, T; Macqueen, KM; Nyiama, T | 1 |
| Cabau, J; Gort, A; Planella, R; Roselló, L | 1 |
| Cohen, DE; Golub, SA; Mayer, KH; Rosenthal, L | 1 |
| Daniels, E; Gaglio, PJ; Sterling, R; Tedaldi, E | 1 |
| Ayliffe, U; Dervisevic, S; Garcia-Diaz, A; Geretti, AM; Gilson, R; Johnson, M; Nebbia, G; Smith, C; Tedder, R | 1 |
| Doerr, HW; Staszewski, S; Stürmer, M | 1 |
| Corona, G; Innocenti, F; Sandron, S; Sartor, I; Tirelli, U; Toffoli, G; Vaccher, E | 1 |
| Bridges, AS; Cohen, MS; Corbett, AH; Dumond, JB; Jung, BH; Kashuba, AD; Patterson, KB; Rezk, NL; Stewart, PW; Yeh, RF | 1 |
| Crumpacker, CS; Gilde, LR; Gotuzzo, E; Isaacs, RD; Kovacs, C; Markowitz, M; Mendo, F; Miller, MD; Morales-Ramirez, JO; Nguyen, BY; Prada, G; Ratanasuwan, W; Teppler, H; Wan, H; Wenning, LA | 1 |
| Brenner, BG; Lalonde, R; Micheli, V; Moisi, D; Ntemgwa, M; Oliveira, M; Wainberg, MA | 1 |
| Killingley, B; Pozniak, A | 1 |
| de Silva, TI; Dockrell, DH; Griffin, MD; Post, FA | 1 |
| Abdool Karim, Q; Abdool Karim, SS | 1 |
| Balán, IC; Carballo-Diéguez, A; El-Sadr, W; Gai, F; Hoffman, S; Mantell, JE; Maslankowski, L; Mayer, K; Morrow, K; Rosen, R | 1 |
| Blanchet, F; Duval, X; Essig, M; Gervais, A; Iordache, L; Kaied, FA; Leport, C; Longuet, P; Peytavin, G | 1 |
| Burger, DM; Droste, JA; Lange, JM; Lowe, SH; Prins, JM; Reiss, P; Repping, S; van der Veen, F; van Leeuwen, E | 1 |
| Blanche, S; Dechaux, M; Jullien, V; Papaleo, A; Salomon, R; Veber, F; Warszawski, J | 1 |
| Battegay, M; Bernasconi, E; Bucher, HC; Cavassini, M; Furrer, H; Hasse, B; Hirschel, B; Kaufmann, G; Vernazza, PL; Wolbers, M | 1 |
| Agrofoglio, L; Bénech, H; Negredo, E; Pruvost, A; Théodoro, F | 1 |
| Nelson, R | 1 |
| Chantratitra, W; Kiertiburanakul, S; Manosuthi, W; Sungkanuparph, S | 1 |
| Arribas, JR; Campo, RE; Chen, SS; Cheng, AK; Dejesus, E; Enejosa, J; Gallant, JE; Gazzard, B; Holmes, CB; McColl, D; Pozniak, AL; Toole, JJ | 1 |
| Aldrovandi, GM; Cantrell, RA; Chi, BH; Chintu, N; Kankasa, C; Kruse, G; Mbewe, F; Safrit, JT; Sinkala, M; Stringer, EM; Stringer, JS | 1 |
| Cunningham, CK; Fletcher, CV; Flynn, PM; Harris, DR; Havens, PL; Kapogiannis, BG; Kiser, JJ; Liu, NX; Major-Wilson, H; Muenz, LR; Viani, RM; Wilson, CM | 1 |
| Colson, P; Henry, M; Solas, C; Tamalet, C; Tomei, C; Villacian, J | 1 |
| Deig, E; Pedrol, E | 1 |
| Abeli, C; Antinori, A; Bongiovanni, M; Capetti, A; Castagna, A; Chiesa, E; Cicconi, P; d'Arminio Monforte, A; de Luca, A; di Biagio, A; Gatti, F; Gianotti, N; Marconi, P; Matti, A; Mussini, C; Nasta, P; Tirelli, V; Torti, C; Zaccarelli, M | 1 |
| Bedini, A; Borghi, V; Esposito, R; Mussini, C; Prati, F; Sabbatini, F | 1 |
| Haefeli, WE; Ketabi-Kiyanvash, N; Storch, CH; Weis, N; Weiss, J | 1 |
| Boojamra, CG; Callebaut, C; Cihlar, T; Gao, Y; Hui, H; Lin, KY; Mackman, RL; Ray, AS; Stray, K; Vela, JE; Zhang, L | 1 |
| Barisoni, L; Hynes, P; McMeeking, A; Rabenou, R; Urbina, A | 1 |
| Chen, J; Cooper, DA; Emery, S; Hazuda, DJ; Kelleher, AD; Law, M; Murray, JM; Nguyen, BY; Teppler, H | 1 |
| Ananworanich, J; Chetchotisakd, P; Hirschel, B; Jupimai, T; Klinbuayam, W; Mahanontharit, A; Nüesch, R; Prasithsirikul, W; Ruxrungtham, K; Srasuebkul, P | 1 |
| Cossarizza, A; Dentone, C; Di Biagio, A; Esposito, R; Ferraresi, R; Mussini, C; Nasi, M; Nemes, E; Pinti, M; Repetto, E; Rosso, R; Viscoli, C | 1 |
| Szczech, LA | 1 |
| Best, B; Diamond, C; Goicoechea, M; Haubrich, R; Jain, S; Kemper, C; Liu, S; Louie, S; Sun, S; Witt, M | 1 |
| Bill, R; Cohen, D; Fisher, A; Grasso, C; Mayer, KH; Mimiaga, MJ; Van Derwarker, R | 1 |
| Guillemi, S; Gutiérrez, S; Harrigan, PR; Jahnke, N; Montaner, JS; Montessori, V | 1 |
| Shacklett, BL | 1 |
| Denton, PW; Estes, JD; Garcia, JV; Haase, AT; Othieno, FA; Payne, D; Powell, DA; Sun, Z; Wege, AK; Wei, BL | 1 |
| Bernasconi, E; Bucher, HC; Cavassini, M; Elzi, L; Furrer, H; Fux, CA; Hirschel, B; Opravil, M; Simcock, M; Vernazza, P; Wolbers, M | 1 |
| Carosi, G; Ceresoli, F; Cologni, G; Cossarizza, A; Costarelli, S; Gargiulo, F; Lapadula, G; Magoni, M; Manca, N; Nasi, M; Nichelatti, M; Pinti, M; Quiros-Roldan, ME; Torti, C | 1 |
| Atta, MG; Fine, DM; Lucas, GM; Perazella, MA | 1 |
| Carballo-Diéguez, A; El-Sadr, WM; Gai, F; Hoffman, S; Mantell, JE; Maslankowski, L; Mayer, KH; Morrow, KM; Rosen, RK | 1 |
| Abel, S; Muirhead, GJ; Ridgway, CE; Russell, D; Whitlock, LA | 1 |
| Ananworanich, J; Côté, HC; Hill, A; Hirschel, B; Jupimai, T; Kerr, SJ; Laopraynak, N; Nuesch, R; Ruxrungtham, K; Saenawat, S | 1 |
| Herrera, L; Moreno, S; Sánchez-de la Rosa, R | 1 |
| Ceccarelli, G; D'Ettorre, G; Massetti, AP; Mastroianni, CM; Vullo, V; Zaffiri, L | 1 |
| Gafni, RI; Hazra, R; Purdy, JB; Reynolds, JC; Zeichner, S | 1 |
| Larsen, CS; Lybaek, D | 1 |
| Anderson, PL; Aquilante, CL; Carten, ML; Fletcher, CV; King, TM; Kiser, JJ | 1 |
| Bulgin-Coleman, D; Fath, M; Fontaine, L; Kantor, C; Mieras, J; Pierone, G; Shearer, J | 1 |
| Stephan, C | 1 |
| Barreiro, P; Corral, A; de Mendoza, C; Garrido, C; González-Lahoz, J; Jiménez-Nacher, I; Poveda, E; Soriano, V; Zahonero, N | 1 |
| Calabresi, A; Carosi, G; Costarelli, S; Izzo, I; Lapadula, G; Quiros-Roldan, E; Torti, C | 1 |
| Battegay, M; Bernasconi, E; Böni, J; Bürgisser, P; Cavassini, M; Furrer, H; Günthard, HF; Hirschel, B; Klimkait, T; Ledergerber, B; Rickenbach, M; Vernazza, PL; von Wyl, V; Yerly, S | 1 |
| Carolo, G; Concia, E; Gottardi, M; Lanzafame, M; Lattuada, E; Vento, S | 1 |
| González-Mena, A; Guelar-Grimberg, A; Knobel-Freud, H; Vallecillo-Sánchez, G | 1 |
| Castrillo-Bustamante, C; Hernández-Hernández, JL; Vejo-Puente, E; Velasco-Montes, J | 1 |
| Bonjoch, A; Clotet, B; Domingo, P; Galindo, MJ; Iribarren, J; Llibre, JM; Martinez-Picado, J; Negredo, E; Pérez-Alvarez, N; Schapiro, J | 1 |
| Ayen, R; Bellido, R; Cardellach, F; Clotet, B; Garrabou, G; Lòpez, S; Miró, O; Morén, C; Negredo, E; Puig, J | 1 |
| Beck, TW; Benveniste, RE; Bischofberger, N; Black, R; Follis, KE; Grant, RF; Sabo, A; Tsai, CC | 1 |
| Agatep, E; Berardi, CJ; Bischofberger, N; Cundy, KC; Dehqanzada, ZA; Lifson, JD; Marthas, ML; Pedersen, NC; Van Rompay, KK; Vasquez, GM | 1 |
| Barditch-Crovo, P; Cundy, KC; Deeks, SG; Hellmann, NS; Hwang, F; Kahn, JO; Lietman, PS; Rooney, JF; Safrin, S | 1 |
| Self, SG; Wick, D | 1 |
| Beck, TW; Bischofberger, N; Emau, P; Follis, KE; Morton, WR; Sun, JC; Tran, CA; Tsai, CC | 1 |
| Bischofberger, N; Brown, CR; Buckler-White, A; Endo, Y; Hirsch, V; Igarashi, T; Martin, MA; Plishka, R | 1 |
| Bischofberger, N; Buch, S; Foresman, L; Kumar, A; Lifson, JD; Narayan, O | 1 |
| Cadman, J | 1 |
| Schouten, J | 1 |
| Anton, KE; Cherrington, JM; Fuller, MD; Lamy, PD; Margot, NA; Miller, MD; Mulato, AS | 1 |
| Buckheit, R; Gilbert, H; Margot, N; Miller, M; Palmer, S; Shaw, N | 1 |
| Barditch-Crovo, P; Coakley, DF; Coleman, RL; Collier, A; Deeks, SG; Kahn, JO; Kearney, BP; Lamy, PD; Lietman, PS; McGowan, I; Miller, M; Safrin, S | 1 |
| Gilden, D | 1 |
| Barditch-Crovo, P; Coakley, DF; Collier, A; Deeks, SG; McGowan, I; Miller, M; Smith, A | 1 |
| Huff, B | 1 |
| Schwetz, BA | 1 |
| Thompson, CA | 1 |
| Pujol, G; Williams, K | 1 |
| Giles, C | 1 |
| Polk, B | 1 |
| Cheng, AK; Isaacson, E; Margot, NA; McGowan, I; Miller, MD; Schooley, RT | 1 |
| Beall, G; Berger, D; Chen, SS; Cheng, AK; Isaacson, E; Lampiris, H; Miller, MD; Myers, RA; Ruane, P; Schooley, RT | 1 |
| Huengsberg, M; Palfreeman, A | 1 |
316 review(s) available for tenofovir and HIV Coinfection
| Article | Year |
|---|---|
Renal adverse drug reactions.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Drug-Related Side Effects and Adverse Reactions; HIV Infections; Humans; Tenofovir | 2021 |
Is tenofovir disoproxil fumarate associated with weight loss?
Topics: Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Randomized Controlled Trials as Topic; Tenofovir; Thailand; Weight Loss | 2021 |
Drug-releasing vaginal rings for HIV/STI and pregnancy prevention: a review of recent advances and clinical applications.
Topics: Adolescent; Contraceptive Devices, Female; Female; HIV Infections; Humans; Pharmaceutical Preparations; Pregnancy; Sexually Transmitted Diseases; Tenofovir | 2022 |
Tribute to John C. Martin at the Twentieth Anniversary of the Breakthrough of Tenofovir in the Treatment of HIV Infections.
Topics: Alanine; Anti-HIV Agents; Drug Therapy, Combination; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Hepatitis B; History, 20th Century; History, 21st Century; HIV; HIV Infections; Humans; Pre-Exposure Prophylaxis; Reverse Transcriptase Inhibitors; Tenofovir | 2021 |
Where are the pregnant and breastfeeding women in new pre-exposure prophylaxis trials? The imperative to overcome the evidence gap.
Topics: Anti-HIV Agents; Breast Feeding; Female; HIV Infections; Humans; Pre-Exposure Prophylaxis; Pregnancy; Tenofovir | 2022 |
Tenofovir-induced renal and bone toxicity: report of two cases and literature review.
Topics: Anti-HIV Agents; Female; Hepatitis B; HIV Infections; Humans; Kidney; Kidney Diseases; Middle Aged; Tenofovir | 2022 |
Acquired HIV drug resistance mutations on first-line antiretroviral therapy in Southern Africa: Systematic review and Bayesian evidence synthesis.
Topics: Adult; Anti-Retroviral Agents; Bayes Theorem; Drug Resistance, Viral; Emtricitabine; HIV Infections; HIV-1; Humans; Lamivudine; Mutation; Tenofovir; Viral Load; Zidovudine | 2022 |
Kidney function in tenofovir disoproxil fumarate-based oral pre-exposure prophylaxis users: a systematic review and meta-analysis of published literature and a multi-country meta-analysis of individual participant data.
Topics: Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Kidney; Pre-Exposure Prophylaxis; Tenofovir | 2022 |
Metabolic Consequences of Antiretroviral Therapy.
Topics: Alanine; Anti-HIV Agents; Female; Glucose; HIV Infections; HIV Integrase Inhibitors; Humans; Tenofovir; Weight Gain | 2022 |
The best backbone for HIV prevention, treatment, and elimination: Emtricitabine+tenofovir.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Emtricitabine; HIV Infections; HIV-1; Humans; Male; Tenofovir | 2022 |
Increased viral load in a hospitalized patient on treatment with crushed bictegravir/emtricitabine/tenofovir alafenamide: A case report and review of the literature.
Topics: Adenine; Adult; Alanine; Amides; Anti-HIV Agents; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Male; Piperazines; Pyridones; Tenofovir; Viral Load | 2022 |
Oral pre-exposure prophylaxis (PrEP) to prevent HIV: a systematic review and meta-analysis of clinical effectiveness, safety, adherence and risk compensation in all populations.
Topics: Anti-HIV Agents; Emtricitabine; Female; HIV Infections; Humans; Male; Pre-Exposure Prophylaxis; Tenofovir; Treatment Outcome | 2022 |
The future of long-acting agents for preexposure prophylaxis.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Emtricitabine; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir | 2022 |
Safety of oral tenofovir disoproxil - emtricitabine for HIV preexposure prophylaxis in adults.
Topics: Adult; Anti-HIV Agents; Emtricitabine; Female; HIV Infections; Humans; Middle Aged; Pre-Exposure Prophylaxis; Tenofovir | 2022 |
How could HIV-1 drug resistance impact preexposure prophylaxis for HIV prevention?
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Broadly Neutralizing Antibodies; Drug Resistance; Emtricitabine; HIV Infections; HIV-1; Humans; Pre-Exposure Prophylaxis; Tenofovir | 2022 |
The Italian PrEPventHIV challenge: a scoping systematic review on HIV pre-exposure prophylaxis monitoring in Italy.
Topics: Anti-HIV Agents; Emtricitabine; Female; HIV Infections; Homosexuality, Male; Humans; Male; Pre-Exposure Prophylaxis; Sexual and Gender Minorities; Tenofovir | 2022 |
Cabotegravir: The First Long-Acting Injectable for HIV Preexposure Prophylaxis.
Topics: Anti-HIV Agents; Emtricitabine; Female; HIV Infections; Humans; Male; Tenofovir | 2023 |
Risks and benefits of oral HIV pre-exposure prophylaxis for people with chronic hepatitis B.
Topics: Antiviral Agents; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Pre-Exposure Prophylaxis; Risk Assessment; Tenofovir | 2022 |
Anti-retroviral drugs induced photosensitivity may be two culprits in mixed formulation, a case report and literature review.
Topics: Benzoxazines; Female; HIV Infections; Humans; Photochemotherapy; Tenofovir | 2022 |
Assessment of Adherence to Clinical Guidelines in Patients with Chronic Hepatitis B.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis B, Chronic; Hepatitis C; HIV Infections; Humans; Liver Neoplasms; Retrospective Studies; Tenofovir; Treatment Outcome | 2022 |
Two-drug regimens for HIV treatment.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Drug Therapy, Combination; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Tenofovir | 2022 |
Cell and Tissue Specific Metabolism of Nucleoside and Nucleotide Drugs: Case Studies and Implications for Precision Medicine.
Topics: Acyclovir; Antiviral Agents; Ganciclovir; HIV Infections; Humans; Nucleosides; Nucleotides; Precision Medicine; Tenofovir | 2023 |
Substance Use and Adherence to HIV Pre-Exposure Prophylaxis in Studies Enrolling Men Who Have Sex with Men and Transgender Women: A Systematic Review.
Topics: Anti-HIV Agents; Female; HIV Infections; Homosexuality, Male; Humans; Male; Medication Adherence; Pre-Exposure Prophylaxis; Prospective Studies; Sexual and Gender Minorities; Substance-Related Disorders; Tenofovir; Transgender Persons | 2023 |
Effectiveness and safety of tenofovir alafenamide in children and adolescents living with HIV: a systematic review.
Topics: Adenine; Adolescent; Anti-HIV Agents; Child; Emtricitabine; HIV Infections; HIV-1; Humans; Infant; Tenofovir | 2023 |
PrEP for women in Europe: a systematic literature review.
Topics: Anti-HIV Agents; Emtricitabine; Female; HIV Infections; Homosexuality, Male; Humans; Male; Pre-Exposure Prophylaxis; Pregnancy; Sexual and Gender Minorities; Tenofovir | 2023 |
Treatment failure and associated factors among people living with HIV on highly active antiretroviral therapy in mainland China: A systematic review and meta-analysis.
Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; China; Cross-Sectional Studies; HIV Infections; Humans; Tenofovir; Treatment Failure | 2023 |
Efficacy and safety of long-acting cabotegravir versus oral tenofovir disoproxil fumarate-emtricitabine as HIV pre-exposure prophylaxis: A systematic review and meta-analysis.
Topics: Anti-HIV Agents; Creatinine; Emtricitabine; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir | 2023 |
Antivirals for prevention of hepatitis B virus mother-to-child transmission in human immunodeficiency virus positive pregnant women co-infected with hepatitis B virus.
Topics: Antiviral Agents; Coinfection; DNA, Viral; Emtricitabine; Female; Hepatitis B e Antigens; Hepatitis B virus; HIV; HIV Infections; HIV Seropositivity; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Pregnancy; Pregnant Women; Ritonavir; Tenofovir; Zidovudine | 2023 |
Drug-induced liver injury secondary to increased levonorgestrel exposure in a patient taking ritonavir.
Topics: Adult; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Darunavir; Female; HIV Infections; Humans; Levonorgestrel; Ritonavir; Tenofovir | 2023 |
Increased human immunodeficiency virus viral load with cerebral infarction due to varicella zoster virus vasculopathy on treatment with bictegravir/emtricitabine/tenofovir alafenamide suspension: a case report and literature review.
Topics: Anti-HIV Agents; Cerebral Infarction; Drug Combinations; Emtricitabine; Herpesvirus 3, Human; Heterocyclic Compounds, 3-Ring; HIV; HIV Infections; Humans; Male; Middle Aged; Tenofovir; Viral Load | 2023 |
Pharmacokinetics of Antiretroviral Drugs in Older People Living with HIV: A Systematic Review.
Topics: Adenine; Adolescent; Aged; Anti-HIV Agents; Anti-Retroviral Agents; Darunavir; HIV Infections; Humans; Pharmaceutical Preparations; Raltegravir Potassium; Tenofovir; Young Adult | 2023 |
Adherence to Oral Pre-Exposure Prophylaxis Intervention by Transgender Women: A Systematic Review.
Topics: Anti-HIV Agents; Female; HIV Infections; Homosexuality, Male; Humans; Male; Medication Adherence; Pre-Exposure Prophylaxis; Sexual and Gender Minorities; Tenofovir; Transgender Persons | 2023 |
Biktarvy for the treatment of HIV infection: Progress and prospects.
Topics: Adenine; Anti-HIV Agents; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Pyridones; Tenofovir | 2023 |
Post-exposure prophylaxis to prevent HIV: new drugs, new approaches, and more questions.
Topics: Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Post-Exposure Prophylaxis; Pre-Exposure Prophylaxis; Tenofovir | 2023 |
Assessing bone mineral density in children and adolescents living with HIV and on treatment with tenofovir disoproxil fumarate: a systematic review.
Topics: Adenine; Adolescent; Bone Density; Child; HIV; HIV Infections; Humans; Tenofovir | 2023 |
Pre-exposure prophylaxis 2.0: new drugs and technologies in the pipeline.
Topics: Adenine; Administration, Cutaneous; Administration, Oral; Alanine; Contraceptive Devices, Female; Delayed-Action Preparations; Deoxyadenosines; Emtricitabine; Female; HIV Infections; Humans; Incidence; Male; Medication Adherence; Pre-Exposure Prophylaxis; Tenofovir | 2019 |
Mosaic effectiveness: measuring the impact of novel PrEP methods.
Topics: Administration, Oral; Anti-HIV Agents; Clinical Trials as Topic; Combined Modality Therapy; Delayed-Action Preparations; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir; Treatment Outcome | 2019 |
PrEP 1.0 and Beyond: Optimizing a Biobehavioral Intervention.
Topics: Anti-HIV Agents; Behavioral Risk Factor Surveillance System; Cognitive Behavioral Therapy; Drug Therapy, Combination; Emtricitabine; Health Promotion; HIV Infections; Humans; Pre-Exposure Prophylaxis; Sexual Behavior; Social Stigma; Tenofovir | 2019 |
Tenofovir Urine Assay to Monitor Adherence to HIV Pre-exposure Prophylaxis.
Topics: Alanine; Anti-HIV Agents; Chromatography, High Pressure Liquid; HIV Infections; Humans; Mass Spectrometry; Medication Adherence; Pre-Exposure Prophylaxis; Tenofovir | 2020 |
Human Immunodeficiency Virus-1 Viral Load Is Elevated in Individuals With Reverse-Transcriptase Mutation M184V/I During Virological Failure of First-Line Antiretroviral Therapy and Is Associated With Compensatory Mutation L74I.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure; Viral Load | 2020 |
Bictegravir, a novel integrase inhibitor for the treatment of HIV infection.
Topics: Adenine; Alanine; Amides; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV Integrase Inhibitors; Humans; Piperazines; Pyridones; Tenofovir | 2019 |
Clinical pharmacology of the single tablet regimen bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF).
Topics: Adenine; Amides; Anti-HIV Agents; Clinical Trials as Topic; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Piperazines; Pyridones; Tablets; Tenofovir | 2019 |
Emerging evidence from a systematic review of safety of pre-exposure prophylaxis for pregnant and postpartum women: where are we now and where are we heading?
Topics: Adult; Anti-HIV Agents; Breast Feeding; Female; HIV Infections; HIV-1; Humans; Postnatal Care; Pre-Exposure Prophylaxis; Pregnancy; Pregnancy Complications, Infectious; Tenofovir; Young Adult | 2020 |
HIV-related nephropathy: new aspects of an old paradigm.
Topics: Acute Kidney Injury; AIDS-Associated Nephropathy; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Chronic Disease; HIV Infections; Humans; Kidney; Risk Factors; Tenofovir | 2020 |
Bone Update: Is It Still an Issue Without Tenofovir Disoproxil Fumarate?
Topics: Adolescent; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone and Bones; Bone Density; Child; Female; Fractures, Bone; HIV Infections; Humans; Osteoporosis; Risk Factors; Tenofovir | 2020 |
Efficacy and safety of the regimens containing tenofovir alafenamide versus tenofovir disoproxil fumarate in fixed-dose single-tablet regimens for initial treatment of HIV-1 infection: A meta-analysis of randomized controlled trials.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; CD4 Lymphocyte Count; HIV Infections; HIV Seropositivity; HIV-1; Humans; Kidney; Randomized Controlled Trials as Topic; Tablets; Tenofovir | 2020 |
The potential role of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) single-tablet regimen in the expanding spectrum of fixed-dose combination therapy for HIV.
Topics: Adenine; Alanine; Anti-HIV Agents; CD4 Lymphocyte Count; Comorbidity; Drug Combinations; Emtricitabine; Equivalence Trials as Topic; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Piperazines; Pyridones; Risk Factors; Socioeconomic Factors; Tablets; Tenofovir | 2020 |
Tenofovir alafenamide use in pregnant and lactating women living with HIV.
Topics: Adenine; Alanine; Anti-HIV Agents; Female; HIV Infections; Humans; Lactation; Pregnancy; Pregnancy Complications, Infectious; Randomized Controlled Trials as Topic; Tenofovir | 2020 |
Update on HIV prevention and preexposure prophylaxis.
Topics: Adenine; Antiviral Agents; Emtricitabine; Female; HIV Infections; Humans; Male; Physician Assistants; Pre-Exposure Prophylaxis; Primary Health Care; Tenofovir; Treatment Outcome | 2020 |
HIV Preexposure Prophylaxis Among Adolescents in the US: A Review.
Topics: Adolescent; Anti-HIV Agents; Female; HIV Infections; Humans; Male; Pre-Exposure Prophylaxis; Surveys and Questionnaires; Tenofovir; United States; Young Adult | 2020 |
Approaches to Objectively Measure Antiretroviral Medication Adherence and Drive Adherence Interventions.
Topics: Adenine; Adult; Anti-HIV Agents; Emtricitabine; Female; Hair; HIV Infections; Humans; Leukocytes, Mononuclear; Male; Medication Adherence; Monitoring, Ambulatory; Organophosphates; Pre-Exposure Prophylaxis; Tenofovir; Viral Load | 2020 |
Point-of-care and Near Real-time Testing for Antiretroviral Adherence Monitoring to HIV Treatment and Prevention.
Topics: Anti-HIV Agents; Counseling; Female; HIV Infections; Humans; Medication Adherence; Point-of-Care Systems; Pre-Exposure Prophylaxis; Public Health; Tenofovir | 2020 |
Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain; Acyclic Monoterpenes; Adenine Nucleotides; Adhesins, Escherichia coli; Adipocytes; Adipocytes, Brown; Adipogenesis; Administration, Inhalation; Administration, Oral; Adrenal Cortex Hormones; Adsorption; Adult; Aeromonas hydrophila; Africa; Aged; Aged, 80 and over; Agrobacterium tumefaciens; Air; Air Pollutants; Air Pollution; Air Pollution, Indoor; Algorithms; Alkaloids; Alkynes; Allosteric Regulation; Amines; Amino Acid Sequence; Amino Acids; Amino Acids, Branched-Chain; Aminoisobutyric Acids; Aminopyridines; Amyotrophic Lateral Sclerosis; Anaerobic Threshold; Angiography; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animal Distribution; Animal Feed; Animal Nutritional Physiological Phenomena; Animals; Ankle Joint; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Inflammatory Agents; Antibodies, Bacterial; Antifungal Agents; Antimalarials; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antioxidants; Antiretroviral Therapy, Highly Active; Antiviral Agents; Aotidae; Apelin; Apoptosis; Arabidopsis Proteins; Argentina; Arginine; Artemisinins; Arthritis, Experimental; Arthritis, Rheumatoid; Arthroscopy; Aspergillus; Aspergillus niger; Asteraceae; Asthma; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; Auditory Cortex; Autoantibodies; Autophagy; Bacteria; Bacterial Infections; Bacterial Proteins; Bacterial Typing Techniques; Base Composition; Base Sequence; Basketball; Beclin-1; Benzhydryl Compounds; Benzimidazoles; Benzo(a)pyrene; Benzofurans; Benzoxazines; Bereavement; beta Catenin; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Betacoronavirus; Betaine; Binding Sites; Biofilms; Biological Assay; Biological Availability; Biological Evolution; Biomarkers; Biomechanical Phenomena; Biopolymers; Biopsy; Bismuth; Blood Glucose; Blood Platelets; Blood Pressure; Body Composition; Body Weight; Bone Marrow; Bone Marrow Cells; Bone Regeneration; Boron; Botrytis; Brain Ischemia; Brain Neoplasms; Brain-Derived Neurotrophic Factor; Brazil; Breast Neoplasms; Breath Tests; Bronchoalveolar Lavage Fluid; Burkholderia; C-Reactive Protein; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Calcification, Physiologic; Calcium; Calcium Signaling; Calorimetry, Differential Scanning; Cameroon; Camptothecin; Candida; Candida albicans; Capillaries; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Carbohydrate Conformation; Carbon; Carbon Dioxide; Carbon Isotopes; Carcinoma, Ovarian Epithelial; Cardiac Output; Cardiomyopathy, Hypertrophic; Cardiotonic Agents; Cardiovascular Diseases; Caregivers; Carps; Case-Control Studies; Catalase; Catalysis; Cats; CD4 Lymphocyte Count; Cell Culture Techniques; Cell Differentiation; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Survival; Cells, Cultured; Cellulose; Centrosome; Ceratopogonidae; Chickens; Child; China; Cholera Toxin; Choline; Cholinesterases; Chromatography, High Pressure Liquid; Chromatography, Liquid; Chromatography, Micellar Electrokinetic Capillary; Chromatography, Reverse-Phase; Chronic Disease; Cinnamates; Cities; Citrates; Climate Change; Clinical Trials, Phase III as Topic; Coal; Coal Mining; Cohort Studies; Coinfection; Colchicine; Colony Count, Microbial; Colorectal Neoplasms; Coloring Agents; Common Cold; Complement Factor H; Computational Biology; Computer Simulation; Continuous Positive Airway Pressure; Contrast Media; Coordination Complexes; Coronary Artery Bypass; Coronavirus 3C Proteases; Coronavirus Infections; Coronavirus Protease Inhibitors; Corynebacterium glutamicum; Cosmetics; COVID-19; Creatinine; Cross-Sectional Studies; Crotonates; Crystallography, X-Ray; Cues; Culicidae; Culture Media; Curcuma; Cyclopentanes; Cyclopropanes; Cymbopogon; Cystine; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Cytokines; Databases, Genetic; Death; Dendritic Cells; Density Functional Theory; Depsides; Diabetes Mellitus, Type 2; Diamond; Diarylheptanoids; Dibenzofurans; Dibenzofurans, Polychlorinated; Diclofenac; Diet; Dietary Carbohydrates; Dietary Supplements; Diffusion Magnetic Resonance Imaging; Dioxins; Diphenylamine; Disease Outbreaks; Disease Susceptibility; Disulfides; Dithiothreitol; Dizocilpine Maleate; DNA Methylation; DNA-Binding Proteins; DNA, Bacterial; Dogs; Dose-Response Relationship, Drug; Double-Blind Method; Doublecortin Protein; Drosophila melanogaster; Droughts; Drug Carriers; Drug Combinations; Drug Delivery Systems; Drug Liberation; Drug Resistance; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Dust; Dynactin Complex; Dysferlin; Echo-Planar Imaging; Echocardiography; Edaravone; Egypt; Elasticity; Electrodes; Electrolytes; Emodin; Emtricitabine; Endometriosis; Endothelium, Vascular; Endotoxins; Energy Metabolism; Energy Transfer; Enterobacteriaceae; Enterococcus faecalis; Enterotoxigenic Escherichia coli; Environmental Monitoring; Enzyme Inhibitors; Epidemiologic Factors; Epigenesis, Genetic; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Vaccines; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Esterases; Esterification; Ethanol; Ethiopia; Ethnicity; Eucalyptus; Evidence-Based Practice; Exercise; Exercise Tolerance; Extracorporeal Membrane Oxygenation; Family; Fatty Acids; Feedback; Female; Ferric Compounds; Fibrin Fibrinogen Degradation Products; Filtration; Fish Diseases; Flavonoids; Flavonols; Fluorodeoxyglucose F18; Follow-Up Studies; Food Microbiology; Food Preservation; Forests; Fossils; Free Radical Scavengers; Freund's Adjuvant; Fruit; Fungi; Gallium; Gender Identity; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Genes, Bacterial; Genes, Plant; Genetic Predisposition to Disease; Genitalia; Genotype; Glomerulonephritis, IGA; Glottis; Glucocorticoids; Glucose; Glucuronides; Glutathione Transferase; Glycogen Synthase Kinase 3 beta; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Grassland; Guinea Pigs; Half-Life; Head Kidney; Heart Atria; Heart Rate; Heart Septum; HEK293 Cells; Hematopoietic Stem Cells; Hemodynamics; Hep G2 Cells; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Hepatocytes; Hesperidin; High-Frequency Ventilation; High-Temperature Requirement A Serine Peptidase 1; Hippocampus; Hirudins; History, 20th Century; History, 21st Century; HIV Infections; Homeostasis; Hominidae; Housing, Animal; Humans; Hydrocarbons, Brominated; Hydrogen Bonding; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydroxybutyrates; Hydroxyl Radical; Hypertension; Hypothyroidism; Image Interpretation, Computer-Assisted; Immunoconjugates; Immunogenic Cell Death; Indoles; Infant, Newborn; Infant, Premature; Infarction, Middle Cerebral Artery; Inflammation; Inflammation Mediators; Infrared Rays; Inhibitory Concentration 50; Injections, Intravenous; Interferon-gamma; Interleukin-23; Interleukin-4; Interleukin-6; Intermediate Filaments; Intermittent Claudication; Intestine, Small; Iridoid Glucosides; Iridoids; Iron; Isomerism; Isotope Labeling; Isoxazoles; Itraconazole; Kelch-Like ECH-Associated Protein 1; Ketoprofen; Kidney Failure, Chronic; Kinetics; Klebsiella pneumoniae; Lactams, Macrocyclic; Lactobacillus; Lactulose; Lakes; Lamivudine; Laparoscopy; Laparotomy; Laryngoscopy; Leucine; Limit of Detection; Linear Models; Lipid A; Lipopolysaccharides; Listeria monocytogenes; Liver; Liver Cirrhosis; Logistic Models; Longitudinal Studies; Losartan; Low Back Pain; Lung; Lupinus; Lupus Erythematosus, Systemic; Machine Learning; Macular Degeneration; Madin Darby Canine Kidney Cells; Magnetic Phenomena; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Magnetics; Malaria, Falciparum; Male; Mannans; MAP Kinase Signaling System; Mass Spectrometry; Melatonin; Membrane Glycoproteins; Membrane Proteins; Meniscectomy; Menisci, Tibial; Mephenytoin; Mesenchymal Stem Cells; Metal Nanoparticles; Metal-Organic Frameworks; Methionine; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Mice, Obese; Mice, Transgenic; Microbial Sensitivity Tests; Microcirculation; MicroRNAs; Microscopy, Video; Microtubules; Microvascular Density; Microwaves; Middle Aged; Minimally Invasive Surgical Procedures; Models, Animal; Models, Biological; Models, Molecular; Models, Theoretical; Molecular Docking Simulation; Molecular Structure; Molecular Weight; Morus; Mouth Floor; Multicenter Studies as Topic; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Muscle, Skeletal; Myocardial Ischemia; Myocardium; NAD; NADP; Nanocomposites; Nanoparticles; Naphthols; Nasal Lavage Fluid; Nasal Mucosa; Neisseria meningitidis; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasms, Experimental; Neural Stem Cells; Neuroblastoma; Neurofilament Proteins; Neurogenesis; Neurons; New York; NF-E2-Related Factor 2; NF-kappa B; Nicotine; Nitriles; Nitrogen; Nitrogen Fixation; North America; Observer Variation; Occupational Exposure; Ochrobactrum; Oils, Volatile; Olea; Oligosaccharides; Omeprazole; Open Field Test; Optimism; Oregon; Oryzias; Osmolar Concentration; Osteoarthritis; Osteoblasts; Osteogenesis; Ovarian Neoplasms; Ovariectomy; Oxadiazoles; Oxidation-Reduction; Oxidative Stress; Oxygen; Ozone; p38 Mitogen-Activated Protein Kinases; Pakistan; Pandemics; Particle Size; Particulate Matter; Patient-Centered Care; Pelargonium; Peptides; Perception; Peripheral Arterial Disease; Peroxides; Pets; Pharmaceutical Preparations; Pharmacogenetics; Phenobarbital; Phenols; Phenotype; Phosphates; Phosphatidylethanolamines; Phosphines; Phospholipids; Phosphorus; Phosphorylation; Photoacoustic Techniques; Photochemotherapy; Photosensitizing Agents; Phylogeny; Phytoestrogens; Pilot Projects; Plant Components, Aerial; Plant Extracts; Plant Immunity; Plant Leaves; Plant Oils; Plants, Medicinal; Plasmodium berghei; Plasmodium falciparum; Platelet Activation; Platelet Function Tests; Pneumonia, Viral; Poaceae; Pogostemon; Poloxamer; Poly I; Poly(ADP-ribose) Polymerase Inhibitors; Polychlorinated Biphenyls; Polychlorinated Dibenzodioxins; Polycyclic Compounds; Polyethylene Glycols; Polylysine; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Population Dynamics; Portasystemic Shunt, Transjugular Intrahepatic; Positron Emission Tomography Computed Tomography; Postoperative Complications; Postprandial Period; Potassium Cyanide; Predictive Value of Tests; Prefrontal Cortex; Pregnancy; Prepulse Inhibition; Prevalence; Procalcitonin; Prodrugs; Prognosis; Progression-Free Survival; Proline; Proof of Concept Study; Prospective Studies; Protein Binding; Protein Conformation; Protein Domains; Protein Folding; Protein Multimerization; Protein Sorting Signals; Protein Structure, Secondary; Proton Pump Inhibitors; Protozoan Proteins; Psychometrics; Pulse Wave Analysis; Pyridines; Pyrrolidines; Quality of Life; Quantum Dots; Quinoxalines; Quorum Sensing; Radiopharmaceuticals; Rain; Random Allocation; Randomized Controlled Trials as Topic; Rats; Rats, Sprague-Dawley; Rats, Wistar; RAW 264.7 Cells; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Receptor, PAR-1; Receptors, CXCR4; Receptors, Estrogen; Receptors, Glucocorticoid; Receptors, Interleukin-1; Receptors, Interleukin-17; Receptors, Notch; Recombinant Fusion Proteins; Recombinant Proteins; Reducing Agents; Reflex, Startle; Regional Blood Flow; Regression Analysis; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Tract Diseases; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Risk Assessment; Risk Factors; Rituximab; RNA, Messenger; RNA, Ribosomal, 16S; ROC Curve; Rosmarinic Acid; Running; Ruthenium; Rutin; Sarcolemma; Sarcoma; Sarcopenia; Sarcoplasmic Reticulum; SARS-CoV-2; Scavenger Receptors, Class A; Schools; Seasons; Seeds; Sequence Analysis, DNA; Severity of Illness Index; Sex Factors; Shock, Cardiogenic; Short Chain Dehydrogenase-Reductases; Signal Transduction; Silver; Singlet Oxygen; Sinusitis; Skin; Skin Absorption; Small Molecule Libraries; Smoke; Socioeconomic Factors; Soil; Soil Microbiology; Solid Phase Extraction; Solubility; Solvents; Spain; Spectrometry, Mass, Electrospray Ionization; Spectroscopy, Fourier Transform Infrared; Speech; Speech Perception; Spindle Poles; Spleen; Sporothrix; Staphylococcal Infections; Staphylococcus aureus; Stereoisomerism; Stomach Neoplasms; Stress, Physiological; Stroke Volume; Structure-Activity Relationship; Substrate Specificity; Sulfonamides; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Rate; T-Lymphocytes, Cytotoxic; Tandem Mass Spectrometry; Temperature; Tenofovir; Terpenes; Tetracycline; Tetrapleura; Textiles; Thermodynamics; Thiobarbituric Acid Reactive Substances; Thrombin; Thyroid Hormones; Thyroid Neoplasms; Tibial Meniscus Injuries; Time Factors; Tissue Distribution; Titanium; Toluidines; Tomography, X-Ray Computed; Tooth; Tramadol; Transcription Factor AP-1; Transcription, Genetic; Transfection; Transgender Persons; Translations; Treatment Outcome; Triglycerides; Ubiquinone; Ubiquitin-Specific Proteases; United Kingdom; United States; Up-Regulation; Vascular Stiffness; Veins; Ventricular Remodeling; Viral Load; Virulence Factors; Virus Replication; Vitis; Voice; Voice Quality; Wastewater; Water; Water Pollutants, Chemical; Water-Electrolyte Balance; Weather; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Young Adult; Zoogloea | 2022 |
Lamivudine/Tenofovir Disoproxil Fumarate is an Appropriate PrEP Regimen.
Topics: Administration, Oral; Anti-HIV Agents; HIV Infections; Homosexuality; Humans; Lamivudine; Pre-Exposure Prophylaxis; Tenofovir | 2020 |
Tenofovir alafenamide vs. tenofovir disoproxil fumarate: an updated meta-analysis of 14 894 patients across 14 trials.
Topics: Adenine; Alanine; Anti-HIV Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; HIV Infections; Humans; Randomized Controlled Trials as Topic; Tenofovir | 2020 |
Same-day prescribing of daily oral pre-exposure prophylaxis for HIV prevention.
Topics: Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Drug Prescriptions; Emtricitabine; Female; HIV; HIV Infections; Humans; Male; Practice Patterns, Physicians'; Pre-Exposure Prophylaxis; Safe Sex; Tenofovir; United States | 2021 |
A Bayesian averted infection framework for PrEP trials with low numbers of HIV infections: application to the results of the DISCOVER trial.
Topics: Adenine; Anti-HIV Agents; Bayes Theorem; Emtricitabine; Equivalence Trials as Topic; HIV Infections; Humans; Outcome Assessment, Health Care; Pre-Exposure Prophylaxis; Sample Size; Tenofovir | 2020 |
A review of reported cases of HIV pre-exposure prophylaxis failure with resultant breakthrough HIV infections.
Topics: Anti-HIV Agents; HIV Infections; Homosexuality, Male; Humans; Male; Medication Adherence; Pre-Exposure Prophylaxis; Tenofovir | 2021 |
Risks of metabolic syndrome and diabetes with integrase inhibitor-based therapy.
Topics: Alanine; Anti-HIV Agents; Diabetes Mellitus; HIV Infections; HIV Integrase Inhibitors; Humans; Metabolic Syndrome; Tenofovir; Weight Gain | 2021 |
Primary HIV-1 infection in users of pre-exposure prophylaxis.
Topics: Emtricitabine; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; HIV Seropositivity; HIV-1; Humans; Pre-Exposure Prophylaxis; Tenofovir; Viral Load | 2021 |
Risk of adverse coronavirus disease 2019 outcomes for people living with HIV.
Topics: CD4 Lymphocyte Count; COVID-19; HIV Infections; Humans; Tenofovir; Viral Load | 2021 |
Risks of metabolic syndrome and diabetes with integrase inhibitor-based therapy: Republication.
Topics: Diabetes Mellitus; HIV Infections; HIV Integrase Inhibitors; Humans; Metabolic Syndrome; Tenofovir | 2021 |
Evaluating the combination of emtricitabine/ tenofovir alafenamide fumarate to reduce the risk of sexually acquired HIV-1-infection in at-risk adults.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Emtricitabine; Female; Fumarates; HIV Infections; HIV-1; Humans; Male; Tenofovir | 2021 |
Topical microbicides for preventing sexually transmitted infections.
Topics: Acrylic Resins; Adenine; Administration, Intravaginal; Agaricales; Anti-HIV Agents; Anti-Infective Agents, Local; Bias; Cellulose; Female; HIV Infections; Humans; Naphthalenesulfonates; Placebos; Polymers; Pyrimidines; Seaweed; Sexually Transmitted Diseases; Tenofovir | 2021 |
Impact of Integrase inhibitors and tenofovir alafenamide on weight gain in people with HIV.
Topics: Alanine; Anti-HIV Agents; HIV Infections; HIV Integrase Inhibitors; Humans; Tenofovir; Weight Gain | 2021 |
What's new in bone disease and fractures in HIV?
Topics: Anti-HIV Agents; Bone Density; Bone Diseases, Metabolic; Fractures, Bone; HIV Infections; Humans; Tenofovir | 2021 |
Safety of Tenofovir Disoproxil Fumarate for Pregnant Women Facing the Coronavirus Disease 2019 Pandemic.
Topics: Adult; Anti-HIV Agents; Antiviral Agents; Cohort Studies; COVID-19; COVID-19 Drug Treatment; Female; HIV Infections; Humans; Pandemics; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Pregnant Women; Reverse Transcriptase Inhibitors; SARS-CoV-2; Tenofovir | 2021 |
Tenofovir Alafenamide for HIV Prevention: Review of the Proceedings from the Gates Foundation Long-Acting TAF Product Development Meeting.
Topics: Adenine; Adolescent; Alanine; Animals; Anti-HIV Agents; Female; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir | 2021 |
Weight Change Following Antiretroviral Therapy Switch in People With Viral Suppression: Pooled Data from Randomized Clinical Trials.
Topics: Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Prospective Studies; Randomized Controlled Trials as Topic; Tenofovir | 2021 |
The effectiveness of tenofovir-based pre-exposure prophylaxis for prevention of HIV acquisition among sub-Saharan African women at high risk: a systematic review.
Topics: Africa South of the Sahara; Anti-HIV Agents; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; HIV Infections; Humans; Medication Adherence; Pre-Exposure Prophylaxis; Randomized Controlled Trials as Topic; Tenofovir | 2021 |
Prevalence and factors associated with SARS-CoV-2 seropositivity in the Spanish HIV Research Network Cohort.
Topics: Adult; Anti-HIV Agents; COVID-19; Cross-Sectional Studies; Emtricitabine; Female; HIV Infections; Humans; Male; Prevalence; Reverse Transcriptase Inhibitors; Seroepidemiologic Studies; Spain; Tenofovir | 2021 |
The predicted risk of adverse pregnancy outcomes as a result of treatment-associated obesity in a hypothetical population receiving tenofovir alafenamide/emtricitabine/dolutegravir, tenofovir disoproxil fumarate/emtricitabine/dolutegravir or tenofovir dis
Topics: Alanine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Obesity; Oxazines; Piperazines; Pregnancy; Pregnancy Outcome; Pyridones; Tenofovir | 2021 |
Tenofovir alafenamide nephrotoxicity: a case report and literature review.
Topics: Adenine; Alanine; Anti-HIV Agents; Emtricitabine; Female; HIV Infections; Humans; Middle Aged; Tenofovir | 2021 |
The future of pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) infection.
Topics: Administration, Intravaginal; Anti-HIV Agents; Clinical Trials as Topic; Contraceptive Devices, Female; Drug Administration Schedule; Drug Combinations; Drugs, Investigational; Emtricitabine; Female; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Male; Pre-Exposure Prophylaxis; Reverse Transcriptase Inhibitors; Tenofovir | 2017 |
Offering pre-exposure prophylaxis for HIV prevention to pregnant and postpartum women: a clinical approach.
Topics: Anti-HIV Agents; Counseling; Emtricitabine; Female; HIV Infections; Humans; Lactation; Male; Postpartum Period; Pre-Exposure Prophylaxis; Pregnancy; Tenofovir | 2017 |
A cost-savings analysis of a candidate universal antiretroviral regimen.
Topics: Adenine; Anti-HIV Agents; Drug Combinations; Drugs, Generic; Drugs, Investigational; Emtricitabine; HIV Infections; Humans; Tenofovir | 2017 |
Candidates for inclusion in a universal antiretroviral regimen: tenofovir alafenamide.
Topics: Adenine; Alanine; Anti-HIV Agents; HIV Infections; HIV-1; Humans; Male; Prodrugs; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir | 2017 |
Compatibility of next-generation first-line antiretrovirals with rifampicin-based antituberculosis therapy in resource limited settings.
Topics: Adenine; Alanine; Alkynes; Anti-Retroviral Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug Interactions; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Oxazines; Piperazines; Pyridones; Rifampin; Tenofovir | 2017 |
The ADVANCE study: a groundbreaking trial to evaluate a candidate universal antiretroviral regimen.
Topics: Adenine; Anti-HIV Agents; Drug Combinations; HIV Infections; Humans; Randomized Controlled Trials as Topic; Tenofovir | 2017 |
A Review of the Efficacy and Safety of Genvoya® (Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide) in the Management of HIV-1 Infection.
Topics: Anti-HIV Agents; Clinical Trials, Phase III as Topic; Cobicistat; Diarrhea; Disease Management; Drug Combinations; Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Emtricitabine; Headache; HIV Infections; HIV-1; Humans; Nausea; Quinolones; Randomized Controlled Trials as Topic; Tenofovir; Treatment Outcome | 2018 |
Antiretroviral dose optimization: the future of efavirenz 400 mg dosing.
Topics: Adenine; Alkynes; Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Dose-Response Relationship, Drug; HIV Infections; Humans; Organophosphonates; Tenofovir; Treatment Outcome | 2017 |
Safety of oral tenofovir disoproxil fumarate-based HIV pre-exposure prophylaxis use in lactating HIV-uninfected women.
Topics: Administration, Oral; Animals; Anti-HIV Agents; Breast Feeding; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Infant; Infant, Newborn; Lactation; Pre-Exposure Prophylaxis; Tenofovir | 2017 |
Tenofovir for Prevention of HIV Infection.
Topics: Anti-HIV Agents; HIV Infections; Humans; Tenofovir | 2017 |
Kidney Disease in HIV: Moving beyond HIV-Associated Nephropathy.
Topics: AIDS-Associated Nephropathy; Anti-Retroviral Agents; Apolipoprotein L1; Apolipoproteins; HIV Infections; Humans; Kidney Transplantation; Lipoproteins, HDL; Renal Insufficiency, Chronic; Risk Factors; Tenofovir | 2017 |
The Vaginal Microbiome and its Potential to Impact Efficacy of HIV Pre-exposure Prophylaxis for Women.
Topics: Anti-HIV Agents; Dysbiosis; Female; HIV Infections; Humans; Microbiota; Pre-Exposure Prophylaxis; Randomized Controlled Trials as Topic; Tenofovir; Vagina | 2017 |
Factors Contributing to the Antiviral Effectiveness of Tenofovir.
Topics: Animals; Anti-HIV Agents; Antiviral Agents; Drug Delivery Systems; HIV Infections; Humans; Tenofovir; Treatment Outcome; Viral Load; Virus Replication | 2017 |
Antiretroviral therapy for pregnant women living with HIV or hepatitis B: a systematic review and meta-analysis.
Topics: Adult; Anti-Retroviral Agents; Drug Combinations; Emtricitabine; Female; Hepatitis B; HIV Infections; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Ritonavir; Tenofovir; Young Adult; Zidovudine | 2017 |
The microbiome and HIV prevention strategies in women.
Topics: Anti-Retroviral Agents; Female; Gardnerella vaginalis; HIV Infections; Humans; Microbiota; Pre-Exposure Prophylaxis; Pyrimidines; Tenofovir; Treatment Failure; Vagina; Vaginosis, Bacterial | 2018 |
Raltegravir Once-Daily Tablet: A Review in HIV-1 Infection.
Topics: Adult; Anti-HIV Agents; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Raltegravir Potassium; Tablets; Tenofovir | 2017 |
An update on the treatment options for HBV/HCV coinfection.
Topics: Anti-HIV Agents; Antiviral Agents; Coinfection; Guanine; Hepatitis C; HIV Infections; Humans; Tenofovir | 2017 |
Tenofovir disoproxil fumarate as pre-exposure prophylaxis for HIV prevention in women with osteoporosis: a case report and review of the literature.
Topics: Anti-HIV Agents; Biomarkers; Female; Follow-Up Studies; HIV Infections; Humans; Medication Adherence; Middle Aged; Osteoporosis; Patient Outcome Assessment; Pre-Exposure Prophylaxis; Tenofovir | 2018 |
Role of tenofovir alafenamide (TAF) in the treatment and prophylaxis of HIV and HBV infections.
Topics: Adenine; Alanine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir; Treatment Outcome | 2018 |
Potential kidney toxicity from the antiviral drug tenofovir: new indications, new formulations, and a new prodrug.
Topics: Adenine; Alanine; Antiviral Agents; Bone Density; Drug Interactions; Glomerular Filtration Rate; Hepatitis B; HIV Infections; Humans; Kidney Diseases; Pre-Exposure Prophylaxis; Prodrugs; Tenofovir | 2018 |
In what circumstances could nondaily preexposure prophylaxis for HIV substantially reduce program costs?
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-HIV Agents; Disease Transmission, Infectious; Female; Health Care Costs; HIV Infections; Humans; Male; Middle Aged; Pre-Exposure Prophylaxis; Pregnancy; Tenofovir; Young Adult | 2018 |
Noncommunicable diseases in adolescents with perinatally acquired HIV-1 infection in high-income and low-income settings.
Topics: Adolescent Health; Anti-HIV Agents; HIV Infections; HIV-1; Humans; Income; Noncommunicable Diseases; Tenofovir | 2018 |
The Influence of Cervicovaginal Microbiota on Mucosal Immunity and Prophylaxis in the Battle against HIV.
Topics: Africa South of the Sahara; Anti-HIV Agents; Cervix Uteri; Female; HIV; HIV Infections; Humans; Immunity, Mucosal; Lactobacillus; Microbiota; Pre-Exposure Prophylaxis; Tenofovir; Vagina | 2018 |
Fixed dose darunavir boosted with cobicistat combined with emtricitabine and tenofovir alafenamide fumarate.
Topics: Anti-HIV Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Darunavir; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Randomized Controlled Trials as Topic; Tenofovir | 2018 |
HIV Preexposure Prophylaxis: A Review.
Topics: Anti-HIV Agents; Disease Transmission, Infectious; Drug Combinations; Emtricitabine; HIV Infections; Humans; Pre-Exposure Prophylaxis; Risk Factors; Tenofovir | 2018 |
Continued Interest and Controversy: Vitamin D in HIV.
Topics: Anti-HIV Agents; Bone Density; Dietary Supplements; Female; HIV; HIV Infections; Humans; Male; Risk; Tenofovir; Vitamin D; Vitamin D Deficiency | 2018 |
Weighing the Evidence of Efficacy of Oral PrEP for HIV Prevention in Women in Southern Africa.
Topics: Administration, Oral; Africa, Southern; Anti-HIV Agents; Disease Transmission, Infectious; Female; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir; Treatment Outcome | 2018 |
Pre-exposure Prophylaxis for HIV Infection in the Older Patient: What can be Recommended?
Topics: Aged; Aged, 80 and over; Anti-HIV Agents; Drug Interactions; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Middle Aged; Pre-Exposure Prophylaxis; Tenofovir; Treatment Outcome | 2018 |
Bictegravir.
Topics: Adenine; Amides; Anti-HIV Agents; Clinical Trials, Phase III as Topic; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Oxazines; Piperazines; Pyridones; Tenofovir | 2018 |
Dolutegravir and rilpivirine for the maintenance treatment of virologically suppressed HIV-1 infection.
Topics: Anti-HIV Agents; Drug Interactions; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Oxazines; Piperazines; Pyridones; Randomized Controlled Trials as Topic; Rilpivirine; Tenofovir | 2018 |
The averted infections ratio: a novel measure of effectiveness of experimental HIV pre-exposure prophylaxis agents.
Topics: Anti-HIV Agents; Drug Therapy, Combination; Emtricitabine; Health Services Accessibility; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir; Treatment Outcome | 2018 |
Pharmacology of Antiretrovirals in the Female Genital Tract for HIV Prevention.
Topics: Anti-HIV Agents; Emtricitabine; Female; Genitalia, Female; Gonadal Steroid Hormones; HIV Infections; Humans; Microbiota; Pre-Exposure Prophylaxis; Tenofovir | 2018 |
Darunavir for the treatment of HIV infection.
Topics: Adenine; Clinical Trials as Topic; Cobicistat; Darunavir; Drug Therapy, Combination; Emtricitabine; Half-Life; HIV Infections; HIV Protease Inhibitors; Humans; Tenofovir; Treatment Outcome | 2018 |
Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection.
Topics: Adenine; Alanine; Anti-HIV Agents; Bone Density; Cobicistat; Darunavir; Dose-Response Relationship, Drug; Drug Therapy, Combination; Emtricitabine; Genes, MDR; HIV Infections; HIV-1; Humans; Renal Reabsorption; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2018 |
Dual antiretroviral therapy with tenofovir (TDF) and darunavir/ritonavir (DRV/RTV) in an HIV-1 positive patient: a case report, review, and meta-analysis of the literature on dual treatment strategies using protease inhibitors in combination with an NRTI.
Topics: Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Darunavir; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Time Factors; Treatment Outcome; Viral Load | 2018 |
The pharmacokinetics, pharmacodynamics, and clinical role of fixed dose combination of tenofovir disoproxil fumarate, lamivudine and reduced dose efavirenz (TLE-400) in treating HIV-1 infection.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dose-Response Relationship, Drug; Drug Combinations; HIV Infections; HIV-1; Humans; Lamivudine; Tenofovir | 2018 |
Lamivudine plus tenofovir combination therapy versus lamivudine monotherapy for HBV/HIV coinfection: a meta-analysis.
Topics: Alanine Transaminase; Antiviral Agents; Coinfection; Drug Therapy, Combination; Hepatitis B; Hepatitis B e Antigens; HIV Infections; Humans; Lamivudine; RNA, Viral; Tenofovir; Treatment Outcome | 2018 |
Tolerability of Current Antiretroviral Single-Tablet Regimens
Topics: Adenine; Alanine; Anti-Retroviral Agents; Cobicistat; Darunavir; Drug Combinations; Emtricitabine; HIV Infections; Humans; Tablets; Tenofovir | 2018 |
Doravirine: First Global Approval.
Topics: Anti-HIV Agents; Drug Approval; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Pyridones; Reverse Transcriptase Inhibitors; Tablets; Tenofovir; Triazoles | 2018 |
Comparative effectiveness of anti-viral drugs with dual activity for treating hepatitis B and HIV co-infected patients: a network meta-analysis.
Topics: Adenine; Adult; Aged; Antiviral Agents; Coinfection; Emtricitabine; Female; Hepatitis B; Hepatitis B virus; HIV; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Network Meta-Analysis; Organophosphonates; Tenofovir; Treatment Outcome; Young Adult | 2018 |
Global and national guidance for the use of pre-exposure prophylaxis during peri-conception, pregnancy and breastfeeding.
Topics: Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Breast Feeding; Drug Therapy, Combination; Female; Global Health; HIV Infections; Humans; Middle Aged; Practice Guidelines as Topic; Pre-Exposure Prophylaxis; Preconception Care; Pregnancy; Pregnancy Complications, Infectious; Tenofovir | 2018 |
Community and activists demand for tenofovir/emtricitabine or lamivudine/dolutegravir and routine viral load testing.
Topics: Anti-HIV Agents; Drug Monitoring; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Residence Characteristics; Tenofovir; Viral Load | 2019 |
Darunavir-cobicistat-emtricitabine-tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era.
Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Drug Combinations; Emtricitabine; HIV; HIV Infections; Humans; Protease Inhibitors; Randomized Controlled Trials as Topic; Tenofovir | 2018 |
Getting pre-exposure prophylaxis (PrEP) to the people: opportunities, challenges and emerging models of PrEP implementation.
Topics: Administration, Oral; Anti-HIV Agents; Emtricitabine; Health Equity; Health Services Accessibility; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir | 2018 |
Going global: the adoption of the World Health Organization's enabling recommendation on oral pre-exposure prophylaxis for HIV.
Topics: Administration, Oral; Anti-HIV Agents; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Practice Guidelines as Topic; Pre-Exposure Prophylaxis; Tenofovir; World Health Organization | 2018 |
An evaluation of elvitegravir plus cobicistat plus tenofovir alafenamide plus emtricitabine as a single-tablet regimen for the treatment of HIV in children and adolescents.
Topics: Adenine; Adolescent; Alanine; Anti-HIV Agents; Child; Cobicistat; Emtricitabine; HIV Infections; Humans; Quinolones; Tablets; Tenofovir; United States; United States Food and Drug Administration | 2019 |
Genetic variation of kinases and activation of nucleotide analog reverse transcriptase inhibitor tenofovir.
Topics: Antiretroviral Therapy, Highly Active; Genetic Variation; HIV; HIV Infections; Humans; Reverse Transcriptase Inhibitors; Tenofovir | 2019 |
Bictegravir in a fixed-dose tablet with emtricitabine and tenofovir alafenamide for the treatment of HIV infection: pharmacology and clinical implications.
Topics: Adenine; Alanine; Amides; Animals; Anti-HIV Agents; Drug Combinations; Drug Interactions; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Piperazines; Pyridones; Tablets; Tenofovir | 2019 |
A Review of Telehealth Innovations for HIV Pre-Exposure Prophylaxis (PrEP).
Topics: Anti-HIV Agents; Continuity of Patient Care; Cost-Benefit Analysis; Emtricitabine; HIV Infections; Humans; Male; Mobile Applications; Pre-Exposure Prophylaxis; Primary Health Care; Telemedicine; Tenofovir | 2019 |
Fifty Years in Search of Selective Antiviral Drugs.
Topics: Acyclovir; Antiviral Agents; DNA Virus Infections; DNA Viruses; HIV; HIV Infections; Humans; Molecular Structure; Tenofovir; Valacyclovir | 2019 |
Drug Resistance During HIV Pre-Exposure Prophylaxis.
Topics: Animals; Anti-HIV Agents; Anti-Retroviral Agents; Drug Resistance, Viral; Emtricitabine; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir | 2019 |
Planning HIV therapy to prevent future comorbidities: patient years for tenofovir alafenamide.
Topics: Adenine; Age Factors; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Clinical Trials as Topic; Comorbidity; Disease Management; Drug-Related Side Effects and Adverse Reactions; HIV Infections; Humans; Life Style; Tenofovir; Treatment Outcome | 2019 |
Antiretroviral agents in pre-exposure prophylaxis: emerging and advanced trends in HIV prevention.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Emtricitabine; HIV Infections; HIV-1; Humans; Infectious Disease Transmission, Vertical; Pre-Exposure Prophylaxis; Tenofovir | 2019 |
Tenofovir-associated kidney disease in Africans: a systematic review.
Topics: Africa; Anti-HIV Agents; HIV Infections; Humans; Kidney; Kidney Diseases; Renal Insufficiency; Tenofovir | 2019 |
Implementation Strategies to Increase PrEP Uptake in the South.
Topics: Anti-HIV Agents; Emtricitabine; Epidemics; HIV Infections; Homosexuality, Male; Humans; Male; Mass Screening; Medication Adherence; Patient Protection and Affordable Care Act; Pre-Exposure Prophylaxis; Safe Sex; Sexual and Gender Minorities; Social Stigma; Telemedicine; Tenofovir; United States | 2019 |
Preexposure Prophylaxis for the Prevention of HIV Infection: Evidence Report and Systematic Review for the US Preventive Services Task Force.
Topics: Administration, Oral; Anti-Retroviral Agents; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Male; Medication Adherence; Pre-Exposure Prophylaxis; Risk; Tenofovir | 2019 |
Current and Future PrEP Medications and Modalities: On-demand, Injectables, and Topicals.
Topics: Administration, Topical; Adult; Anti-HIV Agents; Anti-Infective Agents; Contraceptive Devices, Female; Emtricitabine; Female; HIV Infections; Homosexuality, Male; Humans; Injections; Male; Pre-Exposure Prophylaxis; Sexual and Gender Minorities; Tenofovir | 2019 |
Antiretroviral Effects on HBV/HIV Co-infection and the Natural History of Liver Disease.
Topics: Anti-Retroviral Agents; Coinfection; Disease Progression; DNA, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Liver Cirrhosis; Male; Prevalence; Prognosis; Risk Assessment; Survival Analysis; Tenofovir; Treatment Outcome | 2019 |
Pre-Exposure Prophylaxis for HIV Prevention in Women: Current Status and Future Directions.
Topics: Anti-HIV Agents; Emtricitabine; Female; HIV Infections; Homosexuality, Male; Humans; Male; Pre-Exposure Prophylaxis; Risk-Taking; Sexual and Gender Minorities; Tenofovir | 2019 |
HIV pre-exposure prophylaxis for adolescent girls and young women in Africa: from efficacy trials to delivery.
Topics: Adolescent; Anti-HIV Agents; Female; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir; Young Adult | 2019 |
Virologically suppressed HIV-infected patients on TDF-containing regimens significantly benefit from switching to TAF-containing regimens: A meta-analysis of randomized controlled trials.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; HIV Infections; HIV-1; Humans; Randomized Controlled Trials as Topic; Tenofovir; Treatment Outcome | 2019 |
Guides concerning tenofovir exposure via breastfeeding: A comparison of drug dosages by developmental stage.
Topics: Animals; Anti-HIV Agents; Antiviral Agents; Female; Hepatitis B; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Male; Milk, Human; Pregnancy; Pregnancy Complications, Infectious; Tenofovir | 2019 |
Emtricitabine/tenofovir disoproxil fumarate: a review of its use in HIV-1 pre-exposure prophylaxis.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Patient Acceptance of Health Care; Randomized Controlled Trials as Topic; Safe Sex; Sexual Behavior; Sexuality; Tenofovir | 2013 |
Use of antiretrovirals for HIV prevention: what do we know and what don't we know?
Topics: Adenine; Administration, Oral; Administration, Topical; Anti-HIV Agents; Chemoprevention; Female; HIV Infections; Humans; Male; Medication Adherence; Organophosphonates; Randomized Controlled Trials as Topic; Risk Reduction Behavior; Sexual Behavior; Tenofovir | 2013 |
Preexposure prophylaxis for HIV prevention: where have we been and where are we going?
Topics: Adenine; Administration, Oral; Anti-HIV Agents; Deoxycytidine; Drug Combinations; Emtricitabine; HIV Infections; Humans; Medication Adherence; Organophosphonates; Risk Factors; Tenofovir | 2013 |
Bone health in children and adolescents with perinatal HIV infection.
Topics: Adenine; Adolescent; Anti-HIV Agents; Bone Density; Bone Diseases; Child; HIV Infections; Humans; Organophosphonates; Prevalence; Tenofovir | 2013 |
Viral hepatitis and HIV: update and management.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Antiviral Agents; Coinfection; Drug Therapy, Combination; Guanine; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Organophosphonates; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; Tenofovir | 2013 |
[Pre-exposure prophylaxis for the prevention of sexual HIV transmission; new preventative strategy using tenofovir/emtricitabine].
Topics: Adenine; Anti-HIV Agents; Chemoprevention; Deoxycytidine; Emtricitabine; HIV Infections; Humans; Netherlands; Organophosphonates; Patient Compliance; Risk-Taking; Sexual Behavior; Tenofovir | 2013 |
Suppression of HBV by tenofovir in HBV/HIV coinfected patients: a systematic review and meta-analysis.
Topics: Adenine; Anti-HIV Agents; Coinfection; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Organophosphonates; Tenofovir | 2013 |
Hepatitis B in HIV-infected patients.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Coinfection; Drug Resistance, Viral; Hepatitis B Vaccines; Hepatitis B, Chronic; Hepatitis D; HIV Infections; Humans; Lamivudine; Organophosphonates; Tenofovir | 2013 |
EFV/FTC/TDF-associated hepatotoxicity: a case report and review.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Cyclopropanes; Deoxycytidine; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Liver; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Viral Load | 2013 |
Single-tablet regimens in HIV: does it really make a difference?
Topics: Adenine; Anti-HIV Agents; Carbamates; Cobicistat; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Humans; Nitriles; Organophosphonates; Pyrimidines; Quinolones; Reverse Transcriptase Inhibitors; Rilpivirine; Tablets; Tenofovir; Thiazoles | 2014 |
Safety of tenofovir during pregnancy for the mother and fetus: a systematic review.
Topics: Adenine; Animals; Female; Fetal Development; HIV Infections; Humans; Infant, Newborn; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Tenofovir | 2013 |
Antiretroviral therapy, immune suppression and renal impairment in HIV-positive persons.
Topics: Adenine; Anti-Retroviral Agents; HIV Infections; Humans; Immunosuppression Therapy; Kidney Diseases; Organophosphonates; Protease Inhibitors; Tenofovir | 2014 |
[Mechanism of action and pharmacokinetics of rilpivirine].
Topics: Adenine; Adult; Aged; Animals; Anti-HIV Agents; Biological Availability; Child; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Deoxycytidine; Drug Administration Routes; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Emtricitabine; Food-Drug Interactions; Half-Life; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Intestinal Absorption; Molecular Structure; Nanoparticles; Nitriles; Organophosphonates; Proton Pump Inhibitors; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; Tenofovir | 2013 |
Systemic preexposure prophylaxis for HIV: translating clinical data to clinical practice.
Topics: Adenine; Anti-HIV Agents; Cost-Benefit Analysis; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Incidence; Medication Adherence; Organophosphonates; Risk Reduction Behavior; Safe Sex; Tenofovir | 2014 |
Effects of hormonal contraception on antiretroviral drug metabolism, pharmacokinetics and pharmacodynamics.
Topics: Adenine; Anti-HIV Agents; Contraception; Contraceptives, Oral, Hormonal; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Deoxycytidine; Drug Interactions; Emtricitabine; Family Planning Services; Female; HIV Infections; HIV-1; Humans; Organophosphonates; Pregnancy; Progestins; Tenofovir; Treatment Outcome | 2014 |
Tenofovir, emtricitabine, and darunavir/ritonavir pharmacokinetics in an HIV-infected patient after Roux-en-Y gastric bypass surgery.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Darunavir; Deoxycytidine; Emtricitabine; Gastric Bypass; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Ritonavir; Sulfonamides; Tenofovir | 2014 |
An overview of antiretroviral pre-exposure prophylaxis of HIV infection.
Topics: Adenine; Anti-HIV Agents; Cyclohexanes; Drug Resistance, Viral; Female; HIV Infections; Humans; Male; Maraviroc; Medication Adherence; Nitriles; Organophosphonates; Pre-Exposure Prophylaxis; Pyridones; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; Tenofovir; Triazoles | 2014 |
Advances in the treatment of hepatitis B virus/hepatitis C virus coinfection.
Topics: Adenine; Antiviral Agents; Coinfection; DNA, Viral; Drug Therapy, Combination; Guanine; Hepacivirus; Hepatitis B; Hepatitis B virus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Organophosphonates; Ribavirin; RNA, Viral; Tenofovir; Virus Replication | 2014 |
Tenofovir-induced nephrotoxicity: incidence, mechanism, risk factors, prognosis and proposed agents for prevention.
Topics: Adenine; Animals; Anti-HIV Agents; HIV Infections; Humans; Incidence; Kidney Diseases; Organophosphonates; Reverse Transcriptase Inhibitors; Risk Factors; Tenofovir | 2014 |
Virological efficacy of abacavir: systematic review and meta-analysis.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Dideoxynucleosides; Emtricitabine; HIV Infections; Humans; Lamivudine; Organophosphonates; Randomized Controlled Trials as Topic; Tenofovir; Treatment Outcome | 2014 |
Pre-exposure prophylaxis of HIV: A right way to go or a long way to go?
Topics: Anti-HIV Agents; Cost-Benefit Analysis; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Male; Patient Compliance; Pre-Exposure Prophylaxis; Randomized Controlled Trials as Topic; Risk-Taking; Sexual Behavior; Tenofovir; Treatment Outcome | 2016 |
48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Lipids; Lopinavir; Nitriles; Organophosphonates; Oxazines; Piperazines; Pyridones; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Randomized Controlled Trials as Topic; Rilpivirine; Ritonavir; Tenofovir; Time Factors; Treatment Outcome; Viral Load | 2014 |
Review of tenofovir use in HIV-infected children.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Bone and Bones; Child; Child, Preschool; Drug Utilization; Drug-Related Side Effects and Adverse Reactions; HIV Infections; Humans; Kidney; Organophosphonates; Tenofovir; Young Adult | 2015 |
Microbicides and their potential as a catalyst for multipurpose sexual and reproductive health technologies.
Topics: Adenine; Anti-HIV Agents; Anti-Infective Agents; Female; Gels; HIV Infections; Humans; Male; Organophosphonates; Reproductive Health; Tenofovir; Women's Health | 2014 |
Emtricitabine/rilpivirine/tenofovir disoproxil fumarate single-tablet regimen: a review of its use in HIV infection.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Humans; Nitriles; Organophosphonates; Pyrimidines; Rilpivirine; Tablets; Tenofovir | 2014 |
Oral preexposure prophylaxis to prevent HIV infection: clinical and public health implications.
Topics: Anti-HIV Agents; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Incidence; Male; Medication Adherence; Public Health; Risk Factors; Risk Reduction Behavior; Safe Sex; Tenofovir; United States; Vulnerable Populations | 2014 |
Antiretroviral drugs for prevention of mother-to-child transmission: pharmacologic considerations for a public health approach.
Topics: Adenine; Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Child; Cyclopropanes; Drug Resistance, Viral; Drug Therapy; HIV; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Organophosphonates; Public Health; Tenofovir | 2014 |
Pre-exposure prophylaxis to prevent HIV infection: current status, future opportunities and challenges.
Topics: Anti-HIV Agents; Drug Combinations; Emtricitabine; HIV Infections; Humans; Practice Guidelines as Topic; Pre-Exposure Prophylaxis; Randomized Controlled Trials as Topic; Tenofovir | 2015 |
Choice of antiretroviral drugs for postexposure prophylaxis for adults and adolescents: a systematic review.
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Therapy, Combination; Emtricitabine; HIV; HIV Infections; Humans; Lopinavir; Post-Exposure Prophylaxis; Ritonavir; Tenofovir; World Health Organization | 2015 |
[The newest developments of the study on anti-HIV drugs].
Topics: Adenine; Anti-HIV Agents; HIV Infections; Humans; Organophosphates; Organophosphonates; Piperazines; Pyridones; Reverse Transcriptase Inhibitors; Tenofovir | 2015 |
Comparative effectiveness of tenofovir in treatment-naïve HIV-infected patients: systematic review and meta-analysis.
Topics: Anti-HIV Agents; Bone Density; CD4 Lymphocyte Count; HIV Infections; HIV-1; Humans; Lipids; Tenofovir; Treatment Outcome; Viral Load | 2015 |
Tenofovir-based oral preexposure prophylaxis prevents HIV infection among women.
Topics: Administration, Oral; Anti-HIV Agents; Chemoprevention; Disease Transmission, Infectious; Female; HIV Infections; Humans; Male; Medication Adherence; Pre-Exposure Prophylaxis; Tenofovir; Treatment Outcome | 2016 |
What people want from sex and preexposure prophylaxis.
Topics: Anti-HIV Agents; Chemoprevention; Disease Transmission, Infectious; Emtricitabine; Female; HIV Infections; Humans; Male; Pre-Exposure Prophylaxis; Safe Sex; Tenofovir; United States | 2016 |
The European preexposure prophylaxis revolution.
Topics: Anti-HIV Agents; Chemoprevention; Disease Transmission, Infectious; Emtricitabine; Europe; Female; HIV Infections; Humans; Male; Pre-Exposure Prophylaxis; Tenofovir; Treatment Outcome | 2016 |
Elevations in Serum Creatinine With Tenofovir-Based HIV Pre-Exposure Prophylaxis: A Meta-Analysis of Randomized Placebo-Controlled Trials.
Topics: Anti-HIV Agents; Creatinine; Drug Therapy, Combination; HIV Infections; Humans; Pre-Exposure Prophylaxis; Randomized Controlled Trials as Topic; Tenofovir | 2016 |
Current concepts for PrEP adherence in the PrEP revolution: from clinical trials to routine practice.
Topics: Anti-HIV Agents; Chemoprevention; Clinical Trials as Topic; Delivery of Health Care; Disease Transmission, Infectious; Emtricitabine; HIV Infections; Humans; Medication Adherence; Pre-Exposure Prophylaxis; Tenofovir; Treatment Outcome | 2016 |
Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis?
Topics: Anti-HIV Agents; Chemoprevention; Disease Transmission, Infectious; Drug Resistance, Viral; Emtricitabine; HIV Infections; Humans; Models, Theoretical; Pre-Exposure Prophylaxis; Tenofovir | 2016 |
Nondaily preexposure prophylaxis for HIV prevention.
Topics: Administration, Oral; Animals; Anti-HIV Agents; Chemoprevention; Clinical Trials as Topic; Disease Models, Animal; Disease Transmission, Infectious; Emtricitabine; Female; HIV Infections; Humans; Macaca; Male; Pre-Exposure Prophylaxis; Tenofovir | 2016 |
Safety of oral tenofovir disoproxil fumarate-based pre-exposure prophylaxis for HIV prevention.
Topics: Administration, Oral; Animals; Anti-HIV Agents; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Pre-Exposure Prophylaxis; Risk; Tenofovir | 2016 |
Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus.
Topics: Adenine; Alanine; Animals; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone Density; Drug Stability; Fanconi Syndrome; HIV Infections; HIV-1; Humans; Kidney; Prodrugs; Tenofovir; Virus Replication | 2016 |
Elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide for the treatment of HIV in adults.
Topics: Anti-HIV Agents; Bone Density; Clinical Trials as Topic; Cobicistat; Drug Combinations; Drug Resistance, Viral; Emtricitabine; HIV Infections; Humans; Quinolones; Tablets; Tenofovir | 2016 |
Renal and Bone Adverse Effects of a Tenofovir-Based Regimen in the Treatment of HIV-Infected Children: A Systematic Review.
Topics: Anti-HIV Agents; Bone Diseases; Child; HIV Infections; Humans; Kidney Diseases; Randomized Controlled Trials as Topic; Tenofovir; Treatment Outcome | 2016 |
Tenofovir and bone health.
Topics: Anti-HIV Agents; Bone Diseases, Metabolic; Fractures, Bone; HIV Infections; Humans; Tenofovir | 2016 |
Successful Implementation of HIV Preexposure Prophylaxis: Lessons Learned From Three Clinical Settings.
Topics: Ambulatory Care Facilities; Anti-HIV Agents; Delivery of Health Care; Emtricitabine; Health Maintenance Organizations; HIV Infections; Humans; Pre-Exposure Prophylaxis; Primary Health Care; Risk Reduction Behavior; Tenofovir | 2016 |
The role of tenofovir alafenamide in future HIV management.
Topics: Adenine; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug-Related Side Effects and Adverse Reactions; HIV Infections; Humans; Prodrugs; Tenofovir; Treatment Outcome | 2016 |
PrEP as Peri-conception HIV Prevention for Women and Men.
Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Kenya; Male; Medication Adherence; Pre-Exposure Prophylaxis; Pregnancy; Pregnancy Complications, Infectious; Prenatal Care; Randomized Controlled Trials as Topic; Tenofovir; Uganda | 2016 |
Care of Patients With HIV Infection: Antiretroviral Drug Regimens.
Topics: Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Emtricitabine; HIV Fusion Inhibitors; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Tenofovir | 2016 |
Chronic Kidney Disease and Antiretroviral Therapy in HIV-Positive Individuals: Recent Developments.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Glomerular Filtration Rate; HIV Infections; HIV Protease Inhibitors; Humans; Longitudinal Studies; Prevalence; Prospective Studies; Renal Insufficiency, Chronic; Risk Factors; Tenofovir | 2016 |
Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF).
Topics: Adenine; Alanine; Antiviral Agents; HIV Infections; Humans; Tenofovir | 2016 |
Effectiveness and safety of oral HIV preexposure prophylaxis for all populations.
Topics: Administration, Oral; Adult; Anti-HIV Agents; Chemoprevention; Female; HIV Infections; Humans; Male; Placebos; Pre-Exposure Prophylaxis; Tenofovir; Young Adult | 2016 |
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection.
Topics: Adenine; Adolescent; Adult; Alanine; Anti-HIV Agents; Clinical Trials, Phase III as Topic; Cobicistat; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Humans; Quinolones; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir | 2016 |
Renal effects of novel antiretroviral drugs.
Topics: Adenine; Alanine; Anti-HIV Agents; Atazanavir Sulfate; Cobicistat; Creatinine; Disease Progression; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Oxazines; Piperazines; Proteinuria; Pyridones; Quinolones; Raltegravir Potassium; Renal Insufficiency, Chronic; Tenofovir | 2017 |
Pharmacologic Considerations for Preexposure Prophylaxis in Transgender Women.
Topics: Anti-HIV Agents; Delivery of Health Care, Integrated; Directive Counseling; Emtricitabine; Female; Health Status Disparities; HIV Infections; Humans; Male; Medication Adherence; Pre-Exposure Prophylaxis; Tenofovir; Transgender Persons | 2016 |
Tenofovir Alafenamide.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Bone Density; Female; HIV Infections; HIV-1; Humans; Prodrugs; Reverse Transcriptase Inhibitors; Tablets; Tenofovir | 2016 |
Key toxicity issues with the WHO-recommended first-line antiretroviral therapy regimen.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Randomized Controlled Trials as Topic; Tenofovir; World Health Organization | 2016 |
Dolutegravir(DTG, S/GSK1349572) combined with other ARTs is superior to RAL- or EFV-based regimens for treatment of HIV-1 infection: a meta-analysis of randomized controlled trials.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Raltegravir Potassium; Randomized Controlled Trials as Topic; Tenofovir; Treatment Outcome | 2016 |
The efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in antiretroviral regimens for HIV-1 therapy: Meta-analysis.
Topics: Adenine; Alanine; Anti-HIV Agents; HIV Infections; HIV-1; Humans; RNA, Viral; Tenofovir; Treatment Outcome | 2016 |
Systematic review of renal and bone safety of the antiretroviral regimen efavirenz, emtricitabine, and tenofovir disoproxil fumarate in patients with HIV infection.
Topics: Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Bone Diseases; Clinical Trials as Topic; Cyclopropanes; Drug Interactions; Emtricitabine; HIV Infections; Humans; Incidence; Kidney Diseases; Tenofovir; Treatment Outcome | 2016 |
Topics: Absorptiometry, Photon; Adult; Air Pollutants; Alkynes; Alleles; Animals; Anthracenes; Anthraquinones; Anti-HIV Agents; Benzoxazines; Black or African American; Bone Density; Bone Density Conservation Agents; C-Reactive Protein; Calcium, Dietary; Capsid Proteins; Cardiomyopathy, Dilated; Cardiovascular Diseases; CD4 Lymphocyte Count; Cholesterol; Collagen Type I; Cyclopropanes; Darunavir; Disease Models, Animal; Drug Therapy, Combination; Echocardiography; Emtricitabine; Epitopes; Female; Femur Neck; Gene Expression Profiling; Genetic Predisposition to Disease; Hepatitis, Viral, Animal; Hip Joint; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunization; Inflammation Mediators; Lipoproteins, LDL; Lupus Erythematosus, Systemic; Male; Mice; Mice, Inbred BALB C; Nitrates; Osteocalcin; Oxidation-Reduction; Parathyroid Hormone; Parvovirus B19, Human; Peptides; Phenotype; Pilot Projects; Polymorphism, Single Nucleotide; Raltegravir Potassium; Ritonavir; RNA, Viral; Sodium Chloride; Tenofovir; Transcriptome; Uterine Cervical Dysplasia; Uterine Cervical Neoplasms; Vaccines; Vascular Endothelial Growth Factor A; Vitamin D; Young Adult | 2016 |
Managing chronic kidney disease in the older adults living with HIV.
Topics: Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; Chronic Disease; Darunavir; Drug Substitution; HIV Infections; Humans; Kidney; Kidney Diseases; Lopinavir; Middle Aged; Tenofovir | 2017 |
Tenofovir disoproxil fumarate safety for women and their infants during pregnancy and breastfeeding.
Topics: Africa South of the Sahara; Anti-HIV Agents; Breast Feeding; Disease Transmission, Infectious; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; Humans; Infant; Infant, Newborn; Pre-Exposure Prophylaxis; Pregnancy; Tenofovir | 2017 |
Where next with preexposure prophylaxis?
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine; HIV Infections; Humans; Organophosphonates; Pre-Exposure Prophylaxis; Randomized Controlled Trials as Topic; Tenofovir | 2017 |
Pre-exposure prophylaxis (PrEP) for men who have sex with men in Europe: review of evidence for a much needed prevention tool.
Topics: Anti-HIV Agents; Emtricitabine; Europe; HIV Infections; Homosexuality, Male; Humans; Male; Patient Acceptance of Health Care; Pre-Exposure Prophylaxis; Sexual Behavior; Tenofovir | 2017 |
Comparative effectiveness of tenofovir in HIV-infected treatment-experienced patients: systematic review and meta-analysis.
Topics: Antiretroviral Therapy, Highly Active; Biomarkers; Bone Density; CD4 Lymphocyte Count; Fractures, Bone; HIV Infections; Humans; Lipid Metabolism; Lipids; Publication Bias; Randomized Controlled Trials as Topic; Retreatment; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure; Treatment Outcome; Viral Load | 2017 |
Tenofovir alafenamide fumarate for the treatment of HIV infection.
Topics: Adenine; Alanine; Anti-HIV Agents; Clinical Trials as Topic; Drug Interactions; Drug Resistance, Viral; HIV Infections; Humans; Tenofovir | 2016 |
Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns.
Topics: Animals; Anti-HIV Agents; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir | 2017 |
Emtricitabine + tenofovir alafenamide for the treatment of HIV.
Topics: Adenine; Anti-HIV Agents; Bone Density; Emtricitabine; HIV Infections; HIV-1; Humans; Kidney; Leukocytes, Mononuclear; Prodrugs; Tenofovir | 2017 |
Safety of Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy Regimens in Pregnancy for HIV-Infected Women and Their Infants: A Systematic Review and Meta-Analysis.
Topics: Anti-HIV Agents; Birth Weight; CD4 Lymphocyte Count; Female; HIV Infections; Humans; Infant, Low Birth Weight; Infant, Newborn; Infectious Disease Transmission, Vertical; Patient Safety; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Tenofovir | 2017 |
Treatment of chronic hepatitis B infection: an update of Swedish recommendations.
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Guanine; Hepatitis B, Chronic; HIV Infections; Humans; Immunocompromised Host; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Cirrhosis; Liver Transplantation; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Sweden; Tenofovir | 2008 |
Tenofovir: what have over 1 million years of patient experience taught us?
Topics: Adenine; Anti-HIV Agents; Clinical Trials as Topic; Drug Resistance, Viral; HIV Infections; Humans; Organophosphonates; Tenofovir | 2008 |
Kidney disease in patients with HIV infection and AIDS.
Topics: Adenine; HIV Infections; Humans; Kidney Diseases; Organophosphonates; Risk Factors; Tenofovir | 2008 |
[Hepatitis B in patients with HIV infection].
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Comorbidity; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Guanine; Hepatitis B; Hepatitis B Vaccines; Hepatitis B virus; HIV; HIV Infections; Humans; Interferon-alpha; Lamivudine; Nucleosides; Organophosphonates; Practice Guidelines as Topic; Pyrimidinones; Reverse Transcriptase Inhibitors; Telbivudine; Tenofovir; Thymidine; Virus Replication | 2008 |
Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals.
Topics: Adenine; Anti-HIV Agents; Female; HIV Infections; Humans; Organophosphonates; Randomized Controlled Trials as Topic; Risk; Tenofovir | 2009 |
Tenofovir-associated nephrotoxicity in two HIV-infected adolescent males.
Topics: Adenine; Adolescent; Age Factors; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Black or African American; Blood Urea Nitrogen; CD4 Lymphocyte Count; Creatinine; Diagnosis, Differential; HIV Infections; Humans; Hypophosphatemia; Infectious Disease Transmission, Vertical; Male; Organophosphonates; Renal Insufficiency; Reverse Transcriptase Inhibitors; Rickets; Risk Factors; Safety; Tenofovir | 2009 |
[Tenofovir: pharmacology and interactions].
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Biological Availability; Biotransformation; Child; Child, Preschool; Deoxyadenine Nucleotides; DNA, Viral; Drug Interactions; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Kidney Diseases; Liver Diseases; Middle Aged; Molecular Structure; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Virus Replication; Young Adult | 2008 |
[Clinical data II. Clinical experience of tenofovir DF in combination with protease inhibitors].
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Clinical Trials as Topic; Cohort Studies; Deoxycytidine; Diabetic Nephropathies; Double-Blind Method; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Emtricitabine; HIV; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; Humans; Kidney Diseases; Multicenter Studies as Topic; Organophosphonates; Randomized Controlled Trials as Topic; Retrospective Studies; Reverse Transcriptase Inhibitors; Salvage Therapy; Tenofovir; Treatment Outcome | 2008 |
[Clinical data I. Clinical experience with tenofovir in combination with nonnucleoside analogue transcriptase inhibitors].
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Clinical Trials, Phase III as Topic; Double-Blind Method; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; Humans; Multicenter Studies as Topic; Organophosphonates; Patient Acceptance of Health Care; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2008 |
[Tenofovir as a strategy to avoid or limit adverse effects].
Topics: Adenine; Anemia; Anti-HIV Agents; Antimetabolites; Clinical Trials as Topic; DNA, Mitochondrial; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Glucose Metabolism Disorders; HIV Infections; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Multicenter Studies as Topic; Organophosphonates; Prospective Studies; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Stavudine; Tenofovir; Thymidine; Zidovudine | 2008 |
[Tenofovir DF in rescue regimens].
Topics: Adenine; Anti-HIV Agents; Antimetabolites; Clinical Trials, Phase III as Topic; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; HIV; HIV Infections; HIV Reverse Transcriptase; Humans; Multicenter Studies as Topic; Mutation; Organophosphonates; Randomized Controlled Trials as Topic; Retrospective Studies; Reverse Transcriptase Inhibitors; Salvage Therapy; Selection, Genetic; Tenofovir; Thymidine; Treatment Failure; Viral Load; Zalcitabine | 2008 |
[Role of tenofovir in HIV and hepatitis C virus coinfection].
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Chemical and Drug Induced Liver Injury; Disease Progression; Drug Hypersensitivity; Drug Interactions; Drug Therapy, Combination; Fatty Liver; Glucose Metabolism Disorders; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver; Liver Cirrhosis; Organophosphonates; Reverse Transcriptase Inhibitors; Ribavirin; Tenofovir | 2008 |
[Management of renal toxicity in HIV-positive patients. What to measure, how to measure it and how frequently].
Topics: Adenine; Algorithms; Anti-HIV Agents; beta 2-Microglobulin; Clinical Trials as Topic; Cohort Studies; Creatinine; Drug Monitoring; Female; HIV Infections; Humans; Hypophosphatemia; Incidence; Kidney Diseases; Kidney Function Tests; Kidney Tubules; Male; Organophosphonates; Proteinuria; Reverse Transcriptase Inhibitors; Tenofovir; Time Factors | 2008 |
[Are all analogue combinations equal?].
Topics: Adenine; Anti-HIV Agents; Antimetabolites; Antiretroviral Therapy, Highly Active; Cardiovascular Diseases; Clinical Trials as Topic; Cohort Studies; Drug Interactions; Drug Therapy, Combination; Dyslipidemias; Gastrointestinal Diseases; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Organophosphonates; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Thymidine | 2008 |
[Current role of tenofovir in clinical medicine].
Topics: Adenine; Anti-HIV Agents; Antimetabolites; Antiretroviral Therapy, Highly Active; Chemical and Drug Induced Liver Injury; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Dyslipidemias; Glucose Metabolism Disorders; Hepatitis, Viral, Human; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Liver Diseases; Meta-Analysis as Topic; Organophosphonates; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Retrospective Studies; Reverse Transcriptase Inhibitors; Salvage Therapy; Tenofovir; Thymidine; Viral Load | 2008 |
Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: is it time to move on from zidovudine?
Topics: Adenine; Adult; Africa South of the Sahara; Animals; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone Diseases; Child; Child, Preschool; Congenital Abnormalities; Disease Models, Animal; Drug Resistance, Viral; Female; Health Services Accessibility; HIV Infections; HIV-1; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Macaca; Mitochondria; Nevirapine; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Tenofovir; Zidovudine | 2009 |
The CASTLE study: atazanavir/r versus lopinavir/r in antiretroviral-naive patients.
Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Lopinavir; Multicenter Studies as Topic; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Randomized Controlled Trials as Topic; Ritonavir; Tenofovir; Treatment Outcome | 2009 |
Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.
Topics: Adenine; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Intention to Treat Analysis; Lamivudine; Male; Organophosphonates; Randomized Controlled Trials as Topic; Regression Analysis; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load | 2009 |
Pharmacogenetics of tenofovir treatment.
Topics: Adenine; Anti-HIV Agents; Anti-Retroviral Agents; HIV Infections; HIV-1; Humans; Kidney Diseases; Kidney Tubules; Multidrug Resistance-Associated Proteins; Organic Anion Transporters; Organophosphonates; Pharmacogenetics; Polymorphism, Genetic; Tenofovir | 2009 |
Renal toxicity associated with tenofovir use.
Topics: Adenine; Animals; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; Humans; Kidney; Kidney Diseases; Male; Mitochondria; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2010 |
Economic evaluation of ART in resource-limited countries.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cost-Benefit Analysis; Developing Countries; Drug Monitoring; Health Care Costs; HIV Infections; Humans; Organophosphonates; RNA, Viral; Stavudine; Tenofovir; Viral Load | 2010 |
Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients.
Topics: Adenine; Anti-HIV Agents; HIV Infections; Humans; Kidney Diseases; Organophosphonates; Tenofovir | 2010 |
The risk of HIV drug resistance following implementation of pre-exposure prophylaxis.
Topics: Adenine; Animals; Anti-HIV Agents; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; HIV; HIV Infections; Humans; Organophosphonates; Risk Assessment; Tenofovir; Viremia | 2010 |
Systemic preexposure prophylaxis for human immunodeficiency virus infection.
Topics: Adenine; Animals; Anti-HIV Agents; Antiviral Agents; Deoxycytidine; Emtricitabine; Female; HIV; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Occupational Exposure; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Reverse Transcriptase Inhibitors; Risk Factors; Risk-Taking; Tenofovir | 2010 |
Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Child; Cyclopropanes; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Lamivudine; Nevirapine; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Zidovudine | 2010 |
Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection.
Topics: Adenine; Chemoprevention; Deoxycytidine; Drug Interactions; Emtricitabine; Female; Food-Drug Interactions; HIV Infections; Humans; Male; Organophosphonates; Tenofovir | 2011 |
[What's new in dermatological treatments?].
Topics: Adenine; Anti-HIV Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Cyclosporine; Dermatofibrosarcoma; Dermatologic Agents; Dermatology; Drug Therapy, Combination; Etanercept; Follow-Up Studies; Gels; HIV Infections; Humans; Imatinib Mesylate; Immunoglobulin G; Immunosuppressive Agents; Ipilimumab; Melanoma; Neoplasm Staging; Organophosphonates; Piperazines; Psoriasis; Pyrimidines; Receptors, Tumor Necrosis Factor; Skin Diseases; Skin Neoplasms; Survival Analysis; Tenofovir; Treatment Outcome; Ustekinumab | 2010 |
The impact of human immunodeficiency virus on viral hepatitis.
Topics: Adenine; Antiviral Agents; Deoxycytidine; Disease Progression; Drug Therapy, Combination; Emtricitabine; Guanine; Hepatitis B; Hepatitis C; Hepatitis Viruses; HIV Infections; Humans; Interferon-alpha; Lamivudine; Nucleosides; Organophosphonates; Pyrimidinones; Telbivudine; Tenofovir; Thymidine | 2011 |
Renal disease associated with antiretroviral therapy in the treatment of HIV.
Topics: Adenine; Anti-Retroviral Agents; Atazanavir Sulfate; HIV Infections; Humans; Indinavir; Kidney Diseases; Oligopeptides; Organophosphonates; Pyridines; Tenofovir | 2011 |
Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings.
Topics: Adenine; Administration, Oral; Anti-HIV Agents; Chemoprevention; Clinical Trials as Topic; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Risk; Tenofovir; United States | 2011 |
Update on microbicide research and development - seeking new HIV prevention tools for women.
Topics: Adenine; Administration, Intravaginal; Adult; Africa South of the Sahara; Anti-HIV Agents; Anti-Infective Agents; Clinical Trials as Topic; Cyclohexanes; Drug Discovery; Female; HIV Infections; Humans; Male; Maraviroc; Organophosphonates; Pyridines; Pyrimidines; Tenofovir; Triazoles; Urea | 2011 |
Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence.
Topics: Adenine; Animals; Fanconi Syndrome; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Diseases; Kidney Tubules, Proximal; Organophosphonates; Risk Factors; Tenofovir | 2011 |
The clinical potential of the acyclic (and cyclic) nucleoside phosphonates: the magic of the phosphonate bond.
Topics: Adenine; Antineoplastic Agents; Antiviral Agents; Cidofovir; Cytosine; Guanosine; Hepatitis B; HIV Infections; Humans; Organophosphonates; Prodrugs; Structure-Activity Relationship; Tenofovir | 2011 |
Endocrine complications of human immunodeficiency virus infection: hypogonadism, bone disease and tenofovir-related toxicity.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone Diseases; Endocrine System Diseases; HIV; HIV Infections; Humans; Hypogonadism; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2011 |
HIV prevention in southern Africa: why we must reassess our strategies?
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adolescent; Adult; Anti-HIV Agents; Circumcision, Male; Condoms; Condoms, Female; Female; HIV Infections; HIV Seropositivity; Humans; Interdisciplinary Communication; Male; Middle Aged; Organophosphonates; Preventive Medicine; Risk Reduction Behavior; Tenofovir; Young Adult | 2011 |
Promising prevention approaches: tenofovir gel and prophylactic use of antiretroviral medications.
Topics: Adenine; Anti-HIV Agents; Female; Gels; HIV Infections; Humans; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2011 |
Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid).
Topics: Adenine; Adult; Amniotic Fluid; Anti-HIV Agents; Cyclohexanes; Enfuvirtide; Female; Fetal Blood; Fetus; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Maraviroc; Nevirapine; Organophosphonates; Peptide Fragments; Placenta; Pregnancy; Pregnancy Complications, Infectious; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Tenofovir; Triazoles; Viral Load; Zidovudine | 2011 |
Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence.
Topics: Adenine; Administration, Oral; Administration, Topical; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Male; Medication Adherence; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2012 |
How to manage HIV-infected patients with chronic kidney disease in the HAART era.
Topics: Adenine; Albuminuria; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Black People; Cystatin C; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Failure, Chronic; Organophosphonates; Prevalence; Proteinuria; Risk Factors; Tenofovir; Viral Load | 2012 |
Formulation, pharmacokinetics and pharmacodynamics of topical microbicides.
Topics: Adenine; Animals; Anti-HIV Agents; Anti-Infective Agents, Local; Female; HIV; HIV Infections; Humans; Mice; Organophosphonates; Tenofovir; Treatment Outcome; Vaginal Creams, Foams, and Jellies | 2012 |
Microbicides for HIV prevention.
Topics: Adenine; Administration, Intravaginal; Anti-HIV Agents; Anti-Infective Agents, Local; Developing Countries; Drug Delivery Systems; Drug Resistance, Viral; Female; HIV Infections; Humans; Organophosphonates; Tenofovir | 2011 |
A review of the virological efficacy of the 4 World Health Organization-recommended tenofovir-containing regimens for initial HIV therapy.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Lamivudine; Nevirapine; Organophosphonates; Tenofovir; Treatment Failure; Viral Load; World Health Organization | 2012 |
Drug delivery in multiple indication (multipurpose) prevention technologies: systems to prevent HIV-1 transmission and unintended pregnancies or HSV-2 transmission.
Topics: Adenine; Administration, Intravaginal; Anti-Infective Agents; Antiviral Agents; Biopharmaceutics; Contraception; Disease Transmission, Infectious; Drug Delivery Systems; Female; Herpes Genitalis; Herpesvirus 2, Human; HIV Infections; HIV-1; Humans; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Pregnancy, Unplanned; Tenofovir | 2012 |
Overview of microbicides for the prevention of human immunodeficiency virus.
Topics: Adenine; Anti-HIV Agents; Anti-Infective Agents; Clinical Trials as Topic; Female; HIV; HIV Infections; Humans; Organophosphonates; Tenofovir | 2012 |
HIV prevention by oral preexposure prophylaxis.
Topics: Adenine; Administration, Oral; Animals; Anti-Retroviral Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Female; HIV Infections; HIV Seronegativity; Humans; Male; Mucous Membrane; Organophosphonates; Protein Binding; Rectum; Tenofovir; Vagina; Virus Replication | 2012 |
A drug evaluation of 1% tenofovir gel and tenofovir disoproxil fumarate tablets for the prevention of HIV infection.
Topics: Adenine; Animals; Anti-HIV Agents; Gels; HIV Infections; Humans; Organophosphonates; Reverse Transcriptase Inhibitors; Tablets; Tenofovir | 2012 |
Relative risk of renal disease among people living with HIV: a systematic review and meta-analysis.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Anti-HIV Agents; Anti-Retroviral Agents; Chronic Disease; Female; HIV Infections; Humans; Kidney Diseases; Male; Odds Ratio; Organophosphonates; Survival Rate; Tenofovir | 2012 |
New advances in chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Coinfection; Disease Progression; Drug Resistance, Viral; Female; Guanine; Guidelines as Topic; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis D; HIV Infections; Humans; Interferons; Liver Cirrhosis; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Risk Factors; Tenofovir | 2012 |
Role of raltegravir in HIV-1 management.
Topics: Adenine; Animals; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Tenofovir | 2012 |
Where rilpivirine meets with tenofovir, the start of a new anti-HIV drug combination era.
Topics: Adenine; Animals; Anti-HIV Agents; Deoxycytidine; Drug Combinations; Drug Therapy, Combination; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Emtricitabine; Emtricitabine, Rilpivirine, Tenofovir Drug Combination; HIV Infections; HIV-1; Humans; Nitriles; Organophosphonates; Oxazines; Pyrimidines; Rilpivirine; Tenofovir | 2012 |
Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Coinfection; Deoxycytidine; Dideoxynucleosides; Disease Progression; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Emtricitabine; Hepatitis C, Chronic; HIV Infections; Homosexuality, Male; Humans; Interferon-alpha; Lamivudine; Liver Cirrhosis; Liver Diseases; Male; Oligopeptides; Organophosphonates; Polyethylene Glycols; Proline; Pyrrolidinones; Raltegravir Potassium; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Substance Abuse, Intravenous; Tenofovir; Treatment Outcome | 2012 |
Tenofovir: quo vadis anno 2012 (where is it going in the year 2012)?
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Combinations; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2012 |
Topical microbicides for prevention of sexually transmitted infections.
Topics: Acrylic Resins; Adenine; Administration, Topical; Agaricales; Anti-HIV Agents; Anti-Infective Agents, Local; Cellulose; Female; HIV Infections; Humans; Male; Naphthalenesulfonates; Organophosphonates; Polymers; Seaweed; Sexually Transmitted Diseases; Tenofovir | 2012 |
[HIV preexposure prophylaxis].
Topics: Adenine; Administration, Oral; Animals; Anti-HIV Agents; Chemoprevention; Clinical Trials as Topic; Deoxycytidine; Drug Combinations; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; HIV Infections; Humans; Male; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir | 2012 |
Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals.
Topics: Adenine; Administration, Oral; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Male; Organophosphonates; Premedication; Randomized Controlled Trials as Topic; Risk; Risk-Taking; Tenofovir; Unsafe Sex | 2012 |
What primary care providers need to know about preexposure prophylaxis for HIV prevention: a narrative review.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Directive Counseling; Emtricitabine; Evidence-Based Medicine; Heterosexuality; HIV Infections; Homosexuality; Humans; Medication Adherence; Organophosphonates; Primary Health Care; Risk Assessment; Risk-Taking; Sexual Partners; Tenofovir | 2012 |
Combinational therapies for HIV: a focus on EVG/COBI/FTC/TDF.
Topics: Adenine; Anti-HIV Agents; Carbamates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cobicistat; Deoxycytidine; Drug Combinations; Drug Resistance, Multiple, Viral; Emtricitabine; HIV Infections; Humans; Organophosphonates; Quinolones; Tenofovir; Thiazoles | 2012 |
Update on tenofovir toxicity in the kidney.
Topics: Adenine; Animals; Anti-HIV Agents; Antiviral Agents; Hepatitis B; HIV Infections; Humans; Kidney; Kidney Diseases; Organophosphonates; Risk Factors; Tenofovir | 2013 |
Considerations regarding antiretroviral chemoprophylaxis in MSM.
Topics: Adenine; Administration, Oral; Animals; Anti-HIV Agents; Chemoprevention; Clinical Trials as Topic; Deoxycytidine; Disease Models, Animal; Drug-Related Side Effects and Adverse Reactions; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Leukocytes, Mononuclear; Male; Medication Adherence; Organophosphonates; Plasma; Tenofovir; Treatment Outcome | 2012 |
Current status of topical antiretroviral chemoprophylaxis.
Topics: Adenine; Administration, Intravaginal; Administration, Topical; Anilides; Anti-HIV Agents; Chemoprevention; Clinical Trials, Phase II as Topic; Female; Furans; HIV Infections; Humans; Organophosphonates; Pyrimidines; Tenofovir; Thioamides; Treatment Outcome | 2012 |
Emtricitabine/tenofovir in the treatment of HIV infection: current PK/PD evaluation.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Emtricitabine; HIV Infections; HIV-1; Humans; Organophosphonates; Practice Guidelines as Topic; Tenofovir | 2012 |
Antiretrovirals for HIV Exposure Prophylaxis.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Dideoxynucleosides; Emtricitabine; HIV; HIV Infections; Humans; Lamivudine; Occupational Exposure; Organophosphonates; Stavudine; Tenofovir; Zidovudine | 2012 |
Oral antiretroviral chemoprophylaxis: current status.
Topics: Adenine; Administration, Oral; Animals; Anti-HIV Agents; Chemoprevention; Clinical Trials as Topic; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Male; Medication Adherence; Organophosphonates; Tenofovir | 2012 |
The clinical pharmacology of antiretrovirals for HIV prevention.
Topics: Adenine; Administration, Oral; Administration, Topical; Anti-Retroviral Agents; Chemoprevention; Clinical Trials as Topic; Colon; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Organophosphonates; Tenofovir; Vagina | 2012 |
Rectal microbicide development.
Topics: Adenine; Administration, Rectal; Administration, Topical; Anilides; Anti-HIV Agents; Chemoprevention; Clinical Trials, Phase I as Topic; Drug-Related Side Effects and Adverse Reactions; Furans; HIV Infections; Homosexuality, Male; Humans; Male; Organophosphonates; Tenofovir; Thioamides | 2012 |
Complete resolution of erythrodermic psoriasis in an HIV and HCV patient unresponsive to antipsoriatic treatments after highly active antiretroviral therapy (Ritonavir, Atazanavir, Emtricitabine, Tenofovir).
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Hepatitis C, Chronic; HIV Infections; Humans; Immunocompromised Host; Male; Middle Aged; Oligopeptides; Organophosphonates; Psoriasis; Pyridines; Ritonavir; Tenofovir; Treatment Outcome | 2012 |
Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection.
Topics: Adenine; Animals; Anti-HIV Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Resistance, Viral; Drug Synergism; Drug Therapy, Combination; Hepatitis B; HIV Infections; HIV-1; Humans; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir | 2002 |
Tenofovir: a nucleotide analog for the management of human immunodeficiency virus infection.
Topics: Adenine; Adenosine Monophosphate; Anti-HIV Agents; Biological Availability; HIV Infections; HIV-1; Humans; Inhibitory Concentration 50; Organophosphonates; Organophosphorus Compounds; Randomized Controlled Trials as Topic; Tenofovir; Treatment Outcome; Viral Load | 2003 |
Tenofovir disoproxil fumarate.
Topics: Adenine; Animals; Clinical Trials as Topic; HIV Infections; HIV-1; Humans; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2003 |
Thymidine analogue-sparing highly active antiretroviral therapy (HAART).
Topics: Adenine; Antiretroviral Therapy, Highly Active; Clinical Trials as Topic; Dideoxynucleosides; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-Associated Lipodystrophy Syndrome; Humans; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Time Factors | 2003 |
Tenofovir disoproxil fumarate.
Topics: Adenine; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Mutation; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Stavudine; Tenofovir; Treatment Outcome | 2003 |
Effect of tenofovir on didanosine absorption in patients with HIV.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Area Under Curve; Clinical Trials as Topic; Didanosine; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2003 |
Newer treatments for HIV in children.
Topics: Adenine; Anti-Bacterial Agents; Anti-HIV Agents; Child; Deoxycytidine; Didanosine; Drug Therapy, Combination; Emtricitabine; Enfuvirtide; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; Humans; Microbial Sensitivity Tests; Organophosphonates; Organophosphorus Compounds; Peptide Fragments; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Stavudine; Tenofovir | 2004 |
The continuing evolution of HIV therapy.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Carbamates; CD4 Lymphocyte Count; Cyclopropanes; Delayed-Action Preparations; Deoxycytidine; Didanosine; Dideoxynucleosides; Drug Monitoring; Emtricitabine; Furans; HIV Infections; Humans; Lamivudine; Nevirapine; Oligopeptides; Organophosphates; Organophosphonates; Organophosphorus Compounds; Oxazines; Pyridines; Randomized Controlled Trials as Topic; Stavudine; Sulfonamides; Tenofovir; Treatment Outcome; Viral Load; Zidovudine | 2003 |
Management of chronic hepatitis B in the HIV-infected patient.
Topics: Adenine; Algorithms; Antiviral Agents; Clinical Trials as Topic; Decision Trees; Drug Therapy, Combination; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2004 |
Editorial comment: HIV and HBV coinfection--a coming-of-age in treatment strategies.
Topics: Adenine; Antiviral Agents; Comorbidity; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Guanine; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2004 |
Fanconi's syndrome in HIV+ adults: report of three cases and literature review.
Topics: Adenine; Adult; Anti-Retroviral Agents; Bone Density; Calcitriol; Calcium; Fanconi Syndrome; Female; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; Phosphates; Tenofovir | 2004 |
Biochemical and mechanistic basis for the activity of nucleoside analogue inhibitors of HIV reverse transcriptase.
Topics: Adenine; Cytidine Triphosphate; Deoxycytidine; Deoxycytidine Monophosphate; Deoxyribonucleotides; Dioxolanes; DNA, Viral; Emtricitabine; HIV Infections; HIV Reverse Transcriptase; Humans; Kinetics; Molecular Structure; Nucleosides; Organophosphonates; Organophosphorus Compounds; Phosphorylation; Protein Binding; Protein Conformation; Purine Nucleosides; Reverse Transcriptase Inhibitors; Substrate Specificity; Tenofovir; Zalcitabine | 2004 |
Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics.
Topics: Adenine; Administration, Oral; Animals; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Interactions; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir | 2004 |
K65R-associated virologic failure in HIV-infected patients receiving tenofovir-containing triple nucleoside/nucleotide reverse transcriptase inhibitor regimens.
Topics: Adenine; Clinical Trials as Topic; Dideoxynucleosides; Drug Interactions; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; Humans; Mutation; Organophosphonates; Prospective Studies; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure | 2004 |
Severe metabolic acidosis and renal failure in an HIV-1 patient receiving tenofovir.
Topics: Acidosis, Lactic; Acute Kidney Injury; Adenine; HIV Infections; Humans; Kidney Function Tests; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; Prognosis; Reverse Transcriptase Inhibitors; Risk Assessment; Severity of Illness Index; Tenofovir | 2004 |
Treatment of hepatitis B virus infection in patients coinfected with HIV.
Topics: Adenine; Antiviral Agents; Hepatitis B, Chronic; HIV Infections; Humans; Interferon-alpha; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2004 |
Tenofovir disoproxil fumarate (Viread) for the treatment of HIV infection.
Topics: Adenine; Animals; Clinical Trials as Topic; HIV Infections; Humans; Organophosphonates; Tenofovir | 2003 |
Tenofovir disoproxil fumarate: a review of its use in the management of HIV infection.
Topics: Adenine; Area Under Curve; Biological Availability; Double-Blind Method; Drug Interactions; Half-Life; HIV Infections; Humans; Metabolic Clearance Rate; Organophosphonates; Randomized Controlled Trials as Topic; Tenofovir; Tissue Distribution | 2005 |
Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel.
Topics: Adenine; Antiviral Agents; Comorbidity; Deoxycytidine; Disease Progression; Drug Monitoring; Emtricitabine; Hepatitis B, Chronic; HIV Infections; Humans; Interferon-alpha; Lamivudine; Organophosphonates; Tenofovir | 2005 |
Adverse effects of antiretroviral therapy for HIV infection: a review of selected topics.
Topics: Adenine; Alkynes; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cardiovascular Diseases; Cyclopropanes; Drug Monitoring; Drug Therapy, Combination; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Kidney Diseases; Lopinavir; Metabolic Syndrome; Nevirapine; Organophosphonates; Oxazines; Pyrimidinones; Risk Factors; Tenofovir | 2005 |
Editorial comment: tenofovir nephrotoxicity--vigilance required.
Topics: Adenine; Fanconi Syndrome; Glycosuria; HIV Infections; Humans; Hypokalemia; Hypophosphatemia; Organophosphonates; Proteinuria; Renal Insufficiency; Reverse Transcriptase Inhibitors; Tenofovir | 2005 |
Fanconi syndrome associated with use of tenofovir in HIV-infected patients: a case report and review of the literature.
Topics: Adenine; Fanconi Syndrome; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2005 |
Management of HIV-infected patients with multidrug-resistant virus.
Topics: Adenine; Anti-HIV Agents; Anti-Retroviral Agents; Atazanavir Sulfate; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Enfuvirtide; HIV Envelope Protein gp41; HIV Infections; HIV-1; Humans; Oligopeptides; Organophosphonates; Peptide Fragments; Pyridines; Pyrones; Randomized Controlled Trials as Topic; Sulfonamides; Tenofovir; Treatment Failure; Viral Load | 2004 |
Tenofovir and didanosine: a dangerous liaison.
Topics: Adenine; Anti-HIV Agents; Didanosine; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; Organophosphonates; Tenofovir | 2005 |
Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.
Topics: Adenine; Age Factors; Alkynes; Atazanavir Sulfate; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Liver; Oligopeptides; Organophosphonates; Oxazines; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Sex Factors; Tenofovir | 2005 |
Severe toxicity associated with the combination of tenofovir and didanosine: case report and review.
Topics: Acidosis, Lactic; Acute Disease; Adenine; Anti-HIV Agents; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Liver Failure; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2005 |
[The treatment of HIV infection].
Topics: Adenine; Anti-Retroviral Agents; Carbamates; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Drug Therapy, Combination; Furans; HIV Infections; Humans; Lamivudine; Nevirapine; Organophosphates; Organophosphonates; Risk Factors; Sulfonamides; Tenofovir; Zidovudine | 2005 |
Use of tenofovir disoproxil fumarate and emtricitabine combination in HIV-infected patients.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Organophosphonates; Tenofovir | 2006 |
Perspectives on the development of acyclic nucleotide analogs as antiviral drugs.
Topics: Adenine; Animals; Antiviral Agents; Dogs; Drug Design; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Nucleotides; Organophosphonates; Randomized Controlled Trials as Topic; Tenofovir | 2006 |
Tenofovir disoproxil fumarate for the treatment of HIV infection.
Topics: Adenine; Animals; Drug Administration Schedule; Drug Interactions; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B; HIV Infections; Humans; Organophosphonates; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir | 2006 |
An update and review of antiretroviral therapy.
Topics: Adenine; Animals; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Carbamates; Clinical Trials as Topic; Deoxycytidine; Dideoxynucleosides; Drug Administration Schedule; Drug Combinations; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Drugs, Investigational; Emtricitabine; Enfuvirtide; Furans; HIV Envelope Protein gp41; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Oligopeptides; Organophosphates; Organophosphonates; Patient Compliance; Peptide Fragments; Pyridines; Pyrones; Reverse Transcriptase Inhibitors; Sulfonamides; Tenofovir | 2006 |
Antiretroviral therapy for hepatitis B virus-HIV-coinfected patients: promises and pitfalls.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Antiviral Agents; Deoxycytidine; Drug Combinations; Emtricitabine; Guanine; Hepatitis B; Hepatitis B virus; HIV Infections; HIV-1; Humans; Lamivudine; Organophosphonates; Preventive Medicine; Tenofovir | 2006 |
Tenofovir disoproxil fumarate-emtricitabine coformulation for once-daily dual NRTI backbone.
Topics: Adenine; Animals; Chemistry, Pharmaceutical; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Emtricitabine; HIV Infections; HIV Reverse Transcriptase; Humans; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2006 |
Evolving simplified treatment strategies for HIV infection: the role of a single-class quadruple-nucleoside/nucleotide regimen of trizivir and tenofovir.
Topics: Adenine; Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; HIV Infections; HIV-1; Humans; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Zidovudine | 2006 |
Tenofovir plus didanosine as Nrti backbone in HIV-infected subjects.
Topics: Adenine; Anti-HIV Agents; Didanosine; Drug Antagonism; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; Humans; Organophosphonates; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Tenofovir | 2006 |
[Renal toxicity in HIV-infected patients receiving HAART including tenofovir].
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Interactions; HIV Infections; Humans; Kidney Diseases; Organophosphonates; Tenofovir | 2006 |
Efavirenz/emtricitabine/tenofovir disoproxil fumarate fixed-dose combination: first-line therapy for all?
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Humans; Organophosphonates; Oxazines; Reverse Transcriptase Inhibitors; Tenofovir | 2007 |
Renal safety of tenofovir disoproxil fumarate.
Topics: Adenine; Anti-HIV Agents; Clinical Trials as Topic; HIV Infections; Humans; Kidney; Kidney Diseases; Organophosphonates; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir | 2007 |
Treatment of chronic hepatitis B in HIV-infected patients in 2007.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; HIV Infections; Humans; Interferon-alpha; Lamivudine; Nucleosides; Organophosphonates; Pyrimidinones; Telbivudine; Tenofovir; Thymidine | 2007 |
Pre-exposure prophylaxis for HIV infection: what if it works?
Topics: Adenine; Anti-HIV Agents; Attitude of Health Personnel; Drug Administration Schedule; Female; HIV Infections; HIV Seropositivity; Humans; Male; Organophosphonates; Public Health; Risk-Taking; Tenofovir | 2007 |
Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Resistance, Multiple, Viral; HIV Infections; HIV-1; Humans; Lamivudine; Mutation; Organophosphonates; Practice Guidelines as Topic; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure; Treatment Outcome; Viral Load; Zidovudine | 2007 |
The first once-daily single-tablet regimen for the treatment of HIV-infected patients.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Humans; Organophosphonates; Reverse Transcriptase Inhibitors; Tablets; Tenofovir; Therapeutic Equivalency | 2007 |
HIV-1 infection and the kidney: an evolving challenge in HIV medicine.
Topics: Acute Disease; Acute Kidney Injury; Adenine; AIDS-Associated Nephropathy; Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Black or African American; Chronic Disease; Comorbidity; Disease Progression; HIV Infections; HIV-1; Humans; Kidney; Kidney Diseases; Kidney Failure, Chronic; Kidney Transplantation; Mice; Mice, Transgenic; Microcirculation; Organophosphonates; Tenofovir; Viral Proteins | 2007 |
Tenofovir gel--the new HIV prevention 'banker'?
Topics: Adenine; Anti-HIV Agents; Clinical Trials, Phase II as Topic; Drug Approval; Female; HIV Infections; Humans; Organophosphonates; Tenofovir; Vaginal Creams, Foams, and Jellies | 2007 |
Kidney biopsy in HIV: beyond HIV-associated nephropathy.
Topics: Acute Disease; Adenine; AIDS-Associated Nephropathy; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biopsy; Comorbidity; Diabetic Nephropathies; Diagnosis, Differential; Female; HIV Infections; Humans; Hypertension; Immune Complex Diseases; Kidney; Kidney Diseases; Kidney Glomerulus; Middle Aged; Nephritis, Interstitial; Organophosphonates; Risk Assessment; Risk Factors; Tenofovir | 2008 |
Experience with tenofovir disoproxil fumarate for antiretroviral therapy.
Topics: Adenine; Adult; Anti-HIV Agents; Anti-Retroviral Agents; Child; Drug Interactions; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; Humans; Organophosphonates; Randomized Controlled Trials as Topic; Tenofovir; Treatment Outcome | 2008 |
The potential place of tenofovir in antiretroviral treatment regimens.
Topics: Adenine; Anti-HIV Agents; Drug Resistance, Viral; HIV; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir | 2001 |
680 trial(s) available for tenofovir and HIV Coinfection
| Article | Year |
|---|---|
Tenofovir-diphosphate in peripheral blood mononuclear cells during low, medium and high adherence to emtricitabine/ tenofovir alafenamide vs. emtricitabine/ tenofovir disoproxil fumarate.
Topics: Alanine; Anti-HIV Agents; Diphosphates; Emtricitabine; HIV Infections; Humans; Leukocytes, Mononuclear; Tenofovir | 2021 |
Brief Report: Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Females Living With HIV: An Integrated Analysis of 5 Trials.
Topics: Adenine; Adolescent; Adult; Aged; Alanine; Amides; Anti-HIV Agents; Child; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Middle Aged; Piperazines; Pyridones; Tenofovir; Treatment Outcome; Young Adult | 2021 |
An Open-Label Pharmacokinetic and Pharmacodynamic Assessment of Tenofovir Gel and Oral Emtricitabine/Tenofovir Disoproxil Fumarate.
Topics: Anti-HIV Agents; Cross-Over Studies; Emtricitabine; Female; HIV Infections; HIV-1; Homosexuality, Male; Humans; Male; Pre-Exposure Prophylaxis; Reverse Transcriptase Inhibitors; Sexual and Gender Minorities; Tenofovir | 2022 |
Simplifying TREAtment and Monitoring for HIV (STREAM HIV): protocol for a randomised controlled trial of point-of-care urine tenofovir and viral load testing to improve HIV outcomes.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; HIV Infections; Humans; Point-of-Care Systems; Point-of-Care Testing; Randomized Controlled Trials as Topic; South Africa; Tenofovir; Viral Load | 2021 |
HIV Incidence Among Pregnant and Nonpregnant Women in the FACTS-001 Trial: Implications for HIV Prevention, Especially PrEP Use.
Topics: Adolescent; Adult; Female; HIV Infections; Humans; Incidence; Infectious Disease Transmission, Vertical; Pre-Exposure Prophylaxis; Pregnancy; Pregnancy Complications, Infectious; Pregnant Women; Risk Factors; Sexual Behavior; South Africa; Tenofovir; Young Adult | 2021 |
Bone changes with candidate PrEP regimens containing tenofovir disoproxil fumarate and/or maraviroc and/or emtricitabine in US men and women: HPTN 069/ACTG A5305.
Topics: Adult; Anti-HIV Agents; Double-Blind Method; Emtricitabine; Female; HIV Infections; Humans; Male; Maraviroc; Tenofovir | 2022 |
Integration of pre-exposure prophylaxis services into public HIV care clinics in Kenya: a pragmatic stepped-wedge randomised trial.
Topics: Adult; Ambulatory Care Facilities; Anti-HIV Agents; Female; HIV Infections; Humans; Kenya; Male; Medication Adherence; Pre-Exposure Prophylaxis; Tenofovir | 2021 |
Bone mineral density, kidney function and participant-reported outcome measures in women who switch from tenofovir disoproxil emtricitabine and a nonnucleoside reverse transcriptase inhibitor to abacavir, lamivudine and dolutegravir.
Topics: Adult; Anti-HIV Agents; Bone Density; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Kidney; Lamivudine; Middle Aged; Oxazines; Patient Reported Outcome Measures; Piperazines; Pyridones; Reverse Transcriptase Inhibitors; Tenofovir | 2022 |
Genital Mucosal Drug Concentrations and anti-HIV Activity in Tenofovir-Based PrEP Products: Intravaginal Ring vs. Oral Administration.
Topics: Administration, Intravaginal; Administration, Oral; Anti-HIV Agents; Emtricitabine; Female; Genitalia; HIV Infections; Humans; Tenofovir | 2022 |
Brief Report: Bictegravir/Emtricitabine/Tenofovir Alafenamide Efficacy in Participants With Preexisting Primary Integrase Inhibitor Resistance Through 48 Weeks of Phase 3 Clinical Trials.
Topics: Alanine; Amides; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Male; Middle Aged; Piperazines; Pyridones; Retrospective Studies; Tenofovir | 2022 |
CAPRISA 018: a phase I/II clinical trial study protocol to assess the safety, acceptability, tolerability and pharmacokinetics of a sustained-release tenofovir alafenamide subdermal implant for HIV prevention in women.
Topics: Alanine; Anti-HIV Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Delayed-Action Preparations; Female; HIV Infections; Humans; Tenofovir | 2022 |
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 F
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Lipids; Oxazines; Piperazines; Pyridones; RNA; Tenofovir | 2022 |
Pre-infection plasma cytokines and chemokines as predictors of HIV disease progression.
Topics: Adolescent; Adult; Anti-HIV Agents; Biomarkers; CD4-CD8 Ratio; Chemokines; Cohort Studies; Disease Progression; Double-Blind Method; Female; HIV Infections; HIV Seropositivity; HIV-1; Humans; Immunity; Prognosis; South Africa; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2022 |
Acceptability of an extended duration vaginal ring for HIV prevention and interest in a multi-purpose ring.
Topics: Administration, Intravaginal; Adult; Anti-HIV Agents; Coitus; Contraceptive Devices, Female; Female; HIV Infections; Humans; Male; Patient Acceptance of Health Care; Pre-Exposure Prophylaxis; Pregnancy; Pregnancy, Unplanned; Tenofovir | 2022 |
Population pharmacokinetics of tenofovir, emtricitabine and intracellular metabolites in transgender women.
Topics: Anti-HIV Agents; Creatinine; Emtricitabine; Female; HIV Infections; Humans; Male; Pre-Exposure Prophylaxis; Tenofovir; Transgender Persons | 2022 |
Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084.
Topics: Anti-HIV Agents; Diketopiperazines; DNA-Directed RNA Polymerases; Emtricitabine; Female; HIV; HIV Infections; Humans; Nucleosides; Pre-Exposure Prophylaxis; Pyridones; Reverse Transcriptase Inhibitors; Tenofovir | 2022 |
Evaluation of tenofovir disoproxil fumarate loaded silver nanoparticle on testicular morphology in experimental type-2 diabetic rats.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; HIV Infections; Male; Metal Nanoparticles; Rats; Rats, Sprague-Dawley; Silver; Tenofovir; Testis | 2022 |
Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non
Topics: Anti-HIV Agents; Darunavir; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Prospective Studies; Pyridones; Ritonavir; RNA; Tenofovir; Viral Load; Zidovudine | 2022 |
Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with HIV: Results of a 96-week, phase 3b, open-label, switch trial in virologically suppressed people ≥65 years of age.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Humans; Tenofovir | 2023 |
Brief Report: Impact of Antiretroviral Regimen on Pregnancy and Infant Outcomes in Women With HIV/ HBV Coinfection.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Coinfection; Emtricitabine; Female; Hepatitis B e Antigens; HIV Infections; Humans; Infant, Newborn; Lamivudine; Pregnancy; Pregnancy Outcome; Tenofovir; Zidovudine | 2022 |
Once-daily dolutegravir versus darunavir plus cobicistat in adults at the time of primary HIV-1 infection: the OPTIPRIM2-ANRS 169 randomized, open-label, Phase 3 trial.
Topics: Adult; Anti-HIV Agents; Cobicistat; Darunavir; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Male; Oxazines; Piperazines; Pyridones; RNA; Tenofovir; Viral Load | 2022 |
Stepped care to optimize pre-exposure prophylaxis (PrEP) effectiveness in pregnant and postpartum women (SCOPE-PP) in South Africa: a randomized control trial.
Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Postpartum Period; Pre-Exposure Prophylaxis; Pregnancy; Pregnant Women; South Africa; Tenofovir | 2022 |
Genital microbiota of women using a 90 day tenofovir or tenofovir and levonorgestrel intravaginal ring in a placebo controlled randomized safety trial in Kenya.
Topics: Administration, Intravaginal; Female; HIV Infections; Humans; Kenya; Levonorgestrel; Microbiota; RNA, Ribosomal, 16S; Tenofovir; Vagina | 2022 |
Maternal and infant renal safety following tenofovir disoproxil fumarate exposure during pregnancy in a randomized control trial.
Topics: Anti-HIV Agents; Calcium; Female; HIV Infections; Humans; Infant; Infant, Newborn; Phosphates; Pregnancy; Tenofovir; Zidovudine | 2022 |
72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Emtricitabine; Female; Follow-Up Studies; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Male; Oxazines; Piperazines; Postpartum Period; Pregnancy; Pyridones; Tenofovir; Viral Load | 2022 |
Tenofovir Disoproxil Fumarate/Emtricitabine and Baricitinib for Patients at High Risk of Severe Coronavirus Disease 2019: The PANCOVID Randomized Clinical Trial.
Topics: Adult; Anti-HIV Agents; COVID-19; COVID-19 Drug Treatment; Dexamethasone; Emtricitabine; HIV Infections; Humans; Tenofovir | 2023 |
Daily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo-controlled randomized trial in healthcare workers.
Topics: Adenine; Anti-HIV Agents; COVID-19; COVID-19 Drug Treatment; Deoxycytidine; Double-Blind Method; Emtricitabine; Health Personnel; HIV Infections; Humans; Hydroxychloroquine; Organophosphonates; Pre-Exposure Prophylaxis; SARS-CoV-2; Tenofovir | 2023 |
Antiretroviral Therapy Adherence During and Postbreastfeeding Cessation Measured by Tenofovir Levels in Hair.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Female; Hair; HIV Infections; Humans; Medication Adherence; Tenofovir; Viremia; Young Adult | 2022 |
Tenofovir, Lamivudine, and Dolutegravir Among Rural Adolescents in Zimbabwe: A Cautionary Tale.
Topics: Adolescent; Adult; Anti-HIV Agents; Child; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Male; Oxazines; Protease Inhibitors; Tenofovir; Viral Load; Young Adult; Zimbabwe | 2022 |
Effect of a Reminder System on Pre-exposure Prophylaxis Adherence in Men Who Have Sex With Men: Prospective Cohort Study Based on WeChat Intervention.
Topics: Anti-HIV Agents; HIV Infections; Homosexuality, Male; Humans; Male; Medication Adherence; Pre-Exposure Prophylaxis; Prospective Studies; Reminder Systems; Sexual and Gender Minorities; Tenofovir | 2022 |
Brief Report: Quantifiable Plasma Tenofovir Among South African Women Using Daily Oral Pre-exposure Prophylaxis During the ECHO Trial.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Medication Adherence; Pre-Exposure Prophylaxis; South Africa; Tenofovir; Young Adult | 2022 |
Brief Report: Efficacy and Safety of Oral Islatravir Once Daily in Combination With Doravirine Through 96 Weeks for Treatment-Naive Adults With HIV-1 Infection Receiving Initial Treatment With Islatravir, Doravirine, and Lamivudine.
Topics: Adult; Anti-HIV Agents; Deoxyadenosines; Drug Combinations; HIV Infections; HIV-1; Humans; Lamivudine; Pyridones; Reverse Transcriptase Inhibitors; RNA; Tenofovir; Triazoles | 2022 |
Randomized Controlled Trial of Automated Directly Observed Therapy for Measurement and Support of PrEP Adherence Among Young Men Who have Sex with Men.
Topics: Anti-HIV Agents; Directly Observed Therapy; HIV Infections; Homosexuality, Male; Humans; Male; Medication Adherence; Pre-Exposure Prophylaxis; Sexual and Gender Minorities; Tenofovir | 2023 |
Alignment of PrEP adherence with periods of HIV risk among adolescent girls and young women in South Africa and Zimbabwe: a secondary analysis of the HPTN 082 randomised controlled trial.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Medication Adherence; Organophosphates; Pre-Exposure Prophylaxis; South Africa; Tenofovir; Young Adult; Zimbabwe | 2022 |
The ATEAM study: Advances in technology to enhance PrEP adherence monitoring (ATEAM) among young men who have sex with men.
Topics: Adolescent; Adult; Anti-HIV Agents; Cross-Over Studies; Emtricitabine; Female; HIV Infections; Homosexuality, Male; Humans; Male; Medication Adherence; Sexual and Gender Minorities; Technology; Tenofovir; Young Adult | 2022 |
Point-of-Care Tenofovir Urine Testing for the Prediction of Treatment Failure and Drug Resistance During Initial Treatment for Human Immunodeficiency Virus Type 1 (HIV-1) Infection.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Case-Control Studies; Emtricitabine; HIV Infections; HIV-1; Humans; Point-of-Care Systems; Retrospective Studies; South Africa; Tenofovir; Treatment Failure | 2023 |
Acceptability of an intravaginal ring for simultaneously preventing HIV infection and pregnancy: Qualitative findings of the Kisumu Combined Ring Study, 2019.
Topics: Adolescent; Contraceptive Devices, Female; Female; HIV Infections; Humans; Pregnancy; Reproducibility of Results; Sexual Behavior; Tenofovir | 2022 |
Randomized, placebo controlled phase I trial of the safety, pharmacokinetics, pharmacodynamics and acceptability of a 90 day tenofovir plus levonorgestrel vaginal ring used continuously or cyclically in women: The CONRAD 138 study.
Topics: Anovulation; Antiviral Agents; Contraceptive Agents; Contraceptive Devices, Female; Diphosphates; Female; HIV Core Protein p24; HIV Infections; Humans; Levonorgestrel; Male; Semen; Tenofovir | 2022 |
EVG/COBI/FTC/TAF Bioequivalence Comparing Whole Tablets with Tablets Dissolved in Tap Water.
Topics: Adenine; Adult; Anti-HIV Agents; Cobicistat; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Male; Tablets; Tenofovir; Therapeutic Equivalency | 2023 |
Bioavailability of dissolved and crushed single tablets of bictegravir, emtricitabine, tenofovir alafenamide in healthy adults: the SOLUBIC randomized crossover study.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Biological Availability; Cross-Over Studies; Emtricitabine; HIV Infections; Humans; Tablets; Tenofovir | 2022 |
Contingency Management for Integrated Harm Reduction Among Men Who Have Sex with Men Who Use Methamphetamine in Los Angeles: A Pilot Assessment.
Topics: Adult; Anti-HIV Agents; Harm Reduction; HIV Infections; Homosexuality, Male; Humans; Los Angeles; Male; Medication Adherence; Methamphetamine; Pre-Exposure Prophylaxis; Sexual and Gender Minorities; Tenofovir | 2023 |
Single dose topical inserts containing tenofovir alafenamide fumarate and elvitegravir provide pre- and post-exposure protection against vaginal SHIV infection in macaques.
Topics: Adenine; Animals; Anti-HIV Agents; Female; Fumarates; HIV Infections; Macaca; Pre-Exposure Prophylaxis; Tenofovir | 2022 |
Efficacy and safety of 400 mg efavirenz versus standard 600 mg dose when taken with tenofovir and lamivudine combination in Indian adult patients with HIV-1 infection: An open-label, interventional, randomized, non-inferiority trial.
Topics: Adult; HIV Infections; HIV-1; Humans; India; Lamivudine; Tenofovir | 2022 |
BEING: Bone Health in Aging Women with HIV: Impact of Switching Antiretroviral Therapy on Bone Mineral Density During the Perimenopausal Period.
Topics: Adenine; Aging; Anti-HIV Agents; Bone Density; COVID-19; Female; HIV Infections; Humans; Middle Aged; Pandemics; Perimenopause; Tenofovir | 2023 |
Weight and Metabolic Changes After Switching From Tenofovir Alafenamide/Emtricitabine (FTC)+Dolutegravir (DTG), Tenofovir Disoproxil Fumarate (TDF)/FTC + DTG, and TDF/FTC/Efavirenz to TDF/Lamivudine/DTG.
Topics: Adenine; Anti-HIV Agents; Benzoxazines; Emtricitabine; HIV Infections; Humans; Lamivudine; Tenofovir | 2023 |
Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial.
Topics: Adenine; Adult; Anti-HIV Agents; Anti-Retroviral Agents; Emtricitabine; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Oxazines; RNA; Tenofovir; Treatment Outcome; Viral Load | 2023 |
Initial Supplementary Dose of Dolutegravir in Second-Line Antiretroviral Therapy: A Noncomparative, Double-Blind, Randomized Placebo-Controlled Trial.
Topics: Adult; Anti-Retroviral Agents; Benzoxazines; Emtricitabine; HIV Infections; Humans; Lamivudine; RNA; Tenofovir | 2023 |
Retention among transgender women treated with dolutegravir associated with tenofovir/lamivudine or emtricitabine in Argentina: TransViiV study.
Topics: Adult; Anti-Retroviral Agents; Argentina; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Prospective Studies; Pyridones; Tenofovir; Transgender Persons | 2023 |
Pregnancy and neonatal safety outcomes of timing of initiation of daily oral tenofovir disoproxil fumarate and emtricitabine pre-exposure prophylaxis for HIV prevention (CAP016): an open-label, randomised, non-inferiority trial.
Topics: Adenine; Anti-HIV Agents; Birth Weight; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Pre-Exposure Prophylaxis; Pregnancy; Premature Birth; South Africa; Stillbirth; Tenofovir; Treatment Outcome | 2023 |
Blood immune cells from people with HIV on antiviral regimens that contain tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF) have differential metabolic signatures.
Topics: Adenine; Alanine; Anti-HIV Agents; HIV Infections; Humans; Leukocytes, Mononuclear; Tenofovir | 2023 |
PrEPare for Work: A Pilot Randomized Controlled Trial of an Intervention to Optimize HIV PrEP Outcomes Among Male Sex Workers.
Topics: Anti-HIV Agents; HIV Infections; Humans; Male; Pilot Projects; Sex Workers; Tenofovir | 2023 |
Population pharmacokinetics of tenofovir given as either tenofovir disoproxil fumarate or tenofovir alafenamide in an African population.
Topics: Adenine; Adult; Anti-HIV Agents; HIV Infections; Humans; Tenofovir | 2023 |
Changes in bone quality after switching from a TDF to a TAF based ART: A pilot randomized study.
Topics: Adenine; Adult; Anti-HIV Agents; Bone and Bones; Female; HIV Infections; Humans; Male; Middle Aged; Pilot Projects; Tenofovir | 2023 |
Pharmacogenetics of tenofovir clearance among Southern Africans living with HIV.
Topics: African People; Anti-HIV Agents; HIV Infections; Humans; Interleukins; Pharmacogenetics; Tenofovir | 2023 |
Pharmacogenetics of tenofovir renal toxicity in HIV-positive Southern Africans.
Topics: Adenine; Adult; African People; Alanine; Anti-HIV Agents; HIV Infections; HIV Seropositivity; Humans; Pharmacogenetics; Tenofovir | 2023 |
No Meaningful Drug-Drug Interactions Are Associated with the Coadministration of ACC007, Lamivudine, and Tenofovir Disoproxil Fumarate.
Topics: Anti-HIV Agents; Cohort Studies; Drug Interactions; HIV Infections; Humans; Lamivudine; Tenofovir | 2023 |
A phase I study to assess safety, pharmacokinetics, and pharmacodynamics of a vaginal insert containing tenofovir alafenamide and elvitegravir.
Topics: Alanine; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Tenofovir | 2023 |
Efficacy and safety of three antiretroviral therapy regimens started in pregnancy up to 50 weeks post partum: a multicentre, open-label, randomised, controlled, phase 3 trial.
Topics: Adenine; Anti-HIV Agents; Benzoxazines; Child; Emtricitabine; Female; HIV Infections; Humans; Male; Pregnancy; RNA; Tenofovir; Viral Load | 2023 |
Bone and Renal Health in Infants With or Without Breastmilk Exposure to Tenofovir-Based Maternal Antiretroviral Treatment in the PROMISE Randomized Trial.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Bone Density; Female; HIV Infections; Humans; Kidney; Lumbar Vertebrae; Milk, Human; Nevirapine; Tenofovir | 2023 |
Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2, non-comparative, randomised controlled trial.
Topics: Adult; Anti-Retroviral Agents; Antitubercular Agents; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Infant; Isoniazid; Lamivudine; Rifampin; RNA; South Africa; Tenofovir; Tuberculosis; Viral Load | 2023 |
First Pharmacokinetic Data of Tenofovir Alafenamide Fumarate and Tenofovir With Dolutegravir or Boosted Protease Inhibitors in African Children: A Substudy of the CHAPAS-4 Trial.
Topics: Adult; Anti-HIV Agents; Antiviral Agents; Atazanavir Sulfate; Child; Darunavir; Emtricitabine; Fumarates; HIV Infections; Humans; Lopinavir; Protease Inhibitors; Ritonavir; Tenofovir | 2023 |
Tenofovir alafenamide plus dolutegravir as a switch strategy in HIV-infected patients: a pilot randomized controlled trial.
Topics: Adenine; Anti-HIV Agents; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Emtricitabine; HIV Infections; Humans; Pilot Projects; RNA; Tenofovir; Treatment Outcome | 2023 |
Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a random
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Anti-Retroviral Agents; Emtricitabine; Female; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV Seropositivity; HIV-1; Humans; Infant, Newborn; Injection Site Reaction; Male; Middle Aged; Rilpivirine; RNA; Tenofovir; Viral Load; Young Adult | 2023 |
Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trial.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Emtricitabine; Female; HIV Infections; HIV-1; Hormones; Humans; Male; Pre-Exposure Prophylaxis; Tenofovir; Thailand; Transgender Persons | 2023 |
Adherence, safety, and choice of the monthly dapivirine vaginal ring or oral emtricitabine plus tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis among African adolescent girls and young women: a randomised, open-label, crossover trial.
Topics: Adolescent; Anti-HIV Agents; Cross-Over Studies; Emtricitabine; Female; HIV Infections; Humans; Pre-Exposure Prophylaxis; Reverse Transcriptase Inhibitors; South Africa; Tenofovir | 2023 |
Evaluating immunological and inflammatory changes of treatment-experienced people living with HIV switching from first-line triple cART regimens to DTG/3TC
Topics: CD4-CD8 Ratio; HIV Infections; Humans; Interleukin-6; Lamivudine; Tenofovir | 2023 |
Safety of low dose efavirenz regimen in Indian adults with HIV-1 infection: Insights from a phase 4 interventional randomised trial.
Topics: Adult; Anti-HIV Agents; Benzoxazines; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Tenofovir; Treatment Outcome; Viral Load | 2023 |
Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary anal
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Anti-HIV Agents; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Pre-Exposure Prophylaxis; Retrospective Studies; Tenofovir; Transgender Persons | 2023 |
DELIVER: A Safety Study of a Dapivirine Vaginal Ring and Oral PrEP for the Prevention of HIV During Pregnancy.
Topics: Emtricitabine; Female; Gestational Age; HIV Infections; Humans; Malawi; Pregnancy; Tenofovir | 2024 |
Protocol for a multicenter, real-world study of HIV pre-exposure prophylaxis among men who have sex with men in China (CROPrEP).
Topics: Adult; Anti-HIV Agents; China; Cohort Studies; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Male; Multicenter Studies as Topic; Pre-Exposure Prophylaxis; Safe Sex; Self Report; Sexual and Gender Minorities; Sexual Behavior; Surveys and Questionnaires; Tenofovir | 2019 |
Efficacy and Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) in Treatment-Naive Adults With HIV-1 and Transmitted Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations.
Topics: Adult; Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Mutation; Pyridones; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Triazoles | 2019 |
Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I.
Topics: Adenine; Adult; Alanine; Amides; Amino Acid Substitution; Anti-HIV Agents; Double-Blind Method; Drug Resistance, Multiple, Viral; Drug Substitution; Drug Therapy, Combination; Emtricitabine; Genotype; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Piperazines; Pyridones; Retrospective Studies; RNA, Viral; Sustained Virologic Response; Tenofovir | 2019 |
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study.
Topics: Adenine; Adult; Aged; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cobicistat; Darunavir; Drug Combinations; Drug Substitution; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Protease Inhibitors; Sustained Virologic Response; Tablets; Tenofovir; Viral Load; Young Adult | 2019 |
Limited correlation between systemic biomarkers and neurocognitive performance before and during HIV treatment.
Topics: Adult; AIDS Dementia Complex; Anti-HIV Agents; Biomarkers; Darunavir; Double-Blind Method; Emtricitabine; Female; HIV Infections; Humans; Inflammation; Male; Maraviroc; Ritonavir; Tenofovir | 2020 |
Linked dual-class HIV resistance mutations are associated with treatment failure.
Topics: Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Viral; Emtricitabine; Female; Genome, Viral; HIV Infections; HIV-1; Humans; Mutation; Nevirapine; Tenofovir; Treatment Failure; Whole Genome Sequencing | 2019 |
HPTN 067/ADAPT: Correlates of Sex-Related Pre-exposure Prophylaxis Adherence, Thai Men Who Have Sex With Men, and Transgender Women, 2012-2013.
Topics: Adolescent; Adult; Emtricitabine; Feasibility Studies; Female; HIV Infections; Homosexuality, Male; Humans; Male; Medication Adherence; Pre-Exposure Prophylaxis; Tenofovir; Transgender Persons; Young Adult | 2019 |
Integrated provision of topical pre-exposure prophylaxis in routine family planning services in South Africa: a non-inferiority randomized controlled trial.
Topics: Adult; Anti-HIV Agents; Family Planning Services; Female; HIV Infections; Humans; Medication Adherence; Pre-Exposure Prophylaxis; Rural Population; South Africa; Tenofovir; Young Adult | 2019 |
Determinants of blood telomere length in antiretroviral treatment-naïve HIV-positive participants enrolled in the NEAT 001/ANRS 143 clinical trial.
Topics: Adult; Aged; Anti-Retroviral Agents; Cross-Sectional Studies; Darunavir; Emtricitabine; Female; HIV Infections; Humans; Logistic Models; Male; Middle Aged; Raltegravir Potassium; Ritonavir; RNA, Viral; Telomere; Tenofovir | 2019 |
Switching from efavirenz to rilpivirine improves sleep quality and self-perceived cognition but has no impact on neurocognitive performances.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cognition; Cyclopropanes; Drug Substitution; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Quality of Life; Rilpivirine; RNA, Viral; Sleep; Tenofovir; Viral Load | 2020 |
Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a m
Topics: Adenine; Aged; Aged, 80 and over; Alanine; Anti-HIV Agents; Bone Density; Cobicistat; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Quinolones; Tablets; Tenofovir | 2019 |
Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed HIV-1 Infected Women: A Randomized, Open-Label, Multicenter, Active-Controlled, Phase 3, Noninferiority Trial.
Topics: Adenine; Adult; Alanine; Amides; Anti-HIV Agents; CD4 Lymphocyte Count; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Male; Middle Aged; Piperazines; Pyridones; Tenofovir; Treatment Outcome; Young Adult | 2019 |
Early safety of tenofovir alafenamide in patients with a history of tubulopathy on tenofovir disoproxil fumarate: a randomized controlled clinical trial.
Topics: Adenine; Alanine; Creatinine; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Diseases; Kidney Tubules, Proximal; Linear Models; Male; Middle Aged; Retinol-Binding Proteins; Tenofovir; Treatment Outcome; United Kingdom | 2020 |
Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001
Topics: Adult; Anti-HIV Agents; Constitutive Androstane Receptor; Darunavir; Emtricitabine; Female; HIV Infections; Humans; Liver-Specific Organic Anion Transporter 1; Male; Multidrug Resistance-Associated Protein 2; Pharmacogenetics; Raltegravir Potassium; Ritonavir; Tenofovir; Viral Load | 2020 |
HIV-1 genetic diversity to estimate time of infection and infer adherence to preexposure prophylaxis.
Topics: Administration, Oral; Animals; Anti-HIV Agents; Double-Blind Method; Female; Genetic Variation; HIV Infections; HIV-1; Humans; Macaca; Male; Medication Adherence; Pre-Exposure Prophylaxis; Tenofovir | 2019 |
Association between HIV antiretroviral therapy and preterm birth based on antenatal ultrasound gestational age determination: a comparative analysis.
Topics: Adult; Anti-HIV Agents; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; Gestational Age; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Logistic Models; Lopinavir; Nevirapine; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Premature Birth; Risk; Ritonavir; Tenofovir; Ultrasonography, Prenatal; Young Adult; Zidovudine | 2019 |
On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial.
Topics: Adult; Anti-HIV Agents; Canada; Double-Blind Method; France; HIV Infections; HIV-1; Homosexuality, Male; Humans; Incidence; Male; Medication Adherence; Pre-Exposure Prophylaxis; Sexual and Gender Minorities; Sexual Behavior; Tenofovir | 2020 |
Elvitegravir-Cobicistat-Emtricitabine-Tenofovir Alafenamide Single-tablet Regimen for Human Immunodeficiency Virus Postexposure Prophylaxis.
Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Humans; Quinolones; Tablets; Tenofovir | 2020 |
Plasma concentration of neurofilament light chain protein decreases after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Central Nervous System Diseases; Creatinine; Drug Administration Schedule; Female; HIV Infections; Humans; Male; Middle Aged; Neurofilament Proteins; Tenofovir | 2019 |
Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Double-Blind Method; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Protease Inhibitors; Tablets; Tenofovir; Treatment Outcome; Viral Load | 2020 |
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phas
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Pharmaceutical Preparations; Piperazines; Pyridones; Tenofovir; Treatment Outcome; Viral Load | 2020 |
Antenatal Intracellular Concentrations of Tenofovir Diphosphate and Emtricitabine Triphosphate and Associations Between Tenofovir Diphosphate and Severe Adverse Pregnancy Outcomes: IMPAACT-PROMISE (1077BF) Trial.
Topics: Adenine; Anti-HIV Agents; Case-Control Studies; Chromatography, Liquid; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Logistic Models; Lopinavir; Medication Adherence; Organophosphates; Polyphosphates; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Retrospective Studies; Ritonavir; Tenofovir | 2020 |
Brief Report: Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Analysis.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Tenofovir; Viral Load; Young Adult | 2020 |
HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens.
Topics: Adenine; Adult; Aged; Alanine; Benzimidazoles; Coinfection; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Female; Fluorenes; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Male; Middle Aged; RNA, Viral; Sofosbuvir; Tenofovir | 2020 |
Comparative Bioavailability of Oral Granule Formulations of the HIV Antiretroviral Drugs Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Biological Availability; Cross-Over Studies; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Pyridones; Reverse Transcriptase Inhibitors; Tablets; Tenofovir; Triazoles; Young Adult | 2020 |
Plasma and intracellular pharmacokinetics of tenofovir disoproxil fumarate and emtricitabine in transgender women receiving feminizing hormone therapy.
Topics: Adult; Anti-HIV Agents; Emtricitabine; Female; HIV Infections; Hormones; Humans; Pharmaceutical Preparations; Pre-Exposure Prophylaxis; Tenofovir; Transgender Persons | 2020 |
Efficacy and safety of lower dose tenofovir disoproxil fumarate and efavirenz versus standard dose in HIV-infected, antiretroviral-naive adults: a multicentre, randomized, noninferiority trial.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Bone Density; China; Cyclopropanes; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glomerular Filtration Rate; HIV Infections; HIV-1; Humans; Male; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load | 2020 |
Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials
Topics: Adenine; Adult; Aged; Alanine; Dideoxynucleosides; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; RNA, Viral; Tenofovir; Treatment Outcome; Young Adult | 2020 |
Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots Following Tenofovir Alafenamide: The TAF-DBS Study.
Topics: Adenine; Adolescent; Adult; Alanine; Anti-HIV Agents; Cross-Over Studies; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Male; Medication Adherence; Middle Aged; Organophosphates; Polyphosphates; Pre-Exposure Prophylaxis; Prospective Studies; Tenofovir; Young Adult | 2020 |
Plasma pharmacokinetics and urinary excretion of tenofovir following cessation in adults with controlled levels of adherence to tenofovir disoproxil fumarate.
Topics: Adult; Anti-HIV Agents; Emtricitabine; Female; Health Behavior; HIV Infections; Humans; Male; Medication Adherence; Middle Aged; Plasma; Tenofovir; Young Adult | 2020 |
An Evaluation of Baseline Kidney Function in the REPRIEVE Trial of Pitavastatin in Human Immunodeficiency Virus.
Topics: Cohort Studies; Comorbidity; Female; Glomerular Filtration Rate; HIV Infections; Humans; Male; Middle Aged; Quinolines; Renal Insufficiency, Chronic; Statistical Distributions; Tenofovir | 2020 |
Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus.
Topics: Adult; Alanine; Amides; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Piperazines; Pyridones; Tenofovir | 2021 |
A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-naïve, virologically suppressed HIV-1 infected adults
Topics: Adenine; Adult; Alanine; Amides; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Male; Mutation; Pilot Projects; Piperazines; Prospective Studies; Protease Inhibitors; Pyridones; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2020 |
Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance.
Topics: Adenine; Amides; Anti-HIV Agents; Double-Blind Method; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Logistic Models; Multivariate Analysis; Oxazines; Piperazines; Pyridones; RNA, Viral; Tenofovir | 2020 |
Real-time monitoring and just-in-time intervention for adherence to pre-exposure prophylaxis among men who have sex with men in China: a multicentre RCT study protocol.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; China; Computer Systems; Early Medical Intervention; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Male; Medication Adherence; Middle Aged; Pre-Exposure Prophylaxis; Prospective Studies; Reminder Systems; Self Report; Tenofovir; Text Messaging; Young Adult | 2020 |
Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Emtricitabine; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Europe; Female; HIV Infections; HIV-1; Homosexuality, Male; Humans; Male; North America; Placebos; Pre-Exposure Prophylaxis; Prevalence; Safety; Sexual and Gender Minorities; Tenofovir; Treatment Outcome | 2020 |
Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain; Acyclic Monoterpenes; Adenine Nucleotides; Adhesins, Escherichia coli; Adipocytes; Adipocytes, Brown; Adipogenesis; Administration, Inhalation; Administration, Oral; Adrenal Cortex Hormones; Adsorption; Adult; Aeromonas hydrophila; Africa; Aged; Aged, 80 and over; Agrobacterium tumefaciens; Air; Air Pollutants; Air Pollution; Air Pollution, Indoor; Algorithms; Alkaloids; Alkynes; Allosteric Regulation; Amines; Amino Acid Sequence; Amino Acids; Amino Acids, Branched-Chain; Aminoisobutyric Acids; Aminopyridines; Amyotrophic Lateral Sclerosis; Anaerobic Threshold; Angiography; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animal Distribution; Animal Feed; Animal Nutritional Physiological Phenomena; Animals; Ankle Joint; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Inflammatory Agents; Antibodies, Bacterial; Antifungal Agents; Antimalarials; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antioxidants; Antiretroviral Therapy, Highly Active; Antiviral Agents; Aotidae; Apelin; Apoptosis; Arabidopsis Proteins; Argentina; Arginine; Artemisinins; Arthritis, Experimental; Arthritis, Rheumatoid; Arthroscopy; Aspergillus; Aspergillus niger; Asteraceae; Asthma; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; Auditory Cortex; Autoantibodies; Autophagy; Bacteria; Bacterial Infections; Bacterial Proteins; Bacterial Typing Techniques; Base Composition; Base Sequence; Basketball; Beclin-1; Benzhydryl Compounds; Benzimidazoles; Benzo(a)pyrene; Benzofurans; Benzoxazines; Bereavement; beta Catenin; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Betacoronavirus; Betaine; Binding Sites; Biofilms; Biological Assay; Biological Availability; Biological Evolution; Biomarkers; Biomechanical Phenomena; Biopolymers; Biopsy; Bismuth; Blood Glucose; Blood Platelets; Blood Pressure; Body Composition; Body Weight; Bone Marrow; Bone Marrow Cells; Bone Regeneration; Boron; Botrytis; Brain Ischemia; Brain Neoplasms; Brain-Derived Neurotrophic Factor; Brazil; Breast Neoplasms; Breath Tests; Bronchoalveolar Lavage Fluid; Burkholderia; C-Reactive Protein; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Calcification, Physiologic; Calcium; Calcium Signaling; Calorimetry, Differential Scanning; Cameroon; Camptothecin; Candida; Candida albicans; Capillaries; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Carbohydrate Conformation; Carbon; Carbon Dioxide; Carbon Isotopes; Carcinoma, Ovarian Epithelial; Cardiac Output; Cardiomyopathy, Hypertrophic; Cardiotonic Agents; Cardiovascular Diseases; Caregivers; Carps; Case-Control Studies; Catalase; Catalysis; Cats; CD4 Lymphocyte Count; Cell Culture Techniques; Cell Differentiation; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Survival; Cells, Cultured; Cellulose; Centrosome; Ceratopogonidae; Chickens; Child; China; Cholera Toxin; Choline; Cholinesterases; Chromatography, High Pressure Liquid; Chromatography, Liquid; Chromatography, Micellar Electrokinetic Capillary; Chromatography, Reverse-Phase; Chronic Disease; Cinnamates; Cities; Citrates; Climate Change; Clinical Trials, Phase III as Topic; Coal; Coal Mining; Cohort Studies; Coinfection; Colchicine; Colony Count, Microbial; Colorectal Neoplasms; Coloring Agents; Common Cold; Complement Factor H; Computational Biology; Computer Simulation; Continuous Positive Airway Pressure; Contrast Media; Coordination Complexes; Coronary Artery Bypass; Coronavirus 3C Proteases; Coronavirus Infections; Coronavirus Protease Inhibitors; Corynebacterium glutamicum; Cosmetics; COVID-19; Creatinine; Cross-Sectional Studies; Crotonates; Crystallography, X-Ray; Cues; Culicidae; Culture Media; Curcuma; Cyclopentanes; Cyclopropanes; Cymbopogon; Cystine; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Cytokines; Databases, Genetic; Death; Dendritic Cells; Density Functional Theory; Depsides; Diabetes Mellitus, Type 2; Diamond; Diarylheptanoids; Dibenzofurans; Dibenzofurans, Polychlorinated; Diclofenac; Diet; Dietary Carbohydrates; Dietary Supplements; Diffusion Magnetic Resonance Imaging; Dioxins; Diphenylamine; Disease Outbreaks; Disease Susceptibility; Disulfides; Dithiothreitol; Dizocilpine Maleate; DNA Methylation; DNA-Binding Proteins; DNA, Bacterial; Dogs; Dose-Response Relationship, Drug; Double-Blind Method; Doublecortin Protein; Drosophila melanogaster; Droughts; Drug Carriers; Drug Combinations; Drug Delivery Systems; Drug Liberation; Drug Resistance; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Dust; Dynactin Complex; Dysferlin; Echo-Planar Imaging; Echocardiography; Edaravone; Egypt; Elasticity; Electrodes; Electrolytes; Emodin; Emtricitabine; Endometriosis; Endothelium, Vascular; Endotoxins; Energy Metabolism; Energy Transfer; Enterobacteriaceae; Enterococcus faecalis; Enterotoxigenic Escherichia coli; Environmental Monitoring; Enzyme Inhibitors; Epidemiologic Factors; Epigenesis, Genetic; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Vaccines; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Esterases; Esterification; Ethanol; Ethiopia; Ethnicity; Eucalyptus; Evidence-Based Practice; Exercise; Exercise Tolerance; Extracorporeal Membrane Oxygenation; Family; Fatty Acids; Feedback; Female; Ferric Compounds; Fibrin Fibrinogen Degradation Products; Filtration; Fish Diseases; Flavonoids; Flavonols; Fluorodeoxyglucose F18; Follow-Up Studies; Food Microbiology; Food Preservation; Forests; Fossils; Free Radical Scavengers; Freund's Adjuvant; Fruit; Fungi; Gallium; Gender Identity; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Genes, Bacterial; Genes, Plant; Genetic Predisposition to Disease; Genitalia; Genotype; Glomerulonephritis, IGA; Glottis; Glucocorticoids; Glucose; Glucuronides; Glutathione Transferase; Glycogen Synthase Kinase 3 beta; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Grassland; Guinea Pigs; Half-Life; Head Kidney; Heart Atria; Heart Rate; Heart Septum; HEK293 Cells; Hematopoietic Stem Cells; Hemodynamics; Hep G2 Cells; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Hepatocytes; Hesperidin; High-Frequency Ventilation; High-Temperature Requirement A Serine Peptidase 1; Hippocampus; Hirudins; History, 20th Century; History, 21st Century; HIV Infections; Homeostasis; Hominidae; Housing, Animal; Humans; Hydrocarbons, Brominated; Hydrogen Bonding; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydroxybutyrates; Hydroxyl Radical; Hypertension; Hypothyroidism; Image Interpretation, Computer-Assisted; Immunoconjugates; Immunogenic Cell Death; Indoles; Infant, Newborn; Infant, Premature; Infarction, Middle Cerebral Artery; Inflammation; Inflammation Mediators; Infrared Rays; Inhibitory Concentration 50; Injections, Intravenous; Interferon-gamma; Interleukin-23; Interleukin-4; Interleukin-6; Intermediate Filaments; Intermittent Claudication; Intestine, Small; Iridoid Glucosides; Iridoids; Iron; Isomerism; Isotope Labeling; Isoxazoles; Itraconazole; Kelch-Like ECH-Associated Protein 1; Ketoprofen; Kidney Failure, Chronic; Kinetics; Klebsiella pneumoniae; Lactams, Macrocyclic; Lactobacillus; Lactulose; Lakes; Lamivudine; Laparoscopy; Laparotomy; Laryngoscopy; Leucine; Limit of Detection; Linear Models; Lipid A; Lipopolysaccharides; Listeria monocytogenes; Liver; Liver Cirrhosis; Logistic Models; Longitudinal Studies; Losartan; Low Back Pain; Lung; Lupinus; Lupus Erythematosus, Systemic; Machine Learning; Macular Degeneration; Madin Darby Canine Kidney Cells; Magnetic Phenomena; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Magnetics; Malaria, Falciparum; Male; Mannans; MAP Kinase Signaling System; Mass Spectrometry; Melatonin; Membrane Glycoproteins; Membrane Proteins; Meniscectomy; Menisci, Tibial; Mephenytoin; Mesenchymal Stem Cells; Metal Nanoparticles; Metal-Organic Frameworks; Methionine; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Mice, Obese; Mice, Transgenic; Microbial Sensitivity Tests; Microcirculation; MicroRNAs; Microscopy, Video; Microtubules; Microvascular Density; Microwaves; Middle Aged; Minimally Invasive Surgical Procedures; Models, Animal; Models, Biological; Models, Molecular; Models, Theoretical; Molecular Docking Simulation; Molecular Structure; Molecular Weight; Morus; Mouth Floor; Multicenter Studies as Topic; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Muscle, Skeletal; Myocardial Ischemia; Myocardium; NAD; NADP; Nanocomposites; Nanoparticles; Naphthols; Nasal Lavage Fluid; Nasal Mucosa; Neisseria meningitidis; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasms, Experimental; Neural Stem Cells; Neuroblastoma; Neurofilament Proteins; Neurogenesis; Neurons; New York; NF-E2-Related Factor 2; NF-kappa B; Nicotine; Nitriles; Nitrogen; Nitrogen Fixation; North America; Observer Variation; Occupational Exposure; Ochrobactrum; Oils, Volatile; Olea; Oligosaccharides; Omeprazole; Open Field Test; Optimism; Oregon; Oryzias; Osmolar Concentration; Osteoarthritis; Osteoblasts; Osteogenesis; Ovarian Neoplasms; Ovariectomy; Oxadiazoles; Oxidation-Reduction; Oxidative Stress; Oxygen; Ozone; p38 Mitogen-Activated Protein Kinases; Pakistan; Pandemics; Particle Size; Particulate Matter; Patient-Centered Care; Pelargonium; Peptides; Perception; Peripheral Arterial Disease; Peroxides; Pets; Pharmaceutical Preparations; Pharmacogenetics; Phenobarbital; Phenols; Phenotype; Phosphates; Phosphatidylethanolamines; Phosphines; Phospholipids; Phosphorus; Phosphorylation; Photoacoustic Techniques; Photochemotherapy; Photosensitizing Agents; Phylogeny; Phytoestrogens; Pilot Projects; Plant Components, Aerial; Plant Extracts; Plant Immunity; Plant Leaves; Plant Oils; Plants, Medicinal; Plasmodium berghei; Plasmodium falciparum; Platelet Activation; Platelet Function Tests; Pneumonia, Viral; Poaceae; Pogostemon; Poloxamer; Poly I; Poly(ADP-ribose) Polymerase Inhibitors; Polychlorinated Biphenyls; Polychlorinated Dibenzodioxins; Polycyclic Compounds; Polyethylene Glycols; Polylysine; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Population Dynamics; Portasystemic Shunt, Transjugular Intrahepatic; Positron Emission Tomography Computed Tomography; Postoperative Complications; Postprandial Period; Potassium Cyanide; Predictive Value of Tests; Prefrontal Cortex; Pregnancy; Prepulse Inhibition; Prevalence; Procalcitonin; Prodrugs; Prognosis; Progression-Free Survival; Proline; Proof of Concept Study; Prospective Studies; Protein Binding; Protein Conformation; Protein Domains; Protein Folding; Protein Multimerization; Protein Sorting Signals; Protein Structure, Secondary; Proton Pump Inhibitors; Protozoan Proteins; Psychometrics; Pulse Wave Analysis; Pyridines; Pyrrolidines; Quality of Life; Quantum Dots; Quinoxalines; Quorum Sensing; Radiopharmaceuticals; Rain; Random Allocation; Randomized Controlled Trials as Topic; Rats; Rats, Sprague-Dawley; Rats, Wistar; RAW 264.7 Cells; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Receptor, PAR-1; Receptors, CXCR4; Receptors, Estrogen; Receptors, Glucocorticoid; Receptors, Interleukin-1; Receptors, Interleukin-17; Receptors, Notch; Recombinant Fusion Proteins; Recombinant Proteins; Reducing Agents; Reflex, Startle; Regional Blood Flow; Regression Analysis; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Tract Diseases; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Risk Assessment; Risk Factors; Rituximab; RNA, Messenger; RNA, Ribosomal, 16S; ROC Curve; Rosmarinic Acid; Running; Ruthenium; Rutin; Sarcolemma; Sarcoma; Sarcopenia; Sarcoplasmic Reticulum; SARS-CoV-2; Scavenger Receptors, Class A; Schools; Seasons; Seeds; Sequence Analysis, DNA; Severity of Illness Index; Sex Factors; Shock, Cardiogenic; Short Chain Dehydrogenase-Reductases; Signal Transduction; Silver; Singlet Oxygen; Sinusitis; Skin; Skin Absorption; Small Molecule Libraries; Smoke; Socioeconomic Factors; Soil; Soil Microbiology; Solid Phase Extraction; Solubility; Solvents; Spain; Spectrometry, Mass, Electrospray Ionization; Spectroscopy, Fourier Transform Infrared; Speech; Speech Perception; Spindle Poles; Spleen; Sporothrix; Staphylococcal Infections; Staphylococcus aureus; Stereoisomerism; Stomach Neoplasms; Stress, Physiological; Stroke Volume; Structure-Activity Relationship; Substrate Specificity; Sulfonamides; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Rate; T-Lymphocytes, Cytotoxic; Tandem Mass Spectrometry; Temperature; Tenofovir; Terpenes; Tetracycline; Tetrapleura; Textiles; Thermodynamics; Thiobarbituric Acid Reactive Substances; Thrombin; Thyroid Hormones; Thyroid Neoplasms; Tibial Meniscus Injuries; Time Factors; Tissue Distribution; Titanium; Toluidines; Tomography, X-Ray Computed; Tooth; Tramadol; Transcription Factor AP-1; Transcription, Genetic; Transfection; Transgender Persons; Translations; Treatment Outcome; Triglycerides; Ubiquinone; Ubiquitin-Specific Proteases; United Kingdom; United States; Up-Regulation; Vascular Stiffness; Veins; Ventricular Remodeling; Viral Load; Virulence Factors; Virus Replication; Vitis; Voice; Voice Quality; Wastewater; Water; Water Pollutants, Chemical; Water-Electrolyte Balance; Weather; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Young Adult; Zoogloea | 2022 |
Youth-friendly services and a mobile phone application to promote adherence to pre-exposure prophylaxis among adolescent men who have sex with men and transgender women at-risk for HIV in Thailand: a randomized control trial.
Topics: Adenine; Adolescent; Adolescent Health Services; Anti-HIV Agents; Condoms; Female; HIV Infections; Homosexuality, Male; Humans; Male; Medication Adherence; Mobile Applications; Pre-Exposure Prophylaxis; Risk-Taking; Sexual and Gender Minorities; Tenofovir; Thailand; Transgender Persons; Young Adult | 2020 |
Bone mineral density, kidney function, weight gain and insulin resistance in women who switch from TDF/FTC/NNRTI to ABC/3TC/DTG.
Topics: Adult; Anti-HIV Agents; Bone Density; Dideoxynucleosides; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Insulin Resistance; Kidney; Lamivudine; Middle Aged; Oxazines; Piperazines; Pyridones; Tenofovir; Weight Gain | 2021 |
Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, n
Topics: Adenine; Adolescent; Adult; Alanine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Body Composition; Body Weight; Cyclopropanes; Duration of Therapy; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2020 |
Effects of vitamin D and calcium supplementation on bone mineral density among Thai youth using daily HIV pre-exposure prophylaxis.
Topics: Absorptiometry, Photon; Adolescent; Anti-HIV Agents; Bone Density; Calcium; Dietary Supplements; Emtricitabine; HIV Infections; Humans; Male; Pre-Exposure Prophylaxis; Tenofovir; Thailand; Vitamin D; Young Adult | 2020 |
Methotrexate Decreases Tenofovir Exposure in Antiretroviral-Suppressed Individuals Living With HIV.
Topics: Anti-HIV Agents; Double-Blind Method; Drug Interactions; Female; HIV Infections; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Tenofovir | 2020 |
Acceptability of a Tenofovir Disoproxil Fumarate Intravaginal Ring for HIV Pre-Exposure Prophylaxis Among Sexually Active Women.
Topics: Administration, Intravaginal; Adolescent; Adult; Anti-HIV Agents; Delayed-Action Preparations; Drug Delivery Systems; Female; HIV Infections; Humans; Patient Satisfaction; Pre-Exposure Prophylaxis; Tenofovir; Young Adult | 2020 |
Acceptability, safety, and patterns of use of oral tenofovir disoproxil fumarate and emtricitabine for HIV pre-exposure prophylaxis in South African adolescents: an open-label single-arm phase 2 trial.
Topics: Adolescent; Adult; Anti-HIV Agents; Emtricitabine; Female; HIV Infections; Humans; Male; Medication Adherence; Pre-Exposure Prophylaxis; South Africa; Tenofovir; Young Adult | 2020 |
Week 96 resistance analyses of the once-daily, single-tablet regimen (STR) darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in adults living with HIV-1 from the phase 3 randomized AMBER and EMERALD trials.
Topics: Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Drug Combinations; Drug Resistance, Multiple, Viral; Emtricitabine; HIV Infections; HIV-1; Sequence Analysis, DNA; Tablets; Tenofovir; Viral Load | 2021 |
Randomized Pilot Study of an Advanced Smart-Pill Bottle as an Adherence Intervention in Patients With HIV on Antiretroviral Treatment.
Topics: Adenine; Adult; Anti-HIV Agents; Anti-Retroviral Agents; Female; HIV Infections; Humans; Male; Middle Aged; Organophosphates; Pilot Projects; Tenofovir | 2021 |
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferiority
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Emtricitabine; Fumarates; HIV Infections; HIV-1; Humans; Lamivudine; Pyridones; Tenofovir; Treatment Outcome; Triazoles | 2021 |
The Impact of a Mobile Gaming Intervention to Increase Adherence to Pre-exposure Prophylaxis.
Topics: Anti-HIV Agents; HIV Infections; Homosexuality, Male; Humans; Male; Medication Adherence; Pre-Exposure Prophylaxis; Sexual and Gender Minorities; Tenofovir; Video Games | 2021 |
Short Communication: Higher Tenofovir Concentrations in Hair Are Associated with Decreases in Viral Load and Not Self-Reported Adherence in HIV-Infected Adolescents with Second-Line Virological Treatment Failure.
Topics: Adolescent; Anti-HIV Agents; Female; Hair; HIV Infections; Humans; Male; Medication Adherence; Self Report; Tenofovir; Treatment Failure; Viral Load; Zimbabwe | 2021 |
Week 96 subgroup analyses of the phase 3, randomized AMBER and EMERALD trials evaluating the efficacy and safety of the once daily darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen in antiretroviral treatment (ART)
Topics: Adult; Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Emtricitabine; HIV Infections; HIV-1; Humans; Middle Aged; Tablets; Tenofovir | 2020 |
Safety, adherence, and HIV-1 seroconversion among women using the dapivirine vaginal ring (DREAM): an open-label, extension study.
Topics: Administration, Intravaginal; Adolescent; Adult; Anti-HIV Agents; Contraceptive Devices, Female; Female; HIV Infections; HIV-1; Humans; Middle Aged; Patient Compliance; Patient Safety; Pyrimidines; Seroconversion; South Africa; Tenofovir; Treatment Outcome; Uganda | 2021 |
Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study.
Topics: Administration, Intravaginal; Adult; Anti-HIV Agents; Contraceptive Devices, Female; Female; HIV Infections; HIV-1; Humans; Malawi; Patient Compliance; Patient Safety; Pyrimidines; Seroconversion; South Africa; Tenofovir; Treatment Outcome; Uganda; Zimbabwe | 2021 |
Impact of postpartum tenofovir-based antiretroviral therapy on bone mineral density in breastfeeding women with HIV enrolled in a randomized clinical trial.
Topics: Absorptiometry, Photon; Adult; Anti-HIV Agents; Bone Density; Breast Feeding; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Lopinavir; Postpartum Period; Ritonavir; Tenofovir; Young Adult | 2021 |
A Mechanistic In Vivo/Ex Vivo Pharmacokinetic-Pharmacodynamic Model of Tenofovir for HIV Prevention.
Topics: Administration, Oral; Administration, Rectal; Adult; Aged; Anti-HIV Agents; Biological Availability; Drug Development; Female; Gels; HIV Core Protein p24; HIV Infections; HIV Seronegativity; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Models, Theoretical; Pre-Exposure Prophylaxis; Rectum; Tenofovir; Virus Replication | 2021 |
Efficacy, safety and central nervous system effects after switch from efavirenz/tenofovir/emtricitabine to doravirine/tenofovir/lamivudine.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System; Cyclopropanes; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Male; Pyridones; Tenofovir; Treatment Outcome; Triazoles | 2021 |
Brief Report: Improvement in Metabolic Health Parameters at Week 48 After Switching From a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen to the 2-Drug Regimen of Dolutegravir/Lamivudine: The TANGO Study.
Topics: Adult; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Blood Glucose; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Insulin Resistance; Lamivudine; Lipids; Metabolic Syndrome; Oxazines; Piperazines; Pyridones; Tenofovir; Viral Load; Weight Gain | 2021 |
A Phase 2b Study to Evaluate the Safety and Efficacy of VRC01 Broadly Neutralizing Monoclonal Antibody in Reducing Acquisition of HIV-1 Infection in Women in Sub-Saharan Africa: Baseline Findings.
Topics: Adolescent; Adult; AIDS Vaccines; Antibodies, Monoclonal; Botswana; Broadly Neutralizing Antibodies; Chlamydia; Chlamydia Infections; Contraception; Double-Blind Method; Female; Gonorrhea; HIV Antibodies; HIV Infections; HIV-1; Humans; Incidence; Kenya; Malawi; Middle Aged; Mozambique; Prevalence; Sexually Transmitted Diseases; South Africa; Syphilis; Tenofovir; Trichomonas; Trichomonas Infections; Young Adult | 2021 |
Brief Report: Switching to DOR/3TC/TDF Maintains HIV-1 Virologic Suppression Through Week 144 in the DRIVE-SHIFT Trial.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Pyridones; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Triazoles; Weight Gain; Weight Loss | 2021 |
Administration of zoledronic acid alleviates osteoporosis in HIV patients by suppressing osteoclastogenesis via regulating RANKL expression.
Topics: Adult; Anti-Retroviral Agents; Bone Density; Bone Density Conservation Agents; Cell Proliferation; Cells, Cultured; Cyclic AMP-Dependent Protein Kinase Catalytic Subunits; Female; HIV Infections; Humans; Male; MAP Kinase Signaling System; MicroRNAs; Middle Aged; Osteoclasts; Osteogenesis; Osteoporosis; RANK Ligand; Smad3 Protein; Tenofovir; Zoledronic Acid | 2021 |
Effect of SMS reminders on PrEP adherence in young Kenyan women (MPYA study): a randomised controlled trial.
Topics: Adolescent; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Kenya; Medication Adherence; Pre-Exposure Prophylaxis; Risk; Tenofovir; Text Messaging; Unsafe Sex; Young Adult | 2021 |
Kidney injury biomarkers during exposure to tenofovir-based preexposure prophylaxis.
Topics: Adult; Anti-HIV Agents; Biomarkers; Emtricitabine; HIV Infections; Humans; Kidney; Pre-Exposure Prophylaxis; Tenofovir | 2021 |
Tenofovir disoproxil fumarate and emtricitabine maintenance strategy in virologically controlled adults with low HIV-1 DNA: 48 week results from a randomized, open-label, non-inferiority trial.
Topics: Adenine; Adult; Anti-HIV Agents; DNA; Emtricitabine; HIV Infections; HIV-1; Humans; Tenofovir; Treatment Outcome; Viral Load | 2021 |
A Phase I Evaluation of the Pharmacokinetics and Tolerability of the HIV-1 Maturation Inhibitor GSK3640254 and Tenofovir Alafenamide/Emtricitabine in Healthy Participants.
Topics: Adenine; Alanine; Anti-HIV Agents; Emtricitabine; Healthy Volunteers; HIV Infections; HIV-1; Humans; Male; Tenofovir | 2021 |
Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Drug Therapy, Combination; Emtricitabine; Female; Gestational Age; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Oxazines; Piperazines; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Pyridones; Tenofovir; Ultrasonography, Prenatal | 2021 |
Three-year study of pre-existing drug resistance substitutions and efficacy of bictegravir/emtricitabine/tenofovir alafenamide in HIV-1 treatment-naive participants.
Topics: Alanine; Amides; Anti-HIV Agents; Drug Combinations; Drug Resistance; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Piperazines; Pyridones; Retrospective Studies; Tenofovir | 2021 |
Using the adherence-efficacy relationship of emtricitabine and tenofovir disoproxil fumarate to calculate background hiv incidence: a secondary analysis of a randomized, controlled trial.
Topics: Anti-HIV Agents; Bayes Theorem; Emtricitabine; Female; HIV Infections; Homosexuality, Male; Humans; Male; Pre-Exposure Prophylaxis; Sexual and Gender Minorities; Tenofovir | 2021 |
Pharmacokinetic-pharmacodynamic modelling of atazanavir in hair among adolescents on antiretroviral treatment in Zimbabwe.
Topics: Adolescent; Anti-Retroviral Agents; Atazanavir Sulfate; Caregivers; Female; Hair; HIV Infections; Humans; Lamivudine; Male; Medication Adherence; Models, Biological; Overweight; Ritonavir; Tenofovir; Thinness; Viral Load; Zimbabwe | 2021 |
Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Adenine; Adult; Aged; Alanine; Anti-HIV Agents; Double-Blind Method; Drug Therapy, Combination; Emtricitabine; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Pre-Exposure Prophylaxis; Tenofovir; Treatment Outcome; Young Adult | 2021 |
Estimated pill intake with on-demand PrEP with oral TDF/FTC using TFV-DP concentration in dried blood spots in the ANRS IPERGAY trial.
Topics: Adenine; Adult; Anti-HIV Agents; Emtricitabine; Female; HIV Infections; Homosexuality, Male; Humans; Male; Medication Adherence; Organophosphates; Pre-Exposure Prophylaxis; Sexual and Gender Minorities; Tenofovir | 2021 |
Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV.
Topics: Adolescent; Adult; Anti-HIV Agents; Child; Darunavir; Drug Resistance; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load; Young Adult; Zidovudine | 2021 |
Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women.
Topics: Administration, Oral; Adult; Aged; Anti-HIV Agents; Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedule; Drug Resistance; Female; HIV Infections; HIV Integrase Inhibitors; Homosexuality, Male; Humans; Injections, Intramuscular; Intention to Treat Analysis; Male; Medication Adherence; Middle Aged; Pre-Exposure Prophylaxis; Pyridones; Tenofovir; Transgender Persons; Young Adult | 2021 |
Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study.
Topics: Adenine; Adolescent; Adult; Aged; Alanine; Amides; Anti-HIV Agents; Black or African American; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV Seropositivity; HIV-1; Humans; Male; Middle Aged; Piperazines; Pyridones; RNA; Tenofovir; United States; Viral Load | 2021 |
Impact of Medication Adherence on Virologic Failure in A5202: A Randomized, Partially Blinded, Phase 3B Study.
Topics: Adult; Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Medication Adherence; RNA, Viral; Self Report; Tenofovir; Treatment Failure; Viral Load | 2017 |
Detection of new HIV infections in a multicentre HIV antiretroviral pre-exposure prophylaxis trial.
Topics: Anti-HIV Agents; Double-Blind Method; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV Seropositivity; HIV-1; Humans; Pre-Exposure Prophylaxis; Tenofovir | 2017 |
Bone mineral density reductions after tenofovir disoproxil fumarate initiation and changes in phosphaturia: a secondary analysis of ACTG A5224s.
Topics: Adult; Anti-HIV Agents; Bone Density; Dideoxynucleosides; Female; Glomerular Filtration Rate; Hip; HIV Infections; Humans; Hypophosphatemia, Familial; Male; Middle Aged; Phosphates; Spine; Tenofovir; Young Adult | 2017 |
Insulin-Like Growth Factor Is Associated with Changes in Body Composition with Antiretroviral Therapy Initiation.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Body Composition; Cyclopropanes; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Insulin-Like Growth Factor I; Lamivudine; Male; Prospective Studies; Tenofovir; Zidovudine | 2017 |
Evaluation of a Multidrug Assay for Monitoring Adherence to a Regimen for HIV Preexposure Prophylaxis in a Clinical Study, HIV Prevention Trials Network 073.
Topics: Anti-HIV Agents; Drug Resistance, Multiple, Viral; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; Humans; Male; Medication Adherence; Pre-Exposure Prophylaxis; Tenofovir | 2017 |
Herpes Simplex Virus Type 2 Acquisition Among HIV-1-Infected Adults Treated With Tenofovir Disoproxyl Fumarate as Part of Combination Antiretroviral Therapy: Results From the ACTG A5175 PEARLS Study.
Topics: Adolescent; Adult; Antiviral Agents; Female; Herpes Simplex; Herpesvirus 2, Human; HIV Infections; HIV-1; Humans; International Cooperation; Male; Medication Adherence; Middle Aged; Pre-Exposure Prophylaxis; Proportional Hazards Models; Seroconversion; Tenofovir; Young Adult | 2017 |
Acceptability of and Adherence to an Antiretroviral-Based Vaginal Microbicide among Pregnant Women in the United States.
Topics: Administration, Intravaginal; Adolescent; Adult; Alabama; Anti-Infective Agents; Anti-Retroviral Agents; Cohort Studies; Female; HIV Infections; Humans; Medication Adherence; Patient Acceptance of Health Care; Philadelphia; Pregnancy; Pregnant Women; Tenofovir; Treatment Outcome; United States; Vaginal Creams, Foams, and Jellies; Young Adult | 2018 |
Efficacy and safety of a once-daily single-tablet regimen of tenofovir, lamivudine, and efavirenz assessed at 144 weeks among antiretroviral-naïve and experienced HIV-1-infected Thai adults.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Prospective Studies; Tablets; Tenofovir; Thailand | 2017 |
Brief Report: Recovery of Bone Mineral Density After Discontinuation of Tenofovir-Based HIV Pre-exposure Prophylaxis.
Topics: Absorptiometry, Photon; Adult; Anti-HIV Agents; Bone Density; Bone Diseases; Emtricitabine; Female; Follow-Up Studies; HIV Infections; Homosexuality, Male; Humans; Male; Patient Compliance; Pre-Exposure Prophylaxis; Tenofovir | 2017 |
HIV disease progression among women following seroconversion during a tenofovir-based HIV prevention trial.
Topics: Adult; CD4 Lymphocyte Count; Disease Progression; Female; HIV Infections; HIV Seropositivity; Humans; Placebos; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load; Young Adult | 2017 |
Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Prospective Studies; Rilpivirine; Tenofovir; Treatment Outcome; Viral Load | 2017 |
Switching to the single-tablet regimen of elvitegravir, cobicistat, emtricitabine, and tenofovir DF from non-nucleoside reverse transcriptase inhibitor plus coformulated emtricitabine and tenofovir DF regimens: Week 96 results of STRATEGY-NNRTI.
Topics: Adult; Antiretroviral Therapy, Highly Active; Cobicistat; Drug Combinations; Drug Substitution; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Patient Reported Outcome Measures; Quinolones; Tablets; Tenofovir; Time Factors; Treatment Outcome | 2017 |
Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label
Topics: Adult; Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Middle Aged; Oxazines; Piperazines; Pyridones; Tenofovir; Treatment Outcome | 2017 |
Efficacy of oral pre-exposure prophylaxis (PrEP) for HIV among women with abnormal vaginal microbiota: a post-hoc analysis of the randomised, placebo-controlled Partners PrEP Study.
Topics: Adult; Anti-HIV Agents; Dysbiosis; Emtricitabine; Female; Gardnerella vaginalis; HIV Infections; HIV Seropositivity; HIV-1; Humans; Kenya; Microbiota; Pre-Exposure Prophylaxis; Prospective Studies; Sexual Partners; Tenofovir; Uganda; Vagina; Vaginosis, Bacterial | 2017 |
High levels of adherence to a rectal microbicide gel and to oral Pre-Exposure Prophylaxis (PrEP) achieved in MTN-017 among men who have sex with men (MSM) and transgender women.
Topics: Administration, Oral; Administration, Rectal; Adolescent; Adult; Anti-HIV Agents; Cross-Over Studies; Emtricitabine; Female; Gels; HIV Infections; Homosexuality, Male; Humans; Male; Medication Adherence; Middle Aged; Pre-Exposure Prophylaxis; Tenofovir; Transgender Persons; Young Adult | 2017 |
Combination antiretroviral therapy improves cognitive performance and functional connectivity in treatment-naïve HIV-infected individuals.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Brain; Cognition; Diffusion Tensor Imaging; Emtricitabine; HIV Infections; Humans; Male; Tenofovir | 2017 |
Is laboratory screening prior to antiretroviral treatment useful in Johannesburg, South Africa? Baseline findings of a clinical trial.
Topics: Adult; Albuminuria; Anemia; Anti-HIV Agents; Antigens; CD4 Lymphocyte Count; Cities; Clinical Laboratory Techniques; Coinfection; Cost-Benefit Analysis; Creatinine; Female; Health Care Costs; Hemoglobins; Hepatitis B; HIV Infections; Humans; Kidney Diseases; Male; Mass Screening; Neutropenia; South Africa; Tenofovir; Transaminases | 2017 |
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Dideoxynucleosides; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Internationality; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Prognosis; Pyridones; Risk Assessment; Survival Rate; Tenofovir; Treatment Outcome; Young Adult | 2017 |
Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiori
Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Double-Blind Method; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Male; Middle Aged; Oxazines; Piperazines; Prognosis; Pyridones; Risk Assessment; Survival Rate; Tenofovir; Treatment Outcome; Young Adult | 2017 |
Week 48 resistance analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF versus Atazanavir + Ritonavir + Emtricitabine/Tenofovir DF in HIV-1 infected women (WAVES study GS-US-236-0128).
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cobicistat; Drug Resistance, Viral; Emtricitabine; Female; Genotype; HIV Infections; HIV-1; Humans; Microbial Sensitivity Tests; Mutation; Quinolones; Sequence Analysis, DNA; Tenofovir; Time Factors; Treatment Failure; Treatment Outcome; Viral Load | 2017 |
Changes in Liver Steatosis After Switching From Efavirenz to Raltegravir Among Human Immunodeficiency Virus-Infected Patients With Nonalcoholic Fatty Liver Disease.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Body Mass Index; Body Weight; Cyclopropanes; Dideoxynucleosides; Drug Substitution; Drug Therapy, Combination; Elasticity Imaging Techniques; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Raltegravir Potassium; Tenofovir; Triglycerides; Waist-Hip Ratio | 2017 |
Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial.
Topics: Administration, Oral; Adult; Anti-HIV Agents; Biological Availability; Coinfection; Double-Blind Method; Emtricitabine; Female; Hepatitis B; Hepatitis C; HIV Infections; HIV-1; Humans; Male; Quality of Life; Raltegravir Potassium; RNA, Viral; Tenofovir; Viral Load | 2017 |
Prevalent Herpes Simplex Virus-2 Increases the Risk of Incident Bacterial Vaginosis in Women from South Africa.
Topics: Administration, Intravaginal; Administration, Oral; Adult; Cross-Sectional Studies; Developing Countries; Double-Blind Method; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; Gels; Herpes Genitalis; Herpesvirus 2, Human; HIV Infections; HIV Seronegativity; Humans; Incidence; Risk Factors; South Africa; Tenofovir; Unsafe Sex; Vaginosis, Bacterial; Young Adult | 2018 |
Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial.
Topics: Administration, Oral; Adult; Anti-HIV Agents; Drug Administration Schedule; Emtricitabine; Feasibility Studies; Female; HIV Infections; Humans; Medication Adherence; Pre-Exposure Prophylaxis; South Africa; Tenofovir; Treatment Outcome; Young Adult | 2018 |
Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppr
Topics: Adult; Cobicistat; Darunavir; Drug Administration Schedule; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Tenofovir; Treatment Outcome; Viral Load | 2018 |
Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppressi
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Darunavir; Dideoxynucleosides; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Medication Therapy Management; Middle Aged; Ritonavir; RNA, Viral; Tenofovir; Viral Load | 2017 |
Vitamin D3 Supplementation Increases Spine Bone Mineral Density in Adolescents and Young Adults With Human Immunodeficiency Virus Infection Being Treated With Tenofovir Disoproxil Fumarate: A Randomized, Placebo-Controlled Trial.
Topics: Adolescent; Anti-HIV Agents; Bone Density; Bone Density Conservation Agents; Calcium-Regulating Hormones and Agents; Cholecalciferol; Double-Blind Method; Female; HIV Infections; Humans; Male; Placebos; Spine; Tenofovir; Treatment Outcome; Young Adult | 2018 |
Tenofovir disoproxil fumarate/emtricitabine plus ritonavir-boosted lopinavir or cobicistat-boosted elvitegravir as a single-tablet regimen for HIV post-exposure prophylaxis.
Topics: Adult; Anti-HIV Agents; Cobicistat; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Medication Adherence; Post-Exposure Prophylaxis; Prospective Studies; Quinolones; Reverse Transcriptase Inhibitors; Ritonavir; Tablets; Tenofovir | 2017 |
HIV treatment simplification to elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate (E/C/F/TDF) plus darunavir: a pharmacokinetic study.
Topics: Adult; Aged; Anti-HIV Agents; Cobicistat; Darunavir; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Integrase Inhibitors; Male; Middle Aged; Protease Inhibitors; Quinolones; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Viral Load | 2017 |
TDF and quantitative ultrasound bone quality in African patients on second line ART, ANRS 12169 2LADY sub-study.
Topics: Adult; Antiretroviral Therapy, Highly Active; Bone and Bones; Bone Demineralization, Pathologic; Bone Density; Burkina Faso; Cameroon; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Osteoporosis; Senegal; Tenofovir | 2017 |
Acceptability of a Tenofovir Disoproxil Fumarate Vaginal Ring for HIV Prevention Among Women in New York City.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Coitus; Contraceptive Devices, Female; Female; HIV Infections; Humans; New York City; Patient Acceptance of Health Care; Pre-Exposure Prophylaxis; Sexual Partners; Tenofovir | 2018 |
Universal test and treat and the HIV epidemic in rural South Africa: a phase 4, open-label, community cluster randomised trial.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Emtricitabine; Female; HIV Infections; HIV Seropositivity; Humans; Incidence; Male; Mass Screening; Middle Aged; Research Design; South Africa; Tenofovir; Treatment Outcome; Young Adult | 2018 |
Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health.
Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone Density; Drug Substitution; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Male; Middle Aged; Osteoporosis; Oxazines; Pelvic Bones; Piperazines; Pyridones; Rilpivirine; Spine; Tenofovir; Treatment Outcome | 2018 |
Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies.
Topics: Adult; Aged; Anti-HIV Agents; Bone Density; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Reverse Transcriptase Inhibitors; Rilpivirine; Tenofovir; Treatment Outcome; Viral Load | 2018 |
Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment.
Topics: Adenine; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone Density; Cobicistat; Drug Combinations; Drug Substitution; Emtricitabine; HIV Infections; HIV-1; Humans; Kidney; Quinolones; RNA, Viral; Tenofovir; Treatment Outcome | 2018 |
Metabolic Effects of Preexposure Prophylaxis With Coformulated Tenofovir Disoproxil Fumarate and Emtricitabine.
Topics: Absorptiometry, Photon; Adiposity; Administration, Oral; Adult; Anti-HIV Agents; Body Mass Index; Body Weight; Double-Blind Method; Emtricitabine; Female; HIV Infections; Humans; Lipid Metabolism; Lipids; Male; Pre-Exposure Prophylaxis; Tenofovir; Transgender Persons; Young Adult | 2018 |
Daily and Nondaily Oral Preexposure Prophylaxis in Men and Transgender Women Who Have Sex With Men: The Human Immunodeficiency Virus Prevention Trials Network 067/ADAPT Study.
Topics: Adolescent; Adult; Anti-HIV Agents; Drug Administration Schedule; Emtricitabine; Female; HIV Infections; Homosexuality, Male; Humans; Male; Medication Adherence; Pre-Exposure Prophylaxis; Tenofovir; Transgender Persons; Young Adult | 2018 |
Switching from abacavir to tenofovir disoproxil fumarate is associated with rises in soluble glycoprotein VI, suggesting changes in platelet-collagen interactions.
Topics: Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Blood Platelets; CD40 Antigens; Collagen; Dideoxynucleosides; Drug Substitution; Female; HIV Infections; Humans; Male; Middle Aged; P-Selectin; Platelet Membrane Glycoproteins; Prospective Studies; Tenofovir; Treatment Outcome; von Willebrand Factor; Young Adult | 2018 |
Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study.
Topics: Administration, Oral; Adult; Brazil; Emtricitabine; Feasibility Studies; Female; HIV Infections; Homosexuality, Male; Humans; Incidence; Male; Medication Adherence; Middle Aged; Pre-Exposure Prophylaxis; Risk-Taking; Sexually Transmitted Diseases, Viral; Tenofovir; Transgender Persons; Young Adult | 2018 |
Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trial.
Topics: Adenine; Adult; Aged; Anti-Retroviral Agents; Dideoxynucleosides; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2018 |
Brief Report: Efficacy and Safety of Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF) in Virologically Suppressed Women.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cobicistat; Double-Blind Method; Drug Combinations; Drug Resistance, Viral; Drug-Related Side Effects and Adverse Reactions; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Integrase Inhibitors; Protease Inhibitors; Quinolones; RNA, Viral; Tenofovir | 2018 |
First-line Raltegravir/Emtricitabine/Tenofovir Combination in Human Immunodeficiency Virus Type 2 (HIV-2) Infection: A Phase 2, Noncomparative Trial (ANRS 159 HIV-2).
Topics: Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-2; Humans; Integrase Inhibitors; Male; Middle Aged; Raltegravir Potassium; RNA, Viral; Tenofovir; Viral Load | 2018 |
A LC/MS/MS method for determination of tenofovir in human plasma and its application to toxicity monitoring.
Topics: Anti-HIV Agents; Chromatography, Liquid; Drug Monitoring; HIV Infections; Humans; Linear Models; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry; Tenofovir | 2018 |
Virological and immunological responses to raltegravir and dolutegravir in the gut-associated lymphoid tissue of HIV-infected men and women.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Colon, Transverse; DNA, Viral; Emtricitabine; Female; Gene Expression; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Ileum; Immunity, Innate; Lymphoid Tissue; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Raltegravir Potassium; Receptors, Antigen, T-Cell, gamma-delta; Rectum; RNA, Viral; Tenofovir; Treatment Outcome | 2018 |
Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV-coinfected individuals receiving tenofovir disoproxil fumarate.
Topics: Adenine; Adult; Antiviral Agents; Benzimidazoles; Coinfection; Drug Interactions; Fluorenes; Hepatitis C; HIV Infections; Humans; Male; Middle Aged; Organophosphates; Ribavirin; Sofosbuvir; Tenofovir; Uridine Monophosphate | 2018 |
Pre-exposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine and Kidney Tubular Dysfunction in HIV-Uninfected Individuals.
Topics: Adult; Albuminuria; Alpha-Globulins; Anti-HIV Agents; Biomarkers; Cross-Sectional Studies; Emtricitabine; Female; Glomerular Filtration Rate; HIV; HIV Infections; Humans; Kidney Diseases; Kidney Function Tests; Male; Pre-Exposure Prophylaxis; Proteinuria; Tenofovir; Transgender Persons; Urine; Young Adult | 2018 |
Pharmacokinetics and Pharmacodynamics of Tenofovir Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments in Women: A Cross-Compartmental Study With Directly Observed Dosing.
Topics: Adenine; Administration, Rectal; Adult; Anti-HIV Agents; Body Fluids; Dose-Response Relationship, Drug; Female; Gels; Glycerol; HIV Infections; Humans; Middle Aged; Organophosphates; Pre-Exposure Prophylaxis; Rectum; Tenofovir; Treatment Outcome; Vagina; Vaginal Creams, Foams, and Jellies; Virus Replication; Young Adult | 2018 |
Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phas
Topics: Adult; Aged; Amides; Anti-HIV Agents; Dideoxynucleosides; Double-Blind Method; Drug Substitution; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Sustained Virologic Response; Tenofovir; Viral Load; Young Adult | 2018 |
Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, ph
Topics: Adenine; Adult; Aged; Alanine; Amides; Anti-Retroviral Agents; Drug Substitution; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Male; Middle Aged; Piperazines; Protease Inhibitors; Pyridones; Sustained Virologic Response; Tenofovir; Viral Load; Young Adult | 2018 |
Zoledronic acid is superior to tenofovir disoproxil fumarate-switching for low bone mineral density in adults with HIV.
Topics: Absorptiometry, Photon; Adult; Aged; Anti-HIV Agents; Australia; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Drug Substitution; Female; Femur Neck; HIV Infections; Humans; Lumbar Vertebrae; Male; Middle Aged; Spain; Tenofovir; Treatment Outcome; Viral Load; Zoledronic Acid | 2018 |
Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women.
Topics: Adult; Contraceptive Devices, Female; Female; HIV Infections; HIV-1; Humans; Levonorgestrel; Models, Biological; Tenofovir | 2018 |
Patient-Reported Symptoms Over 48 Weeks Among Participants in Randomized, Double-Blind, Phase III Non-inferiority Trials of Adults with HIV on Co-formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Co-formulated Abacavir, Dolutegravir,
Topics: Adenine; Adolescent; Adult; Aged; Alanine; Amides; Anti-HIV Agents; Cohort Studies; Emtricitabine; Europe; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Male; Middle Aged; Piperazines; Pyridones; Tenofovir; United States; Young Adult | 2018 |
MALDI Mass Spectrometry Imaging Reveals Heterogeneous Distribution of Tenofovir and Tenofovir Diphosphate in Colorectal Tissue of Subjects Receiving a Tenofovir-Containing Enema.
Topics: Adenine; Colon; Enema; HIV Infections; Humans; Molecular Imaging; Organophosphates; Rectum; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tenofovir | 2018 |
Tenofovir Disoproxil Fumarate Use during Pregnancy and Infant Bone Health: the Tenofovir in Pregnancy Pilot Study.
Topics: Adult; Anti-HIV Agents; Bone and Bones; Bone Density; China; Coinfection; Female; Hepatitis B; HIV Infections; Humans; Infant; Infant Health; Pilot Projects; Pregnancy; Pregnancy Complications, Infectious; Tenofovir; Young Adult | 2018 |
FAME-04: A Phase 1 trial to assess the safety, acceptability, pharmacokinetics and pharmacodynamics of film and gel formulations of tenofovir.
Topics: Adolescent; Adult; Anti-HIV Agents; Chromatography, Liquid; Double-Blind Method; Female; HIV Infections; Humans; Middle Aged; Pre-Exposure Prophylaxis; Tandem Mass Spectrometry; Tenofovir; Vaginal Creams, Foams, and Jellies; Virus Replication; Young Adult | 2018 |
Effect of Hormonal Contraception on Pharmacokinetics of Vaginal Tenofovir in Healthy Women: Increased Tenofovir Diphosphate in Injectable Depot Medroxyprogesterone Acetate Users.
Topics: Administration, Intravaginal; Adult; Anti-HIV Agents; Contraceptive Agents, Female; Drug Interactions; Female; Healthy Volunteers; HIV Infections; Humans; Medroxyprogesterone Acetate; Menstrual Cycle; Middle Aged; Prospective Studies; Tenofovir; Treatment Outcome; Vaginal Creams, Foams, and Jellies; Young Adult | 2019 |
Tenofovir disoproxil fumarate appears to disrupt the relationship of vitamin D and parathyroid hormone.
Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Black or African American; Bone and Bones; Bone Density; Cohort Studies; Emtricitabine; Female; HIV; HIV Infections; Humans; Male; Parathyroid Hormone; Pre-Exposure Prophylaxis; Tenofovir; Vitamin D; Vitamin D Deficiency; White People; Young Adult | 2018 |
Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial.
Topics: Administration, Intravaginal; Adult; Anti-HIV Agents; Contraceptive Devices, Female; Cross-Over Studies; Drug Compounding; Drug Delivery Systems; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Maraviroc; Patient Satisfaction; Pre-Exposure Prophylaxis; Tenofovir; Young Adult | 2018 |
Similar neurocognitive outcomes after 48 weeks in HIV-1-infected participants randomized to continue tenofovir/emtricitabine + atazanavir/ritonavir or simplify to abacavir/lamivudine + atazanavir.
Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cognition; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Interleukin-6; Lamivudine; Male; Memory, Short-Term; Middle Aged; Neuropsychological Tests; Prospective Studies; Ritonavir; Tenofovir | 2019 |
Safety, efficacy, and dose response of the maturation inhibitor GSK3532795 (formerly known as BMS-955176) plus tenofovir/emtricitabine once daily in treatment-naive HIV-1-infected adults: Week 24 primary analysis from a randomized Phase IIb trial.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; Half-Life; HIV Infections; HIV-1; Humans; Male; Middle Aged; RNA, Viral; Tenofovir; Treatment Outcome; Triterpenes | 2018 |
Maximizing participant retention in a phase 2B HIV prevention trial in Kampala, Uganda: The MTN-003 (VOICE) Study.
Topics: Administration, Intravaginal; Administration, Oral; Adult; Albuterol, Ipratropium Drug Combination; Anti-HIV Agents; Clinical Trials as Topic; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; Gels; HIV Infections; Humans; Longitudinal Studies; Patient Participation; Tenofovir; Uganda | 2018 |
Predicted antiviral activity of tenofovir versus abacavir in combination with a cytosine analogue and the integrase inhibitor dolutegravir in HIV-1-infected South African patients initiating or failing first-line ART.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cytosine; Dideoxynucleosides; Drug Combinations; Drug Resistance, Viral; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Male; Middle Aged; Mutation; Oxazines; Piperazines; Pyridones; South Africa; Tenofovir; Viral Load; Young Adult | 2019 |
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferior
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Double-Blind Method; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; RNA, Viral; Tenofovir; Viral Load | 2019 |
Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Anti-HIV Agents; Disease Transmission, Infectious; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; Humans; Placebos; South Africa; Tenofovir; Treatment Outcome; Vaginal Creams, Foams, and Jellies | 2018 |
Symtuza
Topics: Anti-HIV Agents; Darunavir; Drug Combinations; HIV Infections; Humans; Medication Adherence; Tenofovir | 2018 |
Lipid levels, insulin resistance and cardiovascular risk over 96 weeks of antiretroviral therapy: a randomised controlled trial comparing low-dose stavudine and tenofovir.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Blood Glucose; Cardiovascular Diseases; Double-Blind Method; Female; HIV Infections; HIV-1; Humans; India; Insulin Resistance; Lipids; Male; Risk Factors; South Africa; Stavudine; Tenofovir; Uganda | 2018 |
Seminal Tenofovir Concentrations, Viral Suppression, and Semen Quality With Tenofovir Alafenamide, Compared With Tenofovir Disoproxil Fumarate (Spanish HIV/AIDS Research Network, PreEC/RIS 40).
Topics: Adenine; Adult; Alanine; Anti-Retroviral Agents; Cobicistat; Emtricitabine; HIV Infections; HIV-1; Humans; Male; Middle Aged; Prospective Studies; Quinolones; RNA, Viral; Semen; Semen Analysis; Tenofovir | 2019 |
No change in health-related quality of life for at-risk U.S. women and men starting HIV pre-exposure prophylaxis (PrEP): Findings from HPTN 069/ACTG A5305.
Topics: Adolescent; Adult; Aged; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Quality of Life; Tenofovir; United States | 2018 |
Self-initiated continuation of and adherence to HIV pre-exposure prophylaxis (PrEP) after PrEP demonstration project roll-off in men who have sex with men: associations with risky decision making, impulsivity/disinhibition, and sensation seeking.
Topics: Adult; Aged; Anti-HIV Agents; Decision Making; HIV Infections; Homosexuality, Male; Humans; Impulsive Behavior; Male; Medication Adherence; Middle Aged; Pre-Exposure Prophylaxis; Risk-Taking; Sexual and Gender Minorities; Tenofovir | 2019 |
Efficacy and Safety of Tenofovir Disoproxil Fumarate Versus Low-Dose Stavudine Over 96 Weeks: A Multicountry Randomized, Noninferiority Trial.
Topics: Adult; Anti-HIV Agents; Bone and Bones; Double-Blind Method; Equivalence Trials as Topic; Female; HIV Infections; Humans; Kidney; Male; South Africa; Stavudine; Tenofovir; Uganda; Young Adult | 2019 |
Randomized clinical trial on efficacy of fixed-dose efavirenz/tenofovir/emtricitabine on alternate days versus continuous treatment.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2019 |
Tenofovir Gel for Prevention of Herpes Simplex Virus Type 2 Acquisition: Findings From the VOICE Trial.
Topics: Adolescent; Adult; Antiviral Agents; Double-Blind Method; Female; Herpes Genitalis; Herpesvirus 2, Human; HIV Infections; HIV-1; Humans; Incidence; Pre-Exposure Prophylaxis; Sexual Behavior; Tenofovir; Vaginal Creams, Foams, and Jellies; Young Adult | 2019 |
Higher rates of HBsAg clearance with tenofovir-containing therapy in HBV/HIV co-infection.
Topics: Adult; Anti-HIV Agents; Coinfection; Female; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Male; Middle Aged; Retrospective Studies; Tenofovir | 2019 |
Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Lamivudine; Male; Oxazines; Piperazines; Pyridones; Tenofovir; Treatment Outcome; Viral Load | 2019 |
Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-infer
Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Tenofovir; Treatment Outcome | 2019 |
Vaginal microbiota and mucosal pharmacokinetics of tenofovir in healthy women using tenofovir and tenofovir/levonorgestrel vaginal rings.
Topics: Adenine; Adult; Anti-HIV Agents; Antiviral Agents; Contraceptive Agents, Hormonal; Contraceptive Devices, Female; Device Removal; Female; Herpes Genitalis; HIV Infections; Humans; Levonorgestrel; Microbiota; Middle Aged; Mucous Membrane; Organophosphates; Tenofovir; Vagina; Young Adult | 2019 |
Once-daily Doravirine for Initial Treatment of Adults Living With Human Immunodeficiency Virus-1: An Integrated Safety Analysis.
Topics: Adult; Anti-HIV Agents; Emtricitabine; HIV Infections; HIV-1; Humans; Pyridones; Tenofovir; Triazoles | 2020 |
Changes in Bone Mass After Discontinuation of Preexposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine in Young Men Who Have Sex With Men: Extension Phase Results of Adolescent Trials Network Protocols 110 and 113.
Topics: Adolescent; Adult; Anti-HIV Agents; Bone Density; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Male; Pre-Exposure Prophylaxis; Sexual and Gender Minorities; Tenofovir; Young Adult | 2020 |
Baseline Characteristics Explain Differences in Effectiveness of Randomization to Daily Oral TDF/FTC PrEP Between Transgender Women and Cisgender Men Who Have Sex With Men in the iPrEx Trial.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Emtricitabine; Female; HIV Infections; Humans; Male; Pre-Exposure Prophylaxis; Sex Factors; Tenofovir; Transgender Persons; Treatment Outcome | 2019 |
NZPrEP Demonstration Project: protocol for an open-label, single-arm trial of HIV pre-exposure prophylaxis (PrEP) to determine feasibility, acceptability, adverse and behavioural effects of PrEP provision to gay and bisexual men in publicly funded sexual
Topics: Emtricitabine; Feasibility Studies; HIV Infections; Homosexuality, Male; Humans; Logistic Models; Male; New Zealand; Pre-Exposure Prophylaxis; Safe Sex; Sexual and Gender Minorities; Sexual Behavior; Tenofovir | 2019 |
Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/
Topics: Adenine; Adult; Aged; Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Drug Combinations; Drug Substitution; Emtricitabine; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Protease Inhibitors; Sustained Virologic Response; Tablets; Tenofovir; Treatment Outcome; Viral Load | 2019 |
Brief Report: Routine Use of Oral PrEP in a Phase 2 Rectal Microbicide Study of Tenofovir Reduced-Glycerin 1% Gel (MTN-017).
Topics: Administration, Rectal; Anti-HIV Agents; Female; Gels; Global Health; HIV Infections; Homosexuality, Male; Humans; Male; Pre-Exposure Prophylaxis; Tenofovir; Transgender Persons | 2019 |
Urine Tenofovir Concentrations Correlate With Plasma and Relate to Tenofovir Disoproxil Fumarate Adherence: A Randomized, Directly Observed Pharmacokinetic Trial (TARGET Study).
Topics: Adult; Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Male; Pharmaceutical Preparations; Plasma; Pre-Exposure Prophylaxis; Tenofovir | 2020 |
Short- and Long-Term Pharmacologic Measures of HIV Pre-exposure Prophylaxis Use Among High-Risk Men Who Have Sex With Men in HPTN 067/ADAPT.
Topics: Adult; Emtricitabine; Hair; HIV Infections; Homosexuality, Male; Humans; Male; Medication Adherence; Pre-Exposure Prophylaxis; Tenofovir | 2019 |
Pre-exposure prophylaxis differentially alters circulating and mucosal immune cell activation in herpes simplex virus type 2 seropositive women.
Topics: Adult; Female; Genitalia, Female; Herpes Genitalis; Herpesvirus 2, Human; HIV Infections; Humans; Immunity, Mucosal; Mucous Membrane; Pre-Exposure Prophylaxis; T-Lymphocytes; Tenofovir; Virus Shedding | 2019 |
Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1.
Topics: Adult; Alkynes; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Lamivudine; Male; Obesity; Oxazines; Piperazines; Pregnancy; Pyridones; RNA, Viral; Tenofovir; Viral Load; Weight Gain | 2019 |
Prolonged Effect of Zoledronic Acid on Bone Mineral Density and Turnover in HIV-Infected Adults on Tenofovir: A Randomized, Open-Label Study.
Topics: Adult; Biomarkers; Bone Density; Bone Remodeling; Female; Fractures, Bone; HIV Infections; Humans; Male; Middle Aged; Tenofovir; Treatment Outcome; Zoledronic Acid | 2019 |
Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Darunavir; Developing Countries; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Nitriles; Prospective Studies; Pyridazines; Pyrimidines; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Viral Load | 2019 |
Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Oxazines; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2013 |
Impact of switching from zidovudine to tenofovir disoproxil fumarate on bone mineral density and markers of bone metabolism in virologically suppressed HIV-1 infected patients; a substudy of the PREPARE study.
Topics: Adenine; Adult; Anti-HIV Agents; Biomarkers; Bone and Bones; Bone Density; Cohort Studies; Down-Regulation; Drug Substitution; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Parathyroid Hormone; Tenofovir; Vitamin D; Zidovudine | 2013 |
Adherence profiles and therapeutic responses of treatment-naive HIV-infected patients starting boosted atazanavir-based therapy in the ANRS 134-COPHAR 3 trial.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Deoxycytidine; Drug Administration Schedule; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Medication Adherence; Middle Aged; Oligopeptides; Organophosphonates; Prospective Studies; Pyridines; Ritonavir; Surveys and Questionnaires; Tenofovir; Viral Load | 2013 |
Randomized trial of clinical safety of daily oral tenofovir disoproxil fumarate among HIV-uninfected men who have sex with men in the United States.
Topics: Adenine; Adolescent; Anti-HIV Agents; Boston; CD4 Lymphocyte Count; Double-Blind Method; Follow-Up Studies; Georgia; HIV Infections; HIV Seronegativity; Homosexuality, Male; Humans; Hypophosphatemia; Male; Medication Adherence; Middle Aged; Organophosphonates; San Francisco; Tenofovir; Treatment Outcome | 2013 |
Women with pregnancies had lower adherence to 1% tenofovir vaginal gel as HIV preexposure prophylaxis in CAPRISA 004, a phase IIB randomized-controlled trial.
Topics: Adenine; Adult; Anti-HIV Agents; Attitude to Health; Double-Blind Method; Female; HIV Infections; Humans; Medication Adherence; Multivariate Analysis; Odds Ratio; Organophosphonates; Pregnancy; South Africa; Tenofovir; Vaginal Creams, Foams, and Jellies; Young Adult | 2013 |
Neither microbial translocation nor TLR responsiveness are likely explanations for preexisting immune activation in women who subsequently acquired HIV in CAPRISA 004.
Topics: Adenine; Anti-HIV Agents; Bacterial Translocation; Cytokines; Fatty Acid-Binding Proteins; Female; HIV Infections; HIV-1; Humans; Killer Cells, Natural; Lipopolysaccharide Receptors; Lipopolysaccharides; Lymphocyte Activation; Organophosphonates; Tenofovir; Toll-Like Receptor 2; Toll-Like Receptor 4; Toll-Like Receptor 7; Toll-Like Receptor 8; Toll-Like Receptors | 2013 |
Sexual risk behavior among HIV-uninfected men who have sex with men participating in a tenofovir preexposure prophylaxis randomized trial in the United States.
Topics: Adenine; Adolescent; Adult; Amphetamine-Related Disorders; Anti-HIV Agents; Boston; Double-Blind Method; Follow-Up Studies; Georgia; Health Knowledge, Attitudes, Practice; HIV Infections; HIV Seronegativity; Homosexuality, Male; Humans; Male; Middle Aged; Organophosphonates; Risk Assessment; Risk-Taking; San Francisco; Sexual Partners; Tenofovir; Treatment Outcome; Unsafe Sex | 2013 |
Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Cobicistat; Deoxycytidine; Double-Blind Method; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir; Thiazoles; Treatment Outcome; Viral Load | 2013 |
Abacavir/lamivudine versus tenofovir/emtricitabine with atazanavir/ritonavir for treatment-naive Japanese patients with HIV-1 infection: a randomized multicenter trial.
Topics: Adenine; Adult; Anti-HIV Agents; Antiviral Agents; Asian People; Atazanavir Sulfate; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Oligopeptides; Organophosphonates; Pilot Projects; Pyridines; Ritonavir; Tenofovir; Treatment Outcome | 2013 |
Pharmacokinetic interactions between lersivirine and zidovudine, tenofovir disoproxil fumarate/emtricitabine and abacavir/lamivudine.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug Interactions; Emtricitabine; Female; Healthy Volunteers; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Nitriles; Organophosphonates; Pyrazoles; Tenofovir; Young Adult; Zidovudine | 2013 |
A phase 1 randomized, double blind, placebo controlled rectal safety and acceptability study of tenofovir 1% gel (MTN-007).
Topics: Adenine; Administration, Rectal; Adult; Anti-HIV Agents; Double-Blind Method; Female; Gels; HIV Infections; Humans; Intestinal Mucosa; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Organophosphonates; Rectum; Tenofovir; Transcriptome; Young Adult | 2013 |
Intentions to use preexposure prophylaxis among current phase 2B preventive HIV-1 vaccine efficacy trial participants.
Topics: Adenine; Adolescent; Adult; AIDS Vaccines; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Heterosexuality; HIV Infections; Homosexuality, Male; Humans; Intention; Male; Middle Aged; Organophosphonates; Research Design; Surveys and Questionnaires; Tenofovir; Young Adult | 2013 |
Long-term body composition and metabolic changes in HIV-infected children switched from stavudine to tenofovir and from protease inhibitors to efavirenz.
Topics: Absorptiometry, Photon; Adenine; Adolescent; Alkynes; Anti-Retroviral Agents; Benzoxazines; Blood Glucose; Body Composition; Child; Child, Preschool; Cohort Studies; Cyclopropanes; Female; HIV Infections; Humans; Lamivudine; Linear Models; Lipids; Longitudinal Studies; Male; Organophosphonates; Stavudine; Tenofovir | 2013 |
Early upper digestive tract side effects of zidovudine with tenofovir plus emtricitabine in West African adults with high CD4 counts.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cote d'Ivoire; Deoxycytidine; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Emtricitabine; Female; Gastrointestinal Diseases; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Tenofovir; Zidovudine | 2013 |
A randomized, comparative safety study of a prefilled plastic and user-filled paper applicator with candidate microbicide tenofovir 1% gel.
Topics: Adenine; Administration, Intravaginal; Adolescent; Adult; Anti-HIV Agents; Cross-Over Studies; Drug Delivery Systems; Female; HIV Infections; Humans; Middle Aged; Organophosphonates; Paper; Patient Acceptance of Health Care; Plastics; Tenofovir; Treatment Outcome; Vaginal Creams, Foams, and Jellies; Young Adult | 2013 |
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Substance Abuse, Intravenous; Tenofovir; Thailand; Treatment Outcome; Young Adult | 2013 |
Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Organophosphonates; Pilot Projects; Prospective Studies; Pyrrolidinones; Raltegravir Potassium; Ritonavir; RNA Stability; RNA, Viral; Tenofovir; Viral Load | 2013 |
Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults.
Topics: Adenine; Adult; Alanine; Anti-Retroviral Agents; Area Under Curve; Dose-Response Relationship, Drug; Fatigue; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nausea; Organophosphates; Organophosphonates; RNA, Viral; Single-Blind Method; Statistics, Nonparametric; Tenofovir; Viral Load; Young Adult | 2013 |
Impact of a tenofovir disoproxil fumarate plus ritonavir-boosted protease inhibitor-based regimen on renal function in HIV-infected individuals: a prospective, multicenter study.
Topics: Adenine; Adult; Anti-HIV Agents; Creatinine; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney; Kidney Diseases; Male; Middle Aged; Organophosphonates; Prospective Studies; Protease Inhibitors; Proteinuria; Ritonavir; Statistics, Nonparametric; Tenofovir | 2013 |
Variability of raltegravir plasma levels in the clinical setting.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; HIV Infections; Humans; Lamivudine; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Tenofovir | 2013 |
96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Bone and Bones; Bone Density; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Glomerular Filtration Rate; HIV Infections; HIV-1; Humans; Kidney; Lamivudine; Male; Organophosphonates; Tenofovir; Time Factors; Treatment Outcome | 2013 |
Switching tenofovir/emtricitabine plus lopinavir/r to raltegravir plus Darunavir/r in patients with suppressed viral load did not result in improvement of renal function but could sustain viral suppression: a randomized multicenter trial.
Topics: Adenine; Adult; Anti-HIV Agents; Darunavir; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Kidney; Kidney Function Tests; Lopinavir; Male; Middle Aged; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Sulfonamides; Tenofovir; Viral Load | 2013 |
Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Carbamates; Coinfection; Cyclopropanes; Drug Interactions; Female; Hepatitis C; HIV Infections; Humans; Imidazoles; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Pyrrolidines; Ritonavir; Tenofovir; Valine; Viral Nonstructural Proteins; Young Adult | 2013 |
Evaluation of four tenofovir-containing regimens as first-line treatments in Cameroon and Senegal: the ANRS 12115 DAYANA Trial.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cameroon; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; HIV Infections; HIV-1; Humans; Male; Medication Adherence; Middle Aged; Organophosphonates; Senegal; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2014 |
Pharmacokinetics and safety of tenofovir in HIV-infected women during labor and their infants during the first week of life.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Drug Administration Schedule; Female; Fetal Blood; HIV Infections; Humans; Infant, Newborn; Labor, Obstetric; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Tenofovir; Young Adult | 2014 |
Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency?
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Calcitriol; Calcium; Double-Blind Method; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Glomerular Filtration Rate; HIV; HIV Infections; Humans; Hypophosphatemia; Male; Organophosphonates; Parathyroid Hormone; Phosphates; Reverse Transcriptase Inhibitors; Tenofovir; Vitamin D Deficiency; Vitamin D-Binding Protein | 2013 |
Raltegravir-emtricitabine-tenofovir as HIV nonoccupational post-exposure prophylaxis in men who have sex with men: safety, tolerability and adherence.
Topics: Adenine; Adult; Anti-HIV Agents; Biomarkers; Creatine Kinase; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Male; Medication Adherence; Organophosphonates; Prospective Studies; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Tenofovir | 2014 |
Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa.
Topics: Adenine; Adult; Africa, Eastern; Anti-HIV Agents; Cohort Studies; Deoxycytidine; Emtricitabine; Family Characteristics; Female; HIV Infections; HIV Seropositivity; Humans; Male; Medication Adherence; Multivariate Analysis; Organophosphonates; Regression Analysis; Tenofovir | 2013 |
Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.
Topics: Adenine; Adult; CD4 Lymphocyte Count; Dideoxynucleosides; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Kaplan-Meier Estimate; Lamivudine; Male; Organophosphonates; Oxazines; Piperazines; Pyridones; Pyrrolidinones; Raltegravir Potassium; RNA, Viral; Tenofovir | 2013 |
Safety, adherence and acceptability of intermittent tenofovir/emtricitabine as HIV pre-exposure prophylaxis (PrEP) among HIV-uninfected Ugandan volunteers living in HIV-serodiscordant relationships: a randomized, clinical trial.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Male; Organophosphonates; Patient Compliance; Tenofovir; Uganda | 2013 |
Participant experiences and facilitators and barriers to pill use among men who have sex with men in the iPrEx pre-exposure prophylaxis trial in San Francisco.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Antiviral Agents; Deoxycytidine; Double-Blind Method; Emtricitabine; Focus Groups; Health Knowledge, Attitudes, Practice; HIV Infections; HIV-1; Homosexuality, Male; Humans; Interviews as Topic; Male; Medication Adherence; Middle Aged; Organophosphonates; Qualitative Research; Risk Factors; San Francisco; Tenofovir; Young Adult | 2013 |
Effect of food on rilpivirine/emtricitabine/tenofovir disoproxil fumarate, an antiretroviral single-tablet regimen for the treatment of HIV infection.
Topics: Adenine; Adult; Anti-HIV Agents; Cross-Over Studies; Deoxycytidine; Drug Combinations; Emtricitabine; Fasting; Female; Food-Drug Interactions; HIV Infections; Humans; Male; Middle Aged; Nitriles; Organophosphonates; Pyrimidines; Rilpivirine; Tablets; Tenofovir; Young Adult | 2014 |
Low body weight in females is a risk factor for increased tenofovir exposure and drug-related adverse events.
Topics: Adenine; Adult; Anti-HIV Agents; Body Weight; Bone Resorption; Female; HIV Infections; Humans; Middle Aged; Organophosphonates; Risk Factors; Tenofovir | 2013 |
Dynamics of immune reconstitution and activation markers in HIV+ treatment-naïve patients treated with raltegravir, tenofovir disoproxil fumarate and emtricitabine.
Topics: Adenine; Adult; Anti-HIV Agents; Biomarkers; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lymphocyte Activation; Male; Middle Aged; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Tenofovir; Young Adult | 2013 |
Limited HIV-1 superinfection in seroconverters from the CAPRISA 004 Microbicide Trial.
Topics: Adenine; Adult; Anti-Infective Agents; Chemoprevention; env Gene Products, Human Immunodeficiency Virus; Female; gag Gene Products, Human Immunodeficiency Virus; HIV Infections; HIV-1; Humans; Incidence; Kenya; Organophosphonates; Sequence Analysis, DNA; South Africa; Superinfection; Tenofovir; Vaginal Creams, Foams, and Jellies; Viral Load; Young Adult | 2014 |
Efficacy of preexposure prophylaxis for HIV-1 prevention among high-risk heterosexuals: subgroup analyses from a randomized trial.
Topics: Adenine; Adult; Anti-Retroviral Agents; Chemoprevention; Deoxycytidine; Emtricitabine; Female; Heterosexuality; HIV Infections; HIV-1; Humans; Incidence; Kenya; Male; Organophosphonates; Placebos; Tenofovir; Treatment Outcome; Uganda | 2013 |
Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP).
Topics: Adenine; Administration, Oral; Adult; Demography; Dose-Response Relationship, Drug; Female; Hair; HIV Infections; Humans; Male; Medication Adherence; Organophosphonates; Tenofovir | 2014 |
Sensitive tenofovir resistance screening of HIV-1 from the genital and blood compartments of women with breakthrough infections in the CAPRISA 004 tenofovir gel trial.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Drug Resistance, Viral; Female; Gels; HIV Infections; HIV-1; Humans; Organophosphonates; Polymerase Chain Reaction; South Africa; Tenofovir; Vagina; Vaginal Creams, Foams, and Jellies; Viral Load; Young Adult | 2014 |
Renal events among women treated with tenofovir/emtricitabine in combination with either lopinavir/ritonavir or nevirapine.
Topics: Adenine; Adult; Antiviral Agents; Creatinine; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Kidney Diseases; Lopinavir; Nevirapine; Organophosphonates; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome | 2014 |
HIV-1 genital shedding in HIV-infected patients randomized to second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; Follow-Up Studies; Genitalia; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Male; Organophosphonates; Risk Factors; Ritonavir; Tenofovir; Time Factors; Treatment Outcome; Viral Load; Virus Shedding | 2014 |
Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Chemoprevention; Creatinine; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Kidney; Kidney Function Tests; Male; Metabolic Clearance Rate; Middle Aged; Organophosphonates; Phosphorus; Placebos; Tenofovir; Young Adult | 2014 |
Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults.
Topics: Adenine; Adolescent; Adult; Aged; Alanine; Anti-HIV Agents; Area Under Curve; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Male; Middle Aged; Plasma; Prodrugs; Tenofovir; Young Adult | 2014 |
Vitamin D3 supplementation increases fibroblast growth factor-23 in HIV-infected youths treated with tenofovir disoproxil fumarate.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Cholecalciferol; Dietary Supplements; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; HIV Infections; Humans; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Young Adult | 2014 |
Comparison of body composition changes between atazanavir/ritonavir and lopinavir/ritonavir each in combination with tenofovir/emtricitabine in antiretroviral-naïve patients with HIV-1 infection.
Topics: Absorptiometry, Photon; Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Body Composition; Deoxycytidine; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Lopinavir; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir; Tomography, X-Ray Computed; Young Adult | 2014 |
Cardiovascular disease risk factors in HIV-infected women after initiation of lopinavir/ritonavir- and nevirapine-based antiretroviral therapy in Sub-Saharan Africa: A5208 (OCTANE).
Topics: Adenine; Adult; Africa South of the Sahara; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Blood Pressure; Body Mass Index; Cardiovascular Diseases; CD4-Positive T-Lymphocytes; Cholesterol, HDL; Cholesterol, LDL; Deoxycytidine; Emtricitabine; Endpoint Determination; Female; HIV Infections; HIV-1; Humans; Linear Models; Logistic Models; Lopinavir; Multivariate Analysis; Nevirapine; Organophosphonates; Prospective Studies; Risk Factors; Ritonavir; RNA, Viral; Tenofovir; Triglycerides | 2014 |
Measuring adherence by visual inspection of returned empty gel applicators in the CAPRISA 004 microbicide trial.
Topics: Adenine; Administration, Intravaginal; Adult; Anti-Infective Agents; Coitus; Double-Blind Method; Drug Delivery Systems; Female; Follow-Up Studies; Gels; HIV Infections; Humans; Multivariate Analysis; Organophosphonates; Patient Compliance; Proportional Hazards Models; Rural Population; South Africa; Tenofovir; Urban Population | 2014 |
High level of viral suppression and low switch rate to second-line antiretroviral therapy among HIV-infected adult patients followed over five years: retrospective analysis of the DART trial.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cross-Sectional Studies; Dideoxynucleosides; Drug Combinations; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Nevirapine; Probability; Retrospective Studies; RNA, Viral; Tenofovir; Uganda; Viral Load; Zidovudine | 2014 |
Bone mineral density changes among HIV-uninfected young adults in a randomised trial of pre-exposure prophylaxis with tenofovir-emtricitabine or placebo in Botswana.
Topics: Absorptiometry, Photon; Adolescent; Adult; Anti-HIV Agents; Bone Density; Botswana; Communicable Disease Control; Emtricitabine; Female; Forearm; Hip; HIV Infections; Humans; Longitudinal Studies; Male; Pre-Exposure Prophylaxis; Spine; Tenofovir; Young Adult | 2014 |
Phenotypic and genotypic analyses to guide selection of reverse transcriptase inhibitors in second-line HIV therapy following extended virological failure in Uganda.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Inhibitory Concentration 50; Microbial Sensitivity Tests; Organophosphonates; Tenofovir; Uganda; Zidovudine | 2014 |
Impact of an adherence intervention on the effectiveness of tenofovir gel in the CAPRISA 004 trial.
Topics: Adenine; Adult; Anti-HIV Agents; Anti-Infective Agents, Local; Double-Blind Method; Female; Gels; Health Behavior; HIV Infections; Humans; Incidence; Medication Adherence; Models, Psychological; Motivational Interviewing; Organophosphonates; Socioeconomic Factors; South Africa; Tenofovir; Treatment Outcome | 2014 |
Adherence in the CAPRISA 004 tenofovir gel microbicide trial.
Topics: Adenine; Administration, Intravaginal; Adult; Anti-HIV Agents; Anti-Infective Agents, Local; Counseling; Double-Blind Method; Female; Follow-Up Studies; Gels; HIV Infections; HIV-1; Humans; Incidence; Kaplan-Meier Estimate; Medication Adherence; Motivational Interviewing; Organophosphonates; Rural Population; Sexual Behavior; Socioeconomic Factors; South Africa; Tenofovir; Treatment Outcome; Urban Population | 2014 |
Rilpivirine versus efavirenz with emtricitabine/tenofovir disoproxil fumarate in treatment-naïve HIV-1-infected patients with HIV-1 RNA ≤100,000 copies/mL: week 96 pooled ECHO/THRIVE subanalysis.
Topics: Adenine; Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Antiviral Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nitriles; Organophosphonates; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; RNA, Viral; Tenofovir; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2014 |
Risk behaviors and risk factors for HIV infection among participants in the Bangkok tenofovir study, an HIV pre-exposure prophylaxis trial among people who inject drugs.
Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Risk-Taking; Substance-Related Disorders; Tenofovir; Thailand | 2014 |
HLA alleles association with changes in bone mineral density in HIV-1-infected adults changing treatment to tenofovir-emtricitabine or abacavir-lamivudine.
Topics: Adenine; Adult; Alleles; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone Density; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; HLA-DQ Antigens; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Tenofovir | 2014 |
Normal laboratory reference intervals among healthy adults screened for a HIV pre-exposure prophylaxis clinical trial in Botswana.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Botswana; Deoxycytidine; Emtricitabine; Female; Hematologic Tests; HIV Infections; Humans; Male; Organophosphonates; Reference Values; Tenofovir; Young Adult | 2014 |
Hip structural parameters over 96 weeks in HIV-infected adults switching treatment to tenofovir-emtricitabine or abacavir-lamivudine.
Topics: Adenine; Anti-HIV Agents; Bone Density; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug Substitution; Emtricitabine; Female; Hip Joint; HIV Infections; Humans; Lamivudine; Male; Organophosphonates; Radiography; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2014 |
Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial.
Topics: Adenine; Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Brazil; Coinfection; Cyclopropanes; Drug Therapy, Combination; Female; France; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; RNA, Viral; Tenofovir; Treatment Outcome; Tuberculosis; Viral Load | 2014 |
Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-Infected adults treated with rilpivirine or Efavirenz for 96 weeks in the ECHO and THRIVE trials.
Topics: Absorptiometry, Photon; Adolescent; Adult; Aged; Aged, 80 and over; Alkynes; Anti-HIV Agents; Benzoxazines; Body Fat Distribution; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Rilpivirine; Tenofovir; Young Adult; Zidovudine | 2014 |
Persistent viremia in human immunodeficiency virus/hepatitis B coinfected patients undergoing long-term tenofovir: virological and clinical implications.
Topics: Adenine; Adult; Coinfection; DNA, Viral; Drug Resistance, Viral; Female; Follow-Up Studies; Genotype; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Prospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Viral Load; Viremia; Virus Replication | 2014 |
Combination antiretroviral treatment for women previously treated only in pregnancy: week 24 results of AIDS clinical trials group protocol a5227.
Topics: Adenine; Adult; Alkynes; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Organophosphonates; Pregnancy; Prospective Studies; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load | 2014 |
HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention.
Topics: Adenine; Adult; Anti-HIV Agents; Biomarkers; Cohort Studies; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Seropositivity; Humans; Male; Medication Adherence; Organophosphonates; Predictive Value of Tests; Proportional Hazards Models; Tenofovir; Young Adult | 2014 |
A 48-week study of fat molecular alterations in HIV naive patients starting tenofovir/emtricitabine with lopinavir/ritonavir or efavirenz.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Gene Expression Regulation; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lopinavir; Organophosphonates; Ritonavir; Subcutaneous Fat; Tenofovir; Transcriptome | 2014 |
Renal function of participants in the Bangkok tenofovir study--Thailand, 2005-2012.
Topics: Adult; Anti-HIV Agents; Creatinine; Cross-Sectional Studies; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney; Kidney Function Tests; Linear Models; Male; Middle Aged; Pre-Exposure Prophylaxis; Reverse Transcriptase Inhibitors; Tenofovir; Thailand | 2014 |
Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study.
Topics: Absorptiometry, Photon; Adenine; Administration, Oral; Adult; Alanine; Bone Density; CD4 Lymphocyte Count; Cholesterol; Creatinine; Double-Blind Method; Female; HIV Infections; HIV-1; Humans; Male; Prodrugs; Proteinuria; RNA, Viral; Tenofovir; United States | 2014 |
Role of a 48-week pegylated interferon therapy in hepatitis B e antigen positive HIV-co-infected patients on cART including tenofovir: EMVIPEG study.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; Coinfection; Deoxycytidine; Drug Carriers; Emtricitabine; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Interferon-alpha; Lamivudine; Male; Middle Aged; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Tenofovir; Treatment Outcome; Viral Load | 2014 |
Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results o
Topics: Adenine; Adult; Anti-HIV Agents; Carbamates; Cobicistat; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Protease Inhibitors; Quinolones; Ritonavir; Tenofovir; Thiazoles; Viral Load | 2014 |
Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week r
Topics: Adenine; Adult; Anti-HIV Agents; Carbamates; Cobicistat; Deoxycytidine; Emtricitabine; Female; HIV; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Quinolones; Reverse Transcriptase Inhibitors; Tenofovir; Thiazoles; Viral Load | 2014 |
Syphilis predicts HIV incidence among men and transgender women who have sex with men in a preexposure prophylaxis trial.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Female; HIV Infections; Homosexuality, Male; Humans; Incidence; Male; Middle Aged; Organophosphonates; Placebos; Pre-Exposure Prophylaxis; Prevalence; Syphilis; Tenofovir; Transgender Persons; Treatment Outcome; Young Adult | 2014 |
Predictors of suboptimal CD4 response among women achieving virologic suppression in a randomized antiretroviral treatment trial, Africa.
Topics: Adenine; Adult; Africa; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lopinavir; Nevirapine; Organophosphonates; Ritonavir; Tenofovir; Treatment Outcome | 2014 |
Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial.
Topics: Adenine; Administration, Oral; Adult; Anti-Retroviral Agents; Antiviral Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; Herpes Genitalis; Herpesvirus 2, Human; Heterosexuality; HIV Infections; HIV Seronegativity; HIV-1; Humans; Incidence; Male; Medication Adherence; Organophosphonates; RNA, Viral; Tenofovir | 2014 |
Atazanavir exposure is effective during pregnancy regardless of tenofovir use.
Topics: Adolescent; Adult; Area Under Curve; Atazanavir Sulfate; Drug Administration Schedule; Drug Monitoring; Drug Therapy, Combination; Female; Gestational Age; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Pregnancy; Pregnancy Trimester, Third; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load | 2015 |
First-line antiretroviral therapy with nevirapine versus lopinavir-ritonavir based regimens in a resource-limited setting.
Topics: Adenine; Adult; CD4 Lymphocyte Count; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Nevirapine; Organophosphonates; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load; Zidovudine | 2014 |
Clinical assessment of potential drug interactions of faldaprevir, a hepatitis C virus protease inhibitor, with darunavir/ritonavir, efavirenz, and tenofovir.
Topics: Adenine; Adult; Alkynes; Aminoisobutyric Acids; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Coinfection; Cyclopropanes; Darunavir; Drug Interactions; Female; Healthy Volunteers; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Leucine; Male; Middle Aged; Oligopeptides; Organophosphonates; Proline; Protease Inhibitors; Quinolines; Ritonavir; Sulfonamides; Tenofovir; Thiazoles; Young Adult | 2014 |
Accuracy of Self-Report and Pill-Count Measures of Adherence in the FEM-PrEP Clinical Trial: Implications for Future HIV-Prevention Trials.
Topics: Adenine; Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; Humans; Interviews as Topic; Kenya; Male; Medication Adherence; Middle Aged; Organophosphonates; Pre-Exposure Prophylaxis; Predictive Value of Tests; Qualitative Research; Self Report; Tenofovir; Treatment Outcome | 2015 |
Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cholesterol, HDL; Cholesterol, LDL; Darunavir; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides; Tenofovir; Treatment Outcome | 2014 |
Changes in proteinuria and albuminuria with initiation of antiretroviral therapy: data from a randomized trial comparing tenofovir disoproxil fumarate/emtricitabine versus abacavir/lamivudine.
Topics: Adenine; Adult; Albuminuria; Anti-HIV Agents; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Linear Models; Male; Organophosphonates; Proteinuria; Tenofovir | 2014 |
High medication adherence during periconception periods among HIV-1-uninfected women participating in a clinical trial of antiretroviral pre-exposure prophylaxis.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Cohort Studies; Double-Blind Method; Female; Fertilization; HIV Infections; Humans; Kenya; Medication Adherence; Organophosphonates; Pre-Exposure Prophylaxis; Pregnancy; Pregnancy Complications, Infectious; Proportional Hazards Models; Regression Analysis; Tenofovir; Uganda; Young Adult | 2014 |
Improvement in bone mineral density after switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: two-centre randomized pilot study (OsteoTDF study).
Topics: Adenine; Adult; Anti-HIV Agents; Bone Density; Dideoxynucleosides; Female; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Osteoporosis; Pilot Projects; Tenofovir; Treatment Outcome | 2014 |
FEM-PrEP: adherence patterns and factors associated with adherence to a daily oral study product for pre-exposure prophylaxis.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Logistic Models; Male; Medication Adherence; Multivariate Analysis; Organophosphonates; Risk Factors; Tenofovir; Young Adult | 2014 |
The RADAR study: week 48 safety and efficacy of RAltegravir combined with boosted DARunavir compared to tenofovir/emtricitabine combined with boosted darunavir in antiretroviral-naive patients. Impact on bone health.
Topics: Adenine; Adult; Bone Density; Darunavir; Deoxycytidine; Emtricitabine; HIV Infections; HIV-1; Humans; Middle Aged; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Sulfonamides; Tenofovir | 2014 |
Factors Associated with Adherence and Concordance Between Measurement Strategies in an HIV Daily Oral Tenofovir/Emtricitibine as Pre-exposure Prophylaxis (Prep) Clinical Trial, Botswana, 2007-2010.
Topics: Administration, Oral; Adult; Anti-HIV Agents; Botswana; Emtricitabine; Female; HIV Infections; Humans; Logistic Models; Male; Medication Adherence; Multivariate Analysis; Pre-Exposure Prophylaxis; Self Report; Surveys and Questionnaires; Tenofovir | 2015 |
Increased bone resorption during tenofovir plus lopinavir/ritonavir therapy in Chinese individuals with HIV.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Biomarkers; Bone Remodeling; Bone Resorption; Collagen Type I; Drug Combinations; Drug Substitution; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Peptides; Ritonavir; Tenofovir; Young Adult | 2015 |
HIV disease progression in seroconvertors from the CAPRISA 004 tenofovir gel pre-exposure prophylaxis trial.
Topics: Adenine; Disease Progression; Female; Gels; HIV Infections; Humans; Organophosphonates; Placebos; Pre-Exposure Prophylaxis; Reverse Transcriptase Inhibitors; Tenofovir; Vagina | 2015 |
Pre-exposure prophylaxis does not affect the fertility of HIV-1-uninfected men.
Topics: Adenine; Adult; Anti-Retroviral Agents; Chemoprevention; Deoxycytidine; Emtricitabine; Female; Fertility; HIV Infections; Humans; Male; Organophosphonates; Placebos; Pre-Exposure Prophylaxis; Pregnancy; Tenofovir | 2014 |
Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial.
Topics: Adenine; Adult; Atazanavir Sulfate; Darunavir; Deoxycytidine; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; RNA, Viral; Sulfonamides; Tenofovir; Therapeutic Equivalency; Viral Load | 2014 |
Trial participation disclosure and gel use behavior in the CAPRISA 004 tenofovir gel trial.
Topics: Adenine; Administration, Intravaginal; Adult; Anti-HIV Agents; Disclosure; Female; Gels; HIV Infections; Humans; Male; Medication Adherence; Organophosphonates; Patient Acceptance of Health Care; Sexual Behavior; Sexual Partners; Tenofovir | 2014 |
Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Double-Blind Method; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Kenya; Male; Organophosphonates; Placebos; Pre-Exposure Prophylaxis; Tenofovir; Treatment Outcome; Uganda | 2014 |
Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive patients.
Topics: Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cobicistat; Cyclopropanes; Drug Resistance, Viral; Emtricitabine; Female; Genotype; HIV Infections; HIV-1; Humans; Male; Microbial Sensitivity Tests; Mutation; Quinolones; Tenofovir; Time Factors; Treatment Outcome; Viral Load | 2015 |
Correlation between compartmental tenofovir concentrations and an ex vivo rectal biopsy model of tissue infectibility in the RMP-02/MTN-006 phase 1 study.
Topics: Administration, Oral; Administration, Rectal; Adult; Biopsy; Cellulose; Dose-Response Relationship, Drug; Double-Blind Method; Female; Gels; HIV Infections; Humans; Male; Rectum; Tenofovir; Vaginal Creams, Foams, and Jellies; Young Adult | 2014 |
Understanding Adherence to Daily and Intermittent Regimens of Oral HIV Pre-exposure Prophylaxis Among Men Who Have Sex with Men in Kenya.
Topics: Administration, Oral; Anti-HIV Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Emtricitabine; Female; HIV Infections; Homosexuality, Male; Humans; Kenya; Male; Medication Adherence; Middle Aged; Outcome Assessment, Health Care; Pre-Exposure Prophylaxis; Socioeconomic Factors; Tenofovir | 2015 |
Sino-implant (II)® continuation and effect of concomitant tenofovir disoproxil fumarate-emtricitabine use on plasma levonorgestrel concentrations among women in Bondo, Kenya.
Topics: Adenine; Adolescent; Adult; Antiviral Agents; Contraceptive Agents, Female; Deoxycytidine; Drug Combinations; Drug Implants; Emtricitabine; Female; HIV Infections; Humans; Kenya; Levonorgestrel; Longitudinal Studies; Organophosphonates; Polypharmacy; Prospective Studies; Tenofovir; Young Adult | 2015 |
Switching from zidovudine/lamivudine to tenofovir/emtricitabine improves fat distribution as measured by fat mass ratio.
Topics: Absorptiometry, Photon; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Fat Distribution; Drug Combinations; Drug Substitution; Emtricitabine; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Regression Analysis; Tenofovir; Zidovudine | 2015 |
Drug resistance and plasma viral RNA level after ineffective use of oral pre-exposure prophylaxis in women.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Female; High-Throughput Nucleotide Sequencing; HIV Infections; HIV-1; Humans; Organophosphonates; Plasma; Pre-Exposure Prophylaxis; RNA, Viral; Tenofovir | 2015 |
Assessing the implementation effectiveness and safety of 1% tenofovir gel provision through family planning services in KwaZulu-Natal, South Africa: study protocol for an open-label randomized controlled trial.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Clinical Protocols; Family Planning Services; Female; Gels; Health Services Accessibility; HIV Infections; Humans; Organophosphonates; Program Evaluation; Quality Improvement; Quality Indicators, Health Care; Research Design; Rural Health Services; South Africa; Tenofovir; Time Factors; Treatment Outcome; Urban Health Services; Women's Health Services; Young Adult | 2014 |
Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Kidney Function Tests; Kidney Glomerulus; Male; Medication Adherence; Middle Aged; Organophosphonates; Tenofovir; Young Adult | 2015 |
Liver and renal safety of tenofovir disoproxil fumarate in combination with emtricitabine among African women in a pre-exposure prophylaxis trial.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Anti-HIV Agents; Aspartate Aminotransferases; Black People; Chemical and Drug Induced Liver Injury; Creatinine; Deoxycytidine; Double-Blind Method; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Kidney Diseases; Organophosphonates; Phosphorus; Pre-Exposure Prophylaxis; Reverse Transcriptase Inhibitors; Tenofovir; Young Adult | 2014 |
Tenofovir plasma concentrations related to estimated glomerular filtration rate changes in first-line regimens in African HIV-infected patients: ANRS 12115 DAYANA substudy.
Topics: Adolescent; Adult; Africa South of the Sahara; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Chromatography, Liquid; Female; Glomerular Filtration Rate; HIV Infections; HIV-1; Humans; Male; Middle Aged; Plasma; Tandem Mass Spectrometry; Tenofovir; Young Adult | 2015 |
Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single- or dual-agent preexposure prophylaxis.
Topics: Adenine; Anti-HIV Agents; Anti-Retroviral Agents; Deoxycytidine; Double-Blind Method; Drug Resistance, Viral; Emtricitabine; HIV Infections; HIV Seropositivity; HIV-1; Humans; Organophosphonates; Risk; Tenofovir | 2015 |
Long-term efficacy and safety of tenofovir disoproxil fumarate in HIV-1-infected adolescents failing antiretroviral therapy: the final results of study GS-US-104-0321.
Topics: Adenine; Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone Density; Child; Double-Blind Method; Drug Resistance, Viral; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Placebos; RNA, Viral; Tenofovir; Treatment Failure; Viral Load | 2015 |
Tenofovir-based preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Administration, Intravaginal; Administration, Oral; Adolescent; Adult; Africa South of the Sahara; Anti-Retroviral Agents; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Seropositivity; HIV-1; Humans; Medication Adherence; Middle Aged; Organophosphonates; Pre-Exposure Prophylaxis; Surveys and Questionnaires; Tenofovir; Young Adult | 2015 |
A randomized comparative trial of continued abacavir/lamivudine plus efavirenz or replacement with efavirenz/emtricitabine/tenofovir DF in hypercholesterolemic HIV-1 infected individuals.
Topics: Adult; Alkynes; Benzoxazines; Cholesterol; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Hypercholesterolemia; Lamivudine; Male; Middle Aged; Tenofovir | 2015 |
A randomized, open-label study of the safety and efficacy of switching stavudine or zidovudine to tenofovir disoproxil fumarate in HIV-1-infected children with virologic suppression.
Topics: Adenine; Adolescent; Anti-HIV Agents; Child; Child, Preschool; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV-1; Humans; Male; Organophosphonates; RNA, Viral; Stavudine; Tenofovir; Treatment Outcome; Viral Load; Zidovudine | 2015 |
Influence of ABCC2 and ABCC4 polymorphisms on tenofovir plasma concentrations in Thai HIV-infected patients.
Topics: Adult; Anti-HIV Agents; Asian People; Cross-Sectional Studies; Female; Genotyping Techniques; HIV Infections; Humans; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Polymorphism, Genetic; Tenofovir | 2015 |
Patient-Reported Outcomes After a Switch to a Single-Tablet Regimen of Rilpivirine, Emtricitabine, and Tenofovir DF in HIV-1-Positive, Virologically Suppressed Individuals: Additional Findings From a Randomized, Open-Label, 48-Week Trial.
Topics: Adult; Anti-HIV Agents; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Male; Medication Adherence; Middle Aged; Patient Outcome Assessment; Patient Satisfaction; Rilpivirine; Tenofovir | 2015 |
Week 120 efficacy of tenofovir, lamivudine and lopinavir/r-based second-line antiretroviral therapy in treatment-experienced HIV patients.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; China; Cohort Studies; Drug Resistance, Viral; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Ritonavir; Tenofovir | 2015 |
Low risk of lamivudine-resistant HBV and hepatic flares in treated HIV-HBV-coinfected patients from Côte d'Ivoire.
Topics: Adult; Alanine Transaminase; Antiretroviral Therapy, Highly Active; Antiviral Agents; Aspartate Aminotransferases; Coinfection; Cote d'Ivoire; DNA, Viral; Drug Resistance, Viral; Emtricitabine; Female; Genotype; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV-1; HIV-2; Humans; Lamivudine; Male; Prospective Studies; Tenofovir; Viral Load | 2015 |
Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor-Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Male; Organophosphonates; RNA, Viral; Tenofovir | 2015 |
The lipid-lowering effect of tenofovir/emtricitabine: a randomized, crossover, double-blind, placebo-controlled trial.
Topics: Adult; Anti-HIV Agents; Cross-Over Studies; Double-Blind Method; Emtricitabine; Female; HIV Infections; Humans; Lipids; Male; Middle Aged; Placebos; Tenofovir | 2015 |
Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Double-Blind Method; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Intention to Treat Analysis; Longitudinal Studies; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load | 2015 |
High Mortality Among Non-HIV-Infected People Who Inject Drugs in Bangkok, Thailand, 2005-2012.
Topics: Accidents, Traffic; Adenine; Adult; Anti-HIV Agents; Cause of Death; Double-Blind Method; Drug Overdose; Female; HIV Infections; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Needle Sharing; Organophosphonates; Pre-Exposure Prophylaxis; Risk-Taking; Substance Abuse, Intravenous; Surveys and Questionnaires; Tenofovir; Thailand | 2015 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Arthralgia; Bone Density; Carbamates; CD4 Lymphocyte Count; Cobicistat; Deoxycytidine; Double-Blind Method; Drug Combinations; Emtricitabine; Female; Headache; HIV Infections; Humans; Kidney; Male; Nausea; Organophosphonates; Quinolones; Respiration Disorders; Sleep Initiation and Maintenance Disorders; Tenofovir; Thiazoles; Treatment Outcome; Viral Load | 2015 |
Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial.
Topics: Absorptiometry, Photon; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Bone Density; Chemoprevention; Cytoplasm; Double-Blind Method; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Placebos; Plasma; Tenofovir; Young Adult | 2015 |
Plasma and Intracellular Pharmacokinetics of Tenofovir Disoproxil Fumarate 300 mg Every 48 Hours vs 150 mg Once Daily in HIV-Infected Adults With Moderate Renal Function Impairment.
Topics: Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Cytoplasm; Female; HIV Infections; Humans; Male; Middle Aged; Plasma; Renal Insufficiency; Tenofovir; Time Factors | 2015 |
Sexual Relationships Outside Primary Partnerships and Abstinence Are Associated With Lower Adherence and Adherence Gaps: Data From the Partners PrEP Ancillary Adherence Study.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Male; Medication Adherence; Middle Aged; Organophosphonates; Pre-Exposure Prophylaxis; Sexual Abstinence; Sexual Partners; Tenofovir; Uganda; Young Adult | 2015 |
A Phase 1 Randomized, Open Label, Rectal Safety, Acceptability, Pharmacokinetic, and Pharmacodynamic Study of Three Formulations of Tenofovir 1% Gel (the CHARM-01 Study).
Topics: Adult; Anti-HIV Agents; Anti-Infective Agents, Local; Chemistry, Pharmaceutical; Female; Gels; HIV Infections; Humans; Immunophenotyping; Intestinal Mucosa; Male; Medication Adherence; Microbiota; Middle Aged; Phenotype; Rectum; T-Lymphocyte Subsets; Tenofovir; Treatment Outcome; Young Adult | 2015 |
Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Bone Density; Darunavir; Drug Therapy, Combination; Emtricitabine; Female; HIV; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Male; Middle Aged; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Viral Load; Young Adult | 2015 |
The impact of adherence to preexposure prophylaxis on the risk of HIV infection among people who inject drugs.
Topics: Adult; Anti-HIV Agents; Double-Blind Method; Female; HIV Infections; Humans; Male; Medical Records; Medication Adherence; Middle Aged; Pre-Exposure Prophylaxis; Risk Assessment; Substance Abuse, Intravenous; Tenofovir; Young Adult | 2015 |
Distal leg epidermal nerve fiber density as a surrogate marker of HIV-associated sensory neuropathy risk: risk factors and change following initial antiretroviral therapy.
Topics: Adult; Anti-Retroviral Agents; Cross-Sectional Studies; Female; HIV Infections; Humans; Leg; Male; Peripheral Nervous System Diseases; Risk Factors; Sensory Receptor Cells; Skin; Stavudine; Tenofovir; Thailand; Zidovudine | 2015 |
Patient-Reported Symptoms Over 48 Weeks in a Randomized, Open-Label, Phase IIIb Non-Inferiority Trial of Adults with HIV Switching to Co-Formulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF versus Continuation of Non-Nucleoside Reverse Tra
Topics: Adult; Anti-HIV Agents; Cobicistat; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Patient Outcome Assessment; Quality of Life; Quinolones; Tenofovir | 2015 |
[In Process Citation].
Topics: Age Factors; Aged; Comorbidity; Cross-Sectional Studies; Darunavir; Drug Interactions; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Middle Aged; Raltegravir Potassium; Tenofovir | 2015 |
Less Bone Loss With Maraviroc- Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 Study.
Topics: Adult; Anti-HIV Agents; Bone Density; Cyclohexanes; Female; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Pelvic Bones; Tenofovir; Triazoles | 2015 |
Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Deoxycytidine; Drug Substitution; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Viral Load; Zidovudine | 2015 |
Depression and Oral FTC/TDF Pre-exposure Prophylaxis (PrEP) Among Men and Transgender Women Who Have Sex With Men (MSM/TGW).
Topics: Adolescent; Adult; Anti-HIV Agents; Cross-Sectional Studies; Depression; Emtricitabine; Female; HIV Infections; Homosexuality, Male; Humans; Longitudinal Studies; Male; Middle Aged; Pre-Exposure Prophylaxis; Sexual Behavior; Tenofovir; Transgender Persons | 2016 |
Pharmacokinetics of Raltegravir in HIV-Infected Patients on Rifampicin-Based Antitubercular Therapy.
Topics: Adult; Anti-HIV Agents; Antibiotics, Antitubercular; Coinfection; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Raltegravir Potassium; Rifampin; Tenofovir; Tuberculosis | 2015 |
Risk of HIV-1 acquisition among women who use diff erent types of injectable progestin contraception in South Africa: a prospective cohort study.
Topics: Adult; Cohort Studies; Contraception Behavior; Contraceptive Agents, Female; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Incidence; Medroxyprogesterone Acetate; Norethindrone; Proportional Hazards Models; Risk Factors; South Africa; Tenofovir; Young Adult | 2015 |
Genital Tenofovir Concentrations Correlate With Protection Against HIV Infection in the CAPRISA 004 Trial: Importance of Adherence for Microbicide Effectiveness.
Topics: Adenine; Adult; Anti-HIV Agents; Case-Control Studies; Cervix Uteri; Female; Gels; HIV Infections; Humans; Medication Adherence; Organophosphonates; South Africa; Tenofovir; Tissue Distribution; Vagina; Young Adult | 2015 |
Brief Report: Cobicistat Compared With Ritonavir as a Pharmacoenhancer for Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate: Week 144 Results.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Cobicistat; Deoxycytidine; Double-Blind Method; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; RNA, Viral; Tenofovir; Thiazoles; Viral Load | 2015 |
Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation.
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Emtricitabine; Female; HIV Infections; Humans; Middle Aged; Organophosphates; Rilpivirine; Tenofovir; Young Adult | 2015 |
A Phase 1 Randomized, Blinded Comparison of the Pharmacokinetics and Colonic Distribution of Three Candidate Rectal Microbicide Formulations of Tenofovir 1% Gel with Simulated Unprotected Sex (CHARM-02).
Topics: Administration, Rectal; Adult; Anti-HIV Agents; Cross-Over Studies; Disease Transmission, Infectious; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Gels; HIV Infections; Humans; Male; Middle Aged; Plasma; Tenofovir; Unsafe Sex | 2015 |
Tenofovir Gel for the Prevention of Herpes Simplex Virus Type 2 Infection.
Topics: Adenine; Administration, Intravaginal; Adult; Double-Blind Method; Female; Follow-Up Studies; Gels; Herpes Genitalis; Herpesvirus 2, Human; HIV Infections; HIV Seronegativity; Humans; Incidence; Kaplan-Meier Estimate; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Young Adult | 2015 |
Patient-Reported Symptoms over 48 Weeks in a Randomized, Open-Label, Phase 3b Non-inferiority Trial of Adults with HIV Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF Versus Continuation of Ritonavir-Boosted Protease In
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Combinations; Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Emtricitabine; Female; HIV Infections; Humans; Logistic Models; Male; Patient Outcome Assessment; Patient Satisfaction; Protease Inhibitors; Ritonavir; Tenofovir | 2015 |
Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066).
Topics: Adult; Anti-HIV Agents; Benchmarking; Body Fluids; Drug Administration Schedule; Emtricitabine; Female; Healthy Volunteers; HIV Infections; Humans; Male; Patient Compliance; Pre-Exposure Prophylaxis; ROC Curve; Tablets; Tenofovir | 2016 |
Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis.
Topics: Adult; Anti-HIV Agents; Dideoxynucleosides; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Male; Medication Adherence; Middle Aged; Ritonavir; South Australia; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2015 |
Rapid Antiretroviral Therapy Initiation for Women in an HIV-1 Prevention Clinical Trial Experiencing Primary HIV-1 Infection during Pregnancy or Breastfeeding.
Topics: Adult; Africa, Eastern; Anti-HIV Agents; Breast Feeding; Early Medical Intervention; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Post-Exposure Prophylaxis; Pregnancy; Pregnancy Complications, Infectious; Tenofovir; Young Adult | 2015 |
Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial.
Topics: Absorptiometry, Photon; Adult; Anti-HIV Agents; Biomarkers; Bone Density; Bone Diseases, Metabolic; CD4 Lymphocyte Count; Comorbidity; Darunavir; Drug Therapy, Combination; Emtricitabine; Europe; Female; HIV Infections; Humans; Inflammation; Male; Middle Aged; Osteopetrosis; Raltegravir Potassium; Ritonavir; Tenofovir; Viral Load | 2015 |
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Combinations; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; RNA, Viral; Tenofovir; Viral Load | 2016 |
A phase 1 randomized placebo-controlled safety and pharmacokinetic trial of a tenofovir disoproxil fumarate vaginal ring.
Topics: Adolescent; Adult; Anti-HIV Agents; Body Fluids; Chemoprevention; Contraceptive Devices, Female; Disease Transmission, Infectious; Female; Healthy Volunteers; HIV Infections; Humans; Middle Aged; Placebos; Tenofovir; Young Adult | 2016 |
HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial.
Topics: Adult; Anti-HIV Agents; Brazil; Clinical Trials, Phase III as Topic; Condoms; Delivery of Health Care, Integrated; Directive Counseling; Ecuador; Emtricitabine; Female; HIV Infections; Homosexuality, Male; Humans; Male; Medication Adherence; Peru; Pre-Exposure Prophylaxis; Sexual Partners; South Africa; Tenofovir; Thailand; Transgender Persons; United States | 2015 |
On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection.
Topics: Adult; Condoms; Double-Blind Method; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Homosexuality, Male; Humans; Kaplan-Meier Estimate; Male; Medication Adherence; Middle Aged; Pre-Exposure Prophylaxis; Risk Factors; Sexual Behavior; Sexually Transmitted Diseases; Tenofovir | 2015 |
Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study.
Topics: Adult; Albuminuria; Bone Density; Cobicistat; Drug Substitution; Drug Therapy, Combination; Emtricitabine; Female; Glomerular Filtration Rate; HIV Infections; Humans; Male; Middle Aged; Proteinuria; Quinolones; Renal Insufficiency; Tenofovir | 2016 |
Tenofovir is associated with increased tubular proteinuria and asymptomatic renal tubular dysfunction in Ghana.
Topics: Adult; Anti-HIV Agents; Antiviral Agents; Causality; Comorbidity; Drug-Related Side Effects and Adverse Reactions; Female; Ghana; HIV Infections; Humans; Kidney Diseases; Male; Middle Aged; Prevalence; Proteinuria; Risk Assessment; Tenofovir | 2015 |
Regulatory T-Cell Activity But Not Conventional HIV-Specific T-Cell Responses Are Associated With Protection From HIV-1 Infection.
Topics: Adult; AIDS Vaccines; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Immunity, Cellular; Lymphocyte Activation; Male; Pre-Exposure Prophylaxis; Prospective Studies; T-Lymphocytes, Regulatory; Tenofovir | 2016 |
Associations between vitamin D metabolites, antiretroviral therapy and bone mineral density in people with HIV.
Topics: Adult; Anti-HIV Agents; Body Mass Index; Bone Density; Calcitriol; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Hip Joint; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Osteoporosis; Prospective Studies; Tenofovir; Vitamin D | 2016 |
Switching from a two-tablet regimen of tenofovir/emtricitabine and efavirenz to a one-tablet regimen may affect patients' perceptions and drug management.
Topics: Adult; Alkynes; Benzoxazines; Cohort Studies; Cyclopropanes; Drug Administration Schedule; Drug Combinations; Emtricitabine; Female; Health Surveys; HIV Infections; Humans; Male; Medication Adherence; Middle Aged; Patient Satisfaction; Prospective Studies; Tablets; Tenofovir; Treatment Outcome | 2016 |
Brief Report: HIV-1 Evolution in Breakthrough Infections in a Human Trial of Oral Pre-exposure Prophylaxis With Emtricitabine and Tenofovir Disoproxil Fumarate.
Topics: Anti-HIV Agents; Botswana; CD4 Lymphocyte Count; Double-Blind Method; Emtricitabine; Evolution, Molecular; HIV Antibodies; HIV Infections; HIV-1; Humans; Pre-Exposure Prophylaxis; Tenofovir; Treatment Outcome; Viral Load | 2016 |
Assessment of Oral Fluid HIV Test Performance in an HIV Pre-Exposure Prophylaxis Trial in Bangkok, Thailand.
Topics: Adult; Anti-HIV Agents; Female; HIV Antibodies; HIV Infections; HIV-1; HIV-2; Humans; Immunoenzyme Techniques; Male; Mass Screening; Middle Aged; Pre-Exposure Prophylaxis; Reagent Kits, Diagnostic; Reproducibility of Results; Sensitivity and Specificity; Tenofovir; Thailand; Young Adult | 2015 |
Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Disease Progression; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Gastrointestinal Diseases; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Proportional Hazards Models; Pyridines; Pyrones; Ritonavir; Sulfonamides; Tenofovir; Young Adult | 2016 |
Preexposure prophylaxis-selected drug resistance decays rapidly after drug cessation.
Topics: Anti-HIV Agents; Drug Resistance, Viral; Emtricitabine; Family Characteristics; Female; High-Throughput Nucleotide Sequencing; HIV; HIV Infections; Humans; Male; Mutation, Missense; Placebos; Pre-Exposure Prophylaxis; RNA, Viral; Sequence Analysis, DNA; Tenofovir | 2016 |
Proportion and factors associated with Hepatitis B viremia in antiretroviral treatment naïve and experienced HIV co-infected Ghanaian patients.
Topics: Adolescent; Adult; Anti-HIV Agents; Antiviral Agents; Coinfection; Cross-Sectional Studies; Female; Ghana; Hepatitis B; Hepatitis B virus; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Tenofovir; Viral Load; Viremia; Young Adult | 2016 |
Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study.
Topics: Adolescent; Adult; Anti-HIV Agents; Atazanavir Sulfate; Australia; Europe; Female; Glomerular Filtration Rate; HIV Infections; Humans; Male; Middle Aged; Prospective Studies; Renal Insufficiency, Chronic; Tenofovir; United States; Young Adult | 2016 |
Does Adherence Change When No One is Looking? Comparing Announced and Unannounced Tenofovir Levels in a PrEP Trial.
Topics: Adult; Anti-HIV Agents; Drug Monitoring; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Male; Medication Adherence; Pre-Exposure Prophylaxis; Self Care; Sexual Partners; Tenofovir; Uganda | 2016 |
Comparison of subjective and objective adherence measures for preexposure prophylaxis against HIV infection among serodiscordant couples in East Africa.
Topics: Adult; Africa, Eastern; Anti-Retroviral Agents; Disease Transmission, Infectious; Double-Blind Method; Family Characteristics; Female; HIV Infections; Humans; Male; Medication Adherence; Pre-Exposure Prophylaxis; Tenofovir | 2016 |
Symptoms, Side Effects and Adherence in the iPrEx Open-Label Extension.
Topics: Adult; Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Male; Medication Adherence; Pre-Exposure Prophylaxis; Tenofovir | 2016 |
Distinct genital tract HIV-specific antibody profiles associated with tenofovir gel.
Topics: Administration, Topical; Adult; Anti-Retroviral Agents; Female; Follow-Up Studies; Genitalia, Female; HIV Antibodies; HIV Core Protein p24; HIV Envelope Protein gp120; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Immunoglobulin A; Immunoglobulin G; Tenofovir; Treatment Outcome; Vaginal Creams, Foams, and Jellies; Young Adult | 2016 |
Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results.
Topics: Adenine; Alanine; Albuminuria; Anti-HIV Agents; Bone Density; CD4 Lymphocyte Count; Cobicistat; Double-Blind Method; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Proteinuria; Quinolones; RNA, Viral; Tenofovir | 2016 |
Divergent adherence estimates with pharmacokinetic and behavioural measures in the MTN-003 (VOICE) study.
Topics: Adult; Anti-HIV Agents; Double-Blind Method; Female; HIV Infections; Humans; Logistic Models; Medication Adherence; Pre-Exposure Prophylaxis; Tenofovir | 2016 |
Bone Mineral Density Changes Among Young, Healthy African Women Receiving Oral Tenofovir for HIV Preexposure Prophylaxis.
Topics: Adolescent; Adult; Anti-HIV Agents; Bone Density; Female; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir; Uganda; Young Adult; Zimbabwe | 2016 |
Rare emergence of drug resistance in HIV-1 treatment-naïve patients after 48 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; CD4 Lymphocyte Count; Cobicistat; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Quinolones; Tenofovir; Young Adult | 2016 |
Reporting of Adherence in the VOICE Trial: Did Disclosure of Product Nonuse Increase at the Termination Visit?
Topics: Administration, Oral; Adult; Anti-HIV Agents; Deception; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; Gels; HIV Infections; Humans; Medication Adherence; Middle Aged; Pre-Exposure Prophylaxis; Self Disclosure; South Africa; Tenofovir; Uganda; Young Adult; Zimbabwe | 2016 |
A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine.
Topics: Adult; Anti-HIV Agents; Dose-Response Relationship, Drug; Emtricitabine; Female; Forecasting; HIV Infections; Humans; Male; New York; Pre-Exposure Prophylaxis; Tenofovir; Translational Research, Biomedical; Young Adult | 2016 |
Medroxyprogesterone acetate levels among Kenyan women using depot medroxyprogesterone acetate in the FEM-PrEP trial.
Topics: Adolescent; Adult; Contraceptive Agents, Female; Delayed-Action Preparations; Drug Interactions; Emtricitabine; Female; HIV Infections; Humans; Kenya; Medroxyprogesterone Acetate; Pre-Exposure Prophylaxis; Pregnancy; Pregnancy Tests; Tenofovir; Young Adult | 2016 |
Nucleoside-Sparing Regimens With Raltegravir and a Boosted Protease Inhibitor: An Unsettled Issue.
Topics: Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Dose-Response Relationship, Drug; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Raltegravir Potassium; Ritonavir; RNA, Viral; Surveys and Questionnaires; Tenofovir; Treatment Outcome | 2016 |
Low Risk of Proximal Tubular Dysfunction Associated With Emtricitabine-Tenofovir Disoproxil Fumarate Preexposure Prophylaxis in Men and Women.
Topics: Adolescent; Adult; Anti-HIV Agents; Chemoprevention; Female; HIV Infections; Humans; Male; Middle Aged; Placebos; Pre-Exposure Prophylaxis; Renal Insufficiency; Tenofovir; Urinalysis; Young Adult | 2016 |
Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, activ
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Antiviral Agents; Double-Blind Method; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Tenofovir | 2016 |
Longitudinal increase in vitamin D binding protein levels after initiation of tenofovir/lamivudine/efavirenz among individuals with HIV.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Bone Resorption; Cyclopropanes; Female; HIV Infections; Humans; Lamivudine; Longitudinal Studies; Male; Middle Aged; Plasma; Tenofovir; Vitamin D-Binding Protein; Young Adult | 2016 |
Sharing of Investigational Drug Among Participants in the Voice Trial.
Topics: Administration, Oral; Adult; Anti-HIV Agents; Double-Blind Method; Drugs, Investigational; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; HIV Infections; Humans; Medication Adherence; Pre-Exposure Prophylaxis; South Africa; Substance-Related Disorders; Tenofovir; Vaginal Creams, Foams, and Jellies; Young Adult | 2016 |
Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected Adults.
Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Coinfection; Drug Combinations; Drug Substitution; Emtricitabine; Female; Hepatitis B; HIV Infections; Humans; Male; Middle Aged; Quinolones; Tenofovir; Treatment Outcome | 2016 |
An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy.
Topics: Adult; Algorithms; Anti-HIV Agents; Cobicistat; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; Oxazines; Patient Safety; Piperazines; Pyridones; Quinolones; Risk; Tenofovir | 2016 |
Differential CD4+ cell count increase and CD4+ : CD8+ ratio normalization with maraviroc compared with tenofovir.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-CD8 Ratio; Cyclohexanes; Darunavir; Double-Blind Method; Emtricitabine; Female; Flow Cytometry; HIV Infections; Humans; Male; Maraviroc; Placebos; Prospective Studies; Tenofovir; Treatment Outcome; Triazoles | 2016 |
Protocol for an open-label, single-arm trial of HIV pre-exposure prophylaxis (PrEP) among people at high risk of HIV infection: the NSW Demonstration Project PRELUDE.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Emtricitabine; Female; HIV Infections; Hospitals, Private; Humans; Male; Medication Adherence; Middle Aged; New South Wales; Pre-Exposure Prophylaxis; Public Health Practice; Research Design; Risk-Taking; Self Report; Tenofovir; Time Factors; Young Adult | 2016 |
Neurocognition with maraviroc compared with tenofovir in HIV.
Topics: Adult; AIDS-Related Complex; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cognition; Cyclohexanes; Double-Blind Method; Female; HIV Infections; Humans; Male; Maraviroc; Neuropsychological Tests; Placebos; Tenofovir; Treatment Outcome; Triazoles; United States | 2016 |
Analysis of the Endogenous Deoxynucleoside Triphosphate Pool in HIV-Positive and -Negative Individuals Receiving Tenofovir-Emtricitabine.
Topics: Adult; Anti-HIV Agents; Case-Control Studies; Deoxyadenine Nucleotides; Deoxycytosine Nucleotides; Deoxyguanine Nucleotides; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Leukocytes, Mononuclear; Linear Models; Male; Tenofovir; Thymine Nucleotides | 2016 |
Population Pharmacokinetics of Tenofovir in HIV-1-Uninfected Members of Serodiscordant Couples and Effect of Dose Reporting Methods.
Topics: Adult; Anti-HIV Agents; Body Weight; Creatinine; Double-Blind Method; Electronic Health Records; Emtricitabine; Family Characteristics; Female; HIV Infections; HIV-1; Humans; Male; Medication Adherence; Models, Statistical; Monitoring, Physiologic; Pre-Exposure Prophylaxis; Sexual Partners; Tenofovir | 2016 |
Project Gel a Randomized Rectal Microbicide Safety and Acceptability Study in Young Men and Transgender Women.
Topics: Administration, Rectal; Adolescent; Adult; Anti-HIV Agents; Chlamydia Infections; Cross-Sectional Studies; Female; Gels; Herpes Genitalis; HIV Infections; Homosexuality, Male; Humans; Male; Sexually Transmitted Diseases; Tenofovir; Transgender Persons; Young Adult | 2016 |
Perceived Risk Among Human Immunodeficiency Virus Serodiscordant Couples in East Africa Taking Oral Pre-Exposure Prophylaxis.
Topics: Adolescent; Adult; Anti-HIV Agents; Cross-Sectional Studies; Female; Heterosexuality; HIV Infections; HIV Seronegativity; Humans; Kenya; Male; Medication Adherence; Perception; Pre-Exposure Prophylaxis; Risk; Sexual Partners; Surveys and Questionnaires; Tenofovir; Uganda; Young Adult | 2016 |
Maraviroc/raltegravir simplification strategy following 6 months of quadruple therapy with tenofovir/emtricitabine/maraviroc/raltegravir in treatment-naive HIV patients.
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cyclohexanes; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Maintenance Chemotherapy; Male; Maraviroc; Middle Aged; Raltegravir Potassium; Tenofovir; Treatment Outcome; Triazoles; Viral Load; Young Adult | 2016 |
Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study.
Topics: Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Cobicistat; Double-Blind Method; Emtricitabine; Female; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; International Cooperation; Quinolones; Ritonavir; RNA, Viral; Tenofovir; Viral Load | 2016 |
Emtricitabine-Triphosphate in Dried Blood Spots as a Marker of Recent Dosing.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Case-Control Studies; Dried Blood Spot Testing; Drug Administration Schedule; Emtricitabine; Female; Half-Life; HIV; HIV Infections; Humans; Male; Medication Adherence; Middle Aged; Prospective Studies; Tenofovir | 2016 |
The effect of Tenofovir on renal function among Ugandan adults on long-term antiretroviral therapy: a cross-sectional enrolment analysis.
Topics: Adolescent; Adult; Anti-HIV Agents; Anti-Retroviral Agents; Creatinine; Cross-Sectional Studies; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney; Male; Middle Aged; Prospective Studies; Renal Insufficiency; Tenofovir; Uganda; Young Adult | 2016 |
Tenofovir disoproxil fumarate-associated hypophosphatemia as determined by fractional excretion of filtered phosphate in HIV-infected patients.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Creatinine; Female; HIV Infections; HIV-1; Humans; Hypophosphatemia; Male; Phosphates; Prospective Studies; Tenofovir | 2016 |
Changes in plasma levels of oxidized lipoproteins and lipoprotein subfractions with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy and associations with common carotid artery intima-media thickness: ACTG 5260s.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Carotid Intima-Media Thickness; Darunavir; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Linear Models; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Oxidation-Reduction; Prospective Studies; Raltegravir Potassium; Ritonavir; RNA, Viral; Tenofovir | 2017 |
Treatment of HIV infection with a raltegravir-based regimen increases LDL levels, but improves HDL cholesterol efflux capacity.
Topics: Adult; Anti-HIV Agents; Biological Transport, Active; Cholesterol, HDL; Emtricitabine; Female; HIV Infections; Humans; Lipoproteins, LDL; Male; Middle Aged; Raltegravir Potassium; RNA, Viral; Tenofovir; Young Adult | 2017 |
Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biomarkers; Comorbidity; Female; HIV Infections; HIV-1; Humans; Inflammation Mediators; Male; ROC Curve; Tenofovir | 2016 |
Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial.
Topics: Adenine; Adolescent; Alanine; Anti-HIV Agents; Area Under Curve; CD4 Lymphocyte Count; Child; Cobicistat; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lost to Follow-Up; Male; Quinolones; RNA, Viral; South Africa; Tablets; Tenofovir; Thailand; Uganda; United States; Viral Load | 2016 |
Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention.
Topics: Adult; Anti-Retroviral Agents; Black or African American; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; Gestational Age; HIV Infections; Humans; Infant; Infant Mortality; Infant, Low Birth Weight; Infant, Newborn; Infant, Premature; Infectious Disease Transmission, Vertical; Nevirapine; Perinatal Care; Pregnancy; Pregnancy Outcome; Tenofovir; Young Adult; Zidovudine | 2016 |
Topics: Absorptiometry, Photon; Adult; Air Pollutants; Alkynes; Alleles; Animals; Anthracenes; Anthraquinones; Anti-HIV Agents; Benzoxazines; Black or African American; Bone Density; Bone Density Conservation Agents; C-Reactive Protein; Calcium, Dietary; Capsid Proteins; Cardiomyopathy, Dilated; Cardiovascular Diseases; CD4 Lymphocyte Count; Cholesterol; Collagen Type I; Cyclopropanes; Darunavir; Disease Models, Animal; Drug Therapy, Combination; Echocardiography; Emtricitabine; Epitopes; Female; Femur Neck; Gene Expression Profiling; Genetic Predisposition to Disease; Hepatitis, Viral, Animal; Hip Joint; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunization; Inflammation Mediators; Lipoproteins, LDL; Lupus Erythematosus, Systemic; Male; Mice; Mice, Inbred BALB C; Nitrates; Osteocalcin; Oxidation-Reduction; Parathyroid Hormone; Parvovirus B19, Human; Peptides; Phenotype; Pilot Projects; Polymorphism, Single Nucleotide; Raltegravir Potassium; Ritonavir; RNA, Viral; Sodium Chloride; Tenofovir; Transcriptome; Uterine Cervical Dysplasia; Uterine Cervical Neoplasms; Vaccines; Vascular Endothelial Growth Factor A; Vitamin D; Young Adult | 2016 |
Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-lin
Topics: Absorptiometry, Photon; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Composition; CD4 Lymphocyte Count; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; International Cooperation; Lamivudine; Lopinavir; Male; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Viral Load | 2017 |
Efficacy and safety of tenofovir-containing antiretroviral therapy in women who acquired HIV while enrolled in tenofovir gel prophylaxis trials.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Emtricitabine; Female; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Patient Safety; Pregnancy; Primary Prevention; RNA, Viral; South Africa; Tenofovir; Treatment Outcome; Vaginal Creams, Foams, and Jellies; Viral Load; Zidovudine | 2017 |
Optimizing Pre-Exposure Antiretroviral Prophylaxis Adherence in Men Who Have Sex with Men: Results of a Pilot Randomized Controlled Trial of "Life-Steps for PrEP".
Topics: Adult; Anti-HIV Agents; Cognitive Behavioral Therapy; Counseling; HIV Infections; Humans; Male; Medication Adherence; Outcome Assessment, Health Care; Pilot Projects; Pre-Exposure Prophylaxis; Tenofovir; Young Adult | 2017 |
Factors associated with the uptake of and adherence to HIV pre-exposure prophylaxis in people who have injected drugs: an observational, open-label extension of the Bangkok Tenofovir Study.
Topics: Adult; Anti-HIV Agents; Double-Blind Method; Drug Users; Female; HIV Infections; HIV-1; Humans; Incidence; Male; Medication Adherence; Middle Aged; Pre-Exposure Prophylaxis; Risk-Taking; Substance Abuse, Intravenous; Tenofovir; Thailand; Time Factors; Young Adult | 2017 |
Markov Mixed Effects Modeling Using Electronic Adherence Monitoring Records Identifies Influential Covariates to HIV Preexposure Prophylaxis.
Topics: Adult; Anti-HIV Agents; Double-Blind Method; Drug Therapy, Combination; Electronic Health Records; Emtricitabine; Female; HIV Infections; Humans; Male; Markov Chains; Medication Adherence; Middle Aged; Models, Psychological; Sexual Behavior; Tenofovir; Young Adult | 2017 |
MTN-017: A Rectal Phase 2 Extended Safety and Acceptability Study of Tenofovir Reduced-Glycerin 1% Gel.
Topics: Adolescent; Adult; Antiretroviral Therapy, Highly Active; Female; Gels; Glycerol; HIV Infections; HIV-1; Homosexuality, Male; Humans; Male; Medication Adherence; Middle Aged; Rectum; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Young Adult | 2017 |
Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis.
Topics: Adolescent; Anti-HIV Agents; Bone Density; Creatinine; Emtricitabine; Fibroblast Growth Factor-23; Glomerular Filtration Rate; HIV Infections; Homosexuality, Male; Humans; Kidney; Male; Parathyroid Hormone; Pre-Exposure Prophylaxis; Renal Insufficiency; Tenofovir; Young Adult | 2017 |
Concentrations of Pro-Inflammatory Cytokines Are Not Associated with Senescence Marker p16INK4a or Predictive of Intracellular Emtricitabine/Tenofovir Metabolite and Endogenous Nucleotide Exposures in Adults with HIV Infection.
Topics: Adult; Aged; Anti-HIV Agents; Biomarkers; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p16; Cytokines; Emtricitabine; Female; HIV Infections; Humans; Inflammation; Male; Middle Aged; Nucleotides; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Young Adult | 2016 |
Efficacy and safety of "unboosting" atazanavir in a randomized controlled trial among HIV-infected patients receiving tenofovir DF.
Topics: Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Biomarkers; CD4 Lymphocyte Count; Drug Substitution; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Reverse Transcriptase Inhibitors; Tenofovir; Time Factors; Treatment Outcome; Viral Load | 2017 |
Renal safety of lithium in HIV-infected patients established on tenofovir disoproxil fumarate containing antiretroviral therapy: analysis from a randomized placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Drug Interactions; Glomerular Filtration Rate; HIV; HIV Infections; Humans; Kidney; Lithium Compounds; Middle Aged; Tenofovir; Viral Load; Young Adult | 2017 |
Switch as maintenance to elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate: week 48 results in a clinical cohort.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cobicistat; Cohort Studies; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Maintenance Chemotherapy; Male; Middle Aged; Polymerase Chain Reaction; Quinolones; RNA, Viral; Tablets; Tenofovir; Viral Load; Viremia | 2017 |
Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial.
Topics: Adenine; Adolescent; Adult; Alanine; Amides; Double-Blind Method; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Male; Oxazines; Piperazines; Pyridones; RNA, Viral; Tenofovir; Viral Load; Young Adult | 2017 |
Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-i
Topics: Adenine; Adult; Alanine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Middle Aged; Rilpivirine; Tenofovir | 2017 |
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Rilpivirine; Tenofovir | 2017 |
Brief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed Adults.
Topics: Adenine; Alanine; Anti-HIV Agents; CD4 Lymphocyte Count; Double-Blind Method; HIV Infections; HIV-1; Humans; Middle Aged; Tenofovir; Treatment Outcome; Viral Load | 2017 |
Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results.
Topics: Adenine; Alanine; Anti-HIV Agents; Bone Density; CD4 Lymphocyte Count; Cobicistat; Double-Blind Method; Emtricitabine; HIV Infections; Humans; Middle Aged; Quinolones; Tenofovir; Treatment Outcome; United States | 2017 |
Addition of single-dose tenofovir and emtricitabine to intrapartum nevirapine to reduce perinatal HIV transmission.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Nevirapine; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Tenofovir | 2008 |
Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; DNA Mutational Analysis; DNA, Viral; Drug Resistance, Viral; Female; Genotype; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Male; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Tenofovir; Time Factors; Treatment Outcome; Virus Replication | 2008 |
Lack of a significant drug interaction between raltegravir and tenofovir.
Topics: Adenine; Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2008 |
Zidovudine/lamivudine/abacavir plus tenofovir in HIV-infected naive patients: a 96-week prospective one-arm pilot study.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Endpoint Determination; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Pilot Projects; Prospective Studies; Spain; Tenofovir; Treatment Outcome; Viral Load; Zidovudine | 2008 |
Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Brachial Artery; CD4 Lymphocyte Count; Cyclopropanes; Endothelium, Vascular; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Organophosphonates; Prospective Studies; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine; Tenofovir; Time Factors; Zidovudine | 2008 |
A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; DNA, Viral; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Prospective Studies; Tenofovir; Thailand; Treatment Outcome; Zidovudine | 2008 |
Comparison of the antiviral activity of adefovir and tenofovir on hepatitis B virus in HIV-HBV-coinfected patients.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Proportional Hazards Models; Tenofovir; Treatment Outcome; Viral Load | 2008 |
The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Creatinine; Double-Blind Method; Female; Glomerular Filtration Rate; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Phosphorus; Proteinuria; Reverse Transcriptase Inhibitors; Stavudine; Tenofovir; Young Adult; Zidovudine | 2008 |
Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone.
Topics: Adenine; Adult; Anti-HIV Agents; Blood; Cohort Studies; Deoxycytidine; Dideoxynucleosides; Emtricitabine; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Middle Aged; Multivariate Analysis; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Tenofovir; Treatment Outcome; Viral Load | 2008 |
Effectiveness and safety of generic fixed-dose combination of tenofovir/emtricitabine/efavirenz in HIV-1-infected patients in Western India.
Topics: Adenine; Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Drugs, Generic; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Immunosuppression Therapy; India; Male; Middle Aged; Organophosphonates; Prevalence; Tenofovir; Treatment Outcome; Young Adult | 2008 |
Population pharmacokinetics of tenofovir in HIV-1-infected pregnant women and their neonates (ANRS 12109).
Topics: Adenine; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Maternal-Fetal Exchange; Organophosphonates; Population Groups; Pregnancy; Pregnancy Complications, Infectious; Prenatal Exposure Delayed Effects; Tenofovir | 2009 |
High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients.
Topics: Adenine; Adult; Amino Acid Substitution; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Mutation, Missense; Nevirapine; Organophosphonates; Tenofovir; Treatment Outcome; Viral Load; Viral Proteins | 2009 |
[Two novel fixed formulations of nucleoside analogues (tenofovir-emtricitabine, and abacavir-lamivudine). Prospective, open study on clinical practice and therapeutic perspectives, in patients naïve and in subjects pre-treated with antiretrovirals].
Topics: Adenine; Adult; Antiviral Agents; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Prospective Studies; Reverse Transcriptase Inhibitors; Tenofovir | 2008 |
Changes in sexual risk behavior among participants in a PrEP HIV prevention trial.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Counseling; Double-Blind Method; Female; Ghana; HIV Infections; Humans; Interviews as Topic; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Risk Reduction Behavior; Risk-Taking; Sexual Behavior; Sexual Partners; Surveys and Questionnaires; Tenofovir; Treatment Outcome; Unsafe Sex; Young Adult | 2008 |
Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus-1-hepatitis B virus coinfected individuals: similar effectiveness of lamivudine, tenofovir, or combination therapy.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biopsy; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B; Hepatitis B virus; HIV Infections; HIV-1; Humans; Immunosuppression Therapy; Lamivudine; Liver; Male; Middle Aged; Models, Biological; Organophosphonates; Prospective Studies; Tenofovir; Viral Load; Young Adult | 2009 |
Assessment of the steady-state pharmacokinetic interaction between etravirine administered as two different formulations and tenofovir disoproxil fumarate in healthy volunteers.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Belgium; Cross-Over Studies; Drug Interactions; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Netherlands; Nitriles; Organophosphonates; Pyridazines; Pyrimidines; Tenofovir; Young Adult | 2009 |
Tenofovir use in human immunodeficiency virus-1-infected children in the United kingdom and Ireland.
Topics: Adenine; Adolescent; Anti-HIV Agents; Child; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; Humans; Ireland; Male; Organophosphonates; Pediatrics; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; United Kingdom | 2009 |
Abacavir/3TC vs. tenofovir/FTC: interim results from ACTG 5202.
Topics: Adenine; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2008 |
Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir.
Topics: Adenine; Adult; Anti-HIV Agents; Area Under Curve; Cross-Sectional Studies; Dideoxynucleosides; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Longitudinal Studies; Lopinavir; Male; Middle Aged; Organophosphonates; Pilot Projects; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Treatment Outcome | 2009 |
Tolerance and viral resistance after single-dose nevirapine with tenofovir and emtricitabine to prevent vertical transmission of HIV-1.
Topics: Adenine; Adult; Anti-HIV Agents; Cambodia; Cote d'Ivoire; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; Female; Genotype; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Nevirapine; Organophosphonates; Pregnancy; RNA, Viral; South Africa; Tenofovir; Viral Load | 2009 |
Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Patient Compliance; Tenofovir | 2009 |
A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Spain; Tenofovir; Treatment Failure; Treatment Outcome | 2009 |
A randomized trial of two-drug versus three-drug tenofovir-containing maintenance regimens in virologically controlled HIV-1 patients.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; France; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Tenofovir; Treatment Outcome; Viral Load | 2009 |
Safety evaluation of 1% tenofovir gel in healthy men.
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Cellulose; Circumcision, Male; Gels; Glycerol; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Penis; Phosphates; Propylene Glycols; Reverse Transcriptase Inhibitors; Single-Blind Method; Tenofovir; Treatment Outcome; Young Adult | 2009 |
Improvements in cheek volume in lipoatrophic individuals switching away from thymidine nucleoside reverse transcriptase inhibitors.
Topics: Absorptiometry, Photon; Adenine; Adult; Aged; Body Composition; Cheek; Dideoxynucleosides; Female; HIV Infections; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Male; Middle Aged; Organophosphonates; Quality of Life; Reverse Transcriptase Inhibitors; Stavudine; Tenofovir; Zidovudine | 2009 |
Switch from a ZDV/3TC-based regimen to a completely once daily (QD) regimen of emtricitabine/tenofovir DF fixed dose combination plus a third QD agent (SONETT).
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Emtricitabine; Female; Hemoglobins; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Prospective Studies; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load; Young Adult; Zidovudine | 2009 |
Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cardiovascular Diseases; CD4 Lymphocyte Count; Deoxycytidine; Dideoxynucleosides; Double-Blind Method; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Male; Organophosphonates; Pyrimidinones; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome | 2009 |
A randomized comparative trial of continued zidovudine/lamivudine or replacement with tenofovir disoproxil fumarate/emtricitabine in efavirenz-treated HIV-1-infected individuals.
Topics: Adenine; Adipose Tissue; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Emtricitabine; Extremities; Female; HIV Infections; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Lipids; Male; Middle Aged; Organophosphonates; Tenofovir; Young Adult; Zidovudine | 2009 |
Modulation of K65R selection by zidovudine inclusion: analysis of HIV resistance selection in subjects with virologic failure receiving once-daily abacavir/lamivudine/zidovudine and tenofovir DF (study COL40263).
Topics: Adenine; Adult; Amino Acid Substitution; Anti-HIV Agents; Dideoxynucleosides; Drug Administration Schedule; Drug Resistance, Multiple, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Pilot Projects; RNA, Viral; Tenofovir; Treatment Failure; Zidovudine | 2009 |
Modified directly observed antiretroviral therapy compared with self-administered therapy in treatment-naive HIV-1-infected patients: a randomized trial.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Aged; Anti-HIV Agents; Deoxycytidine; Dose-Response Relationship, Drug; Emtricitabine; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Organophosphonates; Pyrimidinones; Retrospective Studies; RNA, Viral; Stavudine; Tenofovir; Treatment Outcome; Young Adult | 2009 |
Covert use, vaginal lubrication, and sexual pleasure: a qualitative study of urban U.S. Women in a vaginal microbicide clinical trial.
Topics: Adenine; Administration, Intravaginal; Adult; Anti-HIV Agents; Anti-Infective Agents, Local; Black or African American; Cohort Studies; Coitus; Female; Heterosexuality; HIV Infections; Humans; Interpersonal Relations; Interviews as Topic; Lubricants; Male; Organophosphonates; Patient Satisfaction; Pleasure; Sexual Behavior; Sexual Partners; Tenofovir; United States; Urban Population; Vagina; Vaginal Creams, Foams, and Jellies | 2010 |
Development of HIV-1 drug resistance through 144 weeks in antiretroviral-naïve subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in study GS-01-934.
Topics: Adenine; Alkynes; Amino Acid Substitution; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Genome, Viral; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Mutation, Missense; Organophosphonates; Tenofovir; Treatment Failure; Zidovudine | 2009 |
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial.
Topics: Adenine; Adult; Alkynes; Analysis of Variance; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Double-Blind Method; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Prognosis; Pyrrolidinones; Raltegravir Potassium; RNA, Viral; Safety; Tenofovir; Treatment Outcome; Viral Load | 2009 |
Raltegravir as effective as efavirenz in 144-week data.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Double-Blind Method; Drug Therapy, Combination; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Lamivudine; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Tenofovir; Time Factors; Treatment Outcome | 2009 |
[Efficacy and safety of TAM-sparing antiretroviral regimens in naïve HIV-positive patients].
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Hyperinsulinism; Hyperlipidemias; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Prospective Studies; Tenofovir; Thymidine; Treatment Outcome; Young Adult | 2009 |
Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Emtricitabine; Female; HIV Infections; HLA-B Antigens; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Tenofovir; Treatment Outcome; Viral Load | 2009 |
Modified directly observed therapy to improve HIV treatment outcomes: little impact with potent, once-daily therapy in unselected antiretroviral-naïve patients.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Lopinavir; Medication Adherence; Organophosphonates; Pyrimidinones; Ritonavir; Self Administration; Stavudine; Tenofovir; Treatment Outcome | 2009 |
Steady-state amprenavir and tenofovir pharmacokinetics after coadministration of unboosted or ritonavir-boosted fosamprenavir with tenofovir disoproxil fumarate in healthy volunteers.
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Carbamates; Cross-Over Studies; Drug Administration Schedule; Drug Eruptions; Drug Interactions; Drug Therapy, Combination; Female; Furans; HIV Infections; Humans; Male; Middle Aged; Organophosphates; Organophosphonates; Prodrugs; Ritonavir; Sulfonamides; Tenofovir; Young Adult | 2010 |
Intrapartum tenofovir and emtricitabine reduces low-concentration drug resistance selected by single-dose nevirapine for perinatal HIV prevention.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Infectious Disease Transmission, Vertical; Mutation; Nevirapine; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2009 |
Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Community Health Services; Female; HIV; HIV Infections; Home Care Services; Humans; Lamivudine; Male; Nevirapine; Organophosphonates; Stavudine; Tenofovir; Uganda; Zidovudine | 2009 |
Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.
Topics: Adenine; Adolescent; Adult; Analysis of Variance; Anti-HIV Agents; CD4 Lymphocyte Count; Deoxycytidine; Dideoxynucleosides; Double-Blind Method; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Female; Fractures, Bone; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; RNA, Viral; Tenofovir; Therapeutic Equivalency; Time Factors; Treatment Failure; Viral Load; Young Adult | 2009 |
Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Africa; Aged; Anemia; Anti-Retroviral Agents; CD4 Lymphocyte Count; Creatinine; Dideoxynucleosides; Disease Progression; Drug Monitoring; Female; Glomerular Filtration Rate; Hemoglobins; HIV Infections; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Male; Middle Aged; Neutropenia; Neutrophils; Nevirapine; Organophosphonates; RNA, Viral; Tenofovir; Urea; Viral Load; Zidovudine | 2010 |
Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction.
Topics: Adenine; Adult; Anti-HIV Agents; Biomarkers; Cardiovascular Diseases; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lipids; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Viral Load | 2010 |
Adipocyte differentiation, mitochondrial gene expression and fat distribution: differences between zidovudine and tenofovir after 6 months.
Topics: Adenine; Adipocytes; Adipose Tissue; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cell Differentiation; Cyclopropanes; Drug Therapy, Combination; Fatty Acids; Female; Gene Expression; Genes, Mitochondrial; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Male; Mitochondria; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Up-Regulation; Zidovudine | 2009 |
Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lipids; Lopinavir; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2010 |
Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate + emtricitabine promptly improves triglycerides and low-density lipoprotein cholesterol in dyslipidaemic patients.
Topics: Adenine; Adult; Anti-HIV Agents; Cholesterol, LDL; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Nucleosides; Organophosphonates; Tenofovir; Triglycerides | 2010 |
Abacavir and tenofovir disoproxil fumarate co-administration results in a nonadditive antiviral effect in HIV-1-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxyguanine Nucleotides; Dideoxynucleosides; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; RNA, Viral; Tenofovir; Treatment Outcome | 2010 |
Long-term efficacy and safety of once-daily nevirapine in combination with tenofovir and emtricitabine in the treatment of HIV-infected patients: a 72-week prospective multicenter study (TENOR-trial).
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nevirapine; Organophosphonates; Prospective Studies; Tenofovir; Treatment Outcome | 2009 |
Patient-reported outcomes in virologically suppressed, HIV-1-Infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF.
Topics: Adenine; Adolescent; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Patient Compliance; Patient Preference; Puerto Rico; Quality of Life; Reverse Transcriptase Inhibitors; Severity of Illness Index; Tablets; Tenofovir; Treatment Outcome; United States; Young Adult | 2010 |
Mitochondrial changes during D-drug-containing once-daily therapy in HIV-positive treatment-naive patients.
Topics: Adenine; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cross-Sectional Studies; Cyclopropanes; Didanosine; Dideoxynucleosides; DNA, Mitochondrial; Drug Administration Schedule; Female; HIV; HIV Infections; Humans; Lamivudine; Male; Mitochondria; Organophosphonates; Reverse Transcriptase Inhibitors; RNA; RNA, Mitochondrial; Tenofovir | 2010 |
Impact of low abundance HIV variants on response to ritonavir-boosted atazanavir or fosamprenavir given once daily with tenofovir/emtricitabine in antiretroviral-naive HIV-infected patients.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Atazanavir Sulfate; Carbamates; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Emtricitabine; Furans; Genetic Variation; HIV Infections; HIV-1; Humans; Middle Aged; Oligopeptides; Organophosphates; Organophosphonates; Pyridines; Ritonavir; RNA, Viral; Sequence Analysis, RNA; Sulfonamides; Tenofovir; Treatment Failure | 2010 |
The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Darunavir; Deoxycytidine; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Tenofovir; Treatment Outcome; Young Adult | 2010 |
Tenofovir/emtricitabine combination results in lower bone-mineral density.
Topics: Adenine; Anti-HIV Agents; Bone Density; Deoxycytidine; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Humans; Organophosphonates; Tenofovir; Treatment Outcome | 2010 |
Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study.
Topics: Adenine; Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; beta 2-Microglobulin; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Glomerular Filtration Rate; HIV Infections; HIV-1; Humans; Kidney; Lamivudine; Male; Middle Aged; Organophosphonates; Retinol-Binding Proteins; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2010 |
Gastrointestinal tolerability and quality of life in antiretroviral-naive HIV-1-infected patients: data from the CASTLE study.
Topics: Adenine; Adult; Aged; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; Gastrointestinal Diseases; HIV Infections; HIV-1; Humans; Irritable Bowel Syndrome; Lopinavir; Male; Medication Adherence; Middle Aged; Oligopeptides; Organophosphonates; Prospective Studies; Pyridines; Pyrimidinones; Quality of Life; Ritonavir; Surveys and Questionnaires; Tenofovir; Young Adult | 2010 |
A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cholesterol; Dyslipidemias; Epidemiologic Methods; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Pilot Projects; Tenofovir; Young Adult | 2010 |
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.
Topics: Adenine; Administration, Intravaginal; Adolescent; Adult; Anti-HIV Agents; Anti-Infective Agents, Local; Double-Blind Method; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Incidence; Organophosphonates; Patient Compliance; Pregnancy; Pregnancy Outcome; Rural Population; Sexual Behavior; South Africa; Tenofovir; Urban Population; Vaginal Creams, Foams, and Jellies; Viral Load; Young Adult | 2010 |
Short communication: Comparable safety and efficacy with once-daily versus twice-daily dosing of lopinavir/ritonavir tablets with emtricitabine + tenofovir DF in antiretroviral-naïve, HIV type 1-infected subjects: 96 week final results of the randomized t
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Humans; Lopinavir; Organophosphonates; Pyrimidinones; Ritonavir; Tenofovir | 2010 |
Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV.
Topics: Adenine; Administration, Oral; Adult; Anti-HIV Agents; Biological Availability; Deoxycytidine; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; Humans; Male; Organophosphonates; Plasma; Quinolones; Tablets; Tenofovir | 2010 |
Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults.
Topics: Adenine; Adult; Anti-HIV Agents; Darunavir; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Male; Nitriles; Organophosphonates; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Tenofovir; Treatment Outcome | 2010 |
Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus.
Topics: Adenine; Adult; Anti-HIV Agents; Antiviral Agents; CD4 Lymphocyte Count; DNA, Viral; Drug Resistance, Viral; Female; Follow-Up Studies; Guanine; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Kaplan-Meier Estimate; Kidney; Male; Middle Aged; Organophosphonates; Prospective Studies; Tenofovir; Time Factors; Virus Replication | 2010 |
Maternal and nenonatal tenofovir and emtricitabine to prevent vertical transmission of HIV-1: tolerance and resistance.
Topics: Adenine; Adult; Antiviral Agents; Cambodia; Cote d'Ivoire; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; Genotype; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Organophosphonates; Pregnancy; RNA, Viral; South Africa; Tenofovir; Viral Load | 2010 |
Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study.
Topics: Absorptiometry, Photon; Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Bone and Bones; Bone Density; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Europe; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Tenofovir; Young Adult | 2010 |
Efficacy of tenofovir disoproxil fumarate/emtricitabine compared with emtricitabine alone in antiretroviral-naive HIV-HBV coinfection in Thailand.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; Deoxycytidine; DNA, Viral; Emtricitabine; Female; Hepatitis B, Chronic; HIV Infections; Humans; Male; Organophosphonates; Prospective Studies; Tenofovir; Thailand | 2010 |
Pharmacokinetics and pharmacodynamics of the non-nucleoside reverse-transcriptase inhibitor etravirine in treatment-experienced HIV-1-infected patients.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Aged; Darunavir; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Nitriles; Organophosphonates; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2010 |
Antiretroviral therapies in women after single-dose nevirapine exposure.
Topics: Adenine; Adult; Anti-HIV Agents; Anti-Retroviral Agents; CD4 Lymphocyte Count; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Infectious Disease Transmission, Vertical; Kaplan-Meier Estimate; Linear Models; Lopinavir; Nevirapine; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Pyrimidinones; Ritonavir; Statistics, Nonparametric; Tenofovir; Treatment Failure; Young Adult | 2010 |
Population pharmacokinetics of nevirapine in HIV-1-infected pregnant women and their neonates.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Infant, Newborn; Nevirapine; Organophosphonates; Pregnancy; Tenofovir; Treatment Outcome; Young Adult; Zidovudine | 2011 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Follow-Up Studies; HIV; HIV Antibodies; HIV Infections; HIV Seropositivity; Homosexuality, Male; Humans; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Nausea; Organophosphonates; Patient Compliance; RNA, Viral; Tenofovir; Transsexualism; Young Adult | 2010 |
Effect of boosted fosamprenavir or lopinavir-based combinations on whole-body insulin sensitivity and lipids in treatment-naive HIV-type-1-positive men.
Topics: Adenine; Adipose Tissue; Adult; Anti-HIV Agents; Blood Glucose; Carbamates; Confidence Intervals; Drug Administration Schedule; Drug Combinations; Dyslipidemias; Furans; HIV Infections; HIV-1; Humans; Insulin; Insulin Resistance; Lamivudine; Lipids; Lopinavir; Male; Organophosphates; Organophosphonates; Pyrimidinones; Ritonavir; Sulfonamides; Tenofovir | 2010 |
Low level of the K103N HIV-1 above a threshold is associated with virological failure in treatment-naive individuals undergoing efavirenz-containing therapy.
Topics: Adenine; Adult; Alkynes; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Organophosphonates; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral; Tenofovir; Treatment Failure; Viral Load | 2011 |
Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men.
Topics: Adenine; Antiviral Agents; Deoxycytidine; Double-Blind Method; Drug Therapy, Combination; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Male; Organophosphonates; Tenofovir; Unsafe Sex | 2011 |
Co-enrollment in multiple HIV prevention trials - experiences from the CAPRISA 004 Tenofovir gel trial.
Topics: Adenine; Adult; Africa South of the Sahara; Anti-HIV Agents; Clinical Trials, Phase II as Topic; Female; Gels; HIV Infections; Humans; Organophosphonates; Patient Participation; Patient Selection; Randomized Controlled Trials as Topic; Self Report; Tenofovir; Young Adult | 2011 |
Intracellular nucleotide levels during coadministration of tenofovir disoproxil fumarate and didanosine in HIV-1-infected patients.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Chromatography, Liquid; Deoxyadenine Nucleotides; Deoxyguanine Nucleotides; Didanosine; Dideoxynucleotides; Female; HIV Infections; Humans; Male; Middle Aged; Nucleotides; Organophosphonates; Tandem Mass Spectrometry; Tenofovir; Young Adult | 2011 |
Atazanavir pharmacokinetics with and without tenofovir during pregnancy.
Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; Drug Administration Schedule; Drug Monitoring; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infectious Disease Transmission, Vertical; Oligopeptides; Organophosphonates; Postpartum Period; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Trimester, Third; Prospective Studies; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Treatment Outcome | 2011 |
A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel.
Topics: Adenine; Adult; Anti-HIV Agents; Biomarkers; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Genitalia, Female; HIV Infections; Humans; Immunity, Mucosal; Mucous Membrane; Organophosphonates; Semen; Tenofovir; Vaginal Douching; Young Adult | 2011 |
Early changes in inflammatory and pro-thrombotic biomarkers in patients initiating antiretroviral therapy with abacavir or tenofovir.
Topics: Adenine; Adult; Anti-HIV Agents; Biomarkers; C-Reactive Protein; Coagulants; Dideoxynucleosides; Female; HIV Infections; Humans; Inflammation Mediators; Interleukin-6; Longitudinal Studies; Male; Middle Aged; Organophosphonates; Plasminogen Activator Inhibitor 1; Tenofovir; Thrombosis; Vascular Cell Adhesion Molecule-1 | 2011 |
Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis.
Topics: Adenine; Adult; Anti-HIV Agents; Darunavir; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; Genetic Association Studies; HIV Infections; HIV-1; Humans; Lopinavir; Male; Mutation; Organophosphonates; Polymorphism, Genetic; Pyrimidinones; Ritonavir; RNA, Viral; Sulfonamides; Tenofovir; Treatment Failure; Viral Load | 2011 |
Tenofovir discontinuation could predispose to urolithiasis in atazanavir-treated patients.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Male; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Urolithiasis | 2011 |
Initial results reported on raltegravir once-daily dosing.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV Integrase Inhibitors; Humans; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Tenofovir; Treatment Outcome | 2011 |
Metabolic benefits of switching to tenofovir/lamivudine after long-term use of stavudine/lamivudine in NNRTI-based antiretroviral regimens: a prospective study.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Female; HIV Infections; Humans; Lamivudine; Lipid Metabolism; Male; Middle Aged; Organophosphonates; Prospective Studies; Stavudine; Tenofovir; Treatment Outcome | 2011 |
Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial.
Topics: Adenine; Administration, Intravaginal; Adolescent; Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Organophosphonates; Patient Selection; Prevalence; Reverse Transcriptase Inhibitors; Risk Assessment; Risk Factors; Rural Population; Sex Factors; Sexual Behavior; South Africa; Tenofovir; Treatment Outcome; Urban Population; Vaginal Creams, Foams, and Jellies; Women's Health; Young Adult | 2011 |
Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; CD4 Lymphocyte Count; Cobicistat; Cyclopropanes; Deoxycytidine; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Patient Compliance; Patient Selection; Quinolones; Tenofovir; Thiazoles; Treatment Outcome | 2011 |
Beliefs about antiretroviral therapy, treatment adherence and quality of life in a 48-week randomised study of continuation of zidovudine/lamivudine or switch to tenofovir DF/emtricitabine, each with efavirenz.
Topics: Adenine; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Combinations; Drug Substitution; Drug Therapy, Combination; Emtricitabine; Female; Health Knowledge, Attitudes, Practice; HIV Infections; HIV-1; Humans; Lamivudine; Male; Medication Adherence; Middle Aged; Organophosphonates; Quality of Life; Tenofovir; Treatment Outcome; Young Adult; Zidovudine | 2011 |
Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN study).
Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; Deoxycytidine; Drug Therapy, Combination; Dyslipidemias; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lipids; Male; Nevirapine; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir; Viral Load | 2011 |
Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Cardiovascular Diseases; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nevirapine; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Treatment Outcome | 2011 |
Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG
Topics: Absorptiometry, Photon; Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Bone Density; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; Fractures, Bone; HIV Infections; Humans; Intention to Treat Analysis; Lamivudine; Male; Middle Aged; Oligopeptides; Organophosphonates; Osteoporosis; Pyridines; Risk Factors; Ritonavir; Tenofovir; Viral Load | 2011 |
Steady-state pharmacokinetics of tenofovir-based regimens in HIV-infected pediatric patients.
Topics: Adenine; Adolescent; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Child; Cyclopropanes; Drug Administration Schedule; Female; HIV Infections; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir | 2011 |
Low-density lipoprotein size and lipoprotein-associated phospholipase A2 in HIV-infected patients switching to abacavir or tenofovir.
Topics: Adenine; Adult; Anti-HIV Agents; Cardiovascular Diseases; Cholesterol, LDL; Clinical Protocols; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lipoproteins; Lipoproteins, LDL; Male; Middle Aged; Organophosphonates; Phospholipases A2; Reverse Transcriptase Inhibitors; Tenofovir | 2011 |
Treatment of advanced HIV disease in antiretroviral-naïve HIV-1-infected patients receiving once-daily atazanavir/ritonavir or twice-daily lopinavir/ritonavir, each in combination with tenofovir disoproxil fumarate and emtricitabine.
Topics: Adenine; Adult; Aged; Antiviral Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Organophosphonates; Prospective Studies; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome; Young Adult | 2011 |
Effects of the H2-receptor antagonist famotidine on the pharmacokinetics of atazanavir-ritonavir with or without tenofovir in HIV-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Cohort Studies; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Famotidine; Female; Histamine H2 Antagonists; HIV Infections; Humans; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir; Viral Load | 2011 |
Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Carbamates; CD4 Lymphocyte Count; Cobicistat; Deoxycytidine; Double-Blind Method; Drug Administration Schedule; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; RNA, Viral; Tenofovir; Thiazoles; Treatment Outcome | 2011 |
Randomized comparison of metabolic and renal effects of saquinavir/r or atazanavir/r plus tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients.
Topics: Adenine; Adult; Atazanavir Sulfate; Deoxycytidine; Drug Administration Schedule; Dyslipidemias; Emtricitabine; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Diseases; Male; Oligopeptides; Organophosphonates; Pyridines; Saquinavir; Tenofovir; Treatment Outcome | 2011 |
Predicting product adherence in a topical microbicide safety trial in Pune, India.
Topics: Adenine; Adolescent; Adult; Anti-Infective Agents; Anti-Infective Agents, Local; Condoms; Female; HIV Infections; Humans; India; Medication Adherence; Middle Aged; Organophosphonates; Predictive Value of Tests; Prospective Studies; Risk Reduction Behavior; Sexual Partners; Social Support; Socioeconomic Factors; Tenofovir; Young Adult | 2012 |
Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Infant; Infectious Disease Transmission, Vertical; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Young Adult | 2011 |
Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Deoxycytidine; Dideoxynucleosides; Double-Blind Method; Emtricitabine; Female; HIV; HIV Infections; Humans; Kaplan-Meier Estimate; Lamivudine; Male; Middle Aged; Organophosphonates; RNA, Viral; Tenofovir; Viral Load | 2011 |
Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK.
Topics: Absorptiometry, Photon; Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load | 2011 |
Virological response and resistance profiles after 24 months of first-line antiretroviral treatment in adults living in Bangui, Central African Republic.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Central African Republic; DNA Fingerprinting; Drug Resistance, Viral; Female; Genetic Variation; Health Services Accessibility; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Medication Adherence; Oligopeptides; Organophosphonates; Prospective Studies; Pyridines; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Viral Load; Young Adult; Zidovudine | 2012 |
Enrollment characteristics and risk behaviors of injection drug users participating in the Bangkok Tenofovir Study, Thailand.
Topics: Adenine; Administration, Oral; Adult; AIDS Vaccines; Communicable Disease Control; Double-Blind Method; Female; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Placebos; Risk; Risk-Taking; Substance Abuse, Intravenous; Tenofovir; Thailand | 2011 |
Evaluation of cardiovascular biomarkers in HIV-infected patients switching to abacavir or tenofovir based therapy.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biomarkers; Cardiovascular Diseases; Deoxycytidine; Dideoxynucleosides; E-Selectin; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Plasma; Tenofovir; Vascular Cell Adhesion Molecule-1 | 2011 |
A randomized, pilot trial to evaluate glomerular filtration rate by creatinine or cystatin C in naive HIV-infected patients after tenofovir/emtricitabine in combination with atazanavir/ritonavir or efavirenz.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Creatinine; Cyclopropanes; Cystatin C; Deoxycytidine; Emtricitabine; Female; Glomerular Filtration Rate; HIV Infections; Humans; Male; Middle Aged; Oligopeptides; Organophosphonates; Pilot Projects; Pyridines; Ritonavir; Tenofovir | 2012 |
Characteristics of HIV-1 serodiscordant couples enrolled in a clinical trial of antiretroviral pre-exposure prophylaxis for HIV-1 prevention.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Cohort Studies; Deoxycytidine; Emtricitabine; Female; Heterosexuality; HIV Infections; HIV Seronegativity; HIV Seropositivity; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Risk-Taking; Sexual Behavior; Tenofovir; Young Adult | 2011 |
Glomerular dysfunction and associated risk factors over 4-5 years following antiretroviral therapy initiation in Africa.
Topics: Adenine; Adult; Africa; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Creatinine; Dideoxynucleosides; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Diseases; Kidney Glomerulus; Lamivudine; Male; Nevirapine; Organophosphonates; Risk Factors; Tenofovir; Time Factors; Zidovudine | 2011 |
Predictors of limb fat gain in HIV positive patients following a change to tenofovir-emtricitabine or abacavir-lamivudine.
Topics: Adenine; Adipose Tissue; Adult; Biomarkers; Body Fat Distribution; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Extremities; HIV Infections; Humans; Lamivudine; Middle Aged; Organophosphonates; Predictive Value of Tests; Tenofovir | 2011 |
Changes in condom use during a microbicide clinical trial in Pune, India.
Topics: Adenine; Adult; Anti-HIV Agents; Cohort Studies; Condoms; Counseling; Female; Follow-Up Studies; Gels; Health Knowledge, Attitudes, Practice; HIV Infections; Humans; India; Male; Middle Aged; Odds Ratio; Organophosphonates; Risk Factors; Risk Reduction Behavior; Sex Distribution; Sexual Behavior; Sexual Partners; Surveys and Questionnaires; Tenofovir; Young Adult | 2012 |
Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir versus lopinavir/ritonavir in HIV-infected, treatment-naive patients who participated in the CASTLE Study.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir | 2012 |
HIV-1 protease inhibitors and clinical malaria: a secondary analysis of the AIDS Clinical Trials Group A5208 study.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Incidence; Lopinavir; Malaria; Nevirapine; Organophosphonates; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Treatment Outcome | 2012 |
Dynamics of cognitive change in HIV-infected individuals commencing three different initial antiretroviral regimens: a randomized, controlled study.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cognition; Cognition Disorders; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir; Zidovudine | 2012 |
The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Organophosphonates; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load | 2012 |
Raltegravir, tenofovir DF, and emtricitabine for postexposure prophylaxis to prevent the sexual transmission of HIV: safety, tolerability, and adherence.
Topics: Adenine; Adult; Anti-HIV Agents; Boston; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Patient Compliance; Post-Exposure Prophylaxis; Pyrrolidinones; Raltegravir Potassium; Tenofovir; Young Adult | 2012 |
What's love got to do with it? Explaining adherence to oral antiretroviral pre-exposure prophylaxis for HIV-serodiscordant couples.
Topics: Adenine; Administration, Oral; Adult; Anti-HIV Agents; Attitude to Health; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV Seronegativity; HIV Seropositivity; Humans; Interpersonal Relations; Male; Medication Adherence; Middle Aged; Organophosphonates; Sexual Partners; Tenofovir; Uganda; Young Adult | 2012 |
Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir: a randomized, placebo-controlled trial.
Topics: Adenine; Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cholecalciferol; Double-Blind Method; Drug Interactions; Female; HIV Infections; Humans; Male; Multicenter Studies as Topic; Organophosphonates; Parathyroid Hormone; Placebos; Tenofovir; Vitamins; Young Adult | 2012 |
Mitochondrial function, inflammation, fat and bone in HIV lipoatrophy: randomized study of uridine supplementation or switch to tenofovir.
Topics: Adenine; Adipocytes; Adipose Tissue; Adult; Anti-HIV Agents; Apoptosis; Bone Density; DNA, Mitochondrial; Female; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Inflammation; Male; Middle Aged; Mitochondria; Organophosphonates; Reverse Transcriptase Inhibitors; RNA; RNA, Mitochondrial; Tenofovir; Uridine; Viral Load | 2012 |
Evidence for a shift to anaerobic metabolism in adipose tissue in efavirenz-containing regimens for HIV with different nucleoside backbones.
Topics: Adenine; Adipose Tissue; Adult; Alkynes; Anaerobiosis; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Electron Transport Complex IV; Female; Gene Expression Regulation; HIV Infections; HIV-1; Humans; Ion Channels; Lipogenesis; Male; Middle Aged; Mitochondrial Proteins; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Uncoupling Protein 2; Zidovudine | 2012 |
A randomized study of tenofovir disoproxil fumarate in treatment-experienced HIV-1 infected adolescents.
Topics: Adenine; Adolescent; Anti-HIV Agents; Child; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Treatment Outcome; Viremia | 2012 |
Treatment outcomes of recommended first-line antiretroviral regimens in resource-limited clinics.
Topics: Adenine; Adult; Age Factors; Anti-HIV Agents; CD4 Lymphocyte Count; Cross-Sectional Studies; Deoxycytidine; Developing Countries; Drug Costs; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Nevirapine; Organophosphonates; Retrospective Studies; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2012 |
Changes in body composition and mitochondrial DNA in HIV-1-infected patients switching to fixed-dose abacavir/lamivudine or tenofovir/emtricitabine: a substudy of the BICOMBO trial.
Topics: Adenine; Adult; Anti-HIV Agents; Body Composition; Bone Density; Deoxycytidine; Dideoxynucleosides; DNA, Mitochondrial; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Tenofovir | 2012 |
A comparison of measured and estimated glomerular filtration rate in successfully treated HIV-patients with preserved renal function.
Topics: Adenine; Adult; Anti-HIV Agents; Body Mass Index; Deoxycytidine; Emtricitabine; Female; Glomerular Filtration Rate; HIV Infections; Humans; Lamivudine; Linear Models; Male; Middle Aged; Netherlands; Organophosphonates; Pilot Projects; Research Design; Statistics, Nonparametric; Tenofovir; Treatment Outcome; Zidovudine | 2012 |
Comparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trial.
Topics: Adenine; Adult; Alkaline Phosphatase; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biomarkers; Bone and Bones; Bone Density; Creatinine; Cystatin C; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Kidney; Kidney Function Tests; Lamivudine; Male; Middle Aged; Organophosphonates; Osteocalcin; Tenofovir; Time Factors; Treatment Outcome | 2012 |
Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV-1; Homosexuality, Male; Humans; Kenya; Male; Middle Aged; Organophosphonates; Patient Compliance; Sex Workers; Tenofovir | 2012 |
CAPRISA 004 tenofovir microbicide trial: no impact of tenofovir gel on the HIV transmission bottleneck.
Topics: Adenine; Anti-HIV Agents; Anti-Infective Agents, Local; Cervix Uteri; Cohort Studies; Female; Gels; HIV Infections; HIV-1; Humans; Mucous Membrane; Organophosphonates; Tenofovir | 2012 |
Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial.
Topics: Abortion, Spontaneous; Adenine; Adult; Anti-HIV Agents; Body Height; Body Weight; Breast Feeding; Burns; Cause of Death; Child, Preschool; Congenital Abnormalities; Drug Combinations; Female; Follow-Up Studies; Fractures, Bone; Growth; HIV Infections; HIV Seropositivity; Humans; Infant; Infant Mortality; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Male; Measles; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Prevalence; Respiratory Tract Infections; Tenofovir; Uganda; Zidovudine; Zimbabwe | 2012 |
Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine.
Topics: Absorptiometry, Photon; Adenine; Adult; Bone Density; Bone Remodeling; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2012 |
From in vitro EC₅₀ to in vivo dose-response for antiretrovirals using an HIV disease model. Part I: a framework.
Topics: Adenine; Anti-HIV Agents; Cyclohexanes; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Inhibitory Concentration 50; Male; Maraviroc; Models, Biological; Nitriles; Organophosphonates; Oxazines; Piperazines; Pyridazines; Pyridones; Pyrimidines; RNA, Viral; Tenofovir; Triazoles | 2012 |
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Cobicistat; Deoxycytidine; Double-Blind Method; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Quinolones; Ritonavir; Tenofovir; Thiazoles | 2012 |
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cobicistat; Cyclopropanes; Deoxycytidine; Double-Blind Method; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Quinolones; Tenofovir; Thiazoles | 2012 |
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Bone Density; Contraception Behavior; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Seropositivity; HIV-1; HIV-2; Humans; Kaplan-Meier Estimate; Male; Organophosphonates; Proportional Hazards Models; RNA, Viral; Sexual Behavior; Tenofovir; Viral Load; Young Adult | 2012 |
Preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Anti-Retroviral Agents; Case-Control Studies; Deoxycytidine; Double-Blind Method; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Female; HIV Infections; HIV Seropositivity; HIV-1; Humans; Incidence; Kaplan-Meier Estimate; Medication Adherence; Organophosphonates; Risk-Taking; RNA, Viral; Sexual Behavior; Tenofovir; Treatment Failure; Viral Load; Young Adult | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Blind Method; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Female; Heterosexuality; HIV Infections; HIV Seropositivity; HIV-1; Humans; Incidence; Male; Middle Aged; Organophosphonates; Pregnancy; RNA, Viral; Sexual Behavior; Tenofovir; Young Adult | 2012 |
Tenofovir use and renal insufficiency among pregnant and general adult population of HIV-infected, ART-naïve individuals in Lilongwe, Malawi.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Body Mass Index; CD4 Lymphocyte Count; Creatinine; Cyclopropanes; Drug Combinations; Female; HIV Infections; Humans; Lamivudine; Malawi; Male; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Renal Insufficiency; Tenofovir | 2012 |
Safety of tenofovir gel, a vaginal microbicide, in South African women: results of the CAPRISA 004 Trial.
Topics: Adenine; Administration, Intravaginal; Anti-HIV Agents; Anti-Infective Agents, Local; Bone and Bones; Female; Follow-Up Studies; Gastrointestinal Tract; HIV Infections; Humans; Kidney; Organophosphonates; South Africa; Tenofovir; Vaginal Creams, Foams, and Jellies | 2013 |
RMP-02/MTN-006: A phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil fumarate.
Topics: Adenine; Administration, Oral; Administration, Rectal; Adult; Aged; Anti-HIV Agents; Double-Blind Method; Female; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Patient Satisfaction; Rectum; Tenofovir; Treatment Outcome; United States; Vaginal Creams, Foams, and Jellies | 2012 |
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Male; Organophosphonates; Tenofovir | 2012 |
Neurocognitive impairment in patients randomized to second-line lopinavir/ritonavir-based antiretroviral therapy vs. lopinavir/ritonavir monotherapy.
Topics: Adenine; Adult; CD4 Lymphocyte Count; Cognition Disorders; Depression; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Viral Load | 2012 |
Effect of adherence as measured by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharmacokinetics in treatment-naive HIV-infected patients.
Topics: Adenine; Adult; Aged; Alleles; Atazanavir Sulfate; Cytochrome P-450 CYP3A; Deoxycytidine; Drug Interactions; Drug Therapy, Combination; Emtricitabine; Female; Genotype; HIV Infections; HIV Protease Inhibitors; Humans; Male; Medication Adherence; Middle Aged; Models, Biological; Nonlinear Dynamics; Oligopeptides; Organophosphonates; Pharmacogenetics; Pyridines; Ritonavir; Tenofovir; Young Adult | 2012 |
The early effects of stavudine compared with tenofovir on adipocyte gene expression, mitochondrial DNA copy number and metabolic parameters in South African HIV-infected patients: a randomized trial.
Topics: Adenine; Adipocytes; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biomarkers; DNA Copy Number Variations; DNA, Mitochondrial; Dose-Response Relationship, Drug; Female; Gene Expression Profiling; Glucose; HIV Infections; Humans; Inflammation; Lipid Metabolism; Male; Middle Aged; Organophosphonates; Prospective Studies; Reverse Transcriptase Inhibitors; South Africa; Stavudine; Tenofovir | 2013 |
Pharmacokinetic modelling of efavirenz, atazanavir, lamivudine and tenofovir in the female genital tract of HIV-infected pre-menopausal women.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Female; Genitalia, Female; HIV Infections; Humans; Lamivudine; Models, Biological; Oligopeptides; Organophosphonates; Premenopause; Pyridines; Reverse Transcriptase Inhibitors; Tenofovir | 2012 |
Adherence and acceptability in MTN 001: a randomized cross-over trial of daily oral and topical tenofovir for HIV prevention in women.
Topics: Adenine; Administration, Oral; Administration, Topical; Adolescent; Adult; Anti-HIV Agents; Cross-Over Studies; Female; HIV Infections; Humans; Medication Adherence; Middle Aged; Organophosphonates; Patient Acceptance of Health Care; Patient Preference; Sexual Partners; South Africa; Tenofovir; Uganda; United States; Vaginal Creams, Foams, and Jellies | 2013 |
A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: the HIV STAR study.
Topics: Adenine; Adult; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; Male; Organophosphonates; Ritonavir; Tenofovir | 2012 |
Intensification of antiretroviral therapy through addition of enfuvirtide in naive HIV-1-infected patients with severe immunosuppression does not improve immunological response: results of a randomized multicenter trial (ANRS 130 Apollo).
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cyclopropanes; Deoxycytidine; Drug Combinations; Emtricitabine; Enfuvirtide; Female; HIV Envelope Protein gp41; HIV Infections; HIV-1; Humans; Immune Tolerance; Lopinavir; Male; Organophosphonates; Peptide Fragments; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load | 2013 |
The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV-1-infected pregnant women.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Europe; Female; Fetal Blood; HIV Infections; HIV-1; Humans; Infectious Disease Transmission, Vertical; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Trimester, Third; Tenofovir; Viral Load; Young Adult | 2013 |
Raltegravir pharmacokinetics in treatment-naive patients is not influenced by race: results from the raltegravir early therapy in African-Americans living with HIV (REAL) study.
Topics: Adenine; Adult; Black or African American; Body Mass Index; CD4 Lymphocyte Count; Deoxycytidine; Drug Administration Schedule; Emtricitabine; Female; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; Humans; Male; Middle Aged; Organophosphonates; Pyrrolidinones; Racial Groups; Raltegravir Potassium; Tenofovir; Viral Load; White People | 2013 |
Maraviroc once-daily nucleoside analog-sparing regimen in treatment-naive patients: randomized, open-label pilot study.
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Cyclohexanes; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Oligopeptides; Organophosphonates; Pilot Projects; Pyridines; Ritonavir; RNA, Viral; Tenofovir; Triazoles; Viral Load; Young Adult | 2013 |
Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical Trials Group study A5224s, substudy of A5202.
Topics: Adenine; Adipose Tissue; Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; DNA, Mitochondrial; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Male; Mitochondria; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Treatment Outcome | 2013 |
A 72-week randomized study of the safety and efficacy of a stavudine to zidovudine switch at 24 weeks compared to zidovudine or tenofovir disoproxil fumarate when given with lamivudine and nevirapine.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Diet; Drug Administration Schedule; Drug Substitution; Female; Glomerular Filtration Rate; Hemoglobins; HIV Infections; Humans; Lamivudine; Male; Nevirapine; Organophosphonates; Peripheral Nervous System Diseases; Stavudine; Tenofovir; Treatment Outcome; Viral Load; Zidovudine | 2012 |
Impact of switching from zidovudine/lamivudine to tenofovir/emtricitabine on lipoatrophy: the RECOMB study.
Topics: Absorptiometry, Photon; Adenine; Adipose Tissue; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Male; Middle Aged; Organophosphonates; Prospective Studies; Tenofovir; Treatment Outcome | 2013 |
Efficacy and safety of lersivirine (UK-453,061) versus efavirenz in antiretroviral treatment-naive HIV-1-infected patients: week 48 primary analysis results from an ongoing, multicenter, randomized, double-blind, phase IIb trial.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Intention to Treat Analysis; Male; Middle Aged; Mutation; Nitriles; Organophosphonates; Pyrazoles; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Young Adult | 2013 |
A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results
Topics: Adenine; Adult; Alanine Transaminase; Anti-HIV Agents; Aspartate Aminotransferases; Atazanavir Sulfate; Bilirubin; Bone Density; Carbamates; Cobicistat; Confidence Intervals; Creatinine; Deoxycytidine; Double-Blind Method; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Quinolones; Ritonavir; RNA, Viral; Tenofovir; Thiazoles; Triglycerides | 2013 |
SWIFT: prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen.
Topics: Adenine; Adult; Aged; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Biomarkers; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Kaplan-Meier Estimate; Lamivudine; Male; Middle Aged; Organophosphonates; Prospective Studies; Protease Inhibitors; Proteinuria; Risk; Tenofovir | 2013 |
MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Cross-Over Studies; Female; HIV Infections; Humans; Middle Aged; Organophosphonates; Phosphorous Acids; Phosphorylation; Rectum; Tablets; Tenofovir; Vagina; Vaginal Creams, Foams, and Jellies; Young Adult | 2013 |
Pharmacokinetics of an increased atazanavir dose with and without tenofovir during the third trimester of pregnancy.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Atazanavir Sulfate; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Oligopeptides; Organophosphonates; Postpartum Period; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Trimester, Second; Pregnancy Trimester, Third; Prospective Studies; Pyridines; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Young Adult | 2013 |
Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Follow-Up Studies; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir; Virus Replication | 2002 |
Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; HIV Infections; Humans; Interferon-alpha; Lamivudine; Liver Cirrhosis; Middle Aged; Organophosphonates; Organophosphorus Compounds; Pilot Projects; Tenofovir; Time Factors; Viral Load | 2002 |
An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals.
Topics: Adenine; Adult; Anti-HIV Agents; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Follow-Up Studies; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Lymphocyte Count; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load | 2003 |
Determining the relative efficacy of highly active antiretroviral therapy.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studies; Cyclopropanes; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Organophosphonates; Organophosphorus Compounds; Oxazines; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome | 2003 |
Extended treatment with tenofovir disoproxil fumarate in treatment-experienced HIV-1-infected patients: genotypic, phenotypic, and rebound analyses.
Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1; Humans; Male; Mutation; Organophosphonates; Organophosphorus Compounds; Phenotype; RNA, Viral; Tenofovir | 2003 |
Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naive chronically HIV-1-infected individuals.
Topics: Adenine; Adult; Anti-HIV Agents; Chronic Disease; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; Prodrugs; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Viral Load | 2003 |
Evolution of lipid abnormalities in patients switched from stavudine- to tenofovir-containing regimens.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Double-Blind Method; Female; HIV Infections; Humans; Lipids; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; RNA, Viral; Stavudine; Tenofovir | 2003 |
Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Male; Mutation; Organophosphonates; Organophosphorus Compounds; Placebos; RNA; Tenofovir; Viral Load | 2003 |
Change to abacavir-lamivudine-tenofovir combination treatment in patients with HIV-1 who had complete virological suppression.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Viral Load | 2003 |
Single-dose and steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected children.
Topics: Adenine; Adolescent; Anti-HIV Agents; Area Under Curve; Child; Child, Preschool; Drug Combinations; Female; Half-Life; HIV Infections; Humans; Male; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2004 |
Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Anti-HIV Agents; CD4 Lymphocyte Count; Double-Blind Method; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Multivariate Analysis; Mutation; Organophosphonates; Organophosphorus Compounds; Phenotype; Placebos; Predictive Value of Tests; Regression Analysis; RNA, Viral; Tenofovir; Thymidine | 2004 |
Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Male; Mutation; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2004 |
Renal safety of tenofovir in HIV treatment-experienced patients.
Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; HIV Infections; Humans; Kidney Diseases; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir | 2004 |
Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Antiviral Agents; Area Under Curve; Atazanavir Sulfate; Chromatography, High Pressure Liquid; Drug Interactions; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Organophosphonates; Organophosphorus Compounds; Pyridines; Ritonavir; Spectrophotometry, Ultraviolet; Tenofovir | 2004 |
Tenofovir treatment in an unselected cohort of highly antiretroviral experienced HIV positive patients.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Mutation; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Treatment Outcome | 2004 |
Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Double-Blind Method; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; Oxazines; Prospective Studies; Stavudine; Tenofovir; Viral Load | 2004 |
Genotypic determinants of the virological response to tenofovir disoproxil fumarate in nucleoside reverse transcriptase inhibitor-experienced patients.
Topics: Adenine; Codon; Cohort Studies; France; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Multivariate Analysis; Organophosphonates; Point Mutation; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir | 2004 |
Safety and efficacy of once-daily didanosine, tenofovir and nevirapine as a simplification antiretroviral approach.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-CD8 Ratio; Chemical and Drug Induced Liver Injury; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lipids; Male; Nevirapine; Organophosphonates; Pancreatitis; Patient Compliance; Quality of Life; RNA, Viral; Tenofovir | 2004 |
Selection of K65R mutation in HIV-2-infected patients receiving tenofovir-containing regimen.
Topics: Adenine; Cohort Studies; Drug Therapy, Combination; France; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-2; Humans; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Tenofovir; Time Factors | 2004 |
Ninety-six-week efficacy of combination therapy with lamivudine and tenofovir in patients coinfected with HIV-1 and wild-type hepatitis B virus.
Topics: Adenine; Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; Hepatitis B; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Tenofovir | 2004 |
Patterns of resistance emerging in HIV-1 from antiretroviral-experienced patients undergoing intensification therapy with tenofovir disoproxil fumarate.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Amino Acid Substitution; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; HIV Infections; HIV-1; Humans; Organophosphonates; Phenotype; Placebos; Polymorphism, Single Nucleotide; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; RNA, Viral; Tenofovir | 2004 |
Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection.
Topics: Adenine; Adult; Drug Resistance, Viral; Female; Hepatitis B, Chronic; HIV Infections; Humans; Immunosuppressive Agents; Lamivudine; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2004 |
New once-daily HIV combination better tolerated.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Lamivudine; Organophosphonates; Oxazines; Tenofovir; Zidovudine | 2004 |
Saquinavir trough concentration before and after switching NRTI to tenofovir in patients treated with once-daily saquinavir hard gel capsule/ritonavir 1600 mg/100 mg.
Topics: Adenine; Adult; Capsules; Drug Administration Schedule; Drug Therapy, Combination; Gels; HIV Infections; HIV Protease Inhibitors; Humans; Organophosphonates; Ritonavir; Saquinavir; Tenofovir | 2004 |
Tenofovir regimen compared with Combivir.
Topics: Adenine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Europe; Female; Follow-Up Studies; HIV Infections; Humans; Lamivudine; Male; Maximum Tolerated Dose; Organophosphonates; Risk Assessment; Severity of Illness Index; Single-Blind Method; Tenofovir; Treatment Outcome; United States; Viral Load; Zidovudine | 2005 |
Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study.
Topics: Adenine; Adult; Double-Blind Method; Female; HIV Infections; HIV-1; Humans; Kidney Diseases; Male; Organophosphonates; Tenofovir; Time Factors | 2005 |
Early virological failure with a combination of tenofovir, didanosine and efavirenz.
Topics: Adenine; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Didanosine; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Mutation; Organophosphonates; Oxazines; Pyrimidinones; RNA, Viral; Tenofovir; Time Factors; Treatment Failure; Viremia | 2005 |
Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Creatinine; Female; HIV Infections; Humans; Kidney Diseases; Longitudinal Studies; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2005 |
Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine.
Topics: Adenine; Adult; Anti-HIV Agents; CD4-Positive T-Lymphocytes; Didanosine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; HIV Infections; Humans; Lymphopenia; Male; Organophosphonates; Retrospective Studies; Tenofovir; Virus Replication | 2005 |
Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Cholesterol; Drug Administration Schedule; Drug Resistance, Multiple, Viral; HIV Infections; HIV-1; Humans; Lipids; Lopinavir; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Saquinavir; Tenofovir; Viral Load | 2005 |
Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patients.
Topics: Adenine; Anti-HIV Agents; Cell Count; Chromatography, Liquid; Cross-Sectional Studies; Didanosine; Half-Life; HIV Infections; HIV-1; Humans; Kinetics; Longitudinal Studies; Mass Spectrometry; Organophosphonates; Phosphorylation; Reference Standards; Tenofovir | 2005 |
The steady-state pharmacokinetics of nelfinavir in combination with tenofovir in HIV-infected patients.
Topics: Adenine; Adult; Aged; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Nelfinavir; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Time Factors | 2005 |
Long-term hepatitis B virus dynamics in HIV-hepatitis B virus-co-infected patients treated with tenofovir disoproxil fumarate.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; DNA, Viral; Epidemiologic Methods; Female; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Tenofovir; Viral Load; Virus Replication | 2005 |
Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz: 12-week results from a randomized trial.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Didanosine; Drug Combinations; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Oxazines; Tenofovir; Treatment Failure | 2005 |
Comparative selection of the K65R and M184V/I mutations in human immunodeficiency virus type 1-infected patients enrolled in a trial of first-line triple-nucleoside analog therapy (Tonus IMEA 021).
Topics: Adenine; Dideoxynucleosides; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Mutation; Organophosphonates; Pilot Projects; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; RNA, Viral; Sequence Analysis, Protein; Tenofovir; Treatment Failure; Viral Load | 2005 |
Compromised immunologic recovery in treatment-experienced patients with HIV infection receiving both tenofovir disoproxil fumarate and didanosine in the TORO studies.
Topics: Adenine; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Enfuvirtide; HIV Envelope Protein gp41; HIV Infections; Humans; Organophosphonates; Peptide Fragments; Tenofovir; Time Factors; Viral Load | 2005 |
Is tenofovir involved in hypophosphatemia and decrease of tubular phosphate reabsorption in HIV-positive adults?
Topics: Adenine; Adult; Anti-HIV Agents; Cross-Sectional Studies; Female; HIV Infections; Humans; Hypophosphatemia; Kidney Tubules, Proximal; Male; Middle Aged; Organophosphonates; Phosphates; Tenofovir | 2006 |
Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir.
Topics: Adenine; Adult; Antiviral Agents; DNA-Directed DNA Polymerase; DNA, Viral; Drug Resistance, Viral; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Models, Molecular; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; Selection, Genetic; Tenofovir | 2005 |
Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects.
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Time Factors; Treatment Failure | 2005 |
Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection.
Topics: Adenine; Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Child; Child, Preschool; Drug Resistance, Viral; Female; HIV Infections; Humans; Male; Organophosphonates; Salvage Therapy; Tenofovir; Viral Load | 2005 |
Simplification therapy with once-daily didanosine, tenofovir and efavirenz in HIV-1-infected adults with viral suppression receiving a more complex antiretroviral regimen: final results of the EFADITE trial.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Didanosine; Dose-Response Relationship, Drug; HIV Infections; HIV-1; Humans; Male; Middle Aged; Odds Ratio; Organophosphonates; Oxazines; Prospective Studies; RNA, Viral; Tenofovir; Treatment Outcome | 2005 |
Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.
Topics: Adenine; Adolescent; Adult; Aged; Alkynes; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Deoxycytidine; Emtricitabine; Female; HIV; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Oxazines; Prospective Studies; RNA, Viral; Tenofovir; Zidovudine | 2006 |
Improvement in dyslipidaemia after switching stavudine to tenofovir and replacing protease inhibitors with efavirenz in HIV-infected children.
Topics: Adenine; Adolescent; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Child; Cyclopropanes; Dyslipidemias; Female; HIV Infections; HIV-1; Humans; Lipids; Male; Organophosphonates; Oxazines; Protease Inhibitors; Stavudine; Tenofovir; Treatment Outcome; Viral Load | 2005 |
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Female; Genotype; HIV Infections; Humans; Middle Aged; Organophosphonates; Patient Compliance; Sexual Abstinence; Tenofovir; Vaginal Creams, Foams, and Jellies | 2006 |
96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lipids; Lopinavir; Male; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Ritonavir; RNA, Viral; Saquinavir; Tenofovir; Time Factors; Treatment Outcome | 2006 |
Increased antiretroviral potency by the addition of enfuvirtide to a four-drug regimen in antiretroviral-naive, HIV-infected patients.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Synergism; Drug Therapy, Combination; Enfuvirtide; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; Humans; Lamivudine; Lopinavir; Organophosphonates; Oxazines; Patient Compliance; Peptide Fragments; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome | 2006 |
An open-label, randomized comparative pilot study of a single-class quadruple therapy regimen versus a 2-class triple therapy regimen for individuals initiating antiretroviral therapy.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Organophosphonates; Oxazines; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Zidovudine | 2006 |
Absence of clinically relevant pharmacokinetic interaction between ribavirin and tenofovir in healthy subjects.
Topics: Adenine; Adult; Antiviral Agents; Drug Interactions; Female; Hepatitis C; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Ribavirin; Tenofovir | 2006 |
Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Mutation; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Salvage Therapy; Tenofovir; Treatment Failure | 2006 |
Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Developing Countries; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; RNA, Viral; Tenofovir; Treatment Outcome; Uganda; Viral Load; Zidovudine; Zimbabwe | 2006 |
Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children.
Topics: Adenine; Adolescent; Age Factors; Anti-Retroviral Agents; Bone Density; Bone Development; Child; Female; HIV Infections; Humans; Male; Organophosphonates; Salvage Therapy; Tenofovir | 2006 |
Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903.
Topics: Adenine; Alkynes; Benzoxazines; Cyclopropanes; Double-Blind Method; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; Stavudine; Tenofovir; Treatment Outcome | 2006 |
Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection.
Topics: Adenine; Anti-HIV Agents; Chi-Square Distribution; DNA, Viral; Drug Resistance, Viral; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Lamivudine; Organophosphonates; Prospective Studies; Reverse Transcriptase Inhibitors; Statistics, Nonparametric; Tenofovir; Treatment Failure | 2006 |
A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Biomarkers; Body Fat Distribution; Dideoxynucleosides; Female; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lipids; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Stavudine; Tenofovir; Zidovudine | 2006 |
Virologic response of zidovudine, lamivudine, and tenofovir disoproxil fumarate combination in antiretroviral-naive HIV-1-infected patients.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Pilot Projects; Tenofovir; Viral Load; Zidovudine | 2006 |
Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Organophosphonates; Oxazines; RNA, Viral; Tenofovir; Time Factors; Viral Load; Zidovudine | 2006 |
Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127.
Topics: Adenine; Adult; Alanine Transaminase; Anti-HIV Agents; Antiviral Agents; DNA, Viral; Double-Blind Method; Female; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Tenofovir; Treatment Outcome | 2006 |
Renal function in patients receiving tenofovir with ritonavir/lopinavir or ritonavir/atazanavir in the HIV Outpatient Study (HOPS) cohort.
Topics: Adenine; Adult; Atazanavir Sulfate; Cohort Studies; Female; HIV Infections; Humans; Kidney; Lopinavir; Male; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Ritonavir; Tenofovir | 2006 |
Efficacy and safety of tenofovir double-dose in treatment-experienced HIV-infected patients: the TENOPLUS study.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Mutation; Organophosphonates; Pilot Projects; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Viral Load | 2007 |
Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: factors associated with response.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Genotype; Hepatitis B; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Tenofovir; Viral Load | 2007 |
Antiretroviral efficacy and virological profile of a zidovudine/lamivudine/tenofovir disoproxil fumarate combination therapy in antiretroviral-naive patients.
Topics: Adenine; Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Mutation; Organophosphonates; Pilot Projects; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure; Treatment Outcome; Zidovudine | 2006 |
Metabolic and anthropometric changes one year after switching from didanosine/stavudine to tenofovir in HIV-infected patients.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Body Weight; CD4 Lymphocyte Count; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Creatinine; Didanosine; Female; Glomerular Filtration Rate; Glycated Hemoglobin; Hemoglobins; HIV Infections; Humans; Lactic Acid; Male; Middle Aged; Organophosphonates; Phosphates; Skinfold Thickness; Stavudine; Tenofovir; Treatment Outcome; Triglycerides; Uric Acid; Viral Load | 2007 |
No change in calculated creatinine clearance after tenofovir initiation among Thai patients.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Body Weight; Creatinine; Female; HIV Infections; Humans; Kidney; Kidney Function Tests; Lamivudine; Male; Organophosphonates; Tenofovir; Thailand | 2007 |
Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression.
Topics: Adenine; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Patient Compliance; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load | 2007 |
Molecular basis of antagonism between K70E and K65R tenofovir-associated mutations in HIV-1 reverse transcriptase.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Computer Simulation; Dideoxynucleosides; Drug Resistance, Multiple, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutagenesis, Site-Directed; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2007 |
Renal function in antiretroviral-experienced patients treated with tenofovir disoproxil fumarate associated with atazanavir/ritonavir.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Creatinine; Female; France; HIV Infections; HIV Protease Inhibitors; Humans; Kidney Diseases; Male; Middle Aged; Models, Biological; Oligopeptides; Organophosphonates; Prognosis; Prospective Studies; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Treatment Outcome | 2007 |
The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Body Composition; Cholesterol; Drug Administration Schedule; Female; HIV; HIV Infections; Humans; Leukocytes, Mononuclear; Lipodystrophy; Male; Middle Aged; Mitochondria; Organophosphonates; Oxygen Consumption; Stavudine; Tenofovir; Treatment Outcome; Triglycerides | 2007 |
The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients.
Topics: Adenine; Administration, Oral; Adult; Antiretroviral Therapy, Highly Active; Case-Control Studies; Drug Interactions; Female; Genotype; HIV Infections; HIV Protease Inhibitors; Humans; Kidney; Lopinavir; Male; Membrane Transport Proteins; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Organic Anion Transport Protein 1; Organophosphonates; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Treatment Outcome | 2008 |
Lopinavir/Ritonavir pharmacokinetic profile: impact of sex and other covariates following a change from twice-daily to once-daily therapy.
Topics: Adenine; Adult; Area Under Curve; Capsules; Chromatography, High Pressure Liquid; Drug Administration Schedule; Drug Combinations; Drug Interactions; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Organophosphonates; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Sex Factors; Tenofovir | 2007 |
Compromised immunologic recovery in patients receiving tipranavir/ritonavir coadministered with tenofovir and didanosine in Randomized Evaluation of Strategic Intervention in multidrug-resiStant patients with tipranavir (RESIST) studies.
Topics: Adenine; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Organophosphonates; Pyridines; Pyrones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Sulfonamides; Tenofovir; Treatment Outcome; Viral Load | 2007 |
Renal safety of tenofovir in HIV-infected children: a prospective, 96-week longitudinal study.
Topics: Adenine; Adolescent; Anti-HIV Agents; Child; Child, Preschool; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Diseases; Male; Organophosphonates; Prospective Studies; Tenofovir | 2007 |
Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Area Under Curve; Atazanavir Sulfate; Chromatography, Liquid; Drug Combinations; Drug Interactions; Drug Monitoring; Female; Half-Life; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Matched-Pair Analysis; Metabolic Clearance Rate; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Tandem Mass Spectrometry; Tenofovir; Time Factors; Treatment Outcome | 2007 |
Low-level K65R mutation in HIV-1 reverse transcriptase of treatment-experienced patients exposed to abacavir or didanosine.
Topics: Adenine; Alleles; Didanosine; Dideoxynucleosides; Double-Blind Method; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Organophosphonates; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2007 |
Pregnancy prevention practices among women with multiple partners in an HIV prevention trial.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Condoms; Contraception; Contraception Behavior; Contraceptive Agents, Female; Female; Health Behavior; HIV Infections; Humans; Interviews as Topic; Organophosphonates; Pregnancy; Sex Work; Tenofovir | 2007 |
Determinants of high-risk sexual behavior during post-exposure prophylaxis to prevent HIV infection.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Interviews as Topic; Lamivudine; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Risk Factors; Risk-Taking; Sexual Partners; Surveys and Questionnaires; Tenofovir; Treatment Outcome | 2008 |
Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study.
Topics: Adenine; Adolescent; Adult; Aged; Australia; Canada; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Lamivudine; Latin America; Male; Middle Aged; Organic Chemicals; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; RNA, Viral; Tenofovir; Thailand; Time Factors; Treatment Outcome; United States | 2007 |
Acceptability of tenofovir gel as a vaginal microbicide by US male participants in a Phase I clinical trial (HPTN 050).
Topics: Adenine; Administration, Intravaginal; Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Patient Satisfaction; Sexually Transmitted Diseases; Tenofovir; Treatment Outcome; Vaginal Creams, Foams, and Jellies | 2007 |
Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis.
Topics: Adenine; Adult; Alkynes; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Zidovudine | 2008 |
Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial.
Topics: Adenine; Adult; Antiviral Agents; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Nevirapine; Organophosphonates; Pregnancy; Reverse Transcriptase Inhibitors; Tenofovir; Zambia | 2007 |
Observational study on HIV-infected subjects failing HAART receiving tenofovir plus didanosine as NRTI backbone.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Didanosine; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Mutation; Organophosphonates; Retrospective Studies; Reverse Transcriptase Inhibitors; Sequence Analysis, DNA; Tenofovir; Treatment Outcome | 2007 |
Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; HIV; HIV Infections; HIV Integrase Inhibitors; Humans; Lamivudine; Linear Models; Organic Chemicals; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; RNA, Viral; Statistics, Nonparametric; Tenofovir; Time Factors; Viral Load; Virus Integration; Virus Latency; Virus Replication | 2007 |
Interruptions of tenofovir/emtricitabine-based antiretroviral therapy in patients with HIV/hepatitis B virus co-infection.
Topics: Adenine; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Deoxycytidine; Drug Administration Schedule; Emtricitabine; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Male; Organophosphonates; Tenofovir; Thailand; Transaminases; Treatment Outcome; Viral Load | 2008 |
Effects of the change from Stavudine to tenofovir in human immunodeficiency virus-infected children treated with highly active antiretroviral therapy: studies on mitochondrial toxicity and thymic function.
Topics: Adenine; Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Blood Glucose; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Child; DNA, Mitochondrial; Female; HIV Infections; Humans; Lipids; Male; Mitochondria; Organophosphonates; Stavudine; Tenofovir; Thymus Gland; Viral Load | 2008 |
Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy.
Topics: Adenine; Adult; Drug Therapy, Combination; Female; Glomerular Filtration Rate; HIV Infections; HIV Protease Inhibitors; Humans; Kidney Diseases; Kidney Tubules; Male; Middle Aged; Nucleosides; Organophosphonates; Prospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Time | 2008 |
Plasma HIV load and proviral DNA decreases after two standard antiretroviral regimens in HIV-positive patients naïve to antiretrovirals.
Topics: Adenine; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Biomarkers; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cyclopropanes; DNA, Viral; Drug Administration Schedule; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Viral Load | 2008 |
Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load | 2008 |
Acceptability of tenofovir gel as a vaginal microbicide among women in a phase I trial: a mixed-methods study.
Topics: Adenine; Administration, Intravaginal; Adult; Anti-Infective Agents, Local; Cohort Studies; Female; HIV Infections; Humans; Middle Aged; Organophosphonates; Patient Acceptance of Health Care; Patient Satisfaction; Tenofovir; Treatment Outcome; Vaginal Creams, Foams, and Jellies | 2008 |
The effects of cotrimoxazole or tenofovir co-administration on the pharmacokinetics of maraviroc in healthy volunteers.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Anti-Infective Agents; CCR5 Receptor Antagonists; Cyclohexanes; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Organophosphonates; Receptors, CCR5; Statistics as Topic; Tenofovir; Triazoles; Trimethoprim, Sulfamethoxazole Drug Combination | 2008 |
Changes in metabolic toxicity after switching from stavudine/didanosine to tenofovir/lamivudine--a Staccato trial substudy.
Topics: Absorptiometry, Photon; Adenine; Adult; Anti-HIV Agents; Body Fat Distribution; Didanosine; DNA, Mitochondrial; HIV Infections; Humans; Lamivudine; Lipids; Liver Function Tests; Organophosphonates; Ritonavir; RNA, Viral; Saquinavir; Stavudine; Tenofovir; Thailand | 2008 |
Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients.
Topics: Adenine; Adult; Female; Gene Frequency; Genotype; HIV Infections; Humans; Kidney; Male; Membrane Transport Proteins; Metabolic Clearance Rate; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Organic Anion Transport Protein 1; Organophosphonates; Polymorphism, Single Nucleotide; Reverse Transcriptase Inhibitors; Tenofovir | 2008 |
An open-label pilot study to determine the efficacy of lopinavir/ritonavir and tenofovir DF in the treatment of HIV-infected patients experiencing first virologic failure on a non-nucleoside-based regimen.
Topics: Adenine; Adult; Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lopinavir; Middle Aged; Organophosphonates; Pilot Projects; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome | 2008 |
Risk of early virological failure of once-daily tenofovir-emtricitabine plus twice-daily nevirapine in antiretroviral therapy-naive HIV-infected patients.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Nevirapine; Oligopeptides; Organophosphonates; Pyridines; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load | 2008 |
Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(Phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults.
Topics: Adenine; Adolescent; Adult; Antiviral Agents; Double-Blind Method; Female; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; RNA, Viral; T-Lymphocytes; Tenofovir | 1998 |
PMPA trials recruiting.
Topics: Adenine; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; HIV Infections; Humans; Hydroxyurea; Organophosphonates; Organophosphorus Compounds; Tenofovir; Viral Load | 1998 |
Adefovir and tenofovir susceptibilities of HIV-1 after 24 to 48 weeks of adefovir dipivoxil therapy: genotypic and phenotypic analyses of study GS-96-408.
Topics: Adenine; Anti-HIV Agents; Double-Blind Method; Genes, Viral; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Mutation; Organophosphonates; Organophosphorus Compounds; Phenotype; Reverse Transcriptase Inhibitors; Tenofovir | 2001 |
Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults.
Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Drug Tolerance; Female; Genotype; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; RNA, Viral; Tenofovir | 2001 |
Hydroxyurea does not enhance the anti-HIV activity of low-dose tenofovir disoproxil fumarate.
Topics: Adenine; Adult; Anti-HIV Agents; Cohort Studies; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Hydroxyurea; Male; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2001 |
Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF.
Topics: Adenine; Double-Blind Method; Drug Resistance, Viral; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Organophosphonates; Organophosphorus Compounds; Phenotype; RNA, Viral; Tenofovir; Time Factors | 2002 |
Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study.
Topics: Adenine; Adult; CD4 Lymphocyte Count; Double-Blind Method; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Organophosphorus Compounds; RNA, Viral; Tenofovir; Time Factors | 2002 |
2008 other study(ies) available for tenofovir and HIV Coinfection
| Article | Year |
|---|---|
Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections.
Topics: Adenine; Animals; Anti-HIV Agents; Antiviral Agents; Cell Line; Female; Hepatitis B; Hepatitis B virus; HIV Core Protein p24; HIV Infections; HIV-1; Humans; Magnetic Resonance Spectroscopy; Male; Organophosphonates; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Inhibitors; Tenofovir | 2007 |
Human immunodeficiency virus type 1 isolates with the reverse transcriptase (RT) mutation Q145M retain nucleoside and nonnucleoside RT inhibitor susceptibility.
Topics: Amino Acid Sequence; Anti-HIV Agents; Drug Resistance, Viral; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation; Nucleosides; Phenotype; Reverse Transcriptase Inhibitors | 2009 |
Reverse transcriptase inhibitors as potential colorectal microbicides.
Topics: Adenine; Anilides; Anti-HIV Agents; Anti-Infective Agents, Local; Colon; Drug Resistance, Viral; Furans; HIV Infections; HIV-1; Humans; Leukocytes, Mononuclear; Organophosphonates; Pyrimidines; Rectum; Reverse Transcriptase Inhibitors; Tenofovir; Thioamides; Tissue Culture Techniques; Virus Replication | 2009 |
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
Topics: Adenine; Anti-HIV Agents; Cell Survival; Cells, Cultured; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Macrophages; Nucleosides; Nucleotides; Organophosphonates; Tenofovir | 2010 |
PMPA and PMEA prodrugs for the treatment of HIV infections and human papillomavirus (HPV) associated neoplasia and cancer.
Topics: Adenine; Antineoplastic Agents; Antiviral Agents; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; HeLa Cells; HIV; HIV Infections; Humans; Microbial Sensitivity Tests; Molecular Structure; Organophosphonates; Papillomavirus Infections; Prodrugs; Structure-Activity Relationship; Tenofovir; Tumor Cells, Cultured | 2014 |
ω-Functionalized Lipid Prodrugs of HIV NtRTI Tenofovir with Enhanced Pharmacokinetic Properties.
Topics: Animals; Antiviral Agents; Area Under Curve; Half-Life; HIV Infections; Humans; Liver; Mice; Molecular Structure; Oxidation-Reduction; Prodrugs; Tenofovir | 2021 |
Persistent HBV replication and serological response during up to 15 years of tenofovir-based antiretroviral therapy in HIV/HBV-coinfected patients: a multicentre prospective cohort study.
Topics: Coinfection; DNA, Viral; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Prospective Studies; Tenofovir | 2021 |
Impact of switch from tenofovir disoproxil fumarate-based regimens to tenofovir alafenamide-based regimens on lipid profile, weight gain and cardiovascular risk score in people living with HIV.
Topics: Alanine; Anti-HIV Agents; Cardiovascular Diseases; Heart Disease Risk Factors; HIV Infections; Humans; Lipids; Retrospective Studies; Risk Factors; Tenofovir; Weight Gain | 2021 |
Acute myocardial infarction associated with abacavir and tenofovir based antiretroviral drug combinations in the United States.
Topics: Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; HIV Infections; HIV-1; Humans; Lamivudine; Myocardial Infarction; Tenofovir; United States | 2021 |
Safety of Tenofovir Alafenamide in People With HIV Who Experienced Proximal Renal Tubulopathy on Tenofovir Disoproxil Fumarate.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Creatinine; Cystatin C; Female; HIV Infections; Humans; Kidney Diseases; Kidney Tubules, Proximal; Male; Middle Aged; Tenofovir | 2021 |
Cerebrospinal fluid exposure to bictegravir/emtricitabine/tenofovir in HIV-1-infected patients with CNS impairment.
Topics: Adenine; Aged; Alanine; Amides; Anti-HIV Agents; Chromatography, Liquid; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Middle Aged; Oxazines; Piperazines; Pyridones; Tandem Mass Spectrometry; Tenofovir | 2021 |
Transformation of tenofovir into stable ProTide nanocrystals with long-acting pharmacokinetic profiles.
Topics: Adenine; Alanine; Animals; Anti-HIV Agents; Drug Stability; Female; HIV Infections; HIV-1; Humans; Male; Nanoparticles; Organophosphates; Prodrugs; Rats, Sprague-Dawley; Tenofovir; Therapeutic Equivalency | 2021 |
Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living with HIV: Lipid Changes and Statin Underutilization.
Topics: Alanine; Anti-HIV Agents; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Retrospective Studies; Tenofovir | 2021 |
T cell derived HIV-1 is present in the CSF in the face of suppressive antiretroviral therapy.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; T-Lymphocytes; Tenofovir | 2021 |
Real-world efficacy and safety of switching to bictegravir/emtricitabine/tenofovir alafenamide in older people living with HIV.
Topics: Aged; Aged, 80 and over; Alanine; Drug Combinations; Drug Substitution; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Piperazines; Pyridones; Retrospective Studies; Tenofovir; Treatment Outcome | 2021 |
Antiretroviral therapy use in selected countries in Latin America during 2013-2017: results from the Latin American Workshop in HIV Study Group.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; HIV Infections; Humans; Latin America; Tenofovir | 2021 |
Switching from efavirenz to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide reduces central nervous system symptoms in people living with HIV.
Topics: Adenine; Adult; Alanine; Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System; Cobicistat; Cyclopropanes; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Male; Prospective Studies; Quality of Life; Quinolones; Sleep Quality; Tenofovir | 2021 |
Physiologically Based Pharmacokinetic Modeling of 3 HIV Drugs in Combination and the Role of Lymphatic System after Subcutaneous Dosing. Part 1: Model for the Free-Drug Mixture.
Topics: Animals; HIV Infections; Lopinavir; Lymphatic System; Ritonavir; Tenofovir | 2022 |
Physiologically Based Pharmacokinetic Modeling of 3 HIV Drugs in Combination and the Role of Lymphatic System after Subcutaneous Dosing. Part 2: Model for the Drug-combination Nanoparticles.
Topics: Drug Combinations; HIV Infections; Humans; Lopinavir; Lymphatic System; Models, Biological; Nanoparticles; Tenofovir | 2022 |
Analytical Lifecycle Management (ALM) and Analytical Quality by Design (AQbD) for analytical procedure development of related substances in tenofovir alafenamide fumarate tablets.
Topics: Adenine; Alanine; Anti-HIV Agents; Chromatography, Liquid; Fumarates; HIV Infections; Humans; Tablets; Tenofovir | 2022 |
Combined cART including Tenofovir Disoproxil, Emtricitabine, and Dolutegravir has potent therapeutic effects in HIV-1 infected humanized mice.
Topics: Animals; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Mice; Oxazines; Piperazines; Pyridones; Tenofovir; Viral Load | 2021 |
Drug Resistance, Rather than Low Tenofovir Levels in Blood or Urine, Is Associated with Tenofovir, Emtricitabine, and Efavirenz Failure in Resource-Limited Settings.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Drug Resistance; Emtricitabine; HIV Infections; Humans; South Africa; Tenofovir; Viral Load; Viremia | 2022 |
Crushed bictegravir/emtricitabine/tenofovir alafenamide in a human immunodeficiency virus-positive patient with pancreatic cancer.
Topics: Adenine; Aged; Alanine; Amides; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV; HIV Infections; Humans; Male; Oxazines; Pancreatic Neoplasms; Piperazines; Pyridones; Tenofovir; Treatment Outcome | 2022 |
Short-course daily isoniazid and rifapentine for latent tuberculosis infection in people living with HIV who received coformulated bictegravir/emtricitabine/tenofovir alafenamide.
Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Isoniazid; Latent Tuberculosis; Piperazines; Pyridones; Rifampin; Tenofovir | 2021 |
The Prevalence and Associated Factors of Reduced Bone Mineral Density (BMD) Among Men with Suppressed Viral Load Taking Antiretroviral Therapy.
Topics: Absorptiometry, Photon; Aged; Anti-HIV Agents; Bone Density; Cross-Sectional Studies; Female; HIV Infections; Humans; Male; Osteoporosis; Prevalence; Tenofovir; Viral Load | 2022 |
Retrospective evaluation of an observational cohort by the Central and Eastern Europe Network Group shows a high frequency of potential drug-drug interactions among HIV-positive patients receiving treatment for coronavirus disease 2019 (COVID-19).
Topics: Adenine; Adult; Anti-HIV Agents; COVID-19 Drug Treatment; Drug Interactions; Emtricitabine; Female; HIV Infections; HIV Seropositivity; Humans; Male; Middle Aged; Retrospective Studies; Reverse Transcriptase Inhibitors; SARS-CoV-2; Tenofovir | 2022 |
Tenofovir Alafenamide Plasma Concentrations Are Reduced in Pregnant Women Living With Human Immunodeficiency Virus (HIV): Data From the PANNA Network.
Topics: Adenine; Alanine; Anti-HIV Agents; Female; HIV; HIV Infections; Humans; Pregnancy; Pregnant Women; Tenofovir | 2022 |
Tenofovir plasma trough concentrations in people with HIV treated with doravirine versus other antiretroviral regimens.
Topics: Anti-HIV Agents; HIV Infections; Humans; Pyridones; Tenofovir; Triazoles | 2021 |
Weight gain in treatment-naive HIV-1 infected patients starting abacavir/lamivudine/dolutegravir or tenofovir alafenamide/emtricitabine/bictegravir.
Topics: Alanine; Amides; Anti-HIV Agents; Dideoxynucleosides; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Tenofovir; Weight Gain | 2022 |
Renal function in Japanese HIV-1-positive patients who switch to tenofovir alafenamide fumarate after long-term tenofovir disoproxil fumarate: a single-center observational study.
Topics: Alanine; Anti-HIV Agents; Fumarates; HIV Infections; HIV-1; Humans; Japan; Kidney; Tenofovir | 2021 |
Mutations in muscle-type creatine kinase impact HIV prevention.
Topics: Anti-HIV Agents; Creatine Kinase; HIV Infections; Humans; Muscles; Mutation; Tenofovir | 2022 |
Evolution of Hepatitis B Virus (HBV) Serologic Markers Among Antiretroviral-Naive Young People Living With Human Immunodeficiency Virus Who Had Undergone Neonatal HBV Vaccination and Initiated Antiretroviral Therapy.
Topics: Adolescent; Adult; Anti-Retroviral Agents; DNA-Directed RNA Polymerases; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Core Antigens; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B virus; Herpesvirus 1, Cercopithecine; HIV; HIV Infections; Humans; Infant, Newborn; Retrospective Studies; Tenofovir; Vaccination; Young Adult | 2022 |
Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on estimated glomerular filtration rate slope in patients with HIV: A retrospective observational study.
Topics: Alanine; Anti-HIV Agents; Fumarates; Glomerular Filtration Rate; HIV Infections; Humans; Retrospective Studies; Tenofovir | 2022 |
Osteonecrosis of the humeral head in a human immunodeficiency virus-infected patient under tenofovir disoproxil fumarate-emtricitabine-lopinavir/ritonavir for 10 years: a case report.
Topics: Emtricitabine; Female; HIV; HIV Infections; Humans; Humeral Head; Lopinavir; Middle Aged; Osteonecrosis; Ritonavir; Tenofovir | 2021 |
Impact of nucleos(t)ide reverse transcriptase inhibitor resistance on dolutegravir and protease-inhibitor-based regimens in children and adolescents in Kenya.
Topics: Adolescent; Anti-HIV Agents; Child; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Kenya; Lamivudine; Oxazines; Peptide Hydrolases; Piperazines; Protease Inhibitors; Pyridones; Reverse Transcriptase Inhibitors; Tenofovir | 2022 |
Use of Tenofovir Diphosphate Levels to Predict Viremia During the Postpartum Period in Women Living With Human Immunodeficiency Virus (HIV): A Nested Case-Control Study.
Topics: Adenine; Anti-HIV Agents; Case-Control Studies; Female; HIV; HIV Infections; Humans; Organophosphates; Postpartum Period; Pregnancy; Tenofovir; Viremia | 2022 |
Dolutegravir plus lamivudine versus efavirenz plus tenofovir disoproxil fumarate and lamivudine in antiretroviral-naive adults with HIV-1 infection.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Prospective Studies; Pyridones; Tenofovir | 2022 |
Safety and Tolerability of Once Daily Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide for Postexposure Prophylaxis After Sexual Exposure.
Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Emtricitabine; Fatigue; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Male; Piperazines; Post-Exposure Prophylaxis; Pyridones; Tenofovir | 2022 |
Brief Report: Transgender Women and Preexposure Prophylaxis Care: High Preexposure Prophylaxis Adherence in a Real-World Health Care Setting in New York City.
Topics: Anti-HIV Agents; Female; Global Health; HIV Infections; Homosexuality, Male; Humans; Male; Medication Adherence; New York City; Pre-Exposure Prophylaxis; Tenofovir; Transgender Persons; United States | 2022 |
Pharmacokinetics and tissue distribution of tenofovir, emtricitabine and dolutegravir in mice.
Topics: Animals; Anti-HIV Agents; Chromatography, Liquid; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; Mice; Oxazines; Piperazines; Pyridones; Tandem Mass Spectrometry; Tenofovir; Tissue Distribution | 2022 |
The use of tenofovir in patients with COVID-19.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; COVID-19 Drug Treatment; HIV Infections; Humans; Tenofovir | 2022 |
Point-of-care semi-quantitative test for adherence to tenofovir alafenamide or tenofovir disoproxil fumarate.
Topics: Adult; Alanine; Anti-HIV Agents; Emtricitabine; HIV Infections; HIV-1; Humans; Point-of-Care Systems; Tenofovir | 2022 |
Real-life experience with bictegravir/emtricitabine/tenofovir alafenamide in a large reference clinical centre.
Topics: Adult; Alanine; Amides; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Piperazines; Pyridones; Retrospective Studies; Tenofovir | 2022 |
Effects of tenofovir on telomeres, telomerase and T cell maturational subset distribution in long-term aviraemic HIV-infected adults.
Topics: Adult; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; HIV Infections; Humans; Telomerase; Telomere; Tenofovir | 2022 |
Brief Report: Patients' Experiences and Opinions After Desimplification of Their Single-Tablet Regimens for the Treatment of HIV Infection: A Survey in a Multicentre Cohort.
Topics: Anti-HIV Agents; Drug Combinations; Emtricitabine; HIV Infections; Humans; Lamivudine; Quality of Life; Surveys and Questionnaires; Tablets; Tenofovir | 2022 |
Cost-Effectiveness of Long-Acting Injectable HIV Preexposure Prophylaxis in the United States : A Cost-Effectiveness Analysis.
Topics: Anti-HIV Agents; Child; Cost-Benefit Analysis; Drugs, Generic; Emtricitabine; Female; HIV Infections; Homosexuality, Male; Humans; Male; Pre-Exposure Prophylaxis; Sexual and Gender Minorities; Tenofovir; United States | 2022 |
Current Antiretroviral Treatment Among People With Human Immunodeficiency Virus in the United States: Findings from the Centers for AIDS Research Network of Integrated Clinic Systems Cohort.
Topics: Acquired Immunodeficiency Syndrome; Alanine; Anti-HIV Agents; Anti-Retroviral Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV; HIV Infections; Humans; Tenofovir; United States | 2022 |
Tenofovir alafenamide: An initial experience at Groote Schuur Hospital, Cape Town, South Africa.
Topics: Adult; Alanine; Antiviral Agents; Female; Follow-Up Studies; Glomerular Filtration Rate; Hepatitis B; Hepatitis B e Antigens; HIV Infections; Humans; Male; Middle Aged; Retrospective Studies; South Africa; Tenofovir; Treatment Outcome; Viral Load | 2022 |
Genital Immune Cell Activation and Tenofovir Gel Efficacy: A Case-Control Study.
Topics: Anti-HIV Agents; Case-Control Studies; Deoxyadenosines; Emtricitabine; Female; Genitalia; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir | 2022 |
Long-Term Effectiveness of Rilpivirine-Based Single-Tablet Regimens in a Seven-Year, Two-Center Observational Cohort of People Living with HIV.
Topics: Anti-HIV Agents; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Infectious Disease Transmission, Vertical; Retrospective Studies; Rilpivirine; Tablets; Tenofovir | 2022 |
Response to 'The use of tenofovir in patients with COVID-19'.
Topics: Antiviral Agents; COVID-19 Drug Treatment; HIV Infections; Humans; Lamivudine; Tenofovir | 2022 |
Pharmacokinetics of Tenofovir Alafenamide With Boosted Protease Inhibitors in Pregnant and Postpartum Women Living With HIV: Results From IMPAACT P1026s.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Antiviral Agents; Female; HIV Infections; Humans; Postpartum Period; Pregnancy; Pregnancy Complications, Infectious; Prospective Studies; Protease Inhibitors; Tenofovir | 2022 |
Genital Inflammation Is Not Associated With Decreased Vaginal Tenofovir Concentrations in Women Taking Oral PrEP.
Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Inflammation; Pre-Exposure Prophylaxis; Tenofovir; Vagina | 2022 |
Real-world safety of pre-exposure prophylaxis for HIV.
Topics: Anti-HIV Agents; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir | 2022 |
Effectiveness and safety of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single-tablet combination among HIV-infected patients in Turkey: results from a real world setting.
Topics: Adult; Anti-HIV Agents; Cobicistat; Drug Combinations; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Male; Quinolones; Retrospective Studies; Tablets; Tenofovir; Turkey | 2021 |
A flexural exanthem following postexposure prophylaxis.
Topics: Emtricitabine; Exanthema; HIV Infections; Humans; Tenofovir | 2022 |
HIV pre-exposure prophylaxis adherence test using reverse transcription isothermal amplification inhibition assay.
Topics: Anti-HIV Agents; HIV Infections; Humans; Pre-Exposure Prophylaxis; Reverse Transcription; Tenofovir | 2022 |
Prevalence and Risk Factors of Low Bone Mineral Density in HIV/AIDS Patients: A Chinese Cross-Sectional Study.
Topics: Absorptiometry, Photon; Acquired Immunodeficiency Syndrome; Bone Density; Bone Diseases, Metabolic; Cholesterol; Cross-Sectional Studies; HIV Infections; Humans; Lipoproteins, HDL; Middle Aged; Osteoporosis; Prevalence; Risk Factors; Tenofovir | 2022 |
Inadequate PTH Response to Hypocalcemia in People Living with HIV.
Topics: Calcium; Female; HIV Infections; Humans; Hypocalcemia; Male; Middle Aged; Parathyroid Hormone; Retrospective Studies; Tenofovir | 2022 |
Prevalence and predictors of anemia among adults on highly active antiretroviral therapy in Northeast Ethiopia: A retrospective cohort study.
Topics: Adult; Anemia; Antiretroviral Therapy, Highly Active; Ethiopia; Female; HIV Infections; Humans; Male; Middle Aged; Prevalence; Quality of Life; Retrospective Studies; Tenofovir | 2022 |
HIV-1-infection in a man who has sex with men despite self-reported excellent adherence to pre-exposure prophylaxis, the Netherlands, August 2021: be alert to emtricitabine/tenofovir-resistant strain transmission.
Topics: Anti-HIV Agents; Emtricitabine; HIV Infections; HIV-1; Homosexuality, Male; Humans; Male; Medication Adherence; Netherlands; Pre-Exposure Prophylaxis; Self Report; Sexual and Gender Minorities; Tenofovir | 2022 |
Weight gain during the dolutegravir transition in the African Cohort Study.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Kenya; Lamivudine; Oxazines; Piperazines; Pyridones; Tenofovir; Weight Gain | 2022 |
Intramuscular depot medroxyprogesterone acetate accentuates bone loss associated with tenofovir disoproxil fumarate-containing antiretroviral therapy initiation in young women living with HIV (the BONE: CARE study): a prospective cohort study in Uganda.
Topics: Adult; Bone Density; Contraceptive Agents, Female; Female; HIV Infections; Humans; Male; Medroxyprogesterone Acetate; Prospective Studies; Tenofovir; Uganda; Young Adult | 2022 |
Alignment of PrEP use and sexual behavior over four months among men who have sex with men in the southern United States.
Topics: Anti-HIV Agents; HIV Infections; Homosexuality, Male; Humans; Male; Medication Adherence; Pre-Exposure Prophylaxis; Sexual and Gender Minorities; Sexual Behavior; Tenofovir; United States | 2022 |
Similar CD4/CD8 Ratio Recovery After Initiation of Dolutegravir Plus Lamivudine Versus Dolutegravir or Bictegravir-Based Three-Drug Regimens in Naive Adults With HIV.
Topics: Adult; Amides; Anti-HIV Agents; CD8-Positive T-Lymphocytes; Cohort Studies; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Tenofovir | 2022 |
Changing from Tenofovir/Emtricitabine to Cabotegravir for Pre Exposure Prophylaxis for HIV in Men who have Sex with Men: A Cost Utility Analysis from an Endemic Country.
Topics: Anti-HIV Agents; Cost-Benefit Analysis; Diketopiperazines; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Male; Pre-Exposure Prophylaxis; Pyridones; Sexual and Gender Minorities; Tenofovir | 2022 |
High efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in people with suppressed HIV and preexisting M184V/I.
Topics: Adenine; Adult; Alanine; Amides; Anti-HIV Agents; Clinical Trials as Topic; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Piperazines; Pyridones; RNA; Tenofovir | 2022 |
Characterizing HIV-Preventive, Plasma Tenofovir Concentrations-A Pooled Participant-level Data Analysis From Human Immunodeficiency Virus Preexposure Prophylaxis Clinical Trials.
Topics: Anti-HIV Agents; Clinical Trials, Phase III as Topic; Data Analysis; Emtricitabine; Female; HIV; HIV Infections; Humans; Male; Medication Adherence; Pre-Exposure Prophylaxis; Tenofovir | 2022 |
Bictegravir-based antiretroviral therapy in HIV-1 group O patients: data from real-life bictegravir/emtricitabine/tenofovir alafenamide switches.
Topics: Alanine; Amides; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Piperazines; Pyridones; Tenofovir | 2022 |
Doravirine/tenofovir disoproxyl fumarate/lamivudine-induced alopecia: A case report.
Topics: Alopecia; Anti-HIV Agents; Anti-Retroviral Agents; Emtricitabine; Fumarates; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Pyridones; Tenofovir; Triazoles; Viral Load | 2022 |
Advancing HIV prevention using tenofovir-based pre-exposure prophylaxis.
Topics: Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Male; Pre-Exposure Prophylaxis; Tenofovir | 2022 |
Tenofovir alafenamide fumarate.
Topics: Adenine; Alanine; Anti-HIV Agents; Fumarates; HIV Infections; HIV-1; Humans; Tenofovir | 2022 |
Simplification from tenofovir disoproxil fumarate plus lamivudine or emtricitabine plus ritonavir-boosted protease inhibitor to ritonavir-boosted atazanavir plus lamivudine in virologically suppressed HIV-infected adults with osteopenia: a pilot study.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Bone Diseases, Metabolic; Drug Substitution; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Pilot Projects; Ritonavir; Tenofovir | 2022 |
Oral pre-exposure prophylaxis preference, uptake, adherence and continuation among adolescent girls and young women in Kampala, Uganda: a prospective cohort study.
Topics: Adolescent; Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Pre-Exposure Prophylaxis; Prospective Studies; Tenofovir; Uganda; Young Adult | 2022 |
Fundamental aspects of long-acting tenofovir alafenamide delivery from subdermal implants for HIV prophylaxis.
Topics: Adenine; Alanine; Animals; Anti-HIV Agents; Female; HIV Infections; Mice; Tenofovir | 2022 |
Plasma and breast milk pharmacokinetics of tenofovir alafenamide in mothers with chronic hepatitis B infection.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Female; Hepatitis B; Hepatitis B, Chronic; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Milk, Human; Pregnancy; Tenofovir | 2022 |
Determining the acceptability of point-of-care urine tenofovir testing and its performance in predicting HIV RNA suppression.
Topics: Anti-HIV Agents; HIV Infections; Humans; Point-of-Care Systems; Point-of-Care Testing; Pre-Exposure Prophylaxis; RNA; Tenofovir | 2022 |
Fanconi syndrome in a patient receiving pre-exposure prophylaxis for HIV infection: case report.
Topics: Anti-HIV Agents; Emtricitabine; Fanconi Syndrome; HIV Infections; Humans; Male; Middle Aged; Pre-Exposure Prophylaxis; Proteinuria; Renal Insufficiency; Tenofovir | 2022 |
[Real-world efficacy of switching to bictegravir/ emtricitabine/tenofovir alafenamide in pretreated patients with triple therapy containing rilpivirine].
Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Piperazines; Pyridones; Retrospective Studies; Rilpivirine; Tenofovir | 2022 |
Levels of adherence to contemporary antiretroviral regimens and the likelihood of viral suppression: a cohort study in a Brazilian metropolis.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; Brazil; Cohort Studies; HIV Infections; Humans; Lamivudine; Prospective Studies; Tenofovir | 2023 |
Effect of drug-to-lipid ratio on nanodisc-based tenofovir drug delivery to the brain for HIV-1 infection.
Topics: Anti-HIV Agents; Brain; Delayed-Action Preparations; Drug Carriers; HIV Infections; HIV-1; Humans; Lipids; Tenofovir | 2022 |
Tenofovir disoproxil and renal mitochondrial toxicity: more studies in Africans are needed.
Topics: Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Tenofovir | 2022 |
Renal mitochondrial toxicity: effects of thymidine analogues and tenofovir disoproxil fumarate in African people with HIV.
Topics: Anti-HIV Agents; Ghana; HIV Infections; Humans; Mitochondria; Renal Insufficiency; Tenofovir; Thymidine | 2022 |
Weight changes in patients with sustained viral suppression switching tenofovir disoproxil fumarate to tenofovir alafenamide.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Cardiovascular Diseases; Cholesterol; Drug Substitution; Fumarates; HIV Infections; Humans; Retrospective Studies; Sustained Virologic Response; Tenofovir; Weight Gain | 2022 |
Short-term Neuropsychiatric and Body Weight Changes in Patients Switching From EVG/Cobi/FTC/TAF to BIC/FTC/TAF (PreEC/RIS69).
Topics: Anti-HIV Agents; Body Weight; Emtricitabine; Female; HIV Infections; Humans; Male; Tenofovir | 2022 |
Impact of tenofovir on SARS-CoV-2 infection and severe outcomes among people living with HIV: a propensity score-matched study.
Topics: Anti-HIV Agents; COVID-19; COVID-19 Testing; Emtricitabine; HIV Infections; Humans; Lamivudine; Propensity Score; Prospective Studies; SARS-CoV-2; Tenofovir | 2022 |
Sexual behavior and medication adherence in men who have sex with men participating in a pre-exposure prophylaxis study of combinations of Maraviroc, Tenofovir Disoproxil Fumarate and/or Emtricitabine (HPTN 069/ACTG 5305).
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Emtricitabine; Female; HIV Infections; Homosexuality, Male; Humans; Male; Maraviroc; Medication Adherence; Pre-Exposure Prophylaxis; Sexual and Gender Minorities; Sexual Behavior; Tenofovir | 2022 |
Testicular ultrastructure and hormonal changes following administration of tenofovir disoproxil fumarate-loaded silver nanoparticle in type-2 diabetic rats.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; HIV Infections; Humans; Insulin-Like Growth Factor I; Male; Metal Nanoparticles; Rats; Rats, Sprague-Dawley; Silver; Tenofovir; Testis | 2022 |
HIV drug resistance in persons initiating or reinitiating first-line antiretroviral therapy in Paraguay: Results of a National Patient Survey.
Topics: Adolescent; Adult; Anti-HIV Agents; Anti-Retroviral Agents; Cross-Sectional Studies; Drug Resistance, Viral; Emtricitabine; HIV Infections; HIV-1; Humans; Paraguay; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load | 2022 |
Cumulative tenofovir diphosphate exposure in persons with HIV taking single- vs. multiple-tablet regimens.
Topics: Adenine; Anti-HIV Agents; HIV Infections; Humans; Organophosphates; Tablets; Tenofovir | 2022 |
A Layer Plus Approach to Implementation Research and Collaboration for Long-Acting Injectable Preexposure Prophylaxis for HIV Prevention.
Topics: Anti-HIV Agents; Emtricitabine; Female; HIV Infections; Humans; Male; Pre-Exposure Prophylaxis; Tenofovir | 2022 |
Pill related oesophagitis due to tenofovir disproxil fumarate/emtricitabine (Truvada) HIV pre-exposure prophylaxis.
Topics: Emtricitabine; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Esophagitis; Fumarates; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir | 2022 |
Switching from tenofovir alafenamide to tenofovir disoproxil fumarate improves lipid profile and protects from weight gain.
Topics: Alanine; Anti-HIV Agents; Cholesterol, LDL; Drug Substitution; HIV Infections; Humans; Retrospective Studies; Tenofovir; Weight Gain | 2022 |
Dolutegravir in real life: Self-reported mental and physical health outcomes after transitioning from efavirenz- to dolutegravir-based antiretroviral therapy in a prospective cohort study in Lesotho.
Topics: Adult; Anti-HIV Agents; Benzoxazines; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Lesotho; Male; Middle Aged; Outcome Assessment, Health Care; Oxazines; Prospective Studies; Self Report; Tenofovir | 2023 |
HERACLIS-TAF: a multi-centre prospective cohort study on 2-year safety and efficacy of tenofovir alafenamide in patients with chronic hepatitis B with renal and/or bone disorders or risks.
Topics: Adenine; Adult; Alanine; Hepatitis B, Chronic; HIV Infections; Humans; Phosphates; Prospective Studies; Tenofovir | 2022 |
A Rare Case of Didanosine-Induced Mid-Peripheral Chorioretinal Atrophy Identified Incidentally 11 Years after the Drug Cessation.
Topics: Adult; Atrophy; Choroid Diseases; Didanosine; Emtricitabine; Female; HIV Infections; Humans; Hydroxychloroquine; Retinal Degeneration; Tenofovir; Tomography, Optical Coherence | 2022 |
Daily and on-demand HIV pre-exposure prophylaxis with emtricitabine and tenofovir disoproxil (ANRS PREVENIR): a prospective observational cohort study.
Topics: Adolescent; Adult; Anti-HIV Agents; Emtricitabine; Female; HIV Infections; HIV-1; Homosexuality, Male; Humans; Male; Medication Adherence; Pre-Exposure Prophylaxis; Prospective Studies; Sexual and Gender Minorities; Tenofovir | 2022 |
Switching from a Non-Protease inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice.
Topics: Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir | 2022 |
Low-level viraemia and virologic failure among people living with HIV who received maintenance therapy with co-formulated bictegravir, emtricitabine and tenofovir alafenamide versus dolutegravir-based regimens.
Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Oxazines; Piperazines; Pyridones; Retrospective Studies; Tenofovir; Viral Load; Viremia | 2022 |
HBV in pregnancy: time to consider tenofovir alafenamide (TAF).
Topics: Adenine; Alanine; Female; Hepatitis B virus; HIV Infections; Humans; Pregnancy; Tenofovir | 2022 |
Bictegravir/emtricitabine/tenofovir alafenamide ensures high rates of virological suppression maintenance despite previous resistance in PLWH who optimize treatment in clinical practice.
Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Piperazines; Pyridones; Tenofovir | 2022 |
Plasma and breast milk pharmacokinetics of tenofovir alafenamide in mothers with chronic hepatitis B infection.
Topics: Adenine; Alanine; Antiviral Agents; Female; Hepatitis B, Chronic; HIV Infections; Humans; Milk, Human; Mothers; Tenofovir | 2022 |
The Nucleoside/Nucleotide Analogs Tenofovir and Emtricitabine Are Inactive against SARS-CoV-2.
Topics: Anti-HIV Agents; COVID-19 Drug Treatment; Emtricitabine; HIV Infections; HIV-1; Humans; Nucleosides; Nucleotides; Pandemics; RNA-Dependent RNA Polymerase; RNA, Viral; SARS-CoV-2; Tenofovir | 2022 |
A 28-Year-Old Man With Diffuse Bilateral Pulmonary Nodules.
Topics: Adult; Anti-HIV Agents; Child; Cobicistat; Drug Combinations; Emtricitabine; HIV Infections; Humans; Male; Quinolones; Tenofovir | 2022 |
Impact of feminizing hormone therapy on tenofovir and emtricitabine plasma pharmacokinetics: a nested drug-drug interaction study in a cohort of Brazilian transgender women using HIV pre-exposure prophylaxis.
Topics: Anti-HIV Agents; Brazil; Cohort Studies; Drug Interactions; Emtricitabine; Estradiol; Female; HIV Infections; Humans; Pre-Exposure Prophylaxis; Spironolactone; Tenofovir; Transgender Persons | 2022 |
Impact of pre-existent drug resistance on virological efficacy of single-tablet regimens in people living with HIV.
Topics: Anti-HIV Agents; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Tablets; Tenofovir; Viral Load | 2022 |
Impact of preexisting nucleos(t)ide reverse transcriptase inhibitor resistance on the effectiveness of bictegravir/emtricitabine/tenofovir alafenamide in treatment experience patients.
Topics: Adenine; Anti-HIV Agents; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Male; Reverse Transcriptase Inhibitors; RNA; Tenofovir | 2022 |
Tenofovir disoproxil fumarate and coronavirus disease 2019 outcomes in men with HIV.
Topics: Anti-HIV Agents; Cohort Studies; COVID-19; COVID-19 Testing; Emtricitabine; HIV Infections; Humans; Lamivudine; Male; SARS-CoV-2; Tenofovir | 2022 |
Switch back from TAF to TDF or rather switch forward from metabolic toxicities of drugs to metabolic health of people living with HIV.
Topics: Anti-HIV Agents; HIV Infections; Humans; Tenofovir | 2022 |
Minimal Cross-resistance to Tenofovir in Children and Adolescents Failing ART Makes Them Eligible for Tenofovir-Lamivudine-Dolutegravir Treatment.
Topics: Adolescent; Anti-HIV Agents; Child; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Oxazines; Piperazines; Protease Inhibitors; Pyridones; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Zidovudine | 2022 |
Metabolic-Related Outcomes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Adults With Human Immunodeficiency Virus (HIV): A Multicenter Prospective Cohort Study.
Topics: Adenine; Adult; Anti-HIV Agents; Cholesterol; Female; HIV Infections; HIV-1; Humans; Hypertension; Lipids; Male; Obesity; Prospective Studies; Tenofovir; Triglycerides | 2023 |
Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Drug Resistance; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Malawi; Oxazines; Piperazines; Prospective Studies; Pyridones; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load | 2022 |
Safety and efficacy of a biodegradable implant releasing tenofovir alafenamide for vaginal protection in a macaque model.
Topics: Absorbable Implants; Alanine; Animals; Anti-HIV Agents; Emtricitabine; Female; HIV; HIV Infections; Macaca; Necrosis; Simian Immunodeficiency Virus; Tenofovir | 2022 |
Do anti-HIV drugs pose a threat to photosynthetic microorganisms?
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; HIV-1; Humans; Lamivudine; Photosynthesis; Tenofovir; Water | 2022 |
Excessive Weight Gain: Current Antiretroviral Agents in Virologically Suppressed People with HIV.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Cobicistat; Darunavir; Emtricitabine; HIV Infections; HIV-1; Humans; Tenofovir; Weight Gain | 2022 |
Pharmacokinetics of Emtricitabine/Tenofovir Disoproxil Fumarate Among Transgender Adolescents and Young Adults Without HIV Receiving Gender Affirming Hormones.
Topics: Adolescent; Anti-HIV Agents; Emtricitabine; Female; HIV Infections; Hormones; Humans; Leukocytes, Mononuclear; Male; Pre-Exposure Prophylaxis; Prospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Transgender Persons; Young Adult | 2022 |
Concentrations of Efavirenz, Tenofovir, and Emtricitabine in Obesity: A Cross-Sectional Study.
Topics: Adenine; Alkynes; Anti-Retroviral Agents; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Emtricitabine; HIV Infections; Humans; Obesity, Abdominal; Tenofovir | 2022 |
Effects of the androgen receptor inhibitor enzalutamide on the pharmacokinetics of dolutegravir and tenofovir: a case report.
Topics: Androgen Receptor Antagonists; Benzamides; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Male; Middle Aged; Nitriles; Oxazines; Phenylthiohydantoin; Piperazines; Prostatic Neoplasms; Pyridones; Receptors, Androgen; Tenofovir | 2022 |
Brief Report: Virologic Impact of the Dolutegravir Transition: Prospective Results From the Multinational African Cohort Study.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Cohort Studies; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Oxazines; Prospective Studies; Pyridones; Tenofovir; Uganda; Viral Load | 2022 |
The renal-bone axis in older people living with HIV on stable antiretroviral therapy: A sub-analysis of the GS-US-104-0423 study.
Topics: Adult; Aged; Anti-HIV Agents; Anti-Retroviral Agents; Biomarkers; Bone Density; Cross-Sectional Studies; Female; HIV Infections; Humans; Kidney; Male; Middle Aged; Tenofovir | 2022 |
Effect of alcohol exposure on the efficacy and safety of tenofovir alafenamide fumarate, a major medicine against human immunodeficiency virus.
Topics: Adenine; Alanine; Alcohol Drinking; Anti-HIV Agents; Carboxylic Ester Hydrolases; Chromatography, Liquid; Ethanol; Fumarates; HIV; HIV Infections; Humans; Lipids; Organophosphates; Tandem Mass Spectrometry; Tenofovir | 2022 |
Low prevalence of hepatitis B virus infection in HIV-uninfected pregnant women in Cape Town, South Africa: implications for oral pre-exposure prophylaxis roll out.
Topics: Adult; Cohort Studies; Cross-Sectional Studies; Emtricitabine; Female; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; HIV Infections; Humans; Infant; Pre-Exposure Prophylaxis; Pregnancy; Pregnant Women; Prevalence; South Africa; Tenofovir | 2022 |
Serum Interleukin-6 and Weight Loss in Antiretroviral-naïve and Antiretroviral-treated Patients with HIV/AIDS: Relationships and Predictors.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Case-Control Studies; Emtricitabine; HIV Infections; Humans; Interleukin-6; Lamivudine; Middle Aged; Nevirapine; Tenofovir; Weight Loss; Zidovudine | 2022 |
Higher Risk of Dyslipidemia With Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide than Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate Among Antiretroviral-Naive People Living With HIV in China.
Topics: Adenine; Alanine; Alkynes; Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; Cholesterol, LDL; Cobicistat; Cyclopropanes; Emtricitabine; HIV Infections; HIV-1; Humans; Hypercholesterolemia; Hypertriglyceridemia; Lamivudine; Lipoproteins, HDL; Quinolones; Retrospective Studies; Tenofovir | 2022 |
Performance of Creatinine- and Cystatin C-Based Equations for Glomerular Filtration Rate Estimation in HIV-1-Infected Individuals Receiving Dolutegravir + Tenofovir Disoproxil Fumarate + Lamivudine as Initial Antiretroviral Therapy: A Retrospective Observ
Topics: Adult; Creatinine; Cystatin C; Female; Glomerular Filtration Rate; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Male; Oxazines; Piperazines; Pyridones; Renal Insufficiency, Chronic; Retrospective Studies; Tenofovir | 2022 |
PrEP Use and Adherence among Transgender Persons in Chicago, IL (SHIPP Study, 2014-2018, USA).
Topics: Anti-HIV Agents; Chicago; Female; HIV Infections; Homosexuality, Male; Humans; Male; Medication Adherence; Pre-Exposure Prophylaxis; Tenofovir; Transgender Persons; United States | 2023 |
Continued attendance in a PrEP program despite low adherence and non-protective drug levels among adolescent girls and young women in Kenya: Results from a prospective cohort study.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Child; Contraceptive Agents; Diphosphates; Emtricitabine; Female; HIV Infections; Humans; Infant; Kenya; Male; Medication Adherence; Organophosphates; Pre-Exposure Prophylaxis; Prospective Studies; Tenofovir; Young Adult | 2022 |
A post-mortem analysis of tenofovir, lamivudine, efavirenz and fluconazole penetration in female genital tissues.
Topics: Anti-HIV Agents; Autopsy; Benzoxazines; Chromatography, Liquid; Female; Fluconazole; Genitalia, Female; HIV Infections; Humans; Lamivudine; Tandem Mass Spectrometry; Tenofovir | 2022 |
Use and safety of appearance and performance enhancing supplements in gay, bisexual, and other men who have sex with men receiving daily tenofovir disoproxil fumarate/emtricitabine as HIV pre-exposure prophylaxis.
Topics: Anti-HIV Agents; Cross-Sectional Studies; Emtricitabine; Female; HIV Infections; Homosexuality, Male; Humans; Male; Pre-Exposure Prophylaxis; Sexual and Gender Minorities; Tenofovir | 2023 |
Proximal tubular renal dysfunction among HIV infected patients on Tenofovir versus Tenofovir sparing regimen in western Kenya.
Topics: Adult; Anti-HIV Agents; Cross-Sectional Studies; Fanconi Syndrome; Female; HIV Infections; Humans; Kenya; Male; Phosphates; Tenofovir | 2022 |
A mAb for the detection of the antiretroviral drug emtricitabine.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Emtricitabine; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir | 2022 |
Inflammation and intracellular exposure of dolutegravir, darunavir, tenofovir and emtricitabine in people living with HIV.
Topics: Anti-HIV Agents; Darunavir; Emtricitabine; HIV Infections; Humans; Inflammation; Interleukin-6; Lipopolysaccharide Receptors; Lipopolysaccharides; Tenofovir | 2023 |
The Elegance of the Acyclic Nucleoside Phosphonates (ANPs), Honorary Tribute to Antonín Holý, Who Passed Away on 16 July 2012, at the 10th Anniversary of His Death.
Topics: Anniversaries and Special Events; Anti-HIV Agents; Antiviral Agents; Cidofovir; Emtricitabine; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Nucleosides; Organophosphonates; Prodrugs; Tenofovir | 2022 |
Tenofovir-induced distal renal tubular acidosis: A rare cause of recurrent hypokalaemic paralysis.
Topics: Acidosis, Renal Tubular; Adult; HIV Infections; Humans; Hypokalemia; Male; Nucleotides; Paralysis; Potassium; Reverse Transcriptase Inhibitors; Tenofovir | 2022 |
Safety and efficacy of pharmacotherapy containing INSTIs and chemotherapy drugs in people living with HIV and concomitant colorectal cancer.
Topics: Amides; Anti-HIV Agents; Colorectal Neoplasms; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Integrase Inhibitors; Lamivudine; Piperazines; Pyridones; Raltegravir Potassium; Tenofovir | 2022 |
Economic evaluation of doravirine/tenofovir disoproxil fumarate/lamivudine for HIV-1-infected adults in Russia: a cost-minimization and budget impact analysis.
Topics: Adult; Anti-HIV Agents; Cost-Benefit Analysis; Drug Combinations; Drugs, Essential; Emtricitabine; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; RNA, Viral; Tenofovir; Viral Load | 2022 |
Estimating the budget impact of adopting tenofovir/emtricitabine for pre-exposure prophylaxis of HIV in the public health sector in Namibia (2021 - 2023).
Topics: Anti-HIV Agents; Cost-Benefit Analysis; Emtricitabine; HIV; HIV Infections; Homosexuality, Male; Humans; Male; Namibia; Pre-Exposure Prophylaxis; Public Health; Public Sector; Tenofovir | 2022 |
Vaginal microbial shifts are unaffected by oral pre-exposure prophylaxis in South African women.
Topics: Anti-Bacterial Agents; Cross-Sectional Studies; Emtricitabine; Female; HIV Infections; Humans; Pre-Exposure Prophylaxis; South Africa; Tenofovir; Vagina; Vaginosis, Bacterial | 2022 |
Estimated changes in price discounts for tenofovir-inclusive HIV treatments following introduction of tenofovir alafenamide.
Topics: Anti-HIV Agents; Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Emtricitabine, Rilpivirine, Tenofovir Drug Combination; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; Humans; Tenofovir | 2022 |
The Relationship Between HIV Pre-exposure Prophylaxis Stigma and Treatment Adherence Among Current HIV Pre-exposure Prophylaxis Users in the Southeastern U.S.
Topics: Anti-HIV Agents; HIV Infections; Humans; Male; Medication Adherence; Pre-Exposure Prophylaxis; Tenofovir | 2023 |
Pharmacokinetics, Tolerability, and Safety of Doravirine and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination Tablets in Adolescents Living With HIV: Week 24 Results From IMPAACT 2014.
Topics: Adolescent; Adult; Anti-HIV Agents; Anti-Retroviral Agents; Child; Emtricitabine; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Pyridones; RNA, Viral; Tablets; Tenofovir | 2023 |
Challenges with PrEP Uptake and Adherence Among Gay, Bisexual, and Other Men Who Have Sex with Men in Kisumu, Kenya.
Topics: Anti-HIV Agents; HIV Infections; Homosexuality, Male; Humans; Kenya; Male; Medication Adherence; Pre-Exposure Prophylaxis; Sexual and Gender Minorities; Tenofovir | 2023 |
Impact of Tenofovir Disoproxil Fumarate Use During Pregnancy on Maternal Bone Mineral Density.
Topics: Anti-HIV Agents; Bone Density; Female; HIV Infections; Humans; Pregnancy; Tenofovir; Viral Load | 2022 |
A retrospective analysis of bone loss in tenofovir-emtricitabine therapy for HIV PrEP.
Topics: Anti-HIV Agents; Bone Diseases, Metabolic; Emtricitabine; HIV Infections; Humans; Osteoporosis; Retrospective Studies; Tenofovir | 2022 |
Understanding the Actual Use of Anti-HIV Drugs in Japan from 2016 to 2019: Demonstrating Epidemiological Relevance of NDB Open Data Japan for Understanding Japanese Medical Care.
Topics: Anti-HIV Agents; Fumarates; HIV Infections; Humans; Integrases; Japan; Tablets; Tenofovir | 2022 |
Biocompatible drug delivery systems able to co-deliver antifungal and antiviral agents.
Topics: Aldehydes; Antifungal Agents; Antiviral Agents; Biocompatible Materials; Chitosan; Drug Delivery Systems; Drug Liberation; HIV Infections; Humans; Hydrogels; Imines; Tenofovir | 2022 |
Hepatitis B Virus (HBV) Replication During Tenofovir Therapy Is Frequent in Human Immunodeficiency Virus/HBV Coinfection.
Topics: Cohort Studies; Coinfection; DNA, Viral; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Tenofovir; Viral Load | 2023 |
Urine Tenofovir Levels Strongly Correlate With Virologic Suppression in Patients With Human Immunodeficiency Virus on Tenofovir Alafenamide-Based Antiretroviral Therapy.
Topics: Adenine; Alanine; Anti-HIV Agents; HIV Infections; HIV-1; Humans; Tenofovir | 2023 |
Proximal tubular dysfunction related to tenofovir in people living with HIV/AIDS: a pharmacogenetic study.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Case-Control Studies; Female; HIV Infections; Humans; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Pharmacogenomic Testing; Phosphorus; Tenofovir | 2022 |
Real-world efficacy and safety of dolutegravir plus lamivudine versus tenofovir plus lamivudine and efavirenz in ART-naïve HIV-1-infected adults.
Topics: Adult; Anti-HIV Agents; Benzoxazines; Creatinine; Dideoxynucleosides; HIV Infections; HIV-1; Humans; Lamivudine; Prospective Studies; Pyridones; RNA; Tenofovir; Triglycerides | 2022 |
[The analysis of the availability of fixed-dose combinations in antiretroviral therapy for HIV infection in the Russian Federation].
Topics: Adenine; Anti-HIV Agents; Drug Combinations; Drugs, Essential; Emtricitabine; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Rilpivirine; Tenofovir | 2021 |
Brief Report: Effect of Antiretroviral Switch From Tenofovir Disoproxil fumarate to Tenofovir Alafenamide on Alanine Aminotransferase, Lipid Profiles, and Renal Function in HIV/HBV-Coinfected Individuals in a Nationwide Canadian Study.
Topics: Adenine; Alanine; Alanine Transaminase; Anti-Retroviral Agents; Canada; Cholesterol; Coinfection; Hepatitis B virus; HIV Infections; Humans; Kidney; Lipids; Lipoproteins, HDL; Lipoproteins, LDL; Retrospective Studies; Tenofovir; Triglycerides | 2022 |
Urine tenofovir-monitoring predicts HIV viremia in patients treated with high genetic-barrier regimens.
Topics: Anti-HIV Agents; Cross-Sectional Studies; HIV Infections; Humans; Protease Inhibitors; Ritonavir; Tenofovir; Viral Load; Viremia | 2022 |
Interaction of Depot Medroxyprogesterone Acetate and Tenofovir Disoproxil Fumarate/Emtricitabine on Peripheral Blood Mononuclear Cells and Cervical Tissue Susceptibility to HIV Infection and Pharmacokinetics.
Topics: Emtricitabine; Female; HIV Infections; Humans; Leukocytes, Mononuclear; Medroxyprogesterone Acetate; Tenofovir | 2023 |
Pharmacokinetics and efficacy of topical inserts containing tenofovir alafenamide fumarate and elvitegravir administered rectally in macaques.
Topics: Alanine; Animals; Anti-HIV Agents; Female; Fumarates; HIV Infections; Leukocytes, Mononuclear; Macaca; Tenofovir; Tissue Distribution | 2022 |
Self-reported and pill count measures of adherence to oral HIV PrEP among female sex workers living in South-Western Uganda.
Topics: Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Medication Adherence; Pre-Exposure Prophylaxis; Self Report; Sex Workers; Tenofovir; Uganda; Young Adult | 2022 |
Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and threshold analysis.
Topics: Adenine; Adolescent; Anti-HIV Agents; Cost-Benefit Analysis; Emtricitabine; Female; HIV Infections; Homosexuality, Male; Humans; Male; Pre-Exposure Prophylaxis; Sex Workers; Sexual and Gender Minorities; South Africa; Tenofovir | 2022 |
Persistently elevated alkaline phosphatase could be related to Paget's disease of bone in a patient receiving tenofovir disoproxil fumarate.
Topics: Adenine; Adult; Alkaline Phosphatase; Anti-HIV Agents; HIV Infections; HIV Seropositivity; Humans; Middle Aged; Osteitis Deformans; Tenofovir | 2023 |
Crushed vs dissolved bictegravir/emtricitabine/tenofovir alafenamide.
Topics: Amides; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Pyridones; Tenofovir | 2023 |
Tenofovir disoproxil fumarate/emtricitabine and severity of coronavirus disease 2019 in people with HIV infection.
Topics: Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; COVID-19; Drug Combinations; Emtricitabine; HIV Infections; Humans; Lamivudine; Middle Aged; SARS-CoV-2; Tenofovir | 2022 |
Doravirine/lamivudine/tenofovir disoproxil fumarate-induced hypertriglyceridemia in a newly diagnosed AIDS patient.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Emtricitabine; Fumarates; HIV Infections; Humans; Hypertriglyceridemia; Lamivudine; Tenofovir | 2022 |
Switching to coformulated bictegravir, emtricitabine, and tenofovir alafenamide maintained viral suppression in adults with historical virological failures and K65N/R mutation.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Mutation; Retrospective Studies; Tenofovir; Viral Load | 2023 |
Nucleoside Triphosphate Diphosphohydrolase 1 Exhibits Enzymatic Activity toward Tenofovir Diphosphate.
Topics: Adenosine Triphosphate; Adult; Anti-HIV Agents; Colorectal Neoplasms; Diphosphates; HIV Infections; Humans; Kinetics; Nucleosides; Nucleotides; Tenofovir | 2023 |
Serial changes in renal indices in chronic HCV patients with and without HIV co-infection receiving sofosbuvir and tenofovir-based therapies.
Topics: Antiviral Agents; Coinfection; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Prospective Studies; Sofosbuvir; Tenofovir | 2023 |
Preclinical Considerations for Long-acting Delivery of Tenofovir Alafenamide from Subdermal Implants for HIV Pre-exposure Prophylaxis.
Topics: Adenine; Alanine; Animals; Anti-HIV Agents; Dogs; HIV Infections; Mice; Mice, Inbred C57BL; Pre-Exposure Prophylaxis; Sheep; Tenofovir | 2023 |
Case of organising pneumonia in HIV infection.
Topics: Cryptogenic Organizing Pneumonia; Emtricitabine; HIV Infections; Humans; Male; Pneumonia; Tenofovir | 2022 |
Hypo-osmolar rectal douche tenofovir formulation prevents simian/human immunodeficiency virus acquisition in macaques.
Topics: Animals; HIV; HIV Infections; Homosexuality, Male; Humans; Macaca; Male; Sexual and Gender Minorities; Tenofovir | 2022 |
Adipocyte differentiation of 3T3-L1 cells under tenofovir alafenamide, tenofovir disoproxil fumarate, and integrase strand transfer inhibitors selective challenge: an in-vitro model.
Topics: 3T3-L1 Cells; Adenine; Adipocytes; Animals; Anti-HIV Agents; Cell Differentiation; HIV Infections; Humans; Integrases; Mice; Raltegravir Potassium; Tenofovir | 2023 |
Model-informed intermittent tenofovir disoproxil fumarate and emtricitabine dosing for HIV pre-exposure prophylaxis in subjects with renal impairment: a case report.
Topics: Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Pre-Exposure Prophylaxis; Renal Insufficiency; Tenofovir | 2023 |
Tenofovir disoproxil fumarate withdrawal and cardiovascular risk - Authors' reply.
Topics: Anti-HIV Agents; Cardiovascular Diseases; HIV Infections; Humans; Risk Factors; Tenofovir | 2023 |
Tenofovir disoproxil fumarate withdrawal and cardiovascular risk.
Topics: Anti-HIV Agents; Cardiovascular Diseases; Heart Disease Risk Factors; HIV Infections; Humans; Risk Factors; Tenofovir | 2023 |
[Research advances in HIV pre-exposure prophylaxis drug].
Topics: Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir; United States | 2022 |
Advantages of switching to elvitegravir/cobicistat/emtricitabine/tenofovir therapy in virologically-suppressed people living with human immunodeficiency virus/acquired immune deficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Cobicistat; Drug Combinations; Emtricitabine; HIV; HIV Infections; Humans; Tenofovir | 2022 |
Effect of tenofovir containing ART on renal function in patients with moderate/severe reduced creatinine clearance at baseline: A retrospective study at two referral hospitals in Namibia.
Topics: Anti-HIV Agents; Creatinine; HIV Infections; Humans; Kidney; Male; Namibia; Renal Insufficiency; Retrospective Studies; Tenofovir | 2023 |
Safety and efficacy of switching to elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate in treatment-experienced people with HIV: a multicenter cohort study.
Topics: Adult; Anti-HIV Agents; Cobicistat; Cohort Studies; Emtricitabine; Female; HIV Infections; Humans; Integrase Inhibitors; Male; RNA; Tenofovir | 2023 |
A Novel Algorithm to Improve PrEP Adherence Monitoring Using Dried Blood Spots.
Topics: Anti-HIV Agents; HIV Infections; Humans; Male; Medication Adherence; Tenofovir | 2023 |
Tenofovir Alafenamide for Multiple Drug-Resistant Chronic Hepatitis B: A 3-Year Clinical Trial.
Topics: Adenine; Antiviral Agents; Hepatitis B, Chronic; HIV Infections; Humans; Tenofovir; Treatment Outcome | 2023 |
Updating the Adherence-Response for Oral Emtricitabine/Tenofovir Disoproxil Fumarate for Human Immunodeficiency Virus Pre-Exposure Prophylaxis Among Cisgender Women.
Topics: Anti-HIV Agents; Emtricitabine; Female; HIV; HIV Infections; Humans; Male; Medication Adherence; Pre-Exposure Prophylaxis; Reverse Transcriptase Inhibitors; Tenofovir | 2023 |
Tenofovir-tethered gold nanoparticles as a novel multifunctional long-acting anti-HIV therapy to overcome deficient drug delivery-: an in vivo proof of concept.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Gold; HIV Infections; Humans; Metal Nanoparticles; Peptide Hydrolases; Tenofovir; Tissue Distribution | 2023 |
Dolutegravir-Based Regimen Ensures High Virological Success despite Prior Exposure to Efavirenz-Based First-LINE ART in Cameroon: An Evidence of a Successful Transition Model.
Topics: Adult; Anti-HIV Agents; Benzoxazines; Cameroon; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Tenofovir; Viral Load | 2022 |
Striking differences in weight gain after cART initiation depending on early or advanced presentation: results from the ANRS CO4 FHDH cohort.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; HIV Infections; Humans; Obesity; Tenofovir; Weight Gain | 2023 |
External validation of the PAGE-B score for HCC risk prediction in people living with HIV/HBV coinfection.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Coinfection; Hepatitis B virus; HIV Infections; Humans; Liver Neoplasms; Tenofovir | 2023 |
Recycling Tenofovir in Second-line Antiretroviral Treatment With Dolutegravir: Outcomes and Viral Load Trajectories to 72 weeks.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Lamivudine; Prospective Studies; Pyridones; Tenofovir; Viral Load; Viremia | 2023 |
Preliminary Evaluation of Stability Data for Dolutegravir-Containing Triple Active Formulations Intended for PEPFAR. Degradation of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide as the Limiting Factor.
Topics: Adenine; Alanine; Anti-HIV Agents; HIV Infections; Humans; Hygroscopic Agents; Tablets; Tenofovir | 2023 |
Milk Calcium and Phosphorus in Ugandan Women with HIV on Tenofovir-Based Antiretroviral Therapy.
Topics: Breast Feeding; Calcium; Female; HIV Infections; Humans; Infant; Lactation; Milk, Human; Minerals; Phosphorus; Pregnancy; Tenofovir; Uganda | 2023 |
Tenofovir Plasma Trough Concentrations in People Living with HIV Treated with Tenofovir Disoproxyl Fumarate: Antiretroviral Class or Individual Drug Effect?
Topics: Anti-HIV Agents; Anti-Retroviral Agents; HIV Infections; Humans; Tenofovir | 2023 |
Epidemiology of Tuberculosis Among People Living With HIV in the African Cohort Study From 2013 to 2021.
Topics: CD4 Lymphocyte Count; Cohort Studies; HIV Infections; Humans; Incidence; Lamivudine; Risk Factors; Tenofovir; Thinness; Tuberculosis | 2023 |
Impact of the Early COVID-19 Pandemic on the Number of HIV Preexposure Prophylaxis Uses and the Proportion of Preexposure Prophylaxis Users Receiving Sexually Transmitted Infection Testing Services.
Topics: COVID-19; Emtricitabine; Gonorrhea; HIV Infections; Homosexuality, Male; Humans; Male; Pandemics; Pre-Exposure Prophylaxis; Retrospective Studies; Sexually Transmitted Diseases; Tenofovir | 2023 |
Tenofovir-induced osteoporosis fracture in a patient using PrEP: A pitfall for the oncologist.
Topics: Anti-HIV Agents; HIV Infections; Humans; Oncologists; Osteoporosis; Tenofovir | 2023 |
Perspectives of people living with HIV and health workers about a point-of-care adherence assay: a qualitative study on acceptability.
Topics: Anti-Retroviral Agents; HIV Infections; Humans; Medication Adherence; Point-of-Care Systems; Qualitative Research; South Africa; Tenofovir | 2023 |
Weight Change Following Switch to Dolutegravir for HIV Treatment in Rural Kenya During Country Roll-Out.
Topics: Adult; Anti-HIV Agents; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Kenya; Male; Oxazines; Prospective Studies; Pyridones; Retrospective Studies; Tenofovir; Weight Gain | 2023 |
Immune response to ART initiation in advanced HIV infection.
Topics: Adult; Anti-HIV Agents; Darunavir; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Immunity; Tenofovir | 2023 |
High PrEP uptake and objective longitudinal adherence among HIV-exposed women with personal or partner plans for pregnancy in rural Uganda: A cohort study.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Female; HIV Infections; Humans; Longitudinal Studies; Medication Adherence; Pre-Exposure Prophylaxis; Pregnancy; Pregnancy Outcome; Tenofovir; Uganda | 2023 |
Patient-reported outcomes among virally suppressed people living with HIV after switching to Co-formulated bictegravir, emtricitabine and tenofovir alafenamide.
Topics: Adenine; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Patient Reported Outcome Measures; Quality of Life; Tenofovir; Treatment Outcome | 2023 |
Incidence and risk factors of hypertriglyceridemia in males with human immunodeficiency virus who are treated with combination antiretroviral therapy: a retrospective cohort study.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; HIV Infections; HIV-1; Humans; Hypertriglyceridemia; Incidence; Lamivudine; Male; Retrospective Studies; Risk Factors; Tenofovir; Triglycerides | 2023 |
Renal impairment associated with tenofovir disoproxil fumarate for antiretroviral therapy and HIV pre-exposure prophylaxis: An observational cohort study.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Cohort Studies; Emtricitabine; HIV Infections; Humans; Pre-Exposure Prophylaxis; Renal Insufficiency; Tenofovir | 2023 |
Resistant mutations within the hepatitis B virus reverse transcriptase sequence in treatment failure patients with chronic HBV infection in Vietnam.
Topics: Antiviral Agents; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Mutation; RNA-Directed DNA Polymerase; Telbivudine; Tenofovir; Treatment Failure; Vietnam | 2023 |
Question of Whether Tenofovir Disoproxil Fumarate/Emtricitabine Provides Protection Against Clinical Severity of Coronavirus Disease 2019.
Topics: Anti-HIV Agents; COVID-19; Emtricitabine; HIV; HIV Infections; Humans; Tenofovir; United States | 2023 |
Human Immunodeficiency Virus Status, Tenofovir Exposure, and the Risk of Poor Coronavirus Disease 19 Outcomes: Real-World Analysis From 6 United States Cohorts Before Vaccine Rollout.
Topics: COVID-19; COVID-19 Vaccines; HIV; HIV Infections; Humans; Tenofovir; United States | 2023 |
Tenofovir Concentration Is Not Enough in Intraocular Tissues of Patients With HIV infection.
Topics: Anti-HIV Agents; HIV Infections; Humans; Retrospective Studies; Tandem Mass Spectrometry; Tenofovir; Vitrectomy; Vitreous Body | 2023 |
Point-of-care urine tenofovir testing to predict HIV drug resistance among individuals with virologic failure.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; HIV Infections; HIV-1; Humans; Point-of-Care Systems; Retrospective Studies; Tenofovir | 2023 |
Correlates of self-reported and biomarker based adherence to daily oral HIV pre-exposure prophylaxis among a cohort of predominantly men who have sex with men in Nigeria.
Topics: Adult; Anti-HIV Agents; Biomarkers; Female; HIV Infections; Homosexuality, Male; Humans; Male; Medication Adherence; Nigeria; Pre-Exposure Prophylaxis; Prospective Studies; Self Report; Sexual and Gender Minorities; Tenofovir; Young Adult | 2023 |
Acute antagonism in three-drug combinations for vaginal HIV prevention in humanized mice.
Topics: Animals; Anti-HIV Agents; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Male; Mice; Tenofovir | 2023 |
Weight gain in HIV-infected patients.
Topics: Adenine; Anti-HIV Agents; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Male; Pyridones; Tenofovir; Weight Gain | 2023 |
Viral hepatitis in persons living with HIV in the post-COVID era.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Coinfection; COVID-19; Drug Users; Hepatitis A; Hepatitis B; Hepatitis B, Chronic; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Homosexuality, Male; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Sexual and Gender Minorities; Substance Abuse, Intravenous; Tenofovir | 2023 |
Effect of tenofovir-based HIV pre-exposure prophylaxis against HBV infection in men who have sex with men.
Topics: Anti-HIV Agents; Hepatitis B Surface Antigens; Hepatitis B virus; HIV Infections; Homosexuality, Male; Humans; Male; Pre-Exposure Prophylaxis; Sexual and Gender Minorities; Sexually Transmitted Diseases; Tenofovir | 2023 |
Understanding Retention in the HIV Pre-Exposure Prophylaxis Cascade Among Cisgender Women.
Topics: Anti-HIV Agents; Emtricitabine; Female; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir; United States | 2023 |
Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083.
Topics: Anti-HIV Agents; Emtricitabine; Female; HIV Infections; Humans; Male; Pre-Exposure Prophylaxis; Retrospective Studies; Tenofovir; Transgender Persons | 2023 |
Weight gain following the single substitution of tenofovir disoproxil fumarate by tenofovir alafenamide in HIV-infected people from the French Dat'AIDS cohort: A propensity score-matched analysis.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Propensity Score; Retrospective Studies; Tenofovir; Weight Gain | 2023 |
Real world use of dolutegravir two drug regimens: Erratum.
Topics: Anti-HIV Agents; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Oxazines; Pyridones; Tenofovir | 2023 |
Effect of different antiretroviral therapy on muscle mass, bone mineral density, and trabecular bone score in Chinese HIV-infected males.
Topics: Adult; Anti-HIV Agents; Bone Density; Cancellous Bone; East Asian People; HIV Infections; Humans; Lamivudine; Male; Muscles; Osteoporosis; Retrospective Studies; Sarcopenia; Stavudine; Tenofovir; Young Adult | 2023 |
Population pharmacokinetic modelling to characterize the effect of chronic kidney disease on tenofovir exposure after tenofovir alafenamide administration.
Topics: Adenine; Alanine; Anti-HIV Agents; HIV Infections; Humans; Renal Insufficiency, Chronic; Tenofovir | 2023 |
Tenofovir alafenamide and weight: What do we still need to know to inform clinical decisions?
Topics: Adenine; Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Tenofovir | 2023 |
Changes in local tissue microenvironment in response to subcutaneous long-acting delivery of tenofovir alafenamide in rats and non-human primates.
Topics: Adenine; Alanine; Animals; Anti-HIV Agents; HIV Infections; Macaca mulatta; Rats; Rats, Sprague-Dawley; Tenofovir | 2023 |
Federal Funding For Discovery And Development Of Costly HIV Drugs Was Far More Than Previously Estimated.
Topics: Anti-HIV Agents; Emtricitabine; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; Humans; Pharmaceutical Preparations; Tenofovir | 2023 |
Point-of-care urine tenofovir testing: making a good thing better.
Topics: Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Point-of-Care Systems; Point-of-Care Testing; Tenofovir | 2023 |
Development and Preliminary Validation of the PrEP Empowerment Scale.
Topics: Anti-HIV Agents; HIV Infections; Humans; Medication Adherence; Pre-Exposure Prophylaxis; Reproducibility of Results; Tenofovir | 2023 |
Antiviral activity of tenofovir alafenamide (TAF) against HIV-1 clinical isolates harboring K65R.
Topics: Alanine; Anti-HIV Agents; HIV Infections; HIV Seropositivity; HIV-1; Humans; Prodrugs; Reverse Transcriptase Inhibitors; Tenofovir | 2023 |
Understanding the Uptake and Outcomes of Non-occupational Postexposure Prophylaxis Use Through an Online Medical Platform in China: Web-Based Cross-sectional Study.
Topics: Adult; Anti-HIV Agents; Cross-Sectional Studies; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Male; Pre-Exposure Prophylaxis; Retrospective Studies; Sexual and Gender Minorities; Surveys and Questionnaires; Tenofovir | 2023 |
Association of a Polygenic Risk Score With Osteoporosis in People Living With HIV: The Swiss HIV Cohort Study.
Topics: Bone Density; Bone Diseases, Metabolic; Cohort Studies; Female; HIV; HIV Infections; Humans; Male; Middle Aged; Osteoporosis; Risk Factors; Switzerland; Tenofovir | 2023 |
Dolutegravir-associated resistance mutations after first-line treatment failure in Brazil.
Topics: Anti-Retroviral Agents; Brazil; HIV Infections; Humans; Lamivudine; Mutation; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure | 2023 |
Tenofovir-Containing Antiretroviral Therapy and Clinical Outcomes of SARS-CoV-2 Infection in People Living with HIV.
Topics: Anti-HIV Agents; COVID-19; HIV Infections; HIV-1; Humans; SARS-CoV-2; Tenofovir | 2023 |
Toxicological evaluation of antiretroviral Tenofovir Disoproxil Fumarate on the mollusk Biomphalaria glabrata and its hemocytes.
Topics: Animals; Biomphalaria; Ecosystem; Hemocytes; HIV Infections; Tenofovir | 2023 |
Determinants of Preexposure Prophylaxis Cascade Among Sexual and Gender Minorities in Nigeria.
Topics: Anti-HIV Agents; HIV Infections; Homosexuality, Male; Humans; Male; Medication Adherence; Nigeria; Pre-Exposure Prophylaxis; Sexual and Gender Minorities; Tenofovir | 2023 |
Utilization of Chemometric-Aided UV Spectrophotometric Methods for Concurrent Assessment of Emtricitabine, Tenofovir Disoproxil Fumarate, Elvitegravir, and Cobicistat in Tablet Formulation.
Topics: Adenine; Anti-HIV Agents; Chemometrics; Cobicistat; Drug Combinations; Emtricitabine; HIV Infections; Humans; Tablets; Tenofovir | 2023 |
Treatment persistence of bictegravir/emtricitabine/tenofovir alafenamide and efavirenz + lamivudine + tenofovir disoproxil among HIV-1 patients newly starting treatment in Hunan Province in China.
Topics: China; Drug Combinations; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Lamivudine; Retrospective Studies; Tenofovir | 2023 |
Three-year outcomes for women newly initiated on lifelong antiretroviral therapy during pregnancy - Malawi option B.
Topics: Female; HIV Infections; Humans; Infant; Infant, Newborn; Malawi; Male; Pregnancy; Premature Birth; Prospective Studies; Tenofovir | 2023 |
Weight gain in Namibians with HIV switching from efavirenz to dolutegravir.
Topics: Anti-HIV Agents; Benzoxazines; Emtricitabine; Female; HIV Infections; HIV Integrase Inhibitors; Humans; Lamivudine; Male; Retrospective Studies; Tenofovir; Weight Gain | 2023 |
Treatment-emergent reverse transcriptase resistance during antiretroviral therapy with bictegravir, tenofovir alafenamide, and emtricitabine: A case series.
Topics: Adenine; Anti-HIV Agents; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Tenofovir | 2023 |
Feasibility and acceptability of peer-delivered HIV self-testing and PrEP for young women in Kampala, Uganda.
Topics: Adolescent; Adult; Anti-HIV Agents; Feasibility Studies; Female; HIV Infections; Humans; Pilot Projects; Pre-Exposure Prophylaxis; Self-Testing; Tenofovir; Uganda; Young Adult | 2023 |
Changes in health and sleep quality after anti-retroviral treatment modification in Japanese people living with HIV.
Topics: Anti-Retroviral Agents; Drug Combinations; East Asian People; HIV; HIV Infections; Humans; Male; Quality of Life; Sleep Quality; Tenofovir | 2023 |
[Sleep disorders related to HIV treatment.]
Topics: Adenine; Cross-Sectional Studies; Emtricitabine; HIV Infections; Humans; Pyridones; Sleep Wake Disorders; Spain; Tenofovir | 2023 |
Viral suppression in the era of transition to dolutegravir-based therapy in Cameroon: Children at high risk of virological failure due to the lowly transition in pediatrics.
Topics: Adolescent; Adult; Anti-HIV Agents; Cameroon; Child; Cross-Sectional Studies; Female; HIV Infections; Humans; Lamivudine; Male; Pediatrics; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Viral Load | 2023 |
High rates of kidney impairment among older people (≥ 60 years) living with HIV on first-line antiretroviral therapy at screening for a clinical trial in Kenya.
Topics: Adenine; Aged; Aged, 80 and over; Alanine; Anti-HIV Agents; Anti-Retroviral Agents; Emtricitabine; Female; HIV Infections; Humans; Kenya; Kidney; Male; Middle Aged; Tenofovir | 2023 |
Development and In-House Validation of an Enzyme-Linked Immunosorbent Assay and a Lateral Flow Immunoassay for the Dosage of Tenofovir in Human Saliva.
Topics: Anti-HIV Agents; Enzyme-Linked Immunosorbent Assay; HIV Infections; Humans; Immunoassay; Saliva; Tenofovir | 2023 |
Fanconi syndrome, diabetes insipidus, and acute kidney injury due to tenofovir disoproxil fumarate: A case report.
Topics: Acute Kidney Injury; Adenine; Anti-HIV Agents; Diabetes Insipidus; Diabetes Mellitus; Fanconi Syndrome; Female; HIV Infections; Humans; Middle Aged; Protease Inhibitors; Tenofovir | 2023 |
Identification of integrase inhibitor-related drug resistance mutations in newly diagnosed ART-naïve HIV patients.
Topics: Drug Resistance, Viral; HIV Infections; Humans; Integrase Inhibitors; Mutation; Protease Inhibitors; Tenofovir | 2023 |
No association between use of tenofovir disoproxil fumarate, etravirine, or integrase-strand transfer inhibitors and acquisition or severe outcomes of SARS-CoV-2 infection in people with HIV in the Netherlands.
Topics: Anti-HIV Agents; COVID-19; HIV Infections; Humans; Integrases; Molecular Docking Simulation; Netherlands; SARS-CoV-2; Tenofovir | 2023 |
Blood pressure changes during tenofovir-based antiretroviral therapy among people living with HIV in Lilongwe, Malawi: results from the prospective LighTen Cohort Study.
Topics: Blood Pressure; Cohort Studies; Female; HIV Infections; Humans; Hypertension; Malawi; Prospective Studies; Tenofovir | 2023 |
Quantification of nine antiretroviral drugs in cerebrospinal fluid: An approach to overcome sample collection tube adsorption.
Topics: Adsorption; Ammonium Hydroxide; Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; Chromatography, Liquid; Emtricitabine; HIV Infections; Humans; Lamivudine; Methanol; Ritonavir; Tandem Mass Spectrometry; Tenofovir; Water | 2023 |
No evidence of rapid reversibility of tenofovir alafenamide and/or integrase strand transfer inhibitor-associated weight gain.
Topics: Adult; Alanine; Anti-Retroviral Agents; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Middle Aged; Tenofovir; Virus Integration; Weight Gain | 2023 |
Population-level impact of expanding PrEP coverage by offering long-acting injectable PrEP to MSM in three high-resource settings: a model comparison analysis.
Topics: Black People; Canada; Emtricitabine; Georgia; HIV Infections; Homosexuality, Male; Humans; Male; Netherlands; Pre-Exposure Prophylaxis; Sexual and Gender Minorities; Tenofovir; White | 2023 |
Securing accelerated access to long-acting injectable cabotegravir for HIV prevention in low- and middle-income countries.
Topics: Child; Developing Countries; Drugs, Generic; HIV Infections; Humans; Lamivudine; Tenofovir; United States | 2023 |
Exposure to doravirine, lamivudine, tenofovir, and raltegravir in a patient with HIV after a Roux-en-Y gastric bypass.
Topics: Gastric Bypass; HIV Infections; Humans; Lamivudine; Raltegravir Potassium; Tenofovir | 2023 |
Transcriptomics age acceleration in prolonged treated HIV infection.
Topics: Adenine; Anti-HIV Agents; Emtricitabine; HIV Infections; HIV-1; Humans; Tenofovir; Transcriptome | 2023 |
Is injectable PrEP superior to oral therapy for HIV protection?
Topics: Administration, Oral; Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir | 2023 |
Reply: Effect of tenofovir-based HIV pre-exposure prophylaxis against HBV infection in men who have sex with men.
Topics: Anti-HIV Agents; Emtricitabine; Hepatitis B virus; HIV Infections; Homosexuality, Male; Humans; Male; Pre-Exposure Prophylaxis; Sexual and Gender Minorities; Tenofovir | 2023 |
Heart transplantation and human immunodeficiency virus-navigating drug-drug interactions: a case report.
Topics: Anti-HIV Agents; Emtricitabine; HIV Infections; HIV Seropositivity; HIV-1; Humans; Male; Middle Aged; Tenofovir | 2023 |
Effectiveness of second-generation integrase strand-transfer inhibitor-based regimens for antiretroviral-experienced people with HIV who had viral rebound.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; HIV Infections; Humans; Integrases; Retrospective Studies; Tenofovir | 2023 |
Young age is a key determinant of body weight gain after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in Japanese people living with HIV.
Topics: Adult; Drug Substitution; East Asian People; HIV Infections; Humans; Retrospective Studies; Tenofovir; Weight Gain | 2023 |
Effect of P-glycoprotein and Cotreatment with Sofosbuvir on the Intestinal Permeation of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide Fumarate.
Topics: Adenine; Alanine; Anti-HIV Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; Fumarates; HIV Infections; Humans; Sofosbuvir; Tenofovir | 2023 |
Preexposure Prophylaxis for the Prevention of HIV: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Topics: Adult; Emtricitabine; Female; HIV Infections; Homosexuality, Male; Humans; Male; Sexual and Gender Minorities; Systematic Reviews as Topic; Tenofovir | 2023 |
A novel formulation enabled transformation of 3-HIV drugs tenofovir-lamivudine-dolutegravir from short-acting to long-acting all-in-one injectable.
Topics: Animals; Anti-HIV Agents; Drug Combinations; Heterocyclic Compounds, 3-Ring; HIV Infections; Lamivudine; Leukocytes, Mononuclear; Oxazines; Pharmaceutical Preparations; Pyridones; Tenofovir | 2023 |
Hepatitis B care cascade among people with HIV/HBV coinfection in the North American AIDS Cohort Collaboration on Research and Design, 2012-2016.
Topics: Acquired Immunodeficiency Syndrome; Canada; Coinfection; Cross-Sectional Studies; DNA, Viral; Female; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Male; Middle Aged; Tenofovir | 2023 |
Development of Dispersible Vaginal Tablets of Tenofovir Loaded Mucoadhesive Chitosan Microparticles for Anti-HIV Pre-Exposure Prophylaxis.
Topics: Animals; Anti-HIV Agents; Chitosan; Female; HIV Infections; Humans; Pre-Exposure Prophylaxis; Rabbits; Tablets; Tenofovir; Vaginal Creams, Foams, and Jellies | 2023 |
Prophylaxis by doravirine-lamivudine-tenofovir disoproxil fumarate or elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide after sexual exposure to HIV.
Topics: Adult; Anti-HIV Agents; Cobicistat; Drug-Related Side Effects and Adverse Reactions; Emtricitabine; Fumarates; HIV Infections; Humans; Lamivudine; Tenofovir | 2023 |
Use of Tenofovir Alafenamide Fumarate for HIV Pre-Exposure Prophylaxis and Incidence of Hypertension and Initiation of Statins.
Topics: Adenine; Adolescent; Adult; Female; Fumarates; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Incidence; Male; Pre-Exposure Prophylaxis; Retrospective Studies; Tenofovir | 2023 |
Emergent HIV drug resistance in non-inferiority trials.
Topics: Emtricitabine; HIV Infections; Humans; Tenofovir; Treatment Outcome | 2023 |
Potential cost-effectiveness of community availability of tenofovir, lamivudine, and dolutegravir for HIV prevention and treatment in east, central, southern, and west Africa: a modelling analysis.
Topics: Africa, Western; Cost-Benefit Analysis; Female; HIV Infections; Humans; Lamivudine; Male; Tenofovir | 2023 |
Diagnostic accuracy of a point-of-care urine tenofovir assay, and associations with HIV viraemia and drug resistance among people receiving dolutegravir and efavirenz-based antiretroviral therapy.
Topics: Adult; Benzoxazines; Chromatography, Liquid; Cross-Sectional Studies; Female; HIV Infections; Humans; Male; Point-of-Care Systems; Tandem Mass Spectrometry; Tenofovir; Viremia | 2023 |
Letter to the Editor: Effect of tenofovir-based HIV pre-exposure prophylaxis against HBV infection in men who have sex with men.
Topics: Anti-HIV Agents; Emtricitabine; Hepatitis B virus; HIV Infections; Homosexuality, Male; Humans; Male; Pre-Exposure Prophylaxis; Sexual and Gender Minorities; Tenofovir | 2023 |
First case report of a perinatally HIV-infected infant with HIV resistance to dolutegravir associated with tenofovir/lamivudine/dolutegravir use in mothers.
Topics: Anti-HIV Agents; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Infant; Lamivudine; Mothers; Oxazines; Pregnancy; Tenofovir | 2023 |
Early implementation learnings on acceptability and feasibility of "V": a multi-level PrEP intervention designed with and for adolescent girls and young women in Zimbabwe.
Topics: Adolescent; Anti-HIV Agents; Feasibility Studies; Female; HIV Infections; Humans; Tenofovir; Zimbabwe | 2023 |
Viral dissemination and immune activation modulate antiretroviral drug levels in lymph nodes of SIV-infected rhesus macaques.
Topics: Animals; Anti-Retroviral Agents; COVID-19; Emtricitabine; HIV Infections; Leukocytes, Mononuclear; Lymph Nodes; Macaca mulatta; SARS-CoV-2; Tenofovir | 2023 |
Efficacy estimates of oral pre-exposure prophylaxis for HIV prevention in cisgender women with partial adherence.
Topics: Anti-HIV Agents; Emtricitabine; Female; HIV; HIV Infections; Humans; Male; Medication Adherence; Pre-Exposure Prophylaxis; Tenofovir | 2023 |
Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Anti-Retroviral Agents; Child; COVID-19; Hepatitis C; HIV Infections; Humans; Lamivudine; Practice Guidelines as Topic; Tenofovir | 2023 |
Impact of Treatment Adherence on Efficacy of Dolutegravir + Lamivudine and Dolutegravir + Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Week 144 Analysis of the GEMINI-1 and GEMINI-2 Clinical Studies.
Topics: Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Oxazines; Pyridones; Tenofovir; Treatment Adherence and Compliance | 2023 |
Tolerability of bictegravir/tenofovir alafenamide/emtricitabine versus dolutegravir/lamivudine as maintenance therapy in a real-life setting.
Topics: Adenine; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Lamivudine; Pyridones; Tenofovir | 2023 |
Vaginal microbiome, antiretroviral concentrations, and HIV genital shedding in the setting of hormonal contraception initiation in Malawi.
Topics: Anti-Retroviral Agents; Female; HIV Infections; Hormonal Contraception; Humans; Lamivudine; Levonorgestrel; Malawi; Medroxyprogesterone Acetate; Microbiota; Tenofovir; Vagina | 2023 |
Incidence and factors associated with hepatitis B surface antigen seroclearance in patients co-infected with HBV/HIV during antiretroviral therapy in Guangdong, China.
Topics: Adult; Coinfection; DNA, Viral; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Incidence; Lamivudine; Male; Retrospective Studies; Tenofovir | 2023 |
Outcomes of bictegravir/emtricitabine/tenofovir alafenamide versus efavirenz-based regimens in central China: a real-world assessment.
Topics: Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Tenofovir | 2023 |
Fracture Risk and Association With TDF Use Among People With HIV in Large Integrated Health Systems.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Fractures, Bone; HIV Infections; Humans; Middle Aged; Retrospective Studies; Tenofovir | 2023 |
Antenatal hepatitis B virus sero-prevalence, risk factors, pregnancy outcomes and vertical transmission rate within 24 months after birth in a high HIV prevalence setting.
Topics: Child; Female; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Mothers; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Prevalence; Risk Factors; Seroepidemiologic Studies; Tenofovir | 2023 |
HIV-1 Resistance to Islatravir/Tenofovir Combination Therapy in Wild-Type or NRTI-Resistant Strains of Diverse HIV-1 Subtypes.
Topics: Anti-HIV Agents; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Mutation; Reverse Transcriptase Inhibitors; Tenofovir | 2023 |
Uptake of Oral HIV Pre-Exposure Prophylaxis (PrEP) and Associated Factors among Female Sex Workers in Tanga, Tanzania.
Topics: Anti-HIV Agents; Child; Cross-Sectional Studies; Emtricitabine; Female; HIV Infections; Humans; Pre-Exposure Prophylaxis; Sex Workers; Tanzania; Tenofovir | 2023 |
Consistent efficacy of B/F/TAF in treatment-naïve HIV patients across different baseline HIV-1 RNA levels at week 48.
Topics: Anti-HIV Agents; Drug Combinations; HIV Infections; HIV-1; Humans; RNA; Tenofovir | 2023 |
Severe lactic acidosis during tenofovir disoproxil fumarate and cobicistat combination for HIV patient.
Topics: Acidosis, Lactic; Adenine; Anti-HIV Agents; Cobicistat; Drug Combinations; Female; HIV Infections; Humans; Middle Aged; Tenofovir; Thinness; Treatment Outcome | 2023 |
Geographic Variation in Qualified Health Plan Coverage and Prior Authorization Requirements for HIV Preexposure Prophylaxis.
Topics: Anti-HIV Agents; Cross-Sectional Studies; Emtricitabine; HIV Infections; Humans; Patient Protection and Affordable Care Act; Prior Authorization; Tenofovir; United States | 2023 |
Same-Day Initiation of Oral Pre-Exposure Prophylaxis is High Among Adolescent Men Who Have Sex With Men and Transgender Women in Brazil.
Topics: Adolescent; Anti-HIV Agents; Brazil; Cohort Studies; Emtricitabine; Female; HIV Infections; Homosexuality, Male; Humans; Male; Pre-Exposure Prophylaxis; Prospective Studies; Sexual and Gender Minorities; Tenofovir; Transgender Persons; Young Adult | 2023 |
Model-based predictions of protective HIV pre-exposure prophylaxis adherence levels in cisgender women.
Topics: Anti-HIV Agents; Emtricitabine; Female; HIV Infections; Humans; Male; Medication Adherence; Pre-Exposure Prophylaxis; Tenofovir | 2023 |
Adherence determination using urine-tenofovir point-of-care testing and pharmacy refill records: A cross-sectional study.
Topics: Adult; Anti-HIV Agents; Cross-Sectional Studies; HIV Infections; HIV Seropositivity; Humans; Medication Adherence; Nigeria; Pharmacy; Tenofovir | 2023 |
Adults on pre-exposure prophylaxis (tenofovir-emtricitabine) have faster clearance of anti-HIV monoclonal antibody VRC01.
Topics: Adult; Anti-HIV Agents; Antibodies, Monoclonal; Emtricitabine; HIV Infections; HIV-1; Humans; Male; Pre-Exposure Prophylaxis; Tenofovir | 2023 |
Long term renal function in Asian HIV-1 infected adults receiving tenofovir disoproxil fumarate without protease inhibitors.
Topics: Adult; Anti-HIV Agents; Asian People; Body Weight; Female; Glomerular Filtration Rate; HIV Infections; Humans; Male; Middle Aged; Renal Insufficiency; Tenofovir; Thailand; Zidovudine | 2019 |
Tenofovir DF/emtricitabine/rilpivirine as HIV post-exposure prophylaxis: results from a multicentre prospective study-authors' response.
Topics: Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Prospective Studies; Rilpivirine; Tenofovir | 2019 |
Development of mucoadhesive vaginal films based on HPMC and zein as novel formulations to prevent sexual transmission of HIV.
Topics: Adhesives; Administration, Intravaginal; Animals; Anti-HIV Agents; Cell Line; Chemistry, Pharmaceutical; Drug Liberation; Female; Glycerol; HIV Infections; Humans; Hypromellose Derivatives; Polyethylene Glycols; Polymers; Sexually Transmitted Diseases; Tenofovir; THP-1 Cells; Vagina; Zein | 2019 |
PrEP in China: choices are ahead.
Topics: Anti-HIV Agents; China; Female; HIV Infections; Homosexuality, Male; Humans; Male; Pre-Exposure Prophylaxis; Tenofovir | 2020 |
Life-threatening rhabdomyolysis and Fanconi syndrome related to tenofovir disoproxil fumarate administration in an HIV-infected patient.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Drug Therapy, Combination; Fanconi Syndrome; Fluid Therapy; Glomerular Filtration Rate; HIV Infections; Humans; Male; Middle Aged; Nevirapine; Rhabdomyolysis; Tenofovir | 2020 |
Switching to Tenofovir Alafenamide in Elvitegravir-Based Regimens: Pharmacokinetics and Antiviral Activity in Cerebrospinal Fluid.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Quinolones; Tenofovir | 2020 |
Long-term observation on hepatitis B surface antigen seroclearance in therapy experienced HIV/HBV co-infected Chinese.
Topics: Adult; Anti-HIV Agents; Antiviral Agents; Asian People; China; Coinfection; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B; Hepatitis B Surface Antigens; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Retrospective Studies; Tenofovir; Time Factors; Young Adult | 2020 |
Switching antiretrovirals in older patients.
Topics: Adenine; Aged; Alanine; Bone Density; Cobicistat; Emtricitabine; HIV Infections; HIV-1; Humans; Middle Aged; Quinolones; Tablets; Tenofovir | 2019 |
Clinical diagnosis of sensory neuropathy in HIV patients treated with tenofovir: A 6-month follow-up study.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Combinations; Female; Follow-Up Studies; HIV Infections; Humans; Male; Middle Aged; Peripheral Nervous System Diseases; Somatosensory Disorders; South Africa; Tenofovir | 2019 |
Rates and predictors of switching to tenofovir alafenamide-containing ART in a nationwide cohort.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Drug Interactions; Female; Hepatitis C, Chronic; HIV Infections; Humans; Male; Middle Aged; Risk Factors; Switzerland; Tenofovir | 2019 |
Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: Different effects in patients with or without baseline hypercholesterolemia.
Topics: Adenine; Adult; Anti-HIV Agents; Cholesterol; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Hypercholesterolemia; Lipid Metabolism; Lipidomics; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Retrospective Studies; Rilpivirine; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load | 2019 |
Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Female; HIV Infections; Humans; Risk Factors; Tenofovir; Weight Gain | 2020 |
Antiretroviral Penetration across Three Preclinical Animal Models and Humans in Eight Putative HIV Viral Reservoirs.
Topics: Animals; Anti-HIV Agents; Anti-Retroviral Agents; Atazanavir Sulfate; Emtricitabine; Female; HIV Infections; Humans; In Vitro Techniques; Maraviroc; Mice; Raltegravir Potassium; Tenofovir | 2019 |
Fevers and Night Sweats in a 35-year-old Man With Recent Travel to Southeast Asia.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Asia, Southeastern; Cobicistat; Emtricitabine; HIV Infections; Humans; Laos; Male; Quinolones; Sweating; Tenofovir; Thailand; Travel; United States | 2019 |
High Rates of Hepatitis B Virus (HBV) Functional Cure Among Human Immunodeficiency Virus-HBV Coinfected Patients on Antiretroviral Therapy in Zambia.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Coinfection; Female; Hepatitis B; HIV Infections; Humans; Male; Prospective Studies; Tenofovir; Treatment Outcome; Viral Load; Zambia | 2020 |
Pharmacogenetic determinants of kidney-associated urinary and serum abnormalities in antiretroviral-treated HIV-positive patients.
Topics: Adult; Anti-HIV Agents; ATP Binding Cassette Transporter, Subfamily B; Cohort Studies; Creatinine; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Diseases; Logistic Models; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Phosphates; Polymorphism, Single Nucleotide; Receptors, Calcitriol; Retinol-Binding Proteins; Tenofovir; Vitamin D3 24-Hydroxylase | 2020 |
No impact of previous NRTIs resistance in HIV positive patients switched to DTG+2NRTIs under virological control: Time of viral suppression makes the difference.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Combinations; Drug Resistance, Viral; Female; Genes, Viral; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Mutation; Oxazines; Piperazines; Pyridones; Retrospective Studies; Tenofovir; Viral Load | 2019 |
Development and validation of the first point-of-care assay to objectively monitor adherence to HIV treatment and prevention in real-time in routine settings.
Topics: Anti-HIV Agents; Chromatography, Liquid; Gold; HIV Infections; Humans; Medication Adherence; Metal Nanoparticles; Point-of-Care Testing; Pre-Exposure Prophylaxis; Tandem Mass Spectrometry; Tenofovir | 2020 |
HIV drug resistance in a cohort of HIV-infected MSM in the United States.
Topics: Adult; Cohort Studies; Drug Resistance, Viral; Emtricitabine; HIV Infections; HIV Integrase Inhibitors; HIV-1; Homosexuality, Male; Humans; Male; Phylogeny; Pre-Exposure Prophylaxis; Sexual and Gender Minorities; Tenofovir; United States; Viral Load | 2020 |
HIV 101: fundamentals of antiretroviral therapy.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Integrase Inhibitors; Lamivudine; Life Cycle Stages; Male; Middle Aged; Mutation; Oxazines; Piperazines; Pyridones; RNA, Viral; Tenofovir; Viral Load | 2019 |
Safety of tenofovir during pregnancy: early growth outcomes and hematologic side effects in HIV-exposed uninfected infants.
Topics: Anemia; Anti-HIV Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Growth; HIV Infections; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Male; Neutropenia; Pregnancy; Pregnancy Complications, Infectious; Retrospective Studies; Tenofovir; Treatment Outcome | 2020 |
Where Were the Women? Gender Parity in Clinical Trials.
Topics: Adenine; Alanine; Anti-HIV Agents; Clinical Trials as Topic; Drug Approval; Drug Combinations; Emtricitabine; Equivalence Trials as Topic; Female; HIV Infections; Humans; Male; Pre-Exposure Prophylaxis; Sex Factors; Tenofovir; United States; United States Food and Drug Administration | 2019 |
New PrEP formulation approved…but only for some.
Topics: Adenine; Anti-HIV Agents; Drug Approval; Emtricitabine; Female; HIV Infections; Humans; Male; Pre-Exposure Prophylaxis; Research Design; Sexism; Tenofovir; Transgender Persons; United States; United States Food and Drug Administration | 2019 |
Transgender women on oral HIV pre-exposure prophylaxis have significantly lower tenofovir and emtricitabine concentrations when also taking oestrogen when compared to cisgender men.
Topics: Adult; Anti-HIV Agents; Drug Interactions; Emtricitabine; Estrogens; Female; HIV Infections; Humans; Male; Middle Aged; Pre-Exposure Prophylaxis; Tenofovir; Transgender Persons; Young Adult | 2019 |
HIV Drug Resistance after Failure of 6 Month First-line Therapy in a Hospital: A Case Series.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Tenofovir; Treatment Failure; Viral Load; Zidovudine | 2019 |
Hepatitis B virus seroprevalence among HIV-infected patients receiving combination antiretroviral therapy three decades after universal neonatal hepatitis B immunization program in Taiwan.
Topics: Adult; Anti-Retroviral Agents; Biomarkers; CD4 Lymphocyte Count; Coinfection; Female; Hemochromatosis; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Immunization Programs; Lamivudine; Male; Retrospective Studies; Seroepidemiologic Studies; Syphilis; Taiwan; Tenofovir; Young Adult | 2021 |
Decreased levels of urinary liver-type fatty acid-binding protein after switching from tenofovir disoproxil fumarate to tenofovir alafenamide: a prospective observational study.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Antiviral Agents; beta 2-Microglobulin; Biomarkers; CD4 Lymphocyte Count; Creatinine; Fatty Acid-Binding Proteins; Female; Glomerular Filtration Rate; HIV Infections; Humans; Male; Middle Aged; Prospective Studies; Tenofovir; Treatment Outcome; Viral Load | 2019 |
Association of maternal antiretroviral use with microcephaly in children who are HIV-exposed but uninfected (SMARTT): a prospective cohort study.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Child; Child, Preschool; Cyclopropanes; Drug Combinations; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Male; Microcephaly; Pregnancy; Pregnancy Complications, Infectious; Prospective Studies; Puerto Rico; Tenofovir; Young Adult; Zidovudine | 2020 |
Translational Approach to Predicting the Efficacy of Maraviroc-Based Regimens as HIV Preexposure Prophylaxis.
Topics: Anti-HIV Agents; CD4-Positive T-Lymphocytes; Cohort Studies; Computer Simulation; Demography; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Maraviroc; Pre-Exposure Prophylaxis; Reproductive Tract Infections; Tenofovir; Treatment Outcome | 2020 |
Probenecid-Boosted Tenofovir: A Physiologically-Based Pharmacokinetic Model-Informed Strategy for On-Demand HIV Preexposure Prophylaxis.
Topics: Anti-HIV Agents; Drug Interactions; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; Humans; Models, Biological; Organic Anion Transport Protein 1; Organic Anion Transporters, Sodium-Independent; Pre-Exposure Prophylaxis; Probenecid; Tenofovir | 2020 |
Kaposi's Sarcoma Occurring in HIV Infection Controlled on HAART.
Topics: Ankle; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Emtricitabine; Foot; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lymphedema; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Sarcoma, Kaposi; Skin Neoplasms; Sustained Virologic Response; Tenofovir; Viral Load | 2020 |
Eligibility for differentiated models of HIV treatment service delivery: an estimate from Malawi and Zambia.
Topics: Adolescent; Adult; Anti-HIV Agents; Eligibility Determination; Female; HIV Infections; Humans; Lamivudine; Malawi; Randomized Controlled Trials as Topic; Tenofovir; Zambia | 2020 |
Reversible effect on lipids by switching from tenofovir disoproxil fumarate to tenofovir alafenamide and back.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Cholesterol; Drug Substitution; Female; Germany; HIV Infections; HIV-1; Humans; Logistic Models; Male; Middle Aged; Retrospective Studies; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load | 2019 |
Narrowing down the causes of failure of tenofovir (only) for preexposure prophylaxis.
Topics: Emtricitabine; Genetic Variation; HIV Infections; HIV-1; Humans; Pre-Exposure Prophylaxis; Tenofovir | 2019 |
Successful use of once-daily high-dose darunavir and dolutegravir in multidrug-resistant HIV.
Topics: Adenine; Adult; Anti-HIV Agents; Darunavir; Directly Observed Therapy; Dose-Response Relationship, Drug; Drug Monitoring; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Oxazines; Piperazines; Pyridones; Ritonavir; Tenofovir; Treatment Outcome | 2020 |
On-demand PrEP efficacy: forgiveness or timely dosing.
Topics: Emtricitabine; Forgiveness; HIV Infections; Homosexuality, Male; Humans; Male; Pre-Exposure Prophylaxis; Sexual and Gender Minorities; Tenofovir | 2020 |
HIV preexposure prophylaxis with tenofovir disoproxil fumarate/emtricitabine and changes in kidney function and tubular health.
Topics: Adult; Aged; Anti-HIV Agents; Biomarkers; Creatinine; Cystatin C; Emtricitabine; Female; HIV Infections; Humans; Kidney; Kidney Function Tests; Kidney Glomerulus; Longitudinal Studies; Male; Middle Aged; Pre-Exposure Prophylaxis; Tenofovir | 2020 |
A case of M184V mutant human immunodeficiency virus in a patient using daily pre-exposure prophylaxis.
Topics: Adult; Anti-HIV Agents; Drug Resistance, Viral; Emtricitabine; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homosexuality, Male; Humans; Male; Pre-Exposure Prophylaxis; Reverse Transcriptase Inhibitors; Tenofovir; Virus Replication | 2020 |
Renal function change after switching tenofovir disoproxil fumarate for tenofovir alafenamide in the HIV-positive patients of a metropolitan sexual health service.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Drug Substitution; Female; Glomerular Filtration Rate; HIV Infections; Hospitals, Urban; Humans; Kidney Function Tests; Longitudinal Studies; Male; Middle Aged; Retrospective Studies; Tenofovir | 2019 |
Being prepared to evaluate pregnancy PrEP.
Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Kenya; Pre-Exposure Prophylaxis; Pregnancy; Tenofovir | 2019 |
Response to Noe, Oldenbuettel and Jaeger.
Topics: Adenine; Alanine; HIV Infections; Humans; Tenofovir | 2020 |
Descriptive analysis of World Health Organization-recommended second-line antiretroviral treatment: A retrospective cohort data analysis.
Topics: Adult; Age Factors; CD4 Lymphocyte Count; Databases, Factual; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; Lost to Follow-Up; Male; Medication Adherence; Middle Aged; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; Sex Factors; Tenofovir; Treatment Failure; Viral Load; World Health Organization; Zidovudine | 2019 |
A Subcutaneous Implant of Tenofovir Alafenamide Fumarate Causes Local Inflammation and Tissue Necrosis in Rabbits and Macaques.
Topics: Adenine; Alanine; Animals; Anti-HIV Agents; Delayed-Action Preparations; Drug Implants; Female; Fumarates; HIV Infections; Humans; Inflammation; Macaca mulatta; Male; Necrosis; Polyurethanes; Rabbits; Subcutaneous Tissue; Tenofovir | 2020 |
Response to "Being prepared to evaluate pregnancy PrEP".
Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Kenya; Pre-Exposure Prophylaxis; Pregnancy; Tenofovir | 2019 |
Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in a Rapid-Initiation Model of Care for Human Immunodeficiency Virus Type 1 Infection: Primary Analysis of the DIAMOND Study.
Topics: Adenine; Adolescent; Adult; Aged; Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Diamond; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Prospective Studies; Tenofovir; Viral Load; Young Adult | 2020 |
Evaluation of Selected Outcomes of Combination Antiretroviral Therapy: Yemen Cohort Retrospective Descriptive Studies.
Topics: Adult; Alkynes; Anti-HIV Agents; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Retrospective Studies; Tenofovir; Treatment Outcome; Yemen; Young Adult | 2019 |
Not all is perfect with Tenofovir alafenamide.
Topics: Adenine; Alanine; HIV Infections; Humans; Tenofovir | 2020 |
Switch from tenofovir disoproxil fumarate to raltegravir is not associated with weight gain over 96 weeks.
Topics: Adult; Anti-HIV Agents; Body Mass Index; Emtricitabine; HIV Infections; HIV-1; Humans; Male; Middle Aged; Raltegravir Potassium; Tenofovir; Weight Gain | 2020 |
Continuation of emtricitabine/lamivudine within combination antiretroviral therapy following detection of the M184V/I HIV-1 resistance mutation.
Topics: Adult; Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Tenofovir; Treatment Failure; United Kingdom | 2020 |
Tenofovir Alafenamide for HIV Preexposure Prophylaxis: What Can We DISCOVER About Its True Value?
Topics: Adenine; Alanine; Anti-HIV Agents; Female; HIV Infections; Humans; Male; Pre-Exposure Prophylaxis; Tenofovir; Treatment Outcome | 2020 |
Vaginal Polyelectrolyte Layer-by-Layer Films Based on Chitosan Derivatives and Eudragit
Topics: Administration, Intravaginal; Animals; Anti-HIV Agents; Cattle; Chitosan; Drug Delivery Systems; Female; HIV Infections; Humans; Hydrogen-Ion Concentration; Mucous Membrane; Polymethacrylic Acids; Tenofovir; Vagina | 2020 |
Traditional Chinese Medicine Can Improve the Immune Reconstruction of HIV/AIDS Patients.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Drugs, Chinese Herbal; HIV Infections; Humans; Immune Reconstitution; Lamivudine; Medicine, Chinese Traditional; Middle Aged; Pilot Projects; Prospective Studies; T-Lymphocytes; Tenofovir; Treatment Outcome; Young Adult | 2020 |
Kinetics of Hepatitis B Core-Related Antigen and Anti-Hepatitis B Core Antibody and Their Association With Serological Response in Human Immunodeficiency Virus-Hepatitis B Coinfection.
Topics: Adult; Antiviral Agents; Coinfection; Female; Hepatitis B Antibodies; Hepatitis B Core Antigens; Hepatitis B e Antigens; Hepatitis B, Chronic; HIV Infections; Humans; Male; Middle Aged; Prospective Studies; Tenofovir | 2020 |
On-Demand Oral Pre-exposure Prophylaxis with Tenofovir/Emtricitabine: What Every Clinician Needs to Know.
Topics: Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir | 2020 |
Kaposi's sarcoma in a HIV-positive patient: an exuberant and widespread case report in the Amazon.
Topics: Adult; Anti-HIV Agents; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Male; Oxazines; Piperazines; Pyridones; Sarcoma, Kaposi; Skin Neoplasms; Tenofovir | 2020 |
Descovy Approved for HIV Prexposure Prophylaxis.
Topics: Adenine; Anti-HIV Agents; Drug Approval; Emtricitabine; HIV Infections; Humans; Tenofovir; United States; United States Food and Drug Administration | 2020 |
To Study the Incidence of Tenofovir Related Nephropathies in HIV Infected Patients.
Topics: Anti-HIV Agents; HIV Infections; Humans; Incidence; Kidney Diseases; Tenofovir | 2020 |
Failure to bictegravir and development of resistance mutations in an antiretroviral-experienced patient.
Topics: Adenine; Adult; Alanine; Amides; Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Mutation; Piperazines; Pyridones; Tenofovir; Toxoplasmosis, Cerebral; Treatment Failure | 2020 |
[Low Body Mass Index and impact of antiretroviral therapy on nephrotoxicity, chronic renal disease among HIV-infected patients in Brazzaville, Congo].
Topics: Adult; Antiviral Agents; Body Mass Index; Cohort Studies; Congo; Female; HIV Infections; Humans; Incidence; Kidney Diseases; Male; Renal Insufficiency, Chronic; Retrospective Studies; Risk Factors; Tenofovir | 2020 |
Tenofovir disoproxil fumarate-induced distal renal tubular acidosis: A case report.
Topics: Acidosis, Renal Tubular; Anti-HIV Agents; Female; HIV Infections; Humans; Middle Aged; Tenofovir; Treatment Outcome | 2020 |
Comparison of HIV drug resistance profiles across HIV-1 subtypes A and D for patients receiving a tenofovir-based and zidovudine-based first line regimens in Uganda.
Topics: Adolescent; Adult; Anti-HIV Agents; Drug Resistance, Multiple, Viral; Female; HIV Infections; HIV-1; Humans; Male; Mutation; Retrospective Studies; Tenofovir; Treatment Failure; Uganda; Young Adult; Zidovudine | 2020 |
HIV-1 superinfection in a patient with known HIV-2 - A case report.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cobicistat; Darunavir; Emtricitabine; Female; HIV Infections; HIV Seropositivity; HIV-1; HIV-2; Humans; Male; Middle Aged; Superinfection; Tenofovir; Treatment Outcome | 2020 |
Topics: Administration, Intravaginal; Animals; Biological Transport; Cell Line, Tumor; Darunavir; Disease Models, Animal; Drug Compounding; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Macaca fascicularis; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Tenofovir; Tissue Distribution; Up-Regulation; Vagina | 2020 |
Sustained virologic suppression with abacavir, emtricitabine, and crushed dolutegravir and tenofovir alafenamide in a patient with HIV and eosinophilic esophagitis.
Topics: Adult; Alanine; Anti-HIV Agents; Deglutition Disorders; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Eosinophilic Esophagitis; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Male; Oxazines; Piperazines; Pyridones; Tenofovir; Treatment Outcome; Viral Load | 2020 |
Development of gynecomastia following initiation of bictegravir/emtricitabine/tenofovir alafenamide.
Topics: Adenine; Adult; Alanine; Amides; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Combinations; Emtricitabine; Gynecomastia; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Male; Piperazines; Pyridones; Tenofovir; Treatment Outcome | 2020 |
The S68G polymorphism is a compensatory mutation associated with the drug resistance mutation K65R in CRF01_AE strains.
Topics: Anti-HIV Agents; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Mutation Rate; Polymorphism, Genetic; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure; Virus Replication; Zidovudine | 2020 |
Do genetic variations in proximal tubule transporters influence tenofovir-induced renal dysfunction? An exploratory study in a Ghanaian population.
Topics: Anti-HIV Agents; Ghana; HIV Infections; Humans; Kidney Diseases; Multidrug Resistance-Associated Protein 2; Polymorphism, Single Nucleotide; Tenofovir | 2020 |
Switching tenofovir disoproxil fumarate to tenofovir alafenamide in a real life setting: what are the implications?
Topics: Age Factors; Alanine; Albuminuria; Cholesterol, LDL; Drug Substitution; Female; HIV Infections; Humans; Male; Middle Aged; Proteinuria; Retrospective Studies; Tenofovir; Time Factors | 2020 |
High rates of tenofovir failure in a CRF01_AE-predominant HIV epidemic in the Philippines.
Topics: Adult; Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Epidemics; Female; HIV; HIV Infections; Humans; Male; Philippines; Tenofovir; Treatment Failure; Viral Load; Zidovudine | 2020 |
Uptake, engagement, and adherence to pre-exposure prophylaxis offered after population HIV testing in rural Kenya and Uganda: 72-week interim analysis of observational data from the SEARCH study.
Topics: Adolescent; Adult; Anti-HIV Agents; Emtricitabine; Female; HIV; HIV Infections; Humans; Kenya; Male; Mass Screening; Medication Adherence; Middle Aged; Pre-Exposure Prophylaxis; Rural Population; Sex Workers; Tenofovir; Uganda; Young Adult | 2020 |
Frequency and Predictors of Tenofovir-diphosphate Detection Among Young Kenyan Women in a Real-world Pre-exposure Prophylaxis Implementation Program.
Topics: Anti-HIV Agents; Diphosphates; Emtricitabine; Female; HIV Infections; Humans; Kenya; Medication Adherence; Pre-Exposure Prophylaxis; Pregnancy; Tenofovir | 2020 |
Comparing self-reported medication adherence measures with hair antiretroviral concentration among people living with HIV in Guangxi, China.
Topics: Adult; Anti-HIV Agents; China; Female; Hair; HIV Infections; Humans; Male; Medication Adherence; Middle Aged; Self Report; Surveys and Questionnaires; Tenofovir; Treatment Outcome | 2020 |
Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis: A Cost-Effectiveness Analysis.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Cost-Benefit Analysis; Drugs, Generic; Emtricitabine; Fractures, Bone; HIV Infections; Homosexuality, Male; Humans; Kidney Failure, Chronic; Male; Middle Aged; Pre-Exposure Prophylaxis; Quality-Adjusted Life Years; Tenofovir; United States; Young Adult | 2020 |
How Much Are We Willing to Pay for Preexposure Prophylaxis in the United States?
Topics: Adenine; Alanine; Anti-HIV Agents; Cost-Benefit Analysis; Decision Making, Shared; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Health Services Accessibility; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir; United States | 2020 |
Brief Report: High Accuracy of a Real-Time Urine Antibody-Based Tenofovir Point-of-Care Test Compared With Laboratory-Based ELISA in Diverse Populations.
Topics: Adult; Anti-HIV Agents; Antibodies; Drug Combinations; Drug Monitoring; Emtricitabine; Enzyme-Linked Immunosorbent Assay; Female; HIV Infections; Humans; Kenya; Laboratories; Male; Patient Compliance; Point-of-Care Testing; Sensitivity and Specificity; Tenofovir; Uganda | 2020 |
HIV protease inhibitor ritonavir induces renal fibrosis and dysfunction: role of platelet-derived TGF-β1 and intervention via antioxidant pathways.
Topics: Animals; Antioxidants; Blood Platelets; Fibrosis; Heme Oxygenase-1; HIV Infections; HIV Protease Inhibitors; Kidney Diseases; Mice; Mice, Inbred C57BL; NF-E2-Related Factor 2; Rats; Ritonavir; Tenofovir; Transforming Growth Factor beta1 | 2020 |
Failure of pre-exposure prophylaxis with daily tenofovir/emtricitabine and the scenario of delayed HIV seroconversion.
Topics: Anti-HIV Agents; Emtricitabine; Female; HIV Infections; HIV Seropositivity; Humans; Male; Medication Adherence; Pre-Exposure Prophylaxis; Seroconversion; Tenofovir; Treatment Failure; Young Adult | 2020 |
Changes in Renal Function After Switching From TDF to TAF in HIV-Infected Individuals: A Prospective Cohort Study.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Drug Substitution; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Function Tests; Male; Middle Aged; Prospective Studies; Switzerland; Tenofovir | 2020 |
Mother-to-Child HIV Transmission With In Utero Dolutegravir vs. Efavirenz in Botswana.
Topics: Adult; Alkynes; Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; Botswana; Cyclopropanes; Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP3A Inducers; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Mothers; Oxazines; Piperazines; Pregnancy; Pyridones; Reverse Transcriptase Inhibitors; Risk Factors; Tenofovir; Young Adult | 2020 |
Crushed bictegravir/emtricitabine/tenofovir alafenamide in a human immunodeficiency virus-positive patient with esophageal cancer.
Topics: Adenine; Alanine; Anti-HIV Agents; Drug Combinations; Emtricitabine; Esophageal Neoplasms; Gastrostomy; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Male; Middle Aged; Piperazines; Pyridones; Tablets; Tenofovir | 2020 |
Correlation of pre-exposure prophylaxis adherence to a mental health diagnosis or experience of childhood trauma in high-risk youth.
Topics: Adolescent; Adult; Adult Survivors of Child Adverse Events; Anti-HIV Agents; Anxiety; Cross-Sectional Studies; Depression; Female; HIV Infections; Humans; Male; Medication Adherence; Patient Health Questionnaire; Pre-Exposure Prophylaxis; Prevalence; Tenofovir | 2020 |
High pre-exposure prophylaxis awareness and willingness to pay for pre-exposure prophylaxis among young adults in Western Kenya: results from a population-based survey.
Topics: Adolescent; Adult; Anti-HIV Agents; Condoms; Female; Health Knowledge, Attitudes, Practice; HIV Infections; Humans; Kenya; Male; Patient Acceptance of Health Care; Population Surveillance; Pre-Exposure Prophylaxis; Tenofovir; Young Adult | 2020 |
Bone mineral density changes among people living with HIV who have started with TDF-containing regimen: A five-year prospective study.
Topics: Absorptiometry, Photon; Adult; Anti-HIV Agents; Bone Density; Female; Femur Neck; HIV Infections; Humans; Male; Middle Aged; Osteoporosis; Prevalence; Prospective Studies; Tenofovir; Thailand | 2020 |
Factors associated with tenofovir diphosphate concentrations in dried blood spots in persons living with HIV.
Topics: Adenine; Adolescent; Anti-HIV Agents; Female; HIV Infections; Humans; Male; Organophosphates; Tenofovir | 2020 |
Short-term neuropsychiatric tolerability of bictegravir combined with emtricitabine/tenofovir alafenamide in clinical practice.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Amides; Anti-HIV Agents; Depression; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Male; Middle Aged; Piperazines; Pyridones; Retrospective Studies; Tenofovir; Time Factors; Young Adult | 2020 |
The switch from tenofovir disoproxil fumarate to tenofovir alafenamide determines weight gain in patients on rilpivirine-based regimen.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Emtricitabine; Female; Fumarates; HIV Infections; HIV-1; Humans; Male; Middle Aged; Retrospective Studies; Rilpivirine; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load; Weight Gain | 2020 |
PrEP for HIV Prevention: Evidence, Global Scale-up, and Emerging Options.
Topics: Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir; United States | 2020 |
Evaluating statewide HIV preexposure prophylaxis implementation using All-Payer Claims Data.
Topics: Adult; Anti-HIV Agents; Emtricitabine; Female; HIV Infections; Humans; Insurance Claim Review; Male; Pre-Exposure Prophylaxis; Rhode Island; Tenofovir | 2020 |
Movement disorder in a patient with Human Immunodeficiency Virus on an anti-retroviral therapy: A Case Report.
Topics: AIDS Dementia Complex; Alkynes; Anti-HIV Agents; Benzoxazines; Blood-Brain Barrier; Brain Stem; Cerebellar Ataxia; Cerebellum; Cyclopropanes; Drug Substitution; Female; Gait Ataxia; HIV Infections; Humans; Lamivudine; Magnetic Resonance Imaging; Mesencephalon; Middle Aged; Neurodegenerative Diseases; Nystagmus, Pathologic; Panic Disorder; Pons; Postural Balance; Sensation Disorders; Tenofovir; Zidovudine | 2020 |
Investigating the effect of antiretroviral switch to tenofovir alafenamide on lipid profiles in people living with HIV.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Cholesterol; Cholesterol, LDL; Cohort Studies; Female; HIV Infections; Humans; Lipid Metabolism; Lipids; Male; Middle Aged; Prospective Studies; Tenofovir; Treatment Outcome | 2020 |
Monitoring the transition to new antiretroviral treatment regimens through an enhanced data system in Kenya.
Topics: Anti-HIV Agents; Data Systems; Database Management Systems; Drug Monitoring; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Kenya; Lamivudine; Oxazines; Piperazines; Pyridones; Tenofovir; Treatment Outcome; Viral Load | 2020 |
Usefulness of therapeutic drug monitoring of rilpivirine and its relationship with virologic response and resistance in a cohort of naive and pretreated HIV-infected patients.
Topics: Adult; Aged; Anti-HIV Agents; Cohort Studies; Drug Monitoring; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Retrospective Studies; Rilpivirine; Tenofovir; Viral Load; Young Adult | 2020 |
Anti-HIV drugs promote β-amyloid deposition and impair learning and memory in BALB/c mice.
Topics: Administration, Oral; AIDS Dementia Complex; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloid Precursor Protein Secretases; Animals; Anti-HIV Agents; Aspartic Acid Endopeptidases; Brain; Cognitive Dysfunction; Disease Models, Animal; Female; Hippocampus; HIV Infections; HIV-1; Learning Disabilities; Lipid Peroxidation; Maze Learning; Memory; Mice; Mice, Inbred BALB C; Nevirapine; Tenofovir | 2020 |
The Lymphoid Tissue Pharmacokinetics of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide in HIV-Infected Persons.
Topics: Adenine; Alanine; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Monitoring; Drug Substitution; Drug Therapy, Combination; Female; HIV Infections; Humans; Lymphoid Tissue; Male; Tenofovir; Tissue Distribution; Treatment Outcome; Viral Load | 2020 |
The Early Results of Vertebral Pathological Compression Fracture of Extra- nodal Lymphoma with HIV-positive Patients Treated by Percutaneous Kyphoplasty.
Topics: Adult; Alkynes; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Benzoxazines; Burkitt Lymphoma; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cementoplasty; Cyclophosphamide; Cyclopropanes; Doxorubicin; Female; Fractures, Compression; HIV Infections; Humans; Kyphoplasty; Lamivudine; Lumbar Vertebrae; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Prednisone; Retrospective Studies; Rituximab; Spinal Fractures; Tenofovir; Tomography, X-Ray Computed; Vincristine; Viral Load | 2020 |
Immunoassay for HIV Drug Metabolites Tenofovir and Tenofovir Diphosphate.
Topics: Adenine; Anti-HIV Agents; HIV Infections; Humans; Immunoassay; Medication Adherence; Organophosphates; Pharmaceutical Preparations; Tenofovir | 2020 |
COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients.
Topics: Adult; Antiretroviral Therapy, Highly Active; Betacoronavirus; Coinfection; Coronavirus Infections; COVID-19; Darunavir; Female; HIV; HIV Infections; Humans; Male; Middle Aged; Pandemics; Pneumonia, Viral; Retrospective Studies; SARS-CoV-2; Severity of Illness Index; Survival Analysis; Tenofovir; Viral Load | 2020 |
Influence of tenofovir exposure in utero on primary dentition.
Topics: Anti-HIV Agents; Child; Child, Preschool; Cross-Sectional Studies; Female; Germany; HIV Infections; Humans; Infant; Infant, Newborn; Male; Pregnancy; Premature Birth; Tenofovir; Tooth, Deciduous | 2020 |
Sleeve Gastrectomy Compared With Roux-en-Y Gastric Bypass in Individuals Living With HIV.
Topics: Adult; Atazanavir Sulfate; Body Mass Index; Gastrectomy; Gastric Bypass; HIV Infections; Humans; Middle Aged; Obesity; Retrospective Studies; Tenofovir; Treatment Outcome | 2020 |
Adenosine Deaminase as a Biomarker of Tenofovir Mediated Inflammation in Naïve HIV Patients.
Topics: Adenosine Deaminase; Adult; Biomarkers; Cytokines; HIV Infections; Humans; Inflammation; Male; Monocytes; Neutrophils; Tenofovir | 2020 |
Management Consideration in Drug-Induced Lactic Acidosis.
Topics: Acidosis, Lactic; Acute Kidney Injury; Aged; Alanine; Continuous Renal Replacement Therapy; Diabetes Mellitus, Type 2; Female; Heart Failure; HIV Infections; Humans; Oliguria; Reverse Transcriptase Inhibitors; Sodium Bicarbonate; Tenofovir | 2020 |
Satisfaction and knowledge among patients with HIV after switching from tenofovir to tenofovir alafenamide in regimens containing emtricitabine and rilpivirine
Topics: Adenine; Adult; Alanine; Antiviral Agents; Drug Combinations; Drug Substitution; Emtricitabine; Female; Health Knowledge, Attitudes, Practice; HIV Infections; Humans; Male; Middle Aged; Patient Satisfaction; Prospective Studies; Rilpivirine; Tenofovir | 2020 |
Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort.
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Anti-HIV Agents; Body Mass Index; CD4 Lymphocyte Count; Comorbidity; Coronavirus Infections; COVID-19; Female; HIV Infections; Humans; Incidence; Logistic Models; Male; Middle Aged; Multivariate Analysis; Pandemics; Pneumonia, Viral; Prospective Studies; Spain; Tenofovir; Young Adult | 2020 |
Previously unreported emergence of A265V substitution in the integrase gene in association with bictegravir virological failure.
Topics: Adenine; Aged; Alanine; Amides; Cell Line; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; HEK293 Cells; HeLa Cells; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; HIV-1; Humans; Male; Mutation; Piperazines; Pyridones; Tenofovir; Treatment Failure | 2020 |
Comparison of adherence measurement tools used in a pre-exposure prophylaxis demonstration study among female sex workers in Benin.
Topics: Adult; Anti-HIV Agents; Benin; Female; HIV Infections; Humans; Medication Adherence; Middle Aged; Pre-Exposure Prophylaxis; Self Report; Sex Workers; Tenofovir | 2020 |
Regional Disparities in Qualified Health Plans' Prior Authorization Requirements for HIV Pre-exposure Prophylaxis in the United States.
Topics: Anti-HIV Agents; Cross-Sectional Studies; Emtricitabine; Health Services Accessibility; HIV Infections; Humans; Patient Protection and Affordable Care Act; Pre-Exposure Prophylaxis; Prior Authorization; Tenofovir; United States | 2020 |
Changes in functional connectivity in people with HIV switching antiretroviral therapy.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Asymptomatic Diseases; Benzoxazines; Cognitive Dysfunction; Connectome; Cyclopropanes; Drug Substitution; Emtricitabine; Executive Function; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Magnetic Resonance Imaging; Male; Memory, Short-Term; Middle Aged; Neuropsychological Tests; Oxazines; Piperazines; Prospective Studies; Pyridones; Raltegravir Potassium; Rilpivirine; Tenofovir | 2020 |
Coronavirus disease 2019 and Pneumocystis jirovecii pneumonia: a diagnostic dilemma in HIV.
Topics: Anti-Bacterial Agents; Anti-HIV Agents; Asthma; Betacoronavirus; Clinical Laboratory Techniques; Coronavirus Infections; COVID-19; COVID-19 Testing; Diagnosis, Differential; DNA, Bacterial; Emtricitabine; Glucocorticoids; HIV Infections; Humans; Lung; Male; Middle Aged; Multiplex Polymerase Chain Reaction; Oxygen Inhalation Therapy; Pandemics; Pneumocystis carinii; Pneumonia, Pneumocystis; Pneumonia, Viral; Prednisolone; Raltegravir Potassium; Real-Time Polymerase Chain Reaction; RNA, Viral; SARS-CoV-2; Tenofovir; Tomography, X-Ray Computed; Trimethoprim, Sulfamethoxazole Drug Combination; Viral Load | 2020 |
Weighing considerations with newer antiretrovirals.
Topics: Adenine; Alanine; Amides; Double-Blind Method; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Oxazines; Piperazines; Pyridones; Tenofovir | 2020 |
Identifying the role of PrimPol in TDF-induced toxicity and implications of its loss of function mutation in an HIV+ patient.
Topics: Animals; Biocatalysis; DNA Primase; DNA-Directed DNA Polymerase; Enzyme Stability; Gene Knockdown Techniques; HIV Infections; Humans; Kidney; Kinetics; Mitochondria; Models, Molecular; Multifunctional Enzymes; Mutation; Protein Multimerization; Protein Structure, Quaternary; Tenofovir | 2020 |
Tenofovir Alafenamide Fumarate Therapy for HIV Treatment: Cardiometabolic and Renal Safety.
Topics: Alanine; Anti-HIV Agents; Cardiovascular Diseases; Female; Fumarates; HIV Infections; Humans; Kidney; Male; Retrospective Studies; Tenofovir | 2020 |
Interspecies Differences in Tenofovir Alafenamide Fumarate Stability in Plasma.
Topics: Adenine; Alanine; Animals; Anti-HIV Agents; Dogs; Fumarates; HIV Infections; Rabbits; Sheep; Tenofovir | 2020 |
Impact of Lamivudine-Based Antiretroviral Treatment on Hepatitis B Viremia in HIV-Coinfected South Africans.
Topics: Adult; Anti-HIV Agents; Antiviral Agents; Coinfection; Female; Follow-Up Studies; Hepatitis B; Hepatitis B virus; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Prospective Studies; Tenofovir; Viral Load; Viremia; Young Adult | 2020 |
Medium-grade proteinuria is a risk factor for incident markers of chronic kidney disease.
Topics: Adult; Age Factors; Anti-HIV Agents; Biomarkers; Disease Progression; Female; Glomerular Filtration Rate; HIV Infections; Humans; Male; Middle Aged; Multivariate Analysis; Practice Guidelines as Topic; Prospective Studies; Proteinuria; Renal Insufficiency, Chronic; Tenofovir | 2020 |
Post-exposure prophylaxis completion and condom use in the context of potential sexual exposure to HIV.
Topics: Adult; Condoms; Emtricitabine; Female; France; HIV Infections; Homosexuality, Male; Humans; Male; Medication Adherence; Multivariate Analysis; Post-Exposure Prophylaxis; Retrospective Studies; Sexual Partners; Tenofovir; Unsafe Sex | 2020 |
The New NNRTI ACC007 Combined with Lamivudine and Tenofovir Disoproxil Fumarate Show Synergy Anti-HIV Activity In Vitro.
Topics: Anti-HIV Agents; Drug Synergism; HIV Infections; HIV-1; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Tenofovir | 2020 |
Pharmacokinetic and Pharmacodynamic Impacts of Depot Medroxyprogesterone Acetate Use on HIV Pre-exposure Prophylaxis in Women.
Topics: Adolescent; Adult; Anti-HIV Agents; Emtricitabine; Female; HIV Infections; Humans; Leukocytes, Mononuclear; Medroxyprogesterone Acetate; Middle Aged; Pilot Projects; Pre-Exposure Prophylaxis; Tenofovir; Young Adult | 2020 |
Prevalence of renal dysfunction among HIV infected patients receiving Tenofovir at Mulago: a cross-sectional study.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Glycosuria; HIV Infections; Humans; Hypercalcemia; Hyperkalemia; Hyperphosphatemia; Hypocalcemia; Hypokalemia; Hypophosphatemia; Lamivudine; Male; Middle Aged; Prevalence; Proteinuria; Renal Insufficiency; Tenofovir; Uganda | 2020 |
Changes in Bone Mineral Density During and After Lactation in Ugandan Women With HIV on Tenofovir-Based Antiretroviral Therapy.
Topics: Absorptiometry, Photon; Adult; Bone Density; Female; HIV Infections; Humans; Lactation; Tenofovir; Uganda; Young Adult | 2020 |
Early changes in bone turnover and inflammatory biomarkers and clinically significant bone mineral density loss over 48 weeks among HIV-infected patients with virological failure of a standard first-line antiretroviral therapy regimen in the SECOND-LINE s
Topics: Absorptiometry, Photon; Adult; Biomarkers; Bone Density; C-Reactive Protein; CD4 Lymphocyte Count; Female; Hip; HIV Infections; HIV-1; Humans; Interleukin-6; Male; Middle Aged; Neopterin; Peptide Fragments; Procollagen; Raltegravir Potassium; Random Allocation; Reverse Transcriptase Inhibitors; Spine; Tenofovir; Treatment Failure; Treatment Outcome; Tumor Necrosis Factor-alpha; Viral Load | 2020 |
Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy : A Cohort Study.
Topics: Adenine; Adult; Aged; Antiretroviral Therapy, Highly Active; Betacoronavirus; Coronavirus Infections; COVID-19; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; Hospitalization; Humans; Incidence; Intensive Care Units; Lamivudine; Male; Middle Aged; Pandemics; Pneumonia, Viral; Reverse Transcriptase Polymerase Chain Reaction; SARS-CoV-2; Severity of Illness Index; Spain; Tenofovir | 2020 |
Cases of coronavirus disease-2019 in HIV-infected transgender women.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Oxazines; Pandemics; Piperazines; Pneumonia, Viral; Pyridones; Ritonavir; SARS-CoV-2; Tenofovir; Transgender Persons | 2020 |
Severe rhabdomyolysis and acute asymptomatic pancreatitis following the concomitant use of Biktarvy in the setting of hyperosmolar diabetic crisis.
Topics: Adenine; Alanine; Anti-HIV Agents; Cholangiopancreatography, Magnetic Resonance; Diabetes Mellitus; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Insulin; Male; Middle Aged; Pancreatitis; Piperazines; Pyridones; Rhabdomyolysis; Tenofovir | 2020 |
Extent of In Utero Transfer of Tenofovir From Mother to Fetus: A Paired Analysis of Hair Specimens Collected at Birth From a Cohort in the United States.
Topics: Adult; Anti-HIV Agents; Delivery, Obstetric; Female; Fetus; Hair; HIV Infections; Humans; Infant, Newborn; Mothers; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Trimesters; Premature Birth; Prospective Studies; Tenofovir; United States; Young Adult | 2021 |
Tenofovir Alafenamide for HIV Preexposure Prophylaxis.
Topics: Adenine; Alanine; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir | 2020 |
Tenofovir Alafenamide for HIV Preexposure Prophylaxis.
Topics: Adenine; Alanine; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir | 2020 |
Intracellular Tenofovir and Emtricitabine Concentrations in Younger and Older Women with HIV Receiving Tenofovir Disoproxil Fumarate/Emtricitabine.
Topics: Adult; Aged; Anti-HIV Agents; CD8-Positive T-Lymphocytes; Emtricitabine; Female; HIV Infections; Humans; Leukocytes, Mononuclear; Middle Aged; Tenofovir | 2020 |
Proximal renal tubular function in HIV-infected children on tenofovir disoproxil fumarate for treatment of HIV infection at two tertiary hospitals in Harare, Zimbabwe.
Topics: Adolescent; Anti-HIV Agents; Child; Cross-Sectional Studies; Fanconi Syndrome; Female; Glomerular Filtration Rate; HIV Infections; Humans; Male; Proteinuria; Reverse Transcriptase Inhibitors; Tenofovir; Tertiary Care Centers; Zimbabwe | 2020 |
HIV antiretroviral therapy and prevention use in US blood donors: a new blood safety concern.
Topics: Adolescent; Adult; Anti-HIV Agents; Blood Donors; Blood Safety; Chromatography, Liquid; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Post-Exposure Prophylaxis; Pre-Exposure Prophylaxis; Risk; Single-Blind Method; Tandem Mass Spectrometry; Tenofovir; Truth Disclosure; United States; Viremia; Young Adult | 2020 |
Therapeutic drug monitoring study on the switch from coformulated 600-mg efavirenz, tenofovir disoproxil fumarate, and emtricitabine to coformulated 400-mg efavirenz, tenofovir disoproxil fumarate, and lamivudine among HIV-positive patients with viral sup
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Combinations; Drug Monitoring; Drug Substitution; Emtricitabine; HIV Infections; Humans; Lamivudine; Male; Prospective Studies; Taiwan; Tenofovir; Treatment Outcome; Viral Load | 2021 |
FGF21 and its Relationship with Inflammatory and Metabolic Parameters in HIV Patients after Antiretroviral Treatment.
Topics: Adult; Anti-Retroviral Agents; Atherosclerosis; Female; Fibroblast Growth Factors; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Inflammation; Inflammation Mediators; Lipid Metabolism; Lopinavir; Male; Metabolic Syndrome; Middle Aged; Prospective Studies; Risk Factors; Ritonavir; Tenofovir; Young Adult | 2020 |
Use of Drug-level Testing and Single-genome Sequencing to Unravel a Case of Human Immunodeficiency Virus Seroconversion on Pre-exposure Prophylaxis.
Topics: Anti-HIV Agents; Emtricitabine; HIV; HIV Infections; Humans; Medication Adherence; Pharmaceutical Preparations; Pre-Exposure Prophylaxis; Seroconversion; Tenofovir | 2021 |
Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: a multicentre cohort study.
Topics: Adult; Anti-HIV Agents; Cobicistat; Darunavir; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Quinolones; Spain; Tenofovir; Treatment Outcome; Viral Load | 2020 |
Long-Term TDF-Inclusive ART and Progressive Rates of HBsAg Loss in HIV-HBV Coinfection-Lessons for Functional HBV Cure?
Topics: Anti-HIV Agents; Australia; Coinfection; DNA, Viral; Drug Administration Schedule; Hepatitis B Surface Antigens; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; RNA, Viral; Tenofovir; Thailand | 2020 |
Bictegravir/emtricitabine/tenofovir alafenamide-induced acute pancreatitis: a case report.
Topics: Acute Disease; Adenine; Adult; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Lipase; Male; Pancreas; Pancreatitis; Piperazines; Pyridones; Tenofovir; Ultrasonography | 2020 |
Tenofovir resistance in early and long-term treated patients on first-line antiretroviral therapy in eight low-income and middle-income countries.
Topics: Anti-HIV Agents; Cameroon; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Tenofovir; Treatment Outcome; Uganda; Viral Load; Zambia | 2020 |
A Comparison of Tenofovir Predose Concentrations in Generic Pre-exposure Prophylaxis Formulations: A Short Communication.
Topics: Adult; Anti-HIV Agents; Drugs, Generic; Female; HIV Infections; Humans; Male; Pre-Exposure Prophylaxis; Retrospective Studies; Tenofovir | 2020 |
PrEParing for Preexposure Prophylaxis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Pre-Exposure Prophylaxis; Tenofovir; United States | 2020 |
Single oral dose for HIV pre or post-exposure prophylaxis: user desirability and biological efficacy in macaques.
Topics: Adenine; Administration, Oral; Animals; Cross-Sectional Studies; Drug Combinations; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Macaca; Male; Patient Compliance; Pre-Exposure Prophylaxis; Quinolones; Rectum; Surveys and Questionnaires; Tenofovir | 2020 |
DISCOVER: much accomplished, but not yet for all.
Topics: Adenine; Alanine; Double-Blind Method; Emtricitabine; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir | 2020 |
Marketing of Tenofovir Disoproxil Fumarate (TDF) Lawsuits and Social Media Misinformation Campaigns' Impact on PrEP Uptake Among Gender and Sexual Minority Individuals.
Topics: Anti-HIV Agents; Cohort Studies; Communication; Emtricitabine; Female; HIV Infections; Humans; Male; Marketing; Pre-Exposure Prophylaxis; Sexual and Gender Minorities; Social Media; Tenofovir | 2021 |
Topical Tenofovir Pre-exposure Prophylaxis and Mucosal HIV-Specific Fc-Mediated Antibody Activities in Women.
Topics: Anti-HIV Agents; Antibody Specificity; Antibody-Dependent Cell Cytotoxicity; Antigens, Viral; CD4 Lymphocyte Count; Female; Gels; HIV Antibodies; HIV Envelope Protein gp120; HIV Infections; HIV-1; Host-Pathogen Interactions; Humans; Immunoglobulin Fc Fragments; Immunoglobulin G; Killer Cells, Natural; Neutrophils; Phagocytosis; Pre-Exposure Prophylaxis; Tenofovir; Viral Load | 2020 |
Assessing the association between platelets and immune recovery in HIV/HBV co-infected patients: A long-term cohort in Asia.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Blood Platelets; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Cohort Studies; Cyclopropanes; Female; Hepatitis B; Hepatitis B virus; HIV Infections; HIV-1; Humans; Immune Reconstitution; Lamivudine; Longitudinal Studies; Male; Platelet Count; Retrospective Studies; Tenofovir | 2020 |
Impact of archived M184V/I mutation on the effectiveness of switch to co-formulated elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide among virally suppressed people living with HIV.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Cobicistat; Emtricitabine; HIV Infections; HIV-1; Humans; Mutation; Quinolones; Retrospective Studies; Tenofovir | 2020 |
Engendering health systems in response to national rollout of dolutegravir-based regimens among women of childbearing potential: a qualitative study with stakeholders in South Africa and Uganda.
Topics: Adult; Female; Government Programs; Health Facilities; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Lamivudine; Oxazines; Piperazines; Pregnancy; Pyridones; Qualitative Research; South Africa; Tenofovir; Uganda | 2020 |
Highly synergistic drug combination prevents vaginal HIV infection in humanized mice.
Topics: Administration, Intravaginal; Animals; Antiviral Agents; Drug Combinations; Drug Synergism; Emtricitabine; Female; HIV Infections; Humans; Mice; Tenofovir; Vagina | 2020 |
Perspectives on the utility and interest in a point-of-care urine tenofovir test for adherence to HIV pre-exposure prophylaxis and antiretroviral therapy: an exploratory qualitative assessment among U.S. clients and providers.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; Focus Groups; Health Personnel; HIV Infections; Humans; Limit of Detection; Male; Medication Adherence; Middle Aged; Point-of-Care Systems; Point-of-Care Testing; Pre-Exposure Prophylaxis; Qualitative Research; Tenofovir; United States | 2020 |
Pharmacokinetics and renal safety of tenofovir alafenamide with boosted protease inhibitors and ledipasvir/sofosbuvir.
Topics: Adenine; Alanine; Anti-HIV Agents; Benzimidazoles; Fluorenes; HIV Infections; Humans; Protease Inhibitors; Sofosbuvir; Tenofovir | 2020 |
Changes in bone microarchitecture with abacavir--lamivudine versus tenofovir disoproxil fumarate--emtricitabine in adults living with HIV.
Topics: Absorptiometry, Photon; Adult; Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; Emtricitabine; Fractures, Bone; HIV Infections; Humans; Incidence; Lamivudine; Osteoporotic Fractures; Tenofovir | 2020 |
Renal proximal tubulopathy in an HIV-infected patient treated with tenofovir alafenamide and gentamicin: a case report.
Topics: Acute Disease; Alanine; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Chemotherapy-Induced Febrile Neutropenia; Deprescriptions; Drug Interactions; Fanconi Syndrome; Gentamicins; Glycosuria; HIV Infections; Hodgkin Disease; Humans; Hypokalemia; Hypophosphatemia; Male; Middle Aged; Proteinuria; Tenofovir | 2020 |
Acceptability of pre-exposure prophylaxis for HIV prevention: facilitators, barriers and impact on sexual risk behaviors among men who have sex with men in Benin.
Topics: Adolescent; Adult; Anti-HIV Agents; Benin; Cities; Condoms; Cross-Sectional Studies; Emtricitabine; Health Services Accessibility; HIV Infections; Homosexuality, Male; Humans; Logistic Models; Male; Middle Aged; Odds Ratio; Patient Acceptance of Health Care; Pre-Exposure Prophylaxis; Risk-Taking; Safe Sex; Sexual and Gender Minorities; Sexual Behavior; Tenofovir; Young Adult | 2020 |
Real-Life Impact on Lipid Profile of a Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected Patients.
Topics: Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Cohort Studies; Female; HIV Infections; Humans; Lipids; Male; Middle Aged; Retrospective Studies; Tenofovir; Young Adult | 2021 |
Association of tenofovir disoproxil fumarate exposure with chronic kidney disease and osteoporotic fracture in US veterans with HIV.
Topics: Adult; Aged; Anti-HIV Agents; Cohort Studies; Female; HIV Infections; Humans; Logistic Models; Male; Middle Aged; Osteoporotic Fractures; Renal Insufficiency, Chronic; Tenofovir; Veterans | 2020 |
Successful Bictegravir/Emtricitabine/Tenofovir Alafenamide Treatment in a HIV Patient With Swallowing Difficulties.
Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Deglutition; Drug Combinations; Emtricitabine; Female; Fruit and Vegetable Juices; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Middle Aged; Piperazines; Pyridones; Solubility; Tenofovir | 2021 |
Population Pharmacokinetic and Pharmacodynamic Analysis To Evaluate a Switch to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in People Living with HIV-1.
Topics: Anti-HIV Agents; Emtricitabine; Fumarates; HIV Infections; HIV-1; Humans; Lamivudine; Pyridones; Tenofovir; Triazoles | 2020 |
Rapid ART start in early HIV infection: Time to viral load suppression and retention in care in a London cohort.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Darunavir; Female; HIV Infections; HIV Integrase Inhibitors; HIV-1; Homosexuality, Male; Humans; London; Male; Retention in Care; RNA, Viral; Tenofovir; Time Factors; Treatment Outcome; Viral Load | 2020 |
Brief Report: Switching From TDF to TAF in HIV/HBV-Coinfected Individuals With Renal Dysfunction-A Prospective Cohort Study.
Topics: Adenine; Aged; Alanine; Anti-HIV Agents; Female; Glomerular Filtration Rate; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Interrupted Time Series Analysis; Kidney Diseases; Kidney Function Tests; Liver; Male; Middle Aged; Prospective Studies; Tenofovir; Viral Load | 2020 |
Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis.
Topics: Adenine; Alanine; Cost-Benefit Analysis; Emtricitabine; Family; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir | 2020 |
Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis.
Topics: Adenine; Alanine; Cost-Benefit Analysis; Emtricitabine; Family; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir | 2020 |
Tenofovir-induced delayed nephro-osteo toxicity.
Topics: Child; Fanconi Syndrome; HIV Infections; Humans; Incidence; Male; Middle Aged; Osteomalacia; Tenofovir | 2020 |
Dynamics of the Decay of Human Immunodeficiency Virus (HIV) RNA and Distribution of Bictegravir in the Genital Tract and Rectum in Antiretroviral-naive Adults Living With HIV-1 Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (Spanish HIV/AIDS
Topics: Adult; Alanine; Amides; Anti-HIV Agents; Emtricitabine; Female; Genitalia; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Male; Piperazines; Prospective Studies; Pyridones; Rectum; RNA; Tenofovir | 2021 |
Small-area spatial-temporal changes in pre-exposure prophylaxis (PrEP) use in the general population and among men who have sex with men in the United States between 2012 and 2018.
Topics: Adult; Anti-HIV Agents; Emtricitabine; Female; HIV Infections; Homosexuality, Male; Humans; Male; Medication Adherence; Pre-Exposure Prophylaxis; Prevalence; Small-Area Analysis; Spatio-Temporal Analysis; Tenofovir; United States | 2020 |
Effect of Pregnancy and Concomitant Antiretrovirals on the Pharmacokinetics of Tenofovir in Women With HIV Receiving Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy Versus Women With HBV Receiving Tenofovir Disoproxil Fumarate Monotherapy.
Topics: Adult; Anti-HIV Agents; Area Under Curve; Drug Interactions; Female; Hepatitis B; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Postpartum Period; Pregnancy; Pregnancy Complications, Infectious; Randomized Controlled Trials as Topic; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Young Adult | 2021 |
COVID-19 in people living with HIV: Clinical implications of dynamics of the immune response to SARS-CoV-2.
Topics: Anti-Retroviral Agents; Antibodies, Neutralizing; Antibodies, Viral; CD4 Lymphocyte Count; Coinfection; COVID-19 Drug Treatment; Cytokines; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Immunity, Humoral; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Reverse Transcriptase Inhibitors; Risk; RNA, Viral; SARS-CoV-2; Severity of Illness Index; Tenofovir; Transgender Persons | 2021 |
Tenofovir alafenamide and rifabutin co-administration does not lead to loss of HIV-1 suppression: A retrospective observational study.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Retrospective Studies; Rifabutin; Tenofovir; Viral Load | 2020 |
Tenofovir alafenamide does not inhibit mitochondrial function and cholesterol biosynthesis in human T lymphoblastoid cell line.
Topics: Adenine; Alanine; Anti-HIV Agents; Cell Line; Cholesterol; DNA, Mitochondrial; HIV Infections; HIV-1; Humans; Membrane Potentials; Mitochondria; T-Lymphocytes; Tenofovir | 2020 |
Tenofovir disoproxil fumarate associated nephrotoxicity: a retrospective cohort study at two referral hospitals in Namibia.
Topics: Anti-HIV Agents; Glomerular Filtration Rate; HIV Infections; Hospitals; Humans; Namibia; Referral and Consultation; Retrospective Studies; Tenofovir | 2021 |
Pharmacokinetics of tenofovir disoproxyl fumarate/emtricitabine in a client on pre-exposure prophylaxis after a total gastrectomy.
Topics: Adolescent; Adult; Anti-HIV Agents; Emtricitabine; Fumarates; Gastrectomy; HIV Infections; Humans; Middle Aged; Pre-Exposure Prophylaxis; Tenofovir; Young Adult | 2020 |
Maraviroc, tenofovir disoproxil fumarate and dapivirine, activate progesterone receptor B in the absence of progestogens.
Topics: Anti-HIV Agents; Binding, Competitive; Cell Line; Contraceptive Agents, Hormonal; HIV Infections; HIV-1; Humans; Immunologic Factors; In Vitro Techniques; Levonorgestrel; Maraviroc; Phosphorylation; Progesterone Congeners; Pyrimidines; Receptors, Progesterone; Tenofovir; Transcriptional Activation | 2020 |
Treatment with Commonly Used Antiretroviral Drugs Induces a Type I/III Interferon Signature in the Gut in the Absence of HIV Infection.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Emtricitabine; Female; Gastrointestinal Microbiome; Gene Expression; HIV; HIV Infections; Humans; Interferon Type I; Male; Middle Aged; Pharmaceutical Preparations; Pre-Exposure Prophylaxis; Tenofovir; Transcriptome | 2020 |
Bone Loss and Lactation in Women Living With HIV: Potential Implications for Long-Term Bone Health.
Topics: Bone Density; Female; HIV Infections; Humans; Lactation; Tenofovir; Uganda | 2020 |
Where are we with pre-exposure prophylaxis use in Central and Eastern Europe? Data from the Euroguidelines in Central and Eastern Europe (ECEE) Network Group.
Topics: Anti-HIV Agents; Emtricitabine; Europe; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir | 2021 |
Efficacy and safety of a single-tablet regimen containing tenofovir disoproxil fumarate 300 mg, lamivudine 300 mg and efavirenz 400 mg as a switch strategy in virologically suppressed HIV-1-infected subjects on nonnucleoside reverse transcriptase inhibito
Topics: Adult; Alkynes; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Combinations; Female; HIV Infections; HIV-1; Humans; India; Lamivudine; Male; Middle Aged; Private Sector; Retrospective Studies; Reverse Transcriptase Inhibitors; Tablets; Tenofovir; Tertiary Care Centers; Treatment Outcome; Viral Load | 2020 |
Growth and Neurodevelopment Outcomes in HIV-, Tenofovir-, and Efavirenz-Exposed Breastfed Infants in the PMTCT Option B+ Program in Malawi.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Breast Feeding; Cyclopropanes; Female; HIV Infections; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Malawi; Male; Pregnancy; Prospective Studies; Tenofovir | 2021 |
Topics: Anti-HIV Agents; Drug Combinations; Gene Expression Regulation, Viral; HIV Infections; Humans; Recombinant Fusion Proteins; tat Gene Products, Human Immunodeficiency Virus; Tenofovir | 2021 |
Tenofovir as a treatment option for multiple sclerosis.
Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Multiple Sclerosis; Tenofovir | 2020 |
Virtual HIV pre-exposure prophylaxis outpatient service in the era of COVID-19.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Anti-HIV Agents; COVID-19; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Ireland; Male; Middle Aged; Pandemics; Pre-Exposure Prophylaxis; SARS-CoV-2; Tenofovir | 2021 |
Detectable HIV RNA in late pregnancy associated with low tenofovir hair levels at time of delivery among women living with HIV in the United States.
Topics: Adult; Anti-HIV Agents; Child; Cohort Studies; Female; Hair; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Pregnancy; RNA; Tenofovir; United States | 2021 |
Once-daily raltegravir with tenofovir disoproxil/emtricitabine as HIV post-exposure prophylaxis following sexual exposure.
Topics: Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Post-Exposure Prophylaxis; Pre-Exposure Prophylaxis; Raltegravir Potassium; Tenofovir | 2021 |
Dyslipidaemia after switch to tenofovir alafenamide (TAF)-based cART regimens in a cohort of HIV-positive patients: what clinical relevance?
Topics: Alanine; Dyslipidemias; HIV Infections; Humans; Tenofovir | 2021 |
Exploring the Use of Oral Pre-exposure Prophylaxis (PrEP) Among Women from Durban, South Africa as Part of the HIV Prevention Package in a Clinical Trial.
Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Pre-Exposure Prophylaxis; South Africa; Tenofovir | 2021 |
Knowledge and barriers of PrEP delivery among diverse groups of potential PrEP users in Central Uganda.
Topics: Administration, Oral; Adult; Emtricitabine; Female; Health Knowledge, Attitudes, Practice; Health Services Accessibility; HIV Infections; Humans; Male; Patient Compliance; Pre-Exposure Prophylaxis; Surveys and Questionnaires; Tenofovir; Uganda | 2020 |
Monoclonal antibodies with subnanomolar affinity to tenofovir for monitoring adherence to antiretroviral therapies: from hapten synthesis to prototype development.
Topics: Animals; Anti-HIV Agents; Antibodies, Monoclonal; Drug Monitoring; Enzyme-Linked Immunosorbent Assay; HIV Infections; Humans; Immunoassay; Mice; Point-of-Care Testing; Tenofovir | 2020 |
Is urinary β2-microglobulin a reliable marker for assessment of renal tubular dysfunction in chronic hepatitis B patients receiving tenofovir therapy?
Topics: Adult; Antiviral Agents; Biomarkers; Creatinine; Glomerular Filtration Rate; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Kidney Diseases; Male; Tenofovir | 2021 |
Melatonin protects against tenofovir-induced nephrotoxicity in rats by targeting multiple cellular pathways.
Topics: Animals; Antiviral Agents; Hepatitis B, Chronic; HIV Infections; Humans; Male; Melatonin; Metabolic Networks and Pathways; Models, Animal; Rats; Renal Insufficiency; Tenofovir | 2021 |
Brief Report: Weight Gain Following ART Initiation in ART-Naïve People Living With HIV in the Current Treatment Era.
Topics: Adult; Alanine; Alkynes; Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Tenofovir; Weight Gain | 2021 |
Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide discontinuation and return to normal weight.
Topics: Adult; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cobicistat; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Quinolones; Tenofovir; Weight Gain | 2021 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate: integrating systematic review findings into practice and policy.
Topics: Adenine; Alanine; HIV Infections; Humans; Policy; Tenofovir | 2020 |
Two-dose emtricitabine/tenofovir alafenamide plus bictegravir prophylaxis protects macaques against SHIV infection.
Topics: Adenine; Alanine; Amides; Animals; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Homosexuality, Male; Humans; Leukocytes, Mononuclear; Macaca; Male; Piperazines; Pre-Exposure Prophylaxis; Pyridones; Sexual and Gender Minorities; Tenofovir | 2021 |
PrEP Demonstration Project Showed Superior Adherence with Tenofovir Alafenamide/Emtricitabine Compared to Tenofovir Disoproxil Fumarate/Emtricitabine in a Sample of Partnered Sexual Minority Men.
Topics: Adenine; Alanine; Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Male; Pre-Exposure Prophylaxis; Sexual and Gender Minorities; Tenofovir; United States | 2021 |
Safety and efficacy of tenofovir alafenamide in liver transplant recipients: A single center experience.
Topics: Adenine; Alanine; HIV Infections; Humans; Liver Transplantation; Retrospective Studies; Tenofovir | 2021 |
Fully synthetic injectable depots with high drug content and tunable pharmacokinetics for long-acting drug delivery.
Topics: Animals; Anti-HIV Agents; Anti-Retroviral Agents; HIV Infections; Leukocytes, Mononuclear; Mice; Tenofovir | 2021 |
Oral PrEP in adolescents in sub-Saharan Africa.
Topics: Adolescent; Africa South of the Sahara; Emtricitabine; HIV Infections; Humans; Pre-Exposure Prophylaxis; Safety; Tenofovir | 2020 |
Optimization of the algorithm diagnosis chronic hepatitis B markers in patients with newly diagnosed HIV infection.
Topics: Algorithms; DNA, Viral; Genotype; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Mutation; Tenofovir | 2020 |
Prescribing rates and characteristics of recipients of tenofovir-containing regimens before and after market entry of tenofovir alafenamide.
Topics: Alanine; Anti-HIV Agents; Antiviral Agents; Comorbidity; Drug Approval; HIV Infections; Humans; Practice Patterns, Physicians'; Tenofovir; United States; United States Food and Drug Administration | 2020 |
Pharmacokinetics of tenofovir alafenamide with and without cobicistat in pregnant and postpartum women living with HIV.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Cobicistat; Emtricitabine; Female; HIV Infections; Humans; Postpartum Period; Pregnancy; Prospective Studies; Tenofovir | 2021 |
Tenofovir alafenamide revisited.
Topics: Alanine; Anti-HIV Agents; Anti-Retroviral Agents; Drug Substitution; HIV Infections; Humans; Tenofovir | 2020 |
Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide as Maintenance Treatment in HIV/HBV-Coinfected Patients.
Topics: Adult; Alanine; Anti-HIV Agents; Cobicistat; Cohort Studies; Drug Combinations; Drug Substitution; Emtricitabine; Female; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Male; Middle Aged; Prospective Studies; Quinolones; Taiwan; Tenofovir | 2021 |
Preoperative rapid suppression of viral load by elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide regimen in human immunodeficiency virus-positive fracture patients significantly reduces postoperative complications.
Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Drug Combinations; Emtricitabine; HIV; HIV Infections; Humans; Postoperative Complications; Quinolones; Tenofovir; Viral Load | 2020 |
Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Adults With HIV and M184V/I Mutation.
Topics: Adult; Aged; Alanine; Anti-HIV Agents; Cobicistat; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Mutation; Quinolones; Tenofovir; Young Adult | 2021 |
Comparison of Trends in Rates of Sexually Transmitted Infections Before vs After Initiation of HIV Preexposure Prophylaxis Among Men Who Have Sex With Men.
Topics: Adult; Anti-HIV Agents; Australia; Cohort Studies; Emtricitabine; Health Risk Behaviors; HIV Infections; Humans; Incidence; Male; Pre-Exposure Prophylaxis; Sexual and Gender Minorities; Sexual Behavior; Sexually Transmitted Diseases; Tenofovir | 2020 |
Universal health care needed to end HIV epidemic in the USA.
Topics: Anti-HIV Agents; Emtricitabine; Epidemics; Female; Health Services Needs and Demand; Healthcare Disparities; HIV Infections; Humans; Male; Tenofovir; United States; Universal Health Care | 2021 |
Short Communication: Evaluation of Antiretroviral Drug Concentrations in Minimally Invasive Specimens for Potential Development of Point-of-Care Drug Assays.
Topics: Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Male; Pharmaceutical Preparations; Point-of-Care Systems; Tenofovir | 2021 |
"I wish to remain HIV negative": Pre-exposure prophylaxis adherence and persistence in transgender women and men who have sex with men in coastal Kenya.
Topics: Adolescent; Adult; Anti-HIV Agents; Dried Blood Spot Testing; Health Risk Behaviors; HIV Infections; Homosexuality, Male; Humans; Interviews as Topic; Kenya; Male; Medication Adherence; Pre-Exposure Prophylaxis; Tenofovir; Transgender Persons; Young Adult | 2021 |
Differences in tenofovir trough concentrations between branded and generic formulations in people taking PrEP.
Topics: Drugs, Generic; Emtricitabine; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir | 2021 |
Acute HIV at the Time of Initiation of Pre-exposure or Post-exposure Prophylaxis: Impact on Drug Resistance and Clinical Outcomes.
Topics: Adult; Anti-HIV Agents; Drug Resistance, Viral; Emtricitabine; Female; HIV Infections; HIV-1; Homosexuality, Male; Humans; Male; Middle Aged; Point-of-Care Testing; Post-Exposure Prophylaxis; Pre-Exposure Prophylaxis; Retrospective Studies; San Francisco; Tenofovir; Treatment Outcome; Undiagnosed Diseases | 2021 |
Urine Tenofovir Levels Measured Using a Novel Immunoassay Predict Human Immunodeficiency Virus Protection.
Topics: Anti-HIV Agents; Emtricitabine; HIV; HIV Infections; Humans; Immunoassay; Medication Adherence; Pre-Exposure Prophylaxis; Tenofovir | 2021 |
HIV incidence after pre-exposure prophylaxis initiation among women and men at elevated HIV risk: A population-based study in rural Kenya and Uganda.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Female; HIV Infections; Homosexuality, Male; Humans; Incidence; Kenya; Male; Medication Adherence; Middle Aged; Pre-Exposure Prophylaxis; Risk; Sex Factors; Tenofovir; Uganda; Young Adult | 2021 |
Preference for daily versus on-demand pre-exposure prophylaxis for HIV and correlates among men who have sex with men: the China Real-world Oral PrEP Demonstration study.
Topics: Administration, Oral; Adult; Anti-HIV Agents; China; Emtricitabine; Female; HIV Infections; Homosexuality, Male; Humans; Infant, Newborn; Male; Patient Preference; Pre-Exposure Prophylaxis; Tenofovir | 2021 |
Failure of pre-exposure prophylaxis with on-demand tenofovir disoproxil fumarate/emtricitabine resulting in emergence of antiretroviral resistance.
Topics: Adult; Anti-HIV Agents; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Emtricitabine; HIV; HIV Infections; Humans; Male; Mutation; Pre-Exposure Prophylaxis; Tenofovir | 2021 |
In vitro Study on Synergistic Interactions Between Free and Encapsulated Q-Griffithsin and Antiretrovirals Against HIV-1 Infection.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Cell Death; Cell Line; Drug Compounding; Drug Liberation; Drug Synergism; Female; HIV Infections; HIV-1; Humans; Inhibitory Concentration 50; Lectins; Nanoparticles; Particle Size; Plant Lectins; Polylactic Acid-Polyglycolic Acid Copolymer; Pyrimidines; Raltegravir Potassium; Recombinant Proteins; Tenofovir | 2021 |
Genetic Associations with Weight Gain among South Africans who Initiated Dolutegravir-Containing and Tenofovir-Containing Regimens.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; Genome-Wide Association Study; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Male; Oxazines; Piperazines; Polymorphism, Genetic; Prodrugs; Pyridones; South Africa; Tenofovir; Weight Gain | 2021 |
Lactoferrin nanoparticles coencapsulated with curcumin and tenofovir improve vaginal defense against HIV-1 infection.
Topics: Animals; Curcumin; Female; HIV Infections; HIV-1; Lactoferrin; Nanoparticles; Rats; Tenofovir | 2021 |
Highlights of HIVR4P // Virtual.
Topics: Anti-HIV Agents; Emtricitabine; Female; HIV Infections; Humans; Male; Pre-Exposure Prophylaxis; Pyridones; Sexual Behavior; Tenofovir | 2021 |
Short Communication: A Descriptive Analysis of Dried Blood Spot Adherence Testing Among Ugandans with HIV Presenting with Cryptococcal Meningitis.
Topics: Anti-HIV Agents; Dried Blood Spot Testing; HIV Infections; Humans; Medication Adherence; Meningitis, Cryptococcal; Tenofovir; Uganda | 2021 |
Tenofovir-based PrEP for COVID-19: an untapped opportunity?
Topics: Anti-HIV Agents; COVID-19; Emtricitabine; HIV Infections; Humans; Medication Adherence; Pre-Exposure Prophylaxis; SARS-CoV-2; Tenofovir | 2021 |
Tenofovir, pregnancy and renal function changes in pregnant women living with HIV.
Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Pregnancy; Pregnant Women; Prospective Studies; Retrospective Studies; Tenofovir | 2021 |
Outcomes associated with treatment change from tenofovir disoproxil fumarate to tenofovir alafenamide in HIV-1-infected patients: a real-world study in Japan.
Topics: Adult; Alanine; Anti-HIV Agents; Fumarates; HIV Infections; HIV-1; Humans; Japan; Prospective Studies; Tenofovir | 2021 |
Summary for Patients: Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV.
Topics: Adult; Alanine; Anti-HIV Agents; HIV Infections; Humans; Lipids; Obesity; Tenofovir; Weight Gain | 2021 |
Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV : A Cohort Study.
Topics: Adult; Alanine; Anti-HIV Agents; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; HIV Infections; Humans; Lipids; Male; Middle Aged; Obesity; Sensitivity and Specificity; Tenofovir; Triglycerides; Weight Gain | 2021 |
Tenofovir and emtricitabine concentrations in hair are comparable between individuals on tenofovir disoproxil fumarate versus tenofovir alafenamide-based ART.
Topics: Adenine; Anti-HIV Agents; Chromatography, High Pressure Liquid; Cobicistat; Dose-Response Relationship, Drug; Emtricitabine; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Hair; Hair Analysis; HIV Infections; Humans; Ritonavir; Tandem Mass Spectrometry; Tenofovir; Tissue Distribution | 2021 |
A Prospective Study Evaluating Changes in Histology, Clinical and Virologic Outcomes in HBV-HIV Co-infected Adults in North America.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Liver; Male; Middle Aged; North America; Prospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Young Adult | 2021 |
A rare case of acute tubular necrosis tenofovir alafenamide-related.
Topics: Adenine; Alanine; HIV Infections; Humans; Necrosis; Tenofovir | 2021 |
Hypophosphatemia in people with HIV: no benefit when switching from tenofovir disoproxil fumarate to tenfovir alafenamide.
Topics: Anti-HIV Agents; Fumarates; HIV Infections; Humans; Hypophosphatemia; Retrospective Studies; Tenofovir | 2021 |
Weight gain before and after switch from TDF to TAF in a U.S. cohort study.
Topics: Adult; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Diabetes Mellitus, Type 2; Female; HIV Infections; Humans; Male; Middle Aged; Sustained Virologic Response; Tenofovir; Treatment Outcome; Weight Gain | 2021 |
Increase in Body Mass Index in Children With HIV, Switched to Tenofovir Alafenamide Fumarate or Dolutegravir Containing Antiretroviral Regimens.
Topics: Adolescent; Alanine; Anti-Retroviral Agents; Body Mass Index; Child; Cohort Studies; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Male; Oxazines; Piperazines; Pyridones; Retrospective Studies; Tenofovir; Weight Gain | 2021 |
Results from a Pre-exposure Prophylaxis Demonstration Project for At-risk Cisgender Women in the United States.
Topics: Adolescent; Adult; Anti-HIV Agents; Emtricitabine; Female; HIV Infections; Humans; Medication Adherence; Middle Aged; Pre-Exposure Prophylaxis; Tenofovir; United States | 2021 |
Changes in alanine aminotransferase levels after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) in HIV-positive people without viral hepatitis in the Swiss HIV Cohort Study.
Topics: Alanine; Alanine Transaminase; Anti-HIV Agents; Cohort Studies; Fumarates; Hepatitis, Viral, Human; HIV Infections; Humans; Male; Middle Aged; Switzerland; Tenofovir | 2021 |
Point-of-Care Test for Assessing Tenofovir Adherence: Feasibility and Recommendations from Women in an Oral PrEP Program in Kenya and Their Healthcare Providers.
Topics: Anti-HIV Agents; Feasibility Studies; Female; Health Personnel; HIV Infections; Humans; Kenya; Medication Adherence; Point-of-Care Testing; Pre-Exposure Prophylaxis; Tenofovir | 2021 |
Immunization by exposure to live virus (SIVmne/HIV-2287) during antiretroviral drug prophylaxis may reduce risk of subsequent viral challenge.
Topics: Animals; Anti-Retroviral Agents; Disease Models, Animal; Female; HIV Infections; HIV-2; Humans; Immunization; Macaca nemestrina; Pre-Exposure Prophylaxis; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Tenofovir | 2021 |
Influence of maternal use of tenofovir disoproxil fumarate or zidovudine in Vietnamese pregnant women with HIV on infant growth, renal function, and bone health.
Topics: beta 2-Microglobulin; Body Height; Endopeptidases; Female; HIV Infections; Humans; Infant; Male; Maternal Exposure; Multivariate Analysis; Pregnancy; Pregnant Women; Prospective Studies; Tenofovir; Vietnam; Zidovudine | 2021 |
Smart vaginal bilayer films of Tenofovir based on Eudragit® L100/natural polymer for the prevention of the sexual transmission of HIV.
Topics: Administration, Intravaginal; Female; HIV Infections; Humans; Polymers; Polymethacrylic Acids; Tenofovir | 2021 |
Electrospun fibers for vaginal administration of tenofovir disoproxil fumarate and emtricitabine in the context of topical pre-exposure prophylaxis.
Topics: Administration, Intravaginal; Animals; Anti-HIV Agents; Emtricitabine; Female; HIV Infections; Humans; Mice; Pre-Exposure Prophylaxis; Tenofovir | 2021 |
Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimen.
Topics: Adult; Anti-HIV Agents; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Prospective Studies; Pyridones; South Africa; Tenofovir; Viral Load | 2021 |
Brief Report: No Difference in Urine Tenofovir Levels in Patients Living With HIV on Unboosted Versus Dose-Adjusted Boosted Tenofovir Alafenamide.
Topics: Adenine; Alanine; Antiretroviral Therapy, Highly Active; Antiviral Agents; Chromatography, Liquid; Female; HIV Infections; Humans; Male; Medication Adherence; Middle Aged; Point-of-Care Systems; San Francisco; Tandem Mass Spectrometry; Tenofovir | 2021 |
Rapid initiation of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in acute and early HIV-1 infection: a DIAMOND subgroup analysis.
Topics: Adolescent; Adult; Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Humans; Tenofovir; Viral Load | 2021 |
A comparison of covariate selection techniques applied to pre-exposure prophylaxis (PrEP) drug concentration data in men and transgender women at risk for HIV.
Topics: Adenine; Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Male; Medication Adherence; Organophosphates; Pre-Exposure Prophylaxis; Tenofovir; Transgender Persons | 2021 |
Tenofovir-induced osteomalacia with hypophosphataemia.
Topics: Antiviral Agents; Fanconi Syndrome; Female; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Hypophosphatemia; Middle Aged; Osteomalacia; Tenofovir | 2021 |
[Effectiveness, safety, and economic impact of the bictegravir/emtricitabine/tenofovir alafenamide regimen in real clinical practice cohort of HIV-1 infected adult patients].
Topics: Adolescent; Adult; Alanine; Amides; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Piperazines; Pyridones; Retrospective Studies; Tenofovir | 2021 |
Changing trends in lipid profile and biomarkers of renal function and bone metabolism before and after switching from tenofovir disoproxil fumarate to tenofovir alafenamide: a prospective observational study.
Topics: Alanine; Anti-HIV Agents; Biomarkers; Fumarates; HIV Infections; Humans; Kidney; Lipids; Prospective Studies; Tenofovir | 2021 |
HIV pre-exposure prophylaxis for men who have sex with men in west Africa: a multicountry demonstration study.
Topics: Adult; Africa, Western; Anti-HIV Agents; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Male; Pilot Projects; Pre-Exposure Prophylaxis; Prospective Studies; Sexual Behavior; Tenofovir; Young Adult | 2021 |
Nationwide Study of Drug Resistance Mutations in HIV-1 Infected Individuals under Antiretroviral Therapy in Brazil.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Brazil; Drug Resistance, Viral; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Male; Middle Aged; Mutation; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure; Viral Load; Zidovudine | 2021 |
COVID-19 and HIV/AIDS in a cohort study in Sao Paulo, Brazil: outcomes and disparities by race and schooling.
Topics: Acquired Immunodeficiency Syndrome; Aged; Brazil; Cohort Studies; COVID-19; HIV Infections; Humans; Retrospective Studies; SARS-CoV-2; Tenofovir | 2022 |
Failure to seroconvert after two doses of BNT162b2 SARS-CoV-2 vaccine in a patient with uncontrolled HIV.
Topics: Adenine; Adult; Alanine; Amides; Antiretroviral Therapy, Highly Active; BNT162 Vaccine; CD4 Lymphocyte Count; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; COVID-19; COVID-19 Vaccines; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Neutralization Tests; Piperazines; Pyridones; RNA, Viral; SARS-CoV-2; Tenofovir; Treatment Failure | 2021 |
Efficacy and tolerability of combined antiretroviral treatment with bictegravir/emtricitabine/tenofovir alafenamide initiated at the time of primary HIV infection.
Topics: Alanine; Amides; Anti-HIV Agents; Anti-Retroviral Agents; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Piperazines; Pyridones; Tenofovir | 2021 |
Emtricitabine triphosphate in dried blood spots predicts future viremia in persons with HIV and identifies mismatch with self-reported adherence.
Topics: Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Medication Adherence; Polyphosphates; Prospective Studies; Self Report; Tenofovir; Viremia | 2021 |
Evaluation of kidney function tests in HIV-positive patients receiving combined antiretroviral therapy.
Topics: Adenine; Anti-HIV Agents; Emtricitabine; HIV Infections; HIV-1; Humans; Kidney Function Tests; Tenofovir | 2021 |
Effect of HIV infection on growth and bone density in peripubertal children in the era of antiretroviral therapy: a cross-sectional study in Zimbabwe.
Topics: Absorptiometry, Photon; Adolescent; Anti-Retroviral Agents; Bone Density; Child; Cross-Sectional Studies; Female; Fractures, Bone; HIV Infections; Humans; Male; Puberty; Tenofovir; Zimbabwe | 2021 |
Bictegravir/emtricitabine/tenofovir alafenamide combination in the management of kidney transplant patients with HIV receiving immunosuppressants.
Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Immunosuppressive Agents; Kidney Transplantation; Piperazines; Protease Inhibitors; Pyridones; Tacrolimus; Tenofovir | 2022 |
Growing data for recycling tenofovir and lamivudine with dolutegravir as empiric second-line antiretroviral therapy in resource-limited settings.
Topics: Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Tenofovir | 2021 |
A 28-Day Toxicity Study of Tenofovir Alafenamide Hemifumarate by Subcutaneous Infusion in Rats and Dogs.
Topics: Adenine; Alanine; Animals; Anti-HIV Agents; Dogs; Edema; HIV Infections; HIV-1; Infusions, Subcutaneous; Male; Organophosphates; Pre-Exposure Prophylaxis; Rats; Tenofovir | 2021 |
Derangement of Liver Enzymes, Hyperglycemia, Anemia, and Associated Factors among HIV-Infected Patients Treated with Tenofovir Disoproxil Fumarate-Based Regimen in Ethiopia: A Prospective Cohort Study.
Topics: Adult; Anemia; Anti-HIV Agents; Blood Glucose; Ethiopia; Female; HIV Infections; Humans; Hyperglycemia; Liver; Male; Middle Aged; Multivariate Analysis; Prospective Studies; Regression Analysis; Surveys and Questionnaires; Tenofovir; Zidovudine | 2021 |
Transmitted drug resistance to Tenofovir/Emtricitabine among persons with newly diagnosed HIV infection in Shenyang city, Northeast China from 2016 to 2018.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Child; Child, Preschool; China; Drug Resistance, Viral; Emtricitabine; Epidemics; Female; Genotype; HIV Infections; HIV-1; Humans; Male; Middle Aged; Phylogeny; Reverse Transcriptase Inhibitors; Tenofovir; Young Adult | 2021 |
Prognostic model for nephrotoxicity among HIV-positive Zambian adults receiving tenofovir disoproxil fumarate-based antiretroviral therapy.
Topics: Adult; Cohort Studies; Female; HIV Infections; Humans; Kidney; Prognosis; Tenofovir | 2021 |
The benefits of tenofovir discontinuation with or without bisphosphonate therapy in osteoporotic people living with HIV.
Topics: Anti-HIV Agents; Bone Density; Diphosphonates; HIV Infections; Humans; Male; Middle Aged; Retrospective Studies; Tenofovir | 2021 |
Hepatitis B reactivation after tenofovir withdrawal in an HIV-infected patient with history of cured hepatitis B virus infection and poor immunological status.
Topics: Antiviral Agents; Hepatitis B; Hepatitis B Antibodies; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Tenofovir | 2021 |
Brief Report: Pharmacokinetics of Bictegravir and Tenofovir in Combination With Darunavir/Cobicistat in Treatment-Experienced Persons With HIV.
Topics: Aged; Amides; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Chromatography, Liquid; Cobicistat; Darunavir; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Male; Middle Aged; Piperazines; Prospective Studies; Pyridones; Tandem Mass Spectrometry; Tenofovir | 2021 |
Mathematical Modelling of the Molecular Mechanisms of Interaction of Tenofovir with Emtricitabine against HIV.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Models, Theoretical; Pre-Exposure Prophylaxis; Reverse Transcription; Tenofovir | 2021 |
A cross-species comparison of antiretroviral penetration into lymph nodes using novel physiologically based pharmacokinetic models.
Topics: Animals; Anti-Retroviral Agents; Emtricitabine; HIV Infections; Lymph Nodes; Models, Biological; Tenofovir | 2021 |
Why Are Patients Switching from Tenofovir Disoproxil Fumarate/Emtricitabine (Truvada) to Tenofovir Alafenamide/Emtricitabine (Descovy) for Pre-Exposure Prophylaxis?
Topics: Adenine; Alanine; Anti-HIV Agents; Cohort Studies; Emtricitabine; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; Humans; Male; Pre-Exposure Prophylaxis; Tenofovir | 2021 |
Impact of dosing strategies on plasma concentrations of tenofovir: Implications in HIV pre-exposure prophylaxis in China.
Topics: Anti-HIV Agents; China; Emtricitabine; HIV Infections; Humans; Male; Pre-Exposure Prophylaxis; Tenofovir | 2021 |
Changes in lipidomic profile by anti-retroviral treatment regimen: An ACTG 5257 ancillary study.
Topics: Adult; Anti-Retroviral Agents; Atazanavir Sulfate; Chi-Square Distribution; Darunavir; Female; HIV Infections; Humans; Lipidomics; Lipids; Male; Mass Spectrometry; Middle Aged; Plasma; Raltegravir Potassium; Tenofovir | 2021 |
Para-aminosalicylic acid significantly reduced tenofovir exposure in human subjects: Mismatched findings from in vitro to in vivo translational research.
Topics: Aminosalicylic Acid; Drug Interactions; HIV Infections; Humans; Male; Research Subjects; Tenofovir; Translational Research, Biomedical | 2022 |
Comparison of weight gain after antiretroviral switch to integrase strand transfer inhibitor or tenofovir alafenamide-based therapy.
Topics: Alanine; Anti-HIV Agents; Drug Substitution; HIV Infections; Humans; Integrase Inhibitors; Retrospective Studies; Tenofovir; Weight Gain | 2022 |
Impact of switching to tenofovir alafenamide on weight gain as compared to maintaining a non-tenofovir alafenamide containing regimen.
Topics: Alanine; Anti-HIV Agents; Body Mass Index; Case-Control Studies; Comorbidity; Female; HIV Infections; Humans; Male; Middle Aged; Retrospective Studies; Tenofovir; Weight Gain | 2021 |
Pharmacokinetics of bictegravir, emtricitabine and tenofovir alafenamide in a gastrectomized patient with HIV.
Topics: Alanine; Amides; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Piperazines; Pyridones; Tenofovir | 2021 |
Predominance of Hepatitis B Virus Genotype A Among Treated HIV Infected Patients Experiencing High Hepatitis B Virus Drug Resistance in Nairobi, Kenya.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Child, Preschool; Cross-Sectional Studies; DNA, Viral; Drug Resistance, Viral; Emtricitabine; Female; Genes, pol; Genotype; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Kenya; Lamivudine; Male; Middle Aged; Tenofovir; Viral Load; Young Adult | 2017 |
Tenofovir disoproxil fumarate-associated renal tubular dysfunction: noninvasive assessment of mitochondrial injury.
Topics: Adult; Aged; Anti-HIV Agents; Cross-Sectional Studies; DNA, Mitochondrial; Female; HIV Infections; Humans; Kidney Diseases; Kidney Tubules; Male; Middle Aged; Mitochondria; Mutation; Polymerase Chain Reaction; Tenofovir | 2017 |
Antiretrovirals, Fractures, and Osteonecrosis in a Large International HIV Cohort.
Topics: Adult; Anti-HIV Agents; Bone Density; CD4 Lymphocyte Count; Cohort Studies; Coinfection; Data Collection; Europe; Female; Femoral Fractures; Fractures, Bone; HIV Infections; Humans; Male; Middle Aged; Osteonecrosis; Regression Analysis; Risk Factors; Tenofovir | 2017 |
Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection-authors' response.
Topics: Adenine; Anti-HIV Agents; Cobicistat; Deoxycytidine; Emtricitabine; HIV Infections; Humans; Organophosphonates; Quinolones; Tenofovir | 2017 |
Metabolic syndrome in patients on first-line antiretroviral therapy containing zidovudine or tenofovir in rural Lesotho, Southern Africa.
Topics: Adult; Anti-HIV Agents; Cross-Sectional Studies; Female; HIV Infections; Humans; Lesotho; Logistic Models; Male; Metabolic Syndrome; Middle Aged; Prevalence; Reverse Transcriptase Inhibitors; Rural Population; Sex Factors; Tenofovir; Zidovudine | 2017 |
Evolution of tenofovir-resistant HIV-1 isolates exposed to tenofovir alafenamide dose escalation.
Topics: Adenine; Alanine; Anti-HIV Agents; Cell Line; Dose-Response Relationship, Drug; Drug Resistance, Viral; Evolution, Molecular; Genotype; HEK293 Cells; HIV Infections; HIV-1; Humans; Microbial Sensitivity Tests; Mutagenesis, Site-Directed; Mutation; Phenotype; Prodrugs; Recombination, Genetic; Tenofovir | 2017 |
Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration.
Topics: Drug Resistance, Viral; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Prevalence; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure; Viral Load; World Health Organization | 2017 |
Tenofovir Inhibits Wound Healing of Epithelial Cells and Fibroblasts from the Upper and Lower Human Female Reproductive Tract.
Topics: Anti-HIV Agents; Cells, Cultured; Cervix Uteri; Endometrium; Epithelial Cells; Female; Fibroblasts; Genitalia, Female; HIV Infections; HIV-1; Humans; Tenofovir; Vagina; Wound Healing | 2017 |
An association between K65R and HIV-1 subtype C viruses in patients treated with multiple NRTIs.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Didanosine; Dideoxynucleosides; Drug Resistance, Viral; Female; Genetic Association Studies; Genotype; HIV Infections; HIV-1; Humans; Male; Multivariate Analysis; Mutation; Reverse Transcriptase Inhibitors; Sequence Analysis, DNA; Stavudine; Tenofovir | 2017 |
US Black Women and Human Immunodeficiency Virus Prevention: Time for New Approaches to Clinical Trials.
Topics: Adult; Anti-HIV Agents; Black or African American; Clinical Trials, Phase III as Topic; Emtricitabine; Female; HIV Infections; Humans; Incidence; Medication Adherence; Pre-Exposure Prophylaxis; Racism; Research Design; Sample Size; Tenofovir; United States | 2017 |
An intravaginal ring for real-time evaluation of adherence to therapy.
Topics: Animals; Anti-HIV Agents; Drug Administration Routes; Female; HIV Infections; Humans; Patient Compliance; Pre-Exposure Prophylaxis; Reverse Transcriptase Inhibitors; Sheep; Software; Tenofovir; Vagina | 2017 |
The effect of veno-venous ECMO on the pharmacokinetics of Ritonavir, Darunavir, Tenofovir and Lamivudine.
Topics: Bayes Theorem; Darunavir; Dose-Response Relationship, Drug; Extracorporeal Membrane Oxygenation; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Middle Aged; Ritonavir; Tenofovir | 2017 |
Short Communication: Resolution of Tenofovir Disoproxil Fumarate Induced Fanconi Syndrome with Switch to Tenofovir Alafenamide Fumarate in a HIV-1 and Hepatitis B Coinfected Patient.
Topics: Adenine; Alanine; Anti-HIV Agents; Coinfection; Fanconi Syndrome; Hepatitis B, Chronic; HIV Infections; Humans; Male; Middle Aged; Tenofovir; Treatment Outcome | 2017 |
Severe hypokalemia due to a possible drug-drug interaction between vinblastine and antiretrovirals in a HIV-infected patient with Hodgkin's lymphoma.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Doxorubicin; Drug Interactions; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; Hodgkin Disease; Humans; Hypokalemia; Middle Aged; Ritonavir; Tenofovir; Treatment Outcome; Vinblastine | 2017 |
Tenofovir alafenamide for hepatitis B: evolution or revolution?
Topics: Anti-HIV Agents; Antiviral Agents; Hepatitis B; Hepatitis B, Chronic; HIV Infections; Humans; Tenofovir | 2016 |
Changes in estimated glomerular filtration rate over time in South African HIV-1-infected patients receiving tenofovir: a retrospective cohort study.
Topics: Adult; Anti-HIV Agents; Black People; CD4 Lymphocyte Count; Cohort Studies; Female; Glomerular Filtration Rate; HIV Infections; HIV-1; Humans; Incidence; Kidney Diseases; Male; Retrospective Studies; Risk Factors; South Africa; Tenofovir | 2017 |
High pre-exposure prophylaxis uptake and early adherence among men who have sex with men and transgender women at risk for HIV Infection: the PrEP Brasil demonstration project.
Topics: Adolescent; Adult; Anti-HIV Agents; Brazil; Emtricitabine; Female; HIV Infections; Homosexuality, Male; Humans; Longitudinal Studies; Male; Medication Adherence; Pre-Exposure Prophylaxis; Prospective Studies; Sexual Behavior; Tenofovir; Transgender Persons; Young Adult | 2017 |
Impact of Antiretroviral Treatment Containing Tenofovir Difumarate on the Telomere Length of Aviremic HIV-Infected Patients.
Topics: Aging; Anti-HIV Agents; Cross-Sectional Studies; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Spain; Telomerase; Telomere; Tenofovir; Treatment Outcome; Viral Load | 2017 |
Bone Density, Microarchitecture, and Tissue Quality After Long-Term Treatment With Tenofovir/Emtricitabine or Abacavir/Lamivudine.
Topics: Absorptiometry, Photon; Anti-HIV Agents; Bone Density; Bone Remodeling; Cross-Sectional Studies; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Spain; Tenofovir | 2017 |
Plasma and saliva concentrations of abacavir, tenofovir, darunavir, and raltegravir in HIV-1-infected patients
.
Topics: Adult; Aged; Anti-HIV Agents; Chromatography, Liquid; Darunavir; Dideoxynucleosides; Drug Monitoring; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Protein Binding; Raltegravir Potassium; Saliva; Tandem Mass Spectrometry; Tenofovir | 2017 |
Factors associated with loss to follow-up after occupational HIV exposure in Cape Town, South Africa: a retrospective cohort study.
Topics: Adult; Anti-HIV Agents; Emtricitabine; Female; Health Personnel; HIV Infections; Humans; Infectious Disease Transmission, Patient-to-Professional; Lamivudine; Lost to Follow-Up; Male; Occupational Exposure; Post-Exposure Prophylaxis; Retrospective Studies; South Africa; Stavudine; Tenofovir; Young Adult; Zidovudine | 2017 |
Association of Tenofovir Use With Risk of Incident Heart Failure in HIV-Infected Patients.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Databases, Factual; Female; Heart Failure; HIV Infections; Humans; Incidence; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Renal Insufficiency, Chronic; Retrospective Studies; Risk Factors; Tenofovir; United States; United States Department of Veterans Affairs | 2017 |
Urine assay for tenofovir to monitor adherence in real time to tenofovir disoproxil fumarate/emtricitabine as pre-exposure prophylaxis.
Topics: Adult; Antiviral Agents; Chromatography, Liquid; Drug Administration Schedule; Emtricitabine; Female; HIV Infections; Humans; Male; Medication Adherence; Middle Aged; Pilot Projects; Pre-Exposure Prophylaxis; Tandem Mass Spectrometry; Tenofovir; Young Adult | 2017 |
Absence of Decline of Kidney Function in Human Immunodeficiency Virus-Infected Patients Under Routine Clinical Management.
Topics: Adult; Anti-HIV Agents; Female; Glomerular Filtration Rate; HIV Infections; HIV-1; Humans; Kidney; Kidney Function Tests; Male; Middle Aged; Prospective Studies; Reverse Transcriptase Inhibitors; Tenofovir | 2017 |
Commonly Transmitted HIV-1 Drug Resistance Mutations in Reverse-Transcriptase and Protease in Antiretroviral Treatment-Naive Patients and Response to Regimens Containing Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Drug Resistance, Viral; Emtricitabine; Europe; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation, Missense; Reverse Transcriptase Inhibitors; Tenofovir; Thymidine; United States | 2017 |
Evaluating the association of single-nucleotide polymorphisms with tenofovir exposure in a diverse prospective cohort of women living with HIV.
Topics: Adult; Anti-HIV Agents; Area Under Curve; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cohort Studies; Cross-Sectional Studies; Female; HIV Infections; Humans; Middle Aged; Neoplasm Proteins; Polymorphism, Single Nucleotide; Prospective Studies; Tenofovir; Young Adult | 2018 |
Renal and bone effects of tenofovir-containing regimens compared in a large, real-world patient population.
Topics: Anti-HIV Agents; Bone and Bones; Databases, Factual; HIV Infections; Humans; Kidney; Tenofovir | 2017 |
HIV prevention: response to pre-exposure prophylaxis failure with tenofovir disoproxil.
Topics: Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir | 2017 |
Preexposure prophylaxis failure with tenofovir disoproxil.
Topics: Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir | 2017 |
Incident AIDS or Death After Initiation of Human Immunodeficiency Virus Treatment Regimens Including Raltegravir or Efavirenz Among Adults in the United States.
Topics: Acquired Immunodeficiency Syndrome; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; Female; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Male; Middle Aged; Raltegravir Potassium; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; United States; Viral Load; Young Adult | 2017 |
Design and in vitro evaluation of tenofovir-loaded vaginal gels for the prevention of HIV infections.
Topics: Animals; Anti-HIV Agents; Biocompatible Materials; Cell Line; Cell Survival; Chemistry, Pharmaceutical; Chitosan; Delayed-Action Preparations; Female; Gels; HIV Infections; Humans; Mice; Nanoparticles; Tenofovir; Vagina; Vaginal Creams, Foams, and Jellies | 2018 |
Stability behavior of antiretroviral drugs and their combinations. 7: Comparative degradation pathways of lamivudine and emtricitabine and explanation to their differential degradation behavior by density functional theory.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; HIV Infections; Lamivudine; Tenofovir | 2017 |
Association of tenofovir disoproxil fumarate with primary allograft survival in HIV-positive kidney transplant recipients.
Topics: Adult; Allografts; Cohort Studies; Female; Graft Survival; HIV Infections; HIV Seropositivity; Humans; Kidney Transplantation; Male; Middle Aged; Retrospective Studies; Tenofovir | 2017 |
Brief Report: Late Efavirenz-Induced Ataxia and Encephalopathy: A Case Series.
Topics: Adult; Alkynes; Anti-HIV Agents; Ataxia; Benzoxazines; Brain Diseases; CD4 Lymphocyte Count; Cyclopropanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; South Africa; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2017 |
Effect of Antiretroviral Therapy on Bone and Renal Health in Young Adults Infected With HIV in Early Life.
Topics: Absorptiometry, Photon; Acid-Base Equilibrium; Adult; Age of Onset; Albuminuria; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone Density; Bone Diseases, Metabolic; Bone Remodeling; Case-Control Studies; Creatinine; Cross-Sectional Studies; Didanosine; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Function Tests; Longitudinal Studies; Male; Osteocalcin; Prospective Studies; Proteinuria; Renal Insufficiency; Risk Factors; Stavudine; Tenofovir; Time Factors; Young Adult | 2017 |
Change in Renal Function among HIV-Infected Koreans Receiving Tenofovir Disoproxil Fumarate-Backbone Antiretroviral Therapy: A 3-Year Follow-Up Study.
Topics: Adult; Anti-HIV Agents; Diet; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Kidney; Kidney Function Tests; Kidney Tubules; Male; Tenofovir | 2017 |
Decreased Absorption of Dolutegravir and Tenofovir Disoproxil Fumarate, But Not Emtricitabine, in an HIV-Infected Patient Following Oral and Jejunostomy-Tube Administration.
Topics: Administration, Oral; Anti-HIV Agents; Drug Therapy, Combination; Emtricitabine; Enteral Nutrition; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Jejunostomy; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Tenofovir | 2017 |
A Mathematical Model to Predict HIV Virological Failure and Elucidate the Role of Lymph Node Drug Penetration.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Lymph Nodes; Medication Adherence; Models, Biological; Mutation; Ritonavir; Tenofovir; Viral Load | 2017 |
Vaginal bacteria modify HIV tenofovir microbicide efficacy in African women.
Topics: Adult; Antiviral Agents; Bacteria; Biodiversity; Female; Gardnerella; HIV Infections; Humans; Lactobacillus; Mass Spectrometry; Microbiota; Proteome; RNA, Ribosomal, 16S; South Africa; Tenofovir; Vagina | 2017 |
Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Clinical Decision-Making; Computational Biology; Cross-Sectional Studies; Cyclopropanes; Drug Resistance, Viral; Emtricitabine; Female; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Male; Monitoring, Physiologic; Nevirapine; pol Gene Products, Human Immunodeficiency Virus; Stavudine; Tanzania; Tenofovir; Treatment Failure; Viral Load | 2017 |
High decay of blood HIV reservoir when tenofovir/emtricitabine/elvitegravir/cobicistat is initiated during the acute primary HIV infection.
Topics: Adult; Anti-HIV Agents; Blood; Cobicistat; Emtricitabine; HIV Infections; HIV-1; Humans; Male; Middle Aged; Quinolones; Secondary Prevention; Tenofovir; Treatment Outcome; Viral Load | 2017 |
Clinical and genetic factors associated with kidney tubular dysfunction in a real-life single centre cohort of HIV-positive patients.
Topics: Adult; Alleles; Anti-HIV Agents; Cohort Studies; Female; HIV Infections; Humans; Kidney Diseases; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Polymorphism, Single Nucleotide; Proteinuria; Tenofovir | 2017 |
Antiretroviral therapy in geriatric HIV patients: the GEPPO cohort study.
Topics: Aged; Aged, 80 and over; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Cross-Sectional Studies; Female; Health Services for the Aged; HIV Infections; HIV-1; Humans; Italy; Logistic Models; Male; Middle Aged; Multiple Chronic Conditions; Polypharmacy; Practice Patterns, Physicians'; Prospective Studies; Tenofovir; Viral Load | 2017 |
Patience for patients.
Topics: Altruism; Drug Approval; Drug Discovery; Drug Industry; Female; HIV Infections; Hope; Humans; Malaria; Malaria Vaccines; Male; Motivation; Ovarian Neoplasms; Patient Satisfaction; Phthalazines; Piperazines; Research Personnel; Rotavirus Vaccines; Tenofovir; Time Factors; Vaccines, Attenuated; Women's Health | 2017 |
Hepatitis B testing and treatment in HIV patients in The Gambia-Compliance with international guidelines and clinical outcomes.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Coinfection; Cross-Sectional Studies; Female; Gambia; Hepatitis B; HIV Infections; Humans; Lamivudine; Male; Mass Screening; Middle Aged; Practice Guidelines as Topic; Tenofovir; Treatment Outcome; Young Adult | 2017 |
Safety and tolerability of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) project.
Topics: Adult; Anti-HIV Agents; Cobicistat; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Maximum Tolerated Dose; Middle Aged; Quinolones; Safety; Tenofovir | 2017 |
Multi-state models for the analysis of time-to-treatment modification among HIV patients under highly active antiretroviral therapy in Southwest Ethiopia.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Ethiopia; Female; HIV Infections; Humans; Lamivudine; Male; Models, Theoretical; Nevirapine; Pregnancy; Retrospective Studies; Stavudine; Tenofovir; Time-to-Treatment; Treatment Failure; Zidovudine | 2017 |
InterPrEP: internet-based pre-exposure prophylaxis with generic tenofovir disoproxil fumarate/emtrictabine in London - analysis of pharmacokinetics, safety and outcomes.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Chemoprevention; Chromatography, Liquid; Disease Transmission, Infectious; Emtricitabine; Female; HIV Infections; Humans; London; Male; Middle Aged; Plasma; Pre-Exposure Prophylaxis; Tenofovir; Treatment Outcome; Young Adult | 2018 |
Urine tenofovir and emtricitabine concentrations provide biomarker for exposure to HIV preexposure prophylaxis.
Topics: Antiviral Agents; Biomarkers; Cross-Sectional Studies; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Male; Pre-Exposure Prophylaxis; Tenofovir; Urinalysis | 2017 |
[Update in HIV therapy: tenofovir alafenamide].
Topics: Adenine; Alanine; Anti-HIV Agents; HIV Infections; Humans; Prodrugs; Tenofovir | 2016 |
Improvement in renal function and resolution of proteinuria in an HIV-infected patient switched from tenofovir disoproxil fumarate to tenofovir alafenamide.
Topics: Adenine; Alanine; Antiviral Agents; Drug Substitution; Female; HIV Infections; Humans; Kidney Diseases; Middle Aged; Proteinuria; Tenofovir | 2017 |
Physician testing for HIV in patients treated with tenofovir disoproxil fumarate and lamivudine monotherapy for hepatitis B virus.
Topics: AIDS Serodiagnosis; Attitude to Health; Cross-Sectional Studies; Hepatitis B; HIV Infections; Humans; Physician-Patient Relations; Practice Patterns, Physicians'; Reverse Transcriptase Inhibitors; Tenofovir | 2018 |
Prevalence of Persistent Renal Dysfunction in Perinatally HIV-infected Thai Adolescents.
Topics: Adolescent; Anti-HIV Agents; Child; Creatinine; Female; Glomerular Filtration Rate; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Male; Prevalence; Proteinuria; Renal Insufficiency, Chronic; Retrospective Studies; Risk Factors; Tenofovir; Thailand | 2018 |
Switching to a rilpivirine/emtricitabine/tenofovir single-tablet regimen in RNA-suppressed patients infected with human immunodeficiency virus 1: Effectiveness, safety and costs at 96 weeks.
Topics: Adult; Anti-HIV Agents; Cholesterol, HDL; Drug Combinations; Drug Substitution; Emtricitabine; Female; Glomerular Filtration Rate; HIV Infections; HIV-1; Humans; Male; Middle Aged; Prospective Studies; Rilpivirine; RNA, Viral; Sustained Virologic Response; Tablets; Tenofovir; Triglycerides; Viral Load | 2017 |
Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study.
Topics: Adolescent; Adult; Anti-HIV Agents; Canada; Cohort Studies; Condoms; Emtricitabine; Follow-Up Studies; France; HIV Infections; HIV-1; Homosexuality, Male; Humans; Male; Medication Adherence; Middle Aged; Pre-Exposure Prophylaxis; Randomized Controlled Trials as Topic; Sexual Behavior; Tenofovir; Young Adult | 2017 |
Predictive factors and prevalence of microalbuminuria in HIV-infected patients: a cross-sectional analysis.
Topics: Adult; Albuminuria; Cross-Sectional Studies; Female; HIV Infections; Humans; Male; Middle Aged; Predictive Value of Tests; Prevalence; Prospective Studies; Reverse Transcriptase Inhibitors; Risk Factors; Tenofovir | 2017 |
Incidence of renal Fanconi syndrome in patients taking antiretroviral therapy including tenofovir disoproxil fumarate.
Topics: Adult; Anti-HIV Agents; Australia; Creatinine; Fanconi Syndrome; HIV Infections; Humans; Incidence; Kidney Diseases; Kidney Function Tests; Male; Middle Aged; Proteinuria; Renal Insufficiency, Chronic; Tenofovir | 2018 |
Misleading
Topics: Adenocarcinoma; Alkynes; Anti-Retroviral Agents; Benzoxazines; Cyclopropanes; Emtricitabine; Fluorodeoxyglucose F18; Gastrectomy; HIV Infections; Humans; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Stomach Neoplasms; Tenofovir; Treatment Outcome | 2018 |
Feasibility, Acceptability, and Adherence with Short-Term HIV Preexposure Prophylaxis in Female Sexual Partners of Migrant Miners in Mozambique.
Topics: Adult; Anti-HIV Agents; Condoms; Directive Counseling; Educational Status; Emtricitabine; Feasibility Studies; Female; Health Knowledge, Attitudes, Practice; HIV Infections; Humans; Medication Adherence; Middle Aged; Mining; Mozambique; Patient Acceptance of Health Care; Pre-Exposure Prophylaxis; Sexual Partners; Tenofovir; Transients and Migrants; Workforce | 2017 |
Brief Report: Selection of HIV-1 Variants With Higher Transmission Potential by 1% Tenofovir Gel Microbicide.
Topics: Anti-HIV Agents; Anti-Infective Agents; Clinical Trials as Topic; Female; gag Gene Products, Human Immunodeficiency Virus; HIV Infections; HIV-1; Humans; Phylogeny; Pre-Exposure Prophylaxis; Sequence Analysis, DNA; South Africa; Tenofovir; Treatment Outcome; Vaginal Creams, Foams, and Jellies; Viral Load | 2017 |
Layer-by-Layer Engineered Microbicide Drug Delivery System Targeting HIV-1 gp120: Physicochemical and Biological Properties.
Topics: Administration, Intravaginal; Animals; Anti-HIV Agents; Anti-Infective Agents, Local; Biological Assay; Calcium Carbonate; Chemical Engineering; Chemistry, Pharmaceutical; Concanavalin A; Cross-Linking Reagents; Drug Delivery Systems; Drug Liberation; Female; Glycogen; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Keratinocytes; Lactobacillus crispatus; Methylmannosides; Mice; Nanoparticles; RAW 264.7 Cells; Swine; Tenofovir; Vagina | 2017 |
Hair levels of preexposure prophylaxis drugs measure adherence and are associated with renal decline among men/transwomen.
Topics: Adult; Aged; Anti-HIV Agents; Blood Chemical Analysis; Drug Utilization; Female; Hair; HIV Infections; Humans; Male; Medication Adherence; Middle Aged; Pre-Exposure Prophylaxis; Tenofovir; Transgender Persons; United States; Young Adult | 2017 |
Factors influencing uptake of pre-exposure prophylaxis: some qualitative insights from an intervention study of men who have sex with men in China.
Topics: Adult; Anti-HIV Agents; China; HIV Infections; Homosexuality, Male; Humans; Male; Patient Acceptance of Health Care; Patient Compliance; Pre-Exposure Prophylaxis; Sexual Partners; Tenofovir; Young Adult | 2018 |
Accumulation of HIV-1 drug resistance in patients on a standard thymidine analogue-based first line antiretroviral therapy after virological failure: implications for the activity of next-line regimens from a longitudinal study in Mozambique.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Longitudinal Studies; Male; Mozambique; Mutation; Nevirapine; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure; Viral Load; Zidovudine | 2017 |
Prevention of vaginal and rectal HIV transmission by antiretroviral combinations in humanized mice.
Topics: Animals; Anti-HIV Agents; Emtricitabine; Female; HIV Infections; Humans; Mice; Pre-Exposure Prophylaxis; Rectum; Tenofovir; Vagina | 2017 |
Simultaneous determination of tenofovir alafenamide and its active metabolites tenofovir and tenofovir diphosphate in HBV-infected hepatocyte with a sensitive LC-MS/MS method.
Topics: Adenine; Alanine; Anti-HIV Agents; Cell Line, Tumor; Chromatography, Liquid; DNA Replication; Half-Life; Hep G2 Cells; Hepatocytes; HIV Infections; HIV-1; Humans; Organophosphates; Prodrugs; Tandem Mass Spectrometry; Tenofovir; Virus Replication | 2017 |
Tenofovir alafenamide nephrotoxicity in an HIV-positive patient: A case report.
Topics: Adenine; Alanine; Anti-HIV Agents; HIV Infections; Humans; Kidney Diseases; Male; Middle Aged; Mitochondria; Prodrugs; Tenofovir | 2017 |
Plasma Tenofovir Levels to Support Adherence to TDF/FTC Preexposure Prophylaxis for HIV Prevention in MSM in Los Angeles, California.
Topics: Adolescent; Adult; Biomarkers; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; HIV Infections; Humans; Los Angeles; Male; Patient Compliance; Pre-Exposure Prophylaxis; Tenofovir; Transgender Persons; Young Adult | 2017 |
Acquisition of wild-type HIV-1 infection in a patient on pre-exposure prophylaxis with high intracellular concentrations of tenofovir diphosphate: a case report.
Topics: Adenine; Anti-HIV Agents; Emtricitabine; HIV Infections; HIV Seropositivity; HIV-1; Homosexuality, Male; Humans; Lymphogranuloma Venereum; Male; Medication Adherence; Middle Aged; Organophosphates; Pre-Exposure Prophylaxis; RNA, Viral; Tenofovir; Transgender Persons; Urinary Tract Infections | 2017 |
Higher Prevalence and Faster Progression of Chronic Kidney Disease in Human Immunodeficiency Virus-Infected Middle-Aged Individuals Compared With Human Immunodeficiency Virus-Uninfected Controls.
Topics: Albuminuria; Anti-HIV Agents; Case-Control Studies; Disease Progression; Female; Follow-Up Studies; Glomerular Filtration Rate; HIV Infections; Humans; Logistic Models; Longitudinal Studies; Male; Middle Aged; Multivariate Analysis; Phosphates; Prevalence; Prospective Studies; Renal Insufficiency, Chronic; Risk Factors; Tenofovir | 2017 |
Effect of Cobicistat on Tenofovir Disoproxil Fumarate (TDF): What Is True for TAF May Also Be True for TDF.
Topics: Adenine; Adult; Aged; Alanine; Anti-HIV Agents; Cobicistat; Drug Combinations; Drug Interactions; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Oxazines; Piperazines; Proportional Hazards Models; Pyridones; Quinolones; Raltegravir Potassium; Ritonavir; Tenofovir; Treatment Outcome | 2018 |
Atazanavir intracellular concentrations remain stable during pregnancy in HIV-infected patients.
Topics: Adult; Atazanavir Sulfate; CD4 Lymphocyte Count; Chromatography, High Pressure Liquid; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant, Newborn; Leukocytes, Mononuclear; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Trimesters; Prospective Studies; Ritonavir; RNA, Viral; Tenofovir; Viral Load | 2017 |
Five-year trends in treatment changes in an adult cohort of HIV/AIDS patients in Ghana: a retrospective cohort study.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Female; Ghana; HIV Infections; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Retrospective Studies; Stavudine; Tenofovir; Young Adult; Zidovudine | 2017 |
Successful treatment with tenofovir alafenamide of a HIV/hepatitis B virus coinfected patient with HIV and hepatitis B virus drug resistance, end-stage renal disease on haemodialysis.
Topics: Adenine; Adult; Alanine; Antiviral Agents; Coinfection; Drug Resistance, Viral; Female; Hepatitis B, Chronic; HIV Infections; Humans; Kidney Failure, Chronic; Renal Dialysis; Tenofovir; Treatment Outcome | 2017 |
Changes in Kidney Function Associated With Daily Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Preexposure Prophylaxis Use in the United States Demonstration Project.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Creatinine; Disease Transmission, Infectious; Emtricitabine; Female; Glomerular Filtration Rate; HIV Infections; Homosexuality, Male; Humans; Kidney Function Tests; Male; Metabolic Clearance Rate; Middle Aged; Pre-Exposure Prophylaxis; Prospective Studies; Proteins; Renal Insufficiency; Tenofovir; Transgender Persons; United States; Urinalysis; Young Adult | 2018 |
Comparison of Measures of Adherence to Human Immunodeficiency Virus Preexposure Prophylaxis Among Adolescent and Young Men Who Have Sex With Men in the United States.
Topics: Adolescent; Anti-HIV Agents; Blood Chemical Analysis; Disease Transmission, Infectious; Emtricitabine; Hair; HIV Infections; Homosexuality, Male; Humans; Male; Medication Adherence; Pre-Exposure Prophylaxis; Tenofovir; United States; Young Adult | 2018 |
Incidence and risk factors for tenofovir-associated nephrotoxicity among human immunodeficiency virus-infected patients in Korea.
Topics: Adult; Anti-Retroviral Agents; Female; HIV Infections; Humans; Incidence; Male; Middle Aged; Renal Insufficiency; Republic of Korea; Retrospective Studies; Risk Factors; Tenofovir | 2019 |
Ledipasvir and tenofovir drug interaction in human immunodeficiency virus-hepatitis C virus coinfected patients: Impact on tenofovir trough concentrations and renal safety.
Topics: Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzimidazoles; Drug Interactions; Drug Therapy, Combination; Female; Fluorenes; Glomerular Filtration Rate; Hepatitis C; HIV Infections; Humans; Male; Middle Aged; Retrospective Studies; Tenofovir | 2018 |
Cumulative exposure of TDF is associated with kidney tubulopathy whether it is currently used or discontinued.
Topics: Adult; Cross-Sectional Studies; Female; HIV Infections; Humans; Kidney Diseases; Kidney Function Tests; Kidney Tubules; Male; Middle Aged; Prospective Studies; Tenofovir | 2018 |
The Female Genital Tract Microbiome Is Associated With Vaginal Antiretroviral Drug Concentrations in Human Immunodeficiency Virus-Infected Women on Antiretroviral Therapy.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Cohort Studies; Deoxycytidine; Emtricitabine; Female; Fumarates; Genitalia, Female; HIV Infections; Humans; Microbiota; Middle Aged; Organophosphonates; Prospective Studies; Tenofovir; Young Adult | 2017 |
Role of tenofovir alafenamide in the jungle of antiretroviral prescription.
Topics: Adenine; Aged; Aged, 80 and over; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; HIV Infections; Humans; Tenofovir | 2018 |
Maternal Tenofovir Disoproxil Fumarate Use During Pregnancy Is Not Associated With Adverse Perinatal Outcomes Among HIV-infected East African Women: A Prospective Study.
Topics: Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Kenya; Longitudinal Studies; Pregnancy; Pregnancy Complications; Prevalence; Prospective Studies; Tenofovir; Treatment Outcome; Uganda; Young Adult | 2017 |
Cost-effectiveness of pre-exposure prophylaxis for HIV prevention in men who have sex with men in the UK: a modelling study and health economic evaluation.
Topics: Adolescent; Adult; Anti-HIV Agents; Cost-Benefit Analysis; Disease Transmission, Infectious; Emtricitabine; England; HIV Infections; Homosexuality, Male; Humans; Male; Middle Aged; Pre-Exposure Prophylaxis; Tenofovir; Young Adult | 2018 |
Community outreach programs and major adherence lapses with antiretroviral therapy in rural Kakamega, Kenya.
Topics: Adolescent; Adult; Anti-HIV Agents; Community Health Workers; Community-Institutional Relations; Female; HIV Infections; House Calls; Humans; Kenya; Male; Medication Adherence; Middle Aged; Rural Population; Stavudine; Survival Analysis; Tenofovir; Young Adult; Zidovudine | 2018 |
Pharmacogenetics-based population pharmacokinetic analysis of tenofovir in Thai HIV-infected patients.
Topics: Anti-HIV Agents; Cross-Sectional Studies; Female; Genotype; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Pharmacogenetics; Polymorphism, Genetic; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Thailand | 2017 |
Regimen Change: Gilead's TAF Drugs Toppling TDFs in HIV Treatment.
Topics: Adenine; Alanine; Drug Therapy, Combination; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; Humans; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2017 |
Human immunodeficiency virus infection acquired through a traditional healer's ritual: a case report.
Topics: Adult; Alkynes; Antiviral Agents; Benzoxazines; Ceremonial Behavior; Cyclopropanes; Enzyme-Linked Immunosorbent Assay; Female; HIV Infections; Humans; Lamivudine; Medicine, Traditional; Tanzania; Tenofovir | 2017 |
Brief Participant-Centered Convergence Interviews Integrate Self-Reports, Product Returns, and Pharmacokinetic Results to Improve Adherence Measurement in MTN-017.
Topics: Adult; Anti-HIV Agents; Counseling; Data Accuracy; Emtricitabine; Female; HIV Infections; Humans; Male; Medication Adherence; Self Report; Tenofovir | 2018 |
Distinct Pattern of Thymidine Analogue Mutations with K65R in Patients Failing Tenofovir-Based Antiretroviral Therapy.
Topics: Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Nigeria; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure; Viral Load; Zidovudine | 2018 |
Utility of Different Adherence Measures for PrEP: Patterns and Incremental Value.
Topics: Administration, Oral; Adult; Anti-HIV Agents; Emtricitabine; Female; Hair; HIV Infections; Humans; Kenya; Male; Medication Adherence; Pre-Exposure Prophylaxis; Self Report; Tenofovir; Uganda | 2018 |
Validation of an LC-MS/MS assay to simultaneously monitor the intracellular active metabolites of tenofovir, emtricitabine, and lamivudine in dried blood spots.
Topics: Anti-HIV Agents; Chromatography, High Pressure Liquid; Dried Blood Spot Testing; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Lamivudine; Leukocytes, Mononuclear; Liquid-Liquid Extraction; Medication Adherence; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Tenofovir | 2018 |
Optimization of tenofovir release from mucoadhesive vaginal tablets by polymer combination to prevent sexual transmission of HIV.
Topics: Acrylic Resins; Administration, Intravaginal; Animals; Chitosan; Delayed-Action Preparations; Female; Galactans; HIV Infections; Humans; Hypromellose Derivatives; Mannans; Mucous Membrane; Plant Gums; Reverse Transcriptase Inhibitors; Tablets; Tenofovir | 2018 |
Preference of Oral Tenofovir Disoproxil Fumarate/Emtricitabine Versus Rectal Tenofovir Reduced-Glycerin 1% Gel Regimens for HIV Prevention Among Cisgender Men and Transgender Women Who Engage in Receptive Anal Intercourse with Men.
Topics: Administration, Oral; Administration, Rectal; Adolescent; Adult; Anti-HIV Agents; Antiviral Agents; Emtricitabine; Female; Gels; HIV Infections; Humans; Lubricants; Male; Patient Acceptance of Health Care; Pre-Exposure Prophylaxis; Sexual Behavior; Sexual Partners; Tenofovir; Transgender Persons; Young Adult | 2017 |
The incidence of first-line antiretroviral treatment changes and related factors among HIV-infected sex workers in Nairobi, Kenya.
Topics: Adult; Anti-HIV Agents; Female; Follow-Up Studies; HIV Infections; Humans; Incidence; Kenya; Male; Middle Aged; Retrospective Studies; Sex Workers; Stavudine; Tenofovir; Time Factors; Zidovudine | 2017 |
The Differential Effects of Human Immunodeficiency Virus and Hepatitis C Virus on Bone Microarchitecture and Fracture Risk.
Topics: Bone Density; Cancellous Bone; Coinfection; Cross-Sectional Studies; Fractures, Bone; Hepacivirus; Hepatitis C; HIV; HIV Infections; Humans; Male; Middle Aged; Osteoporosis; Prospective Studies; Risk Factors; Tenofovir | 2018 |
Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients.
Topics: Adult; Drug Therapy, Combination; Emtricitabine; Female; Glomerular Filtration Rate; HIV Infections; HIV Integrase Inhibitors; Humans; Male; Middle Aged; Proportional Hazards Models; Retrospective Studies; Rilpivirine; Tenofovir; Treatment Outcome | 2017 |
Short Communication: Tenofovir Disoproxil Fumarate/Emtricitabine Fits for All as Appropriate HIV-1 Pre-Exposure Prophylaxis?
Topics: Adult; Anti-HIV Agents; Drug Combinations; Emtricitabine; Female; HIV Core Protein p24; HIV Infections; Humans; Male; Patient Acceptance of Health Care; Pre-Exposure Prophylaxis; Safe Sex; Sexual Partners; Tenofovir; Young Adult | 2018 |
Concomitant AIDS cholangiopathy and Fanconi syndrome as complications of HIV in a single patient.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Cholangitis; Fanconi Syndrome; Female; HIV Infections; Humans; Lamivudine; Middle Aged; Tenofovir; Zidovudine | 2017 |
The Pre-Exposure Prophylaxis-Stigma Paradox: Learning from Canada's First Wave of PrEP Users.
Topics: Adult; Anti-HIV Agents; Canada; Focus Groups; HIV Infections; Homosexuality, Male; Humans; Interviews as Topic; Male; Middle Aged; Pre-Exposure Prophylaxis; Qualitative Research; Safe Sex; Sexual Behavior; Sexual Partners; Social Stigma; Tenofovir | 2018 |
Brief Report: Adherence Biomarker Measurements in Older and Younger HIV-Infected Adults Receiving Tenofovir-Based Therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Biomarkers; Blood Chemical Analysis; Chemistry Techniques, Analytical; Creatinine; Hair; HIV Infections; Humans; Longitudinal Studies; Medication Adherence; Metabolic Clearance Rate; Middle Aged; Tenofovir; Young Adult | 2018 |
Hybrid magneto-plasmonic liposomes for multimodal image-guided and brain-targeted HIV treatment.
Topics: Anti-Retroviral Agents; Blood-Brain Barrier; Brain; Cell Line; Drug Delivery Systems; Gold; HIV Infections; Humans; Liposomes; Magnetics; Metal Nanoparticles; Microglia; Multimodal Imaging; Nanomedicine; Tenofovir | 2017 |
Brief Report: Tenofovir-Associated Nephrotoxicity Among a US National Historical Cohort of HIV-Infected Veterans: Risk Modification by Concomitant Antiretrovirals.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Female; HIV Infections; Humans; Incidence; Male; Middle Aged; Renal Insufficiency; Risk Assessment; Tenofovir; Veterans; Young Adult | 2018 |
Medication Adherence in a Nationwide Cohort of Veterans Initiating Pre-exposure Prophylaxis (PrEP) to Prevent HIV Infection.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-HIV Agents; Emtricitabine; Ethnicity; Female; HIV Infections; Humans; Male; Medication Adherence; Middle Aged; Pre-Exposure Prophylaxis; Sex Factors; Tenofovir; Veterans | 2018 |
Hormonal Contraceptives Differentially Suppress TFV and TAF Inhibition of HIV Infection and TFV-DP in Blood and Genital Tract CD4+ T cells.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Anti-Retroviral Agents; CD4-Positive T-Lymphocytes; Cells, Cultured; Contraceptive Agents; Contraceptives, Oral, Hormonal; Female; Genitalia, Female; HIV Infections; HIV-1; Humans; Middle Aged; Organophosphates; Progestins; Tenofovir | 2017 |
Short Communication: Specimen Processing Impacts Tissue Tenofovir Pharmacokinetic Measurements.
Topics: Adenine; Administration, Oral; Anti-HIV Agents; Biopsy; Culture Media; HIV Infections; Humans; Male; Organophosphates; Pre-Exposure Prophylaxis; Rectum; Specimen Handling; Tenofovir | 2018 |
Clinic-Based Evaluation of a Point-of-Care Creatinine Assay to Screen for Renal Impairment Among HIV-Positive Patients Receiving Tenofovir Disoproxil Fumarate.
Topics: Adult; Anti-HIV Agents; Creatinine; Diagnostic Tests, Routine; Female; HIV Infections; Humans; Male; Point-of-Care Systems; Prospective Studies; Renal Insufficiency; Tenofovir | 2018 |
Wild-type HIV infection despite PrEP: a lot to learn from a case report - Authors' reply.
Topics: Anti-HIV Agents; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir | 2018 |
Wild-type HIV infection despite PrEP: a lot to learn from a case report.
Topics: Anti-HIV Agents; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir | 2018 |
Wild-type HIV infection despite PrEP: a lot to learn from a case report.
Topics: Anti-HIV Agents; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir | 2018 |
Adherence to HIV Postexposure Prophylaxis in a Major Hospital in Northwestern Nigeria.
Topics: Anti-HIV Agents; Cross Infection; Health Personnel; HIV Infections; Hospitals; Humans; Medication Adherence; Nigeria; Occupational Diseases; Occupational Exposure; Post-Exposure Prophylaxis; Retrospective Studies; Tenofovir | 2018 |
Renal function of MDR-TB patients treated with kanamycin regimens or concomitantly with antiretroviral agents.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Female; Follow-Up Studies; Glomerular Filtration Rate; HIV Infections; Humans; Kanamycin; Kaplan-Meier Estimate; Kidney Function Tests; Male; Middle Aged; Namibia; Proportional Hazards Models; Renal Insufficiency; Retrospective Studies; Tenofovir; Tuberculosis, Multidrug-Resistant; Young Adult | 2017 |
Plasma and intracellular pharmacokinetics of tenofovir in patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Alanine; Anti-HIV Agents; Chromatography, Liquid; Cross-Over Studies; Drug Substitution; Female; HIV Infections; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Plasma; Prospective Studies; Tandem Mass Spectrometry; Tenofovir; Young Adult | 2018 |
Renal outcomes in patients initiated on tenofovir disoproxil fumarate-based antiretroviral therapy at a community health centre in Malawi.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Community Health Centers; Female; Glomerular Filtration Rate; HIV Infections; HIV-1; Humans; Incidence; Malawi; Male; Middle Aged; Renal Insufficiency; Retrospective Studies; Risk Factors; Tenofovir | 2018 |
Establishment of intracellular tenofovir-diphosphate as the key determinant for in vitro-in vivo translation of antiviral efficacy.
Topics: Adenine; Alanine; Anti-HIV Agents; Cytoplasm; Databases, Factual; Dose-Response Relationship, Drug; HIV Infections; HIV-1; Humans; Leukocytes, Mononuclear; Meta-Analysis as Topic; Organophosphates; Prodrugs; Tenofovir; Viral Load; Virus Replication | 2018 |
Call to Action: Prevention of Mother-to-Child Transmission of Hepatitis B in Africa.
Topics: Africa South of the Sahara; Antiviral Agents; Child; Female; Hepatitis B; Hepatitis B Vaccines; Hepatitis B virus; HIV Infections; Humans; Immunization Programs; Infectious Disease Transmission, Vertical; Pregnancy; Pregnancy Complications, Infectious; Tenofovir; Viral Load | 2018 |
Secondary Hyperparathyroidism in HIV-Infected Patients in Central Europe.
Topics: Adult; Anti-Retroviral Agents; Calcium; Cross-Sectional Studies; Europe; Female; HIV; HIV Infections; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Parathyroid Hormone; Tenofovir; Vitamin D | 2018 |
Hypersensitivity to antiretroviral drugs.
Topics: Anti-HIV Agents; Drug Hypersensitivity; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Nevirapine; Skin Tests; Tenofovir | 2018 |
Brief Report: Abacavir/Lamivudine and Tenofovir/Emtricitabine in Pregnant Women With HIV: Laboratory and Clinical Outcomes in an Observational National Study.
Topics: Adult; AIDS-Associated Nephropathy; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cesarean Section; Cholesterol; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Hemoglobins; HIV Infections; HIV-1; Humans; Hypertension; Lamivudine; Lipoproteins, LDL; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Pregnancy Trimester, Third; RNA, Viral; Tenofovir | 2018 |
Family planning providers' role in offering PrEP to women.
Topics: Anti-HIV Agents; Emtricitabine; Family Planning Services; Female; Health Education; HIV Infections; Humans; Pre-Exposure Prophylaxis; Sex Education; Sexual Behavior; Tenofovir; United States | 2018 |
Composite films for vaginal delivery of tenofovir disoproxil fumarate and emtricitabine.
Topics: Administration, Intravaginal; Anti-HIV Agents; Cell Line; Cell Line, Tumor; Drug Discovery; Drug Liberation; Emtricitabine; Female; HeLa Cells; HIV Infections; Humans; Male; Nanoparticles; Tenofovir; Vagina | 2019 |
Bone density, microarchitecture, and tissue quality after 1 year of treatment with tenofovir disoproxil fumarate.
Topics: Absorptiometry, Photon; Adult; Anti-HIV Agents; Bone and Bones; Bone Density; Bone Diseases, Metabolic; Cancellous Bone; Female; Femur Neck; HIV Infections; Humans; Longitudinal Studies; Male; Severity of Illness Index; Spine; Tenofovir | 2018 |
Differences in Local and Systemic TFV PK Among Premenopausal Versus Postmenopausal Women Exposed to TFV 1% Vaginal Gel.
Topics: Adenine; Administration, Intravaginal; Administration, Topical; Anti-HIV Agents; Epithelium; Estradiol; Female; HIV; HIV Infections; Humans; Menstrual Cycle; Mucous Membrane; Organophosphates; Postmenopause; Premenopause; Tenofovir; Time Factors; Vagina; Vaginal Creams, Foams, and Jellies | 2018 |
A prospective study of adverse events to antiretroviral therapy in HIV- infected adults in Ekiti State, Nigeria.
Topics: Abdominal Pain; Adolescent; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Substitution; Drug Therapy, Combination; Female; HIV Infections; Humans; Incidence; Lamivudine; Male; Middle Aged; Nausea; Nevirapine; Nigeria; Prospective Studies; Sleep Initiation and Maintenance Disorders; Tenofovir; Young Adult; Zidovudine | 2016 |
Preterm delivery and small-for-gestation outcomes in HIV-infected pregnant women on antiretroviral therapy in rural South Africa: Results from a cohort study, 2010-2015.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Infant, Newborn; Infant, Premature; Infant, Small for Gestational Age; Lamivudine; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Premature Birth; Retrospective Studies; Rural Population; South Africa; Tenofovir; Young Adult | 2018 |
Genital inflammation undermines the effectiveness of tenofovir gel in preventing HIV acquisition in women.
Topics: Cytokines; Female; Genitalia, Female; HIV Infections; Humans; Inflammation; Multivariate Analysis; Tenofovir; Treatment Outcome | 2018 |
Computational Modeling of Antiviral Drug Diffusion from Poly(lactic- co-glycolic-acid) Fibers and Multicompartment Pharmacokinetics for Application to the Female Reproductive Tract.
Topics: Anti-HIV Agents; Computer Simulation; Diffusion; Epithelium; Female; Genitalia, Female; HIV Infections; HIV-1; Humans; Polyesters; Reproductive Tract Infections; Reverse Transcriptase Inhibitors; Tenofovir | 2018 |
[Nephrotoxicity of antiretrovirals other than tenofovir].
Topics: HIV Infections; Humans; Kidney; Kidney Diseases; Reverse Transcriptase Inhibitors; Tenofovir | 2018 |
Awareness and Acceptance of HIV Pre-exposure Prophylaxis among Medical Personnel and Men Who Have Sex with Men in Korea.
Topics: Adult; Anti-HIV Agents; Cross-Sectional Studies; Emtricitabine; Health Knowledge, Attitudes, Practice; Health Personnel; HIV Infections; Homosexuality, Male; Humans; Male; Middle Aged; Patient Acceptance of Health Care; Pre-Exposure Prophylaxis; Republic of Korea; Sexual and Gender Minorities; Sexual Behavior; Sexual Partners; Surveys and Questionnaires; Tenofovir | 2018 |
Implementing preexposure prophylaxis among key populations: an opportunity for patient-centered services and management of hepatitis B.
Topics: Antiviral Agents; Cote d'Ivoire; Disease Transmission, Infectious; Female; Hepatitis B; HIV Infections; Humans; Male; Pre-Exposure Prophylaxis; Sex Workers; Tenofovir | 2018 |
Long-Acting Profile of 4 Drugs in 1 Anti-HIV Nanosuspension in Nonhuman Primates for 5 Weeks After a Single Subcutaneous Injection.
Topics: Animals; Anti-HIV Agents; Drug Carriers; Drug Delivery Systems; Drug Therapy, Combination; HIV Infections; Injections, Subcutaneous; Lamivudine; Leukocytes, Mononuclear; Lopinavir; Lymph Nodes; Macaca nemestrina; Male; Nanoparticles; Ritonavir; Tenofovir | 2018 |
Tenofovir disoproxil fumarate co-administered with lopinavir/ritonavir is strongly associated with tubular damage and chronic kidney disease.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Cross-Sectional Studies; Drug Therapy, Combination; Female; HIV Infections; Humans; Kidney Tubules; Lopinavir; Male; Middle Aged; Renal Insufficiency, Chronic; Risk Factors; Ritonavir; Tenofovir; Vietnam | 2018 |
The cost-effectiveness of HIV pre-exposure prophylaxis in men who have sex with men and transgender women at high risk of HIV infection in Brazil.
Topics: Adult; Anti-HIV Agents; Cost-Benefit Analysis; Emtricitabine; Female; Health Care Costs; HIV Infections; Homosexuality, Male; Humans; Male; Pre-Exposure Prophylaxis; Tenofovir; Transgender Persons | 2018 |
Men who have sex with men more often chose daily than event-driven use of pre-exposure prophylaxis: baseline analysis of a demonstration study in Amsterdam.
Topics: Adult; Anti-HIV Agents; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Male; Medication Adherence; Middle Aged; Pre-Exposure Prophylaxis; Prospective Studies; Risk Factors; Tenofovir; Transgender Persons | 2018 |
Stable Caloric Intake and Continued Virologic Suppression for HIV-Positive Antiretroviral Treatment-Experienced Women After Switching to a Single-Tablet Regimen of Emtricitabine, Rilpivirine, and Tenofovir Disoproxil Fumarate.
Topics: Adult; Anti-HIV Agents; Antiviral Agents; Emtricitabine; Energy Intake; Female; HIV Infections; Humans; Maintenance Chemotherapy; Middle Aged; Reverse Transcriptase Inhibitors; Rilpivirine; Sustained Virologic Response; Tablets; Tenofovir; Treatment Outcome; Viral Load | 2018 |
Antiviral Activity of Tenofovir Alafenamide Against HIV-1 Subtypes and Emergence of K65R.
Topics: Adenine; Alanine; Anti-HIV Agents; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Mutation, Missense; Selection, Genetic; Tenofovir | 2018 |
Translation of clinical trial data to changes in clinical practice: rapid transition from tenofovir disoproxil fumarate to tenofovir alafenamide-based therapies in a Sydney HIV clinic.
Topics: Adenine; Alanine; Ambulatory Care Facilities; Anti-HIV Agents; Antiviral Agents; Australia; HIV Infections; HIV-1; Humans; Medical Audit; Tenofovir; Treatment Outcome | 2018 |
Osteoporosis-Related Fractures in HIV-Infected Patients Receiving Long-Term Tenofovir Disoproxil Fumarate: An Observational Cohort Study.
Topics: Adult; Aged; Anti-HIV Agents; Cohort Studies; Drug Administration Schedule; Female; Fractures, Bone; HIV Infections; Humans; Japan; Longitudinal Studies; Male; Middle Aged; Osteoporosis; Tenofovir | 2018 |
Adipocytes impair efficacy of antiretroviral therapy.
Topics: Adipocytes; Anti-HIV Agents; CD4-Positive T-Lymphocytes; Cells, Cultured; Coculture Techniques; Disease Reservoirs; HIV Infections; HIV-1; Humans; Prodrugs; Reverse Transcriptase Inhibitors; Tenofovir; Virus Replication | 2018 |
Inflammation weakens HIV prevention.
Topics: Acquired Immunodeficiency Syndrome; Female; Genitalia; HIV; HIV Infections; Humans; Inflammation; Tenofovir | 2018 |
Discovery of genetic variants of the kinases that activate tenofovir among individuals in the United States, Thailand, and South Africa: HPTN067.
Topics: Adenylate Kinase; Anti-HIV Agents; Creatine Kinase, MM Form; Genetic Variation; High-Throughput Nucleotide Sequencing; HIV Infections; HIV-1; Humans; Pyruvate Kinase; South Africa; Tenofovir; Thailand; United States | 2018 |
3D printed, controlled release, tritherapeutic tablet matrix for advanced anti-HIV-1 drug delivery.
Topics: Alkynes; Animals; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Delayed-Action Preparations; Drug Liberation; Emtricitabine; HIV Infections; HIV-1; Humans; Printing, Three-Dimensional; Swine; Tablets; Tenofovir | 2019 |
Regimen durability in HIV-infected children and adolescents initiating first-line antiretroviral therapy in a large public sector HIV cohort in South Africa.
Topics: Adolescent; Anti-Retroviral Agents; Child; Child, Preschool; Cohort Studies; Dideoxynucleosides; Female; HIV Infections; Humans; Male; Public Sector; South Africa; Tenofovir; Time Factors; Treatment Outcome; Young Adult | 2018 |
Seroconversion on preexposure prophylaxis: a case report with segmental hair analysis for timed adherence determination.
Topics: Adult; Anti-HIV Agents; Chromatography, Liquid; Disease Transmission, Infectious; Drug Resistance, Multiple, Viral; Emtricitabine; Genotype; Hair; HIV Infections; HIV-1; Homosexuality, Male; Humans; Male; Mass Spectrometry; Medication Adherence; Pre-Exposure Prophylaxis; Seroconversion; Tenofovir | 2018 |
Risk of Nephrotoxicity in Patients With Drug-Resistant Tuberculosis Treated With Kanamycin/Capreomycin With or Without Concomitant Use of Tenofovir-Containing Antiretroviral Therapy.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Capreomycin; Creatinine; Drug Therapy, Combination; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kanamycin; Kidney; Male; Retrospective Studies; Tenofovir; Tuberculosis, Multidrug-Resistant | 2018 |
Effect of Gestational Age at Tenofovir-Emtricitabine-Efavirenz Initiation on Adverse Birth Outcomes in Botswana.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Botswana; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; Female; Fetal Death; Gestational Age; HIV Infections; Humans; Infant, Low Birth Weight; Infectious Disease Transmission, Vertical; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Premature Birth; Stillbirth; Tenofovir | 2018 |
Maximizing the Benefits of HIV Preexposure Prophylaxis.
Topics: Anti-HIV Agents; Emtricitabine; Female; HIV Infections; Humans; Male; Medication Adherence; Pre-Exposure Prophylaxis; Tenofovir | 2018 |
Birth Outcomes for Pregnant Women with HIV Using Tenofovir-Emtricitabine.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Disease Transmission, Infectious; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Infant, Low Birth Weight; Infant, Newborn; Lamivudine; Lopinavir; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Premature Birth; Risk; Ritonavir; Tenofovir; Zidovudine | 2018 |
To use entecavir, tenofovir disoproxil fumarate or tenofovir alafenamide: it's all about choosing the right patient!
Topics: Adenine; Alanine; Anti-HIV Agents; Guanine; HIV Infections; Humans; Tenofovir | 2018 |
Renal health after long-term exposure to tenofovir disoproxil fumarate (TDF) in HIV/HBV positive adults in Ghana.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Coinfection; Female; Ghana; Glomerular Filtration Rate; Hepatitis B; Hepatitis B virus; HIV; HIV Infections; Humans; Hypertension; Kidney; Kidney Diseases; Male; Middle Aged; Proteinuria; Tenofovir; Time Factors | 2018 |
Acceptability of Antiretroviral Pre-exposure Prophylaxis from a Cohort of Sexually Experienced Young Transgender Women in Two U.S. Cities.
Topics: Adolescent; Adult; Anti-HIV Agents; Boston; Chicago; Cities; Cohort Studies; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Patient Acceptance of Health Care; Pre-Exposure Prophylaxis; Sexual Behavior; Sexual Partners; Tenofovir; Transgender Persons; Young Adult | 2018 |
Emerging resistance mutations in PI-naive patients failing an atazanavir-based regimen (ANRS multicentre observational study).
Topics: Adult; Atazanavir Sulfate; Dideoxynucleosides; Drug Combinations; Drug Resistance, Viral; Emtricitabine; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Mutation; Retrospective Studies; Tenofovir; Treatment Failure; Viral Load | 2018 |
CROI 2018: Advances in Antiretroviral Therapy.
Topics: Adenine; Amides; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Congresses as Topic; Deoxyadenosines; Drug Therapy, Combination; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Piperazines; Pyridones; Tenofovir; Viral Load | 2018 |
HBV and HIV viral load but not microbial translocation or immune activation are associated with liver fibrosis among patients in South Africa.
Topics: Adult; Antiretroviral Therapy, Highly Active; Biomarkers; CD4-Positive T-Lymphocytes; Coinfection; Elasticity Imaging Techniques; Female; Hepatitis B; HIV Infections; Humans; Lipopolysaccharide Receptors; Liver Cirrhosis; Male; Middle Aged; South Africa; Tenofovir; Viral Load | 2018 |
Adverse reactions associated with first-line regimens in patient initiating antiretroviral therapy.
Topics: Adolescent; Adult; Aged; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Brazil; Cross-Sectional Studies; Cyclopropanes; Drug-Related Side Effects and Adverse Reactions; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Prospective Studies; Pyridones; Quality of Life; Reverse Transcriptase Inhibitors; Tenofovir; Young Adult | 2018 |
Enhanced HIV viral load suppression with crushed combination tablets containing tenofovir alafenamide and emtricitabine.
Topics: Adenine; Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Male; Middle Aged; Tablets; Tenofovir; Treatment Outcome; Viral Load | 2018 |
Incidence of Acute Kidney Injury in Patients Coinfected with HIV and Hepatitis C Virus Receiving Tenofovir Disoproxil Fumarate and Ledipasvir/Sofosbuvir in a Real-World, Urban, Ryan White Clinic.
Topics: Acute Kidney Injury; Adolescent; Adult; Aged; Antiviral Agents; Benzimidazoles; Coinfection; Female; Fluorenes; Georgia; Hepatitis C, Chronic; HIV Infections; Humans; Incidence; Male; Middle Aged; Retrospective Studies; Reverse Transcriptase Inhibitors; Risk Factors; Sofosbuvir; Tenofovir; Young Adult | 2018 |
Efficacy of single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide in the treatment of HIV-1.
Topics: Adenine; Alanine; Anti-HIV Agents; Clinical Trials as Topic; Cobicistat; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Kidney Diseases; Tablets; Tenofovir | 2018 |
Medication Side Effects and Retention in HIV Treatment: A Regression Discontinuity Study of Tenofovir Implementation in South Africa and Zambia.
Topics: Adult; Anti-HIV Agents; Epidemiologic Methods; Female; HIV Infections; Humans; Male; Medication Adherence; Prospective Studies; South Africa; Tenofovir; Viral Load; Zambia | 2018 |
Patterns and Correlates of Participant Retention in a Multi-City Pre-Exposure Prophylaxis Demonstration Project.
Topics: Adult; Anti-HIV Agents; District of Columbia; Drug Therapy, Combination; Emtricitabine; Female; Florida; HIV Infections; Homosexuality, Male; Humans; Male; Middle Aged; Pre-Exposure Prophylaxis; San Francisco; Tenofovir | 2018 |
The use of HIV post-exposure prophylaxis in forensic medicine following incidents of sexual violence in Hamburg, Germany: a retrospective study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Child; Child, Preschool; Emtricitabine; Female; Germany; HIV Infections; Humans; Male; Medication Adherence; Middle Aged; Post-Exposure Prophylaxis; Raltegravir Potassium; Retrospective Studies; Sex Offenses; Tenofovir; Young Adult | 2018 |
Lipid changes and tolerability in a cohort of adult HIV-infected patients who switched to rilpivirine/emtricitabine/tenofovir due to intolerance to previous combination ART: the PRO-STR study.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Substitution; Dyslipidemias; Emtricitabine; Female; HIV Infections; Humans; Lipids; Male; Prospective Studies; Rilpivirine; Tenofovir; Viral Load | 2018 |
Development of rectal enema as microbicide (DREAM): Preclinical progressive selection of a tenofovir prodrug enema.
Topics: Adenine; Administration, Rectal; Alanine; Animals; Anti-HIV Agents; Anti-Infective Agents; Enema; HIV Infections; HIV-1; Homosexuality, Male; Male; Mice; Organophosphates; Organophosphonates; Pre-Exposure Prophylaxis; Prodrugs; Rectum; Sexual and Gender Minorities; Tenofovir | 2019 |
Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: an observational cohort study.
Topics: Adult; Anti-HIV Agents; CD4-CD8 Ratio; CD8-Positive T-Lymphocytes; Cohort Studies; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Reverse Transcriptase Inhibitors; Tenofovir | 2018 |
Pseudoresistance of hepatitis B virus to tenofovir with emtricitabine.
Topics: Anti-HIV Agents; Coinfection; Drug Resistance, Viral; Emtricitabine; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Male; Middle Aged; Tenofovir | 2018 |
"It Was Not My Aim to Sleep There": The Impact of Timing and Location of Sex on Adherence to Coitally-Dependent HIV Pre-exposure Prophylaxis.
Topics: Adolescent; Adult; Anti-HIV Agents; Coitus; Female; Focus Groups; HIV Infections; Humans; Interviews as Topic; Male; Medication Adherence; Pre-Exposure Prophylaxis; Qualitative Research; Sexual Behavior; Tenofovir; Vaginal Creams, Foams, and Jellies | 2018 |
Impact of Nucleos(t)ide Reverse Transcriptase Inhibitors on Blood Telomere Length Changes in a Prospective Cohort of Aviremic HIV-Infected Adults.
Topics: Adult; Dideoxynucleosides; Female; HIV Infections; Humans; Male; Middle Aged; Prospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Telomerase; Telomere; Tenofovir; Viral Load | 2018 |
What did we learn from the bictegravir switch studies?
Topics: Adenine; Adult; Alanine; Amides; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Piperazines; Protease Inhibitors; Pyridones; Tenofovir | 2018 |
Day-On, Day-Off emtricitabine, tenofovir disoproxil fumarate and efavirenz single tablet regimen (DODO) as maintenance therapy in HIV-infected patients.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Emtricitabine; Female; HIV Infections; Humans; Maintenance Chemotherapy; Male; Middle Aged; Reverse Transcriptase Inhibitors; Tablets; Tenofovir | 2018 |
Biochemical and inflammatory modifications after switching to dual antiretroviral therapy in HIV-infected patients in Italy: a multicenter retrospective cohort study from 2007 to 2015.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4-CD8 Ratio; Cohort Studies; Darunavir; Dideoxynucleosides; Female; HIV Infections; Humans; Inflammation; Italy; Male; Middle Aged; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2018 |
Acquisition of Multidrug-Resistant Human Immunodeficiency Virus Type 1 Infection in a Patient Taking Preexposure Prophylaxis.
Topics: Adult; Anti-HIV Agents; Drug Resistance, Multiple, Viral; Emtricitabine; HIV Infections; HIV Seropositivity; HIV-1; Humans; Male; Medication Adherence; Pre-Exposure Prophylaxis; RNA, Viral; Tenofovir; Thailand | 2018 |
Fecal Coliform Bacterial Detection to Assess Enema Adherence in HIV Prevention Clinical Studies.
Topics: Administration, Rectal; Adult; Anti-HIV Agents; Enema; Enterobacteriaceae; Feces; HIV Infections; Humans; Male; Medication Adherence; Middle Aged; Pre-Exposure Prophylaxis; Sensitivity and Specificity; Sexual Behavior; Tenofovir | 2019 |
Access to sexual health services after the rapid roll out of the launch of pre-exposure prophylaxis for HIV in Melbourne, Australia: a retrospective cross-sectional analysis.
Topics: Adolescent; Adult; Anti-HIV Agents; Cross-Sectional Studies; Drug Therapy, Combination; Emtricitabine; Female; Health Services Accessibility; Health Services Needs and Demand; HIV Infections; Humans; Male; Middle Aged; Pre-Exposure Prophylaxis; Retrospective Studies; Sexually Transmitted Diseases, Viral; Tenofovir; Victoria | 2018 |
Tenofovir alafenamide associated fatal lactic acidosis in an autologous hematopoietic stem cell transplant recipient.
Topics: Acidosis, Lactic; Adenine; Aged; Alanine; Antiviral Agents; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Hepatitis B; Hepatitis C; HIV Infections; Humans; Male; Multiple Myeloma; Tenofovir; Transplantation, Autologous | 2018 |
A pharmacist-led medication switch protocol in an academic HIV clinic: patient knowledge and satisfaction.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Cross-Sectional Studies; Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; Health Knowledge, Attitudes, Practice; Health Surveys; HIV Infections; Humans; Male; Middle Aged; Patient Satisfaction; Pharmacists; Tenofovir | 2018 |
Blood Telomere Length Changes After Ritonavir-Boosted Darunavir Combined With Raltegravir or Tenofovir-Emtricitabine in Antiretroviral-Naive Adults Infected With HIV-1.
Topics: Adult; Analysis of Variance; Anti-HIV Agents; Darunavir; DNA; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Prospective Studies; Raltegravir Potassium; Randomized Controlled Trials as Topic; Ritonavir; Telomere; Tenofovir | 2018 |
HIV health care providers are ready to introduce pre-exposure prophylaxis in Central and Eastern Europe and neighbouring countries: data from the Euroguidelines in Central and Eastern Europe (ECEE) Network Group.
Topics: Adult; Emtricitabine; Europe; Female; Health Personnel; HIV Infections; Humans; Male; Middle Aged; Practice Guidelines as Topic; Pre-Exposure Prophylaxis; Safe Sex; Standard of Care; Surveys and Questionnaires; Tenofovir; Young Adult | 2018 |
Vaginal microbiome modulates topical antiretroviral drug pharmacokinetics.
Topics: Actinobacteria; Adenine; Alanine; Anti-Retroviral Agents; Bacteria; Endocytosis; Female; Gardnerella vaginalis; HIV Infections; Humans; Hydrogen-Ion Concentration; Jurkat Cells; Lactobacillus crispatus; Microbiota; Pyrimidines; Tenofovir; Vagina | 2018 |
Pregnancy outcomes and infant growth among babies with in-utero exposure to tenofovir-based preexposure prophylaxis for HIV prevention.
Topics: Adult; Anti-HIV Agents; Child Development; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; Humans; Infant, Newborn; Kenya; Longitudinal Studies; Maternal-Fetal Exchange; Pre-Exposure Prophylaxis; Pregnancy; Pregnancy Outcome; Tenofovir; Uganda | 2018 |
Exploring an alternative explanation for the second phase of viral decay: Infection of short-lived cells in a drug-limited compartment during HAART.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4-Positive T-Lymphocytes; Cyclopropanes; Emtricitabine; HIV Infections; HIV-1; Host-Pathogen Interactions; Humans; Models, Statistical; Monocytes; RNA, Viral; Tenofovir; Viral Load; Virus Replication | 2018 |
Drug resistance outcomes of long-term ART with tenofovir disoproxil fumarate in the absence of virological monitoring.
Topics: Adult; Africa South of the Sahara; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Reverse Transcriptase Inhibitors; Tenofovir; Time Factors; Treatment Outcome; Viral Load; Viremia | 2018 |
Boosted darunavir, emtricitabine and tenofovir pharmacokinetics in sthe early and late postgastric bypass surgery periods.
Topics: Administration, Oral; Adult; Anti-HIV Agents; Bariatric Surgery; Chromatography, Liquid; Darunavir; Emtricitabine; Female; Gastric Bypass; HIV Infections; Humans; Obesity; Plasma; Tandem Mass Spectrometry; Tenofovir | 2018 |
Antiretroviral potency of 4'-ethnyl-2'-fluoro-2'-deoxyadenosine, tenofovir alafenamide and second-generation NNRTIs across diverse HIV-1 subtypes.
Topics: Adenine; Alanine; Anti-Retroviral Agents; Deoxyadenosines; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Recombination, Genetic; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure | 2018 |
Three HIV Drugs, Atazanavir, Ritonavir, and Tenofovir, Coformulated in Drug-Combination Nanoparticles Exhibit Long-Acting and Lymphocyte-Targeting Properties in Nonhuman Primates.
Topics: Animals; Anti-HIV Agents; Atazanavir Sulfate; Cells, Cultured; Delayed-Action Preparations; Drug Combinations; Drug Delivery Systems; HIV Infections; Humans; Leukocytes, Mononuclear; Lipids; Lymphocytes; Macaca nemestrina; Male; Nanoparticles; Ritonavir; Tenofovir | 2018 |
Adherence to pre-exposure prophylaxis among men who have sex with men: A prospective cohort study.
Topics: Adult; Anti-HIV Agents; China; HIV Infections; Homosexuality, Male; Humans; Male; Medication Adherence; Middle Aged; Motivation; Pre-Exposure Prophylaxis; Prospective Studies; Tenofovir | 2018 |
Biktarvy--another INSTI-based combination for HIV.
Topics: Amides; Anti-HIV Agents; Drug Approval; Drug Combinations; Drug Interactions; Drug Resistance, Viral; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Piperazines; Pyridones; Randomized Controlled Trials as Topic; Tenofovir; United States; United States Food and Drug Administration | 2018 |
Overdose of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in an HIV-1-infected subject with attempted suicide.
Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Drug Combinations; Drug Overdose; Emtricitabine; HIV Infections; Humans; Male; Middle Aged; Quinolones; Renal Insufficiency; Suicide, Attempted; Tenofovir | 2019 |
A Pharmacokinetic/Pharmacodynamic Model to Predict Effective HIV Prophylaxis Dosing Strategies for People Who Inject Drugs.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Emtricitabine; Female; HIV; HIV Infections; Humans; Middle Aged; Pre-Exposure Prophylaxis; Tenofovir; Young Adult | 2018 |
Implementing HIV pre-exposure prophylaxis (PrEP): let's not get caught with our pants down.
Topics: Amphetamine-Related Disorders; Anti-HIV Agents; Cost-Benefit Analysis; Drug Combinations; Emtricitabine; Female; Healthcare Disparities; HIV Infections; Humans; Male; Morals; Patient Selection; Pre-Exposure Prophylaxis; Risk Factors; Sexual and Gender Minorities; Sexual Partners; Tenofovir; Transgender Persons; Treatment Outcome; Unsafe Sex; Vulnerable Populations | 2018 |
Ethics and HIV prevention research: An analysis of the early tenofovir PrEP trial in Nigeria.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Biomedical Research; Community Participation; Dissent and Disputes; Ethical Analysis; Ethics, Research; HIV; HIV Infections; Humans; Nigeria; Patient Advocacy; Pre-Exposure Prophylaxis; Randomized Controlled Trials as Topic; Research Design; Research Personnel; Tenofovir; Thinking | 2019 |
Daily or on-demand oral tenofovir disoproxil fumarate/emtricitabine for HIV pre-exposure prophylaxis: experience from a hospital-based clinic in France.
Topics: Administration, Oral; Adult; Anti-HIV Agents; Chemoprevention; Drug-Related Side Effects and Adverse Reactions; Emtricitabine; Female; HIV Infections; Hospitals; Humans; Incidence; Male; Outpatients; Paris; Pre-Exposure Prophylaxis; Prospective Studies; Sexual Behavior; Tenofovir | 2018 |
Similar tenofovir hair concentrations in men and women after directly observed dosing of tenofovir disoproxil fumarate/emtricitabine: implications for preexposure prophylaxis adherence monitoring.
Topics: Adult; Anti-HIV Agents; Chemoprevention; Chromatography, Liquid; Disease Transmission, Infectious; Emtricitabine; Female; Hair; Healthy Volunteers; HIV Infections; Humans; Male; Middle Aged; Pre-Exposure Prophylaxis; Sex Factors; Tandem Mass Spectrometry; Tenofovir; Young Adult | 2018 |
Measurement of soluble glycoprotein VI in studies of abacavir-based therapy: concerns about test precision.
Topics: Anti-HIV Agents; Collagen; Dideoxynucleosides; Glycoproteins; HIV Infections; Humans; Tenofovir | 2018 |
Risk factors for kidney disease among HIV-1 positive persons in the methadone program.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Drug Therapy, Combination; Female; Glomerular Filtration Rate; HIV Infections; Humans; Indinavir; Kidney Diseases; Male; Methadone; Narcotics; Opiate Substitution Treatment; Opioid-Related Disorders; Poland; Risk Factors; Sex Factors; Tenofovir; Time Factors | 2019 |
Prevalence of risk factors for chronic kidney disease in South African youth with perinatally acquired HIV.
Topics: Adolescent; Africa South of the Sahara; Albuminuria; Anti-Retroviral Agents; CD4 Lymphocyte Count; Child; Comorbidity; Female; Glomerular Filtration Rate; HIV Infections; HIV-1; Humans; Infectious Disease Transmission, Vertical; Male; Prevalence; Renal Insufficiency, Chronic; Risk Factors; Tenofovir; Viral Load | 2019 |
Cost-effectiveness of preexposure prophylaxis for HIV prevention for conception in the United States.
Topics: Adult; Anti-HIV Agents; Chemoprevention; Cost-Benefit Analysis; Disease Transmission, Infectious; Emtricitabine; Female; HIV Infections; Humans; Infant, Newborn; Male; Pre-Exposure Prophylaxis; Tenofovir; United States | 2018 |
HIV Superinfection Drives De Novo Antibody Responses and Not Neutralization Breadth.
Topics: Adult; Anti-HIV Agents; Antibodies, Neutralizing; Female; HEK293 Cells; HIV Antibodies; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Middle Aged; Peptide Fragments; RNA, Viral; Superinfection; Tenofovir | 2018 |
Short Communication: Association of Vitamin D Insufficiency and Protective Tenofovir Diphosphate Concentrations with Bone Toxicity in Adolescent Boys and Young Men Using Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Pre-Exposure Prophylaxis.
Topics: Adolescent; Anti-HIV Agents; Bone and Bones; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Logistic Models; Male; Pre-Exposure Prophylaxis; Prospective Studies; Tenofovir; Vitamin D; Vitamin D Deficiency; Young Adult | 2019 |
HIV Pre-Exposure Prophylaxis Medication for Adolescents and Young Adults: A Position Paper of the Society for Adolescent Health and Medicine.
Topics: Adolescent; Adolescent Health; Adult; Anti-HIV Agents; Emtricitabine; Female; Health Services Accessibility; HIV Infections; Humans; Male; Medication Adherence; Pre-Exposure Prophylaxis; Sexual and Gender Minorities; Tenofovir; Young Adult | 2018 |
Metabolic events in HIV-infected patients using abacavir are associated with erythrocyte inosine triphosphatase activity.
Topics: Adult; Aged; Diabetes Mellitus; Didanosine; Dideoxynucleosides; Erythrocytes; Female; Genotype; HIV Infections; Humans; Hypercholesterolemia; Hypertension; Male; Middle Aged; Pyrophosphatases; Reverse Transcriptase Inhibitors; Tenofovir | 2019 |
Management of Renal Disease: utility of a joint HIV-renal clinic.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Female; HIV Infections; Humans; Incidence; Interdisciplinary Communication; Kidney Diseases; Male; Middle Aged; Tenofovir; United Kingdom | 2019 |
Sexual Risk Compensation in a Pre-exposure Prophylaxis Demonstration Study Among Individuals at Risk of HIV.
Topics: Adult; Anti-HIV Agents; Directive Counseling; Female; Health Surveys; HIV Infections; Homosexuality, Male; Humans; Male; Models, Theoretical; Pre-Exposure Prophylaxis; Tenofovir; Transgender Persons; Unsafe Sex | 2019 |
Freeze-dried bioadhesive vaginal bigels for controlled release of Tenofovir.
Topics: Adhesiveness; Antiviral Agents; Cell Line; Delayed-Action Preparations; Drug Liberation; Female; Galactans; Hexoses; HIV Infections; Humans; Hydrogels; Mannans; Mucous Membrane; Plant Gums; Polysorbates; Sesame Oil; Tenofovir; Vagina | 2019 |
High Prevalence of HBV Lamivudine-Resistant Mutations in HBV/HIV Co-Infected Patients on Antiretroviral Therapy in the Area with the Highest Prevalence of HIV/HBV Co-Infection in China.
Topics: Adult; Anti-HIV Agents; China; Coinfection; DNA-Directed DNA Polymerase; Drug Resistance, Multiple, Viral; Female; Hepatitis B; Hepatitis B virus; HIV; HIV Infections; Humans; Lamivudine; Male; Multivariate Analysis; Mutation; Prevalence; Tenofovir; Viral Load | 2018 |
Differential extracellular, but similar intracellular, disposition of two tenofovir formulations in the male genital tract.
Topics: Adenine; Anti-Retroviral Agents; Blood Cells; Emtricitabine; Genitalia, Male; HIV Infections; Humans; Leukocytes, Mononuclear; Male; Reproductive Tract Infections; Semen; Tenofovir | 2019 |
A three-in-one, long-acting, nanosuspension reformulation of off-patent antiretrovirals for low-income and middle-income countries.
Topics: Alkynes; Animals; Benzoxazines; Cyclopropanes; HIV Infections; Lopinavir; Primates; Tenofovir | 2018 |
Multidrug nanosuspensions: future perspectives on drug delivery system for HIV combination antiretroviral therapy.
Topics: Alkynes; Animals; Benzoxazines; Cyclopropanes; Drug Delivery Systems; HIV; HIV Infections; Lopinavir; Primates; Tenofovir | 2018 |
Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Cholesterol; Cholesterol, LDL; Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; Follow-Up Studies; HIV Infections; Humans; Hypolipidemic Agents; Lipids; Male; Middle Aged; Retrospective Studies; Risk Factors; Spain; Tenofovir; Young Adult | 2019 |
Implementation of a community pharmacy-based pre-exposure prophylaxis service: a novel model for pre-exposure prophylaxis care.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-HIV Agents; Community Pharmacy Services; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Pre-Exposure Prophylaxis; Sexually Transmitted Diseases, Viral; Tenofovir; Washington | 2018 |
Tenofovir disoproxil fumarate discontinuation for renal outcomes: any room for treatment personalization?
Topics: Adult; Anti-HIV Agents; CD4-Positive T-Lymphocytes; Cross-Sectional Studies; Female; HIV Infections; Humans; Kidney; Male; Middle Aged; Precision Medicine; Protease Inhibitors; Tenofovir | 2019 |
Rectal Douching Practices Associated with Anal Intercourse: Implications for the Development of a Behaviorally Congruent HIV-Prevention Rectal Microbicide Douche.
Topics: Administration, Rectal; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Female; Health Surveys; HIV Infections; Humans; Internet; Male; Middle Aged; Patient Acceptance of Health Care; Rectum; Sexual and Gender Minorities; Tenofovir; Therapeutic Irrigation; United States; Young Adult | 2019 |
A two-drug regimen for antiretroviral therapy.
Topics: Adult; Double-Blind Method; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Tenofovir | 2019 |
Impact of Antiretroviral Drugs on Fracture Risk in HIV-Infected Individuals: A Case-Control Study Nested Within the French Hospital Database on HIV (FHDH-ANRS CO4).
Topics: Adult; Anti-Retroviral Agents; Case-Control Studies; Databases, Factual; Female; Fractures, Bone; France; HIV Infections; HIV Protease Inhibitors; Humans; Incidence; Male; Middle Aged; Odds Ratio; Tenofovir | 2019 |
Associations between perceived barriers and benefits of using HIV pre-exposure prophylaxis and medication adherence among men who have sex with men in Western China.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; China; Communication Barriers; HIV; HIV Infections; Homosexuality, Male; Humans; Male; Medication Adherence; Middle Aged; Perception; Pre-Exposure Prophylaxis; Self Report; Sexual and Gender Minorities; Surveys and Questionnaires; Tenofovir; Young Adult | 2018 |
Sleep and neuropsychological performance in HIV+ subjects on efavirenz-based therapy and response to switch in therapy.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System Diseases; Cobicistat; Cyclopropanes; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Sleep Wake Disorders; Tenofovir | 2018 |
Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV-infected patients in clinical practice: results from a multicentre, observ
Topics: Adult; Cobicistat; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Quinolones; Retrospective Studies; RNA, Viral; Tenofovir; Viral Load | 2019 |
Abnormal elevation of international normalized ratio in a patient during the coadministration of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide and warfarin: a case report.
Topics: Adenine; Alanine; Cobicistat; Emtricitabine; HIV Infections; Humans; International Normalized Ratio; Quinolones; Tenofovir; Warfarin | 2019 |
Strengthening HIV-prevention trials: a dose of implementation science?
Topics: Double-Blind Method; Female; HIV Infections; HIV-1; Humans; Implementation Science; South Africa; Tenofovir; Vaginal Creams, Foams, and Jellies | 2018 |
Preclinical Safety Evaluation of HIV-1 gp120 Responsive Microbicide Delivery System in C57BL/6 Female Mice.
Topics: Administration, Intravaginal; Animals; Anti-Infective Agents; Calcium Carbonate; Chemokines; Dynamic Light Scattering; Female; HIV Envelope Protein gp120; HIV Infections; HIV-1; Immunohistochemistry; Interleukin-1alpha; Interleukin-1beta; Interleukin-7; Mice; Mice, Inbred C57BL; Microscopy, Electron, Scanning; Osmolar Concentration; Tenofovir; Tumor Necrosis Factor-alpha; Vagina | 2019 |
Topics: Anti-HIV Agents; Darunavir; Drug Combinations; HIV Infections; Humans; Tenofovir | 2018 |
Symtuza
Topics: Anti-HIV Agents; Darunavir; Drug Combinations; HIV Infections; Humans; Tenofovir; Treatment Outcome | 2018 |
Symtuza
Topics: Anti-HIV Agents; Darunavir; Drug Combinations; HIV Infections; Humans; Tenofovir | 2018 |
Adherence, virological outcome, and drug resistance in Chinese HIV patients receiving first-line antiretroviral therapy from 2011 to 2015.
Topics: Adult; Anti-HIV Agents; China; Drug Resistance, Viral; Female; HIV; HIV Infections; Humans; Lamivudine; Male; Medication Adherence; Middle Aged; Retrospective Studies; Stavudine; Sustained Virologic Response; Tenofovir; Zidovudine | 2018 |
Does Tenofovir-containing First-line Antiretroviral Therapy Mitigate the Impact of Pretreatment Non-nucleoside Reverse Transcriptase Inhibitor Drug Resistance?
Topics: Drug Resistance; High-Throughput Nucleotide Sequencing; HIV; HIV Infections; Humans; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Tenofovir | 2019 |
Nanoencapsulation introduces long-acting phenomenon to tenofovir alafenamide and emtricitabine drug combination: A comparative pre-exposure prophylaxis efficacy study against HIV-1 vaginal transmission.
Topics: Adenine; Animals; Anti-HIV Agents; Cell Line; Delayed-Action Preparations; Drug Liberation; Emtricitabine; Endosomes; Female; HIV Infections; HIV-1; Mice; Nanoparticles; Pre-Exposure Prophylaxis; RNA, Viral; Tenofovir; Vagina; Viral Load | 2019 |
Simplification of combination antiretroviral therapy (cART) and the brain-a real-life experience.
Topics: Adult; Aging; Antiretroviral Therapy, Highly Active; Brain; Cognition; Cognitive Dysfunction; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Neuropsychological Tests; Quality of Life; Retrospective Studies; Reverse Transcriptase Inhibitors; Severity of Illness Index; Tenofovir | 2019 |
Tenofovir disoproxil fumarate/emtricitabine is associated with a higher risk of hypocalcemia compared to abacavir/lamivudine - results from a German cohort study.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Calcium; Cohort Studies; Dideoxynucleosides; Drug Combinations; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Hypocalcemia; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Prevalence; Pyridones; Retrospective Studies; Tenofovir; Treatment Outcome | 2019 |
Low tenofovir level in urine by a novel immunoassay is associated with seroconversion in a preexposure prophylaxis demonstration project.
Topics: Adult; Anti-HIV Agents; Dried Blood Spot Testing; Female; HIV Infections; Humans; Immunoassay; Male; Medication Adherence; Point-of-Care Testing; Pre-Exposure Prophylaxis; Prospective Studies; Seroconversion; Tenofovir; Urinalysis | 2019 |
Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Cohort Studies; Darunavir; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Retrospective Studies; Ritonavir; Tenofovir; Treatment Outcome; Viral Load | 2019 |
Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Dideoxynucleosides; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Italy; Male; Middle Aged; Oxazines; Piperazines; Prospective Studies; Pyridones; Retrospective Studies; Tenofovir; Treatment Outcome | 2019 |
Brief Report: Validation of a Urine Tenofovir Immunoassay for Adherence Monitoring to PrEP and ART and Establishing the Cutoff for a Point-of-Care Test.
Topics: Anti-HIV Agents; Enzyme-Linked Immunosorbent Assay; HIV Infections; Humans; Medication Adherence; Point-of-Care Testing; Pre-Exposure Prophylaxis; Tenofovir | 2019 |
Symfi, Symfi Lo, and Cimduo for HIV.
Topics: Adenine; Administration, Oral; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug Combinations; Drug Interactions; HIV Infections; HIV-1; Humans; Lamivudine; Phosphorous Acids; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2019 |
Tenofovir DF/emtricitabine/rilpivirine as HIV post-exposure prophylaxis: results from a multicentre prospective study.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Medication Adherence; Middle Aged; Post-Exposure Prophylaxis; Prospective Studies; Rilpivirine; Tenofovir; Treatment Outcome; Viral Load | 2019 |
Fanconi Syndrome and Tenofovir Alafenamide: A Case Report.
Topics: Adenine; Alanine; Antiviral Agents; Fanconi Syndrome; HIV Infections; Humans; Male; Middle Aged; Tenofovir | 2019 |
Short Communication: Bioequivalence of Tenofovir Component of Tenofovir/Rilpivirine/Emtricitabine in Digital Pills.
Topics: Adult; Anti-HIV Agents; Capsules; Drug Delivery Systems; Emtricitabine; Emtricitabine, Rilpivirine, Tenofovir Drug Combination; Female; Healthy Volunteers; HIV Infections; Humans; Male; Medication Adherence; Radio Waves; Rilpivirine; Tenofovir; Therapeutic Equivalency; United States; United States Food and Drug Administration | 2019 |
Zidovudine, tenofovir or abacavir? Different adverse effect profiles.
Topics: Dideoxynucleosides; Drug Combinations; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Tenofovir; Zidovudine | 2016 |
Epithelial Cells and Fibroblasts from the Human Female Reproductive Tract Accumulate and Release TFV and TAF to Sustain Inhibition of HIV Infection of CD4+ T cells.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; CD4-Positive T-Lymphocytes; Cervix Uteri; Drug Resistance, Multiple; Endometrium; Epithelial Cells; Female; Fibroblasts; Genitalia, Female; HIV Infections; Humans; Middle Aged; Organophosphates; Tenofovir; Vagina | 2019 |
Impact of pharmacogenetics and pregnancy on tenofovir and emtricitabine pharmacokinetics.
Topics: Adolescent; Adult; Anti-HIV Agents; Emtricitabine; Female; Genotype; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Leukocytes, Mononuclear; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Polymorphism, Single Nucleotide; Pregnancy; Tenofovir; Young Adult | 2019 |
Inflammation status in HIV-positive individuals correlates with changes in bone tissue quality after initiation of ART.
Topics: Absorptiometry, Photon; Adult; Anti-HIV Agents; Biomarkers; Bone and Bones; Bone Density; Bone Remodeling; Cohort Studies; Female; HIV Infections; HIV Seropositivity; Humans; Inflammation; Male; Spain; Tenofovir | 2019 |
Pre-exposure prophylaxis initiation and adherence among Black men who have sex with men (MSM) in three US cities: results from the HPTN 073 study.
Topics: Adolescent; Adult; Anti-HIV Agents; Black or African American; Cities; Emtricitabine; Female; Health Surveys; HIV Infections; Homosexuality, Male; Humans; Male; Medication Adherence; Middle Aged; Pre-Exposure Prophylaxis; Sexual Partners; Tenofovir; United States; Young Adult | 2019 |
Persistence on HIV preexposure prophylaxis medication over a 2-year period among a national sample of 7148 PrEP users, United States, 2015 to 2017.
Topics: Adult; Anti-HIV Agents; Emtricitabine; Female; Health Surveys; HIV Infections; Humans; Male; Medication Adherence; Middle Aged; Pre-Exposure Prophylaxis; Tenofovir; United States; Young Adult | 2019 |
Resistance Analysis of Bictegravir-Emtricitabine-Tenofovir Alafenamide in HIV-1 Treatment-Naive Patients through 48 Weeks.
Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Antiviral Agents; Dideoxynucleosides; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Lamivudine; Piperazines; Pyridones; Reverse Transcriptase Inhibitors; Tenofovir | 2019 |
Rate of viral load change and adherence of HIV adult patients treated with Efavirenz or Nevirapine antiretroviral regimens at 24 and 48 weeks in Yaoundé, Cameroon: a longitudinal cohort study.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cameroon; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Longitudinal Studies; Male; Middle Aged; Nevirapine; Patient Compliance; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Viral Load; Zidovudine | 2019 |
Severe rhabdomyolysis-induced acute kidney injury following concomitant use of Genvoya® (EVG/COBI/FTC/TAF) and simvastatin; a case report.
Topics: Acute Kidney Injury; Anti-HIV Agents; Cobicistat; Drug Combinations; Drug Interactions; Dyslipidemias; Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Emtricitabine; Hepatitis A; Hepatitis C; HIV Infections; Humans; Hypolipidemic Agents; Liver Function Tests; Male; Middle Aged; Quinolones; Renal Dialysis; Rhabdomyolysis; Simvastatin; Tenofovir; Treatment Outcome | 2019 |
Challenges to PrEP use and perceptions of urine tenofovir adherence monitoring reported by individuals on PrEP.
Topics: Adolescent; Adult; Anti-HIV Agents; Community Health Centers; Female; Health Services Accessibility; HIV Infections; Humans; Male; Medication Adherence; Perception; Philadelphia; Pre-Exposure Prophylaxis; Tenofovir; Urban Population; Young Adult | 2019 |
Long-term virological suppression on first-line efavirenz + tenofovir + emtricitabine/lamivudine for HIV-1.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studies; Cyclopropanes; Emtricitabine; Europe; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Sustained Virologic Response; Tenofovir; Treatment Failure; Viral Load; Young Adult | 2019 |
Tenofovir disoproxil fumarate initiation and changes in urinary biomarker concentrations among HIV-infected men and women.
Topics: Acute Kidney Injury; Adult; Anti-HIV Agents; Biomarkers; Female; HIV Infections; Humans; Male; Middle Aged; Tenofovir; Urinalysis | 2019 |
Preexposure Prophylaxis for Mitigating Risk of HIV Transmission During HIV Cure-Related Clinical Trials With a Treatment Interruption.
Topics: Adult; Anti-HIV Agents; Clinical Trials as Topic; HIV Infections; Humans; Male; Pre-Exposure Prophylaxis; Risk Factors; Sexual Partners; Tenofovir; Vaccines; Withholding Treatment | 2019 |
HIV-1 drug resistance testing is essential for heavily-treated patients switching from first- to second-line regimens in resource-limited settings: evidence from routine clinical practice in Cameroon.
Topics: Adolescent; Adult; Anti-HIV Agents; Cameroon; Child; Drug Resistance, Viral; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Male; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine; Tenofovir; Young Adult; Zidovudine | 2019 |
A Comparison of Plasma Efavirenz and Tenofovir, Dried Blood Spot Tenofovir-Diphosphate, and Self-Reported Adherence to Predict Virologic Suppression Among South African Women.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Emtricitabine; Female; HIV Infections; Humans; Logistic Models; Organophosphates; Plasma; Self Report; South Africa; Tenofovir | 2019 |
Effective use of pre-exposure prophylaxis (PrEP) Among stimulant users with multiple condomless sex partners: a longitudinal study of men who have sex with men in Los Angeles.
Topics: Adenine; Adult; Anti-Retroviral Agents; Central Nervous System Stimulants; Condoms; HIV Infections; Homosexuality, Male; Humans; Longitudinal Studies; Los Angeles; Male; Medication Adherence; Organophosphates; Pre-Exposure Prophylaxis; Sexual Partners; Tenofovir; Unsafe Sex | 2019 |
Barriers to HIV pre-exposure prophylaxis among African, Caribbean and Black men in Toronto, Canada.
Topics: Adolescent; Adult; Age Factors; Anti-HIV Agents; Black or African American; Canada; Emtricitabine; Health Knowledge, Attitudes, Practice; Hispanic or Latino; HIV Infections; Homosexuality, Male; Humans; Logistic Models; Male; Middle Aged; Pre-Exposure Prophylaxis; Risk; Surveys and Questionnaires; Tenofovir; Young Adult | 2019 |
Incidence and types of HIV-1 drug resistance mutation among patients failing first-line antiretroviral therapy.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Antiviral Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Incidence; Lamivudine; Male; Middle Aged; Mutation; Nevirapine; Stavudine; Tenofovir; Treatment Failure; Viral Load; Zidovudine | 2019 |
Proteinuria Is Associated With Increased Risk of Fragility Fracture in Men With or at Risk of HIV Infection.
Topics: Adult; Anti-HIV Agents; Fractures, Bone; HIV Infections; Homosexuality, Male; Humans; Male; Middle Aged; Prevalence; Proportional Hazards Models; Prospective Studies; Proteinuria; Risk Factors; Tenofovir | 2019 |
Predictive Value of Tenofovir Diphosphate in Dried Blood Spots for Future Viremia in Persons Living With HIV.
Topics: Adenine; Adult; Anti-HIV Agents; Biomarkers; Female; HIV; HIV Infections; Humans; Male; Medication Adherence; Middle Aged; Organophosphates; Predictive Value of Tests; Tenofovir; Viral Load; Viremia | 2019 |
Lipid profile and renal safety of tenofovir disoproxil fumarate-based anti-retroviral therapy in HIV-infected Chinese patients.
Topics: Adult; Anti-HIV Agents; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney; Lipids; Male; Middle Aged; Retrospective Studies; Tenofovir | 2019 |
Association of HIV Preexposure Prophylaxis With Incidence of Sexually Transmitted Infections Among Individuals at High Risk of HIV Infection.
Topics: Adolescent; Adult; Anti-HIV Agents; Australia; Bisexuality; Drug Therapy, Combination; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Incidence; Male; Middle Aged; Population Surveillance; Pre-Exposure Prophylaxis; Proportional Hazards Models; Sexually Transmitted Diseases; Tenofovir; Unsafe Sex; Young Adult | 2019 |
Occult hepatitis B and HIV infection.
Topics: Anti-Retroviral Agents; Coinfection; DNA, Viral; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir; Virus Activation | 2019 |
Case 11-2019: A 49-Year-Old Man with HIV Infection and Chronic Kidney Disease.
Topics: AIDS-Associated Nephropathy; Anti-Retroviral Agents; Diagnosis, Differential; Drug Resistance, Viral; Glomerulosclerosis, Focal Segmental; Hepatitis C; HIV Infections; HIV-1; Humans; Kidney; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Renal Insufficiency, Chronic; Tenofovir | 2019 |
Unsupervised PrEP in routine practice: a new challenge?
Topics: Adult; Anti-HIV Agents; Emtricitabine; HIV Infections; HIV-1; Homosexuality, Male; Humans; Male; Pre-Exposure Prophylaxis; Tenofovir; Viral Load | 2019 |
Predictors of Disengagement in Care for Individuals Receiving Pre-exposure Prophylaxis (PrEP).
Topics: Adult; Anti-HIV Agents; Black or African American; Drug Combinations; Emtricitabine; Ethnicity; Female; Hispanic or Latino; HIV Infections; Humans; Male; Pre-Exposure Prophylaxis; Retrospective Studies; Risk Factors; Sexual Behavior; Surveys and Questionnaires; Tenofovir | 2019 |
Barriers and Facilitators of PrEP Adherence for Young Men and Transgender Women of Color.
Topics: Anti-HIV Agents; Black or African American; Cohort Studies; Female; Health Knowledge, Attitudes, Practice; Health Services Accessibility; Hispanic or Latino; HIV Infections; Homosexuality, Male; Humans; Interviews as Topic; Male; Medication Adherence; Philadelphia; Pre-Exposure Prophylaxis; Qualitative Research; Risk-Taking; Sexual and Gender Minorities; Social Stigma; Social Support; Tenofovir; Transgender Persons; Young Adult | 2019 |
Population Modeling Highlights Drug Disposition Differences Between Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate in the Blood and Semen.
Topics: Adenine; Adult; Alanine; Anti-Retroviral Agents; Cell Count; Emtricitabine; HIV Infections; HIV-1; Humans; Leukocytes, Mononuclear; Male; Metabolic Clearance Rate; Plasma; Semen; Tenofovir; Tissue Distribution | 2019 |
Tenofovir concentrations in hair strongly predict virologic suppression in breastfeeding women.
Topics: Adult; Africa South of the Sahara; Anti-HIV Agents; Breast Feeding; Female; Hair; HIV Infections; Humans; Longitudinal Studies; Medication Adherence; Postpartum Period; Pregnancy; Sustained Virologic Response; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2019 |
Recent HIV Risk Behavior and Partnership Type Predict HIV Pre-Exposure Prophylaxis Adherence in Men Who Have Sex with Men.
Topics: Adult; Anti-HIV Agents; Female; HIV Infections; Homosexuality, Male; Humans; Male; Medication Adherence; Middle Aged; Pre-Exposure Prophylaxis; Risk-Taking; Sexual Partners; Tenofovir; Young Adult | 2019 |
Perceptions of HIV Preexposure Prophylaxis Among Young Pregnant Women from Rural KwaZulu-Natal, South Africa.
Topics: Adolescent; Anti-HIV Agents; Condoms; Female; Health Knowledge, Attitudes, Practice; HIV Infections; Humans; Male; Motivation; Pre-Exposure Prophylaxis; Pregnancy; Pregnant Women; Risk Reduction Behavior; Sexual Partners; South Africa; Tenofovir; Young Adult | 2019 |
Bictegravir and dolutegravir: head to head at 96 weeks.
Topics: Adenine; Alanine; Amides; Dideoxynucleosides; Double-Blind Method; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Tenofovir | 2019 |
Prevalence of tubulopathy and association with renal function loss in HIV-infected patients.
Topics: Adult; Anti-HIV Agents; Biomarkers; Ethnicity; Female; France; Glomerular Filtration Rate; HIV; HIV Infections; Humans; Kidney Tubules; Male; Middle Aged; Prevalence; Prospective Studies; Renal Insufficiency, Chronic; Tenofovir | 2020 |
Quantification of tenofovir disoproxil fumarate and emtricitabine in generic pre-exposure prophylaxis tablets obtained from the internet.
Topics: Adult; Anti-HIV Agents; Drugs, Generic; Emtricitabine; Female; HIV Infections; Humans; Internet; Male; Pre-Exposure Prophylaxis; Tablets; Tenofovir | 2019 |
Increased tenofovir monoester concentrations in patients receiving tenofovir disoproxil fumarate with ledipasvir/sofosbuvir.
Topics: Adenine; Adolescent; Adult; Antiviral Agents; Benzimidazoles; Blood Chemical Analysis; Chromatography, Liquid; Drug Interactions; Female; Fluorenes; Hepatitis C, Chronic; HIV Infections; Humans; Male; Middle Aged; Phosphorous Acids; Sofosbuvir; Tandem Mass Spectrometry; Tenofovir; Young Adult | 2019 |
Brief Report: Short-Term Adherence Marker to PrEP Predicts Future Nonretention in a Large PrEP Demo Project: Implications for Point-of-Care Adherence Testing.
Topics: Adenine; Adult; Anti-HIV Agents; Dried Blood Spot Testing; Emtricitabine; Female; HIV Infections; Homosexuality, Male; Humans; Male; Medication Adherence; Organophosphates; Point-of-Care Testing; Pre-Exposure Prophylaxis; Proportional Hazards Models; Prospective Studies; Tenofovir | 2019 |
Tenofovir Has Minimal Effect on Biomarkers of Bone Health in Youth with HIV Receiving Initial Antiretroviral Therapy.
Topics: Adolescent; Alkaline Phosphatase; Anti-HIV Agents; Biomarkers; Bone and Bones; Bone Density; Bone Diseases, Metabolic; Female; HIV Infections; Humans; Lymphocyte Activation; Macrophage Activation; Macrophages; Male; Osteopontin; Osteoprotegerin; Parathyroid Hormone; RANK Ligand; Tenofovir; Young Adult | 2019 |
Impact of Estimated Pre-Exposure Prophylaxis (PrEP) Adherence Patterns on Bone Mineral Density in a Large PrEP Demonstration Project.
Topics: Absorptiometry, Photon; Adult; Anti-HIV Agents; Bone Density; Cohort Studies; Dried Blood Spot Testing; Female; Hip; HIV Infections; Homosexuality, Male; Humans; Male; Medication Adherence; Pre-Exposure Prophylaxis; Spine; Tenofovir; Transgender Persons; Young Adult | 2019 |
Depot Medroxyprogesterone Acetate and the Vaginal Microbiome as Modifiers of Tenofovir Diphosphate and Lamivudine Triphosphate Concentrations in the Female Genital Tract of Ugandan Women: Implications for Tenofovir Disoproxil Fumarate/Lamivudine in Preexp
Topics: Adenine; Anti-HIV Agents; Cytidine Triphosphate; Dideoxynucleotides; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Medroxyprogesterone Acetate; Microbiota; Organophosphates; Pre-Exposure Prophylaxis; Tenofovir; Uganda | 2020 |
Low Disclosure of PrEP Nonadherence and HIV-Risk Behaviors Associated With Poor HIV PrEP Adherence in the HPTN 067/ADAPT Study.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Condoms; Directly Observed Therapy; Disclosure; Drug Therapy, Combination; Emtricitabine; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; HIV Infections; Homosexuality, Male; Humans; Male; Medication Adherence; Middle Aged; Pre-Exposure Prophylaxis; Risk-Taking; Sexual and Gender Minorities; Social Networking; South Africa; Surveys and Questionnaires; Tenofovir; Thailand; United States; Young Adult | 2019 |
Long-term virological and serologic responses of chronic hepatitis B virus infection to tenofovir disoproxil fumarate-containing regimens in patients with HIV and hepatitis B coinfection.
Topics: Adult; Antiviral Agents; DNA, Viral; Drug Substitution; Drug Therapy, Combination; Female; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Retrospective Studies; Tenofovir; Treatment Outcome; Viral Load | 2019 |
Tenofovir Plasma Concentration from Preexposure Prophylaxis at the Time of Potential HIV Exposure: a Population Pharmacokinetic Modeling and Simulation Study Involving Serodiscordant Couples in East Africa.
Topics: Adenine; Anti-HIV Agents; Bayes Theorem; Cross-Over Studies; Female; HIV; HIV Infections; Humans; Kenya; Leukocytes, Mononuclear; Male; Organophosphates; Pre-Exposure Prophylaxis; Prospective Studies; Sexual Partners; Tenofovir; Uganda | 2019 |
Preexposure Prophylaxis for the Prevention of HIV Infection: US Preventive Services Task Force Recommendation Statement.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Advisory Committees; Anti-Retroviral Agents; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Male; Medication Adherence; Pre-Exposure Prophylaxis; Risk Assessment; Risk Factors; Tenofovir; United States | 2019 |
Short Communication: Cascade of Antiretroviral Therapy Adherence in Virologically Suppressed Persons Living with HIV.
Topics: Adult; Anti-Retroviral Agents; Cross-Sectional Studies; Dried Blood Spot Testing; Emtricitabine; HIV Infections; Humans; Medication Adherence; Prospective Studies; Sustained Virologic Response; Tenofovir | 2020 |
First year of pre-exposure prophylaxis implementation in France with daily or on-demand tenofovir disoproxil fumarate/emtricitabine.
Topics: Adult; Anti-HIV Agents; Comorbidity; Emtricitabine; Female; France; Health Plan Implementation; HIV Infections; Homosexuality, Male; Humans; Male; Middle Aged; Odds Ratio; Outcome Assessment, Health Care; Pre-Exposure Prophylaxis; Tenofovir; Unsafe Sex | 2019 |
Frequency of Hepatitis B Virus Resistance Mutations in Women Using Tenofovir Gel as Pre-Exposure Prophylaxis.
Topics: Administration, Intravaginal; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Genotype; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Mutation; Pre-Exposure Prophylaxis; South Africa; Tenofovir; Young Adult | 2019 |
The Effect of Low Dose Oral Vitamin D on Bone Mineral Density Changes in HIV Patients: 36 Months Follow Up.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Bone Density; Cyclopropanes; Female; Follow-Up Studies; HIV Infections; Humans; Male; Middle Aged; Parathyroid Hormone; Prospective Studies; Tenofovir; Vitamin D; Vitamin D Deficiency | 2020 |
Cluster headache-like symptoms during treatment with tenofovir disoproxil fumarate and emtricitabine.
Topics: Anti-HIV Agents; Cluster Headache; Emtricitabine; Female; HIV Infections; Humans; Reverse Transcriptase Inhibitors; Tenofovir; Young Adult | 2019 |
A viral genome wide association study and genotypic resistance testing in patients failing first line antiretroviral therapy in the first large countrywide Ethiopian HIV cohort.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Drug Resistance, Viral; Ethiopia; Female; Genome-Wide Association Study; Genotype; HIV Infections; HIV Integrase; HIV-1; Humans; Male; Mutation; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure; Zidovudine | 2019 |
Drug resistance from preferred antiretroviral regimens for HIV infection in South Africa: A modeling study.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Antigens; Drug Resistance, Viral; Female; Heterosexuality; HIV Infections; HIV-1; Humans; Male; Models, Theoretical; Reverse Transcriptase Inhibitors; South Africa; Tenofovir; Viral Load | 2019 |
Treatment of Human Immunodeficiency Virus Infection With Tenofovir Disoproxil Fumarate-Containing Antiretrovirals Maintains Low Bone Formation Rate, But Increases Osteoid Volume on Bone Histomorphometry.
Topics: Adult; Anti-Retroviral Agents; Biomarkers; Bone and Bones; Bone Density; Bone Remodeling; Cytokines; HIV Infections; Humans; Male; Osteogenesis; Tenofovir | 2019 |
Potential Benefits of Switching Liver Transplant Recipients to Tenofovir Alafenamide Prophylaxis.
Topics: Adenine; Alanine; Hepatitis B, Chronic; HIV Infections; Humans; Liver Transplantation; Tenofovir | 2020 |
Pre-treatment and acquired HIV drug resistance in Dar es Salaam, Tanzania in the era of tenofovir and routine viral load monitoring.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cross-Sectional Studies; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Reverse Transcriptase Inhibitors; Tanzania; Tenofovir; Treatment Failure; Viral Load | 2019 |
Comment on: Tenofovir DF/emtricitabine/rilpivirine as HIV post-exposure prophylaxis: results from a multicentre prospective study.
Topics: Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Prospective Studies; Rilpivirine; Tenofovir | 2019 |
Sustained HIV virologic suppression with crushed combination tablets containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide.
Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Drug Therapy, Combination; Emtricitabine; Enteral Nutrition; Gastrostomy; HIV Infections; HIV-1; Humans; Male; Middle Aged; Quinolones; Sustained Virologic Response; Tablets; Tenofovir | 2019 |
Early antiretroviral therapy and daily pre-exposure prophylaxis for HIV prevention among female sex workers in Cotonou, Benin: a prospective observational demonstration study.
Topics: Adult; Anti-HIV Agents; Benin; Emtricitabine; Female; HIV Infections; Humans; Pre-Exposure Prophylaxis; Prospective Studies; Safe Sex; Sex Workers; Sexual Behavior; Tenofovir | 2018 |
Incidence of cutaneous adverse events after exposure to tenofovir-emtricitabine in HIV-uninfected vs HIV-infected patients: pharmacovigilance within a large Midwestern U.S. patient population from the Research on Adverse Drug events And Reports program.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Incidence; Male; Middle Aged; Midwestern United States; Pharmacovigilance; Skin Diseases; Tenofovir; Young Adult | 2019 |
Adherence to Antiretroviral Therapy and Pre-exposure Prophylaxis: TARGETing the Ideal Measure.
Topics: Emtricitabine; HIV Infections; Humans; Plasma; Tenofovir | 2020 |
A mucosal barrier for topical HIV PrEP?
Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Pre-Exposure Prophylaxis; Single-Blind Method; Tenofovir | 2019 |
Tenofovir-associated renal toxicity in a cohort of HIV infected patients in Ghana.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Female; Ghana; HIV Infections; Humans; Incidence; Kidney; Kidney Function Tests; Male; Middle Aged; Renal Insufficiency; Tenofovir | 2019 |
Brief Report: Urine Emtricitabine and Tenofovir Concentrations Provide Markers of Recent Antiretroviral Drug Exposure Among HIV-Negative Men Who Have Sex With Men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Alanine; Anti-HIV Agents; Anti-Retroviral Agents; Biomarkers; Cobicistat; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Male; Middle Aged; Quinolones; Sexual and Gender Minorities; Tenofovir; Time Factors; Young Adult | 2019 |
Brief Report: Relationship Between ABCC4 SNPs and Hepatitis B Virus Suppression During Tenofovir-Containing Antiretroviral Therapy in Patients With HIV/HBV Coinfection.
Topics: Adult; Anti-HIV Agents; Coinfection; DNA, Viral; Female; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Logistic Models; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Polymorphism, Single Nucleotide; Tenofovir | 2019 |
Protocol for a longitudinal study to evaluate the use of tenofovir-based PrEP for safer conception and pregnancy among women in South Africa.
Topics: Adolescent; Adult; Anti-HIV Agents; Female; Fertilization; Follow-Up Studies; HIV; HIV Infections; Humans; Incidence; Medication Adherence; Pre-Exposure Prophylaxis; Pregnancy; Pregnancy Complications, Infectious; Safe Sex; South Africa; Tenofovir; Young Adult | 2019 |
A case of esophageal cancer with human immunodeficiency virus infection that progressed rapidly after neoadjuvant chemoradiotherapy.
Topics: Aged; Alkynes; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoxazines; Chemoradiotherapy; Cisplatin; Cyclopropanes; Deglutition Disorders; Disease Progression; Drug Interactions; Emtricitabine; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fatal Outcome; Female; Fluorouracil; Gastrostomy; HIV Infections; Humans; Neoadjuvant Therapy; Neoplasm Staging; Renal Insufficiency; RNA, Viral; Tenofovir; Viral Load | 2020 |
Drug resistance and optimizing dolutegravir regimens for adolescents and young adults failing antiretroviral therapy.
Topics: Adolescent; Cross-Sectional Studies; Drug Combinations; Drug Resistance, Viral; Female; Genotype; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Medication Adherence; Oxazines; Piperazines; Pyridones; Tenofovir; Treatment Failure; Viral Load; Young Adult; Zimbabwe | 2019 |
Efficacy of Oral Tenofovir Alafenamide/Emtricitabine Combination or Single-Agent Tenofovir Alafenamide Against Vaginal Simian Human Immunodeficiency Virus Infection in Macaques.
Topics: Adenine; Alanine; Animals; Anti-HIV Agents; Chemoprevention; Disease Models, Animal; Disease Transmission, Infectious; Emtricitabine; Female; HIV; HIV Infections; Macaca; Pre-Exposure Prophylaxis; Simian Immunodeficiency Virus; Tenofovir; Treatment Outcome; Vagina | 2019 |
Safety and efficacy of Option B+ ART in Malawi: few severe maternal toxicity events or infant HIV infections among pregnant women initiating tenofovir/lamivudine/efavirenz.
Topics: Adult; Alkynes; Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Malawi; Pregnancy; Pregnancy Complications, Infectious; Tenofovir; Young Adult | 2019 |
Discontinuation of tenofovir due to nephrotoxicity: insight into 12 years of clinical practice
Topics: Adult; Anti-Retroviral Agents; Female; Glomerular Filtration Rate; Hematuria; HIV Infections; Humans; Kidney Diseases; Male; Middle Aged; Proteinuria; Retrospective Studies; Tenofovir | 2019 |
Effects of Highly Active Antiretroviral Therapy on Albuminuria in HIVinfected Persons.
Topics: Adolescent; Adult; Age Factors; Albuminuria; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Female; Glomerular Filtration Rate; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Prospective Studies; Sex Factors; Tenofovir; Young Adult; Zidovudine | 2020 |
Pharmacokinetics of two common antiretroviral regimens in older HIV-infected patients: a pilot study.
Topics: Adenine; Aged; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Black or African American; Cyclopropanes; Data Interpretation, Statistical; Deoxycytidine; Emtricitabine; Female; Frail Elderly; HIV; HIV Infections; Humans; Male; Middle Aged; Oligopeptides; Organophosphonates; Pilot Projects; Pyridines; Ritonavir; Tenofovir; White People | 2013 |
[Tenofovir hypersensitivity to tenofovir (DRESS) syndrome in a female patient infected by HIV].
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Asthenia; Benzoxazines; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Eruptions; Drug Hypersensitivity; Drug Substitution; Emtricitabine; Female; Fever; HIV Infections; Humans; Lamivudine; Nevirapine; Organophosphonates; Reverse Transcriptase Inhibitors; Syndrome; Tenofovir | 2013 |
Urinary beta-2 microglobulin and alpha-1 microglobulin are useful screening markers for tenofovir-induced kidney tubulopathy in patients with HIV-1 infection: a diagnostic accuracy study.
Topics: Adenine; Adult; Alpha-Globulins; Anti-Retroviral Agents; beta 2-Microglobulin; Biomarkers; Chi-Square Distribution; Female; HIV Infections; HIV-1; Humans; Kidney Diseases; Male; Middle Aged; Organophosphonates; Sensitivity and Specificity; Tenofovir | 2013 |
Prophylactic effect of antiretroviral therapy on hepatitis B virus infection.
Topics: Adenine; Adult; Alanine Transaminase; Anti-Retroviral Agents; Antibiotic Prophylaxis; Drug Resistance, Viral; Female; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Core Antigens; Hepatitis B Surface Antigens; HIV Infections; Humans; Kaplan-Meier Estimate; Lamivudine; Male; Organophosphonates; Retrospective Studies; Tenofovir | 2013 |
[Pulmonary hypertension in human immunodeficiency virus-infected patients: the role of antiretroviral therapy].
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cross-Sectional Studies; Drug Therapy, Combination; Female; HIV Infections; Humans; Hypertension, Pulmonary; Lamivudine; Male; Middle Aged; Organophosphonates; Prevalence; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Tricuspid Valve Insufficiency; Ultrasonography | 2014 |
Urine processing impacts uric acid level in HIV-infected adults: implications for diagnosing tenofovir-associated proximal tubulopathy.
Topics: Adenine; Adult; AIDS-Associated Nephropathy; Anti-HIV Agents; HIV Infections; Humans; Organophosphonates; Sensitivity and Specificity; Specimen Handling; Tenofovir; Time Factors; Uric Acid | 2013 |
Cost-effectiveness of pre-exposure prophylaxis (PrEP) in preventing HIV-1 infections in rural Zambia: a modeling study.
Topics: Adenine; Anti-HIV Agents; Cost-Benefit Analysis; Deoxycytidine; Emtricitabine; HIV Infections; HIV-1; Humans; Models, Biological; Organophosphonates; Prevalence; Primary Prevention; Rural Population; Sensitivity and Specificity; Sexual Behavior; Tenofovir; Zambia | 2013 |
Rectal transmission of transmitted/founder HIV-1 is efficiently prevented by topical 1% tenofovir in BLT humanized mice.
Topics: Adenine; Administration, Rectal; Animals; Anti-HIV Agents; Antigens, CD34; Drug Evaluation, Preclinical; Female; Hepatocytes; HIV Infections; HIV-1; Humans; Kaplan-Meier Estimate; Male; Mice; Mice, Transgenic; Organophosphonates; Rectum; Sequence Analysis, DNA; Tenofovir | 2013 |
Boosting HIV treatment options: good news, new challenges.
Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Cobicistat; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir; Thiazoles | 2013 |
Cardiometabolic risk factors among HIV patients on antiretroviral therapy.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Cyclopropanes; Female; HIV; HIV Infections; Humans; Insulin Resistance; Lamivudine; Male; Middle Aged; Nevirapine; Organophosphonates; Risk Factors; Stavudine; Tenofovir; Triglycerides; Zambia; Zidovudine | 2013 |
Access to treatment for HBV infection and its consistency with 2008 European guidelines in a multicentre cross-sectional study of HIV/HBV co-infected patients in Italy.
Topics: Adenine; Adult; Anti-Retroviral Agents; Coinfection; Cross-Sectional Studies; Deoxycytidine; Emtricitabine; Europe; Female; Guideline Adherence; Health Services Accessibility; Hepatitis B; HIV Infections; Humans; Infectious Disease Medicine; Italy; Lamivudine; Male; Multivariate Analysis; Organophosphonates; Practice Guidelines as Topic; Regression Analysis; Tenofovir; Treatment Outcome | 2013 |
Drug synergy of tenofovir and nanoparticle-based antiretrovirals for HIV prophylaxis.
Topics: Adenine; Alkynes; Animals; Anti-HIV Agents; Benzoxazines; Cell Line; Cervix Uteri; Chemistry, Pharmaceutical; Cyclopropanes; Delayed-Action Preparations; Drug Carriers; Drug Synergism; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Inhibitory Concentration 50; Lactic Acid; Macaca; Models, Biological; Nanoparticles; Organophosphonates; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Saquinavir; Spectroscopy, Fourier Transform Infrared; Tenofovir; Tissue Culture Techniques | 2013 |
Left ventricular hypertrophy detected by echocardiography in HIV-infected patients.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Carbamates; Comorbidity; Cross-Sectional Studies; Cyclopropanes; Diabetes Mellitus; Drug Combinations; Dyslipidemias; Echocardiography; Female; Furans; HIV Infections; Humans; Hypertension; Hypertrophy, Left Ventricular; Lamivudine; Lopinavir; Male; Middle Aged; Nevirapine; Organophosphates; Organophosphonates; Risk Factors; Ritonavir; Smoking; Spain; Sulfonamides; Tenofovir; Zidovudine | 2013 |
Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Tenofovir; Thymidine; Treatment Failure; Viral Load; Zidovudine | 2013 |
Influence of HIV infection on response to tenofovir in patients with chronic hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Female; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Spain; Tenofovir; Treatment Outcome; Viral Load | 2013 |
Could FDA approval of pre-exposure prophylaxis make a difference? A qualitative study of PrEP acceptability and FDA perceptions among men who have sex with men.
Topics: Adenine; Adult; Anti-Retroviral Agents; Chemoprevention; Deoxycytidine; Emtricitabine; Focus Groups; Health Knowledge, Attitudes, Practice; HIV Infections; Homosexuality, Male; Humans; Interviews as Topic; Male; Organophosphonates; Patient Acceptance of Health Care; Perception; Qualitative Research; Rhode Island; Sex Workers; Tenofovir; United States; United States Food and Drug Administration | 2014 |
Oral antiretroviral drugs as public health tools for HIV prevention: global implications for adherence, drug resistance, and the success of HIV treatment programs.
Topics: Adenine; Administration, Oral; Anti-HIV Agents; Counseling; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Organophosphonates; Patient Compliance; Public Health; Tenofovir | 2013 |
Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine.
Topics: Adenine; Alkynes; Anti-Retroviral Agents; Benzoxazines; Cyclopropanes; Databases, Factual; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; HIV Infections; HIV-1; Humans; Mutation, Missense; Nevirapine; Organophosphonates; Reverse Transcriptase Inhibitors; RNA, Viral; Stavudine; Tenofovir; Zidovudine | 2013 |
Comparison of tenofovir, zidovudine, or stavudine as part of first-line antiretroviral therapy in a resource-limited-setting: a cohort study.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Female; Health Resources; HIV; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Residence Characteristics; RNA, Viral; Stavudine; Tenofovir; Young Adult; Zidovudine | 2013 |
Tenofovir disoproxil fumarate-associated nephrotoxicity in HIV-infected patients: a prospective controlled study.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; Humans; Incidence; Kidney Diseases; Male; Organophosphonates; Prospective Studies; Tenofovir; Zidovudine | 2013 |
Short communication: Interferon/ribavirin treatment for HCV is associated with the development of hypophosphatemia in HIV/hepatitis C virus-coinfected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Antiviral Agents; Coinfection; Drug Interactions; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Hypophosphatemia; Interferons; Kidney Diseases; Male; Middle Aged; Organophosphonates; Retrospective Studies; Ribavirin; Risk Factors; Tenofovir | 2013 |
In vivo platelet activation and platelet hyperreactivity in abacavir-treated HIV-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Blood Platelets; Case-Control Studies; CD40 Ligand; Cyclic GMP; Deoxyguanine Nucleotides; Dideoxynucleosides; Female; HIV Infections; Humans; Male; Middle Aged; Nitric Oxide; Organophosphonates; P-Selectin; Phospholipases A2, Secretory; Platelet Activation; Platelet Aggregation; Retrospective Studies; Tenofovir | 2013 |
Rates of switching antiretroviral drugs in a primary care service in South Africa before and after introduction of tenofovir.
Topics: Adenine; Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Drug Substitution; Drug-Related Side Effects and Adverse Reactions; Female; HIV; HIV Infections; Humans; Male; Organophosphonates; Primary Health Care; Retrospective Studies; Risk Factors; South Africa; Tenofovir | 2013 |
Vulnerability in research ethics: a way forward.
Topics: Adenine; Alzheimer Disease; Anti-HIV Agents; Cambodia; Community-Based Participatory Research; Ethics Committees, Research; Ethics, Research; HIV Infections; Human Experimentation; Humans; Informed Consent; Moral Obligations; Organophosphonates; Primary Prevention; Randomized Controlled Trials as Topic; Research Personnel; Research Subjects; Sex Workers; Tenofovir; Vulnerable Populations | 2013 |
Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002-2009.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studies; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Europe; HIV Infections; HIV Protease Inhibitors; HIV Seropositivity; HIV-1; Humans; Lamivudine; Lopinavir; Nevirapine; Organophosphonates; Reverse Transcriptase Inhibitors; Risk Factors; Tenofovir; Time Factors; United States | 2013 |
Once-daily darunavir/ritonavir and abacavir/lamivudine versus tenofovir/emtricitabine for treatment-naïve patients with a baseline viral load of more than 100 000 copies/ml.
Topics: Adenine; Anti-HIV Agents; Darunavir; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Organophosphonates; Ritonavir; Sulfonamides; Tenofovir; Viral Load | 2013 |
Ethical considerations in determining standard of prevention packages for HIV prevention trials: examining PrEP.
Topics: Adenine; Anti-HIV Agents; Clinical Trials as Topic; Community-Based Participatory Research; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Ethics, Research; Health Services Needs and Demand; HIV Infections; Humans; Organophosphonates; Practice Guidelines as Topic; Primary Prevention; Research Design; Tenofovir; Treatment Failure; United States; United States Food and Drug Administration | 2013 |
Knowledge of and opinions on HIV preexposure prophylaxis among front-line service providers at Canadian AIDS service organizations.
Topics: Adenine; Adult; Anti-HIV Agents; Canada; Chemoprevention; Deoxycytidine; Emtricitabine; Female; Health Knowledge, Attitudes, Practice; Health Personnel; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Surveys and Questionnaires; Tenofovir | 2013 |
Peripheral T-cell apoptosis is not differentially affected by antiretroviral regimens in HIV-infected patients.
Topics: Adenine; Anti-HIV Agents; Apoptosis; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cross-Sectional Studies; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Organophosphonates; Proto-Oncogene Proteins c-bcl-2; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load | 2013 |
The significance of antiretroviral-associated acute kidney injury in a cohort of ambulatory human immunodeficiency virus-infected patients.
Topics: Acute Kidney Injury; Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; Follow-Up Studies; Glomerular Filtration Rate; HIV; HIV Infections; Humans; Kidney Function Tests; Male; Organophosphonates; Prognosis; Prospective Studies; Risk Factors; Tenofovir | 2013 |
Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1; Humans; Male; Middle Aged; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; South Africa; Tenofovir; Treatment Failure; Viral Load | 2013 |
Update to Interim Guidance for Preexposure Prophylaxis (PrEP) for the Prevention of HIV Infection: PrEP for injecting drug users.
Topics: Adenine; Anti-HIV Agents; Centers for Disease Control and Prevention, U.S.; Deoxycytidine; Emtricitabine; Female; Heterosexuality; HIV Infections; Homosexuality, Male; Humans; Male; Organophosphonates; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Risk Assessment; Substance Abuse, Intravenous; Tenofovir; United States | 2013 |
Study design considerations for evaluating efficacy of systemic preexposure prophylaxis interventions.
Topics: Adenine; Anti-HIV Agents; Clinical Trials, Phase III as Topic; Delayed-Action Preparations; Deoxycytidine; Drug Combinations; Emtricitabine; HIV Infections; Humans; Medication Adherence; Organophosphonates; Randomized Controlled Trials as Topic; Research Design; Sample Size; Tenofovir; Treatment Outcome; United States | 2013 |
Ethics and pre-exposure prophylaxis for HIV infection.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Organophosphonates; Public Health; Risk-Taking; Tenofovir; United States | 2013 |
Topical microbicides--what's new?
Topics: Adenine; Anti-Infective Agents, Local; Anti-Retroviral Agents; Drug Delivery Systems; Female; Gels; HIV Infections; Humans; Male; Medication Adherence; Organophosphonates; Reproductive Health; Tenofovir; Treatment Outcome | 2013 |
HIV pre-exposure prophylaxis in injecting drug users.
Topics: Adenine; Anti-HIV Agents; Female; HIV Infections; Humans; Male; Organophosphonates; Substance Abuse, Intravenous; Tenofovir | 2013 |
Role of traditional risk factors and antiretroviral drugs in the incidence of chronic kidney disease, ANRS CO3 Aquitaine cohort, France, 2004-2012.
Topics: Adenine; Age Factors; Anti-Retroviral Agents; Cohort Studies; Contraindications; Female; France; Glomerular Filtration Rate; HIV Infections; Humans; Incidence; Kaplan-Meier Estimate; Male; Organophosphonates; Poisson Distribution; Prospective Studies; Protease Inhibitors; Regression Analysis; Renal Insufficiency, Chronic; Risk Factors; Sex Factors; Tenofovir | 2013 |
Tenofovir helps prevent HIV in drug users.
Topics: Adenine; Anti-HIV Agents; Drug Users; HIV Infections; Humans; Organophosphonates; Substance-Related Disorders; Tenofovir | 2013 |
Neutrophil gelatinase-associated lipocalin, a marker of tubular dysfunction, is not increased in long-term virologically controlled patients receiving a tenofovir/emtricitabine + nevirapine regimen.
Topics: Acute-Phase Proteins; Adenine; Adult; Anti-HIV Agents; Cross-Sectional Studies; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Lipocalin-2; Lipocalins; Male; Middle Aged; Nevirapine; Organophosphonates; Proto-Oncogene Proteins; Tenofovir | 2013 |
[Pre-exposure prophylaxis for HIV transmission? No, unless].
Topics: Adenine; Anti-HIV Agents; Chemoprevention; Deoxycytidine; Emtricitabine; HIV Infections; Humans; Organophosphonates; Tenofovir | 2013 |
Tenofovir-related Fanconi's syndrome and osteomalacia in a teenager with HIV.
Topics: Adenine; Adolescent; Anti-HIV Agents; Fanconi Syndrome; HIV Infections; Humans; Male; Organophosphonates; Osteomalacia; Tenofovir | 2013 |
[Crucial risk factors for renal function deterioration of HIV-infected patients at the AIDS Clinic in Rambam Hospital].
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Coinfection; Female; Glomerular Filtration Rate; Hepatitis C; HIV Infections; Humans; Israel; Male; Medical Records, Problem-Oriented; Middle Aged; Models, Statistical; Organophosphonates; Renal Insufficiency; Retrospective Studies; Risk Factors; Tenofovir | 2013 |
Effect of antiretroviral therapy on HIV reservoirs in elite controllers.
Topics: Adenine; Anti-HIV Agents; Asymptomatic Diseases; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Deoxycytidine; DNA, Viral; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Immunity, Innate; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Tenofovir; Viremia; Virus Replication | 2013 |
Tenofovir-related nephrotoxicity: an ongoing clinical challenge.
Topics: Adenine; Anti-HIV Agents; Female; HIV Infections; Humans; Kidney Diseases; Male; Middle Aged; Organophosphonates; Risk Factors; Tenofovir | 2013 |
Severe recurrent rhabdomyolysis-induced acute kidney injury in a HIV-infected patient on antiretroviral therapy.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; HIV Infections; Humans; Kidney Tubular Necrosis, Acute; Male; Organophosphonates; Rhabdomyolysis; Tenofovir | 2013 |
HIV-HBV coinfection in Southern Africa and the effect of lamivudine- versus tenofovir-containing cART on HBV outcomes.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Coinfection; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B; Hepatitis B virus; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Prospective Studies; Reverse Transcriptase Inhibitors; South Africa; Tenofovir; Treatment Outcome; Zambia | 2013 |
An evaluation of polycaprolactone matrices for vaginal delivery of the antiviral, tenofovir, in preventing heterosexual transmission of HIV.
Topics: Adenine; Administration, Intravaginal; Antiviral Agents; Drug Delivery Systems; HeLa Cells; Heterosexuality; HIV Infections; Humans; Organophosphonates; Polyesters; Porosity; Powders; Tenofovir | 2013 |
Evolution of glomerular filtration rate in HIV-infected, HIV-HBV-coinfected and HBV-infected patients receiving tenofovir disoproxil fumarate.
Topics: Adenine; Adult; Antiviral Agents; Coinfection; Female; Glomerular Filtration Rate; Hepatitis B, Chronic; HIV Infections; Humans; Kidney Diseases; Male; Middle Aged; Organophosphonates; Risk Factors; Tenofovir | 2013 |
Tubular and glomerular proteinuria in HIV-infected adults with estimated glomerular filtration rate ≥ 60 ml/min per 1.73 m2.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Cross-Sectional Studies; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Glomerulus; Kidney Tubules; Male; Middle Aged; Organophosphonates; Proteinuria; Regression Analysis; Renal Insufficiency, Chronic; Risk Factors; Tenofovir | 2013 |
Preexposure prophylaxis will have a limited impact on HIV-1 drug resistance in sub-Saharan Africa: a comparison of mathematical models.
Topics: Adenine; Adolescent; Adult; Africa South of the Sahara; Aged; Anti-HIV Agents; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Models, Theoretical; Organophosphonates; Pre-Exposure Prophylaxis; Tenofovir; Young Adult | 2013 |
The impact of choice of NNRTI on short-term treatment outcomes among HIV-infected patients prescribed tenofovir and lamivudine in Johannesburg, South Africa.
Topics: Adenine; Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Reverse Transcriptase Inhibitors; South Africa; Tenofovir; Treatment Outcome; Viral Load | 2013 |
[Ophthalmological alterations at the initial diagnosis of HIV infection].
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Cyclohexanes; Deoxycytidine; Drug Therapy, Combination; Early Diagnosis; Emtricitabine; Eye Infections, Viral; HIV Infections; Humans; Lopinavir; Male; Maraviroc; Organophosphonates; Retinal Diseases; Syndrome; Tenofovir; Treatment Outcome; Triazoles; Zidovudine | 2014 |
Safety and efficacy of tenofovir/emtricitabine or abacavir/lamivudine in combination with efavirenz in treatment naïve HIV patients: a 5 year retrospective observational cohort study. (the TOKEN Study).
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cardiovascular Diseases; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Kidney Diseases; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Tenofovir; Viral Load | 2013 |
[ First integrase inhibitor based single tablet regimen].
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Carbamates; Cobicistat; Deoxycytidine; Drug Approval; Drug Combinations; Emtricitabine; HIV Infections; HIV Integrase Inhibitors; Humans; Organophosphonates; Quinolones; Tenofovir; Thiazoles; Treatment Outcome | 2013 |
Non-occupational HIV post-exposure prophylaxis at a Sydney metropolitan sexual health clinic.
Topics: Adenine; Adult; Anti-HIV Agents; Australia; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Male; Middle Aged; Organophosphonates; Post-Exposure Prophylaxis; Practice Guidelines as Topic; Practice Patterns, Physicians'; Risk-Taking; Stavudine; Tenofovir | 2013 |
Hypophosphataemia with non-tenofovir-containing antiretroviral therapy.
Topics: Adenine; Adult; Anti-Retroviral Agents; Cross-Sectional Studies; Female; Glomerular Filtration Rate; HIV Infections; Hospitals, Teaching; Humans; Hypophosphatemia; Male; Middle Aged; Organophosphonates; Phosphates; Prevalence; Prospective Studies; Risk Factors; Tenofovir; Treatment Outcome; United Kingdom | 2013 |
Effect of tenofovir with and without interferon on hepatitis D virus replication in HIV-hepatitis B virus-hepatitis D virus-infected patients.
Topics: Adenine; Adult; Female; Hepatitis B virus; Hepatitis Delta Virus; HIV; HIV Infections; Humans; Interferons; Limit of Detection; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Virus Replication | 2013 |
Increased risk of dialysis and end-stage renal disease among HIV patients in Denmark compared with the background population.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Cohort Studies; Comorbidity; Denmark; Female; HIV Infections; Humans; Incidence; Kidney Failure, Chronic; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Renal Dialysis; Renal Replacement Therapy; Risk Factors; Tenofovir | 2014 |
Acute kidney injury caused by tenofovir disoproxil fumarate and diclofenac co-administration.
Topics: Acute Kidney Injury; Adenine; Adult; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Drug Interactions; Fanconi Syndrome; Female; Germany; HIV Infections; Humans; Hypophosphatemia; Male; Middle Aged; Organophosphonates; Retrospective Studies; Tenofovir | 2013 |
Preexposure prophylaxis reduces HIV risk in injection-drug users.
Topics: Adenine; Adult; Anti-HIV Agents; Centers for Disease Control and Prevention, U.S.; Comorbidity; Deoxycytidine; Drug Administration Schedule; Drug Users; Emtricitabine; Female; Follow-Up Studies; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Male; Organophosphonates; Practice Guidelines as Topic; Pregnancy; Risk Reduction Behavior; Substance Abuse, Intravenous; Tenofovir; United States | 2013 |
Comparison of cardiovascular disease risk markers in HIV-infected patients receiving abacavir and tenofovir: the nucleoside inflammation, coagulation and endothelial function (NICE) study.
Topics: Adenine; Adult; Anti-HIV Agents; Biomarkers; Blood Coagulation; Cardiovascular Diseases; Dideoxynucleosides; Endothelium, Vascular; Female; HIV Infections; Humans; Inflammation; Male; Middle Aged; Organophosphonates; Risk Factors; Tenofovir; Zidovudine | 2014 |
No evidence for selection of HIV-1 with enhanced gag-protease or Nef function among breakthrough infections in the CAPRISA 004 tenofovir microbicide trial.
Topics: Adenine; Anti-HIV Agents; Clinical Trials as Topic; Female; gag Gene Products, Human Immunodeficiency Virus; HIV Infections; HIV-1; Humans; nef Gene Products, Human Immunodeficiency Virus; Organophosphonates; Phylogeny; Sequence Analysis, DNA; Tenofovir; Vaginal Creams, Foams, and Jellies; Virus Replication | 2013 |
Evaluation of renal adverse effects of combination anti-retroviral therapy including tenofovir in HIV-infected patients.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Drug Combinations; Female; Glomerular Filtration Rate; HIV Infections; HIV Protease Inhibitors; Humans; Kidney; Kidney Diseases; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Retrospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir | 2013 |
Changes in bone mineral density over a 2-year period in HIV-1-infected men under combined antiretroviral therapy with osteopenia.
Topics: Absorptiometry, Photon; Adenine; Adult; Anti-HIV Agents; Anti-Retroviral Agents; Bone Density; Bone Diseases, Metabolic; Hip; HIV Infections; HIV-1; Humans; Lumbar Vertebrae; Male; Middle Aged; Organophosphonates; Risk Factors; Tenofovir | 2013 |
Multicompartmental pharmacokinetic model of tenofovir delivery by a vaginal gel.
Topics: Adenine; Anti-HIV Agents; Area Under Curve; Epithelium; Female; HIV Infections; Humans; Models, Statistical; Mucous Membrane; Organophosphates; Organophosphonates; Tenofovir; Vagina; Vaginal Creams, Foams, and Jellies | 2013 |
Acute kidney injury as a presentation of primary renal diffuse large B-cell lymphoma in HIV.
Topics: Acute Kidney Injury; Adenine; Adult; Anti-HIV Agents; Antinematodal Agents; Biopsy; HIV Infections; Humans; Kidney; Kidney Neoplasms; Lymphoma, Large B-Cell, Diffuse; Male; Organophosphonates; Tenofovir; Treatment Outcome | 2014 |
The emergence of drug resistant HIV variants at virological failure of HAART combinations containing efavirenz, tenofovir and lamivudine or emtricitabine within the UK Collaborative HIV Cohort.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studies; Cyclopropanes; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Tenofovir; Treatment Failure | 2014 |
An investigation of the pattern of kidney injury in HIV-positive persons exposed to tenofovir disoproxil fumarate: an examination of a large population database (MHRA database).
Topics: Acute Kidney Injury; Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Databases, Factual; Female; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Population Surveillance; Socioeconomic Factors; Tenofovir | 2014 |
Tenofovir-induced renal tubular dysfunction in vertically HIV-infected patients associated with polymorphisms in ABCC2, ABCC4 and ABCC10 genes.
Topics: Adenine; Anti-HIV Agents; Child; Female; HIV Infections; Humans; Kidney Diseases; Kidney Tubules; Male; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Organophosphonates; Polymorphism, Single Nucleotide; Tenofovir; Young Adult | 2013 |
Low prevalence of renal dysfunction in HIV-infected pregnant women: implications for guidelines for the prevention of mother-to-child transmission of HIV.
Topics: Adenine; Adult; Age Factors; Anti-HIV Agents; CD4 Lymphocyte Count; Contraindications; Creatinine; Female; HIV; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Kidney Diseases; Male; Mothers; Organophosphonates; Pregnancy; Pregnancy Complications; Pregnancy Complications, Infectious; Pregnant Women; Prevalence; South Africa; Tenofovir; Viral Load | 2013 |
Acceptability of pre-exposure prophylaxis among men who have sex with men and transgender women in Northern Thailand.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Female; HIV Infections; Homosexuality, Male; Humans; Male; Middle Aged; Multivariate Analysis; Organophosphonates; Outcome Assessment, Health Care; Patient Acceptance of Health Care; Self Report; Sexual Behavior; Sexual Partners; Tenofovir; Thailand; Transgender Persons; Young Adult | 2013 |
A clinical prediction score for targeted creatinine testing before initiating tenofovir-based antiretroviral treatment in Cambodia.
Topics: Adenine; Adult; Anti-HIV Agents; Cambodia; Clinical Medicine; Creatinine; Cross-Sectional Studies; Decision Support Techniques; Female; HIV Infections; Humans; Kidney Diseases; Male; Metabolic Clearance Rate; Organophosphonates; Tenofovir | 2014 |
Recurrent bone fractures due to tenofovir-induced renal phosphate wasting.
Topics: Adenine; Adult; Anti-HIV Agents; Fractures, Stress; HIV Infections; Humans; Kidney Diseases; Male; Organophosphonates; Phosphates; Radiography; Tenofovir; Whole Body Imaging | 2014 |
Delayed emergence of HIV-1 variants resistant to 4'-ethynyl-2-fluoro-2'-deoxyadenosine: comparative sequential passage study with lamivudine, tenofovir, emtricitabine and BMS-986001.
Topics: Adenine; Amino Acid Sequence; Anti-HIV Agents; Deoxyadenosines; Deoxycytidine; Drug Resistance, Multiple, Viral; Emtricitabine; HIV Infections; HIV-1; Human Immunodeficiency Virus Proteins; Humans; Lamivudine; Molecular Sequence Data; Molecular Structure; Organophosphonates; Tenofovir; Thymidine | 2014 |
Urine liver-type fatty acid-binding protein and kidney injury molecule-1 in HIV-infected patients receiving combined antiretroviral treatment based on tenofovir.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cross-Sectional Studies; Fatty Acid-Binding Proteins; Female; Hepatitis A Virus Cellular Receptor 1; HIV Infections; Humans; Kidney Diseases; Male; Membrane Glycoproteins; Middle Aged; Organophosphonates; Receptors, Virus; Tenofovir | 2014 |
Increases in regimen durability associated with the introduction of tenofovir at a large public-sector clinic in Johannesburg, South Africa.
Topics: Adenine; Adult; Ambulatory Care Facilities; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Female; HIV Infections; Humans; Male; Medication Adherence; Organophosphonates; South Africa; Tenofovir | 2013 |
Common clinical conditions - age, low BMI, ritonavir use, mild renal impairment - affect tenofovir pharmacokinetics in a large cohort of HIV-infected women.
Topics: Adenine; Adult; Age Factors; Anti-HIV Agents; Body Mass Index; Cohort Studies; Female; Glomerular Filtration Rate; HIV Infections; Humans; Middle Aged; Organophosphonates; Prospective Studies; Renal Insufficiency; Ritonavir; Tenofovir; Young Adult | 2014 |
Tenofovir or zidovudine in second-line antiretroviral therapy after stavudine failure in southern Africa.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Female; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Retreatment; South Africa; Stavudine; Tenofovir; Treatment Failure; Treatment Outcome; Viral Load; Zidovudine | 2014 |
Rilpivirine, emtricitabine and tenofovir resistance in HIV-1-infected rilpivirine-naive patients failing antiretroviral therapy.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; HIV Infections; HIV-1; Humans; Nitriles; Organophosphonates; Pyrimidines; Rilpivirine; Sequence Analysis, DNA; Tenofovir; Treatment Failure | 2014 |
CD4(+) cell count, viral load, and drug resistance patterns among heterosexual breakthrough HIV infections in a study of oral preexposure prophylaxis.
Topics: Adenine; Anti-HIV Agents; Botswana; CD4 Lymphocyte Count; Chemoprevention; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Heterosexuality; HIV; HIV Infections; Humans; Organophosphonates; Plasma; Post-Exposure Prophylaxis; Tenofovir; Viral Load | 2014 |
No evidence of sexual risk compensation in the iPrEx trial of daily oral HIV preexposure prophylaxis.
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Female; HIV Infections; Homosexuality, Male; Humans; Male; Middle Aged; Organophosphonates; Pregnancy; Sexual Behavior; Tenofovir; Transgender Persons; Young Adult | 2013 |
Impact of Tenofovir gel as a PrEP on HIV infection: a mathematical model.
Topics: Adenine; Female; Gels; HIV Infections; Humans; Models, Theoretical; Organophosphonates; Reverse Transcriptase Inhibitors; South Africa; Tenofovir | 2014 |
Comparative biophysical properties of tenofovir-loaded, thiolated and nonthiolated chitosan nanoparticles intended for HIV prevention.
Topics: Adenine; Animals; Anti-HIV Agents; Caveolins; Cell Line; Chitosan; Drug Delivery Systems; Fluorometry; HIV Infections; Humans; Hydrogen-Ion Concentration; Microscopy, Electron, Scanning; Microscopy, Electron, Transmission; Nanomedicine; Nanoparticles; Organophosphonates; Sulfhydryl Compounds; Swine; Tenofovir; Thioglycolates | 2014 |
Cost-effectiveness of tenofovir gel in urban South Africa: model projections of HIV impact and threshold product prices.
Topics: Adenine; Anti-HIV Agents; Circumcision, Male; Cost-Benefit Analysis; Female; Forecasting; Herpes Genitalis; Herpesvirus 2, Human; HIV Infections; HIV Seropositivity; Humans; Incidence; Male; Models, Economic; Organophosphonates; Prevalence; South Africa; Tenofovir | 2014 |
Telaprevir therapy, renal impairment, and their effects on the pharmacokinetics of tenofovir in HIV/hepatitis C virus coinfected patients.
Topics: Adenine; Adult; Antiviral Agents; Hepatitis C; HIV Infections; Humans; Kidney Diseases; Male; Oligopeptides; Organophosphonates; Tenofovir | 2014 |
Pharmacogenetics and clinical biomarkers for subtherapeutic plasma efavirenz concentration in HIV-1 infected Thai adults.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Asian People; Benzoxazines; Biomarkers; Cyclopropanes; Cytochrome P-450 Enzyme System; Female; Gene Frequency; HIV Infections; Humans; Lamivudine; Male; Organophosphonates; Polymorphism, Single Nucleotide; Prospective Studies; Tenofovir; Young Adult | 2014 |
Herpes simplex virus type-2 stimulates HIV-1 replication in cervical tissues: implications for HIV-1 transmission and efficacy of anti-HIV-1 microbicides.
Topics: ADP-ribosyl Cyclase 1; Antiviral Agents; Cervix Uteri; Female; Gene Expression Regulation; Herpesvirus 2, Human; HIV Infections; HIV-1; Humans; Polymerase Chain Reaction; Tenofovir; Virus Replication | 2014 |
Factors associated with delayed hepatitis B viral suppression on tenofovir among patients coinfected with HBV-HIV in the CNICS cohort.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Tenofovir; Time Factors; Treatment Outcome; Viral Load | 2014 |
HIV nucleoside reverse transcriptase inhibitors efavirenz and tenofovir change the growth and differentiation of primary gingival epithelium.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cell Differentiation; Cell Proliferation; Cells, Cultured; Cyclopropanes; Dose-Response Relationship, Drug; Gene Expression Regulation; Gingiva; HIV Infections; Humans; Keratin-6; Keratinocytes; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2014 |
Long-term treatment with tenofovir: prevalence of kidney tubular dysfunction and its association with tenofovir plasma concentration.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Comorbidity; Cross-Sectional Studies; Drug Monitoring; Female; HIV Infections; Humans; Kidney Diseases; Kidney Function Tests; Kidney Tubules; Male; Middle Aged; Netherlands; Organophosphonates; Prevalence; Tenofovir | 2014 |
Effect of baseline renal function on tenofovir-containing antiretroviral therapy outcomes in Zambia.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Creatinine; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney; Male; Organophosphonates; Renal Insufficiency; Tenofovir; Zambia | 2014 |
Incomplete reversibility of estimated glomerular filtration rate decline following tenofovir disoproxil fumarate exposure.
Topics: Adenine; Adult; Anti-HIV Agents; Cohort Studies; Drug Administration Schedule; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Diseases; Male; Middle Aged; Organophosphonates; Proportional Hazards Models; Tenofovir; Viral Load | 2014 |
Impact of choice of NRTI in first-line antiretroviral therapy: a cohort analysis of stavudine vs. tenofovir.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Female; Follow-Up Studies; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Proportional Hazards Models; Prospective Studies; South Africa; Stavudine; Survival Analysis; Survival Rate; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2014 |
Early experiences implementing pre-exposure prophylaxis (PrEP) for HIV prevention in San Francisco.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Disease Management; Emtricitabine; Female; HIV Infections; Humans; Male; Organophosphonates; San Francisco; Tenofovir | 2014 |
Incidence and risk factors for incomplete HBV DNA suppression in HIV/HBV-co-infected patients initiating tenofovir-based therapy.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Coinfection; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Incidence; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Risk Factors; Tenofovir; Viral Load; Viremia | 2014 |
Focal bone lesions in HIV-positive patient treated with tenofovir.
Topics: Adenine; Anti-HIV Agents; Bone Diseases; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Tenofovir | 2014 |
Use of hepatitis B surface and "e" antigen quantification during extensive treatment with tenofovir in patients co-infected with HIV-HBV.
Topics: Adenine; Adult; Anti-HIV Agents; Coinfection; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Male; Middle Aged; Multivariate Analysis; Organophosphonates; Prospective Studies; Sensitivity and Specificity; Tenofovir; Viral Load | 2015 |
Disclosure of microbicide gel use to sexual partners: influence on adherence in the CAPRISA 004 trial.
Topics: Adenine; Adolescent; Adult; Anti-Infective Agents; Condoms; Disclosure; Female; Gels; HIV Infections; Humans; Interviews as Topic; Medication Adherence; Organophosphonates; Sexual Behavior; Sexual Partners; Socioeconomic Factors; South Africa; Surveys and Questionnaires; Tenofovir; Young Adult | 2014 |
The rate of recovery in renal function when patients with HIV infection discontinue treatment with tenofovir.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney; Male; Organophosphonates; Prospective Studies; Tenofovir; Withholding Treatment | 2014 |
HIV-1 genital shedding is suppressed in the setting of high genital antiretroviral drug concentrations throughout the menstrual cycle.
Topics: Adenine; Adult; Anti-Retroviral Agents; Deoxycytidine; DNA, Viral; Emtricitabine; Female; Genitalia, Female; HIV Infections; HIV-1; Humans; Menstrual Cycle; Middle Aged; Organophosphonates; Plasma; Ritonavir; RNA, Viral; Tenofovir; Viral Load; Virus Shedding | 2014 |
Leveraging rapid implementation of an HIV treatment policy to reduce confounding in observational analysis of antiretroviral outcomes.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; Humans; Male; Organophosphonates; Stavudine; Tenofovir | 2014 |
Assessing adherence in the CAPRISA 004 tenofovir gel HIV prevention trial: results of a nested case-control study.
Topics: Adenine; Adult; Anti-HIV Agents; Anti-Infective Agents; Case-Control Studies; Condoms; Double-Blind Method; Female; HIV Infections; Humans; Logistic Models; Organophosphonates; Patient Compliance; Rural Population; South Africa; Tenofovir; Treatment Outcome; Urban Population; Vaginal Creams, Foams, and Jellies | 2014 |
Fanconi syndrome accompanied by renal function decline with tenofovir disoproxil fumarate: a prospective, case-control study of predictors and resolution in HIV-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Case-Control Studies; Creatinine; Fanconi Syndrome; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Diseases; Kidney Function Tests; Male; Middle Aged; Organophosphonates; Prognosis; Prospective Studies; Risk Factors; Tenofovir | 2014 |
Molecular basis of the association of H208Y and thymidine analogue resistance mutations M41L, L210W and T215Y in the HIV-1 reverse transcriptase of treated patients.
Topics: Adenine; Anti-HIV Agents; Cell Line; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Mutation, Missense; Organophosphonates; Reverse Transcription; Tenofovir; Zidovudine | 2014 |
Single-tablet, once-daily treatment regimens for HIV.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cobicistat; Cyclopropanes; Cytochrome P-450 CYP3A Inhibitors; Deoxycytidine; Drug Combinations; Emtricitabine; HIV Infections; HIV Integrase Inhibitors; HIV Reverse Transcriptase; Humans; Nitriles; Organophosphonates; Pyrimidines; Quinolones; Reverse Transcriptase Inhibitors; Rilpivirine; Tenofovir; Thiazoles | 2014 |
Higher risk of renal impairment associated with tenofovir use amongst people living with HIV in India: a comparative cohort analysis between Western India and United Kingdom.
Topics: Adenine; Adult; Anti-HIV Agents; Cohort Studies; Female; HIV Infections; Humans; India; Kidney Diseases; Male; Middle Aged; Organophosphonates; Retrospective Studies; Tenofovir; United Kingdom | 2014 |
Retention in care, resource utilization, and costs for adults receiving antiretroviral therapy in Zambia: a retrospective cohort study.
Topics: Adenine; Adult; Ambulatory Care Facilities; Anti-HIV Agents; CD4 Lymphocyte Count; Delivery of Health Care; Female; Guideline Adherence; Health Care Costs; Health Resources; HIV Infections; Humans; Male; Office Visits; Organophosphonates; Patient Dropouts; Retrospective Studies; Tenofovir; Zambia | 2014 |
Increased Dapivirine tissue accumulation through vaginal film codelivery of dapivirine and Tenofovir.
Topics: Adenine; Administration, Intravaginal; Anti-HIV Agents; Anti-Infective Agents; Drug Delivery Systems; Female; HIV Infections; Humans; In Vitro Techniques; Membranes, Artificial; Organophosphonates; Pyrimidines; Tenofovir; Vagina | 2014 |
Virologic and serologic outcomes of mono versus dual HBV therapy and characterization of HIV/HBV coinfection in a US cohort.
Topics: Adenine; Adult; Antibodies, Viral; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; Coinfection; Deoxycytidine; DNA, Viral; Emtricitabine; Female; Follow-Up Studies; Hepatitis B; Hepatitis B e Antigens; HIV Infections; Humans; Lamivudine; Logistic Models; Male; Middle Aged; Organophosphonates; Randomized Controlled Trials as Topic; Retrospective Studies; Tenofovir; United States | 2014 |
Fibroblast growth factor 23 is elevated in tenofovir-related hypophosphatemia.
Topics: Adenine; Adult; Anti-HIV Agents; Bone Density; Fanconi Syndrome; Fibroblast Growth Factor-23; Fibroblast Growth Factors; HIV Infections; Humans; Hypophosphatemia; Male; Organophosphonates; Osteomalacia; Osteoporosis; Tenofovir | 2014 |
Uptake of prevention of mother-to-child-transmission using Option B+ in northern rural Malawi: a retrospective cohort study.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Chemoprevention; Cohort Studies; Cyclopropanes; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Malawi; Nevirapine; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Prenatal Care; Retrospective Studies; Rural Population; Tenofovir; Young Adult | 2014 |
The preventive misconception: experiences from CAPRISA 004.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Anti-Infective Agents, Local; Female; Gels; HIV Infections; Humans; Informed Consent; Medication Adherence; Motivation; Organophosphonates; Personal Satisfaction; South Africa; Tenofovir; Young Adult | 2014 |
Successful switch to rilpivirine/tenofovir/emtricitabine in HIV-1-infected patients with an isolated K103N mutation acquired during prior nonnucleoside reverse transcriptase inhibitor therapy.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, Viral; Drug Substitution; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Mutation; Nitriles; Organophosphonates; Pilot Projects; Prospective Studies; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; Tenofovir; Viral Load; Young Adult | 2014 |
HIV-1 drug resistance in the iPrEx preexposure prophylaxis trial.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Female; Genotype; HIV Infections; HIV-1; Homosexuality, Male; Humans; Male; Mutation; Organophosphonates; RNA, Viral; Tenofovir; Transgender Persons; Viral Load | 2014 |
Sustained virological response after taking crushed elvitegravir-cobicistat-emtricitabine-tenofovir tablets.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Carbamates; Cobicistat; Deoxycytidine; Emtricitabine; Female; HIV; HIV Infections; Humans; Organophosphonates; Powders; Quinolones; Tablets; Tenofovir; Thiazoles; Viral Load | 2014 |
ACOG Committee Opinion no 595: Committee on Gynecologic Practice: Preexposure prophylaxis for the prevention of human immunodeficiency virus.
Topics: Adenine; Anti-Retroviral Agents; Deoxycytidine; Emtricitabine; Female; Gynecology; HIV Infections; Humans; Medication Adherence; Organophosphonates; Risk Factors; Tenofovir | 2014 |
ABCC2*1C and plasma tenofovir concentration are correlated to decreased glomerular filtration rate in patients receiving a tenofovir-containing antiretroviral regimen.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Creatinine; Cyclopropanes; Drug Therapy, Combination; Female; Glomerular Filtration Rate; HIV Infections; HIV-1; Humans; Kidney; Lamivudine; Male; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Organophosphonates; Polymorphism, Single Nucleotide; Reverse Transcriptase Inhibitors; Tenofovir | 2014 |
Hypophosphatemic osteomalacia induced by tenofovir in HIV-infected patients.
Topics: Adult; Anti-HIV Agents; Bone and Bones; Female; HIV Infections; Humans; Hypophosphatemia; Magnetic Resonance Imaging; Male; Middle Aged; Osteomalacia; Tenofovir | 2016 |
An interesting case of 'diabetic foot ulcer' in an HIV-positive patient.
Topics: Adenine; Aged; Antiretroviral Therapy, Highly Active; Biopsy; Deoxycytidine; Diabetes Mellitus, Type 2; Diabetic Foot; Emtricitabine; Herpesvirus 8, Human; HIV Infections; HIV Seropositivity; Humans; Male; Organophosphonates; Sarcoma, Kaposi; Skin Neoplasms; Tenofovir; Treatment Outcome; Ulcer | 2015 |
Perceptions of emtricitabine-tenofovir in HIV PrEP.
Topics: Adenine; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Organophosphonates; Sex Education; Sexual Partners; Tenofovir; United States | 2014 |
Biomarkers of CD4+ T-cell activation as risk factors for tuberculosis-associated immune reconstitution inflammatory syndrome.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Biomarkers; CD4-Positive T-Lymphocytes; Cyclopropanes; Deoxycytidine; Emtricitabine; Enzyme-Linked Immunosorbent Assay; Female; HIV Infections; Humans; Immune Reconstitution Inflammatory Syndrome; Lymphocyte Activation; Male; Middle Aged; Mycobacterium tuberculosis; Organophosphonates; Risk Factors; Tenofovir; Tuberculosis | 2014 |
In vivo effect of two first-line ART regimens on inflammatory mediators in male HIV patients.
Topics: Adenine; Adult; Alkynes; Animals; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Interleukin-10; Interleukin-6; Interleukin-8; Lamivudine; Male; Middle Aged; Organophosphonates; Platelet Activating Factor; Tenofovir; Tumor Necrosis Factor-alpha | 2014 |
Synergistic activity of tenofovir and nevirapine combinations released from polycaprolactone matrices for potential enhanced prevention of HIV infection through the vaginal route.
Topics: Adenine; Anti-HIV Agents; Drug Administration Routes; Drug Synergism; Drug Therapy, Combination; Female; HIV Infections; Humans; Microscopy, Electron, Scanning; Nevirapine; Organophosphonates; Polyesters; Tenofovir; Vagina | 2014 |
Switching from tenofovir/emtricitabine and nevirapine to a tenofovir/emtricitabine/rilpivirine single-tablet regimen in virologically suppressed, HIV-1-infected subjects.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Deoxycytidine; Drug Combinations; Drug Substitution; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nevirapine; Nitriles; Organophosphonates; Prospective Studies; Pyrimidines; Rilpivirine; Tenofovir; Treatment Outcome; Viral Load | 2014 |
Switching STRATEGIES in HIV treatment.
Topics: Adenine; Anti-HIV Agents; Carbamates; Cobicistat; Deoxycytidine; Emtricitabine; Female; HIV; HIV Infections; Humans; Male; Organophosphonates; Protease Inhibitors; Quinolones; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Thiazoles | 2014 |
A chronic kidney disease risk score to determine tenofovir safety in a prospective cohort of HIV-positive male veterans.
Topics: Adenine; Adult; Anti-HIV Agents; Cohort Studies; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Prospective Studies; Renal Insufficiency, Chronic; Risk Assessment; Tenofovir; Veterans | 2014 |
Tenofovir in HIV-infected children. Antiretroviral efficacy, but beware of adverse effects on bone and the kidneys.
Topics: Adenine; Anti-HIV Agents; Bone Diseases; Child; Dose-Response Relationship, Drug; HIV Infections; Humans; Kidney Diseases; Medication Errors; Organophosphonates; Tenofovir | 2014 |
An HBV-HIV co-infected patient treated with tenofovir-based therapy who achieved HBs antigen/antibody seroconversion.
Topics: Adenine; Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Coinfection; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Surface Antigens; HIV Infections; Humans; Male; Organophosphonates; Tenofovir | 2014 |
Pharmacokinetics and preliminary safety study of pod-intravaginal rings delivering antiretroviral combinations for HIV prophylaxis in a macaque model.
Topics: Adenine; Administration, Intravaginal; Animals; Anti-HIV Agents; Delayed-Action Preparations; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV-1; Macaca; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Vagina; Vaginal Creams, Foams, and Jellies | 2014 |
Pharmacokinetics of atazanavir/ritonavir among HIV-infected Thai children concomitantly taking tenofovir disoproxil fumarate.
Topics: Adenine; Adolescent; Anti-HIV Agents; Asian People; Atazanavir Sulfate; Child; Female; HIV Infections; Humans; Lamivudine; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir | 2014 |
Pre-exposure prophylaxis accessibility research and evaluation (PrEPARE Study).
Topics: Adenine; Adult; Anti-HIV Agents; Antiviral Agents; California; Deoxycytidine; Emtricitabine; Health Expenditures; Health Knowledge, Attitudes, Practice; Health Services Accessibility; Health Surveys; HIV Infections; Homosexuality, Male; Humans; Male; Middle Aged; Organophosphonates; Patient Acceptance of Health Care; Pre-Exposure Prophylaxis; Tenofovir; Unsafe Sex | 2014 |
Development of HIV-1 rectal-specific microbicides and colonic tissue evaluation.
Topics: Adenine; Adult; Anilides; Anti-Infective Agents, Local; Colon; Drug Evaluation, Preclinical; Drug Stability; Furans; HIV Infections; HIV-1; Humans; Hydrogels; Middle Aged; Organophosphonates; Semen; Tenofovir; Thioamides; Virus Replication; Young Adult | 2014 |
Effect of antiretroviral HIV therapy on hepatitis B virus replication and pathogenicity.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Coinfection; Deoxycytidine; Emtricitabine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV Reverse Transcriptase; HIV Seropositivity; HIV-1; Humans; Inflammation; Organophosphonates; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; tat Gene Products, Human Immunodeficiency Virus; Tenofovir; Virus Replication; vpr Gene Products, Human Immunodeficiency Virus | 2014 |
It's Time: The Case for PrEP as an Active Comparator in HIV Biomedical Prevention Trials.
Topics: Anti-HIV Agents; Biomedical Research; Comparative Effectiveness Research; Condoms; Emtricitabine; Female; HIV Infections; Humans; Male; Pre-Exposure Prophylaxis; Research Design; Risk; Sexual Behavior; Tenofovir | 2015 |
Safety and efficacy of coformulated efavirenz/emtricitabine/tenofovir single-tablet regimen in treatment-naive patients infected with HIV-1.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Emtricitabine; Europe; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Plasma; Tablets; Tenofovir; Treatment Outcome; Viral Load | 2015 |
Formulation and characterization of polymeric films containing combinations of antiretrovirals (ARVs) for HIV prevention.
Topics: Adenine; Administration, Intravaginal; Administration, Topical; Anti-HIV Agents; Chemistry, Pharmaceutical; Drug Carriers; Drug Combinations; Drug Delivery Systems; Female; HIV Infections; HIV-1; Humans; Organophosphonates; Polymers; Pyrimidines; Tenofovir; Vagina | 2015 |
Proximal renal tubular dysfunction related to antiretroviral therapy among HIV-infected patients in an HIV clinic in Mexico.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Therapy, Combination; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Tubules, Proximal; Longitudinal Studies; Male; Mexico; Middle Aged; Organophosphonates; Prospective Studies; Protease Inhibitors; Proteinuria; Tenofovir | 2015 |
HIV pre-exposure prophylaxis: mucosal tissue drug distribution of RT inhibitor Tenofovir and entry inhibitor Maraviroc in a humanized mouse model.
Topics: Adenine; Animals; Anti-HIV Agents; Cyclohexanes; Disease Models, Animal; Female; HIV Infections; HIV-1; Humans; Maraviroc; Mice; Mucous Membrane; Organophosphonates; Pre-Exposure Prophylaxis; Reverse Transcriptase Inhibitors; Tenofovir; Triazoles; Virus Internalization | 2014 |
Efficacy of prolonged tenofovir therapy on hepatitis delta in HIV-infected patients.
Topics: Adenine; Adult; Antiviral Agents; Hepatitis D, Chronic; HIV Infections; Humans; Liver Cirrhosis; Male; Middle Aged; Organophosphonates; Retrospective Studies; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load | 2014 |
Initiation of rilpivirine, tenofovir and emtricitabine (RPV/TDF/FTC) regimen in 363 patients with virological vigilance assessment in 'real life'.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Genotype; HIV; HIV Infections; Humans; Microbial Sensitivity Tests; Nitriles; Organophosphonates; Pyrimidines; Rilpivirine; Tenofovir | 2014 |
Switching to emtricitabine, tenofovir and rilpivirine as single tablet regimen in virologically suppressed HIV-1-infected patients: a cohort study.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Cohort Studies; Deoxycytidine; Drug Combinations; Drug Substitution; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nitriles; Organophosphonates; Pyrimidines; Retrospective Studies; Rilpivirine; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load | 2015 |
Drug interactions between voriconazole, darunavir/ritonavir and tenofovir/emtricitabine in an HIV-infected patient treated for Aspergillus candidus lung abscess.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antifungal Agents; Aspergillosis; Aspergillus; Darunavir; Drug Interactions; Emtricitabine; HIV Infections; HIV Protease Inhibitors; Humans; Lung Abscess; Male; Ritonavir; Tenofovir; Treatment Outcome; Voriconazole | 2015 |
Assessing adherence to the 2010 antiretroviral guidelines at the antiretroviral rollout clinic in 1 military hospital, South Africa: a retrospective, cross sectional study.
Topics: Adenine; Adult; Anti-Retroviral Agents; Cross-Sectional Studies; Drug Monitoring; Drug Substitution; Female; Guideline Adherence; HIV Infections; Hospitals, Military; Humans; Male; Organophosphonates; Outcome Assessment, Health Care; Practice Guidelines as Topic; Practice Patterns, Physicians'; Retrospective Studies; South Africa; Stavudine; Tenofovir | 2014 |
High prevalence of signs of renal damage despite normal renal function in a cohort of HIV-infected patients: evaluation of associated factors.
Topics: Adenine; Adult; Age Factors; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Cross-Sectional Studies; Diabetes Mellitus; Female; HIV Infections; HIV Protease Inhibitors; Humans; Hypertension; Kidney; Kidney Diseases; Male; Middle Aged; Multivariate Analysis; Organophosphonates; Prevalence; Prospective Studies; Risk Factors; Socioeconomic Factors; Spain; Surveys and Questionnaires; Tenofovir; Viral Load | 2014 |
Long-term exposure to tenofovir continuously decrease renal function in HIV-1-infected patients with low body weight: results from 10 years of follow-up.
Topics: Adenine; Adult; Anti-HIV Agents; Body Weight; Cohort Studies; Female; Glomerular Filtration Rate; HIV Infections; HIV-1; Humans; Longitudinal Studies; Male; Organophosphonates; Renal Insufficiency; Tenofovir; Tokyo | 2014 |
Infection with the frequently transmitted HIV-1 M41L variant has no influence on selection of tenofovir resistance.
Topics: Adenine; Adult; Amino Acid Substitution; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Evolution, Molecular; Female; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Mutation; Organophosphonates; Phenotype; Phylogeny; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load | 2015 |
Lopinavir/r no longer recommended as a first-line regimen: a comparative effectiveness analysis.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort Studies; Deoxycytidine; Emtricitabine; Female; France; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Organophosphonates; Prospective Studies; Tenofovir; Treatment Failure; Viral Load | 2014 |
When is good good enough for HIV-1 prophylaxis?
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Male; Organophosphonates; Pre-Exposure Prophylaxis; Tenofovir | 2014 |
Evaluation of the efficacy and safety of switching to tenofovir, emtricitabine, and rilpivirine in treatment-experienced patients.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Nitriles; Organophosphonates; Pyrimidines; Rilpivirine; Tenofovir; Young Adult | 2015 |
[To evaluate the changes in body composition in male human immunodeficiency virus-related lipodystrophy after different treatment regimens by dual-energy X-ray absorptiometry].
Topics: Absorptiometry, Photon; Adenine; Anti-HIV Agents; Antiviral Agents; Body Composition; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Male; Organophosphonates; Stavudine; Tenofovir; Zidovudine | 2014 |
Factors associated with daily tenofovir exposure in Thai subjects taking combination antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Area Under Curve; Blood Chemical Analysis; Cross-Sectional Studies; Drug Interactions; Female; HIV Infections; Humans; Kidney Function Tests; Male; Middle Aged; Tenofovir; Thailand | 2015 |
Perceptions and Experiences with the VOICE Adherence Strengthening Program (VASP) in the MTN-003 Trial.
Topics: Adult; Anti-HIV Agents; Counseling; Female; HIV Infections; Humans; Interviews as Topic; Male; Medication Adherence; Middle Aged; Patient Acceptance of Health Care; Perception; Pre-Exposure Prophylaxis; Qualitative Research; Surveys and Questionnaires; Tenofovir | 2015 |
Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Clinical Trials, Phase III as Topic; Coinfection; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Organophosphonates; Oxazines; Piperazines; Pyridones; Pyrrolidinones; Raltegravir Potassium; Randomized Controlled Trials as Topic; Regression Analysis; Retrospective Studies; Ritonavir; Tenofovir; Treatment Outcome; Viral Load | 2015 |
Perception of HIV risk and adherence to a daily, investigational pill for HIV prevention in FEM-PrEP.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Blood Chemical Analysis; Chemoprevention; Deoxycytidine; Disease Transmission, Infectious; Emtricitabine; Female; Health Knowledge, Attitudes, Practice; HIV Infections; Humans; Medication Adherence; Organophosphonates; Risk-Taking; Tenofovir; Young Adult | 2014 |
Anti-HIV drug-combination nanoparticles enhance plasma drug exposure duration as well as triple-drug combination levels in cells within lymph nodes and blood in primates.
Topics: Adenine; Animals; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Carriers; Drug Combinations; HIV Infections; HIV Protease Inhibitors; HIV-1; Indinavir; Lipids; Lopinavir; Lymph Nodes; Macaca; Nanoparticles; Organophosphonates; Ritonavir; Tenofovir; Viral Load; Virus Latency | 2015 |
Dose response for starting and stopping HIV preexposure prophylaxis for men who have sex with men.
Topics: Adolescent; Adult; Anti-HIV Agents; Blood Chemical Analysis; Disease Transmission, Infectious; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Pre-Exposure Prophylaxis; Prospective Studies; Rectum; Tenofovir; Time Factors; Young Adult | 2015 |
Tenofovir-Related Nephropathies in HIV-Infected Patients.
Topics: Acute Kidney Injury; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Function Tests; Male; Middle Aged; Proteinuria; Tenofovir | 2015 |
Primary HIV infection presenting as limbic encephalitis and rhabdomyolysis.
Topics: Acute Kidney Injury; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Diagnosis, Differential; Diffusion Magnetic Resonance Imaging; Emtricitabine; HIV Infections; Humans; Limbic Encephalitis; Magnetic Resonance Imaging; Male; Rhabdomyolysis; Tenofovir | 2015 |
Renal impairment in HIV-infected patients initiating tenofovir-containing antiretroviral therapy regimens in a Primary Healthcare Setting in South Africa.
Topics: Adenine; Adult; Age Factors; Anemia; Anti-HIV Agents; CD4 Lymphocyte Count; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney; Logistic Models; Male; Middle Aged; Organophosphonates; Prevalence; Primary Health Care; Renal Insufficiency; Reverse Transcriptase Inhibitors; South Africa; Tenofovir | 2015 |
Elvitegravir/cobicistat/emtricitabine/tenofovir DF in HIV-infected patients with mild-to-moderate renal impairment.
Topics: Adenine; Adult; Anti-HIV Agents; Carbamates; Cobicistat; Cohort Studies; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Quinolones; Renal Insufficiency; Tenofovir; Thiazoles; Treatment Outcome | 2015 |
A pharmacogenetic candidate gene study of tenofovir-associated Fanconi syndrome.
Topics: Adenine; Alleles; Anti-HIV Agents; Biomarkers, Pharmacological; Case-Control Studies; Fanconi Syndrome; Genetic Association Studies; HEK293 Cells; HIV Infections; HIV-1; Humans; Multidrug Resistance-Associated Protein 2; Organophosphonates; Pharmacogenetics; Polymorphism, Single Nucleotide; Sequence Analysis, DNA; Tenofovir | 2015 |
Development of a composite measure of product adherence, protocol compliance, and semen exposure using DNA and protein biomarkers for topical HIV prevention studies.
Topics: Adenine; Administration, Topical; Adult; Anti-HIV Agents; Biomarkers; Cellulose; DNA; Environmental Exposure; Feasibility Studies; Female; Guideline Adherence; HIV Infections; Humans; Keratin-4; Male; Middle Aged; Organophosphonates; Outcome Assessment, Health Care; Patient Compliance; Semen; Tenofovir; Vagina; Young Adult | 2014 |
High interest in preexposure prophylaxis among men who have sex with men at risk for HIV infection: baseline data from the US PrEP demonstration project.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Chemoprevention; Cohort Studies; Deoxycytidine; Disease Transmission, Infectious; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Longitudinal Studies; Male; Organophosphonates; Patient Acceptance of Health Care; Pre-Exposure Prophylaxis; Prospective Studies; Tenofovir; United States; Young Adult | 2015 |
Models for predicting effective HIV chemoprevention in women.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Cell Culture Techniques; Cell Survival; Chemoprevention; Chromatography, Liquid; Cyclohexanes; Disease Transmission, Infectious; Dose-Response Relationship, Drug; Female; HIV Infections; Humans; Maraviroc; Middle Aged; Organ Culture Techniques; Organophosphonates; Tandem Mass Spectrometry; Tenofovir; Triazoles; Vagina; Viral Load; Young Adult | 2015 |
Trend of eGFR in an Italian cohort of mother-to-child HIV-infected patients exposed to tenofovir for at least 2 years.
Topics: Adolescent; Anti-HIV Agents; Child; Female; Glomerular Filtration Rate; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Italy; Longitudinal Studies; Male; Retrospective Studies; Tenofovir; Young Adult | 2015 |
Comparing genotoxic signatures in cord blood cells from neonates exposed in utero to zidovudine or tenofovir.
Topics: Aneuploidy; Anti-HIV Agents; Female; Fetal Blood; Gene Expression; Hematopoietic Stem Cells; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Maternal-Fetal Exchange; Pregnancy; Pregnancy Complications, Infectious; Tenofovir; Zidovudine | 2015 |
Quiz Page January 2015: acute kidney injury in a patient with well-controlled HIV infection.
Topics: Acute Kidney Injury; Adenine; Aged, 80 and over; Anti-HIV Agents; Biopsy; CD4 Lymphocyte Count; Diagnosis, Differential; Diarrhea; HIV Infections; Humans; Hypertension; Immunologic Tests; Kidney; Kidney Function Tests; Male; Monitoring, Physiologic; Organophosphonates; Ritonavir; Tenofovir; Treatment Outcome; Viral Load; Withholding Treatment | 2015 |
Preexposure prophylaxis: a path forward.
Topics: Adenine; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Kidney Glomerulus; Male; Organophosphonates; Tenofovir | 2015 |
No relationship between drug transporter genetic variants and tenofovir plasma concentrations or changes in glomerular filtration rate in HIV-infected adults.
Topics: Adenine; Adult; Anti-HIV Agents; Cohort Studies; Female; Genotype; Glomerular Filtration Rate; HIV Infections; Humans; Male; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Organophosphonates; Plasma; Retrospective Studies; Tenofovir | 2015 |
Therapeutic management and evolution of chronic hepatitis B: does HIV still have an impact? The EPIB 2012 study.
Topics: Adult; Antiviral Agents; Cohort Studies; Comorbidity; Disease Progression; Female; France; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; HIV Infections; HIV Seronegativity; HIV Seropositivity; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Logistic Models; Male; Middle Aged; Multivariate Analysis; Reference Values; Retrospective Studies; Risk Assessment; Statistics, Nonparametric; Survival Analysis; Tenofovir; Treatment Outcome | 2015 |
Pregnancy and contraceptive use among women participating in the FEM-PrEP trial.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraceptive Agents; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Incidence; Medication Adherence; Organophosphonates; Plasma; Pregnancy; Pregnancy Rate; Pregnancy, Unplanned; Tenofovir; Young Adult | 2015 |
The kinetics of the hepatitis B surface antigen level after the initiation of antiretroviral therapy for hepatitis B virus and human immunodeficiency virus coinfected patients.
Topics: Adult; Anti-Retroviral Agents; Coinfection; DNA, Viral; Female; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; HIV Infections; Humans; Immune Reconstitution Inflammatory Syndrome; Kinetics; Male; Middle Aged; Retrospective Studies; RNA, Viral; Tenofovir; Viral Load; Young Adult | 2015 |
Long term reference change value of creatinine in HIV-positive patients with anti-retroviral therapy: A new tool in clinical practice.
Topics: Adult; Anti-HIV Agents; Biomarkers, Pharmacological; Creatinine; Drug Monitoring; Female; HIV Infections; Humans; Kidney Diseases; Longitudinal Studies; Male; Middle Aged; Reference Values; Ritonavir; Tenofovir | 2015 |
Diminished impact of ethnicity as a risk factor for chronic kidney disease in the current HIV treatment era.
Topics: Adenine; Adult; Africa South of the Sahara; Anti-HIV Agents; Cross-Sectional Studies; Female; HIV Infections; Humans; Male; Middle Aged; Netherlands; Organophosphonates; Prevalence; Renal Insufficiency, Chronic; Risk Factors; Tenofovir | 2015 |
Improved detection of resistance at failure to a tenofovir, emtricitabine and efavirenz regimen by ultradeep sequencing.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Emtricitabine; Genotyping Techniques; High-Throughput Nucleotide Sequencing; HIV; HIV Infections; Humans; Microbial Sensitivity Tests; Plasma; Tenofovir; Treatment Failure | 2015 |
Preventing HIV in women--still trying to find their VOICE.
Topics: Adenine; Anti-Retroviral Agents; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Organophosphonates; Pre-Exposure Prophylaxis; Tenofovir | 2015 |
Steady-state pharmacokinetics of rilpivirine under different meal conditions in HIV-1-infected Ugandan adults.
Topics: Adolescent; Adult; Anti-HIV Agents; Diet; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Longitudinal Studies; Male; Middle Aged; Plasma; Rilpivirine; Tenofovir; Uganda; Young Adult | 2015 |
High prevalence of the K65R mutation in HIV-1 subtype C infected patients failing tenofovir-based first-line regimens in South Africa.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1; Humans; Male; Middle Aged; Molecular Sequence Data; Mutation; Organophosphonates; Prevalence; South Africa; Tenofovir; Viral Load; Young Adult | 2015 |
Renal tubular dysfunction associated with tenofovir therapy.
Topics: Adenine; Adult; Anti-HIV Agents; Creatinine; Developing Countries; Diagnosis, Differential; Female; HIV Infections; Humans; Incidence; India; Kidney Diseases; Kidney Tubules; Long-Term Care; Male; Middle Aged; Organophosphonates; Tenofovir | 2014 |
Antibody Maturation in Women Who Acquire HIV Infection While Using Antiretroviral Preexposure Prophylaxis.
Topics: Adenine; Adult; Anti-Retroviral Agents; Antibody Affinity; Cohort Studies; Female; HIV; HIV Antibodies; HIV Infections; Humans; Immunoassay; Organophosphonates; Pre-Exposure Prophylaxis; Randomized Controlled Trials as Topic; Tenofovir; Time Factors; Young Adult | 2015 |
Viral and inflammatory markers in cerebrospinal fluid of patients with HIV-1-associated neurocognitive impairment during antiretroviral treatment switch.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Biomarkers; Cognition Disorders; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Drug Substitution; Emtricitabine; Enzyme-Linked Immunosorbent Assay; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Pilot Projects; Prospective Studies; Tenofovir; Tumor Necrosis Factor-alpha; Viral Load | 2015 |
Switching from tenofovir containing regimens to boosted protease inhibitor monotherapy: Impact on renal function.
Topics: Adult; Anti-HIV Agents; Creatinine; Female; HIV Infections; Humans; Kidney; Male; Protease Inhibitors; Retrospective Studies; Tenofovir | 2016 |
PrEP: A case study.
Topics: Anti-HIV Agents; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Male; Risk Reduction Behavior; Safe Sex; Tenofovir | 2015 |
Efficacy, safety and pharmacokinetics of tenofovir disoproxil fumarate in virologic-suppressed HIV-infected children using weight-band dosing.
Topics: Adenine; Adolescent; Alkynes; Anti-HIV Agents; Benzoxazines; Bone Density; Calcium; CD4 Lymphocyte Count; Child; Child, Preschool; Cyclopropanes; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Organophosphonates; Prospective Studies; RNA, Viral; Tenofovir; Treatment Outcome; Urinalysis; Viral Load | 2015 |
The science of being a study participant: FEM-PrEP participants' explanations for overreporting adherence to the study pills and for the whereabouts of unused pills.
Topics: Adenine; Adult; Clinical Trials as Topic; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Interviews as Topic; Kenya; Medication Adherence; Organophosphonates; South Africa; Tenofovir; Treatment Outcome | 2015 |
Switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: changes in bone turnover markers and circulating sclerostin levels.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Anti-HIV Agents; Biomarkers; Bone Density; Bone Morphogenetic Proteins; Bone Remodeling; Dideoxynucleosides; Female; Genetic Markers; HIV Infections; HIV-1; Humans; Male; Middle Aged; Tenofovir | 2015 |
Antiretroviral chemoprophylaxis: new successes and questions.
Topics: Adenine; Anti-HIV Agents; Anti-Retroviral Agents; Chemoprevention; Deoxycytidine; Drug Combinations; Emtricitabine; Gels; HIV Infections; Humans; Organophosphonates; Tenofovir | 2015 |
Toxicity and clinical outcomes in patients with HIV on zidovudine and tenofovir based regimens: a retrospective cohort study.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Female; HIV Infections; Humans; India; Male; Middle Aged; Retrospective Studies; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load; Weight Gain; Zidovudine | 2015 |
Is zidovudine first-line therapy virologically comparable to tenofovir in resource-limited settings?
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Female; Health Resources; HIV; HIV Infections; Humans; Lamivudine; Lesotho; Logistic Models; Male; Middle Aged; Organophosphonates; Tenofovir; Viral Load; Zidovudine | 2015 |
Nonalbumin proteinuria predominates in biopsy-proven tenofovir nephrotoxicity.
Topics: Anti-HIV Agents; Biomarkers; Biopsy; Female; HIV Infections; Humans; Kidney; Male; Microscopy, Electron, Transmission; Middle Aged; Mitochondria; Proteinuria; Retrospective Studies; Tenofovir | 2015 |
Painless penile papule.
Topics: Adenine; Adult; Anti-Bacterial Agents; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biopsy; CD4 Lymphocyte Count; Coinfection; Deoxycytidine; Emtricitabine; HIV Infections; Humans; Male; Nevirapine; Organophosphonates; Penicillin G Benzathine; Penis; Syphilis, Cutaneous; Tenofovir; Treatment Outcome | 2015 |
Uptake of WHO recommendations for first-line antiretroviral therapy in Kenya, Uganda, and Zambia.
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; Humans; Kenya; Male; Middle Aged; Retrospective Studies; Stavudine; Tenofovir; Uganda; World Health Organization; Young Adult; Zambia | 2015 |
The sheep as a model of preclinical safety and pharmacokinetic evaluations of candidate microbicides.
Topics: Administration, Intravaginal; Animals; Anti-HIV Agents; Contraceptive Devices, Female; Disease Models, Animal; Drug Carriers; Female; HIV Infections; Pyrimidines; Sheep; Tenofovir; Vagina; Vaginal Creams, Foams, and Jellies | 2015 |
Pharmacokinetics of dolutegravir in a premature neonate after HIV treatment intensification during pregnancy.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Cytochrome P-450 CYP3A; Emtricitabine; Female; Glucuronosyltransferase; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Infant, Newborn; Male; Oxazines; Piperazines; Pregnancy; Pyridones; Ritonavir; Tenofovir | 2015 |
Proximal tubular dysfunction in a HIV-1 patient with coadministered tenofovir disoproxil-fumarate and ibuprofen.
Topics: Anti-HIV Agents; Anti-Inflammatory Agents, Non-Steroidal; HIV Infections; HIV-1; Humans; Ibuprofen; Kidney Diseases; Kidney Tubules, Proximal; Male; Middle Aged; Tenofovir | 2015 |
Tenofovir-Associated Nephrotoxicity in Children with Perinatally-Acquired HIV Infection: A Single-Centre Cohort Study.
Topics: Adolescent; Anti-HIV Agents; Child; Female; HIV Infections; Humans; Hypokalemia; Hypophosphatemia; Kidney Diseases; Male; Retrospective Studies; Tenofovir | 2015 |
Triple combination of carbosilane dendrimers, tenofovir and maraviroc as potential microbicide to prevent HIV-1 sexual transmission.
Topics: Adenine; Animals; Anti-HIV Agents; Anti-Infective Agents; Antiviral Agents; Cell Survival; Cyclohexanes; Dendrimers; Drug Combinations; Female; HIV Infections; HIV-1; Humans; Maraviroc; Mice; Mice, Inbred BALB C; Mucous Membrane; Organophosphonates; Silanes; Software; Tenofovir; Triazoles; Vagina | 2015 |
Tenofovir alafenamide for HIV infection: is less more?
Topics: Adenine; Alanine; Anti-HIV Agents; Carbamates; Cobicistat; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Male; Organophosphonates; Quinolones; Tenofovir; Thiazoles | 2015 |
Pharmacokinetics of long-acting tenofovir alafenamide (GS-7340) subdermal implant for HIV prophylaxis.
Topics: Adenine; Alanine; Animals; Anti-HIV Agents; Dogs; Drug Implants; Equipment Design; HIV Infections; HIV-1; Male; Monocytes; Prodrugs; Reverse Transcriptase Inhibitors; Tenofovir | 2015 |
Editorial Commentary: Unmasking the Bare Bones of HIV Preexposure Prophylaxis.
Topics: Anti-HIV Agents; Bone Density; Chemoprevention; Emtricitabine; Female; HIV Infections; Humans; Male; Tenofovir | 2015 |
Tenofovir in Indian children.
Topics: Adolescent; Anti-Retroviral Agents; Child; Child, Preschool; Female; Follow-Up Studies; HIV Infections; Humans; Male; Tenofovir | 2015 |
Pre-exposure prophylaxis works--it's time to deliver.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Health Services Accessibility; HIV Infections; Humans; Organophosphonates; Pre-Exposure Prophylaxis; Tenofovir | 2015 |
A post-partum single-dose TDF/FTC tail does not prevent the selection of NNRTI resistance in women receiving pre-partum ZDV and intrapartum single-dose nevirapine to prevent mother-to- child HIV-1 transmission.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Viral; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Infectious Disease Transmission, Vertical; Mothers; Mutation; Nevirapine; Postpartum Period; Pregnancy; Pregnancy Complications, Infectious; Reverse Transcriptase Inhibitors; Sequence Analysis, DNA; South Africa; Tenofovir; Viral Load; Zidovudine | 2015 |
Pharmacokinetics of tenofovir during pregnancy and postpartum.
Topics: Adolescent; Adult; Anti-HIV Agents; Area Under Curve; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Postpartum Period; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Trimester, Second; Pregnancy Trimester, Third; Prospective Studies; Tenofovir; Young Adult | 2015 |
Meconium Tenofovir Concentrations and Growth and Bone Outcomes in Prenatally Tenofovir Exposed HIV-Uninfected Children.
Topics: Adolescent; Adult; Anti-HIV Agents; Bone Density; Female; Gestational Age; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Male; Maternal Exposure; Meconium; Middle Aged; Pregnancy; Pregnancy Complications, Infectious; Tenofovir; Young Adult | 2015 |
Pre-exposure Prophylaxis Adherence Measured by Plasma Drug Level in MTN-001: Comparison Between Vaginal Gel and Oral Tablets in Two Geographic Regions.
Topics: Administration, Oral; Administration, Topical; Adolescent; Adult; Africa South of the Sahara; Anti-HIV Agents; Cross-Over Studies; Female; HIV Infections; Humans; Medication Adherence; Middle Aged; Patient Acceptance of Health Care; Patient Preference; Pre-Exposure Prophylaxis; Tablets; Tenofovir; United States; Vaginal Creams, Foams, and Jellies; Young Adult | 2016 |
HIV-serodiscordant couples desiring a child: 'treatment as prevention,' preexposure prophylaxis, or medically assisted procreation?
Topics: Adenine; Anti-HIV Agents; Cost-Benefit Analysis; Deoxycytidine; Emtricitabine; Female; Fertile Period; France; Health Care Costs; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Insemination, Artificial; Male; Models, Economic; Organophosphonates; Pre-Exposure Prophylaxis; Pregnancy; Reproductive Techniques, Assisted; Semen; Tenofovir | 2015 |
A LC-MS method to quantify tenofovir urinary concentrations in treated patients.
Topics: Antiretroviral Therapy, Highly Active; Calibration; Chromatography; Chromatography, Liquid; Drug Monitoring; Hepatitis B; HIV Infections; Humans; Limit of Detection; Mass Spectrometry; Reproducibility of Results; Tenofovir; United States; United States Food and Drug Administration; Urinalysis | 2015 |
Acceptability of drug detection monitoring among participants in an open-label pre-exposure prophylaxis study.
Topics: Adult; Anti-HIV Agents; Boston; Chicago; Emtricitabine; Female; HIV Infections; Humans; Interviews as Topic; Male; Medication Adherence; Middle Aged; Patient Acceptance of Health Care; Pre-Exposure Prophylaxis; San Francisco; Tenofovir | 2015 |
Incidence and risk factors for tenofovir-associated renal toxicity in HIV-infected patients.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; Glomerular Filtration Rate; HIV Infections; Humans; Incidence; Longitudinal Studies; Male; Renal Insufficiency; Retrospective Studies; Risk Factors; Spain; Tenofovir | 2015 |
Long-term renal effects of tenofovir-disoproxil-fumarate in vertically HIV-infected children, adolescents, and young adults: a 132-month follow-up study.
Topics: Anti-HIV Agents; Child; Child, Preschool; Female; Follow-Up Studies; Glomerular Filtration Rate; HIV Infections; Humans; Infant; Infant, Newborn; Kidney; Male; Multidrug Resistance-Associated Protein 2; Tenofovir; Viral Load | 2015 |
Liver Fibrosis by Transient Elastography and Virologic Outcomes After Introduction of Tenofovir in Lamivudine-Experienced Adults With HIV and Hepatitis B Virus Coinfection in Ghana.
Topics: Adult; Africa South of the Sahara; Antiviral Agents; Coinfection; Cross-Sectional Studies; Elasticity Imaging Techniques; Female; Ghana; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Tenofovir; Treatment Outcome; Viral Load | 2015 |
Acute kidney injury KDIGO stage 2 to 3 in HIV-positive patients treated with cART--a case series over 11 years in a cohort of 1,153 patients.
Topics: Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Anti-Retroviral Agents; Arteriosclerosis; Diabetes Mellitus; Drug Therapy, Combination; Female; Glomerular Filtration Rate; HIV Infections; Humans; Hypertension; Incidence; Male; Middle Aged; Renal Dialysis; Severity of Illness Index; Tenofovir | 2015 |
Lower Newborn Bone Mineral Content Associated With Maternal Use of Tenofovir Disoproxil Fumarate During Pregnancy.
Topics: Adult; Anti-HIV Agents; Bone Density; Cross-Sectional Studies; Female; HIV Infections; Humans; Infant, Newborn; Maternal Exposure; Pregnancy; Pregnancy Complications, Infectious; Tenofovir; United States | 2015 |
Tenofovir-based antiretroviral therapy in
HBV-HIV coinfection: results from the TREAT Asia HIV Observational Database.
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Biomarkers; CD4 Lymphocyte Count; Cohort Studies; Coinfection; Databases, Factual; Drug Therapy, Combination; Female; Hepatitis B; Hepatitis B virus; HIV Infections; HIV-1; Humans; Kidney Function Tests; Liver Function Tests; Male; Mortality; Reverse Transcriptase Inhibitors; Risk Factors; Tenofovir; Treatment Outcome | 2016 |
Many in VOICE trial didn't use provided prevention products.
Topics: Adenine; Africa South of the Sahara; Anti-Retroviral Agents; Female; Gels; HIV Infections; Humans; Medication Adherence; Organophosphonates; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir | 2015 |
Pharmacological Measures of Treatment Adherence and Risk of HIV Infection in the VOICE Study.
Topics: Administration, Intravaginal; Administration, Oral; Administration, Topical; Anti-HIV Agents; Emtricitabine; Gels; HIV Infections; Humans; Medication Adherence; Pre-Exposure Prophylaxis; Regression Analysis; Risk Factors; Tenofovir | 2016 |
Use of Pharmacokinetic Data in Novel Analyses to Determine the Effect of Topical Microbicides as Preexposure Prophylaxis Against HIV Infection.
Topics: Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Medication Adherence; Tenofovir | 2016 |
HBV genotypes and response to tenofovir disoproxil fumarate in HIV/HBV-coinfected persons.
Topics: Adult; Aged; Antiviral Agents; Coinfection; Drug Resistance, Viral; Female; Genotype; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Retrospective Studies; Switzerland; Tenofovir; Viral Load; Young Adult | 2015 |
Early Initiation of Antiretroviral Therapy Can Functionally Control Productive HIV-1 Infection in Humanized-BLT Mice.
Topics: Adenine; Animals; Anti-HIV Agents; Antigens, CD34; Bone Marrow; CD8-Positive T-Lymphocytes; Disease Models, Animal; Disease Progression; DNA, Viral; Gene Dosage; HIV Infections; HIV-1; Humans; Liver; Mice; Mice, Inbred NOD; Mice, Transgenic; Organophosphonates; Pilot Projects; RNA, Viral; Spleen; Tenofovir; Thymus Gland; Viral Load; Virus Replication | 2015 |
The promises and challenges of pre-exposure prophylaxis as part of the emerging paradigm of combination HIV prevention.
Topics: Anti-HIV Agents; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir | 2015 |
Use of PCR Signal and Therapeutic Drug Monitoring in a Switch Cohort Study to Tenofovir/Emtricitabine/Rilpivirine: A W96 Follow-Up.
Topics: Adult; Anti-HIV Agents; Drug Combinations; Drug Substitution; Drug Therapy, Combination; Emtricitabine; Emtricitabine, Rilpivirine, Tenofovir Drug Combination; Female; Follow-Up Studies; HIV Infections; Humans; Male; Middle Aged; Rilpivirine; Tenofovir; Viral Load | 2015 |
Efficacy and safety in clinical practice of a rilpivirine, tenofovir and emtricitabine single-tablet regimen in virologically suppressed HIV-positive patients on stable antiretroviral therapy.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Retrospective Studies; Rilpivirine; Tenofovir | 2015 |
Tenofovir disoproxil treatment for a HIV-hepatitis B virus coinfected patient undergoing peritoneal dialysis: which dose do we need?
Topics: Antiviral Agents; Coinfection; Hemodialysis Solutions; Hepatitis B; HIV Infections; Humans; Peritoneal Dialysis; Renal Insufficiency; Serum; Tenofovir | 2015 |
A simple, efficient, and sensitive method for simultaneous detection of anti-HIV drugs atazanavir, ritonavir, and tenofovir by use of liquid chromatography-tandem mass spectrometry.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Chromatography, Liquid; HIV Infections; Humans; Ritonavir; Tandem Mass Spectrometry; Tenofovir | 2015 |
Effects of raltegravir combined with tenofovir/emtricitabine on body shape, bone density, and lipids in African-Americans initiating HIV therapy.
Topics: Adult; Anti-HIV Agents; Black or African American; Bone Density; Cohort Studies; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lipid Metabolism; Longitudinal Studies; Male; North Carolina; Raltegravir Potassium; Tenofovir | 2015 |
Efficacy of topical tenofovir against transmission of a tenofovir-resistant SHIV in macaques.
Topics: Administration, Intravaginal; Animals; Disease Models, Animal; Drug Resistance, Viral; Female; Gels; HIV; HIV Infections; Humans; Macaca radiata; Pre-Exposure Prophylaxis; Reverse Transcriptase Inhibitors; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Tenofovir; Vagina | 2015 |
Selective pinning control of the average disease transmissibility in an HIV contact network.
Topics: Antiviral Agents; Computer Simulation; Disease Outbreaks; Feedback; Heterosexuality; HIV Infections; Humans; Incidence; Models, Biological; Risk; Tenofovir | 2015 |
Low Incidence of Renal Dysfunction among HIV-Infected Patients on a Tenofovir-Based First Line Antiretroviral Treatment Regimen in Myanmar.
Topics: Adolescent; Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Creatinine; Female; Glomerular Filtration Rate; HIV Infections; Humans; Male; Middle Aged; Myanmar; Renal Insufficiency; Risk Factors; Switzerland; Tenofovir | 2015 |
Fibroblast growth factor 23: associations with antiretroviral therapy in patients co-infected with HIV and hepatitis C.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Bayes Theorem; Benzoxazines; Canada; Coinfection; Cyclopropanes; Dideoxynucleosides; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Hepatitis C; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Prospective Studies; Risk Factors; Tenofovir | 2016 |
Population pharmacokinetics of tenofovir in HIV/HBV co-infected patients.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Coinfection; Cross-Sectional Studies; Drug Interactions; Drug Therapy, Combination; Hepatitis B, Chronic; HIV Infections; HIV Protease Inhibitors; Humans; Kidney; Models, Biological; Nonlinear Dynamics; Renal Elimination; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Thailand; Treatment Outcome | 2015 |
Hepatitis B surface antigen quantification as a predictor of seroclearance during treatment in HIV-hepatitis B virus coinfected patients from Sub-Saharan Africa.
Topics: Africa; Antiviral Agents; Biomarkers; Cohort Studies; Coinfection; Drug Therapy, Combination; Emtricitabine; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; HIV Infections; Humans; Lamivudine; Predictive Value of Tests; Prospective Studies; Randomized Controlled Trials as Topic; Sensitivity and Specificity; Tenofovir; Time Factors | 2016 |
Loss of Virologic Control and Severe Pneumocystis pneumonia in an HIV-Infected Patient Receiving Chemotherapy for Non-Small Cell Lung Cancer.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Antiretroviral Therapy, Highly Active; Carcinoma, Non-Small-Cell Lung; Cisplatin; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lung Neoplasms; Middle Aged; Oxazines; Pemetrexed; Piperazines; Pneumocystis carinii; Pneumonia, Pneumocystis; Pyridones; Tenofovir; Tomography, X-Ray Computed; Treatment Outcome; Trimethoprim, Sulfamethoxazole Drug Combination; Viral Load | 2016 |
Brief Report: Effects of Tenofovir and Amphotericin B Deoxycholate Coadministration on Kidney Function in Patients Treated for Cryptococcal Meningitis.
Topics: Adult; Amphotericin B; Anti-HIV Agents; Antifungal Agents; Creatinine; Deoxycholic Acid; Drug Combinations; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney; Male; Meningitis, Cryptococcal; Middle Aged; Tenofovir | 2016 |
More Long-term Assessment of Transient Elastography Is Needed for HIV/Hepatitis B Virus-Coinfected Patients Undergoing Treatment With Tenofovir.
Topics: Antiviral Agents; Coinfection; Female; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Liver Cirrhosis; Male; Tenofovir | 2016 |
Reply to Boyd and Lacombe.
Topics: Antiviral Agents; Coinfection; Female; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Liver Cirrhosis; Male; Tenofovir | 2016 |
Pre-exposure prophylaxis is effective at preventing HIV in high risk gay men, study shows.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Emtricitabine; England; HIV Infections; Homosexuality, Male; Humans; Male; Pre-Exposure Prophylaxis; Randomized Controlled Trials as Topic; Tenofovir; Treatment Outcome; Unsafe Sex | 2015 |
High Prevalence of Low Bone Mineral Density and Substantial Bone Loss over 4 Years Among HIV-Infected Persons in the Era of Modern Antiretroviral Therapy.
Topics: Absorptiometry, Photon; Adult; Anti-HIV Agents; Apolipoproteins E; Bone Density; Bone Diseases, Metabolic; Case-Control Studies; CD4 Lymphocyte Count; Female; HIV; HIV Infections; Humans; Longitudinal Studies; Male; Middle Aged; Nutrition Surveys; Osteoporosis; Risk Factors; RNA, Viral; Tenofovir; United States | 2016 |
Effects of renal tubular dysfunction on bone in tenofovir-exposed HIV-positive patients.
Topics: Absorptiometry, Photon; Adult; AIDS-Associated Nephropathy; Anti-HIV Agents; Bone Density; Creatinine; Cross-Sectional Studies; HIV Infections; Humans; Male; Retinol-Binding Proteins; Spine; Tenofovir | 2015 |
Administration of tenofovir disoproxil fumarate-based antiretroviral therapy in an HIV-infected patient following unilateral nephrectomy.
Topics: Adenine; Anti-HIV Agents; Glomerular Filtration Rate; HIV Infections; HIV-1; Humans; Kidney; Male; Middle Aged; Nephrectomy; Tenofovir; Treatment Outcome | 2016 |
Reassuring Birth Outcomes With Tenofovir/Emtricitabine/Efavirenz Used for Prevention of Mother-to-Child Transmission of HIV in Botswana.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Botswana; Cyclopropanes; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Pregnancy; Tenofovir | 2016 |
An intravaginal ring for the sustained delivery of tenofovir disoproxil fumarate.
Topics: Administration, Intravaginal; Anti-HIV Agents; Delayed-Action Preparations; Drug Liberation; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir | 2015 |
Renal Toxicity of Concomitant Exposure to Tenofovir and Inhibitors of Tenofovir's Renal Efflux Transporters in Patients Infected With HIV Type 1.
Topics: Acute Kidney Injury; Adult; Anti-HIV Agents; Cohort Studies; Enzyme Inhibitors; Female; HIV Infections; Humans; Kidney Function Tests; Male; Middle Aged; Tenofovir | 2016 |
The metabolic and cardiovascular consequences of obesity in persons with HIV on long-term antiretroviral therapy.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Cardiovascular Diseases; Cohort Studies; Cyclopropanes; Emtricitabine; Female; HIV Infections; Humans; Male; Metabolic Diseases; Middle Aged; Obesity; Risk Assessment; Tenofovir | 2016 |
Antiretroviral gels: facing the FACTS.
Topics: Adult; Africa South of the Sahara; Anti-HIV Agents; Anti-Infective Agents, Local; Clinical Trials as Topic; Drug Delivery Systems; Female; Gels; HIV Infections; Humans; Medication Adherence; Pyrimidines; Sexual Behavior; Tenofovir; Women's Health | 2015 |
Efficacy and HIV drug resistance profile of second-line ART among patients having received long-term first-line regimens in rural China.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; China; Drug Resistance, Viral; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Mutation; Prospective Studies; Ritonavir; RNA, Viral; Rural Population; Tenofovir; Treatment Outcome; Viral Load | 2015 |
Tenofovir Therapy for Hepatitis B May Be Commonly Prescribed Without HIV Testing.
Topics: Antiviral Agents; Diagnostic Tests, Routine; Female; Hepatitis B, Chronic; HIV Infections; Humans; Male; Middle Aged; Practice Patterns, Physicians'; Retrospective Studies; Risk Factors; Tenofovir | 2016 |
Tenofovir Activating Kinases May Impact the Outcome of HIV Treatment and Prevention.
Topics: Adenine; Anti-HIV Agents; HIV Infections; Humans; Tenofovir | 2015 |
Discovery of Genetic Variants of the Kinases That Activate Tenofovir in a Compartment-specific Manner.
Topics: Adult; Anti-HIV Agents; Cell Compartmentation; Demography; Ethnicity; Female; Gene Knockdown Techniques; Genetic Variation; High-Throughput Nucleotide Sequencing; HIV Infections; Humans; Male; Middle Aged; Mutation, Missense; Protein Kinases; RNA, Small Interfering; Tenofovir; Young Adult | 2015 |
Impact of Sex on the Pharmacokinetics and Pharmacodynamics of 1% Tenofovir Gel.
Topics: Adolescent; Adult; Anti-HIV Agents; Chromatography, Liquid; Female; Gels; HIV; HIV Infections; Humans; Male; Microbial Sensitivity Tests; Pre-Exposure Prophylaxis; Sex Factors; Tandem Mass Spectrometry; Tenofovir; Time Factors; Vaginal Douching; Young Adult | 2016 |
COMPARISON OF THAI GOVERNMENT MANUFACTURED TENOFOVIR (TENOFOVIR GPO300) WITH PRIVATELY MANUFACTURED TENOFOVIR (VIREAD) USED ALONG WITH LAMIVUDINE AND EFAVIRENZ TO TREAT THAI HIV PATIENTS.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Government; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Prospective Studies; Reverse Transcriptase Inhibitors; Tenofovir | 2015 |
Are randomised controlled trials always required?
Topics: Administration, Intravaginal; Anti-Infective Agents, Local; Evidence-Based Medicine; Female; Guideline Adherence; Guidelines as Topic; HIV Infections; Humans; Randomized Controlled Trials as Topic; Tenofovir; Women's Health | 2015 |
Changes in Serum Markers of Inflammation and Endothelial Activation in HIV-Infected Antiretroviral Naive Patients Starting A Treatment with Abacavir-Lamivudine or Tenofovir-Emtricitabine Plus Efavirenz.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Biomarkers; Cyclopropanes; Dideoxynucleosides; Drug Combinations; E-Selectin; Emtricitabine; Female; HIV Infections; Humans; Inflammation; Intercellular Adhesion Molecule-1; Interleukin-6; Lamivudine; Male; Middle Aged; P-Selectin; Tenofovir; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1 | 2016 |
Drug Transporter Genetic Variants Are Not Associated with TDF-Related Renal Dysfunction in Patients with HIV-1 Infection: A Pharmacogenetic Study.
Topics: Adult; Anti-HIV Agents; ATP Binding Cassette Transporter, Subfamily B; Female; Genetic Variation; Genotype; Glomerular Filtration Rate; HIV Infections; HIV-1; Humans; Kidney Diseases; Logistic Models; Male; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Pharmacogenetics; Polymorphism, Single Nucleotide; Tenofovir | 2015 |
Effect of abacavir on sustained virologic response to HCV treatment in HIV/HCV co-infected patients, Cohere in Eurocoord.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Coinfection; Dideoxynucleosides; Drug Combinations; Emtricitabine; Europe; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Lamivudine; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Reverse Transcriptase Inhibitors; Ribavirin; Tenofovir; Zidovudine | 2015 |
Tenofovir alafenamide for HIV: time to switch?
Topics: Adenine; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Male; Tenofovir | 2016 |
Disclosure of pharmacokinetic drug results to understand nonadherence.
Topics: Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Medication Adherence; Plasma; Retrospective Studies; South Africa; Tenofovir; Uganda; Young Adult; Zimbabwe | 2015 |
Higher tenofovir exposure is associated with longitudinal declines in kidney function in women living with HIV.
Topics: Adult; Aged; Anti-HIV Agents; Creatinine; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney; Middle Aged; Prospective Studies; Renal Insufficiency; Tenofovir; Young Adult | 2016 |
Mechanisms of bone disease in HIV and hepatitis C virus: impact of bone turnover, tenofovir exposure, sex steroids and severity of liver disease.
Topics: Absorptiometry, Photon; Adult; Aged; Anti-Retroviral Agents; Bone Density; Bone Diseases; Bone Remodeling; Cross-Sectional Studies; Gonadal Steroid Hormones; Hepatitis C, Chronic; HIV Infections; Humans; Male; Middle Aged; Prospective Studies; Tenofovir | 2016 |
Adherence to Post-Exposure Prophylaxis (PEP) and Incidence of HIV Seroconversion in a Major North American Cohort.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV Seropositivity; Humans; Incidence; Lamivudine; Lopinavir; Male; Medication Adherence; Middle Aged; Post-Exposure Prophylaxis; Quebec; Ritonavir; Tenofovir; Young Adult; Zidovudine | 2015 |
Superior Effectiveness of Zidovudine Compared With Tenofovir When Combined With Nevirapine-based Antiretroviral Therapy in a Large Nigerian Cohort.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort Studies; Female; HIV Infections; Humans; Male; Nevirapine; Retrospective Studies; Tenofovir; Treatment Outcome; Viral Load; Young Adult; Zidovudine | 2016 |
Long-Term Follow-Up of Proteinuria and Estimated Glomerular Filtration Rate in HIV-Infected Patients with Tubular Proteinuria.
Topics: Adult; Aged; Anti-HIV Agents; Disease Progression; Female; Follow-Up Studies; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Diseases; Kidney Tubules; Longitudinal Studies; Male; Middle Aged; Polymerase Chain Reaction; Prospective Studies; Proteinuria; Tenofovir; Time Factors; Viral Load | 2015 |
Optimizing Delivery of Preexposure Prophylaxis--The Next Frontier.
Topics: Anti-HIV Agents; Bisexuality; Black or African American; Community Health Services; Female; Health Knowledge, Attitudes, Practice; HIV Infections; Homosexuality, Male; Humans; Male; Medication Adherence; Pre-Exposure Prophylaxis; Sexual Behavior; Tenofovir; Transgender Persons; Unsafe Sex | 2016 |
Preexposure Prophylaxis Awareness and Use in a Population-Based Sample of Young Black Men Who Have Sex With Men.
Topics: Adolescent; Adult; Anti-HIV Agents; Bisexuality; Black or African American; Chicago; Health Knowledge, Attitudes, Practice; HIV Infections; Homosexuality, Male; Humans; Logistic Models; Male; Pre-Exposure Prophylaxis; Sexual Behavior; Tenofovir; Young Adult | 2016 |
Preexposure Prophylaxis for HIV Infection Integrated With Municipal- and Community-Based Sexual Health Services.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Bisexuality; Chlamydia Infections; Community Health Services; District of Columbia; Female; Florida; Gonorrhea; HIV Infections; Homosexuality, Male; Humans; Male; Medication Adherence; Middle Aged; Organophosphates; Pre-Exposure Prophylaxis; Prospective Studies; Reproductive Health; San Francisco; Sexual Behavior; Syphilis; Tenofovir; Transgender Persons; Unsafe Sex; Young Adult | 2016 |
Proteinuria is common among HIV patients: what are we missing?
Topics: Adult; Anti-HIV Agents; Brazil; CD4 Lymphocyte Count; Cross-Sectional Studies; Female; HIV Infections; Humans; Male; Middle Aged; Poisson Distribution; Prevalence; Proteinuria; Risk Factors; Tenofovir; Young Adult | 2015 |
HIV and the kidney in the acute medical unit.
Topics: Acute Kidney Injury; Anti-Retroviral Agents; Atazanavir Sulfate; HIV Infections; Humans; Tenofovir | 2015 |
PrEP on demand cuts HIV transmission in high risk men, study finds.
Topics: Emtricitabine; HIV Infections; HIV-1; Homosexuality, Male; Humans; Male; Pre-Exposure Prophylaxis; Tenofovir | 2015 |
Welcome to the preexposure prophylaxis revolution.
Topics: Anti-HIV Agents; Chemoprevention; Delivery of Health Care; Disease Transmission, Infectious; Emtricitabine; Female; HIV Infections; Humans; Male; Medication Adherence; Pre-Exposure Prophylaxis; Tenofovir; Treatment Outcome | 2016 |
Tenofovir clearance is reduced in HIV-positive patients with subclinical tubular impairment.
Topics: Adult; Anti-HIV Agents; Asymptomatic Diseases; Cross-Sectional Studies; Female; HIV Infections; Humans; Kidney Function Tests; Male; Middle Aged; Plasma; Renal Insufficiency; Tenofovir; Urine | 2016 |
The physical and psychological effects of HIV infection and its treatment on perinatally HIV-infected children.
Topics: Adolescent; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Child; Child, Preschool; Female; HIV Infections; Humans; Infant, Newborn; Male; Pregnancy; Tenofovir; Treatment Failure | 2015 |
The Epi-TAF for Tenofovir Disoproxil Fumarate?
Topics: Anti-HIV Agents; Bone Diseases; Cost-Benefit Analysis; HIV Infections; Humans; Kidney Diseases; Tenofovir; United States | 2016 |
Concentrations of tenofovir, lamivudine and efavirenz in mothers and children enrolled under the Option B-Plus approach in Malawi.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Chromatography, Liquid; Cyclopropanes; Female; HIV Infections; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Malawi; Pregnancy; Pregnancy Complications, Infectious; Tandem Mass Spectrometry; Tenofovir; Viral Load; Young Adult | 2016 |
Tenofovir DF/emtricitabine and efavirenz combination therapy for HIV infection in patients treated for tuberculosis: the ANRS 129 BKVIR trial.
Topics: Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Emtricitabine; Female; France; HIV Infections; Humans; Male; Middle Aged; Tenofovir; Treatment Outcome; Tuberculosis; Viral Load | 2016 |
Prevalence and significance of proximal renal tubular abnormalities in HIV-infected patients receiving tenofovir.
Topics: Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Cohort Studies; Cross-Sectional Studies; Female; HIV Infections; Humans; Kidney Diseases; Kidney Function Tests; Kidney Tubules, Proximal; Male; Middle Aged; Prevalence; Prospective Studies; Tenofovir; Young Adult | 2016 |
The pharmacokinetics of high-dose methotrexate in people living with HIV on antiretroviral therapy.
Topics: Adult; Aged; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cyclophosphamide; Cytarabine; Dose-Response Relationship, Drug; Doxorubicin; Drug Interactions; Etoposide; Female; Half-Life; HIV Infections; Humans; Ifosfamide; Kidney Function Tests; Male; Methotrexate; Middle Aged; Retrospective Studies; Tenofovir; Vincristine; Young Adult | 2016 |
Antiretroviral therapy management and rationalisation of available resources.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Emtricitabine; Female; HIV Infections; Humans; Italy; Male; Middle Aged; Ritonavir; Surveys and Questionnaires; Tenofovir; Treatment Outcome | 2015 |
Differential Mechanisms of Tenofovir and Tenofovir Disoproxil Fumarate Cellular Transport and Implications for Topical Preexposure Prophylaxis.
Topics: Administration, Intravaginal; Anti-HIV Agents; Biological Transport; Carboxylic Ester Hydrolases; Cell Line; Chromatography, High Pressure Liquid; Endocytosis; Epithelial Cells; Female; Herpes Genitalis; Herpesvirus 2, Human; HIV Infections; HIV-1; Humans; Nitrophenols; Organophosphorus Compounds; T-Lymphocytes; Tandem Mass Spectrometry; Tenofovir | 2015 |
Tenofovir/emtricitabine metabolites and endogenous nucleotide exposures are associated with p16(INK4a) expression in subjects on combination therapy.
Topics: Adult; Aged; Aging; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclin-Dependent Kinase Inhibitor p16; Cyclopropanes; Drug Therapy, Combination; Emtricitabine; Female; Gene Expression; HIV Infections; Humans; Male; Middle Aged; Nucleotides; Ritonavir; Tenofovir; Young Adult | 2016 |
Lamivudine Monotherapy-Based cART Is Efficacious for HBV Treatment in HIV/HBV Coinfection When Baseline HBV DNA <20,000 IU/mL.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; China; Cohort Studies; Coinfection; DNA, Viral; Drug Therapy, Combination; Emtricitabine; Female; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Prospective Studies; Tenofovir | 2016 |
Prevalence of K65R in patients treated with tenofovir disoproxil fumarate: recommendations based on the Frankfurt HIV Cohort Study Resistance Database (FHCS-RD).
Topics: Anti-HIV Agents; Cohort Studies; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation, Missense; Prevalence; Tenofovir | 2016 |
Uncontrolled hepatitis delta virus infection after initial suppression on tenofovir in a HIV/HBV-coinfected patient.
Topics: Adult; Coinfection; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis D; Hepatitis Delta Virus; HIV; HIV Infections; Humans; Male; Tenofovir; Viral Load | 2016 |
Tenofovir exposure alters associations of serum bicarbonate with chronic kidney disease risk in HIV-infected veterans.
Topics: Adult; Anti-HIV Agents; Bicarbonates; HIV Infections; Humans; Male; Middle Aged; Renal Insufficiency, Chronic; Retrospective Studies; Risk Assessment; Serum; Tenofovir; United States; Veterans | 2016 |
Growth indices in breastfed infants pre and postnatally exposed to tenofovir compared with tenofovir-unexposed infants.
Topics: Anti-HIV Agents; Breast Feeding; Child Development; Female; HIV Infections; Humans; Infant; Infant, Newborn; Malawi; Pregnancy; Pregnancy Complications, Infectious; Tenofovir | 2016 |
Top-down and bottom-up modeling in system pharmacology to understand clinical efficacy: An example with NRTIs of HIV-1.
Topics: Anti-HIV Agents; Dose-Response Relationship, Drug; Emtricitabine; HIV Infections; HIV-1; Humans; Lamivudine; Leukocytes, Mononuclear; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2016 |
Novel quantification of tenofovir disoproxil fumarate adherence in human immunodeficiency virus/hepatitis B coinfected patients with incomplete hepatitis B virus viral suppression.
Topics: Antiviral Agents; Coinfection; Defective Viruses; DNA, Viral; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Tenofovir | 2016 |
A Single-Nucleotide Polymorphism in ABCC4 Is Associated with Tenofovir-Related Beta2-Microglobulinuria in Thai Patients with HIV-1 Infection.
Topics: Adult; Antiretroviral Therapy, Highly Active; Female; Gene Frequency; Gene-Environment Interaction; Genotype; HIV Infections; Humans; Kidney Diseases; Lamivudine; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Nevirapine; Polymorphism, Single Nucleotide; Stavudine; Tenofovir; Thailand | 2016 |
Treatment options after virological failure of first-line tenofovir-based regimens in South Africa: an analysis by deep sequencing.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Genotype; Genotyping Techniques; High-Throughput Nucleotide Sequencing; HIV; HIV Infections; Humans; Microbial Sensitivity Tests; South Africa; Tenofovir; Treatment Failure | 2016 |
Presence of Minority Resistant Variants After Failure of a Tenofovir, Emtricitabine, and Rilpivirine Regimen.
Topics: Anti-HIV Agents; Drug Resistance, Viral; Emtricitabine; Genotyping Techniques; High-Throughput Nucleotide Sequencing; HIV Infections; HIV-1; Humans; Rilpivirine; RNA-Directed DNA Polymerase; Tenofovir; Viral Load | 2016 |
Maternal Tenofovir Disoproxil Fumarate Use in Pregnancy and Growth Outcomes among HIV-Exposed Uninfected Infants in Kenya.
Topics: Adult; Anti-HIV Agents; Antibiotic Prophylaxis; Birth Weight; CD4 Lymphocyte Count; Female; HIV Infections; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Kenya; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Retrospective Studies; Tenofovir; Young Adult | 2015 |
Preventing long-term tenofovir renal toxicity by pharmacokinetic assessment.
Topics: Adenine; Anti-HIV Agents; HIV Infections; Humans; Organophosphonates; Tenofovir | 2016 |
Efficacy and Safety of Tenofovir and Lamivudine in Combination with Efavirenz in Patients Co-infected with Human Immunodeficiency Virus and Hepatitis B Virus in China.
Topics: Adult; Alanine Transaminase; Alkynes; Anti-HIV Agents; Aspartate Aminotransferases; Benzoxazines; CD4-Positive T-Lymphocytes; Coinfection; Cyclopropanes; Female; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Male; Tenofovir | 2016 |
Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study.
Topics: Africa South of the Sahara; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Emtricitabine; Global Health; HIV Infections; HIV-1; Humans; Lamivudine; Pre-Exposure Prophylaxis; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load | 2016 |
Incidence of stage 3 chronic kidney disease and progression on tenofovir-based regimens.
Topics: Adult; Anti-HIV Agents; Disease Progression; Female; Glomerular Filtration Rate; HIV Infections; Humans; Incidence; Male; Middle Aged; Renal Insufficiency, Chronic; Retrospective Studies; South Africa; Tenofovir | 2016 |
The Janus kinase inhibitor ruxolitinib reduces HIV replication in human macrophages and ameliorates HIV encephalitis in a murine model.
Topics: Animals; Antiviral Agents; Astrocytes; Blood-Brain Barrier; Disease Models, Animal; Encephalitis, Viral; Gliosis; HIV Infections; HIV-1; Humans; Janus Kinase Inhibitors; Macrophages; Male; Mice; Monocytes; Nitriles; Pyrazoles; Pyrimidines; Tenofovir; Virus Replication | 2016 |
ART influences HIV persistence in the female reproductive tract and cervicovaginal secretions.
Topics: Animals; Anti-HIV Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cells, Cultured; Cervix Uteri; Coculture Techniques; Female; HIV Infections; HIV-1; Humans; Mice, Inbred NOD; Mice, SCID; Mice, Transgenic; Microbial Sensitivity Tests; Receptors, CCR5; RNA, Viral; Tenofovir; Vagina; Virus Replication | 2016 |
Treatment response to unboosted atazanavir in combination with tenofovir disoproxil fumarate and lamivudine in human immunodeficiency virus-1-infected patients who have achieved virological suppression: A therapeutic drug monitoring and pharmacogenetic st
Topics: Adult; Aged; Atazanavir Sulfate; ATP Binding Cassette Transporter, Subfamily B; Drug Combinations; Drug Monitoring; Female; Glucuronosyltransferase; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hyperbilirubinemia; Lamivudine; Male; Middle Aged; Peroxisome-Targeting Signal 1 Receptor; Pharmacogenomic Testing; Polymorphism, Single Nucleotide; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure; Viral Load; Young Adult | 2017 |
Genvoya--a new 4-drug combination for HIV.
Topics: Cobicistat; Drug Combinations; Drug Interactions; Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Emtricitabine; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Quinolones; Randomized Controlled Trials as Topic; Tenofovir; Treatment Outcome | 2016 |
Is Abnormal Urine Protein/Osmolality Ratio Associated with Abnormal Renal Function in Patients Receiving Tenofovir Disoproxil Fumarate?
Topics: Adult; Anti-HIV Agents; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney; Kidney Diseases; Kidney Function Tests; Male; Middle Aged; Osmolar Concentration; Proteinuria; Retrospective Studies; Tenofovir | 2016 |
Uptake of PrEP and condom and sexual risk behavior among MSM during the ANRS IPERGAY trial.
Topics: Adolescent; Anti-HIV Agents; Canada; Condoms; Deoxycytidine; Double-Blind Method; Emtricitabine; Follow-Up Studies; France; HIV Infections; Homosexuality, Male; Humans; Male; Medication Adherence; Middle Aged; Organophosphonates; Outcome Assessment, Health Care; Pre-Exposure Prophylaxis; Risk-Taking; Safe Sex; Sexual Behavior; Sexual Partners; Surveys and Questionnaires; Tenofovir | 2016 |
Bone mineral density decline according to renal tubular dysfunction and phosphaturia in tenofovir-exposed HIV-infected patients.
Topics: Absorptiometry, Photon; Adult; Aged; Anti-HIV Agents; Bone Density; Bone Resorption; Female; HIV Infections; Humans; Hypophosphatemia, Familial; Kidney Diseases; Longitudinal Studies; Male; Middle Aged; Tenofovir; Urinalysis | 2016 |
Urinary β2 microglobulin can predict tenofovir disoproxil fumarate-related renal dysfunction in HIV-1-infected patients who initiate tenofovir disoproxil fumarate-containing antiretroviral therapy.
Topics: Adult; Antiviral Agents; beta 2-Microglobulin; Biomarkers; Female; HIV Infections; Humans; Longitudinal Studies; Male; Middle Aged; Renal Insufficiency; Tenofovir | 2016 |
Social Context of Adherence in an Open-Label 1 % Tenofovir Gel Trial: Gender Dynamics and Disclosure in KwaZulu-Natal, South Africa.
Topics: Adolescent; Adult; Anti-HIV Agents; Female; Gels; Gender Identity; HIV Infections; Humans; Interpersonal Relations; Male; Medication Adherence; Negotiating; Pre-Exposure Prophylaxis; Self Disclosure; Sex Factors; South Africa; Tenofovir | 2016 |
Effects of long-term tenofovir-based combination antiretroviral therapy in HIV-hepatitis B virus coinfection on persistent hepatitis B virus viremia and the role of hepatitis B virus quasispecies diversity.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Australia; Coinfection; Female; Genetic Variation; Genotype; Hepatitis B virus; Hepatitis B, Chronic; High-Throughput Nucleotide Sequencing; HIV Infections; Humans; Male; Middle Aged; Quasispecies; Sequence Analysis, DNA; Tenofovir; Thailand | 2016 |
Tenofovir alafenamide as part of a salvage regimen in a patient with multi-drug resistant HIV and tenofovir-DF-associated renal tubulopathy.
Topics: Acute Kidney Injury; Adenine; Alanine; Anti-HIV Agents; Drug Resistance, Multiple, Viral; HIV Infections; HIV-1; Humans; Male; Middle Aged; Salvage Therapy; Tenofovir | 2016 |
[New NRTI with optimized long-term tolerance].
Topics: Adenine; Alanine; Anti-HIV Agents; Drug Combinations; Drug Tolerance; HIV Infections; Humans; Tenofovir | 2015 |
Changes in Kidney Function and in the Rate of Tubular Dysfunction After Tenofovir Withdrawal or Continuation in HIV-Infected Patients.
Topics: Adult; Aged; Anti-HIV Agents; Female; Follow-Up Studies; Glomerular Filtration Rate; HIV Infections; Humans; Hypophosphatemia, Familial; Kidney Diseases; Kidney Function Tests; Kidney Tubules, Proximal; Male; Middle Aged; Prospective Studies; Tenofovir; Treatment Outcome; Young Adult | 2016 |
Elvitegravir/Cobicistat/Tenofovir/Emtricitabine Penetration in the Cerebrospinal Fluid of Three HIV-Positive Patients.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cobicistat; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Quinolones; Tenofovir | 2016 |
TDF-FTC before and after sex reduced HIV infection but increased GI, renal events in men who have sex with men.
Topics: Emtricitabine; HIV Infections; HIV-1; Homosexuality, Male; Humans; Male; Pre-Exposure Prophylaxis; Tenofovir | 2016 |
Preexposure Prophylaxis with Tenofovir/Emtricitabine Prevents HIV Infection In Men who Have Unprotected Anal Intercourse.
Topics: Anti-HIV Agents; Drug Therapy, Combination; Emtricitabine; HIV; HIV Infections; Homosexuality, Male; Humans; Male; Pre-Exposure Prophylaxis; Tenofovir | 2016 |
PrEP Adherence Patterns Strongly Affect Individual HIV Risk and Observed Efficacy in Randomized Clinical Trials.
Topics: Female; HIV Infections; Humans; Male; Medication Adherence; Models, Biological; Pre-Exposure Prophylaxis; Randomized Controlled Trials as Topic; Sexual Partners; Tenofovir; Treatment Outcome | 2016 |
Self-reported Recent PrEP Dosing and Drug Detection in an Open Label PrEP Study.
Topics: Adult; Anti-HIV Agents; Chromatography, Liquid; Condoms; Dried Blood Spot Testing; Emtricitabine; Female; HIV Infections; Humans; Male; Medication Adherence; Pre-Exposure Prophylaxis; Self Report; Tandem Mass Spectrometry; Tenofovir | 2016 |
In Utero Tenofovir Exposure Is not Associated With Fetal Long Bone Growth.
Topics: Adult; Anti-HIV Agents; Bone Development; Clinical Trials as Topic; Female; Femur; Fetal Development; Follow-Up Studies; HIV Infections; Humans; Humerus; Pregnancy; Pregnancy Complications, Infectious; Tenofovir | 2016 |
Superior Efficacy of a Human Immunodeficiency Virus Vaccine Combined with Antiretroviral Prevention in Simian-Human Immunodeficiency Virus-Challenged Nonhuman Primates.
Topics: AIDS Vaccines; Animals; Anti-HIV Agents; Antibodies, Viral; Drug Synergism; Female; HIV Antibodies; HIV Infections; HIV-1; Humans; Macaca fascicularis; Models, Animal; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Tenofovir; Vaccination | 2016 |
Symptomatic Bradycardia and Heart Failure Triggered by Ivabradine in a Patient Receiving Antiretroviral Therapy.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Benzazepines; Bradycardia; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Emtricitabine; Female; Heart Failure; HIV Infections; Humans; Ivabradine; Middle Aged; Ritonavir; Tenofovir | 2016 |
Tenofovir tablet not effective in preventing HIV in women.
Topics: Adenine; Anti-HIV Agents; Female; HIV Infections; Humans; Organophosphonates; Tablets; Tenofovir | 2011 |
Tenofovir alafenamide: safer, but questions remain.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; HIV Infections; HIV-1; Humans; Organophosphonates; Tenofovir | 2016 |
Is sub-Saharan Africa ready for pre-exposure prophylaxis?
Topics: Administration, Oral; Africa South of the Sahara; Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir | 2016 |
What do we know about tailoring treatment with tenofovir?
Topics: Anti-HIV Agents; HIV Infections; Humans; Tenofovir | 2016 |
Topical Tenofovir Disoproxil Fumarate Nanoparticles Prevent HIV-1 Vaginal Transmission in a Humanized Mouse Model.
Topics: Administration, Intravaginal; Animals; Anti-HIV Agents; Disease Models, Animal; Emulsifying Agents; Female; HIV Infections; HIV-1; Humans; Lactic Acid; Mice; Mice, Transgenic; Nanoparticles; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Primary Prevention; RNA, Viral; Temperature; Tenofovir; Time Factors; Vagina; Vaginal Creams, Foams, and Jellies; Viral Load | 2016 |
Low willingness and actual uptake of pre-exposure prophylaxis for HIV-1 prevention among men who have sex with men in Shanghai, China.
Topics: Adolescent; Adult; Age Factors; Anti-HIV Agents; China; Health Knowledge, Attitudes, Practice; HIV Infections; HIV-1; Homosexuality, Male; Humans; Male; Middle Aged; Patient Acceptance of Health Care; Patient Compliance; Pre-Exposure Prophylaxis; Sexual Behavior; Tenofovir | 2016 |
Editorial.
Topics: Adenine; Alanine; Anti-HIV Agents; Clinical Trials as Topic; Drug Approval; Drug-Related Side Effects and Adverse Reactions; HIV Infections; Humans; Tenofovir | 2016 |
Combination Pod-Intravaginal Ring Delivers Antiretroviral Agents for HIV Prophylaxis: Pharmacokinetic Evaluation in an Ovine Model.
Topics: Administration, Intravaginal; Animals; Anti-HIV Agents; Contraceptive Devices, Female; Cyclohexanes; Delayed-Action Preparations; Drug Combinations; Female; HIV Infections; Humans; Maraviroc; Models, Animal; Primary Prevention; Sheep; Tenofovir; Triazoles; Vagina | 2016 |
Brief Report: Cumulative Tenofovir Disoproxil Fumarate Exposure is Associated With Biomarkers of Tubular Injury and Fibrosis in HIV-Infected Men.
Topics: Biomarkers; Fibrosis; HIV Infections; Humans; Kidney Tubules; Male; Middle Aged; Tenofovir | 2016 |
Comparative risk of failure of ABC/3TC or TDF/FTC based first-line regimens in patients with a high viral load.
Topics: Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; France; HIV Infections; Humans; Lamivudine; Male; Propensity Score; Prospective Studies; Risk Assessment; Tenofovir; Treatment Failure; Viral Load | 2016 |
The ethics of expanding access to cheaper, less effective treatments.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Developed Countries; Developing Countries; Drug Administration Schedule; Ethical Theory; Global Health; Health Services Accessibility; HIV Infections; Humans; South Africa; Stavudine; Tenofovir; Treatment Outcome; United States; United States Food and Drug Administration; World Health Organization; Zidovudine | 2016 |
UK PrEP decision re-ignites HIV activism.
Topics: Anti-HIV Agents; Drug Therapy, Combination; Emtricitabine; England; Health Policy; HIV Infections; Homosexuality, Male; Humans; Male; National Health Programs; Pre-Exposure Prophylaxis; Public Health; Tenofovir; United Kingdom | 2016 |
Renal Function and Tenofovir Disoproxil Fumarate for Preexposure Prophylaxis: How Safe Is Safe Enough?
Topics: Anti-HIV Agents; Emtricitabine; HIV Infections; Pre-Exposure Prophylaxis; Tenofovir | 2016 |
Drug resistance mutations after the first 12 months on antiretroviral therapy and determinants of virological failure in Rwanda.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1; Humans; Logistic Models; Male; Middle Aged; Mutation; Odds Ratio; Retrospective Studies; Rwanda; Tenofovir; Treatment Failure; Viral Load; Young Adult | 2016 |
NHS England should reconsider PrEP decision.
Topics: Emtricitabine; England; HIV Infections; Homosexuality, Male; Humans; Male; Pre-Exposure Prophylaxis; Sexual and Gender Minorities; State Medicine; Tenofovir | 2016 |
Tenofovir disoproxil fumarate-induced Fanconi's syndrome during HIV postexposure prophylaxis.
Topics: Anti-HIV Agents; Fanconi Syndrome; HIV Infections; Humans; Kidney Tubules, Proximal; Male; Middle Aged; Post-Exposure Prophylaxis; Sexual Behavior; Tenofovir; Treatment Outcome; Unsafe Sex | 2016 |
First case report of renal improvement on tenofovir alafenamide in an HIV/hepatitis B virus-coinfected patient with adefovir-induced Fanconi's syndrome.
Topics: Absorptiometry, Photon; Adenine; Alanine; Coinfection; Dose-Response Relationship, Drug; Fanconi Syndrome; Hepatitis B, Chronic; HIV Infections; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Organophosphonates; Tenofovir; Treatment Outcome | 2016 |
[Brief notes. Approval recommendation for fixed combination Descovy(R) in treatment of HIV].
Topics: Adenine; Adolescent; Adult; Alanine; Anti-HIV Agents; Child; Dose-Response Relationship, Drug; Drug Approval; Drug Combinations; Emtricitabine; HIV Infections; Humans; Tenofovir; Young Adult | 2016 |
Disrupted trabecular bone micro-architecture in middle-aged male HIV-infected treated patients.
Topics: Adult; Anti-Retroviral Agents; Bone Density; Bone Diseases; Cancellous Bone; Cross-Sectional Studies; HIV Infections; Humans; Male; Middle Aged; Radius; Tenofovir; Tibia; Tomography, X-Ray Computed | 2016 |
Dually Active HIV/HBV Antiretrovirals as Protection Against Incident Hepatitis B Infections: Potential for Prophylaxis.
Topics: Adult; Antiviral Agents; Chemoprevention; Emtricitabine; Female; Follow-Up Studies; Hepatitis B; HIV Infections; Humans; Lamivudine; Male; Prospective Studies; Tenofovir | 2016 |
Hepatic Safety of Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate Fixed-Dose Single-Tablet Regimen in HIV-Infected Patients with Active Hepatitis C Virus Infection: The hEPAtic Study.
Topics: Adult; Anti-Retroviral Agents; Antiviral Agents; Bilirubin; Case-Control Studies; Coinfection; Drug Therapy, Combination; Emtricitabine; Female; Fibrosis; Hepacivirus; Hepatitis C; HIV Infections; Hospitalization; Humans; Liver; Male; Middle Aged; Retrospective Studies; Rilpivirine; Spain; Tablets; Tenofovir; Transaminases | 2016 |
High resistance barrier to tenofovir alafenamide is driven by higher loading of tenofovir diphosphate into target cells compared to tenofovir disoproxil fumarate.
Topics: Anti-HIV Agents; Cell Line; Dose-Response Relationship, Drug; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Microbial Sensitivity Tests; Mutation; Recombination, Genetic; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Viral Load | 2016 |
Decay of ccc-DNA marks persistence of intrahepatic viral DNA synthesis under tenofovir in HIV-HBV co-infected patients.
Topics: Antiviral Agents; Coinfection; DNA, Circular; DNA, Viral; Hepatitis B; Hepatitis B e Antigens; Hepatitis B virus; HIV Infections; Humans; Tenofovir | 2016 |
Pharmacokinetics and Safety of Tenofovir Alafenamide in HIV-Uninfected Subjects with Severe Renal Impairment.
Topics: Adenine; Aged; Alanine; Anti-HIV Agents; Area Under Curve; Case-Control Studies; Female; Glomerular Filtration Rate; HIV Infections; Humans; Male; Middle Aged; Renal Insufficiency, Chronic; Tenofovir | 2016 |
Risks and benefits HIV preexposure prophylaxis with tenofovir/emtricitabine in an older male with comorbidities.
Topics: Aged; Anti-HIV Agents; Chemoprevention; Comorbidity; Emtricitabine; HIV Infections; Humans; Kidney Diseases; Male; Pre-Exposure Prophylaxis; Risk Assessment; Tenofovir | 2016 |
Treatment failure and drug resistance in HIV-positive patients on tenofovir-based first-line antiretroviral therapy in western Kenya.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Kenya; Male; Middle Aged; Tenofovir; Treatment Failure; Viral Load | 2016 |
Usefulness of an HIV DNA resistance genotypic test in patients who are candidates for a switch to the rilpivirine/emtricitabine/tenofovir disoproxil fumarate combination.
Topics: Anti-HIV Agents; DNA, Viral; Drug Resistance, Viral; Emtricitabine; Genotype; Genotyping Techniques; HIV Infections; Humans; Microbial Sensitivity Tests; Mutation; Proviruses; Rilpivirine; RNA, Viral; Tenofovir | 2016 |
Determinants of bone diseases in tenofovir-treated HIV patients.
Topics: Adenine; Anti-HIV Agents; Bone Diseases; HIV Infections; Humans; Tenofovir | 2016 |
Antileishmanial activity of antiretroviral drugs combined with miltefosine.
Topics: Alkynes; Animals; Anti-Retroviral Agents; Antiprotozoal Agents; Atazanavir Sulfate; Benzoxazines; Coinfection; Cyclopropanes; Darunavir; Delavirdine; Drug Therapy, Combination; HIV Infections; Humans; Leishmania infantum; Leishmaniasis, Visceral; Macrophages; Male; Mice, Inbred BALB C; Nevirapine; Phosphorylcholine; Protease Inhibitors; Reverse Transcriptase Inhibitors; Tenofovir | 2016 |
Medium-grade tubular proteinuria is common in HIV-positive patients and specifically associated with exposure to tenofovir disoproxil Fumarate.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuminuria; Anti-HIV Agents; Cross-Sectional Studies; Female; Germany; HIV; HIV Infections; Humans; Male; Middle Aged; Prevalence; Proteinuria; Risk Factors; Tenofovir; Young Adult | 2016 |
Estimated Glomerular Filtration Rate Trajectories in HIV-Infected Subjects Treated With Different Ritonavir-Boosted Protease Inhibitors and Tenofovir Disoproxil Fumarate or Abacavir.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Comorbidity; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; Glomerular Filtration Rate; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Retrospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Viral Load | 2016 |
[Optimized therapy].
Topics: Adenine; Alanine; Anti-HIV Agents; Dose-Response Relationship, Drug; Drug Substitution; Drug Therapy, Combination; Europe; HIV Infections; Humans; Tenofovir | 2016 |
Integrating Preexposure Prophylaxis for Human Immunodeficiency Virus Prevention Into Women's Health Care in the United States.
Topics: Administration, Oral; Anti-HIV Agents; Decision Making; Delivery of Health Care, Integrated; Female; HIV Infections; Humans; Medication Adherence; Pre-Exposure Prophylaxis; Reproductive Health Services; Risk Assessment; Sexual Behavior; Tenofovir; Women's Health; Women's Health Services | 2016 |
Plasma and Intracellular Concentrations in HIV-Infected Patients Requiring Hemodialysis Dosed With Tenofovir Disoproxil Fumarate and Emtricitabine.
Topics: Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Dose-Response Relationship, Drug; Emtricitabine; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Prospective Studies; Renal Dialysis; Rilpivirine; RNA, Viral; Tenofovir; Young Adult | 2016 |
HIV Infection, Tenofovir, and Urine α1-Microglobulin: A Cross-sectional Analysis in the Multicenter AIDS Cohort Study.
Topics: Alpha-Globulins; Anti-HIV Agents; Cohort Studies; Cross-Sectional Studies; HIV Infections; Humans; Kidney Tubules, Proximal; Male; Middle Aged; Tenofovir | 2016 |
Off-label use of rilpivirine in combination with emtricitabine and tenofovir in HIV-1-infected pediatric patients: A multicenter study.
Topics: Adolescent; Anti-HIV Agents; Child; Drug Therapy, Combination; Emtricitabine; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Male; Off-Label Use; Retrospective Studies; RNA, Viral; Tenofovir; Treatment Outcome | 2016 |
HIV-1 Drug Resistance by Ultra-Deep Sequencing Following Short Course Zidovudine, Single-Dose Nevirapine, and Single-Dose Tenofovir with Emtricitabine for Prevention of Mother-to-Child Transmission.
Topics: Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Mutation; Nevirapine; Pregnancy; Pregnancy Complications, Infectious; Tenofovir; Viral Load; Zidovudine | 2016 |
Adherence to Pre-Exposure Prophylaxis for HIV Prevention in a Clinical Setting.
Topics: Adolescent; Adult; Dose-Response Relationship, Drug; Dried Blood Spot Testing; Female; HIV Infections; Humans; Male; Medication Adherence; Middle Aged; Pre-Exposure Prophylaxis; Self Report; Tenofovir; Young Adult | 2016 |
Genotypic HIV-1 Drug Resistance Among Patients Failing Tenofovir-Based First-Line HAART in South India.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cross-Sectional Studies; Databases, Genetic; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; India; Male; Mutation, Missense; pol Gene Products, Human Immunodeficiency Virus; Prevalence; Sequence Analysis, DNA; Tenofovir; Treatment Failure | 2016 |
Measurement of Vaginal Microbicide Adherence Using Visual Inspection as Compared to Ultra Violet Light Assessment of Returned Empty Gel Applicators.
Topics: Administration, Intravaginal; Adult; Anti-HIV Agents; Coloring Agents; Drug Delivery Systems; Female; Gels; HIV Infections; Humans; Medication Adherence; Tenofovir; Ultraviolet Rays; Young Adult | 2017 |
Treatment. Tenofovir-resistant HIV increasing in Africa.
Topics: Africa; Anti-HIV Agents; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Reverse Transcriptase Inhibitors; Tenofovir | 2016 |
Detectable Tenofovir Levels in Breast-Feeding Infants of Mothers Exposed to Topical Tenofovir.
Topics: Adult; Anti-HIV Agents; Breast Feeding; Female; HIV Infections; HIV-1; Humans; Infant; Lactation; Milk, Human; Mothers; Tenofovir; Vaginal Creams, Foams, and Jellies; Young Adult | 2016 |
Reaching High-Risk Patients for HIV Preexposure Prophylaxis.
Topics: Anti-HIV Agents; Bisexuality; Community Health Services; Female; HIV Infections; Homosexuality, Male; Humans; Male; Medication Adherence; Pre-Exposure Prophylaxis; Tenofovir; Transgender Persons; Unsafe Sex | 2016 |
Factors associated with fractures in HIV-infected persons: which factors matter?
Topics: Adult; Anti-HIV Agents; Bone Density; CD4 Lymphocyte Count; Female; Hepatitis C, Chronic; HIV Infections; Humans; Male; Massachusetts; Middle Aged; Osteoporotic Fractures; Retrospective Studies; Risk Factors; Tenofovir | 2017 |
Virological suppression after use of crushed tenofovir-emtricitabine and dolutegravir tablets in a patient with HIV infection.
Topics: Adult; Antiretroviral Therapy, Highly Active; Dosage Forms; Drug Therapy, Combination; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Male; Oxazines; Piperazines; Pyridones; Sustained Virologic Response; Tablets; Tenofovir; Viral Load | 2016 |
Nephrotoxicity Associated with Concomitant Use of Ledipasvir-Sofosbuvir and Tenofovir in a Patient with Hepatitis C Virus and Human Immunodeficiency Virus Coinfection.
Topics: Antiviral Agents; Benzimidazoles; Coinfection; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C; HIV Infections; Humans; Kidney; Middle Aged; Sofosbuvir; Tenofovir | 2016 |
In-utero exposure to tenofovir is associated with impaired fetal and infant growth: need for follow-up studies in combination antiretroviral therapy/HIV-exposed infants.
Topics: Anti-HIV Agents; Birth Weight; Child Development; Female; Fetal Development; Fetal Growth Retardation; Follow-Up Studies; Growth Disorders; HIV Infections; Humans; Infant; Infectious Disease Transmission, Vertical; Pregnancy; Pregnancy Complications, Infectious; Prenatal Exposure Delayed Effects; Retrospective Studies; Tenofovir | 2016 |
Emtricitabine/tenofovir alafenamide (Descovy) for HIV.
Topics: Adenine; Anti-HIV Agents; Drug Administration Schedule; Emtricitabine; HIV Infections; HIV-1; Humans; Tenofovir; Treatment Outcome | 2016 |
Tenofovir resistance and first-line antiretroviral therapy.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; HIV Infections; Humans; Reverse Transcriptase Inhibitors; Tenofovir | 2016 |
Acute Kidney Injury, Risk Factors, and Prognosis in Hospitalized HIV-Infected Adults in South Africa, Compared by Tenofovir Exposure.
Topics: Acute Kidney Injury; Adolescent; Adult; Anti-HIV Agents; Female; HIV Infections; Hospitalization; Humans; Male; Middle Aged; Prognosis; Prospective Studies; Risk Factors; Survival Analysis; Tenofovir; Tuberculosis; Young Adult | 2017 |
Levels of bone markers in a population of infants exposed in utero and during breastfeeding to tenofovir within an Option B+ programme in Malawi.
Topics: Adult; Alkaline Phosphatase; Alkynes; Anti-HIV Agents; Benzoxazines; Biomarkers; Bone Resorption; Breast Feeding; Collagen Type I; Cyclopropanes; Female; HIV Infections; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Malawi; Male; Peptides; Pregnancy; Tenofovir; Young Adult | 2016 |
Simultaneous quantification of tenofovir, emtricitabine, rilpivirine, elvitegravir and dolutegravir in mouse biological matrices by LC-MS/MS and its application to a pharmacokinetic study.
Topics: Animals; Anti-Retroviral Agents; Chromatography, Liquid; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Mice; Oxazines; Piperazines; Pyridones; Quinolones; Rilpivirine; Solid Phase Extraction; Tandem Mass Spectrometry; Tenofovir | 2016 |
Is There a Need for Viral Load Testing to Assess Treatment Failure in HIV-Infected Patients Who Are about to Change to Tenofovir-Based First-Line Antiretroviral Therapy? Programmatic Findings from Myanmar.
Topics: Adolescent; Adult; Female; HIV; HIV Infections; Humans; Male; Middle Aged; Myanmar; Tenofovir; Treatment Failure; Viral Load; Young Adult | 2016 |
Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter observational study.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Darunavir; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; Male; Medication Adherence; Middle Aged; Proportional Hazards Models; Raltegravir Potassium; Retrospective Studies; Risk; Tenofovir | 2016 |
The HIV-1 reverse transcriptase polymorphism A98S improves the response to tenofovir disoproxil fumarate+emtricitabine-containing HAART both in vivo and in vitro.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Emtricitabine; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Male; Middle Aged; Polymorphism, Genetic; Tenofovir | 2016 |
Serum Phosphate and Creatinine Levels in the First Year of Life in Infants Born to HIV-Positive Mothers Receiving Tenofovir-Based Combination Regimens During Pregnancy and Prolonged Breastfeeding in an Option B+ Program in Malawi.
Topics: Adult; Anti-HIV Agents; Biomarkers; Breast Feeding; Creatinine; Female; HIV Infections; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Malawi; Male; Mothers; Phosphates; Pregnancy; Pregnancy Complications, Infectious; Tenofovir | 2016 |
Renal Dysfunction during Tenofovir Use in a Regional Cohort of HIV-Infected Individuals in the Asia-Pacific.
Topics: Adult; Anti-HIV Agents; Creatinine; Databases, Factual; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney; Kidney Diseases; Male; Middle Aged; Poisson Distribution; Proportional Hazards Models; Prospective Studies; Risk Factors; Tenofovir | 2016 |
Real-World Experiences with Tenofovir Disoproxil Fumarate: Is this the "B-Ticket"?
Topics: Adenine; HIV Infections; Humans; Organophosphonates; Tenofovir | 2016 |
Impact of circulating resistance-associated mutations on HIV pre-exposure prophylaxis (PrEP) efficacy: Modeling from antiretroviral resistance cohort analysis (ARCA) national database.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Drug Resistance, Viral; Emtricitabine; Female; HIV Infections; HIV-1; Homosexuality, Male; Humans; Male; Middle Aged; Mutation; Pre-Exposure Prophylaxis; Risk; Tenofovir | 2016 |
Effects of a switch from tenofovir- to abacavir-based antiretroviral therapy, with or without atazanavir, on renal function.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Deoxycytidine; Dideoxynucleosides; Emtricitabine; Female; HIV Infections; Humans; Kidney; Lamivudine; Male; Middle Aged; Retrospective Studies; Ritonavir; Tenofovir; Viral Load | 2016 |
Anti-retroviral Therapy Based HIV Prevention Among a Sample of Men Who Have Sex with Men in Cape Town, South Africa: Use of Post-exposure Prophylaxis and Knowledge on Pre-exposure Prophylaxis.
Topics: Adult; Aged; Anti-HIV Agents; Condoms; Drug Combinations; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Male; Medication Adherence; Middle Aged; Post-Exposure Prophylaxis; Pre-Exposure Prophylaxis; Risk-Taking; Safe Sex; Sexual and Gender Minorities; Sexual Behavior; South Africa; Surveys and Questionnaires; Tenofovir; Unsafe Sex; Young Adult | 2016 |
Risk of Chronic Kidney Disease among Patients Developing Mild Renal Impairment during Tenofovir-Containing Antiretroviral Treatment.
Topics: Adult; Anti-HIV Agents; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Failure, Chronic; Male; Middle Aged; Tenofovir | 2016 |
Interchangeability between first-line generic antiretroviral products prequalified by WHO using adjusted indirect comparisons.
Topics: Alkynes; Anti-HIV Agents; Area Under Curve; Benzoxazines; Biological Availability; Cyclopropanes; Drug Combinations; Drugs, Generic; Emtricitabine; HIV Infections; Humans; Lamivudine; Models, Statistical; Tenofovir; Therapeutic Equivalency; World Health Organization | 2017 |
[Pre-exposure prophylaxis for HIV: clinical practice and challenge].
Topics: Adult; Anti-HIV Agents; Emtricitabine; Female; HIV Infections; Humans; Male; Pre-Exposure Prophylaxis; Tenofovir | 2016 |
PURLs: On-demand pill protocol protects against HIV.
Topics: Anti-HIV Agents; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Homosexuality, Male; Humans; Male; Medication Adherence; Pre-Exposure Prophylaxis; Tenofovir | 2016 |
Fixed-dose combination emtricitabine/tenofovir/efavirenz initiated during acute HIV infection; 96-week efficacy and durability.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; CD8-Positive T-Lymphocytes; Cyclopropanes; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Male; Medication Adherence; Middle Aged; Prospective Studies; RNA, Viral; Sustained Virologic Response; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2016 |
Cost-effectiveness analysis of pre-exposure prophylaxis for HIV-1 prevention in the Netherlands: a mathematical modelling study.
Topics: Anti-HIV Agents; Cost-Benefit Analysis; Emtricitabine; HIV Infections; HIV-1; Homosexuality, Male; Humans; Male; Models, Theoretical; Netherlands; Pre-Exposure Prophylaxis; Tenofovir | 2016 |
Pre-exposure Prophylaxis Use by Breastfeeding HIV-Uninfected Women: A Prospective Short-Term Study of Antiretroviral Excretion in Breast Milk and Infant Absorption.
Topics: Administration, Oral; Anti-HIV Agents; Breast Feeding; Emtricitabine; Female; HIV Infections; Humans; Lactation; Milk, Human; Pre-Exposure Prophylaxis; Prospective Studies; Tenofovir | 2016 |
Adverse drug reactions associated with antiretroviral therapy in South Africa.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dizziness; Exanthema; Female; Gynecomastia; HIV Infections; Humans; Lipodystrophy; Male; Middle Aged; Nevirapine; Peripheral Nervous System Diseases; Renal Insufficiency; Retrospective Studies; South Africa; Stavudine; Tenofovir; Zidovudine | 2016 |
Long-Term Durability of Tenofovir-Based Antiretroviral Therapy in Relation to the Co-Administration of Other Drug Classes in Routine Clinical Practice.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir | 2016 |
No Evidence That HIV-1 Subtype C Infection Compromises the Efficacy of Tenofovir-Containing Regimens: Cohort Study in the United Kingdom.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Mutation; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure; United Kingdom | 2016 |
Reactions and Receptivity to Framing HIV Prevention Message Concepts About Pre-Exposure Prophylaxis for Black and Latino Men Who Have Sex with Men in Three Urban US Cities.
Topics: Adenine; Adult; Anti-HIV Agents; Black or African American; Black People; Chicago; Cities; Condoms; Deoxycytidine; Emtricitabine; Female; Focus Groups; Health Knowledge, Attitudes, Practice; Hispanic or Latino; HIV Infections; Homosexuality, Male; Humans; Male; Organophosphonates; Patient Acceptance of Health Care; Pre-Exposure Prophylaxis; Qualitative Research; Safe Sex; Tenofovir; United States; Urban Population | 2016 |
Long-Term Outcomes on Antiretroviral Therapy in a Large Scale-Up Program in Nigeria.
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Female; HIV Infections; Humans; Kaplan-Meier Estimate; Male; Medication Adherence; Middle Aged; Nigeria; Retrospective Studies; Tenofovir; Treatment Failure; Viral Load; Young Adult; Zidovudine | 2016 |
Has the phasing out of stavudine in accordance with changes in WHO guidelines led to a decrease in single-drug substitutions in first-line antiretroviral therapy for HIV in sub-Saharan Africa?
Topics: Adult; Africa South of the Sahara; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Drug Substitution; Drug Utilization; Female; Health Policy; HIV Infections; Humans; Male; Prospective Studies; Stavudine; Tenofovir; Zidovudine | 2017 |
Stimuli-sensitive thiolated hyaluronic acid based nanofibers: synthesis, preclinical safety and in vitro anti-HIV activity.
Topics: Animals; Anti-HIV Agents; Drug Liberation; Female; HIV Infections; Humans; Hyaluronic Acid; Mice; Nanofibers; Reproductive Tract Infections; Sulfhydryl Compounds; Tenofovir; Vagina | 2016 |
Impact of tenofovir disoproxil fumarate on bone metabolism and bone mass among perinatally HIV-infected Asian adolescents.
Topics: Adolescent; Antiretroviral Therapy, Highly Active; Biomarkers; Bone and Bones; Bone Density; CD4 Lymphocyte Count; Child; Cross-Sectional Studies; Female; HIV Infections; Humans; Kidney Function Tests; Male; Pregnancy; Prenatal Exposure Delayed Effects; Severity of Illness Index; Tenofovir | 2017 |
Virological failure reduced with HIV-serostatus disclosure, extra baseline weight and rising CD4 cells among HIV-positive adults in Northwestern Uganda.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Body Weight; CD4-Positive T-Lymphocytes; Cohort Studies; Cyclopropanes; Disclosure; Female; HIV Infections; HIV Seropositivity; Humans; Kaplan-Meier Estimate; Lamivudine; Male; Nevirapine; Retrospective Studies; Tenofovir; Treatment Outcome; Uganda | 2016 |
Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cobicistat; Emtricitabine; HIV; HIV Infections; Humans; Male; Middle Aged; Quinolones; Retrospective Studies; Tenofovir; Treatment Outcome; Viral Load | 2017 |
Bone Age and Mineral Density Assessments Using Plain Roentgenograms in Tenofovir-exposed Infants in Malawi and Brazil Enrolled in HIV Prevention Trials Network 057.
Topics: Anti-HIV Agents; Bone Density; Brazil; Cohort Studies; Female; HIV Infections; Humans; Infant; Infant, Newborn; Malawi; Maternal Exposure; Pregnancy; Pregnancy Complications, Infectious; Radiography; Spine; Tenofovir; Wrist | 2017 |
Influences of geo-spatial location on pre-exposure prophylaxis use in South Africa: positioning microbicides for better product uptake.
Topics: Adolescent; Adult; Anti-HIV Agents; Female; Gels; HIV Infections; Humans; Middle Aged; Patient Acceptance of Health Care; Pre-Exposure Prophylaxis; Rural Population; Self Efficacy; Sexual Behavior; South Africa; Suburban Population; Tenofovir; Urban Population; Young Adult | 2017 |
Antiretroviral treatment for HIV infection: Swedish recommendations 2016.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Combinations; Early Detection of Cancer; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Male; Oxazines; Piperazines; Pre-Exposure Prophylaxis; Pyridones; Sweden; Tenofovir | 2017 |
Renal function in HIV/HBV co-infected and HBV mono-infected patients on a long-term treatment with tenofovir in real life setting.
Topics: Adult; Antiviral Agents; Coinfection; Creatinine; Dose-Response Relationship, Drug; Female; Genotype; Glomerular Filtration Rate; Hepatitis B; HIV Infections; Humans; Kidney; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Tenofovir; Time Factors | 2017 |
Model Linking Plasma and Intracellular Tenofovir/Emtricitabine with Deoxynucleoside Triphosphates.
Topics: Adult; Anti-HIV Agents; Computer Simulation; Deoxyadenine Nucleotides; Deoxycytosine Nucleotides; Diphosphates; Emtricitabine; Female; HIV; HIV Infections; Humans; Male; Middle Aged; Models, Biological; Polyphosphates; Prospective Studies; Tenofovir; Young Adult | 2016 |
Misreporting of Product Adherence in the MTN-003/VOICE Trial for HIV Prevention in Africa: Participants' Explanations for Dishonesty.
Topics: Administration, Intravaginal; Administration, Oral; Adult; Anti-HIV Agents; Clinical Trials, Phase II as Topic; Deception; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Epidemics; Female; HIV Infections; Humans; Medication Adherence; Qualitative Research; Self Report; Sexual Partners; South Africa; Tenofovir; Uganda; Young Adult; Zimbabwe | 2017 |
Tenofovir stock shortages have limited impact on clinic- and patient-level HIV treatment outcomes in public sector clinics in South Africa.
Topics: Adult; Ambulatory Care Facilities; Anti-HIV Agents; Female; HIV Infections; Humans; Male; Medically Underserved Area; Middle Aged; National Health Programs; Office Visits; South Africa; Tenofovir; Treatment Outcome | 2017 |
Distal renal tubular acidosis without renal impairment after use of tenofovir: a case report.
Topics: Acidosis, Renal Tubular; Anti-HIV Agents; HIV Infections; Humans; Male; Tenofovir; Young Adult | 2016 |
HIV-1 Subtype C, Tenofovir, and the Relationship With Treatment Failure and Drug Resistance.
Topics: Anti-HIV Agents; Drug Resistance, Viral; HIV Infections; HIV-1; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure | 2016 |
Tenofovir exposure in utero and linear growth in HIV-exposed, uninfected infants.
Topics: Adult; Anthropometry; Anti-HIV Agents; Body Height; Child Development; Female; HIV Infections; Humans; Infant; Infant, Newborn; Male; Maternal-Fetal Exchange; Pregnancy; Pregnancy Complications, Infectious; Prenatal Exposure Delayed Effects; Prospective Studies; South Africa; Tenofovir; Young Adult | 2017 |
Pre-exposure prophylaxis failure with tenofovir disoproxil.
Topics: Adult; Anti-HIV Agents; DNA, Viral; Hepatitis B; Hepatitis B virus; HIV Infections; HIV-1; Humans; Male; Pre-Exposure Prophylaxis; RNA, Viral; Syphilis; Tenofovir; Treatment Failure; Viral Load | 2017 |
Tenofovir disoproxil fumarate-associated bone loss: does vitamin D-binding protein play a role?
Topics: Adenine; Anti-HIV Agents; HIV Infections; Humans; Tenofovir; Vitamin D-Binding Protein | 2017 |
[Tenofovir alafenamide fumarate - a new generation of tenofovir].
Topics: Adenine; Alanine; Anti-HIV Agents; Drug Combinations; HIV Infections; Humans; Tenofovir | 2016 |
Occult HIV-1 drug resistance to thymidine analogues following failure of first-line tenofovir combined with a cytosine analogue and nevirapine or efavirenz in sub Saharan Africa: a retrospective multi-centre cohort study.
Topics: Adult; Africa South of the Sahara; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Nevirapine; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure; Viral Load | 2017 |
Antiretrovirals causing severe pre-eclampsia.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Delivery, Obstetric; Female; HIV Infections; Humans; Infant, Extremely Low Birth Weight; Infant, Newborn; Lamivudine; Nevirapine; Pre-Eclampsia; Pregnancy; Pregnancy Complications, Infectious; Tenofovir; Zidovudine | 2016 |
Real-World Assessment of Renal and Bone Safety among Patients with HIV Infection Exposed to Tenofovir Disoproxil Fumarate-Containing Single-Tablet Regimens.
Topics: Adult; Antiretroviral Therapy, Highly Active; Bone Diseases; Comorbidity; Female; Follow-Up Studies; HIV Infections; Humans; Incidence; Kidney Diseases; Male; Middle Aged; Population Surveillance; Retrospective Studies; Reverse Transcriptase Inhibitors; Risk Factors; Tablets; Tenofovir; United States | 2016 |
Population Pharmacokinetic Modeling of Tenofovir in the Genital Tract of Male HIV-Infected Patients.
Topics: Adult; Anti-HIV Agents; Area Under Curve; Bayes Theorem; Biological Availability; Body Weight; Drug Administration Schedule; Drug Dosage Calculations; Gene Expression; Genitalia, Male; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Male; Markov Chains; Microbial Sensitivity Tests; Middle Aged; Models, Statistical; Monte Carlo Method; Polymorphism, Single Nucleotide; Semen; Tenofovir | 2017 |
Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen.
Topics: Adult; Anti-HIV Agents; Deoxycytidine; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Reverse Transcriptase Inhibitors; Rilpivirine; RNA, Viral; Tablets; Tenofovir; Viral Load | 2017 |
Response to Tenofovir Among Lamivudine-experienced Hepatitis B and HIV-coinfected Adolescents.
Topics: Adolescent; Adult; Antiviral Agents; Child; Coinfection; DNA, Viral; Hepatitis B; HIV Infections; Humans; Lamivudine; Longitudinal Studies; Prospective Studies; Tenofovir; Young Adult | 2017 |
Better late than never: PrEP in England.
Topics: Anti-HIV Agents; Capital Financing; Disease Transmission, Infectious; Emtricitabine; England; Health Policy; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir | 2017 |
Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cardiovascular Diseases; Dideoxynucleosides; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lipids; Male; Middle Aged; Retrospective Studies; Risk Factors; Tenofovir | 2017 |
Virological Response to Tenofovir Disoproxil Fumarate in HIV-Positive Patients with Lamivudine-Resistant Hepatitis B Virus Coinfection in an Area Hyperendemic for Hepatitis B Virus Infection.
Topics: Adult; Coinfection; Drug Combinations; Drug Resistance, Viral; Endemic Diseases; Female; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Male; Tenofovir; Treatment Outcome | 2016 |
[Tenofovir-induced Fanconi syndrome and recovery after treatment cessation: A case report with physiological considerations].
Topics: Adult; Anti-HIV Agents; Fanconi Syndrome; Female; HIV Infections; Humans; Remission Induction; Tenofovir; Withholding Treatment | 2017 |
Infrequent development of drug resistance in HIV-1-infected treatment-naive subjects after 96 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate.
Topics: Adenine; Amino Acid Substitution; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cobicistat; Drug Resistance, Viral; Emtricitabine; Genotype; HIV Infections; HIV-1; Humans; Microbial Sensitivity Tests; Mutation; Organophosphates; Phenotype; Tenofovir | 2017 |
Tenofovir-induced nephrotoxicity: A retrospective cohort study.
Topics: Anti-HIV Agents; Cohort Studies; HIV Infections; Humans; Kidney Diseases; Malaysia; Retrospective Studies; Tenofovir | 2016 |
Pre-exposure prophylaxis: making history.
Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Male; Pre-Exposure Prophylaxis; State Medicine; Tenofovir; United Kingdom | 2017 |
Tenofovir Disoproxil Fumarate Is Not an Inhibitor of Human Organic Cation Transporter 1.
Topics: Adenine; Anti-HIV Agents; HIV Infections; Humans; Organic Cation Transporter 1; Tenofovir | 2017 |
Response to "Tenofovir Disoproxil Fumarate Is Not an Inhibitor of Human Organic Cation Transporter 1".
Topics: Adenine; Anti-HIV Agents; HIV Infections; Humans; Organic Cation Transporter 1; Tenofovir | 2017 |
Tenofovir alafenamide, emtricitabine, elvitegravir, and cobicistat combination therapy for the treatment of HIV.
Topics: Anti-HIV Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cobicistat; Drug Combinations; Drug Interactions; Emtricitabine; HIV Infections; Humans; Quinolones; Tenofovir | 2017 |
Response to 'In-utero exposure to tenofovir is associated with impaired fetal and infant growth' by Denneman et al.
Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infant; Pregnancy; Pregnancy Complications, Infectious; Prenatal Care; Tenofovir | 2017 |
In-utero exposure to tenofovir is associated with impaired fetal and infant growth: need for follow-up studies in combination antiretroviral therapy/HIV-exposed infants: author's reply.
Topics: Anti-HIV Agents; Follow-Up Studies; HIV Infections; Humans; Infant; Infectious Disease Transmission, Vertical; Pregnancy Complications, Infectious; Tenofovir | 2017 |
Tenofovir alafenamide and elvitegravir loaded nanoparticles for long-acting prevention of HIV-1 vaginal transmission.
Topics: Adenine; Alanine; Animals; Delayed-Action Preparations; Disease Transmission, Infectious; Female; HIV Infections; Injections, Subcutaneous; Mice; Mice, SCID; Nanoparticles; Plasma; Quinolones; Tenofovir; Treatment Outcome; Vagina; Viral Load | 2017 |
Treatment-limiting renal tubulopathy in patients treated with tenofovir disoproxil fumarate.
Topics: Adult; Anti-HIV Agents; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Diseases; Male; Middle Aged; Tenofovir | 2017 |
Tenofovir alafenamide (TAF) does not deplete mitochondrial DNA in human T-cell lines at intracellular concentrations exceeding clinically relevant drug exposures.
Topics: Anti-HIV Agents; Cytoplasm; DNA, Mitochondrial; HIV Infections; HIV-1; Humans; Jurkat Cells; Leukocytes, Mononuclear; Prodrugs; T-Lymphocytes; Tenofovir | 2017 |
How to "PrEP" for HIV Prevention in Women.
Topics: Adult; Anti-HIV Agents; Contraceptive Agents, Female; Emtricitabine; Female; HIV Infections; HIV Seronegativity; Humans; Pre-Exposure Prophylaxis; Tenofovir | 2017 |
Real-world persistence with antiretroviral therapy for HIV in the United Kingdom: A multicentre retrospective cohort study.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Medication Adherence; Middle Aged; Retrospective Studies; Rilpivirine; Tenofovir; United Kingdom; Viral Load | 2017 |
Predicting HIV Pre-exposure Prophylaxis Efficacy for Women using a Preclinical Pharmacokinetic-Pharmacodynamic In Vivo Model.
Topics: Animals; Anti-Retroviral Agents; Dose-Response Relationship, Drug; Emtricitabine; Female; Half-Life; HIV Infections; HIV-1; Humans; Mice; Mice, Inbred BALB C; Mice, Transgenic; Pre-Exposure Prophylaxis; Proportional Hazards Models; RNA, Viral; Tenofovir | 2017 |
Longitudinal Assessment of Proximal Tubular Dysfunction in HIV Seropositive and Seronegative Persons: Correlates and Implications.
Topics: Adult; Anti-HIV Agents; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Diseases; Kidney Tubules, Proximal; Male; Middle Aged; Prospective Studies; Tenofovir | 2017 |
Prevalent neuropathy in a cohort of HIV-infected Kenyan sex workers using antiretroviral drugs.
Topics: Adult; Age Factors; Anti-HIV Agents; Female; HIV Infections; Humans; Kenya; Male; Middle Aged; Polyneuropathies; Prevalence; Retrospective Studies; Risk Factors; Sex Workers; Stavudine; Tenofovir; Zidovudine | 2016 |
Confirmation of factors that influence antiretroviral regimen change and the subsequent patient outcomes at a Regional Hospital in rural KwaZulu-Natal.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; HIV Infections; Hospitals; Humans; Lamivudine; Lipodystrophy; Male; Middle Aged; Retrospective Studies; Rural Population; South Africa; Stavudine; Tenofovir; Treatment Outcome; Tuberculosis; Viral Load; Young Adult | 2016 |
[Lack of energy in a patient living with HIV].
Topics: Antiviral Agents; Diagnosis, Differential; Fatigue; HIV; HIV Infections; Humans; Kidney; Kidney Tubular Necrosis, Acute; Male; Middle Aged; Renal Dialysis; Tenofovir | 2017 |
Comment on: Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection.
Topics: Adenine; Anti-HIV Agents; Cobicistat; Deoxycytidine; Emtricitabine; HIV Infections; Humans; Organophosphonates; Quinolones; Tenofovir | 2017 |
Impact of tenofovir dose adjustment on both estimated glomerular filtration rate and tenofovir trough concentration.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney; Kidney Function Tests; Male; Middle Aged; Renal Insufficiency; Retrospective Studies; Severity of Illness Index; Tenofovir | 2017 |
Impact of Tenofovir on Hepatitis Delta Virus Replication in the Swiss Human Immunodeficiency Virus Cohort Study.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Female; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis D; Hepatitis Delta Virus; HIV Infections; Humans; Male; Middle Aged; Switzerland; Tenofovir; Viral Load; Virus Replication | 2017 |
Bone mineral density decline in patients on stable antiretroviral therapy.
Topics: Absorptiometry, Photon; Bone Density; HIV Infections; Humans; Tenofovir | 2017 |
Acute Kidney Injury After Efavirenz/Tenofovir Disoproxil Fumarate/Emtricitabine (Atripla) Overdose.
Topics: Acute Kidney Injury; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Male; Middle Aged; Tenofovir | 2017 |
Influence of Chitosan Swelling Behaviour on Controlled Release of Tenofovir from Mucoadhesive Vaginal Systems for Prevention of Sexual Transmission of HIV.
Topics: Acrylic Resins; Adhesives; Animals; Cattle; Cell Line; Chemistry, Pharmaceutical; Chitosan; Delayed-Action Preparations; Drug Delivery Systems; Female; Galactans; HIV Infections; Humans; Hypromellose Derivatives; Mannans; Mucous Membrane; Plant Gums; Polymers; Sexually Transmitted Diseases; Tablets; Tenofovir; Vagina | 2017 |
Tenofovir prodrugs: similar but not the same.
Topics: Adenine; Anti-HIV Agents; HIV Infections; Humans; Prodrugs; Reverse Transcriptase Inhibitors; Tenofovir | 2017 |
The impact of gastrectomy on the pharmacokinetics of atazanavir and tenofovir.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Gastrectomy; HIV Infections; Humans; Male; Middle Aged; Tenofovir | 2017 |
[Tenofovir-associated Fanconi`s syndrome and rickets in a HIV infected girl].
Topics: Anti-HIV Agents; Child; Fanconi Syndrome; Female; HIV Infections; Humans; Rickets; Tenofovir | 2017 |
Sepsis Mimicker in an Human Immunodeficiency Virus-Infected Patient.
Topics: Alkynes; Anti-Bacterial Agents; Anti-Retroviral Agents; Benzoxazines; Cyclopropanes; Drug Hypersensitivity Syndrome; Exanthema; Fever; HIV Infections; HIV-1; Humans; Male; Reverse Transcriptase Inhibitors; Tenofovir; Thrombocytopenia; Young Adult | 2017 |
Dolutegravir with tenofovir disoproxil fumarate-emtricitabine as HIV postexposure prophylaxis in gay and bisexual men.
Topics: Anti-HIV Agents; Australia; Chemoprevention; Disease Transmission, Infectious; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Male; Medication Adherence; Oxazines; Piperazines; Post-Exposure Prophylaxis; Pyridones; Sexual and Gender Minorities; Tenofovir; Treatment Failure | 2017 |
Switch from ritonavir-boosted to unboosted atazanavir guided by therapeutic drug monitoring.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Bilirubin; Chromatography, High Pressure Liquid; Drug Monitoring; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Retrospective Studies; Ritonavir; Tenofovir | 2008 |
Genetic basis of variation in tenofovir drug susceptibility in HIV-1.
Topics: Adenine; Amino Acid Sequence; Anti-HIV Agents; Drug Resistance, Viral; Genetic Variation; Genotype; HIV Infections; HIV-1; Humans; Lethal Dose 50; Models, Biological; Organophosphonates; Phenotype; Predictive Value of Tests; Tenofovir | 2008 |
Human immunodeficiency virus-induced uveitis: intraocular and plasma human immunodeficiency virus-1 RNA loads.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Aqueous Humor; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Eye Infections, Viral; HIV Antibodies; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Polymerase Chain Reaction; RNA, Viral; Tenofovir; Uveitis, Anterior; Viral Load | 2008 |
FDA notifications. FDA's tentative approval for generic Tenofovir.
Topics: Adenine; Drug Approval; Drugs, Generic; HIV Infections; Humans; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; United States; United States Food and Drug Administration | 2008 |
Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects.
Topics: Adenine; Age Factors; Animals; Anti-HIV Agents; Disease Models, Animal; Female; HIV Infections; HIV-1; Humans; Macaca mulatta; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Reverse Transcriptase Inhibitors; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Tenofovir; Time Factors; Treatment Outcome | 2008 |
The A62V and S68G mutations in HIV-1 reverse transcriptase partially restore the replication defect associated with the K65R mutation.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Didanosine; Dideoxynucleosides; Drug Resistance, Multiple, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Organophosphonates; Point Mutation; Reverse Transcriptase Inhibitors; Stavudine; Tenofovir; Virus Replication | 2008 |
Lack of evidence for an effect of lopinavir/ritonavir on tenofovir renal clearance.
Topics: Adenine; Creatinine; Drug Interactions; Drug Therapy, Combination; Female; Glomerular Filtration Rate; HIV Infections; HIV Protease Inhibitors; Humans; Kidney Tubules; Lopinavir; Male; Organophosphonates; Pyrimidinones; Ritonavir; Sensitivity and Specificity; Tenofovir | 2008 |
A new assay based on solid-phase extraction procedure with LC-MS to measure plasmatic concentrations of tenofovir and emtricitabine in HIV infected patients.
Topics: Adenine; Anti-HIV Agents; Calibration; Chromatography, Liquid; Deoxycytidine; Emtricitabine; HIV Infections; Humans; Organophosphonates; Reproducibility of Results; Sensitivity and Specificity; Solid Phase Extraction; Spectrometry, Mass, Electrospray Ionization; Tenofovir | 2008 |
Can a topical microbicide prevent rectal HIV transmission?
Topics: Adenine; Animals; Anti-Infective Agents, Local; HIV Infections; Macaca; Organophosphonates; Tenofovir | 2008 |
Tenofovir-associated decline in renal function.
Topics: Adenine; Adult; Anti-HIV Agents; Female; Glomerular Filtration Rate; HIV Infections; HIV Protease Inhibitors; Humans; Kidney; Kidney Diseases; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2008 |
Drug-susceptible HIV-1 infection despite intermittent fixed-dose combination tenofovir/emtricitabine as prophylaxis is associated with low-level viremia, delayed seroconversion, and an attenuated clinical course.
Topics: Adenine; Adult; Amino Acid Sequence; Anti-HIV Agents; CD4 Lymphocyte Count; Chemoprevention; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV Seropositivity; HIV-1; HLA Antigens; Humans; Intestinal Mucosa; Male; Microbial Sensitivity Tests; Molecular Sequence Data; Organophosphonates; Phylogeny; Receptors, CCR5; Sequence Alignment; Tenofovir; Time Factors; Viral Load; Viremia | 2008 |
Effect of tenofovir subtraction on HIV plasma viraemia, CD4+ T-cell count and resistance in a patient with baseline K65R and M184V mutations.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Treatment Outcome; Viremia | 2008 |
Combination antiretroviral therapy with tenofovir, emtricitabine or lamivudine, and nevirapine.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Lamivudine; Nevirapine; Organophosphonates; Tenofovir | 2008 |
The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cost-Benefit Analysis; Dideoxynucleosides; Drug Costs; Drug Hypersensitivity; Female; Genetic Testing; Health Care Costs; HIV Infections; HLA-B Antigens; Humans; Male; Middle Aged; Models, Biological; Organophosphonates; Pharmacogenetics; Quality-Adjusted Life Years; Reverse Transcriptase Inhibitors; Sensitivity and Specificity; Tenofovir; Treatment Outcome | 2008 |
Effectiveness and safety of simplification from tenofovir-lamivudine (TDF-3TC) to tenofovir-emtricitabine (TDF-FTC) co-formulation (Truvada) in virologically suppressed HIV-infected patients on HAART.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Central Nervous System; Cohort Studies; Creatinine; Deoxycytidine; Drug Combinations; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; HIV Infections; HIV-1; Humans; Kidney; Lamivudine; Male; Metabolic Clearance Rate; Middle Aged; Organophosphonates; Organophosphorus Compounds; Retrospective Studies; Risk Factors; RNA, Viral; Tenofovir; Viral Load | 2009 |
Disinhibition and risk compensation: scope, definitions, and perspective.
Topics: Adenine; Anti-HIV Agents; Chemoprevention; Clinical Trials as Topic; Counseling; Female; HIV Infections; Humans; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Risk Reduction Behavior; Safe Sex; Sex Work; Sexual Behavior; Sexually Transmitted Diseases; Tenofovir | 2008 |
Adverse effects of tenofovir use in HIV-infected pregnant women and their infants.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Organophosphonates; Pregnancy; Retrospective Studies; Tenofovir | 2008 |
Low trough levels of tipranavir in a combination antiretroviral therapy of tipranavir/ritonavir and tenofovir require therapeutic drug monitoring.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Interactions; Drug Monitoring; Enfuvirtide; HIV Envelope Protein gp41; HIV Infections; Humans; Organophosphonates; Peptide Fragments; Pyridines; Pyrones; Retrospective Studies; Ritonavir; Sulfonamides; Tenofovir | 2008 |
[First line therapy. Tenofovir DF/emtricitabine--the potent backbone].
Topics: Adenine; Anti-HIV Agents; Clinical Trials as Topic; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Organophosphonates; Tenofovir; Viral Load | 2008 |
Sensitivity of phenotypic susceptibility analyses for nonthymidine nucleoside analogues conferred by K65R or M184V in mixtures with wild-type HIV-1.
Topics: Adenine; Anti-HIV Agents; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; Genetic Predisposition to Disease; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Organophosphonates; Phenotype; Plasmids; Tenofovir; Viral Load | 2009 |
The rise and fall of K65R in a Portuguese HIV-1 Drug Resistance database, despite continuously increasing use of tenofovir.
Topics: Adenine; Anti-HIV Agents; Bayes Theorem; Data Interpretation, Statistical; Databases, Nucleic Acid; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Organophosphonates; Portugal; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir | 2009 |
96-week CASTLE data show similar efficacy results.
Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Lopinavir; Multicenter Studies as Topic; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Treatment Outcome; Viral Load | 2008 |
[A case of acute renal failure involving high amounts of tenofovir after HAART start].
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; HIV Infections; Humans; Kidney Failure, Chronic; Male; Middle Aged; Organophosphonates; Tenofovir | 2008 |
Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients.
Topics: Adenine; Alkynes; Alleles; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Medication Adherence; Mutation, Missense; Nevirapine; Organophosphonates; Plasma; Polymerase Chain Reaction; Selection, Genetic; Tenofovir; Treatment Failure | 2009 |
Glomerular filtration rates in HIV-infected patients treated with and without tenofovir: a prospective, observational study.
Topics: Adenine; Adult; Female; Glomerular Filtration Rate; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Prospective Studies; RNA, Viral; Tenofovir; Viral Load | 2009 |
Urinary cystatin C can improve the renal safety follow-up of tenofovir-treated patients.
Topics: Adenine; Anti-HIV Agents; Biomarkers; Creatinine; Cystatin C; Fanconi Syndrome; HIV Infections; Humans; Hypophosphatemia; Organophosphonates; Retrospective Studies; Sensitivity and Specificity; Tenofovir | 2009 |
Molecular analysis of an HBsAg-negative hepatitis B virus mutant selected in a tenofovir-treated HIV-hepatitis B virus co-infected patient.
Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Gene Products, pol; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Mutation; Organophosphonates; Tenofovir; Virus Replication | 2009 |
Population pharmacokinetics of emtricitabine in human immunodeficiency virus type 1-infected pregnant women and their neonates.
Topics: Adenine; Anti-HIV Agents; Area Under Curve; Clinical Trials as Topic; Deoxycytidine; Emtricitabine; Female; Half-Life; HIV Infections; HIV-1; Humans; Infant, Newborn; Maternal-Fetal Exchange; Organophosphonates; Population Groups; Pregnancy; Pregnancy Complications, Infectious; Prenatal Exposure Delayed Effects; Tenofovir | 2009 |
HIV-1 infection of human penile explant tissue and protection by candidate microbicides.
Topics: Adenine; Antiviral Agents; CD4-Positive T-Lymphocytes; Cytokines; Foreskin; HIV Infections; HIV-1; Humans; Langerhans Cells; Male; Naphthalenesulfonates; Organophosphonates; Penis; Polymers; Tenofovir; Tissue Culture Techniques; Urethra; Virus Replication | 2009 |
Comment on: High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; HIV Infections; Humans; Lamivudine; Nevirapine; Organophosphonates; Tenofovir; Treatment Failure; Viral Load | 2009 |
Prolonged use of tenofovir in HIV/hepatitis B virus (HBV)-coinfected individuals does not lead to HBV polymerase mutations and is associated with persistence of lamivudine HBV polymerase mutations.
Topics: Adenine; Adult; Aged; Antiretroviral Therapy, Highly Active; Antiviral Agents; Cross-Sectional Studies; Drug Resistance, Viral; Female; Gene Products, pol; Genotype; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Polymerase Chain Reaction; Retrospective Studies; Tenofovir; Viral Load; Viremia | 2009 |
HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness.
Topics: Adenine; Adult; Anti-HIV Agents; Chemoprevention; Computer Simulation; Cost-Benefit Analysis; Deoxycytidine; Emtricitabine; HIV Infections; Homosexuality; Humans; Male; Organophosphonates; Risk Assessment; Tenofovir; United States | 2009 |
Tenofovir use is associated with an increase in serum alkaline phosphatase in the Swiss HIV Cohort Study.
Topics: Adenine; Adult; Alkaline Phosphatase; Anti-HIV Agents; Cohort Studies; Female; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Switzerland; Tenofovir | 2008 |
[Introduction. Tenofovir].
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; HIV Infections; Humans; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2008 |
[Conclusions. Tenofovir].
Topics: Adenine; Anti-HIV Agents; Drug Resistance, Viral; HIV; HIV Infections; HIV Reverse Transcriptase; Humans; Kidney Diseases; Liver Diseases; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2008 |
A preemptive strike against HIV.
Topics: Adenine; Animals; Clinical Trials as Topic; HIV Infections; Humans; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2009 |
Long-term outcome of tenofovir disoproxil fumarate use against hepatitis B in an HIV-coinfected cohort.
Topics: Adenine; Adult; Antiviral Agents; Deoxycytidine; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; Hepatitis B; Hepatitis B Antigens; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Male; Organophosphonates; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Time Factors; Treatment Outcome; Virus Replication | 2009 |
[Atazanavir-induced nephrolithiasis].
Topics: Adenine; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Hepatitis B, Chronic; Hepatitis C, Chronic; Hepatitis D, Chronic; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Lopinavir; Male; Nephrolithiasis; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine; Tenofovir | 2009 |
Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir.
Topics: Adenine; Adult; Age Factors; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Creatinine; Epidemiologic Methods; Fanconi Syndrome; Female; HIV Infections; Humans; Kidney Function Tests; Kidney Glomerulus; Kidney Tubules; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2009 |
Bone pain due to fractures revealing osteomalacia related to tenofovir-induced proximal renal tubular dysfunction in a human immunodeficiency virus-infected patient.
Topics: Adenine; Bone Density Conservation Agents; Fanconi Syndrome; Female; Fractures, Bone; HIV Infections; Humans; Middle Aged; Organophosphonates; Osteomalacia; Pain; Reverse Transcriptase Inhibitors; Tenofovir | 2009 |
Highly active antiretroviral therapy-associated ptosis in patients with human immunodeficiency virus.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Blepharoptosis; Carbamates; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Middle Aged; Oculomotor Muscles; Organophosphates; Organophosphonates; Sulfonamides; Tenofovir | 2009 |
Mitochondrial function, morphology and metabolic parameters improve after switching from stavudine to a tenofovir-containing regimen.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adenine; Adipose Tissue; Adult; Anti-HIV Agents; Body Fat Distribution; CD4 Lymphocyte Count; Deoxyguanosine; F2-Isoprostanes; Glutathione; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Lopinavir; Male; Mitochondria; Organophosphonates; Pyrimidinones; Ritonavir; Stavudine; Tenofovir; Treatment Outcome; Viral Load | 2009 |
Proximal tubular dysfunction associated with tenofovir and didanosine causing Fanconi syndrome and diabetes insipidus: a report of 3 cases.
Topics: Adenine; Adult; Anti-HIV Agents; Diabetes Insipidus; Didanosine; Drug Therapy, Combination; Fanconi Syndrome; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2009 |
Editorial comment: tenofovir nephrotoxicity--the disconnect between clinical trials and real-world practice.
Topics: Adenine; Anti-HIV Agents; Clinical Trials as Topic; Diabetes Insipidus; Didanosine; Drug Therapy, Combination; Fanconi Syndrome; HIV Infections; Humans; Kidney Function Tests; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Risk Factors; Tenofovir | 2009 |
Gilead is going strong.
Topics: Adenine; Anti-HIV Agents; California; Commerce; Drug Combinations; Drug Industry; HIV Infections; Humans; Organophosphonates; Tenofovir | 2009 |
FDA approves three generics.
Topics: Adenine; Anti-HIV Agents; Drug Approval; Drugs, Generic; HIV Infections; Humans; Lamivudine; Lopinavir; Organophosphonates; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; United States; United States Food and Drug Administration | 2009 |
Progressive renal tubular dysfunction associated with long-term use of tenofovir DF.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Drug Therapy, Combination; Glomerular Filtration Rate; HIV Infections; HIV-1; Humans; Kidney Diseases; Kidney Tubules, Proximal; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Time Factors; Urinalysis; Young Adult | 2009 |
Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study.
Topics: Adenine; Adult; Anti-HIV Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carrier Proteins; Female; Gene Frequency; HIV Infections; Homozygote; Humans; Kidney Tubules; Male; Molecular Sequence Data; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Organic Anion Transporters, Sodium-Independent; Organophosphonates; Polymorphism, Genetic; Renal Insufficiency; Tenofovir | 2009 |
Rationing antiretroviral therapy in Africa--treating too few, too late.
Topics: Adenine; Africa; Anti-Retroviral Agents; CD4 Lymphocyte Count; Developing Countries; Drug Administration Schedule; Health Care Rationing; HIV Infections; Humans; Organophosphonates; Stavudine; Tenofovir; Viral Load | 2009 |
Substituting tenofovir for stavudine in resource-limited settings: there are challenges ahead.
Topics: Adenine; Anti-HIV Agents; Developing Countries; Drug Therapy, Combination; HIV Infections; Humans; Organophosphonates; Stavudine; Tenofovir; Treatment Failure | 2009 |
Initiation of antiretroviral therapy 48 hours after infection with simian immunodeficiency virus potently suppresses acute-phase viremia and blocks the massive loss of memory CD4+ T cells but fails to prevent disease.
Topics: Adenine; Amino Acid Sequence; Animals; Anti-HIV Agents; CD4-Positive T-Lymphocytes; Cells, Cultured; Disease Models, Animal; Drug Administration Schedule; HIV Antibodies; HIV Infections; Humans; Injections; Macaca mulatta; Molecular Sequence Data; Organophosphonates; Sequence Alignment; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Tenofovir; Time Factors; Viremia; Virus Replication | 2009 |
Generic Truvada approved.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Approval; Drug Combinations; Drugs, Generic; Emtricitabine; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir; United States; United States Food and Drug Administration | 2009 |
Mutations in the thumb-connection and RNase H domain of HIV type-1 reverse transcriptase of antiretroviral treatment-experienced patients.
Topics: Adenine; Alkynes; Amino Acid Substitution; Benzoxazines; Cyclopropanes; Drug Resistance, Multiple, Viral; Genetic Variation; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Organophosphonates; Protein Structure, Tertiary; Reverse Transcriptase Inhibitors; Ribonuclease H, Human Immunodeficiency Virus; Stavudine; Tenofovir | 2009 |
Prolonged exposure to tenofovir monotherapy 1 month after treatment discontinuation because of tenofovir-related renal failure.
Topics: Adenine; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Renal Insufficiency; Reverse Transcriptase Inhibitors; Tenofovir; Time Factors; Withholding Treatment | 2009 |
Emtricitabine/tenofovir disoproxil fumarate: in combination with a protease inhibitor in HIV-1 infection.
Topics: Adenine; Anti-HIV Agents; Clinical Trials as Topic; Deoxycytidine; Drug Combinations; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Organophosphonates; Tenofovir | 2009 |
Rhabdomyolysis in an HIV-infected patient on anti-retroviral therapy precipitated by high-dose pravastatin.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Deoxycytidine; Dyslipidemias; Emtricitabine; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Oligopeptides; Organophosphonates; Pravastatin; Pyridines; Rhabdomyolysis; Ritonavir; Tenofovir | 2009 |
Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only?
Topics: Adenine; Amino Acid Substitution; Anti-HIV Agents; CD4 Lymphocyte Count; Dideoxynucleosides; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation, Missense; Organophosphonates; Retrospective Studies; Salvage Therapy; Tenofovir; Treatment Outcome; Viral Load; Zidovudine | 2009 |
Long-term suppressive therapy for pulmonary aspergilloma in an immunocompromised man with AIDS. Is it always necessary?
Topics: Adenine; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antifungal Agents; Aspergillosis; Didanosine; Drug Administration Schedule; Drug Interactions; Fatal Outcome; HIV Infections; Humans; Immunocompromised Host; Lung Diseases, Fungal; Male; Middle Aged; Organophosphonates; Pancreatitis; Radiography; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2009 |
Reduced glomerular filtration rate but sustained virologic response in HIV/hepatitis B co-infected individuals on long-term tenofovir.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; CD4 Lymphocyte Count; Cohort Studies; Female; Glomerular Filtration Rate; Hepatitis B; HIV Infections; Humans; Longitudinal Studies; Male; Middle Aged; Organophosphonates; Tenofovir; Treatment Outcome; Viral Load | 2009 |
Tenofovir-associated renal and bone toxicity.
Topics: Adenine; Adult; Anti-HIV Agents; Creatinine; Fanconi Syndrome; Female; Glycosuria; HIV Infections; Humans; Kidney Diseases; Kidney Function Tests; Kidney Tubules, Proximal; Male; Mass Screening; Middle Aged; Organophosphonates; Osteomalacia; Proteinuria; Radionuclide Imaging; Tenofovir | 2009 |
FDA notifications. Tenofovir in India receives tentative approval.
Topics: Adenine; Drug Approval; HIV Infections; India; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; United States; United States Food and Drug Administration | 2009 |
Renal function in patients with preexisting renal disease receiving tenofovir-containing highly active antiretroviral therapy in the HIV outpatient study.
Topics: Adenine; Adult; Aged; Ambulatory Care Facilities; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Diseases; Kidney Function Tests; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; United States | 2009 |
HIV clinics are halting enrolment of new patients as funding stalls, MSF warns.
Topics: Adenine; Anti-HIV Agents; Developing Countries; Drug Costs; HIV Infections; Hospitals, Special; Humans; Organophosphonates; Stavudine; Tenofovir | 2009 |
The absence of HIV mutations in cerebrospinal fluid and in peripheral blood mononuclear cells during a regimen containing Trizivir plus tenofovir.
Topics: Adenine; Anti-HIV Agents; Cohort Studies; Drug Combinations; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Leukocytes, Mononuclear; Mutation; Organophosphonates; Prospective Studies; Tenofovir; Viremia; Zidovudine | 2009 |
Virological response to initial antiretroviral regimens containing abacavir or tenofovir.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Female; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Tenofovir; Treatment Failure; Treatment Outcome; Viral Load | 2009 |
Efavirenz + emtricitabine + tenofovir: new combination. HIV infection: do not modify ongoing therapy just to use one less tablet. Better adherence than with separate dosing has not been demonstrated, while reduced efficacy is plausible.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Approval; Drug Combinations; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Emtricitabine; Europe; HIV Infections; Humans; Organophosphonates; Oxazines; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load | 2009 |
High rates of active hepatitis B and C co-infections in HIV-1 infected Cameroonian adults initiating antiretroviral therapy.
Topics: Adenine; Adult; Age Factors; Anti-HIV Agents; Anti-Retroviral Agents; Cameroon; Comorbidity; Female; Hepacivirus; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis C; Hepatitis C Antibodies; HIV Infections; HIV-1; Humans; Male; Middle Aged; Multivariate Analysis; Organophosphonates; Pregnancy; Retrospective Studies; Tenofovir; Transaminases | 2010 |
Effectiveness of antiretroviral regimens containing abacavir with tenofovir in treatment-experienced patients: predictors of virological response and drug resistance evolution in a multi-cohort study.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Dideoxynucleosides; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Mutation, Missense; Organophosphonates; Tenofovir; Treatment Failure; Treatment Outcome; Viral Load; Viral Proteins | 2009 |
Efficacy and safety of boosted and unboosted atazanavir-containing antiretroviral regimens in real life: results from a multicentre cohort study.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Cohort Studies; Drug Administration Schedule; Drug Interactions; Female; HIV Infections; HIV Protease Inhibitors; Humans; Kaplan-Meier Estimate; Male; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Treatment Outcome; Viral Load | 2010 |
HIV therapy may be given safely in resource-limited settings without routine laboratory monitoring.
Topics: Adenine; Anti-HIV Agents; Diagnostic Tests, Routine; Glomerular Filtration Rate; Health Resources; HIV Infections; HIV-1; Humans; Incidence; Kidney Diseases; Laboratories; Organophosphonates; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Uganda; Zimbabwe | 2009 |
Renal function with use of a tenofovir-containing initial antiretroviral regimen.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; Glomerular Filtration Rate; HIV Infections; HIV Protease Inhibitors; Humans; Kidney Diseases; Longitudinal Studies; Male; Organophosphonates; Prospective Studies; Reverse Transcriptase Inhibitors; Tenofovir | 2009 |
Hepatitis B in HIV patients: what is the current treatment and what are the challenges?
Topics: Adenine; Antiviral Agents; Deoxycytidine; DNA, Viral; Drug Therapy, Combination; Emtricitabine; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Cirrhosis; Nucleosides; Organophosphonates; Polyethylene Glycols; Pyrimidinones; Recombinant Proteins; Telbivudine; Tenofovir; Thymidine; Transaminases | 2009 |
Conserved T cell and natural killer cell function in treatment-experienced adults receiving tenofovir plus didanosine as nucleoside reverse transcription inhibitor backbone.
Topics: Adenine; Adult; CD4 Lymphocyte Count; Cell Proliferation; Didanosine; Drug Therapy, Combination; Flow Cytometry; Fluorescent Antibody Technique; Follow-Up Studies; HIV Infections; HIV-1; Humans; Immunologic Memory; Immunophenotyping; Interferon-gamma; Killer Cells, Natural; Lamivudine; Logistic Models; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Statistics, Nonparametric; T-Lymphocytes; Tenofovir | 2009 |
Once-daily treatment with saquinavir mesylate (2000 mg) and ritonavir (100 mg) together with a fixed-dose combination of abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/200 mg) in HIV-1-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Area Under Curve; CD4 Lymphocyte Count; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Plasma; Ritonavir; RNA, Viral; Saquinavir; Tenofovir; Treatment Outcome; Viral Load | 2009 |
Subclinical tubular injury in HIV-infected individuals on antiretroviral therapy: a cross-sectional analysis.
Topics: Acetylglucosaminidase; Adenine; Adult; Aged; Albuminuria; Anti-Retroviral Agents; Creatinine; Cross-Sectional Studies; Disease Progression; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Tubules, Proximal; Male; Middle Aged; Organophosphonates; Phosphates; Proteinuria; Retinol-Binding Proteins; Risk Factors; Sensitivity and Specificity; Tenofovir | 2009 |
Lower limb high arterial flow induced by tenofovir and emtricitabine treatment.
Topics: Adenine; Adult; Blood Flow Velocity; Deoxycytidine; Edema; Emtricitabine; HIV Infections; Humans; Leg; Male; Organophosphonates; Tenofovir | 2009 |
Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Creatinine; Fanconi Syndrome; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Function Tests; Male; Middle Aged; Multivariate Analysis; Organophosphonates; Retrospective Studies; Tenofovir | 2010 |
The art of managing human immunodeficiency virus infection: a balancing act.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Emtricitabine; HIV Infections; Humans; Lamivudine; Organophosphonates; Tenofovir; Treatment Outcome | 2009 |
Tenofovir coadministration is not associated with lower unboosted atazanavir plasma exposure in the clinical setting.
Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; Drug Interactions; Drug Therapy, Combination; Female; History, 17th Century; HIV Infections; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Tenofovir | 2009 |
Safety and efficacy of once-daily nevirapine dosing: a multicohort study.
Topics: Adenine; Adult; Anti-HIV Agents; Cohort Studies; Drug Administration Schedule; Drug Hypersensitivity; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nevirapine; Organophosphonates; Retrospective Studies; Tenofovir; Treatment Outcome | 2009 |
A new drug combination therapy for treatment-naive patients with HIV-1 infection, consisting of raltegravir, emtricitabine and tenofovir disoproxil fumarate.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Tenofovir | 2009 |
Prevalence and factors associated with renal impairment in HIV-infected patients, ANRS C03 Aquitaine Cohort, France.
Topics: Adenine; Adult; Anti-HIV Agents; Body Mass Index; CD4 Lymphocyte Count; Creatinine; Epidemiologic Methods; Female; France; HIV Infections; Humans; Hypertension; Indinavir; Kidney; Kidney Function Tests; Male; Middle Aged; Organophosphonates; Renal Insufficiency; Tenofovir | 2010 |
Low-abundance HIV species and their impact on mutational profiles in patients with virological failure on once-daily abacavir/lamivudine/zidovudine and tenofovir.
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Combinations; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Lamivudine; Microbial Sensitivity Tests; Middle Aged; Mutation, Missense; Organophosphonates; RNA, Viral; Tenofovir; Treatment Failure; Viremia; Young Adult; Zidovudine | 2010 |
Early clinical and programmatic outcomes with tenofovir-based antiretroviral therapy in Zambia.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; Humans; Male; Organophosphonates; Tenofovir; Treatment Outcome; Zambia | 2010 |
N348I in HIV-1 reverse transcriptase decreases susceptibility to tenofovir and etravirine in combination with other resistance mutations.
Topics: Adenine; Drug Resistance, Multiple, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutagenesis, Site-Directed; Mutation; Nitriles; Organophosphonates; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Tenofovir | 2010 |
[Protocol for the antiviral therapy of hepatitis B and D].
Topics: Adenine; Antiviral Agents; Biopsy; Guanine; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis D; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Lamivudine; Liver Cirrhosis; Nucleotides; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Tenofovir | 2010 |
Susceptibility to genital herpes as a biomarker predictive of increased HIV risk: expansion of a murine model of microbicide safety.
Topics: Adenine; Administration, Intravaginal; Animals; Anti-Infective Agents; Antiviral Agents; Biomarkers; Disease Models, Animal; Disease Susceptibility; Female; Herpes Genitalis; Herpesvirus 2, Human; HIV Infections; Mice; Mice, Inbred BALB C; Naphthalenesulfonates; Nonoxynol; Organophosphonates; Polymers; Predictive Value of Tests; Risk Assessment; Tenofovir | 2009 |
FDA notifications. Generic efavirenz/emtricitabine/fenofovir has tentative approval.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Approval; Drug Combinations; Drugs, Generic; Emtricitabine; HIV Infections; Humans; Organophosphonates; Tenofovir; United States; United States Food and Drug Administration | 2009 |
Cost-effectiveness of tenofovir as first-line antiretroviral therapy in India.
Topics: Adenine; Adult; Antifungal Agents; Antiretroviral Therapy, Highly Active; Cost-Benefit Analysis; Female; HIV Infections; Humans; India; Male; Organophosphonates; Stavudine; Survival Analysis; Tenofovir; Treatment Outcome; Zidovudine | 2010 |
Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008.
Topics: Adenine; Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Nevirapine; Oligopeptides; Organophosphonates; Proportional Hazards Models; Prospective Studies; Pyridines; Pyrimidinones; Risk Factors; Switzerland; Tenofovir; Zidovudine | 2010 |
DAART for human immunodeficiency virus-infected patients: Studying subjects not at risk for nonadherence and use of untested interventions.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Aged; Anti-HIV Agents; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Viral; Emtricitabine; Female; Genotype; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Organophosphonates; Patient Compliance; Pyrimidinones; Randomized Controlled Trials as Topic; RNA, Viral; Stavudine; Tenofovir; Treatment Outcome; Young Adult | 2010 |
Microbicide research already benefiting thousands--experts.
Topics: Adenine; Anti-HIV Agents; Anti-Infective Agents; Anti-Retroviral Agents; Biomedical Research; HIV Infections; Humans; Organophosphonates; Tenofovir; Vaginal Creams, Foams, and Jellies | 2009 |
Expanded postexposure prophylaxis for simultaneous multiple source HIV exposure in a health-care worker.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Darunavir; Deoxycytidine; Emtricitabine; Enfuvirtide; Female; Fingers; HIV Envelope Protein gp41; HIV Infections; Humans; Infectious Disease Transmission, Patient-to-Professional; Middle Aged; Needlestick Injuries; Occupational Diseases; Organophosphonates; Peptide Fragments; Post-Exposure Prophylaxis; Ritonavir; Sulfonamides; Tenofovir | 2010 |
Incidence of proximal renal tubular dysfunction in patients on tenofovir disoproxil fumarate.
Topics: Adenine; Anti-HIV Agents; Fanconi Syndrome; HIV Infections; Humans; Incidence; Organophosphonates; Retrospective Studies; Tenofovir; United Kingdom | 2010 |
Tolerability of two different combinations of antiretroviral drugs including tenofovir used in occupational and nonoccupational postexposure prophylaxis for HIV.
Topics: Adenine; Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; Humans; Infectious Disease Transmission, Patient-to-Professional; Male; Occupational Exposure; Occupational Health Services; Organophosphonates; Patient Compliance; Tenofovir | 2010 |
Systemic administration of antiretrovirals prior to exposure prevents rectal and intravenous HIV-1 transmission in humanized BLT mice.
Topics: Adenine; Animals; Anti-HIV Agents; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; Flow Cytometry; HIV Infections; HIV-1; Mice; Organophosphonates; Rectum; Tenofovir | 2010 |
International cohort analysis of the antiviral activities of zidovudine and tenofovir in the presence of the K65R mutation in reverse transcriptase.
Topics: Adenine; Amino Acid Substitution; Anti-HIV Agents; California; Cohort Studies; Drug Resistance, Viral; France; Genes, Viral; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Multivariate Analysis; Mutation, Missense; Organophosphonates; RNA, Viral; Tenofovir; Zidovudine | 2010 |
Emerging mutations at virological failure of HAART combinations containing tenofovir and lamivudine or emtricitabine.
Topics: Adenine; Adult; Analysis of Variance; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Organophosphonates; Retrospective Studies; RNA, Viral; Tenofovir; Treatment Failure; Viral Load | 2010 |
Effect of tenofovir disoproxil fumarate on risk of renal abnormality in HIV-1-infected children on antiretroviral therapy: a nested case-control study.
Topics: Adenine; Adolescent; Anti-HIV Agents; Case-Control Studies; Child; Child, Preschool; England; Female; Glomerular Filtration Rate; HIV Infections; HIV-1; Humans; Hypophosphatemia; Ireland; Kidney; Male; Organophosphonates; Salvage Therapy; Tenofovir; Treatment Outcome | 2010 |
Safety and efficacy of tenofovir/emtricitabine plus nevirapine in HIV-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Male; Nevirapine; Organophosphonates; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load | 2010 |
Incomplete reversibility of tenofovir-related renal toxicity in HIV-infected men.
Topics: Adenine; Anti-HIV Agents; Glomerular Filtration Rate; HIV Infections; Humans; Kidney; Kidney Diseases; Male; Middle Aged; Organophosphonates; Tenofovir; Withholding Treatment | 2010 |
Tenofovir and changes in renal function.
Topics: Adenine; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Diseases; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2010 |
A controlled trial of initial antiviral regimens for HIV-1 infection.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Genotype; HIV Infections; HIV-1; Homosexuality, Male; Humans; Lamivudine; Male; Organophosphonates; Tenofovir; Treatment Failure | 2010 |
Efficacy of tenofovir-emtricitabine versus abacavir-lamivudine.
Topics: Adenine; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; HIV Infections; Humans; Lamivudine; Organophosphonates; Tenofovir; Treatment Outcome | 2010 |
Elvucitabine data released at CROI.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials, Phase II as Topic; Cyclopropanes; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Organophosphonates; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Viral Load; Zalcitabine | 2010 |
Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations.
Topics: Adenine; HIV Infections; Humans; Kidney Diseases; Kidney Function Tests; Kidney Tubules; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2010 |
Second-line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Body Mass Index; CD4 Lymphocyte Count; Developing Countries; Drug Resistance, Viral; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; HIV Infections; HIV-1; Humans; Malawi; Male; Medication Adherence; Middle Aged; National Health Programs; Organophosphonates; Prospective Studies; RNA, Viral; Statistics as Topic; Tenofovir; Treatment Failure; Tuberculosis; Urban Population; Viral Load; Zidovudine | 2010 |
Tenofovir/probenecid combination in HIV/HBV-coinfected patients: how to escape Fanconi syndrome recurrence?
Topics: Adenine; Fanconi Syndrome; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Probenecid; Secondary Prevention; Tenofovir | 2010 |
Findings in humanized-mouse model suggest benefit of further studies in HIV pre-exposure prophylaxis.
Topics: Adenine; Animals; Anti-HIV Agents; Bone Marrow Transplantation; Clinical Trials as Topic; Deoxycytidine; Disease Models, Animal; Drug Combinations; Emtricitabine; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV; HIV Antibodies; HIV Infections; Humans; Infection Control; Liver Transplantation; Mice; Occupational Exposure; Organophosphonates; Organophosphorus Compounds; Tenofovir; Thymus Gland; Transplantation Chimera | 2010 |
Raltegravir, tenofovir, and emtricitabine in an HIV-infected patient with HCV chronic hepatitis, NNRTI intolerance and protease inhibitors-induced severe liver toxicity.
Topics: Adenine; Adult; Antiviral Agents; CD4-Positive T-Lymphocytes; Chemical and Drug Induced Liver Injury; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; Hepatitis C, Chronic; HIV Infections; Humans; Liver; Lymphocyte Count; Organophosphonates; Protease Inhibitors; Pyrrolidinones; Raltegravir Potassium; Tenofovir; Treatment Outcome; Viral Load | 2010 |
Report from the 17th Conference on Retroviruses and Opportunistic Infections. Randomized studies of once-daily darunavir and tenofovir/FTC + nevirapine.
Topics: Adenine; Anti-HIV Agents; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; Humans; Nevirapine; Organophosphonates; Randomized Controlled Trials as Topic; Sulfonamides; Tenofovir | 2010 |
Recent FDA approvals and changes.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Child; Delayed-Action Preparations; Didanosine; Drug Approval; Drug Labeling; HIV Infections; Humans; Organophosphonates; Randomized Controlled Trials as Topic; Tenofovir; United States; United States Food and Drug Administration | 2010 |
[Protease inhibitor or non-nucleoside reverse transcriptase inhibitor. ACTG study 5202 in focus].
Topics: Adenine; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; Humans; Lamivudine; Multicenter Studies as Topic; Oligopeptides; Organophosphonates; Pyridines; Randomized Controlled Trials as Topic; Tenofovir | 2010 |
[HIV-therapy-associated immune reconstitution syndrome presenting as immunogenic hyperthyroidism].
Topics: Adenine; Alkynes; Anti-HIV Agents; Autoantibodies; Benzoxazines; Cyclopropanes; Deoxycytidine; Diagnosis, Differential; Drug Therapy, Combination; Emtricitabine; Graves Disease; HIV Infections; HIV-1; Humans; Immune Reconstitution Inflammatory Syndrome; Long-Term Care; Male; Middle Aged; Organophosphonates; Tenofovir; Thyroid Gland; Thyroiditis, Autoimmune | 2010 |
Prevalence and factors associated with renal dysfunction among HIV-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cross-Sectional Studies; Female; Glomerular Filtration Rate; HIV Infections; HIV-1; Humans; Kidney; Kidney Diseases; Kidney Function Tests; Male; Middle Aged; Military Hygiene; Military Personnel; Organophosphonates; Prevalence; Reverse Transcriptase Inhibitors; Risk Factors; Tenofovir; Time Factors | 2010 |
Clonal resistance analyses of HIV type-1 after failure of therapy with didanosine, lamivudine and tenofovir.
Topics: Adenine; Anti-HIV Agents; Didanosine; Drug Resistance, Viral; Drug Therapy, Combination; Genome, Viral; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Organophosphonates; Phenotype; Recombination, Genetic; Reverse Transcriptase Inhibitors; Sequence Analysis, DNA; Tenofovir; Treatment Failure | 2010 |
Advantages of low-cost generic tenofovir instead of D4T for first-line antiretroviral therapy in Burma: a 2-year experience.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cost-Benefit Analysis; HIV Infections; Humans; Myanmar; Organophosphonates; Tenofovir | 2010 |
The exploitation of "Exploitation" in the tenofovir prep trial in Cameroon: Lessons learned from media coverage of an HIV prevention trial.
Topics: Adenine; Anti-HIV Agents; Cameroon; Ethics, Research; Female; HIV Infections; Human Rights; Humans; Internationality; Mass Media; Organophosphonates; Persuasive Communication; Problem Solving; Public Relations; Randomized Controlled Trials as Topic; Tenofovir; Vulnerable Populations | 2010 |
Economic efficiency of genetic screening to inform the use of abacavir sulfate in the treatment of HIV.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Computer Simulation; Cost-Benefit Analysis; Decision Trees; Dideoxynucleosides; Drug Hypersensitivity; Drug-Related Side Effects and Adverse Reactions; Genetic Testing; HIV Infections; HLA-B Antigens; Humans; Middle Aged; Models, Economic; Organophosphonates; Quality-Adjusted Life Years; Tenofovir; United States | 2010 |
Rapid HIV-RNA decline following addition of raltegravir and tenofovir to ongoing highly active antiretroviral therapy in a woman presenting with high-level HIV viraemia at week 38 of pregnancy.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; Humans; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Pyrrolidinones; Raltegravir Potassium; RNA, Viral; Tenofovir; Viral Load; Viremia | 2010 |
Immunodeficiency and renal impairment are risk factors for HIV-associated acute renal failure.
Topics: Acute Kidney Injury; Adenine; Adult; Atazanavir Sulfate; CD4 Lymphocyte Count; Cohort Studies; Female; Glomerular Filtration Rate; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; London; Male; Oligopeptides; Organophosphonates; Pyridines; Risk Factors; Tenofovir | 2010 |
More research needed to find new HIV-suppressive functions of cytotoxic T cells.
Topics: Adenine; Animals; Combined Modality Therapy; Deoxycytidine; Emtricitabine; HIV Infections; Humans; Lymphocyte Depletion; Macaca mulatta; Organophosphonates; Simian Acquired Immunodeficiency Syndrome; T-Lymphocyte Subsets; T-Lymphocytes, Cytotoxic; Tenofovir; Viral Load; Viremia | 2010 |
HIV/AIDS. At last, vaginal gel scores victory against HIV.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Anti-Infective Agents, Local; Female; HIV Infections; HIV-1; Humans; Medication Adherence; Organophosphonates; Randomized Controlled Trials as Topic; South Africa; Tenofovir; Vaginal Creams, Foams, and Jellies; Young Adult | 2010 |
Lower arterial stiffness and Framingham score after switching abacavir to tenofovir in men at high cardiovascular risk.
Topics: Adenine; Cardiovascular Diseases; Dideoxynucleosides; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Risk Assessment; Tenofovir; Vascular Resistance | 2010 |
High frequency of lamivudine resistance mutations in Brazilian patients co-infected with HIV and hepatitis B.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Brazil; Comorbidity; Cross-Sectional Studies; DNA-Directed DNA Polymerase; Drug Resistance, Viral; Female; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Male; Mutation; Organophosphonates; Tenofovir; Viral Core Proteins; Viral Load; Viral Proteins | 2010 |
AZT or tenofovir for patients with the K65R mutation?
Topics: Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Reverse Transcriptase Inhibitors; Tenofovir | 2010 |
Associations of antiretroviral drug use and HIV-specific risk factors with carotid intima-media thickness.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Atherosclerosis; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Risk Factors; Tenofovir; Tunica Intima; Tunica Media | 2010 |
Tenofovir-linked hyperparathyroidism is independently associated with the presence of vitamin D deficiency.
Topics: Adenine; Adult; Female; HIV Infections; HIV-1; Humans; Hyperparathyroidism; Male; Middle Aged; Organophosphonates; Parathyroid Hormone; Tenofovir; United Kingdom; Urban Population; Vitamin D; Vitamin D Deficiency | 2010 |
Short communication: Inadequate vitamin D exacerbates parathyroid hormone elevations in tenofovir users.
Topics: Adenine; Adult; Anti-HIV Agents; Bone Density; Cross-Sectional Studies; Dose-Response Relationship, Drug; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Parathyroid Hormone; Tenofovir; Vitamin D; Vitamin D Deficiency | 2010 |
Antiretroviral vaginal gel shows promise against HIV.
Topics: Adenine; Adult; Anti-HIV Agents; Anti-Retroviral Agents; Clinical Trials as Topic; Female; Gels; HIV Infections; HIV Seropositivity; Humans; Incidence; Infectious Disease Transmission, Vertical; Medication Adherence; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Reverse Transcriptase Inhibitors; South Africa; Tenofovir; Vagina | 2010 |
Maraviroc concentrations in cerebrospinal fluid in HIV-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Chromatography, Liquid; Cyclohexanes; Didanosine; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Organophosphonates; Polymerase Chain Reaction; Tandem Mass Spectrometry; Tenofovir; Triazoles; Viral Load | 2010 |
After CAPRISA 004: time to re-evaluate the HIV lexicon.
Topics: Adenine; Administration, Intravaginal; Administration, Oral; Anti-HIV Agents; Female; Gels; HIV Infections; Humans; Organophosphonates; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir | 2010 |
Tolerability of HIV postexposure prophylaxis with tenofovir/emtricitabine and lopinavir/ritonavir tablet formulation.
Topics: Adenine; Adolescent; Adult; Antiviral Agents; CD4 Lymphocyte Count; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Organophosphonates; Post-Exposure Prophylaxis; Practice Guidelines as Topic; Pyrimidinones; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome; Young Adult | 2010 |
Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens.
Topics: Adaptation, Biological; Adenine; Adult; Amino Acid Substitution; Anti-HIV Agents; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Mutation, Missense; Organophosphonates; pol Gene Products, Human Immunodeficiency Virus; RNA, Viral; Tenofovir | 2010 |
Management and treatment of chronic hepatitis B virus infection in HIV positive and negative patients: the EPIB 2008 study.
Topics: Adenine; Adult; Antiviral Agents; Female; France; Hepatitis B Antibodies; Hepatitis B Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Retrospective Studies; Surveys and Questionnaires; Tenofovir | 2010 |
Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities.
Topics: Acute Kidney Injury; Adenine; Adult; Anti-HIV Agents; Biopsy; Drug Administration Schedule; Female; Glycosuria; HIV Infections; HIV-1; Humans; Kidney Tubular Necrosis, Acute; Kidney Tubules, Proximal; Male; Microscopy, Electron; Middle Aged; Mitochondria; New York City; Organophosphonates; Proteinuria; Renal Dialysis; Renal Insufficiency; Retrospective Studies; Tenofovir; Time Factors | 2010 |
Trial results finally show potential for microbicidal HIV gel.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Anti-HIV Agents; Female; Gels; HIV; HIV Infections; Humans; Organophosphonates; South Africa; Tenofovir; Vagina | 2010 |
Still a long wait for approved HIV-protective gel.
Topics: Adenine; Antiviral Agents; Deoxycytidine; Drug Approval; Drug Combinations; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Technology Transfer; Tenofovir; Vaginal Creams, Foams, and Jellies | 2010 |
Low bone mineral density with tenofovir: does statistically significant mean clinically significant?
Topics: Adenine; Adult; Anti-HIV Agents; Bone Density; Bone Diseases; Female; Fractures, Bone; HIV Infections; Humans; Incidence; Male; Organophosphonates; Tenofovir | 2010 |
[Two cases of Fanconi's syndrome induced by tenofovir in the Ivory Coast].
Topics: Adenine; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cote d'Ivoire; Cyclopropanes; Drug Therapy, Combination; Enterobacter aerogenes; Enterobacteriaceae Infections; Fanconi Syndrome; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Malaria; Male; Middle Aged; Organophosphonates; Pyelonephritis; Pyrimidinones; Ritonavir; Tenofovir | 2011 |
Preventing HIV infection: turning the tide for young women.
Topics: Adenine; Adolescent; Africa South of the Sahara; Antiviral Agents; Female; HIV Infections; HIV-1; Humans; Motivation; Naphthalenesulfonates; Organophosphonates; Polymers; Tenofovir; Vaginal Creams, Foams, and Jellies; Young Adult | 2010 |
Changes in the renal function after tenofovir-containing antiretroviral therapy initiation in a Senegalese cohort (ANRS 1215).
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; Glomerular Filtration Rate; HIV Infections; HIV-1; Humans; Incidence; Kidney; Kidney Function Tests; Male; Middle Aged; Organophosphonates; Renal Insufficiency; Senegal; Tenofovir | 2010 |
The impact of gender and anchor drugs on TDF renal toxicity.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Dideoxynucleosides; Emtricitabine; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney; Lamivudine; Male; Organophosphonates; Sex Factors; Tenofovir | 2010 |
A tailored dose of tenofovir could reduce its impact on bone mass in HIV Type 1-infected children and adolescents: a report from 5 years of clinical experience.
Topics: Adenine; Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone and Bones; Calcification, Physiologic; Child; Child, Preschool; Female; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Tenofovir | 2010 |
In vitro evaluation of viability, integrity, and inflammation in genital epithelia upon exposure to pharmaceutical excipients and candidate microbicides.
Topics: Adenine; Anilides; Anti-Infective Agents; Benzofurans; Cell Line; Cell Survival; Cervix Uteri; Epithelium; Female; Furans; HIV Infections; Humans; In Vitro Techniques; Interleukin-8; Laurates; Monoglycerides; Naphthalenesulfonates; Organophosphonates; Polymers; Reverse Transcriptase Inhibitors; Tenofovir; Thioamides | 2010 |
Implications of HIV PrEP trials results.
Topics: Adenine; Anti-HIV Agents; Chemoprevention; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Randomized Controlled Trials as Topic; Tenofovir; Treatment Outcome; United States | 2011 |
Prevention. Study reveals that vaginal gel reduces HIV, herpes.
Topics: Adenine; Female; Gels; Herpes Genitalis; HIV Infections; Humans; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Vagina | 2010 |
Virologic and clinical outcomes in HIV/HBV coinfected patients on tenofovir-containing HAART.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Hepatitis B, Chronic; HIV Infections; Humans; Organophosphonates; Tenofovir | 2010 |
[Human immunodeficiency virus and Chagas disease coinfection treated successfully with benznidazole and a raltegravir-based antiretroviral regimen: a case report].
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Chagas Disease; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Nitroimidazoles; Oligopeptides; Organophosphonates; Paraguay; Pyridines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Spain; Tenofovir; Trypanocidal Agents; Zidovudine | 2011 |
Liver fibrosis changes in HIV-HBV-coinfected patients: clinical, biochemical and histological effect of long-term tenofovir disoproxil fumarate use.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort Studies; DNA, Viral; Female; Hepacivirus; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C; Hepatitis D, Chronic; HIV Infections; Humans; Liver Cirrhosis; Male; Middle Aged; Organophosphonates; Tenofovir; Viral Load | 2010 |
Occult HBV infection in untreated HIV-infected adults in Côte d'Ivoire.
Topics: Adenine; Adult; Aged; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cote d'Ivoire; Cross-Sectional Studies; Deoxycytidine; DNA, Viral; Emtricitabine; Female; Hepatitis B Antibodies; Hepatitis B Core Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Prevalence; Tenofovir; World Health Organization; Young Adult | 2010 |
Tenofovir disoproxil fumarate and bone mineral density: a 60-month longitudinal study in a cohort of HIV-infected youths.
Topics: Adenine; Adolescent; Antiretroviral Therapy, Highly Active; Biomarkers; Bone Density; Child; Child, Preschool; Collagen Type I; Female; Follow-Up Studies; HIV; HIV Infections; Humans; Longitudinal Studies; Male; Organophosphonates; Peptides; Tenofovir; Young Adult | 2010 |
High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study.
Topics: Absorptiometry, Photon; Adenine; Aged; Antiretroviral Therapy, Highly Active; Bone Density; Cohort Studies; Cross-Sectional Studies; Disease Progression; Female; HIV Infections; Humans; Longitudinal Studies; Male; Middle Aged; Organophosphonates; Osteoporosis; Prevalence; Radionuclide Imaging; Reverse Transcriptase Inhibitors; Risk Factors; Tenofovir | 2010 |
A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Ill-Housed Persons; Male; Middle Aged; Organophosphonates; Patient Compliance; Tenofovir; Viral Load | 2010 |
[Immune reconstitution inflammatory syndrome associated with eosinophilic pustular folliculitis in an HIV-infected patient].
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Diagnosis, Differential; Emtricitabine; Eosinophilia; Folliculitis; HIV Infections; Humans; Immune Reconstitution Inflammatory Syndrome; Organophosphonates; Rosacea; Skin Diseases, Infectious; Tenofovir | 2011 |
The role of nucleoside and nucleotide analogues in nodular regenerative hyperplasia in HIV-infected patients: a case control study.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Case-Control Studies; Didanosine; Female; HIV Infections; Humans; Hyperplasia; Hypertension, Portal; Liver; Liver Regeneration; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Stavudine; Tenofovir | 2011 |
Incidence and risk factors for tenofovir-associated renal function decline among Thai HIV-infected patients with low-body weight.
Topics: Adenine; Adult; Anti-HIV Agents; Body Mass Index; Body Weight; Cohort Studies; Drug Interactions; Female; Glomerular Filtration Rate; HIV Infections; HIV Protease Inhibitors; Humans; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Organophosphonates; Renal Insufficiency; Retrospective Studies; Risk Factors; Tenofovir; Thailand | 2010 |
Prospective study of renal function in HIV-infected pediatric patients receiving tenofovir-containing HAART regimens.
Topics: Adenine; Adolescent; Antiretroviral Therapy, Highly Active; Child; Female; HIV Infections; Humans; Kidney Diseases; Kidney Function Tests; Male; Organophosphonates; Prospective Studies; Proteinuria; Spain; Tenofovir | 2011 |
Tenofovir-induced kidney disease: an acquired renal tubular mitochondriopathy.
Topics: Acute Kidney Injury; Adenine; Animals; Anti-HIV Agents; Drug Administration Schedule; Glycosuria; HIV Infections; HIV-1; Humans; Kidney Tubular Necrosis, Acute; Kidney Tubules, Proximal; Mitochondria; Organophosphonates; Proteinuria; Renal Dialysis; Renal Insufficiency; Tenofovir; Time Factors | 2010 |
Oral preexposure prophylaxis for HIV--another arrow in the quiver?
Topics: Adenine; Administration, Oral; Anti-HIV Agents; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Male; Organophosphonates; Patient Compliance; Tenofovir | 2010 |
[Long-term therapy for chronic hepatitis B in HIV co-infected patients].
Topics: Adenine; Antiretroviral Therapy, Highly Active; Antiviral Agents; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Guanine; Hepatitis B, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Nucleosides; Organophosphonates; Pyrimidinones; Recombinant Proteins; Telbivudine; Tenofovir; Thymidine | 2010 |
Lipid-lowering effect of tenofovir in HIV-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Anticholesteremic Agents; Female; HIV Infections; Humans; Lipids; Male; Middle Aged; Organophosphonates; Tenofovir; Treatment Outcome | 2011 |
First real success for anti-HIV gel: a new start for HIV microbicides?
Topics: Adenine; Adolescent; Adult; Anti-Infective Agents; Controlled Clinical Trials as Topic; Disease Transmission, Infectious; Female; HIV Infections; Humans; Organophosphonates; Sexually Transmitted Diseases, Viral; South Africa; Tenofovir; Treatment Outcome; Vaginal Creams, Foams, and Jellies; Young Adult | 2010 |
No impact of oral tenofovir disoproxil fumarate on herpes simplex virus shedding in HIV-infected adults.
Topics: Adenine; Adult; AIDS-Related Opportunistic Infections; Canada; Female; Herpes Simplex; Herpesvirus 1, Human; Herpesvirus 2, Human; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Tenofovir; Virus Shedding | 2011 |
Implementing a tenofovir-based first-line regimen in rural Lesotho: clinical outcomes and toxicities after two years.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Female; HIV Infections; Humans; Lesotho; Male; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Rural Population; Tenofovir; Treatment Outcome | 2011 |
Avascular necrosis of the talus in a HIV-infected patient.
Topics: Adenine; Carbamates; Deoxycytidine; Emtricitabine; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Immunocompromised Host; Male; Middle Aged; Organophosphates; Organophosphonates; Orthotic Devices; Osteonecrosis; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Talus; Tenofovir | 2010 |
The ART of preventing HIV.
Topics: Adenine; Adult; Anti-HIV Agents; Anti-Retroviral Agents; Circumcision, Male; Deoxycytidine; Emtricitabine; Female; HIV Infections; Homosexuality, Male; Humans; Male; Organophosphonates; Random Allocation; Risk Assessment; Tenofovir | 2011 |
Microbicides & their implications in HIV prevention.
Topics: Adenine; Anti-HIV Agents; Anti-Infective Agents; Clinical Trials as Topic; Female; HIV Infections; Humans; India; Organophosphonates; Risk Factors; Sex Factors; Tenofovir | 2010 |
HIV-2 goes global: an unaddressed issue in Indian anti-retroviral programmes.
Topics: Adenine; Anti-HIV Agents; HIV Infections; HIV-2; Humans; India; Organophosphonates; Prevalence; Tenofovir; Zidovudine | 2010 |
AIDS: Drugs that prevent HIV infection.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Administration, Intravaginal; Administration, Oral; Animals; Anti-HIV Agents; Condoms; Controlled Clinical Trials as Topic; Deoxycytidine; Drug Combinations; Emtricitabine; Female; HIV Infections; Homosexuality, Male; Humans; Male; Medication Adherence; Organophosphonates; Placebos; Reverse Transcriptase Inhibitors; Safe Sex; Tenofovir; Vaginal Creams, Foams, and Jellies | 2011 |
HIV prevention in women: next steps.
Topics: Adenine; Administration, Intravaginal; Anti-HIV Agents; Clinical Trials, Phase III as Topic; Coitus; Female; HIV Infections; Humans; Organophosphonates; Tenofovir; Vaginal Creams, Foams, and Jellies | 2011 |
Cost effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in treatment-naïve human immunodeficiency virus-infected patients in the United States.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Cost-Benefit Analysis; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Markov Chains; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Quality-Adjusted Life Years; Reverse Transcriptase Inhibitors; Risk Assessment; Ritonavir; Tenofovir; United States | 2011 |
Lactic acidosis after concomitant treatment with metformin and tenofovir in a patient with HIV infection.
Topics: Acidosis, Lactic; Acute Kidney Injury; Adenine; Aged; Anti-HIV Agents; Diabetes Mellitus, Type 2; Drug Interactions; HIV Infections; Humans; Hypoglycemic Agents; Male; Metformin; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2011 |
Analysis of drug resistance during HIV RNA viraemia in the MONET trial of darunavir/ritonavir monotherapy.
Topics: Adenine; Adult; Anti-HIV Agents; Clinical Trials as Topic; Darunavir; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Molecular Typing; Mutation; Organophosphonates; Ritonavir; RNA, Viral; Sulfonamides; Tenofovir; Treatment Outcome; Virus Replication | 2011 |
Is tenofovir-related renal toxicity incompletely reversible?
Topics: Adenine; Adult; Anti-HIV Agents; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Diseases; Male; Middle Aged; Organophosphonates; Tenofovir | 2011 |
[HIV infected women with intense bone and muscular pain and general weakness].
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Fanconi Syndrome; Female; Hepatitis, Viral, Human; HIV Infections; Humans; Hypophosphatemia; Middle Aged; Muscle Weakness; Musculoskeletal Diseases; Organophosphonates; Osteomalacia; Pain; Radionuclide Imaging; Radiopharmaceuticals; Substance Abuse, Intravenous; Technetium Tc 99m Medronate; Tenofovir | 2011 |
HIV-2 infection, end-stage renal disease and protease inhibitor intolerance: which salvage regimen?
Topics: Adenine; Adult; Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; HIV-2; Humans; Kidney Failure, Chronic; Lamivudine; Male; Organophosphonates; Protease Inhibitors; Pyrrolidinones; Raltegravir Potassium; Renal Dialysis; Salvage Therapy; Tenofovir; Treatment Outcome | 2011 |
Managing hepatitis B/HIV co-infected: adding entecavir to truvada (tenofovir disoproxil/emtricitabine) experienced patients.
Topics: Adenine; Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Deoxycytidine; DNA, Viral; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; Guanine; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Prospective Studies; Tenofovir; Treatment Outcome | 2011 |
Analysis of resistance testing in South Trinidad.
Topics: Adenine; Anti-HIV Agents; Darunavir; Drug Resistance, Multiple; Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; Humans; Mutation; Organophosphonates; Patient Compliance; Sulfonamides; Tenofovir; Trinidad and Tobago | 2010 |
Low incidence of renal impairment observed in tenofovir-treated patients.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Case-Control Studies; Cohort Studies; Female; HIV Infections; Humans; Incidence; Male; Middle Aged; Organophosphonates; Renal Insufficiency; Retrospective Studies; Risk Factors; Tenofovir | 2011 |
Determination of the antiretroviral drug tenofovir in plasma from HIV-infected adults by ultrafast isotope dilution MALDI-triple quadrupole tandem mass spectrometry.
Topics: Adenine; Adult; Anti-HIV Agents; HIV Infections; Humans; Isotope Labeling; Linear Models; Organophosphonates; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tandem Mass Spectrometry; Tenofovir; Triglycerides | 2011 |
[HIV and AIDS: what's new in 2010?].
Topics: Adenine; Anti-HIV Agents; Anti-Retroviral Agents; Chemoprevention; Gels; HIV Infections; Humans; Organophosphonates; Tenofovir | 2011 |
[Renal adverse reactions of antiretroviral medication: proximal tubular dysfunction associated with tenofovir].
Topics: Adenine; Anti-HIV Agents; Fanconi Syndrome; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Tenofovir | 2011 |
Formulation of tenofovir-loaded functionalized solid lipid nanoparticles intended for HIV prevention.
Topics: Adenine; Administration, Intravaginal; Anti-HIV Agents; Cell Culture Techniques; Cell Line; Cell Survival; Chemistry, Pharmaceutical; Drug Carriers; Epithelial Cells; Female; Heparin; HIV Infections; Humans; Lipids; Microscopy, Electron, Transmission; Nanoparticles; Organophosphonates; Particle Size; Phase Transition; Polylysine; Surface Properties; Tenofovir; Vagina | 2011 |
Six-year follow-up of hepatitis B surface antigen concentrations in tenofovir disoproxil fumarate treated HIV-HBV-coinfected patients.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Follow-Up Studies; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Young Adult | 2011 |
Tenofovir-induced renal toxicity in 324 HIV-infected, antiretroviral-naïve patients.
Topics: Adenine; Adult; Anti-HIV Agents; Cohort Studies; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Diseases; Male; Middle Aged; Multivariate Analysis; Organophosphonates; Tenofovir | 2011 |
Preexposure chemoprophylaxis for HIV prevention.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Male; Organophosphonates; Risk-Taking; Sexual Behavior; Tenofovir | 2011 |
Preexposure chemoprophylaxis for HIV prevention.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Male; Organophosphonates; Risk-Taking; Sexual Behavior; Tenofovir | 2011 |
Preexposure chemoprophylaxis for HIV prevention.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Male; Organophosphonates; Tenofovir | 2011 |
Preexposure chemoprophylaxis for HIV prevention.
Topics: Adenine; Age Factors; Anti-HIV Agents; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Kaplan-Meier Estimate; Male; Organophosphonates; Tenofovir; Young Adult | 2011 |
Preexposure chemoprophylaxis for HIV prevention.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Costs; Drug Therapy, Combination; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Male; Organophosphonates; Risk; Tenofovir | 2011 |
Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection.
Topics: Acute Disease; Adenine; Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Prospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2011 |
Synergistic in vitro anti-HIV type 1 activity of tenofovir with carbohydrate-binding agents (CBAs).
Topics: Adenine; Anti-HIV Agents; Cell Line; Drug Synergism; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Organophosphonates; Tenofovir | 2011 |
Clinical experience with nevirapine combined with tenofovir plus emtricitabine or lamivudine-containing regimens in HIV-infected subjects.
Topics: Adenine; Adult; Anti-HIV Agents; Australia; Deoxycytidine; Drug Administration Schedule; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lost to Follow-Up; Male; Medical Audit; Middle Aged; Nevirapine; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2011 |
Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons.
Topics: Adenine; Anti-Retroviral Agents; Biomarkers, Pharmacological; Cardiovascular Diseases; CD4 Lymphocyte Count; Cohort Studies; Dideoxynucleosides; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Risk Factors; Tenofovir; United States; Veterans; Viral Load | 2011 |
Improvement in chronic renal impairment following the discontinuation of tenofovir in two HIV-infected patients.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biomarkers; Biopsy; Chronic Disease; Creatinine; Drug Substitution; Glomerular Filtration Rate; HIV Infections; Humans; Kidney; Kidney Diseases; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2011 |
Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide HIV reverse transcriptase inhibitors.
Topics: Adenine; Animals; Anti-HIV Agents; Chemoprevention; Deoxyadenine Nucleotides; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lymphocytes; Lymphoid Tissue; Macaca; Organophosphonates; Prodrugs; Rectum; Reverse Transcriptase Inhibitors; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Substrate Specificity; Tenofovir | 2011 |
Long-term renal safety of tenofovir disoproxil fumarate in vertically HIV-infected children, adolescents and young adults: a 60-month follow-up study.
Topics: Adenine; Adolescent; Adult; Child; Cohort Studies; Creatinine; Female; Follow-Up Studies; Glomerular Filtration Rate; HIV Infections; Humans; Kidney; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2011 |
Increased risk of abnormal proximal renal tubular function with HIV infection and antiretroviral therapy.
Topics: Adenine; Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Cross-Sectional Studies; Fanconi Syndrome; Female; France; HIV Infections; HIV-1; Humans; Kidney Tubules, Proximal; Logistic Models; Male; Middle Aged; Odds Ratio; Oligopeptides; Organophosphonates; Prevalence; Pyridines; Risk Assessment; Risk Factors; Tenofovir; Time Factors | 2011 |
Tenofovir-induced Fanconi syndrome and osteomalacia in two HIV-infected patients: role of intracellular tenofovir diphosphate levels and review of the literature.
Topics: Adenine; Adult; Anti-HIV Agents; Diphosphates; Fanconi Syndrome; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Osteomalacia; Radionuclide Imaging; Tenofovir; Whole Body Imaging | 2011 |
Study halted: no benefit seen from antiretroviral pill in preventing HIV in women.
Topics: Adenine; Adult; Africa; Anti-Retroviral Agents; Deoxycytidine; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Organophosphonates; Patient Compliance; Pregnancy; Pregnancy Rate; Randomized Controlled Trials as Topic; Tenofovir; Treatment Failure | 2011 |
One percent tenofovir applied topically to humanized BLT mice and used according to the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection, validating the BLT model for evaluation of new microbicide candidates.
Topics: Adenine; Administration, Topical; Animals; Base Sequence; CD4-Positive T-Lymphocytes; Chimera; Disease Models, Animal; DNA Primers; Drug Evaluation, Preclinical; Female; HIV Infections; Humans; Mice; Organophosphonates; Receptors, CCR5; Reverse Transcriptase Inhibitors; Tenofovir; Vagina | 2011 |
[Efavirenz in fixed combination with tenofovir and emtricitabine. Long-term effectiveness verified in new studies].
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Deoxycytidine; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Humans; Medication Adherence; Organophosphonates; Tenofovir; Treatment Outcome; Viral Load | 2011 |
Early end for FEM-PrEP HIV prevention trial.
Topics: Adenine; Administration, Oral; Anti-HIV Agents; Deoxycytidine; Drug Combinations; Emtricitabine; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; HIV Infections; Humans; Kenya; Organophosphonates; Organophosphorus Compounds; Patient Compliance; Randomized Controlled Trials as Topic; South Africa; Tanzania; Tenofovir | 2011 |
Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction.
Topics: Adenine; Anti-HIV Agents; Female; HIV Infections; Humans; Kidney; Kidney Diseases; Kidney Tubules; Male; Multidrug Resistance-Associated Proteins; Organophosphonates; Polymorphism, Single Nucleotide; Tenofovir | 2011 |
Synergy against drug-resistant HIV-1 with the microbicide antiretrovirals, dapivirine and tenofovir, in combination.
Topics: Adenine; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Organophosphonates; Pyrimidines; Reverse Transcriptase Inhibitors; Tenofovir | 2011 |
Relationship between renal dysfunction, nephrotoxicity and death among HIV adults on tenofovir.
Topics: Adenine; Adult; Anti-HIV Agents; Cohort Studies; Creatinine; Female; HIV Infections; Humans; Kidney; Male; Middle Aged; Organophosphonates; Renal Insufficiency; Risk Factors; South Africa; Tenofovir | 2011 |
Population pharmacokinetics of atazanavir/ritonavir in HIV-1-infected children and adolescents.
Topics: Adenine; Adolescent; Anti-HIV Agents; Atazanavir Sulfate; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Drug Monitoring; Female; Follow-Up Studies; HIV Infections; Humans; Male; Models, Biological; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir; Tissue Distribution | 2011 |
Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Female; HIV Infections; Humans; Ischemic Attack, Transient; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Organophosphonates; Proportional Hazards Models; Renal Insufficiency, Chronic; Risk Factors; Stroke; Tenofovir; United States; United States Department of Veterans Affairs | 2011 |
Epidemiological impact of tenofovir gel on the HIV epidemic in South Africa.
Topics: Adenine; Anti-HIV Agents; Cost-Benefit Analysis; Female; HIV Infections; Humans; Incidence; Models, Biological; Organophosphonates; Prevalence; South Africa; Tenofovir; Vaginal Creams, Foams, and Jellies | 2011 |
Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Antiviral Agents; Case-Control Studies; Female; Gene Products, pol; Glomerular Filtration Rate; Hepatitis B, Chronic; HIV Infections; Humans; Linear Models; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Young Adult | 2011 |
Engineering tenofovir loaded chitosan nanoparticles to maximize microbicide mucoadhesion.
Topics: Adenine; Adhesiveness; Analysis of Variance; Animals; Anti-HIV Agents; Cell Survival; Chitosan; Drug Carriers; Drug Compounding; Epithelial Cells; Epithelium; Female; HIV Infections; Humans; In Vitro Techniques; Lactobacillus; Microscopy, Electron, Transmission; Nanoparticles; Organophosphonates; Particle Size; Solubility; Surface Properties; Swine; Tenofovir; Vagina | 2011 |
Renal impairment in HIV-1 infected patients receiving antiretroviral regimens including tenofovir in a resource-limited setting.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Anti-Retroviral Agents; Female; HIV Infections; HIV-1; Humans; Kidney Function Tests; Male; Middle Aged; Organophosphonates; Protease Inhibitors; Renal Insufficiency; Retrospective Studies; Tenofovir; Thailand | 2011 |
Determination of kidney function before tenofovir initiation: four-fold difference in need of tenofovir dose reduction depending on method used.
Topics: Adenine; Adult; Anti-HIV Agents; Dose-Response Relationship, Drug; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Diseases; Male; Organophosphonates; Retrospective Studies; Tenofovir | 2011 |
Comparison of abacavir/lamivudine and tenofovir/emtricitabine among treatment-naive HIV-infected patients initiating therapy.
Topics: Adenine; Adult; Anti-HIV Agents; Canada; Cohort Studies; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug Substitution; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Tenofovir; Treatment Failure; Virus Replication | 2011 |
Tenofovir and emtricitabine cerebrospinal fluid-to-plasma ratios correlate to the extent of blood-brainbarrier damage.
Topics: Adenine; Adult; Blood-Brain Barrier; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Pilot Projects; Tenofovir | 2011 |
Membranous nephropathy in an HIV-positive patient complicated with hepatitis B virus infection.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Emtricitabine; Glomerulonephritis, Membranous; Hepatitis B; HIV Infections; Humans; Male; Nephrotic Syndrome; Organophosphonates; Prednisolone; Tenofovir | 2011 |
pH-responsive nanoparticles releasing tenofovir intended for the prevention of HIV transmission.
Topics: Adenine; Administration, Intravaginal; Anti-HIV Agents; Cell Line; Cell Survival; Drug Carriers; Drug Compounding; Epithelial Cells; Female; HIV Infections; Humans; Hydrogen-Ion Concentration; Lactic Acid; Lactobacillus; Microscopy, Confocal; Microscopy, Electron, Transmission; Microscopy, Fluorescence; Nanoparticles; Organophosphonates; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Polymethacrylic Acids; Solubility; Surface Properties; Tenofovir; Vagina | 2011 |
Severe acute renal failure in an HIV-infected patient after only 2 weeks of tenofovir-based antiretroviral therapy.
Topics: Acute Kidney Injury; Adenine; Anti-HIV Agents; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Tenofovir; Treatment Outcome | 2011 |
Subcellular renal proximal tubular mitochondrial toxicity with tenofovir treatment.
Topics: Adenine; Animals; Cardiomyopathies; Cell Separation; DNA, Mitochondrial; Female; HIV Infections; HIV-1; Humans; Kidney Tubules, Proximal; Lasers; Liver Failure; Male; Mice; Mice, Inbred C57BL; Microdissection; Mitochondria; Organophosphonates; Reverse Transcriptase Inhibitors; Staining and Labeling; Tenofovir | 2011 |
Rilpivirine: a step forward in tailored HIV treatment.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials, Phase III as Topic; Cyclopropanes; Delavirdine; Deoxycytidine; Drug Design; Drug Resistance, Viral; Emtricitabine; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Multicenter Studies as Topic; Mutation; Nevirapine; Nitriles; Organophosphonates; Pyrimidines; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Rilpivirine; Tenofovir; Viral Load | 2011 |
Antiretrovirals for HIV prevention: translating promise into praxis.
Topics: Adenine; Administration, Cutaneous; Administration, Oral; Algorithms; Anti-HIV Agents; Anti-Retroviral Agents; Congresses as Topic; Deoxycytidine; Emtricitabine; Female; Gels; Global Health; HIV Infections; Humans; Organophosphonates; Primary Prevention; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Sexual Behavior; Tenofovir; Treatment Outcome; Women's Health | 2011 |
Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women.
Topics: Adenine; Administration, Intravaginal; Administration, Oral; Africa South of the Sahara; Anti-HIV Agents; Anti-Retroviral Agents; Coitus; Deoxycytidine; Early Termination of Clinical Trials; Emtricitabine; Female; Gels; HIV Infections; Humans; Incidence; Organophosphonates; Primary Prevention; Randomized Controlled Trials as Topic; Rectum; Reverse Transcriptase Inhibitors; Tenofovir; Time Factors; Vagina; Women's Health | 2011 |
Tenofovir works as pre-exposure prophylaxis against HIV, two studies confirm.
Topics: Adenine; Anti-HIV Agents; HIV Infections; Humans; Organophosphonates; Randomized Controlled Trials as Topic; Sexual Partners; Tenofovir | 2011 |
Cost and cost-effectiveness of switching from d4T or AZT to a TDF-based first-line regimen in a resource-limited setting in rural Lesotho.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cost-Benefit Analysis; Developing Countries; Female; Health Care Costs; HIV Infections; Humans; Lesotho; Male; Middle Aged; Organophosphonates; Pregnancy; Rural Population; Stavudine; Tenofovir; Zidovudine | 2011 |
Antiretroviral prophylaxis: a defining moment in HIV control.
Topics: Adenine; Administration, Oral; Anti-HIV Agents; Anti-Retroviral Agents; Botswana; Clinical Trials as Topic; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Kenya; Male; Organophosphonates; Tenofovir; Uganda | 2011 |
Association of osteonecrosis and osteoporosis in HIV-1-infected patients.
Topics: Absorptiometry, Photon; Adenine; Alcohol Drinking; Anti-HIV Agents; California; Female; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Osteonecrosis; Osteoporosis; Prednisolone; Tenofovir | 2011 |
Concentrations of tenofovir and emtricitabine in saliva: implications for preexposure prophylaxis of oral HIV acquisition.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Saliva; Sexual Behavior; Tenofovir | 2011 |
Bilateral pathologic hip fractures associated with antiretroviral therapy: a case report.
Topics: Accidental Falls; Adenine; Alendronate; Anti-HIV Agents; Bone Density Conservation Agents; Comorbidity; Fanconi Syndrome; Female; Femoral Neck Fractures; Fractures, Spontaneous; Hip Fractures; HIV Infections; Humans; Magnetic Resonance Imaging; Middle Aged; Organophosphonates; Osteoporotic Fractures; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure | 2011 |
Impact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients.
Topics: Adenine; Adult; Anti-HIV Agents; Asian People; Body Weight; Cohort Studies; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney; Male; Middle Aged; Multivariate Analysis; Organophosphonates; Retrospective Studies; Tenofovir | 2011 |
Patient-reported outcomes and low-level residual HIV-RNA in adolescents perinatally infected with HIV-1 after switching to one-pill fixed-dose regimen.
Topics: Adenine; Adolescent; Alkynes; Anti-HIV Agents; Antiviral Agents; Benzoxazines; Child; Cyclopropanes; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Patient Satisfaction; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2012 |
Antiretroviral therapy alone resulted in successful resolution of large idiopathic esophageal ulcers in a patient with acute retroviral syndrome.
Topics: Adenine; Adult; Anti-HIV Agents; Antiviral Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Esophageal Diseases; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Organophosphonates; Pyrimidinones; Ritonavir; RNA, Viral; Syndrome; Tenofovir; Ulcer | 2011 |
Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Cohort Studies; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Retrospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Viral Load | 2011 |
A comparison of tenofovir-associated renal function changes in HIV-infected African Americans vs Caucasians.
Topics: Adenine; Adult; Anti-HIV Agents; Black or African American; Creatinine; Drug Monitoring; Female; Glomerular Filtration Rate; HIV; HIV Infections; Humans; Kidney; Male; Middle Aged; Organophosphonates; Renal Insufficiency; Tenofovir; United States; White People; Withholding Treatment | 2011 |
HIV-HBV vaccine escape mutant infection with loss of HBV surface antibody and persistent HBV viremia on tenofovir/emtricitabine without antiviral resistance.
Topics: Adenine; Antiviral Agents; Coinfection; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Hepatitis B; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B virus; HIV Infections; HIV-1; Humans; Male; Middle Aged; Mutation; Organophosphonates; Tenofovir; Viral Load; Viremia | 2011 |
Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy.
Topics: Adenine; Anti-Retroviral Agents; Cell Line; Drug Resistance, Viral; HEK293 Cells; HIV Infections; HIV-1; Humans; Models, Biological; Organophosphonates; Tenofovir; Virus Replication | 2011 |
Impact of tenofovir versus abacavir on HIV-related endothelial dysfunction.
Topics: Adenine; Adult; Anti-HIV Agents; Case-Control Studies; Chemokine CCL2; Dideoxynucleosides; Endothelium, Vascular; Female; HIV Infections; HIV-1; Humans; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Vascular Cell Adhesion Molecule-1; Vasodilation | 2011 |
Comparative outcomes of tenofovir-based and zidovudine-based antiretroviral therapy regimens in Lusaka, Zambia.
Topics: Adenine; Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Organophosphonates; Proportional Hazards Models; Retrospective Studies; Risk Factors; Tenofovir; Zambia; Zidovudine | 2011 |
Population pharmacokinetics of tenofovir in HIV-1-infected pediatric patients.
Topics: Adenine; Adolescent; Anti-HIV Agents; Child; Child, Preschool; HIV Infections; HIV-1; Humans; Kidney; Organophosphonates; Plasma; Tenofovir | 2011 |
Modeling interventions to assess HIV epidemic impact in Africa.
Topics: Adenine; Anti-HIV Agents; Female; HIV Infections; Humans; Organophosphonates; Tenofovir | 2011 |
Persistent decline in estimated but not measured glomerular filtration rate on tenofovir may reflect tubular rather than glomerular toxicity.
Topics: Adenine; Adult; Alpha-Globulins; Anti-HIV Agents; Creatinine; Female; Glomerular Filtration Rate; HIV Infections; HIV-1; Humans; Kidney Glomerulus; Kidney Tubules; Male; Middle Aged; Organophosphonates; Randomized Controlled Trials as Topic; Renal Plasma Flow, Effective; Serum Albumin; Tenofovir; Time Factors; Treatment Outcome | 2011 |
Optimizing initial therapy for HIV infection.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Dideoxynucleosides; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Male; Organophosphonates; Tenofovir | 2011 |
Fanconi syndrome-like tubular acidosis associated with a tenofovir-containing antiretroviral regimen in a human immunodeficiency virus-1-infected Asian woman.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Fanconi Syndrome; Female; HIV Infections; HIV-1; Humans; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2012 |
Predictors of HBeAg status and hepatitis B viraemia in HIV-infected patients with chronic hepatitis B in the HAART era in Brazil.
Topics: Adenine; Adult; Alanine Transaminase; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Brazil; CD4 Lymphocyte Count; Cross-Sectional Studies; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Retrospective Studies; Risk Factors; Tenofovir; Viral Load; Viremia | 2011 |
Assessing recovery of renal function after tenofovir disoproxil fumarate discontinuation.
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Drug Administration Schedule; Female; Glomerular Filtration Rate; HIV Infections; Humans; Japan; Kidney Diseases; Kidney Function Tests; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Young Adult | 2012 |
Pharmacokinetics of tenofovir following intravaginal and intrarectal administration of tenofovir gel to rhesus macaques.
Topics: Adenine; Administration, Intravaginal; Administration, Rectal; Animals; Antiviral Agents; Area Under Curve; Body Fluids; Dose-Response Relationship, Drug; Female; Gels; HIV Infections; HIV-1; Humans; Macaca mulatta; Organophosphonates; Rectum; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Tenofovir; Vagina | 2012 |
Microbicide might protect pregnant women from HIV. Susceptibility is high for them.
Topics: Adenine; Disease Susceptibility; Female; HIV Infections; Humans; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Reverse Transcriptase Inhibitors; Tenofovir | 2011 |
Neither proteinuria nor albuminuria is associated with endothelial dysfunction in HIV-infected patients without diabetes or hypertension.
Topics: Adenine; Adult; Albuminuria; Alkynes; Anti-HIV Agents; Benzoxazines; Brachial Artery; Chi-Square Distribution; Creatinine; Cyclopropanes; Dideoxynucleosides; Endothelium, Vascular; Female; Glomerular Filtration Rate; HIV Infections; Humans; Linear Models; Male; Middle Aged; Organophosphonates; Proteinuria; Tenofovir; Ultrasonography; Vasodilation | 2011 |
Efficacy, adherence and tolerability of once daily tenofovir DF-containing antiretroviral therapy in former injecting drug users with HIV-1 receiving opiate treatment: results of a 48-week open-label study.
Topics: Adenine; Adult; Analgesics, Opioid; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Male; Maximum Tolerated Dose; Medication Adherence; Methadone; Middle Aged; Organophosphonates; Substance Abuse, Intravenous; Survival Rate; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2011 |
Bone turnover, osteoprotegerin/RANKL and inflammation with antiretroviral initiation: tenofovir versus non-tenofovir regimens.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Biomarkers; Bone Density; Bone Remodeling; CD4 Lymphocyte Count; Collagen Type I; Cytokines; Female; HIV Infections; Humans; Inflammation; Longitudinal Studies; Male; NF-kappa B; Organophosphonates; Osteoprotegerin; Protease Inhibitors; RANK Ligand; Tenofovir; Tumor Necrosis Factor-alpha; Young Adult | 2011 |
Pre-exposure chemoprophylaxis of HIV infection: quo vadis?
Topics: Adenine; Administration, Intravaginal; Administration, Oral; Administration, Topical; Anti-HIV Agents; Clinical Trials as Topic; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Molecular Structure; Organophosphonates; Patient Compliance; Tenofovir | 2012 |
Sustained virological response to a raltegravir-containing salvage therapy in an HIV-2-infected patient.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; CD4 Lymphocyte Count; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV Protease Inhibitors; HIV-2; Humans; Lopinavir; Male; Middle Aged; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Salvage Therapy; Tenofovir; Treatment Outcome; Viral Load | 2011 |
The price of tenofovir-emtricitabine undermines the cost-effectiveness and advancement of pre-exposure prophylaxis.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Cost-Benefit Analysis; Deoxycytidine; Drug Costs; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Models, Economic; Organophosphonates; Tenofovir | 2011 |
Durable protection from vaginal simian-human immunodeficiency virus infection in macaques by tenofovir gel and its relationship to drug levels in tissue.
Topics: Adenine; Animals; Anti-HIV Agents; Cells, Cultured; Drug Stability; Female; Half-Life; HIV Infections; HIV-1; Humans; Leukocytes, Mononuclear; Longitudinal Studies; Organophosphonates; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Tenofovir; Vagina; Vaginal Creams, Foams, and Jellies | 2012 |
Acceptability of an "on-demand" pre-exposure HIV prophylaxis trial among men who have sex with men living in France.
Topics: Adenine; Adult; Anti-HIV Agents; Chemoprevention; Deoxycytidine; Drug Combinations; Educational Status; Emtricitabine; France; HIV Infections; HIV Serosorting; Homosexuality, Male; Humans; Male; Organophosphonates; Patient Acceptance of Health Care; Patient Selection; Post-Exposure Prophylaxis; Research Subjects; Risk Reduction Behavior; Self Administration; Tenofovir; Unsafe Sex | 2012 |
Long-term outcome of primary non-responders to tenofovir therapy in HIV/HBV-co-infected patients: impact of HBV genotype G.
Topics: Adenine; Adult; Anti-HIV Agents; Coinfection; Deoxycytidine; DNA Mutational Analysis; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; Genotype; Hepatitis B; Hepatitis B virus; HIV; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Retrospective Studies; Tenofovir; Time Factors; Treatment Outcome | 2012 |
Different baseline characteristics and different outcomes of HIV-infected patients receiving HAART through clinical trials compared with routine care in Mexico.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Clinical Trials as Topic; Deoxycytidine; Emtricitabine; Epidemiologic Methods; Female; HIV Infections; Humans; Kaplan-Meier Estimate; Lopinavir; Male; Mexico; Nevirapine; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir | 2012 |
Tenofovir induced acute kidney injury in a patient with unilateral renal agenesis despite initially non-impaired renal function.
Topics: Acute Kidney Injury; Adenine; Adult; Anti-HIV Agents; Congenital Abnormalities; HIV Infections; Humans; Kidney; Kidney Diseases; Male; Organophosphonates; Tenofovir | 2011 |
Pregnancy-related effects on tenofovir pharmacokinetics: a population study with 186 women.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Drug Monitoring; Female; HIV Infections; HIV-1; Humans; Middle Aged; Models, Biological; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Trimester, Second; Pregnancy Trimester, Third; Reverse Transcriptase Inhibitors; Tenofovir; Young Adult | 2012 |
Simultaneous delivery of tenofovir and acyclovir via an intravaginal ring.
Topics: Acyclovir; Adenine; Administration, Intravaginal; Animals; Anti-HIV Agents; Antiviral Agents; Delayed-Action Preparations; Disease Models, Animal; Drug Combinations; Drug Delivery Systems; Equipment Design; Female; Herpes Genitalis; Herpesvirus 2, Human; HIV Infections; HIV-1; Humans; Organophosphonates; Rabbits; Sexually Transmitted Diseases, Viral; Tenofovir; Treatment Outcome | 2012 |
In vitro resistance profile of the candidate HIV-1 microbicide drug dapivirine.
Topics: Adenine; Anti-HIV Agents; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Mutation; Organophosphonates; Pyrimidines; Reverse Transcriptase Inhibitors; Tenofovir | 2012 |
Early markers of tubular dysfunction in antiretroviral-experienced HIV-infected patients treated with tenofovir versus abacavir.
Topics: Adenine; Anti-HIV Agents; Biomarkers; Cohort Studies; Cytochromes c; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Glomerular Filtration Rate; Glutathione Transferase; HIV Infections; Humans; Kidney Diseases; Kidney Tubules, Proximal; Lamivudine; Male; Middle Aged; Mitochondria; Organophosphonates; Tenofovir; Time Factors | 2012 |
Evaluating the extent of potential resistance to pre-exposure prophylaxis within the UK HIV-1-infectious population of men who have sex with men.
Topics: Adenine; Anti-HIV Agents; Cohort Studies; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Homosexuality, Male; Humans; Logistic Models; Male; Organophosphonates; Prevalence; Tenofovir; United Kingdom; Viral Load | 2012 |
In utero exposure to tenofovir disoproxil fumarate does not impair growth and bone health in HIV-uninfected children born to HIV-infected mothers.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone and Bones; Child; Child, Preschool; Cohort Studies; Cross-Sectional Studies; Female; Fetus; HIV; HIV Infections; HIV Seropositivity; Humans; Infant; Infectious Disease Transmission, Vertical; Italy; Male; Observation; Organophosphonates; Pregnancy; Reverse Transcriptase Inhibitors; Tenofovir | 2011 |
Abacavir, didanosine and tenofovir do not induce inflammatory, apoptotic or oxidative stress genes in coronary endothelial cells.
Topics: Adenine; Anti-HIV Agents; Apoptosis; Cardiovascular Diseases; Cell Adhesion Molecules; Coronary Vessels; Cytokines; Didanosine; Dideoxynucleosides; Endothelial Cells; Gene Expression; Gene Expression Profiling; HIV Infections; HIV-1; Humans; Inflammation; NADPH Oxidases; Organophosphonates; Oxidative Stress; Primary Cell Culture; Proto-Oncogene Proteins; Tenofovir | 2011 |
Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Area Under Curve; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Male; Organophosphonates; Tenofovir | 2011 |
FDA notifications. Complera approved.
Topics: Adenine; Deoxycytidine; Drug Approval; Drug Combinations; Drug Labeling; Emtricitabine; HIV Infections; Humans; Nitriles; Organophosphonates; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; Tenofovir; United States; United States Food and Drug Administration | 2011 |
Recent HIV-1 infection: to treat or not to treat, that is the question.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Organophosphonates; Ritonavir; Tenofovir; Viral Load | 2012 |
Comparison between Elecsys HBsAg II and architect HBsAg QT assays for quantification of hepatitis B surface antigen among patients coinfected with HIV and hepatitis B virus.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Coinfection; Female; Genotype; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Reagent Kits, Diagnostic; Tenofovir | 2012 |
Tenofovir-induced nephrotoxicity: myths and facts.
Topics: Adenine; Animals; Anti-HIV Agents; Evidence-Based Medicine; HIV Infections; HIV-1; Humans; Kidney Diseases; Organophosphonates; Reverse Transcriptase Inhibitors; Risk Factors; Tenofovir | 2012 |
Renal function declines more in tenofovir- than abacavir-based antiretroviral therapy in low-body weight treatment-naïve patients with HIV infection.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Body Weight; Demography; Dideoxynucleosides; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kaplan-Meier Estimate; Male; Multivariate Analysis; Organophosphonates; Risk Factors; Tenofovir | 2012 |
Combination of antiretroviral drugs as microbicides.
Topics: Adenine; Anti-Infective Agents, Local; Anti-Retroviral Agents; Drug Therapy, Combination; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Organophosphonates; Receptors, HIV; Tenofovir | 2012 |
Quasispecies analysis and in vitro susceptibility of HBV strains isolated from HIV-HBV-coinfected patients with delayed response to tenofovir.
Topics: Adenine; Adult; Antiviral Agents; Cloning, Molecular; Coinfection; DNA, Viral; Drug Resistance, Viral; Female; Genotype; Hep G2 Cells; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Sequence Analysis, DNA; Tenofovir; Transfection | 2012 |
Renal function in HIV-infected children and adolescents treated with tenofovir disoproxil fumarate and protease inhibitors.
Topics: Adenine; Adolescent; Anti-HIV Agents; Child; Female; HIV Infections; HIV Protease Inhibitors; Humans; Kidney; Kidney Diseases; Kidney Function Tests; Male; Organophosphonates; Prospective Studies; Tenofovir | 2012 |
HIV preexposure prophylaxis: new data and potential use.
Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Deoxycytidine; Emtricitabine; Evidence-Based Medicine; Female; HIV Infections; HIV-1; Homosexuality, Male; Humans; Male; Organophosphonates; Tenofovir | 2011 |
Effect of abacavir on acute changes in biomarkers associated with cardiovascular dysfunction.
Topics: Adenine; Adult; Anti-HIV Agents; Biomarkers; Cardiovascular Diseases; Case-Control Studies; Dideoxynucleosides; Female; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Risk Factors; Tenofovir | 2012 |
Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents.
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; Hip Fractures; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Organophosphonates; Osteoporotic Fractures; Retrospective Studies; Risk; Risk Factors; Ritonavir; Spinal Fractures; Tenofovir; Time Factors; Treatment Outcome; Wrist Injuries; Young Adult | 2012 |
An unrecognised case of tenofovir-associated Fanconi syndrome.
Topics: Adenine; Adolescent; Anti-HIV Agents; Fanconi Syndrome; HIV Infections; Humans; Male; Organophosphonates; Tenofovir | 2012 |
Association of tenofovir exposure with kidney disease risk in HIV infection.
Topics: Adenine; Adult; Anti-HIV Agents; Female; Follow-Up Studies; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Failure, Chronic; Male; Middle Aged; Organophosphonates; Proteinuria; Risk Factors; Tenofovir; Time Factors; Treatment Outcome | 2012 |
Standardized comparison of the relative impacts of HIV-1 reverse transcriptase (RT) mutations on nucleoside RT inhibitor susceptibility.
Topics: Adenine; Algorithms; Anti-HIV Agents; Dideoxynucleosides; Drug Resistance, Multiple, Viral; Genomics; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Least-Squares Analysis; Mutation; Nucleosides; Organophosphonates; Phenotype; Reverse Transcriptase Inhibitors; Tenofovir; Thymidine; Zidovudine | 2012 |
Kinetics of hepatitis B surface and envelope antigen and prediction of treatment response to tenofovir in antiretroviral-experienced HIV-hepatitis B virus-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Male; Organophosphonates; Prospective Studies; Tenofovir; Treatment Outcome | 2012 |
Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention.
Topics: Adenine; Administration, Oral; Anti-HIV Agents; Antiviral Agents; Clinical Trials as Topic; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Patient Compliance; Risk Factors; Tenofovir; Treatment Outcome; Vaginal Creams, Foams, and Jellies | 2012 |
Increase in serum mitochondrial creatine kinase levels induced by tenofovir administration.
Topics: Adenine; Adult; Analysis of Variance; Anti-HIV Agents; Antibodies, Monoclonal; Antiretroviral Therapy, Highly Active; Cohort Studies; Creatine Kinase, Mitochondrial Form; Electrophoresis, Agar Gel; Enzyme-Linked Immunosorbent Assay; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Tenofovir | 2012 |
Least among equals.
Topics: Adenine; Anti-HIV Agents; HIV Infections; Humans; Organophosphonates; Tenofovir | 2012 |
Reduced quantitative ultrasound bone mineral density in HIV-infected patients on antiretroviral therapy in Senegal.
Topics: Adenine; Adult; Anti-HIV Agents; Anti-Retroviral Agents; Body Mass Index; Bone Density; Case-Control Studies; Female; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Protease Inhibitors; Senegal; Tenofovir; Viral Load | 2012 |
Preservation HIV-1-specific IFNγ+ CD4+ T-cell responses in breakthrough infections after exposure to tenofovir gel in the CAPRISA 004 microbicide trial.
Topics: Adenine; Adult; Anti-HIV Agents; Anti-Infective Agents; CD4-Positive T-Lymphocytes; Female; HIV Infections; HIV-1; Humans; Interferon-gamma; Organophosphonates; South Africa; Tenofovir; Vaginal Creams, Foams, and Jellies | 2012 |
The British HIV Association/British Association for Sexual Health and HIV Position Statement on pre-exposure prophylaxis in the UK.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Combinations; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Tenofovir; United Kingdom | 2012 |
Immune reconstitution renal-limited sarcoidosis presenting as acute kidney injury.
Topics: Acute Kidney Injury; Adenine; Adult; AIDS-Associated Nephropathy; Anti-Retroviral Agents; Atazanavir Sulfate; Female; HIV Infections; Humans; Oligopeptides; Organophosphonates; Prednisone; Pyridines; Ritonavir; Sarcoidosis; Tenofovir; Young Adult | 2012 |
Adverse drug reactions to antiretroviral therapy (ARVs): incidence, type and risk factors in Nigeria.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Cohort Studies; Cyclopropanes; Drug-Related Side Effects and Adverse Reactions; Exanthema; Female; HIV Infections; Humans; Incidence; Lamivudine; Male; Middle Aged; Nevirapine; Nigeria; Organophosphonates; Pain; Retrospective Studies; Risk Factors; Stavudine; Tenofovir; Zidovudine | 2012 |
Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Female; France; HIV; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Mutation, Missense; Organophosphonates; Retrospective Studies; RNA, Viral; Selection, Genetic; Tenofovir; Treatment Failure; Viral Load | 2012 |
Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants.
Topics: Adenine; Anti-HIV Agents; Body Size; Child Development; Drug Therapy, Combination; Female; HIV Infections; Humans; Infant; Infant, Low Birth Weight; Infant, Newborn; Infant, Small for Gestational Age; Male; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Prospective Studies; Risk Factors; Tenofovir | 2012 |
L-selectin and P-selectin are novel biomarkers of cervicovaginal inflammation for preclinical mucosal safety assessment of anti-HIV-1 microbicide.
Topics: Adenine; Animals; Anti-Infective Agents; Benzalkonium Compounds; Biomarkers; Carboxymethylcellulose Sodium; Cervix Uteri; Chemokine CCL2; Female; HIV Infections; Inflammation; Interleukin-6; L-Selectin; Mice; Mice, Inbred C57BL; Mucous Membrane; Nonoxynol; Organophosphonates; P-Selectin; Sodium Dodecyl Sulfate; Tenofovir | 2012 |
Pharmacokinetics and topical vaginal effects of two tenofovir gels in rabbits.
Topics: Adenine; Administration, Intravaginal; Administration, Rectal; Animals; Anti-HIV Agents; Body Fluids; Female; HIV Infections; Lymph Nodes; Organophosphonates; Rabbits; Tenofovir; Vagina; Vaginal Creams, Foams, and Jellies | 2012 |
Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir.
Topics: Adenine; Adult; Alkynes; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Female; Glomerular Filtration Rate; HIV Infections; HIV Protease Inhibitors; Humans; Kidney; Lopinavir; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Treatment Outcome | 2012 |
Characterization of UC781-tenofovir combination gel products for HIV-1 infection prevention in an ex vivo ectocervical model.
Topics: Adenine; Anilides; Anti-HIV Agents; Anti-Retroviral Agents; Cervix Uteri; Chromatography, High Pressure Liquid; Female; Furans; Gels; HIV Infections; Humans; In Vitro Techniques; Organophosphonates; Tandem Mass Spectrometry; Tenofovir; Thioamides | 2012 |
Development of polylactide and polyethylene vinyl acetate blends for the manufacture of vaginal rings.
Topics: Adenine; Anti-Infective Agents; Antiviral Agents; Biocompatible Materials; Body Fluids; Contraceptive Devices, Female; Diffusion; Drug Delivery Systems; Female; HIV Infections; Humans; Microscopy, Electron, Scanning; Organophosphonates; Polyesters; Polymers; Polyvinyls; Tenofovir; Vagina | 2012 |
Intravaginal ring delivery of tenofovir disoproxil fumarate for prevention of HIV and herpes simplex virus infection.
Topics: Adenine; Antiviral Agents; Cell Culture Techniques; Chemoprevention; Contraceptive Devices, Female; Female; Herpes Genitalis; HIV; HIV Infections; Humans; Organ Culture Techniques; Organophosphonates; Simplexvirus; Tenofovir | 2012 |
The cost-effectiveness of pre-exposure prophylaxis for HIV infection in South African women.
Topics: Adenine; Adult; Anti-HIV Agents; Chemoprevention; Cost-Benefit Analysis; Female; HIV Infections; Humans; Incidence; Middle Aged; Organophosphonates; Survival Analysis; Tenofovir; Treatment Outcome | 2012 |
Cutaneous CD8+ T-cell infiltrates associated with human immunodeficiency virus.
Topics: Adenine; Alopecia; Anti-HIV Agents; Antigens, Differentiation, T-Lymphocyte; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD8-Positive T-Lymphocytes; Deoxycytidine; Diagnosis, Differential; Emtricitabine; HIV Infections; Humans; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Oligopeptides; Organophosphonates; Prednisone; Pseudolymphoma; Pyridines; Ritonavir; Skin; Tenofovir | 2012 |
Renal toxicity of long-term therapy with tenofovir in HIV-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Dideoxynucleosides; Disease Progression; Female; Follow-Up Studies; Glomerular Filtration Rate; HIV Infections; Hospitals, Veterans; Humans; Incidence; Kidney; Male; Middle Aged; New York City; Organophosphonates; Outpatient Clinics, Hospital; Pilot Projects; Proportional Hazards Models; Renal Insufficiency, Chronic; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir | 2012 |
Reformulated tenofovir gel for use as a dual compartment microbicide.
Topics: Adenine; Anti-HIV Agents; Anti-Infective Agents; Disease Transmission, Infectious; Female; HIV Infections; HIV-1; Humans; Organ Culture Techniques; Organophosphonates; Rectum; Tenofovir; Treatment Outcome; Vagina; Vaginal Creams, Foams, and Jellies | 2012 |
Does maternal use of tenofovir during pregnancy affect growth of HIV-exposed uninfected infants?
Topics: Adenine; Anti-HIV Agents; Body Size; Female; HIV Infections; Humans; Infant, Newborn; Male; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Tenofovir | 2012 |
Case report of cytomegalovirus retinitis in an HIV-positive patient with a CD4-count nadir of 254 cells per μl.
Topics: Adenine; Administration, Oral; Adult; Alkynes; Anti-HIV Agents; Aqueous Humor; Benzoxazines; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cyclopropanes; Cytomegalovirus; Cytomegalovirus Retinitis; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Male; Organophosphonates; Polymerase Chain Reaction; Tenofovir; Visual Acuity | 2012 |
Antiretroviral prophylaxis for HIV prevention reaches a key milestone.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Combinations; Emtricitabine; HIV Infections; Humans; Organophosphonates; Tenofovir | 2012 |
Patient-reported symptoms on the antiretroviral regimen efavirenz/emtricitabine/tenofovir.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cohort Studies; Cross-Sectional Studies; Cyclopropanes; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; Health Status; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Quality of Life; Severity of Illness Index; Tenofovir; Treatment Outcome; Veterans | 2012 |
An intravaginal ring for the simultaneous delivery of multiple drugs.
Topics: Acyclovir; Adenine; Administration, Intravaginal; Animals; Antiviral Agents; Delayed-Action Preparations; Drug Delivery Systems; Equipment Design; Female; HIV; HIV Infections; Humans; Organophosphonates; Reverse Transcriptase Inhibitors; Silicon; Tenofovir; Tensile Strength | 2012 |
The deleterious influence of tenofovir-based therapies on the progression of atherosclerosis in HIV-infected patients.
Topics: Adenine; Atherosclerosis; Chemokine CCL2; HIV Infections; Interleukin-6; Organophosphonates; Prospective Studies; Reverse Transcriptase Inhibitors; Tenofovir | 2012 |
Impact of antiretroviral dosing frequency and pill burden on adherence among newly diagnosed, antiretroviral-naive HIV patients.
Topics: Adenine; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studies; Cyclopropanes; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Male; Medication Adherence; Middle Aged; Organophosphonates; Prospective Studies; Tenofovir | 2012 |
How good is "good enough"? The case for varying standards of evidence according to need for new interventions in HIV prevention.
Topics: Adenine; Administration, Intravaginal; Administration, Oral; Anti-HIV Agents; Deoxycytidine; Drug Combinations; Emtricitabine; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Ethical Analysis; Ethical Theory; Ethics, Research; Evidence-Based Medicine; Female; Gels; Guidelines as Topic; Health Services Accessibility; Health Services Needs and Demand; HIV Infections; Homosexuality, Male; Humans; Male; Organophosphonates; Organophosphorus Compounds; Primary Prevention; Randomized Controlled Trials as Topic; Research Subjects; Sex Work; Tenofovir; Therapeutic Equipoise; United States; United States Food and Drug Administration | 2012 |
Renal function and incidence of chronic kidney disease in HIV patients: a Danish cohort study.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Cohort Studies; Denmark; Female; Glomerular Filtration Rate; HIV Infections; Humans; Incidence; Kidney; Linear Models; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Renal Insufficiency, Chronic; Tenofovir | 2012 |
Sustained local delivery of structurally diverse HIV-1 microbicides released from sublimation enthalpy controlled matrices.
Topics: Adenine; Animals; Anti-HIV Agents; Cells, Cultured; Contraceptive Devices, Female; Delayed-Action Preparations; Deoxycytidine; Drug Delivery Systems; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Macrophages; Monocytes; Organophosphonates; Sheep; Structure-Activity Relationship; Sublimation, Chemical; T-Lymphocytes; Tenofovir | 2012 |
Tenofovir in second-line ART in Zambia and South Africa: collaborative analysis of cohort studies.
Topics: Adenine; Adult; Africa South of the Sahara; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort Studies; Female; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; South Africa; Tenofovir; Treatment Outcome; Viral Load; Zambia | 2012 |
Long-term hepatitis B virus surface antigen decay in HIV-1/hepatitis B virus-coinfected adults initiating a tenofovir-containing regimen.
Topics: Adenine; Adult; Anti-HIV Agents; Coinfection; Hepatitis B Surface Antigens; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Middle Aged; Organophosphonates; Tenofovir; Treatment Outcome; Viral Load | 2012 |
Preexposure prophylaxis for HIV--where do we go from here?
Topics: Adenine; Anti-Retroviral Agents; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Pregnancy; Tenofovir | 2012 |
Clinical decisions. Preexposure prophylaxis for HIV prevention.
Topics: Adenine; Adolescent; Anti-Retroviral Agents; Deoxycytidine; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Safe Sex; Tenofovir | 2012 |
Five-year review of HIV-hepatitis B virus (HBV) co-infected patients in a New York City AIDS center.
Topics: Adenine; Adult; Anti-HIV Agents; Coinfection; Female; Hepatitis B; Hepatitis B e Antigens; HIV Infections; Humans; Liver Cirrhosis; Male; Middle Aged; New York City; Organophosphonates; Retrospective Studies; Tenofovir | 2012 |
The introduction of new antiretroviral-based HIV prevention methods into health systems: an update.
Topics: Adenine; Africa South of the Sahara; Anti-Retroviral Agents; Deoxycytidine; Drug Combinations; Emtricitabine; HIV Infections; Humans; Organophosphonates; Tenofovir; Vaginal Creams, Foams, and Jellies | 2012 |
Prevention. Using PrEP cost-effective in high-risk MSM groups.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Combinations; Drug Costs; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Male; Organophosphonates; Risk Factors; Tenofovir | 2012 |
Research. Fetuses unaffected by tenofovir, 1-year-olds appear slightly smaller.
Topics: Adenine; Female; Fetus; Growth; HIV Infections; Humans; Infant; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Reverse Transcriptase Inhibitors; Tenofovir | 2012 |
Lamivudine or emtricitabine (XTC)/protease inhibitor dual therapy as a harm-reduction strategy in patients with tenofovir-related renal toxicity: a case-control study.
Topics: Adenine; Adult; Aged; Case-Control Studies; CD4 Lymphocyte Count; Chi-Square Distribution; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Kidney Diseases; Kidney Function Tests; Lamivudine; Male; Middle Aged; Organophosphonates; Protease Inhibitors; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load | 2012 |
Pharmacokinetics and pharmacodynamics of the reverse transcriptase inhibitor tenofovir and prophylactic efficacy against HIV-1 infection.
Topics: Adenine; Administration, Oral; Dose-Response Relationship, Drug; HIV Infections; HIV-1; Humans; Intracellular Space; Kinetics; Models, Biological; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Viral Load | 2012 |
Case report: management and HBV sequencing in a patient co-infected with HBV and HIV failing tenofovir.
Topics: Adenine; Anti-HIV Agents; Coinfection; Drug Resistance, Viral; Gene Products, pol; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Organophosphonates; Sequence Analysis, DNA; Tenofovir; Viral Load; Young Adult | 2012 |
Innate immune activation enhances hiv acquisition in women, diminishing the effectiveness of tenofovir microbicide gel.
Topics: Adenine; Adult; Anti-HIV Agents; Avian Proteins; Case-Control Studies; Coinfection; Cytokines; Disease Susceptibility; Female; Herpes Genitalis; Herpesvirus 2, Human; HIV Infections; Humans; Immunity, Innate; Logistic Models; Lymphocyte Activation; Organophosphonates; Platelet Count; Principal Component Analysis; Randomized Controlled Trials as Topic; Risk Factors; Tenofovir; Vaginal Creams, Foams, and Jellies; Young Adult | 2012 |
Trends in HIV-1 reverse transcriptase resistance-associated mutations and antiretroviral prescription data from 2003-2010.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Prescriptions; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Organophosphonates; Prevalence; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure; Zidovudine | 2012 |
FDA paves the way for pre-exposure HIV prophylaxis.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Deoxycytidine; Drug Combinations; Emtricitabine; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Primary Prevention; Tenofovir; United States; United States Food and Drug Administration | 2012 |
Tenofovir-associated proteinuria.
Topics: Adenine; Anti-HIV Agents; Creatine; Female; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Proteinuria; Renal Insufficiency, Chronic; Tenofovir | 2013 |
Interim guidance for clinicians considering the use of preexposure prophylaxis for the prevention of HIV infection in heterosexually active adults.
Topics: Adenine; Administration, Oral; Adult; Anti-Retroviral Agents; Centers for Disease Control and Prevention, U.S.; Contraindications; Deoxycytidine; Drug Labeling; Emtricitabine; Female; Heterosexuality; HIV Infections; Homosexuality; Humans; Male; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Randomized Controlled Trials as Topic; Risk; Sexual Behavior; Tenofovir; United States | 2012 |
Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Sequence Data; Mutation, Missense; Organophosphonates; Selection, Genetic; Sequence Analysis, DNA; Tenofovir; Treatment Failure | 2012 |
High rate of reversibility of renal damage in a cohort of HIV-infected patients receiving tenofovir-containing antiretroviral therapy.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Female; HIV Infections; Humans; Kidney; Kidney Diseases; Kidney Function Tests; Male; Middle Aged; Organophosphonates; Tenofovir; Time Factors; Withholding Treatment | 2012 |
[A single tablet against HIV: new combination preparation improves therapy].
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Carbamates; CD4 Lymphocyte Count; Clinical Trials, Phase III as Topic; Cobicistat; Cyclopropanes; Deoxycytidine; Double-Blind Method; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Glomerular Filtration Rate; HIV Infections; Humans; Oligopeptides; Organophosphonates; Pyridines; Quinolones; Randomized Controlled Trials as Topic; Ritonavir; Tenofovir; Thiazoles; Viral Load | 2012 |
Macro CK2 accumulation in tenofovir-treated HIV patients is facilitated by CK oligomer stabilization but is not predictive for pathology.
Topics: Adenine; Anti-HIV Agents; Catalysis; Creatine Kinase, Mitochondrial Form; Enzyme Stability; Follow-Up Studies; Glomerular Filtration Rate; HIV Infections; Humans; Hypophosphatemia; Organophosphonates; Protein Multimerization; Tenofovir | 2013 |
Cost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoring.
Topics: Adenine; Adult; Africa South of the Sahara; Anti-Retroviral Agents; Cost-Benefit Analysis; Drug Resistance, Viral; Epidemics; Female; Genotype; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Stochastic Processes; Tenofovir; Treatment Outcome; Zidovudine | 2012 |
Preexposure prophylaxis for the prevention of HIV transmission to women.
Topics: Adenine; Anti-HIV Agents; Chemoprevention; Cost-Benefit Analysis; Deoxycytidine; Directive Counseling; Emtricitabine; Family Characteristics; Female; HIV Infections; Humans; Male; Medication Adherence; Organophosphonates; Primary Health Care; Primary Prevention; Reproductive Behavior; Risk-Taking; Tenofovir; United States; United States Food and Drug Administration | 2013 |
Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort.
Topics: Adenine; Alkynes; Anti-Retroviral Agents; Atazanavir Sulfate; Benzoxazines; Cohort Studies; Cyclopropanes; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Italy; Longitudinal Studies; Lopinavir; Oligopeptides; Organophosphonates; Prospective Studies; Pyridines; Retrospective Studies; Ritonavir; Tenofovir; Time Factors | 2013 |
Emtricitabine/rilpivirine/tenofovir disoproxil fumarate single-tablet regimen: a guide to its use in HIV-1 infection.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Humans; Nitriles; Organophosphonates; Patient Compliance; Pyrimidines; Rilpivirine; RNA, Viral; Tenofovir; Time Factors; Treatment Outcome | 2012 |
FDA treads carefully with PrEP.
Topics: Adenine; Anti-HIV Agents; Chemoprevention; Deoxycytidine; Drug Approval; Drug Combinations; Drug Resistance, Viral; Emtricitabine; HIV Infections; Humans; Medication Adherence; Organophosphonates; Tenofovir; United States; United States Food and Drug Administration | 2012 |
Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure.
Topics: Adenine; Adult; Anti-HIV Agents; Blood Chemical Analysis; Chromatography, Liquid; Deoxycytidine; Desiccation; Emtricitabine; Erythrocytes; Female; Half-Life; HIV Infections; Humans; Leukocytes, Mononuclear; Male; Medication Adherence; Middle Aged; Organophosphonates; Plasma; Specimen Handling; Tandem Mass Spectrometry; Tenofovir; Young Adult | 2013 |
Safety and efficacy of tenofovir/IQP-0528 combination gels - a dual compartment microbicide for HIV-1 prevention.
Topics: Adenine; Administration, Mucosal; Anti-Infective Agents; Cell Line; Cell Survival; Chemoprevention; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Organophosphonates; Pyrimidinones; Tenofovir; Tissue Culture Techniques; Vaginal Creams, Foams, and Jellies | 2012 |
Antiretroviral medications as prevention: will the new paradigm reverse the HIV epidemic?
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Epidemics; Female; HIV Infections; Homosexuality, Male; Humans; Male; Organophosphonates; Randomized Controlled Trials as Topic; Risk Factors; Tenofovir | 2012 |
Differential effects of tenofovir/emtricitabine and abacavir/lamivudine on human leukocyte recruitment.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Cell Adhesion; Cell Adhesion Molecules; Cell Communication; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Endothelial Cells; HIV Infections; Humans; Lamivudine; Leukocytes; Organophosphonates; Tenofovir | 2012 |
Single nucleotide polymorphisms in ABCC2 associate with tenofovir-induced kidney tubular dysfunction in Japanese patients with HIV-1 infection: a pharmacogenetic study.
Topics: Adenine; Adult; Cohort Studies; Cross-Sectional Studies; Female; Genetic Predisposition to Disease; HIV Infections; HIV-1; Humans; Japan; Kidney Diseases; Kidney Tubules; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Organophosphonates; Polymorphism, Single Nucleotide; Tenofovir | 2012 |
Quantification of tenofovir in human plasma by solid-phase extraction and high-performance liquid chromatography coupled with UV detection.
Topics: Adenine; Calibration; Chromatography, High Pressure Liquid; Drug Monitoring; Female; HIV Infections; Humans; Male; Organophosphonates; Reference Standards; Reproducibility of Results; Solid Phase Extraction; Spectrophotometry, Ultraviolet; Tenofovir | 2012 |
A perspective on progress and gaps in HIV prevention science.
Topics: Adenine; Administration, Oral; Administration, Topical; Anal Canal; Anti-HIV Agents; Chemoprevention; Deoxycytidine; Drug Combinations; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; HIV Infections; Humans; Immunity, Innate; Male; Medication Adherence; Mouth Mucosa; Mucous Membrane; Organophosphonates; Organophosphorus Compounds; Sexual Partners; Tenofovir; Vagina; Vaginal Creams, Foams, and Jellies | 2012 |
Risk factors and outcome of HIV-associated idiopathic noncirrhotic portal hypertension.
Topics: Adenine; Adult; Anti-HIV Agents; Case-Control Studies; Chemical and Drug Induced Liver Injury; Didanosine; Drug Therapy, Combination; Female; HIV Infections; Humans; Hypertension, Portal; Liver; Male; Middle Aged; Multivariate Analysis; Netherlands; Organophosphonates; Risk Factors; Stavudine; Tenofovir; Young Adult | 2012 |
Drug-induced acute interstitial nephritis mimicking acute tubular necrosis after initiation of tenofovir-containing antiretroviral therapy in patient with HIV-1 infection.
Topics: Acute Disease; Adenine; Aged; Anti-Retroviral Agents; Biopsy; Diagnosis, Differential; HIV Infections; HIV-1; Humans; Kidney; Kidney Tubular Necrosis, Acute; Male; Nephritis, Interstitial; Organophosphonates; Tenofovir | 2012 |
The effect of tenofovir on vitamin D metabolism in HIV-infected adults is dependent on sex and ethnicity.
Topics: Adenine; Adult; Anti-HIV Agents; Bone Density; Calcium; Cohort Studies; Ethnicity; Female; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Parathyroid Hormone; Phosphates; Prospective Studies; Regression Analysis; Sex Factors; Tenofovir; Vitamin D | 2012 |
Incidence of renal toxicity in HIV-infected, antiretroviral-naïve patients starting tenofovir/emtricitabine associated with efavirenz, atazanavir/ritonavir, or lopinavir/ritonavir.
Topics: Adenine; Adult; Alkynes; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Deoxycytidine; Emtricitabine; Female; Glomerular Filtration Rate; Glycosuria; HIV Infections; HIV Protease Inhibitors; Humans; Kidney Diseases; Lopinavir; Male; Middle Aged; Oligopeptides; Organophosphonates; Proteinuria; Pyridines; Retrospective Studies; Ritonavir; Tenofovir | 2013 |
A 90-day tenofovir reservoir intravaginal ring for mucosal HIV prophylaxis.
Topics: Adenine; Administration, Intravaginal; Animals; Anti-HIV Agents; Chromatography, High Pressure Liquid; Delayed-Action Preparations; Equipment Design; Female; HIV Infections; Irritants; Organophosphonates; Polyurethanes; Sheep; Tenofovir; Vagina; Vaginal Creams, Foams, and Jellies | 2012 |
Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation, Missense; Organophosphonates; Selection, Genetic; Tenofovir; Time Factors; Treatment Failure | 2013 |
Raltegravir central nervous system tolerability in clinical practice: results from a multicenter observational study.
Topics: Adenine; Anti-HIV Agents; Central Nervous System; Drug Administration Schedule; Drug Interactions; Female; HIV Infections; Humans; Male; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Tenofovir; Treatment Outcome; Viral Load | 2012 |
Age-related differences in plasma and intracellular tenofovir concentrations in HIV-1-infected children, adolescents and adults.
Topics: Adenine; Adolescent; Adult; Age Factors; Anti-HIV Agents; Biological Availability; Child; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Female; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Tandem Mass Spectrometry; Tenofovir | 2013 |
The influence of HLA supertype on thymidine analogue associated with low peripheral fat in HIV.
Topics: Adenine; Anti-HIV Agents; Australia; Biomarkers; Blood Glucose; Body Fat Distribution; CD4 Lymphocyte Count; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Female; Genotype; HIV Infections; HIV-Associated Lipodystrophy Syndrome; HLA Antigens; HLA-A1 Antigen; HLA-B8 Antigen; HLA-DQ Antigens; Humans; Lamivudine; Linkage Disequilibrium; Male; Middle Aged; Multicenter Studies as Topic; Organophosphonates; Predictive Value of Tests; Randomized Controlled Trials as Topic; Tenofovir; Thymidine | 2012 |
Increased time exposure to tenofovir is associated with a greater decrease in estimated glomerular filtration rate in HIV patients with kidney function of less than 60 ml/min/1.73 m2.
Topics: Adenine; Anti-HIV Agents; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Failure, Chronic; Kidney Function Tests; Male; Middle Aged; Organophosphonates; Risk Factors; Tenofovir; Time Factors | 2012 |
Five-year on-treatment efficacy of lamivudine-, tenofovir- and tenofovir + emtricitabine-based HAART in HBV-HIV-coinfected patients.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Coinfection; Deoxycytidine; Emtricitabine; Female; Hepatitis B; Hepatitis B e Antigens; Hepatitis B virus; HIV Infections; HIV-1; Humans; Lamivudine; Male; Organophosphonates; Retrospective Studies; Tenofovir; Treatment Outcome; Viral Load; Virus Replication | 2012 |
Coadministration of tenofovir decreased atazanavir plasma concentration after unilateral nephrectomy.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Drug Interactions; HIV Infections; Humans; Liver Function Tests; Male; Nephrectomy; Oligopeptides; Organophosphonates; Pyridines; Tenofovir | 2013 |
Microbicides are promoted as offering a 'female-controlled' HIV prevention method: so can they revolutionize the HIV crisis of young women in Kenya?
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Anti-Infective Agents; Awards and Prizes; Chemoprevention; Condoms; Condoms, Female; Female; HIV Infections; Humans; Incidence; Kenya; Middle Aged; Negotiating; Organophosphonates; Prevalence; Sexual Partners; Spouse Abuse; Tenofovir; Women's Health; Women's Rights; Young Adult | 2012 |
[Preexposure prophylaxis for HIV infection--current data and recommendations].
Topics: Adenine; Africa; Anti-HIV Agents; Controlled Clinical Trials as Topic; Deoxycytidine; Drug Resistance, Viral; Early Termination of Clinical Trials; Emtricitabine; Female; HIV Infections; Humans; Male; Organophosphonates; Risk Factors; Tenofovir | 2012 |
Tenofovir diphosphate and emtricitabine triphosphate concentrations in blood cells compared with isolated peripheral blood mononuclear cells: a new measure of antiretroviral adherence?
Topics: Adenine; Adult; Anti-HIV Agents; Blood Cells; Deoxycytidine; Diphosphates; Emtricitabine; Female; HIV Infections; Humans; Leukocytes, Mononuclear; Male; Medication Adherence; Middle Aged; Organophosphonates; Polyphosphates; Tenofovir | 2013 |
Inefficient vaginal transmission of tenofovir-resistant HIV-1.
Topics: Adenine; Animals; Anti-HIV Agents; Disease Models, Animal; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1; Humans; Mice; Mucous Membrane; Mutation, Missense; Organophosphonates; Suppression, Genetic; Tenofovir; Vagina | 2013 |
Association between tenofovir exposure and reduced kidney function in a cohort of HIV-positive patients: results from 10 years of follow-up.
Topics: Adenine; Adult; Anti-HIV Agents; Canada; Cohort Studies; Female; Follow-Up Studies; Glomerular Filtration Rate; HIV Infections; HIV Seropositivity; Humans; Kidney Diseases; Male; Organophosphonates; Proportional Hazards Models; Tenofovir | 2013 |
FDA approves new 4-drug once-a-day HIV treatment.
Topics: Adenine; Carbamates; Cobicistat; Deoxycytidine; Drug Administration Schedule; Drug Approval; Drug Combinations; Emtricitabine; HIV Infections; Humans; Organophosphonates; Quinolones; Tenofovir; Thiazoles; United States; United States Food and Drug Administration | 2012 |
A 4-drug combination (Stribild) for HIV.
Topics: Adenine; Anti-HIV Agents; Carbamates; Clinical Trials as Topic; Cobicistat; Deoxycytidine; Double-Blind Method; Drug Approval; Drug Combinations; Drug Interactions; Drug Resistance, Multiple, Viral; Emtricitabine; HIV; HIV Infections; Humans; Organophosphonates; Quinolones; Randomized Controlled Trials as Topic; Tenofovir; Thiazoles; United States; United States Food and Drug Administration | 2012 |
HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir.
Topics: Adenine; Adult; Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genetic Variation; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Male; Middle Aged; Molecular Sequence Data; Organophosphonates; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Tenofovir | 2013 |
Absence of liver steatosis in HIV-HCV co-infected patients receiving regimens containing tenofovir or abacavir.
Topics: Adenine; Adult; Anti-HIV Agents; Coinfection; Dideoxynucleosides; Fatty Liver; Female; Genotype; Hepatitis C; HIV Infections; Humans; Liver; Male; Multivariate Analysis; Organophosphonates; Prevalence; Retrospective Studies; Reverse Transcriptase Inhibitors; Risk Factors; Tenofovir | 2013 |
[Efficacy and tolerance of tenofovir-lamivudine-efavirenz combination in HIV-1 patients in Fann Teaching Hospital in Dakar].
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Hospitals, Teaching; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Senegal; Tenofovir; Treatment Outcome | 2013 |
Tenofovir treatment duration predicts proteinuria in a multiethnic United States Cohort of children and adolescents with perinatal HIV-1 infection.
Topics: Adenine; Adolescent; Anti-HIV Agents; Black or African American; Child; Cohort Studies; Female; Hispanic or Latino; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Male; Multivariate Analysis; Odds Ratio; Organophosphonates; Prevalence; Prospective Studies; Proteinuria; Renal Insufficiency, Chronic; Statistics, Nonparametric; Tenofovir; United States | 2013 |
Tenofovir use and urinary biomarkers among HIV-infected women in the Women's Interagency HIV Study (WIHS).
Topics: Acetylglucosaminidase; Acute-Phase Proteins; Adenine; Adult; beta 2-Microglobulin; Biomarkers; Female; HIV Infections; Humans; Lipocalin-2; Lipocalins; Middle Aged; Organophosphonates; Prospective Studies; Proto-Oncogene Proteins; Reverse Transcriptase Inhibitors; Tenofovir | 2013 |
Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug Interactions; Ethambutol; Female; Genotype; HIV Infections; Humans; Isoniazid; Lamivudine; Male; Middle Aged; Organophosphonates; Oxidoreductases, N-Demethylating; Pharmacogenetics; Polymorphism, Single Nucleotide; Pyrazinamide; Reverse Transcriptase Inhibitors; Rifampin; Tenofovir; Tuberculosis; Young Adult | 2013 |
Coverage, context and targeted prevention: optimising our impact.
Topics: Adenine; Anti-HIV Agents; Circumcision, Male; Deoxycytidine; Emtricitabine; Female; Health Priorities; HIV Infections; Humans; Male; Organophosphonates; Sexual Behavior; Tenofovir; United States; Vaginal Creams, Foams, and Jellies | 2013 |
Spray drying tenofovir loaded mucoadhesive and pH-sensitive microspheres intended for HIV prevention.
Topics: Adenine; Cell Survival; Chemistry, Pharmaceutical; Drug Carriers; HIV Infections; Humans; Hydrogen-Ion Concentration; Microspheres; Organophosphonates; Particle Size; Tenofovir | 2013 |
Tenofovir, emtricitabine intracellular and plasma, and efavirenz plasma concentration decay following drug intake cessation: implications for HIV treatment and prevention.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Combinations; Emtricitabine; Female; Half-Life; HIV Infections; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Organophosphonates; Tandem Mass Spectrometry; Tenofovir; Young Adult | 2013 |
Tenofovir plasma concentrations in post-menopausal versus pre-menopausal HIV-infected women.
Topics: Adenine; Adult; Anti-HIV Agents; Attention; Female; HIV Infections; Humans; Middle Aged; Organophosphonates; Plasma; Postmenopause; Premenopause; Tenofovir | 2013 |
Inhibition of telomerase activity by human immunodeficiency virus (HIV) nucleos(t)ide reverse transcriptase inhibitors: a potential factor contributing to HIV-associated accelerated aging.
Topics: Adenine; Adult; Aging; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Case-Control Studies; Cells, Cultured; Deoxycytidine; Dideoxynucleosides; Emtricitabine; Enzyme Activation; Female; HIV; HIV Infections; Humans; Lamivudine; Leukocytes, Mononuclear; Male; Middle Aged; Organophosphonates; Polymerase Chain Reaction; Regression Analysis; Reverse Transcriptase Inhibitors; Risk Factors; Telomerase; Telomere; Telomere Shortening; Tenofovir; Time Factors; Young Adult; Zidovudine | 2013 |
Low prevalence of transmitted K65R and other tenofovir resistance mutations across different HIV-1 subtypes: implications for pre-exposure prophylaxis.
Topics: Adenine; Anti-HIV Agents; Drug Resistance, Viral; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Viral; Global Health; HIV Infections; HIV-1; Humans; Mutation; Organophosphonates; Population Surveillance; RNA-Directed DNA Polymerase; Tenofovir | 2012 |
Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus.
Topics: Adenine; Adult; Aged; Antiretroviral Therapy, Highly Active; Antiviral Agents; Australia; Coinfection; Deoxycytidine; DNA, Viral; Emtricitabine; Female; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Male; Medication Adherence; Middle Aged; Organophosphonates; Tenofovir; Thailand; Treatment Failure; United States | 2013 |
Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cost-Benefit Analysis; Cyclopropanes; Deoxycytidine; Drug Combinations; Drugs, Generic; Emtricitabine; Female; HIV Infections; Humans; Male; Models, Theoretical; Organophosphonates; Quality-Adjusted Life Years; Reverse Transcriptase Inhibitors; Tenofovir; United States | 2013 |
HIV transmission may be prevented by intravaginal tenofovir ring.
Topics: Adenine; Administration, Intravaginal; Anti-HIV Agents; Drug Delivery Systems; Female; HIV Infections; Humans; Organophosphonates; Tenofovir | 2012 |
Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Genotype; HIV Infections; HIV-1; Humans; Mutation; Nitriles; Organophosphonates; Prevalence; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; Tenofovir | 2013 |
ASN clinical pathological conference. Tenofovir-related ATN (severe).
Topics: Adenine; Anti-HIV Agents; Biopsy; Diagnosis, Differential; Glomerulonephritis, IGA; HIV Infections; Humans; Kidney Tubular Necrosis, Acute; Male; Middle Aged; Organophosphonates; Predictive Value of Tests; Risk Factors; Severity of Illness Index; Staphylococcal Infections; Tenofovir | 2013 |
A model of HIV drug resistance driven by heterogeneities in host immunity and adherence patterns.
Topics: Adenine; Anti-HIV Agents; Computer Simulation; Drug Resistance, Viral; HIV Infections; Humans; Medication Adherence; Models, Immunological; Organophosphonates; Tenofovir; Viral Load | 2013 |
Tenofovir plasma concentrations according to companion drugs: a cross-sectional study of HIV-positive patients with normal renal function.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Chromatography, Liquid; Cross-Sectional Studies; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Mass Spectrometry; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir | 2013 |
Promising new agents on the horizon.
Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Clinical Trials as Topic; HIV Infections; HIV Protease Inhibitors; Humans; Nitriles; Oligopeptides; Organophosphonates; Organophosphorus Compounds; Pyridazines; Pyridines; Pyrimidines; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load | 2002 |
Tenofovir DF expanded access. Criteria for U.S. program.
Topics: Adenine; Drug Approval; Europe; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir; United States; United States Food and Drug Administration | 2001 |
Antiretroviral news from ICAAC 2000.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Drug Administration Schedule; Drug Resistance; HIV Infections; Humans; Lopinavir; Organophosphonates; Organophosphorus Compounds; Pyrimidinones; Ritonavir; Tenofovir | 2000 |
Tenofovir gel studied.
Topics: Adenine; Anti-HIV Agents; Clinical Trials, Phase I as Topic; Female; Gels; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Tenofovir; United States | 2002 |
Highlights of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).
Topics: Adenine; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Administration Schedule; Drug Combinations; Drug Resistance, Microbial; Drug Therapy; Epoetin Alfa; Erythropoietin; Hepatitis C; HIV Infections; Humans; Lamivudine; Organophosphonates; Organophosphorus Compounds; Recombinant Proteins; Saquinavir; Tenofovir; Zidovudine | 2002 |
The prevalence and determinants of the K65R mutation in HIV-1 reverse transcriptase in tenofovir-naive patients.
Topics: Adenine; Anti-HIV Agents; Databases, Factual; Dideoxynucleosides; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Mutation; Organophosphonates; Organophosphorus Compounds; Prevalence; Reverse Transcriptase Inhibitors; Tenofovir | 2002 |
[First nucleotide analog against HIV. Lowers viral load also in drug resistance].
Topics: Adenine; Anti-HIV Agents; Clinical Trials, Phase II as Topic; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir | 2002 |
[Tenofovir in Study 903. Also effective and tolerable in first-line therapy].
Topics: Adenine; Anti-HIV Agents; Clinical Trials as Topic; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Stavudine; Tenofovir; Treatment Outcome; Viral Load | 2002 |
Marked elevation of the creatine phosphokinase level in a patient receiving tenofovir.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Creatine Kinase; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2002 |
Phenotypic and genotypic HIV-1 drug resistance assays provide complementary information.
Topics: Adenine; Anti-HIV Agents; Carbamates; Didanosine; Dideoxynucleosides; Drug Resistance, Viral; Furans; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Microbial Sensitivity Tests; Organophosphonates; Organophosphorus Compounds; Phenotype; Reverse Transcriptase Inhibitors; Sulfonamides; Tenofovir; Zalcitabine | 2002 |
Editorial comment: a tale of two viruses.
Topics: Adenine; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B; Hepatitis B Vaccines; HIV Infections; Humans; Lamivudine; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir | 2002 |
Would switching the protease inhibitors (PI) to tenoforvir be an option in controlling hypertriglyceridaemia secondary to PIs? A case report.
Topics: Adenine; HIV Infections; HIV Protease Inhibitors; Humans; Hypertriglyceridemia; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir | 2002 |
Tenofovir DF trial announced by Gilead.
Topics: Adenine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir | 2000 |
Prevention: new approach will test tenofovir for persons at high risk.
Topics: Adenine; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Risk Factors; Tenofovir | 2002 |
Rapid communication: acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity.
Topics: Acute Kidney Injury; Adenine; Adult; Anti-HIV Agents; Chronic Disease; HIV Infections; Humans; Kidney; Kidney Diseases; Male; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2002 |
Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus.
Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2003 |
Tenofovir (Viread(R)) access for poor countries.
Topics: Adenine; Developing Countries; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir | 2002 |
Tenofovir helps beat hepatitis B.
Topics: Adenine; Antiviral Agents; CD4 Lymphocyte Count; Hepatitis B; Hepatitis B virus; HIV; HIV Infections; Humans; Male; Organophosphonates; Organophosphorus Compounds; Tenofovir; Viral Load | 2003 |
Rapid hepatitis B virus-DNA decay in co-infected HIV-hepatitis B virus 'e-minus' patients with YMDD mutations after 4 weeks of tenofovir therapy.
Topics: Adenine; Adult; Anti-HIV Agents; DNA, Viral; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2003 |
New uses for tenofovir: more questions about d4T.
Topics: Adenine; Drug Therapy, Combination; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Stavudine; Tenofovir | 2003 |
Renal lesions in HIV-1-positive patient treated with tenofovir.
Topics: Acute Kidney Injury; Adenine; Anti-HIV Agents; Fanconi Syndrome; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2003 |
Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus.
Topics: Acidosis; Adenine; Adult; Anti-HIV Agents; Creatinine; Diabetes Insipidus, Nephrogenic; Drug Monitoring; Fanconi Syndrome; Glycosuria; HIV Infections; Humans; Middle Aged; Organophosphonates; Organophosphorus Compounds; Proteinuria; Renal Insufficiency; Tenofovir | 2003 |
[96-week treatment outcome confirms long term efficacy of tenofovir DF].
Topics: Adenine; Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; Humans; Multicenter Studies as Topic; Organophosphonates; Organophosphorus Compounds; Randomized Controlled Trials as Topic; Tenofovir; Time Factors; Treatment Outcome | 2003 |
Liquid chromatographic assay for the antiviral nucleotide analogue tenofovir in plasma using derivatization with chloroacetaldehyde.
Topics: Acetaldehyde; Adenine; Chromatography, Liquid; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Reproducibility of Results; Reverse Transcriptase Inhibitors; Sensitivity and Specificity; Spectrometry, Fluorescence; Tenofovir | 2003 |
Pancreatitis in an HIV-infected person on a tenofovir, didanosine and stavudine containing highly active antiretroviral treatment.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Didanosine; Drug Interactions; Female; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Pancreatitis; Ritonavir; Stavudine; Tenofovir | 2003 |
Antiviral Research--16th Annual International Conference. Satellite symposium: clinical update on antiviral drugs. 27 April-1 May 2003, Savannah, GA, USA.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Clinical Trials as Topic; Enfuvirtide; Ganciclovir; Hepatitis B; HIV Envelope Protein gp41; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Peptide Fragments; Tenofovir; Valganciclovir | 2003 |
Fatal lactic acidosis and mimicking Guillain-Barré syndrome in an adolescent with human immunodeficiency virus infection.
Topics: Acidosis, Lactic; Adenine; Adolescent; Antiretroviral Therapy, Highly Active; Carbamates; Diagnosis, Differential; Didanosine; Disease Progression; Drug Therapy, Combination; Fatal Outcome; Female; Furans; Guillain-Barre Syndrome; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Organophosphonates; Organophosphorus Compounds; Risk Assessment; Severity of Illness Index; Stavudine; Sulfonamides; Tenofovir | 2003 |
Tenofovir disoproxil fumarate.
Topics: Adenine; Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Kidney Diseases; Mutation; Organophosphonates; Organophosphorus Compounds; Tenofovir; Time Factors | 2003 |
Tenofovir disoproxil fumarate.
Topics: Adenine; Anti-HIV Agents; Drug Resistance, Viral; Drug Synergism; Gastrointestinal Diseases; HIV Infections; HIV-1; Humans; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2003 |
Preemptive use of antiretroviral drugs to prevent sexual transmission of HIV to high-risk uninfected MSM.
Topics: Adenine; Anti-HIV Agents; Centers for Disease Control and Prevention, U.S.; Clinical Trials as Topic; HIV Infections; Homosexuality, Male; Humans; Male; Organophosphonates; Organophosphorus Compounds; Politics; Research Support as Topic; Tenofovir; United States | 2003 |
Sensitive determination of tenofovir in human plasma samples using reversed-phase liquid chromatography.
Topics: Adenine; Chromatography, High Pressure Liquid; Drug Monitoring; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Reproducibility of Results; Reverse Transcriptase Inhibitors; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Tenofovir | 2003 |
Pancreatitis with didanosine and tenofovir disoproxil fumarate [corrected].
Topics: Adenine; Adult; Didanosine; Drug Interactions; Fatal Outcome; Female; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; Pancreatitis; Tenofovir | 2003 |
[HIV therapy: tenofir DF is available in 68 developing countries at production costs price].
Topics: Adenine; Administration, Oral; Anti-HIV Agents; Developing Countries; Drug Costs; Drug Industry; Health Services Accessibility; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2003 |
Role of baseline human immunodeficiency virus genotype as a predictor of viral response to tenofovir in heavily pretreated patients.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Female; HIV; HIV Infections; Humans; Male; Organophosphonates; Organophosphorus Compounds; RNA, Viral; Tenofovir | 2003 |
Summaries for patients. Treatment for resistant HIV-1 infection.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Male; Mutation; Organophosphonates; Organophosphorus Compounds; Placebos; RNA; Tenofovir; Viral Load | 2003 |
Tenofovir disoproxil fumarate.
Topics: Adenine; Anti-HIV Agents; Drug Interactions; Drug Resistance, Viral; Hepatitis B virus; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2003 |
Cambodia: can a drug provide some protection?
Topics: Adenine; Animals; Anti-HIV Agents; Cambodia; Controlled Clinical Trials as Topic; Female; Haplorhini; HIV Infections; Humans; International Cooperation; Male; Organophosphonates; Organophosphorus Compounds; Sex Work; Simian Acquired Immunodeficiency Syndrome; Tenofovir | 2003 |
[Further indications for tenofovir].
Topics: Adenine; Anti-HIV Agents; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Tenofovir; Viral Load | 2003 |
Management of chronic hepatitis B in an HIV-positive patient with 3TC-resistant hepatitis B virus.
Topics: Adenine; Adult; Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Interferon-alpha; Lamivudine; Liver Cirrhosis; Male; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2003 |
Warning issued on non-response rates.
Topics: Adenine; Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; HIV Infections; Humans; Lamivudine; Multicenter Studies as Topic; Organophosphonates; Organophosphorus Compounds; Randomized Controlled Trials as Topic; Tenofovir | 2003 |
Acute tubular necrosis in a patient receiving tenofovir.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Creatinine; HIV Infections; Humans; Kidney Tubular Necrosis, Acute; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2003 |
Triple combinations regimens for HIV.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Multicenter Studies as Topic; Organophosphonates; Organophosphorus Compounds; Oxazines; Randomized Controlled Trials as Topic; Tenofovir; Treatment Failure | 2003 |
Complex patterns of viral load decay under antiretroviral therapy: influence of pharmacokinetics and intracellular delay.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; HIV Infections; HIV-1; Humans; Models, Biological; Organophosphonates; Organophosphorus Compounds; Ritonavir; Tenofovir; Time Factors; Viral Load; Virus Replication | 2004 |
Meeting notes from the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Exploring once-daily tenofovir + 3TC + abacavir: an argument for clinical-trials-based data.
Topics: Adenine; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Organophosphonates; Organophosphorus Compounds; Pilot Projects; Reverse Transcriptase Inhibitors; Tenofovir | 2003 |
BMS issues PK notice regarding ATV + TDF.
Topics: Adenine; Anti-HIV Agents; Area Under Curve; Atazanavir Sulfate; Clinical Trials as Topic; Drug Industry; HIV Infections; Humans; Oligopeptides; Organophosphonates; Organophosphorus Compounds; Pyridines; Tenofovir; United States; United States Food and Drug Administration | 2003 |
Failure of combination abacavir + tenofovir + lamivudine (3TC).
Topics: Adenine; Dideoxynucleosides; HIV Infections; Humans; Lamivudine; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir | 2003 |
Meeting notes from the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Suboptimal response to once-daily abacavir + 3TC + tenofovir.
Topics: Adenine; Anti-HIV Agents; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Multicenter Studies as Topic; Organophosphonates; Organophosphorus Compounds; Randomized Controlled Trials as Topic; Tenofovir | 2003 |
Treatment of chronic hepatitis B in the human immunodeficiency virus-infected patient: present and future.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Forecasting; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Interferon-alpha; Lamivudine; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir | 2003 |
Tenofovir: a nucleotide analogue reverse-transcriptase inhibitor for treatment of HIV infection.
Topics: Adenine; Aged; Child; Clinical Trials as Topic; Counseling; Education, Continuing; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Safety; Tenofovir; Treatment Outcome; United States | 2004 |
Early nonresponse for tenofovir regimen.
Topics: Adenine; Anti-HIV Agents; Dideoxynucleosides; HIV Infections; Humans; Lamivudine; Organophosphonates; Organophosphorus Compounds; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure | 2003 |
Can AIDS drug also prevent HIV infection?
Topics: Adenine; Anti-HIV Agents; Clinical Trials as Topic; Female; HIV Infections; HIV-1; Homosexuality, Male; Humans; Male; Organophosphonates; Organophosphorus Compounds; Primary Prevention; Sex Work; Tenofovir; Virus Replication | 2004 |
Molecular mechanisms of tenofovir resistance conferred by human immunodeficiency virus type 1 reverse transcriptase containing a diserine insertion after residue 69 and multiple thymidine analog-associated mutations.
Topics: Adenine; Adenosine Triphosphate; Cells, Cultured; DNA Primers; DNA Transposable Elements; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Kinetics; Models, Molecular; Mutation; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; Serine; Tenofovir; Thymidine | 2004 |
Antiretroviral therapy and HIV/hepatitis B virus coinfection.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Antiviral Agents; Hepatitis B; Hepatitis B virus; HIV; HIV Infections; Humans; Lamivudine; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2004 |
High rate of virologic failure with once-daily ddI/3TC/TDF.
Topics: Adenine; Didanosine; HIV Infections; Humans; Lamivudine; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load | 2003 |
Hepatitis B infection in an HIV-positive man treated with tenofovir: a case of re-infection or reactivation?
Topics: Adenine; Adult; Hepatitis B Antibodies; Hepatitis B virus; HIV Infections; Humans; Male; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir; Virus Activation | 2004 |
French investigators warn of LPV/TDF/ddI interaction.
Topics: Adenine; CD4 Lymphocyte Count; Didanosine; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Organophosphonates; Organophosphorus Compounds; Pyrimidinones; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load | 2003 |
Which nucleoside and nucleotide backbone combinations select for the K65R mutation in HIV-1 reverse transcriptase.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Didanosine; Dideoxynucleosides; Drug Resistance, Multiple, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Nucleosides; Nucleotides; Organophosphonates; Organophosphorus Compounds; Prevalence; Tenofovir | 2004 |
Tenofovir-related nephrotoxicity in HIV-infected patients.
Topics: Acute Kidney Injury; Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Didanosine; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; Oxazines; Tenofovir | 2004 |
EU issues warning about HAART regimen.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Didanosine; Dideoxynucleosides; Drug Resistance, Viral; European Union; HIV Infections; Humans; Lamivudine; Organophosphonates; Organophosphorus Compounds; Patient Selection; Pilot Projects; Safety; Tenofovir; Treatment Failure; Viral Load | 2004 |
Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load.
Topics: Adenine; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Didanosine; Drug Interactions; Drug Therapy, Combination; Follow-Up Studies; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load | 2004 |
Didanosine-associated toxicity: a predictable complication of therapy with tenofovir and didanosine?
Topics: Adenine; Adult; Anti-HIV Agents; Creatinine; Didanosine; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; Humans; Kidney Diseases; Male; Middle Aged; Organophosphonates; Tenofovir | 2004 |
Improvement of dyslipidemia in patients switching from stavudine to tenofovir: preliminary results.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; Humans; Hyperlipidemias; Male; Organophosphonates; Organophosphorus Compounds; Prospective Studies; Reverse Transcriptase Inhibitors; Stavudine; Tenofovir | 2004 |
Atazanavir (Reyataz): new recommendations if combined with tenofovir (Viread) -- and warning on Viagra, Cialis, and Levitra.
Topics: Adenine; Atazanavir Sulfate; Carbolines; Drug Information Services; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; Imidazoles; Oligopeptides; Organophosphonates; Organophosphorus Compounds; Piperazines; Purines; Pyridines; Reverse Transcriptase Inhibitors; Sildenafil Citrate; Sulfones; Tadalafil; Tenofovir; Triazines; Vardenafil Dihydrochloride | 2004 |
Virologic outcome after switching from a nucleoside reverse transcriptase inhibitor to tenofovir in patients with undetectable HIV-1 RNA plasma level.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Organophosphonates; Retrospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Treatment Outcome; Viremia | 2004 |
Haemolytic anaemia after nucleotide antiretroviral treatment discontinuation in a chronic hepatitis B-virus co-infected AIDS patient.
Topics: Adenine; Adult; Anemia, Hemolytic; Antiretroviral Therapy, Highly Active; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Organophosphonates; Tenofovir | 2004 |
The K65R mutation in HIV-1 reverse transcriptase.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Organophosphonates; Point Mutation; Reverse Transcriptase Inhibitors; Tenofovir | 2004 |
In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
Topics: Adenine; Adult; Antiviral Agents; Cell Line; DNA-Directed DNA Polymerase; DNA, Viral; Dose-Response Relationship, Drug; Drug Resistance, Viral; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Middle Aged; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Transfection; Virus Replication | 2004 |
Phenotypic impact of HIV reverse transcriptase M184I/V mutations in combination with single thymidine analog mutations on nucleoside reverse transcriptase inhibitor resistance.
Topics: Adenine; Algorithms; Anti-HIV Agents; Databases, Genetic; Didanosine; Dideoxynucleosides; Drug Resistance, Multiple, Viral; HIV; HIV Infections; Humans; Mutation; Organophosphonates; Organophosphorus Compounds; Phenotype; Reverse Transcriptase Inhibitors; Stavudine; Tenofovir; Thymidine; Zalcitabine; Zidovudine | 2004 |
Proximal tubular kidney damage and tenofovir: a role for mitochondrial toxicity?
Topics: Adenine; Adult; Anti-HIV Agents; DNA, Mitochondrial; HIV Infections; HIV-1; Humans; Kidney Diseases; Kidney Tubules, Proximal; Male; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2004 |
Tubulopathy consecutive to tenofovir-containing antiretroviral therapy in two patients infected with human immunodeficiency virus-1.
Topics: Adenine; Anti-HIV Agents; Drug Therapy, Combination; Fanconi Syndrome; HIV Infections; HIV-1; Humans; Hypophosphatemia; Kidney Tubules; Organophosphonates; Organophosphorus Compounds; Polyuria; Reverse Transcriptase Inhibitors; Tenofovir | 2004 |
Lichenoid drug eruption to tenofovir in an HIV/hepatitis B virus co-infected patient.
Topics: Adenine; Anti-HIV Agents; Drug Eruptions; Hepatitis B, Chronic; HIV Infections; Humans; Lichenoid Eruptions; Male; Middle Aged; Organophosphonates; Tenofovir | 2004 |
Nephrolithiasis and hydronephrosis in an HIV-infected man receiving tenofovir.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; HIV Infections; Humans; Hydronephrosis; Kidney Calculi; Male; Organophosphonates; Tenofovir | 2004 |
AIDS research. Cambodian leader throws novel prevention trial into limbo.
Topics: Adenine; Anti-HIV Agents; Cambodia; Controlled Clinical Trials as Topic; Female; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Sex Work; Tenofovir | 2004 |
Fatal lactic acidosis associated with coadministration of didanosine and tenofovir disoproxil fumarate.
Topics: Acidosis, Lactic; Adenine; Anti-HIV Agents; Area Under Curve; Comorbidity; Didanosine; Drug Interactions; Fatal Outcome; Female; HIV Infections; Humans; Lactates; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2004 |
Acute onset of pancreatitis with concomitant use of tenofovir and didanosine.
Topics: Acute Disease; Adenine; Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Pancreatitis; Tenofovir | 2004 |
Correlation between rules-based interpretation and virtual phenotype interpretation of HIV-1 genotypes for predicting drug resistance in HIV-infected individuals.
Topics: Adenine; Amino Acid Substitution; Anti-HIV Agents; Didanosine; Dideoxynucleosides; Drug Resistance, Viral; Genotype; HIV Infections; HIV-1; Humans; Microbial Sensitivity Tests; Mutation; Nucleosides; Organophosphonates; Phenotype; Protease Inhibitors; Reverse Transcriptase Inhibitors; Tenofovir | 2004 |
Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Blood-Testis Barrier; Cyclopropanes; Enfuvirtide; Genitalia, Male; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Oxazines; Peptide Fragments; Tenofovir | 2004 |
[3 years' data of tenofovir. Confirmed as a valuable building block].
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; HIV Reverse Transcriptase; Humans; Lamivudine; Organophosphonates; Oxazines; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir | 2004 |
[5 years' data are convincing. Lopinavir as primary therapy is effective and safe in the long term].
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Clinical Trials as Topic; Cyclopropanes; Drug Synergism; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Long-Term Care; Lopinavir; Organophosphonates; Oxazines; Pyrimidinones; Ritonavir; Tenofovir; Viral Load | 2004 |
Prevention trials starting.
Topics: Adenine; Adult; Africa; Clinical Trials as Topic; Female; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir; United States | 2004 |
Cambodia stops important tenofovir prevention trial.
Topics: Adenine; Cambodia; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir | 2004 |
Trial of antiretroviral for HIV prevention on hold.
Topics: Adenine; Anti-HIV Agents; Cambodia; Controlled Clinical Trials as Topic; Double-Blind Method; Ethics Committees, Research; Ethics, Research; Female; HIV Infections; Humans; Insurance, Health; International Cooperation; National Institutes of Health (U.S.); Organophosphonates; Organophosphorus Compounds; Research Design; Sex Work; Tenofovir; United States; Women, Working | 2004 |
Intracellular pharmacology of emtricitabine and tenofovir.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Half-Life; HIV Infections; Humans; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2004 |
Tenofovir, equivalence, and noninferiority.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Tenofovir; Viral Load | 2004 |
Increasing prevalence of HIV-1 reverse transcriptase mutation K65R correlates with tenofovir utilization.
Topics: Adenine; Anti-HIV Agents; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Organophosphonates; Prevalence; Reverse Transcriptase Inhibitors; Tenofovir | 2004 |
Tenofovir use in a patient with a severe renal impairment.
Topics: Adenine; Adult; Diabetic Nephropathies; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2004 |
Successful therapy of hepatitis B with tenofovir in HIV-infected patients failing previous adefovir and lamivudine treatment.
Topics: Adenine; Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Chronic Disease; DNA-Directed DNA Polymerase; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Male; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Viral Load | 2004 |
Predictors of selection of K65R: tenofovir use and lack of thymidine analogue mutations.
Topics: Adenine; Anti-HIV Agents; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Thymidine | 2004 |
Impact of a treatment including tenofovir plus didanosine on the selection of the 65R mutation in highly drug-experienced HIV-infected patients.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Databases, Genetic; Didanosine; DNA, Viral; Drug Resistance, Multiple, Viral; Gene Deletion; Genotype; HIV Infections; HIV-1; Humans; Mutation; Organophosphonates; Tenofovir | 2004 |
Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: a cohort and case-control study.
Topics: Adenine; Albuminuria; Antiretroviral Therapy, Highly Active; Case-Control Studies; Cohort Studies; Creatinine; Follow-Up Studies; HIV Infections; Humans; Organophosphonates; Proteinuria; Renal Insufficiency; Tenofovir | 2004 |
Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects.
Topics: Adenine; Adult; Anti-HIV Agents; Area Under Curve; Drug Combinations; Drug Interactions; Gels; Half-Life; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Middle Aged; Organophosphonates; Ritonavir; Saquinavir; Tenofovir | 2005 |
Prevalence and conditions of selection of the K65R mutation in the reverse transcriptase gene of HIV-1.
Topics: Adenine; Amino Acid Substitution; Anti-HIV Agents; Drug Resistance, Viral; Gene Frequency; Genes, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Organophosphonates; Point Mutation; Reverse Transcriptase Inhibitors; Selection, Genetic; Tenofovir | 2005 |
Warning on two specific 3-drug regimens: Viread + Didanosine + either Sustiva or Viramune.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Nevirapine; Organophosphonates; Oxazines; Tenofovir; United States; United States Food and Drug Administration | 2004 |
CD4 cell decline with didanosine and tenofovir and failure of triple nucleoside/nucleotide regimens may be related.
Topics: Adenine; Anti-HIV Agents; CD4-Positive T-Lymphocytes; Didanosine; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; Lymphopenia; Organophosphonates; Purine-Nucleoside Phosphorylase; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure | 2004 |
Antiretroviral therapy with tenofovir is associated with mild renal dysfunction.
Topics: Adenine; Anti-HIV Agents; Creatinine; Cross-Sectional Studies; Cystatin C; Cystatins; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Diseases; Organophosphonates; Proteinuria; Tenofovir | 2005 |
Low rate of treatment failure on antiretroviral therapy with tenofovir, lamivudine and zidovudine.
Topics: Adenine; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Organophosphonates; Retrospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Treatment Failure; Zidovudine | 2005 |
The experts speak. Studying the potential of tenofovir to prevent sexual transmission of HIV: first steps. Interview by Vicki Glaser.
Topics: Adenine; Communicable Disease Control; Female; HIV Infections; Humans; Male; Organophosphonates; Primary Prevention; Risk Assessment; Sensitivity and Specificity; Sexually Transmitted Diseases; Tenofovir; Treatment Outcome | 2005 |
Early virological failure in treatment-naive HIV-infected adults receiving didanosine and tenofovir plus efavirenz or nevirapine.
Topics: Adenine; Adult; Aged; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Didanosine; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nevirapine; Organophosphonates; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir | 2005 |
Tenofovir-induced acute renal failure in an HIV patient with normal renal function.
Topics: Acute Kidney Injury; Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; HIV Infections; Humans; Male; Organophosphonates; Renal Dialysis; Tenofovir | 2005 |
Tenofovir: a pill to prevent HIV?
Topics: Adenine; Anti-HIV Agents; Drugs, Investigational; HIV Infections; Humans; Organophosphonates; Tenofovir | 2005 |
Meeting notes from ICAAC. Tenofovir + ddI: a combination to avoid.
Topics: Adenine; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load | 2005 |
Meeting notes from ICAAC. Tenofovir + emtricitabine vs. AZT + 3TC.
Topics: Adenine; CD4 Lymphocyte Count; Deoxycytidine; Emtricitabine; HIV Infections; Humans; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load; Zidovudine | 2005 |
Selection of a rare resistance profile in an HIV-1-infected patient exhibiting a failure to an antiretroviral regimen including tenofovir DF.
Topics: Adenine; Adult; Anti-HIV Agents; Didanosine; Dideoxynucleosides; Drug Resistance, Viral; Female; Gabon; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Lopinavir; Microbial Sensitivity Tests; Mutation; Organophosphonates; Pyrimidinones; Tenofovir; Viral Load | 2005 |
Serum hypophosphatemia in tenofovir disoproxil fumarate recipients is multifactorial in origin, questioning the utility of its monitoring in clinical practice.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Blood Chemical Analysis; Creatinine; Fanconi Syndrome; Female; HIV Infections; Humans; Hypophosphatemia; Lopinavir; Male; Organophosphonates; Phosphates; Prospective Studies; Pyrimidinones; Reproducibility of Results; Tenofovir; Urea | 2005 |
Predictors of residual viremia in HIV-infected patients successfully treated with efavirenz and lamivudine plus either tenofovir or stavudine.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; DNA, Viral; Female; HIV; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Multivariate Analysis; Organophosphonates; Oxazines; RNA, Viral; Stavudine; Tenofovir; Viremia | 2005 |
Women testing tenofovir for HIV prevention.
Topics: Adenine; Anti-HIV Agents; Clinical Trials as Topic; Female; HIV Infections; Humans; Nigeria; Organophosphonates; Sex Work; Tenofovir | 2005 |
AIDS clinical trials. More woes for novel HIV prevention approach.
Topics: Adenine; Anti-HIV Agents; Centers for Disease Control and Prevention, U.S.; Clinical Trials as Topic; HIV Infections; Humans; Nigeria; Organophosphonates; Patient Selection; Sex Work; Substance Abuse, Intravenous; Tenofovir; Thailand; United States | 2005 |
Early virologic failure in a pilot study evaluating the efficacy of therapy containing once-daily abacavir, lamivudine, and tenofovir DF in treatment-naive HIV-infected patients.
Topics: Adenine; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Organophosphonates; Pilot Projects; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure; Viral Load | 2005 |
Switching from protease inhibitors to a single-class regimen of abacavir/lamivudine/zidovudine plus tenofovir in patients with HIV load suppression.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load; Zidovudine | 2005 |
The durability of virological success of tenofovir and didanosine dosed at either 400 or 250 mg once daily.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Didanosine; Drug Administration Schedule; HIV Infections; HIV-1; Humans; Organophosphonates; Retrospective Studies; Survival Rate; Tenofovir; Treatment Failure; Viral Load | 2005 |
The use of a triple nucleoside-nucleotide regimen for nonoccupational HIV post-exposure prophylaxis.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Chi-Square Distribution; HIV Infections; Humans; Lamivudine; Male; Nelfinavir; Organophosphonates; Reverse Transcriptase Inhibitors; Risk Assessment; Risk-Taking; Stavudine; Tenofovir; Zidovudine | 2005 |
Resistance mutations before and after tenofovir regimen failure in HIV-1 infected patients.
Topics: Adenine; Amino Acid Substitution; Anti-HIV Agents; Drug Resistance, Viral; France; HIV Infections; HIV-1; Humans; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure | 2005 |
Fatal lactic acidosis associated with tenofovir and abacavir.
Topics: Acidosis, Lactic; Adenine; Anti-HIV Agents; Dideoxynucleosides; Fatal Outcome; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Tenofovir | 2005 |
[Acute renal failure, Fanconi syndrome and insipidus diabetes in a HIV-infected patient treated with Tenofovir].
Topics: Acute Kidney Injury; Adenine; Adult; Diabetes Insipidus; Fanconi Syndrome; HIV Infections; Humans; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2005 |
Tenofovir helpful for patients with HBV.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Hepatitis B; HIV Infections; Humans; Organophosphonates; Randomized Controlled Trials as Topic; Tenofovir | 2005 |
Risk factors for CD4 lymphopenia in patients treated with a tenofovir/didanosine high dose-containing highly active antiretroviral therapy regimen.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Didanosine; Female; HIV Infections; Humans; Lymphopenia; Male; Organophosphonates; Risk Factors; Tenofovir | 2005 |
Severe efavirenz-induced hypersensitivity syndrome (not-DRESS) with acute renal failure.
Topics: Acute Kidney Injury; Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Hypersensitivity; Ghana; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Mycobacterium tuberculosis; Organophosphonates; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Tuberculosis | 2006 |
We must not let protestors derail trials of pre-exposure prophylaxis for HIV.
Topics: Adenine; Health Knowledge, Attitudes, Practice; HIV Infections; Humans; Organophosphonates; Public Opinion; Public Policy; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir | 2005 |
The abandoned trials of pre-exposure prophylaxis for HIV: what went wrong?
Topics: Adenine; Global Health; Health Knowledge, Attitudes, Practice; HIV Infections; Humans; Organophosphonates; Patient Advocacy; Public Opinion; Randomized Controlled Trials as Topic; Research Design; Reverse Transcriptase Inhibitors; Tenofovir | 2005 |
Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Cytidine Triphosphate; Dideoxynucleosides; Dideoxynucleotides; Drug Interactions; Female; HIV Infections; Humans; Lamivudine; Leukocytes, Mononuclear; Male; Middle Aged; Organophosphonates; Prospective Studies; Tenofovir | 2005 |
Incidence of and risk factors for tenofovir-induced nephrotoxicity: a retrospective cohort study.
Topics: Adenine; Adult; Anti-HIV Agents; Creatinine; Female; HIV Infections; Humans; Hypophosphatemia; Kidney; Kidney Diseases; Male; Metabolic Clearance Rate; Middle Aged; Organophosphonates; Proteinuria; Retrospective Studies; Risk Factors; Tenofovir; Urinalysis | 2005 |
Tenofovir and changes in renal function.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; HIV Infections; Humans; Kidney Diseases; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2005 |
Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy.
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Area Under Curve; Bayes Theorem; Female; HIV Infections; HIV-1; Humans; Kidney Function Tests; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2005 |
Progression of renal impairment under therapy with tenofovir.
Topics: Adenine; Anti-HIV Agents; Case-Control Studies; Disease Progression; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Diseases; Organophosphonates; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir | 2005 |
Low frequency of renal function impairment during one-year of therapy with tenofovir-containing regimens in the real-world: a case-control study.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Case-Control Studies; Creatinine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; HIV Infections; Humans; Incidence; Kidney; Kidney Diseases; Kidney Function Tests; Male; Organophosphonates; Probability; Prognosis; Reference Values; Retrospective Studies; Reverse Transcriptase Inhibitors; Risk Assessment; Severity of Illness Index; Tenofovir | 2005 |
HIV/AIDS. Prevention cocktails: combining tools to Stop HIV's spread.
Topics: Acyclovir; Adenine; Anti-HIV Agents; Antidepressive Agents, Second-Generation; Antiviral Agents; Bupropion; Circumcision, Male; Clinical Trials as Topic; Contraceptive Devices, Female; Female; Herpes Genitalis; Herpesvirus 2, Human; HIV; HIV Infections; Humans; Hygiene; Male; Organophosphonates; Sexual Behavior; Tenofovir; Viral Load | 2005 |
Protests may slow down trials.
Topics: Adenine; Bisexuality; Clinical Trials as Topic; Europe; HIV Infections; Homosexuality, Male; Humans; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Thailand; Time Factors; United States | 2005 |
Tenofovir-induced renal tubular dysfunction presenting with hypocalcaemia.
Topics: Adenine; Anti-HIV Agents; Bone Density Conservation Agents; Fanconi Syndrome; HIV Infections; Humans; Hydroxycholecalciferols; Hypocalcemia; Male; Middle Aged; Organophosphonates; Phosphates; Tenofovir; Treatment Outcome | 2006 |
The development of hypophosphataemic osteomalacia with myopathy in two patients with HIV infection receiving tenofovir therapy.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Fanconi Syndrome; Female; HIV Infections; Humans; Hypophosphatemia; Male; Middle Aged; Muscular Diseases; Organophosphonates; Osteomalacia; Reverse Transcriptase Inhibitors; Tenofovir | 2005 |
High rate of virological failure in maintenance antiretroviral therapy with didanosine and tenofovir.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Didanosine; Drug Resistance, Multiple, Viral; HIV Infections; HIV-1; Humans; Mutation; Organophosphonates; Tenofovir; Treatment Failure | 2005 |
Protease inhibitors and non-nucleoside reverse transcriptase inhibitors have a comparable effect on the CD4 cell change after switching to tenofovir-based regimens.
Topics: Adenine; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2005 |
Absence of new thymidine-associated mutations and evidence of an immune virologic response over a 12-month period in a cohort of antiretroviral-experienced HIV-1-infected subjects treated with tenofovir combination therapy.
Topics: Adenine; Cohort Studies; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Thymidine; Viral Load | 2005 |
AIDS. Promote HIV chemoprophylaxis research, don't prevent it.
Topics: Adenine; Africa; Anti-HIV Agents; Asia; Community Participation; Controlled Clinical Trials as Topic; Counseling; Developing Countries; Drug Costs; Female; Health Services Accessibility; HIV Infections; Humans; Latin America; Male; Organophosphonates; Patient Selection; Tenofovir | 2005 |
The tenofovir pre-exposure prophylaxis trial in Thailand: researchers should show more openness in their engagement with the community.
Topics: Adenine; Anti-HIV Agents; Clinical Trials as Topic; Community Networks; HIV Infections; Human Rights; Humans; Needle-Exchange Programs; Organophosphonates; Patient Advocacy; Research Design; Substance-Related Disorders; Tenofovir; Thailand | 2005 |
Response to Joep M. A. Lange.
Topics: Adenine; Cambodia; Clinical Trials as Topic; Health Services Accessibility; HIV Infections; Humans; Organophosphonates; Patient Advocacy; Research Design; Sex Work; Tenofovir | 2005 |
HIV Pathogenesis and Treatment - Third International AIDS Society Conference.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Chemistry, Pharmaceutical; Clinical Trials as Topic; Congresses as Topic; Darunavir; Drugs, Investigational; Enfuvirtide; HIV Envelope Protein gp41; HIV Infections; HIV-1; Humans; Nitriles; Organophosphonates; Peptide Fragments; Pyrimidines; Receptors, CCR5; Reverse Transcriptase Inhibitors; Rilpivirine; Societies, Scientific; Sulfonamides; Tenofovir; Zalcitabine | 2005 |
Dose-dependent influence of didanosine on immune recovery in HIV-infected patients treated with tenofovir.
Topics: Adenine; Adult; CD4 Lymphocyte Count; Didanosine; Dose-Response Relationship, Immunologic; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Retrospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Treatment Outcome | 2005 |
Renal tubular toxicity associated with tenofovir assessed using urine-beta 2 microglobulin, percentage of tubular reabsorption of phosphate and alkaline phosphatase levels.
Topics: Absorption; Adenine; Adult; Alkaline Phosphatase; Antiretroviral Therapy, Highly Active; beta 2-Microglobulin; Creatinine; HIV Infections; HIV-1; Humans; Kidney Tubules; Middle Aged; Organophosphonates; Phosphates; Phosphorus; Reverse Transcriptase Inhibitors; Tenofovir; Uric Acid | 2005 |
Less than the sum of its parts: failure of a tenofovir-abacavir-Lamivudine triple-nucleoside regimen.
Topics: Adenine; Anti-HIV Agents; Dideoxynucleosides; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Organophosphonates; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure | 2005 |
Sensitive assay for determining plasma tenofovir concentrations by LC/MS/MS.
Topics: Adenine; Calibration; Chromatography, High Pressure Liquid; HIV Infections; Humans; Mass Spectrometry; Organophosphonates; Reference Standards; Reverse Transcriptase Inhibitors; Sensitivity and Specificity; Tenofovir | 2006 |
Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; DNA, Viral; Drug Resistance, Viral; Evolution, Molecular; Female; Genes, pol; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Tenofovir; Viral Load; Viremia; Virus Replication | 2005 |
Stakeholder consultation to address issues related to tenofovir prophylactic research.
Topics: Adenine; Anti-HIV Agents; HIV Infections; Humans; Organophosphonates; Referral and Consultation; Research; Tenofovir | 2005 |
A 12-month treatment with tenofovir does not impair bone mineral accrual in HIV-infected children.
Topics: Absorptiometry, Photon; Adenine; Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone Density; Child; HIV Infections; Humans; Organophosphonates; Stavudine; Tenofovir | 2005 |
Improved lipid profiles and maintenance of virologic control in heavily pretreated HIV-infected patients who switched from stavudine to tenofovir treatment.
Topics: Adenine; Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Lipid Metabolism; Male; Middle Aged; Organophosphonates; Retrospective Studies; Stavudine; Tenofovir | 2006 |
Assessment of drug-drug interactions between tenofovir disoproxil fumarate and the nonnucleoside reverse transcriptase inhibitors nevirapine and efavirenz in HIV-infected patients.
Topics: Adenine; Administration, Oral; Alkynes; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Nevirapine; Organophosphonates; Oxazines; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir | 2006 |
Tenofovir trials raise ethical issues.
Topics: Adenine; Clinical Trials as Topic; Ethics, Medical; HIV Infections; Humans; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2005 |
[Simply convincing. New fixed combination for HIV therapy].
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Clinical Trials as Topic; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Patient Compliance; Practice Guidelines as Topic; Survival Rate; Tenofovir | 2005 |
Should tenofovir ever be used in association with didanosine?
Topics: Adenine; Anti-HIV Agents; Contraindications; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure; Viral Load | 2005 |
Wild type and YMDD variant of hepatitis B virus: no difference in viral kinetics on lamivudine/tenofovir therapy in HIV-HBV co-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; DNA, Viral; Drug Resistance, Viral; Genetic Variation; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Kinetics; Lamivudine; Male; Middle Aged; Organophosphonates; RNA, Viral; Tenofovir | 2006 |
Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy.
Topics: Acid-Base Equilibrium; Acute Kidney Injury; Adenine; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Creatinine; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Kidney; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2006 |
Case study: an active, 24-year-old woman positive for HIV.
Topics: Adenine; Adult; Anti-Retroviral Agents; Deoxycytidine; Disease Progression; Emtricitabine; Female; HIV Infections; Humans; Organophosphonates; Ritonavir; Tenofovir | 2006 |
Longitudinal study on mitochondrial effects of didanosine-tenofovir combination.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Didanosine; DNA, Mitochondrial; Drug Therapy, Combination; Electron Transport Complex IV; HIV Infections; HIV-1; Humans; Longitudinal Studies; Organophosphonates; Oxidative Phosphorylation; Prospective Studies; Retrospective Studies; Tenofovir | 2006 |
Retrovirus meeting. Novel attacks on HIV move closer to reality.
Topics: Adenine; Animals; Anti-HIV Agents; Evolution, Molecular; HIV Infections; HIV-1; Humans; Organic Chemicals; Organophosphonates; Primates; Pyrrolidinones; Raltegravir Potassium; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Tenofovir | 2006 |
Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients.
Topics: Adenine; Adult; Antiviral Agents; Cohort Studies; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Tenofovir; Treatment Outcome | 2006 |
Serum creatinine changes in HIV-seropositive patients receiving tenofovir.
Topics: Acute Kidney Injury; Adenine; Creatinine; Cross-Sectional Studies; HIV Infections; Humans; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2006 |
Exploring mitochondrial nephrotoxicity as a potential mechanism of kidney dysfunction among HIV-infected patients on highly active antiretroviral therapy.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biopsy; Didanosine; DNA, Mitochondrial; Drug Therapy, Combination; Female; HIV Infections; Humans; Kidney; Male; Microscopy, Electron; Middle Aged; Mitochondria; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2006 |
Registration problems for antiretrovirals in Africa.
Topics: Adenine; Africa; Anti-Retroviral Agents; Developing Countries; Drug and Narcotic Control; HIV Infections; Humans; Organophosphonates; Tenofovir | 2006 |
Suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Didanosine; Drug Interactions; HIV Infections; Humans; Mitochondria; Organophosphonates; Purine-Nucleoside Phosphorylase; Tenofovir | 2006 |
Clinical and genotypic correlates of mutation K65R in HIV-infected patients failing regimens not including tenofovir.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort Studies; Drug Resistance, Viral; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Male; Middle Aged; Multivariate Analysis; Mutation; Organophosphonates; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure | 2006 |
Virological response to HIV-1 nucleoside/nucleotide reverse transcriptase inhibitors-based, tenofovir DF-including regimens in the ANRS Aquitaine Cohort.
Topics: Adenine; Cohort Studies; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; France; HIV Infections; HIV Reverse Transcriptase; HIV-1; Hospitals, University; Humans; Lamivudine; Mutation; Organophosphonates; Retrospective Studies; Reverse Transcriptase Inhibitors; Species Specificity; Tenofovir; Treatment Outcome; Viral Load; Zidovudine | 2006 |
Improvement of dyslipidemia during different HAART regimens: tenofovir- versus stavudine-containing antiretroviral combinations.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dyslipidemias; HIV Infections; Humans; Organophosphonates; Stavudine; Tenofovir | 2006 |
Tenofovir for chronic hepatitis B virus infection in HIV-coinfected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Clinical Trials as Topic; Hepatitis B e Antigens; Hepatitis B, Chronic; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Tenofovir | 2006 |
Short-term safety and tolerability of didanosine combined with high- versus low-dose tenofovir disproxil fumarate in ambulatory HIV-1-infected persons.
Topics: Adenine; Adult; Anti-HIV Agents; Didanosine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Organophosphonates; Retrospective Studies; Tenofovir | 2006 |
Higher risk of hyperglycemia in HIV-infected patients treated with didanosine plus tenofovir.
Topics: Adenine; Adult; Anti-HIV Agents; Blood Glucose; Didanosine; Drug Therapy, Combination; Fasting; Female; Follow-Up Studies; HIV Infections; Humans; Hyperglycemia; Linear Models; Male; Organophosphonates; Retrospective Studies; Risk Factors; RNA, Viral; Tenofovir; Time Factors; Treatment Outcome; Virus Replication | 2006 |
Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patients.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biological Evolution; Drug Administration Schedule; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; Genotype; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Retrospective Studies; RNA, Viral; Stavudine; Tenofovir; Treatment Failure; Viral Load | 2006 |
Tenofovir-associated kidney diseases and interactions between tenofovir and other antiretrovirals.
Topics: Acute Kidney Injury; Adenine; Adult; Anti-HIV Agents; Drug Interactions; Female; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Tenofovir | 2006 |
The role of drug interactions and monitoring in the prevention of tenofovir-associated kidney disease.
Topics: Acute Kidney Injury; Adenine; Anti-HIV Agents; Drug Interactions; HIV Infections; Humans; Organophosphonates; Tenofovir | 2006 |
Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Prospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load; Viremia; Zidovudine | 2006 |
Investigating new antiretroviral combinations.
Topics: Adenine; Anti-HIV Agents; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Organophosphonates; Pilot Projects; Randomized Controlled Trials as Topic; Tenofovir | 2006 |
Comment on: suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir.
Topics: Adenine; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; HIV Infections; Humans; Organophosphonates; Purine-Nucleoside Phosphorylase; Tenofovir | 2006 |
Report from the 13th retrovirus conference. Renal tenofovir debate continues.
Topics: Adenine; Glomerular Filtration Rate; HIV Infections; Humans; Kidney; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2006 |
Truvada trials hold promise for new HIV prevention strategy. Once-a-day might keep HIV away.
Topics: Adenine; Centers for Disease Control and Prevention, U.S.; Clinical Trials as Topic; Female; HIV Infections; HIV Seronegativity; Humans; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; United States | 2006 |
FDA makes final approvals.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Approval; Drug Combinations; Emtricitabine; HIV Infections; Humans; Organophosphonates; Tenofovir; United States; United States Food and Drug Administration | 2006 |
Tenofovir DF and emtricitabine vs. zidovudine and lamivudine.
Topics: Adenine; Anti-Retroviral Agents; Bias; Data Interpretation, Statistical; Deoxycytidine; Emtricitabine; HIV Infections; Humans; Lamivudine; Organophosphonates; Research Design; Tenofovir; Zidovudine | 2006 |
Renal safety of tenofovir disoproxil fumarate in HIV-1 treatment-experienced patients with adverse events related to prior NRTI use: data from a prospective, observational, multicenter study.
Topics: Adenine; Adult; HIV Infections; HIV-1; Humans; Kidney; Middle Aged; Organophosphonates; Prospective Studies; Reverse Transcriptase Inhibitors; Tenofovir | 2006 |
Virologic and immunologic efficacy of the tenofovir/didanosine/lamivudine regimen.
Topics: Adenine; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2006 |
Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients.
Topics: Adenine; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Drug Interactions; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Male; Nevirapine; Oligopeptides; Organophosphonates; Oxazines; Pyridines; Retrospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir | 2006 |
Tenofovir DF and emtricitabine vs. zidovudine and lamivudine.
Topics: Adenine; Bone Density; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; HIV; HIV Infections; Humans; Lamivudine; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Zidovudine | 2006 |
Nephrotoxicity in a child with perinatal HIV on tenofovir, didanosine and lopinavir/ritonavir.
Topics: Adenine; Anti-HIV Agents; Child; Diabetes Insipidus, Nephrogenic; Didanosine; Drug Therapy, Combination; Fanconi Syndrome; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Kidney; Kidney Diseases; Lopinavir; Organophosphonates; Pregnancy; Pregnancy Complications; Pyrimidinones; Ritonavir; Tenofovir | 2006 |
Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Dyslipidemias; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Prospective Studies; Risk Factors; Stavudine; Tenofovir | 2006 |
FDA notifications. Two tenofovir containing products are approved.
Topics: Adenine; Drug Approval; Drug Therapy, Combination; HIV Infections; Humans; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; United States; United States Food and Drug Administration | 2006 |
Moving toward assured access to treatment in microbicide trials. Global Campaign for Microbicides.
Topics: Adenine; Anti-HIV Agents; Cambodia; Cameroon; Clinical Trials as Topic; Consensus Development Conferences as Topic; Global Health; Health Policy; Health Services Accessibility; HIV Infections; HIV Seropositivity; Humans; International Agencies; Nigeria; Organophosphonates; Patient Rights; Political Systems; Politics; Randomized Controlled Trials as Topic; Refusal to Treat; Risk-Taking; Social Justice; Tenofovir; United Nations | 2006 |
Impact of modelling intra-subject variability on tests based on non-linear mixed-effects models in cross-over pharmacokinetic trials with application to the interaction of tenofovir on atazanavir in HIV patients.
Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; Bias; Cross-Over Studies; Drug Interactions; France; HIV Infections; Humans; Likelihood Functions; Nonlinear Dynamics; Oligopeptides; Organophosphonates; Pyridines; Tenofovir | 2007 |
AIDS drug trial turned away; protests by prostitutes in Cambodia ended Tenofovir testing.
Topics: Adenine; Anti-HIV Agents; Cambodia; Clinical Trials as Topic; Developing Countries; Female; HIV Infections; Humans; Internationality; Organophosphonates; Refusal to Participate; Reverse Transcriptase Inhibitors; Sex Work; Tenofovir; Women | 2006 |
Hypokalemia in HIV patients on tenofovir.
Topics: Adenine; Adolescent; Adult; Body Weight; Child; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Hypokalemia; Kidney Diseases; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Risk Factors; Ritonavir; Tenofovir; Time Factors | 2006 |
Rapid improvement of liver function in a patient with HIV and hepatitis B coinfection treated with lamivudine and tenofovir.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; Hepatitis; HIV Infections; Humans; Lamivudine; Liver Function Tests; Organophosphonates; Tenofovir; Zidovudine | 2006 |
Efavirenz/emtricitabine/tenofovir disoproxil fumarate: triple combination tablet.
Topics: Adenine; Alkynes; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Deoxycytidine; Drug Combinations; Emtricitabine; HIV Infections; Humans; Organophosphonates; Oxazines; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2006 |
Urinary beta2-microglobulin as a possible sensitive marker for renal injury caused by tenofovir disoproxil fumarate.
Topics: Adenine; Adult; Anti-HIV Agents; beta 2-Microglobulin; Biomarkers; Creatinine; Female; HIV Infections; HIV-1; Humans; Kidney Tubules; Lopinavir; Male; Middle Aged; Organophosphonates; Pyrimidinones; Tenofovir; Thinness | 2006 |
Evaluation of hypophosphataemia in tenofovir disoproxil fumarate (TDF)-exposed and TDF-unexposed HIV-infected out-patients receiving highly active antiretroviral therapy.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Female; HIV Infections; Humans; Hypophosphatemia; Incidence; Male; Organophosphonates; Prospective Studies; Reverse Transcriptase Inhibitors; Risk Factors; Tenofovir; Treatment Outcome; United States | 2006 |
Estimating renal function in patients on tenofovir disoproxil fumarate: suggestions for safer use.
Topics: Adenine; Creatinine; Dose-Response Relationship, Drug; Fanconi Syndrome; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Diseases; Organophosphonates; Osteomalacia; Reverse Transcriptase Inhibitors; Tenofovir | 2006 |
Acute renal failure in HIV patients with liver cirrhosis receiving tenofovir: a report of two cases.
Topics: Acute Kidney Injury; Adenine; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; HIV Infections; Humans; Liver Cirrhosis; Male; Organophosphonates; Tenofovir | 2006 |
Change to a once-daily combination including boosted atazanavir in HIV-1-infected children.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Atazanavir Sulfate; Child; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Oligopeptides; Organophosphonates; Prospective Studies; Pyridines; Ritonavir; Tenofovir; Virus Replication | 2006 |
Hepatitis delta virus super-infection in a co-infected patient with the human immunodeficiency virus type 1 and a surface antigen-negative hepatitis B virus variant.
Topics: Adenine; Alanine Transaminase; Amino Acid Sequence; Anti-HIV Agents; Follow-Up Studies; Hepatitis B; Hepatitis B virus; Hepatitis D; HIV Infections; HIV-1; Homosexuality, Male; Humans; Male; Middle Aged; Molecular Sequence Data; Organophosphonates; RNA, Viral; Superinfection; Tenofovir; Time Factors; Viral Load | 2006 |
Chemoprophylaxis of HIV infection: moving forward with caution.
Topics: Adenine; Animals; Antiviral Agents; Chemoprevention; Disease Models, Animal; HIV Infections; HIV-1; Humans; Macaca mulatta; Organophosphonates; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Tenofovir | 2006 |
Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges.
Topics: Adenine; Animals; Anti-HIV Agents; Chemoprevention; Disease Models, Animal; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Macaca mulatta; Male; Organophosphonates; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Tenofovir | 2006 |
Short communication metabolic and mitochondrial effects of switching antiretroviral-experienced patients to enfuvirtide, tenofovir and saquinavir/ritonavir.
Topics: Adenine; Adult; Aged; Antiretroviral Therapy, Highly Active; DNA, Mitochondrial; Electron Transport Complex III; Electron Transport Complex IV; Enfuvirtide; Female; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV Protease Inhibitors; Humans; Insulin; Leukocytes, Mononuclear; Male; Middle Aged; Mitochondria; Organophosphonates; Oxygen Consumption; Peptide Fragments; Prospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Tenofovir | 2006 |
Long-term follow-up of patients with initial early virologic failure after being treated with once-daily tenofovir/abacavir/lamivudine.
Topics: Adenine; Anti-HIV Agents; Dideoxynucleosides; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Follow-Up Studies; HIV; HIV Infections; Humans; Lamivudine; Organophosphonates; RNA, Viral; Tenofovir; Treatment Failure | 2006 |
The role of tenofovir in the prevention of HIV infections.
Topics: Adenine; Anti-HIV Agents; HIV Infections; Humans; Organophosphonates; Tenofovir | 2006 |
Virological outcome of chronic hepatitis B virus infection in HIV-coinfected patients receiving anti-HBV active antiretroviral therapy.
Topics: Adenine; Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Chi-Square Distribution; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Organophosphonates; Regression Analysis; RNA, Viral; Statistics, Nonparametric; Tenofovir; Treatment Outcome | 2006 |
One pill, once daily: now an option for HIV patients.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug Combinations; HIV Infections; Humans; Organophosphonates; Oxazines; Tenofovir | 2006 |
A once-daily combination tablet (Atripla) for HIV.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Combinations; Drug Interactions; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Emtricitabine; HIV Infections; Humans; Organophosphonates; Oxazines; Tenofovir | 2006 |
Once-daily dosing and the treatment of HIV disease.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Emtricitabine; HIV Infections; Humans; Organophosphonates; Oxazines; Tenofovir | 2006 |
Pre-exposure prophylaxis effective.
Topics: Adenine; Anti-HIV Agents; Clinical Trials as Topic; Drug Administration Schedule; Female; Ghana; HIV Infections; Humans; Organophosphonates; Tenofovir | 2006 |
Toward a pharmacogenetic understanding of nucleotide and nucleoside analogue toxicity.
Topics: Adenine; Anti-HIV Agents; Fanconi Syndrome; Haplotypes; HIV Infections; Humans; Membrane Transport Proteins; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Organophosphonates; Pharmacogenetics; Polymorphism, Single Nucleotide; Tenofovir | 2006 |
Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Case-Control Studies; Fanconi Syndrome; Female; Gene Frequency; Genetic Predisposition to Disease; Haplotypes; HIV Infections; Humans; Male; Membrane Transport Proteins; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Organophosphonates; Point Mutation; Polymorphism, Single Nucleotide; Statistics as Topic; Tenofovir | 2006 |
A novel hepatitis B virus mutation with resistance to adefovir but not to tenofovir in an HIV-hepatitis B virus-co-infected patient.
Topics: Adenine; Adult; Drug Resistance, Viral; Gene Products, pol; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2006 |
HIV prophylaxis still has no clear cut answer.
Topics: Adenine; Centers for Disease Control and Prevention, U.S.; Female; HIV Infections; Humans; National Institutes of Health (U.S.); Organophosphonates; Placebos; Reverse Transcriptase Inhibitors; Risk Factors; Tenofovir; United States | 2006 |
Report from the XVI International AIDS Conference. Preexposure prophylaxis studies move forward.
Topics: Adenine; Adolescent; Adult; Condoms; Double-Blind Method; Female; HIV Infections; Humans; Organophosphonates; Placebos; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir | 2006 |
Aminotransferase elevation in HIV/hepatitis B virus co-infected patients treated with two active hepatitis B virus drugs.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; DNA, Viral; Female; Hepatitis B; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Tenofovir; Transaminases | 2006 |
K65R development among subtype C HIV-1-infected patients in tenofovir DF clinical trials.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Mutation; Organophosphonates; Tenofovir; Treatment Failure | 2007 |
Rate of virologic failure and selection of drug resistance mutations using different triple nucleos(t)ide analogue combinations in HIV-infected patients.
Topics: Adenine; Adult; Anti-Retroviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Proportional Hazards Models; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure; Viral Load; Zidovudine | 2006 |
Anti-HIV agents. Trying times for tenofovir and abacavir.
Topics: Adenine; Adult; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Organophosphonates; Tenofovir; Viral Load | 2003 |
Five-year data out on Viread.
Topics: Adenine; Anti-HIV Agents; Double-Blind Method; Drug Administration Schedule; HIV Infections; Humans; Organophosphonates; Randomized Controlled Trials as Topic; Stavudine; Tenofovir | 2006 |
Anti-HIV agents. Low rate of early virologic failure seen with a combination of Trizivir and tenofovir.
Topics: Adenine; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Organophosphonates; Tenofovir; Viral Load; Zidovudine | 2004 |
Workshop explores racial PK differences, TDF-PI interaction.
Topics: Adenine; HIV Infections; HIV Protease Inhibitors; Humans; Organophosphonates; Racial Groups; Reverse Transcriptase Inhibitors; Tenofovir | 2006 |
Macroenzyme creatine kinase (CK) type 2 in HIV-infected patients is significantly associated with TDF and consists of ubiquitous mitochondrial CK.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Cohort Studies; Creatine Kinase, Mitochondrial Form; Female; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Tenofovir | 2006 |
Editorial comment: tenofovir-related nephrotoxicity--who's at risk?
Topics: Adenine; Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Kidney Diseases; Organophosphonates; Reverse Transcriptase Inhibitors; Risk Factors; Tenofovir | 2007 |
Induction therapy with enfuvirtide-based highly active antiretroviral therapy in a patient with acute HIV-1 infection.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Emtricitabine; Enfuvirtide; HIV Envelope Protein gp41; HIV Infections; HIV-1; Humans; Lopinavir; Male; Organophosphonates; Peptide Fragments; Pyrimidinones; Ritonavir; Tenofovir; Viral Load; Viremia | 2007 |
No response to first-line tenofovir+lamivudine+efavirenz despite optimization according to baseline resistance testing: impact of resistant minority variants on efficacy of low genetic barrier drugs.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Multiple, Viral; HIV Infections; HIV-1; Humans; Lamivudine; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2007 |
Prevention. Anti-HIV drug could prevent transmission in women.
Topics: Adenine; Administration, Topical; Female; HIV Infections; Humans; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2007 |
Unlikely association of multidrug-resistance protein 2 single-nucleotide polymorphisms with tenofovir-induced renal adverse events.
Topics: Adenine; Anti-HIV Agents; Confounding Factors, Epidemiologic; HIV Infections; Humans; Membrane Transport Proteins; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Organophosphonates; Point Mutation; Polymorphism, Single Nucleotide; Renal Insufficiency; Tenofovir | 2007 |
Long-term follow-up of patients taking tenofovir DF with low-level HIV-1 viremia and the K65R substitution in HIV-1 RT.
Topics: Adenine; Anti-HIV Agents; Anti-Retroviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Long-Term Care; Longitudinal Studies; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load | 2007 |
Response to Schmutz et al., 'Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection'.
Topics: Adenine; Drug Therapy, Combination; Hepatitis B; HIV Infections; Humans; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure | 2007 |
Response to Blaas et al., 'Acute renal failure in HIV patients with liver cirrhosis receiving tenofovir: a report of two cases'.
Topics: Acute Kidney Injury; Adenine; HIV Infections; Humans; Liver Cirrhosis; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2007 |
CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load.
Topics: Adenine; Adult; Aging; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cohort Studies; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Italy; Male; Middle Aged; Organophosphonates; Risk Factors; Sex Characteristics; Tenofovir; Treatment Outcome; Viral Load | 2007 |
Evidence and possible consequences of the phosphorylation of nucleoside reverse transcriptase inhibitors in human red blood cells.
Topics: Adenine; Anti-HIV Agents; Drug Interactions; Drug Therapy, Combination; Erythrocytes; HIV Infections; Humans; Lamivudine; Nucleosides; Organophosphonates; Phosphorylation; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Zidovudine | 2007 |
Possible allergic cross-reaction to didanosine and tenofovir in an HIV-1-infected woman.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Didanosine; Drug Hypersensitivity; Drug Interactions; Female; HIV Infections; HIV-1; Humans; Organophosphonates; Tenofovir | 2007 |
Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Black People; Cholesterol; Cross-Sectional Studies; Cyclopropanes; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; Fasting; Female; Hispanic or Latino; HIV Infections; HIV Protease Inhibitors; HIV Seronegativity; HIV Seropositivity; HIV-1; Humans; Indinavir; Lamivudine; Lipids; Lipoproteins, HDL; Lipoproteins, LDL; Multivariate Analysis; Nelfinavir; Nevirapine; Organophosphonates; Ritonavir; Stavudine; Tenofovir; Triglycerides; United States; White People | 2007 |
Acute interstitial nephritis of HIV-positive patients under atazanavir and tenofovir therapy in a retrospective analysis of kidney biopsies.
Topics: Acute Kidney Injury; Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Female; Fluorescent Antibody Technique; HIV Infections; Humans; Immunohistochemistry; Kidney; Male; Microscopy, Electron; Middle Aged; Nephritis, Interstitial; Oligopeptides; Organophosphonates; Pyridines; Retrospective Studies; Tenofovir | 2007 |
Virologic characterization of HIV type 1 with a codon 70 deletion in reverse transcriptase.
Topics: Adenine; Antiviral Agents; Cell Line, Transformed; Codon; Deoxycytidine; Didanosine; Dideoxynucleosides; Drug Resistance, Viral; Emtricitabine; HeLa Cells; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Organophosphonates; Point Mutation; Reassortant Viruses; Reverse Transcriptase Inhibitors; Tenofovir | 2007 |
Relevance of a combined UV and single mass spectrometry detection for the determination of tenofovir in human plasma by HPLC in therapeutic drug monitoring.
Topics: Adenine; Calibration; Drug Monitoring; HIV Infections; Humans; Mass Spectrometry; Organophosphonates; Reference Standards; Reverse Transcriptase Inhibitors; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Tenofovir | 2007 |
Chronic renal failure among HIV-1-infected patients.
Topics: Adenine; Adult; Aged; Anti-Retroviral Agents; CD4 Lymphocyte Count; Creatinine; Female; Glomerular Filtration Rate; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hypertension; Indinavir; Kidney; Kidney Failure, Chronic; Male; Middle Aged; Organophosphonates; Prospective Studies; Reverse Transcriptase Inhibitors; Tenofovir | 2007 |
Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration's Adverse Event Reporting System.
Topics: Adenine; Adult; Adverse Drug Reaction Reporting Systems; Atazanavir Sulfate; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Hospitalization; Humans; Male; Middle Aged; Nephrolithiasis; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; United States | 2007 |
Reversibility of cirrhosis in HIV/HBV coinfection.
Topics: Adenine; Adult; Alanine Transaminase; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; DNA, Viral; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Liver Cirrhosis; Male; Organophosphonates; Platelet Count; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Viral Load; Virus Replication | 2007 |
Does tenofovir influence efavirenz pharmacokinetics?
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug Interactions; Drug Therapy, Combination; Female; Genotype; HIV Infections; Humans; Liver; Longitudinal Studies; Male; Middle Aged; Models, Biological; Organophosphonates; Oxidoreductases, N-Demethylating; Phenotype; Reverse Transcriptase Inhibitors; Switzerland; Tenofovir | 2007 |
Improvements in parameters of end-stage liver disease in patients with HIV/HBV-related cirrhosis treated with tenofovir.
Topics: Adenine; CD4 Lymphocyte Count; DNA, Viral; Follow-Up Studies; Hepatitis B; Hepatitis B e Antigens; Hepatitis B virus; HIV Infections; Humans; Liver Cirrhosis; Liver Failure; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Severity of Illness Index; Tenofovir; Time Factors; Treatment Outcome; Viral Load | 2007 |
Assessment of adverse events associated with antiretroviral regimens for postexposure prophylaxis for occupational and nonoccupational exposures to prevent transmission of human immunodeficiency virus.
Topics: Adenine; Adult; Anti-HIV Agents; Chemoprevention; Drug Combinations; Female; HIV Infections; Humans; Lamivudine; Logistic Models; Male; Middle Aged; New York; Occupational Exposure; Occupational Health Services; Organophosphonates; Patient Compliance; Public Health Administration; Retrospective Studies; Risk Factors; Sex Factors; Student Health Services; Tenofovir; Universities; Zidovudine | 2007 |
The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years.
Topics: Adenine; Adult; Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Anti-Retroviral Agents; Antiviral Agents; Body Weight; CD4 Lymphocyte Count; Creatinine; Drug Therapy, Combination; Female; HIV Infections; Humans; Kidney; Kidney Diseases; Male; Organophosphonates; Product Surveillance, Postmarketing; Reverse Transcriptase Inhibitors; Risk Factors; Tenofovir | 2007 |
Transmission of multidrug-resistant HIV-1: 5 years of immunological and virological survey.
Topics: Adenine; Anti-Retroviral Agents; CD4 Lymphocyte Count; Drug Resistance, Multiple, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Mutation; Organophosphonates; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Viral Load | 2007 |
Cutaneous reactions with tenofovir disoproxil fumarate: a report of nine cases.
Topics: Adenine; Adult; Drug Eruptions; Drug Therapy, Combination; Exanthema; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Skin; Tenofovir | 2007 |
Pharmacokinetics of once-daily tenofovir, emtricitabine, ritonavir and fosamprenavir in HIV-infected subjects.
Topics: Adenine; Adolescent; Adult; Antiviral Agents; Carbamates; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Organophosphates; Organophosphonates; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Sulfonamides; Tenofovir; Treatment Outcome | 2007 |
Tenofovir renal safety in HIV-infected patients: results from the SCOLTA Project.
Topics: Adenine; Adult; Age Factors; Anti-HIV Agents; Cohort Studies; Comorbidity; Female; Follow-Up Studies; HIV Infections; Humans; Incidence; Italy; Kidney Diseases; Male; Middle Aged; Organophosphonates; Prevalence; Prospective Studies; Risk Factors; Severity of Illness Index; Sex Factors; Tenofovir | 2008 |
Renal function in Tenofovir-exposed and Tenofovir-unexposed patients receiving highly active antiretroviral therapy in the HIV Outpatient Study.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Creatinine; HIV Infections; Humans; Organophosphonates; Outpatients; Tenofovir | 2007 |
Molecular mechanisms of bidirectional antagonism between K65R and thymidine analog mutations in HIV-1 reverse transcriptase.
Topics: Adenine; DNA Repair; Drug Resistance, Multiple, Viral; Genetic Engineering; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Models, Molecular; Mutation; Organophosphonates; Protein Binding; Reverse Transcriptase Inhibitors; Tenofovir; Thymidine | 2007 |
Amprenavir and didanosine are associated with declining kidney function among patients receiving tenofovir.
Topics: Adenine; Adult; Age Factors; Analysis of Variance; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Weight; Carbamates; Creatinine; Didanosine; Drug Interactions; Female; Furans; Glomerular Filtration Rate; HIV Infections; HIV-1; Humans; Kidney; Linear Models; Male; Middle Aged; Organophosphonates; Sulfonamides; Tenofovir; Time Factors | 2007 |
Causes and consequences of hypokalemia in patients on tenofovir disoproxil fumarate.
Topics: Adenine; Adult; Cause of Death; Drug Monitoring; Drug Synergism; Fanconi Syndrome; Female; Guideline Adherence; HIV Infections; HIV-1; Humans; Hypokalemia; Male; Middle Aged; Organophosphonates; Product Surveillance, Postmarketing; Reverse Transcriptase Inhibitors; Tenofovir | 2007 |
Effect of tenofovir on renal glomerular and tubular function.
Topics: Adenine; Anti-Retroviral Agents; Case-Control Studies; Cross-Sectional Studies; Glomerular Filtration Rate; HIV Infections; HIV-1; Humans; Kidney Diseases; Kidney Glomerulus; Kidney Tubules; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2007 |
Porphyria cutanea tarda in an HIV-1-infected patient after the initiation of tipranavir/ritonavir: case report.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Middle Aged; Organophosphonates; Porphyria Cutanea Tarda; Pyridines; Pyrones; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Tenofovir | 2007 |
HPV oral infection. Case report of an HIV-positive Nigerian sex worker.
Topics: Adenine; Adult; Alphapapillomavirus; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Dideoxynucleosides; Emtricitabine; Female; HIV Infections; Humans; Italy; Lamivudine; Lopinavir; Mouth Mucosa; Nigeria; Organophosphonates; Papillomavirus Infections; Pyrimidinones; Ritonavir; Sex Work; Stomatitis; Tenofovir; Treatment Refusal; Zidovudine | 2007 |
A second chance for microbicides.
Topics: Adenine; Adult; Anti-HIV Agents; Anti-Infective Agents; Clinical Trials as Topic; Female; HIV Infections; Humans; Organophosphonates; Prevalence; Rural Health Services; Sex Work; South Africa; Tenofovir; Vaginal Creams, Foams, and Jellies | 2007 |
Bone disease and pathologic fractures in a patient with tenofovir-induced Fanconi syndrome.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone Diseases; Fanconi Syndrome; Female; Femoral Neck Fractures; HIV Infections; Humans; Middle Aged; Organophosphonates; Tenofovir | 2007 |
Early onset of tenofovir-induced renal failure: case report and review of the literature.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Antiretroviral Therapy, Highly Active; Biopsy; HIV Infections; Humans; Liver; Male; Organophosphonates; Renal Insufficiency; Tenofovir; Time Factors; Treatment Outcome | 2007 |
Adverse events experienced by three children taking tenofovir and didanosine in combination.
Topics: Adenine; Anti-HIV Agents; Child; Child, Preschool; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Male; Organophosphonates; Tenofovir; Viral Load | 2007 |
[Hypophosphatemia and multiple fractures in patient with human immunodeficiency virus infection treated with tenofovir].
Topics: Adenine; Adult; Fractures, Bone; HIV Infections; Humans; Hypophosphatemia; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2007 |
Hepatitis B virus and HIV coinfection: results of a survey on treatment practices and recommendations for therapy.
Topics: Adenine; Adult; Anti-Retroviral Agents; Antiviral Agents; Drug Therapy, Combination; Female; Guideline Adherence; Health Care Surveys; Hepatitis B Vaccines; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Organophosphonates; Practice Guidelines as Topic; Practice Patterns, Physicians'; Tenofovir; United States | 2007 |
Predictors and kinetics of occult hepatitis B virus infection in HIV-infected persons.
Topics: Adenine; Adult; Alanine Transaminase; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biomarkers; Carrier State; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cohort Studies; DNA, Viral; Female; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Core Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; HIV Infections; HIV-1; Humans; Lamivudine; London; Male; Organophosphonates; Prevalence; Tenofovir | 2007 |
Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Antineoplastic Agents, Phytogenic; Antiretroviral Therapy, Highly Active; Area Under Curve; Camptothecin; Drug Therapy, Combination; HIV Infections; Humans; Irinotecan; Lamivudine; Lopinavir; Male; Middle Aged; Organophosphonates; Pyrimidinones; Ritonavir; Sarcoma, Kaposi; Tenofovir; White People | 2008 |
Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis.
Topics: Adenine; Administration, Oral; Adult; Alkynes; Anti-Retroviral Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; Genitalia, Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Tenofovir; Zidovudine | 2007 |
Variations in reverse transcriptase and RNase H domain mutations in human immunodeficiency virus type 1 clinical isolates are associated with divergent phenotypic resistance to zidovudine.
Topics: Adenine; Amino Acid Sequence; Deoxycytidine; Drug Resistance, Multiple, Viral; Genetic Variation; HIV Infections; HIV-1; Humans; Molecular Sequence Data; Mutation; Organophosphonates; Phenotype; Ribonuclease H; RNA-Directed DNA Polymerase; Sequence Homology, Amino Acid; Tenofovir; Zidovudine | 2007 |
Diverse approaches useful for microbicide trials.
Topics: Adenine; Animals; Anti-HIV Agents; Anti-Infective Agents; Bias; Clinical Trials as Topic; Female; HIV Infections; Humans; Male; Organophosphonates; South Africa; Tenofovir | 2007 |
Is phosphatemia the best tool to monitor renal tenofovir toxicity?
Topics: Adenine; Biomarkers; Creatinine; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Diseases; Kidney Tubules; Organophosphonates; Phosphates; Tenofovir | 2007 |
Semen quality and drug concentrations in seminal plasma of patients using a didanosine or didanosine plus tenofovir containing antiretroviral regimen.
Topics: Adenine; Adult; Anti-HIV Agents; Cross-Sectional Studies; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Semen; Sperm Motility; Spermatozoa; Tenofovir | 2007 |
Increased beta-2 microglobulinuria in human immunodeficiency virus-1-infected children and adolescents treated with tenofovir.
Topics: Adenine; Adolescent; Adult; beta 2-Microglobulin; Child; Child, Preschool; Cross-Sectional Studies; Female; HIV Infections; Humans; Male; Organophosphonates; Proteinuria; Reverse Transcriptase Inhibitors; Tenofovir; Urine | 2007 |
CD4+ T-cell count increase in HIV-1-infected patients with suppressed viral load within 1 year after start of antiretroviral therapy.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort Studies; Female; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Tenofovir; Time Factors; Viral Load | 2007 |
Specificity enhancement with LC-positive ESI-MS/MS for the measurement of nucleotides: application to the quantitative determination of carbovir triphosphate, lamivudine triphosphate and tenofovir diphosphate in human peripheral blood mononuclear cells.
Topics: Adenine; Anti-HIV Agents; Cytidine Triphosphate; Deoxyguanine Nucleotides; Dideoxynucleosides; Dideoxynucleotides; HIV Infections; Humans; Lamivudine; Leukocytes, Mononuclear; Organophosphonates; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Tenofovir | 2008 |
Female-initiated prevention strategies key to tackling HIV.
Topics: Adenine; Africa South of the Sahara; Anti-HIV Agents; Condoms, Female; Diaphragm; Female; HIV Infections; Humans; Organophosphonates; Primary Prevention; Reverse Transcriptase Inhibitors; Rwanda; Tenofovir; Women | 2007 |
Tenofovir resistance among HIV-infected patients failing a fixed-dose combination of stavudine, lamivudine, and nevirapine in a resource-limited setting.
Topics: Adenine; Adult; Anti-HIV Agents; Cohort Studies; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Nevirapine; Organophosphonates; Stavudine; Tenofovir; Thailand; Treatment Outcome | 2007 |
Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Area Under Curve; Atazanavir Sulfate; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Leukocytes, Mononuclear; Male; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir | 2008 |
Selection of L74V mutation in reverse transcriptase of HIV-1 subtype D by a tenofovir DF-lamivudine based regimen.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Female; Follow-Up Studies; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2007 |
Reply to Crane et al., 'Amprenavir and didanosine are associated with declining kidney function among patients receiving tenofovir'.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney; Male; Organophosphonates; Retrospective Studies; Tenofovir | 2007 |
Congenital pyelectasis in children born from mothers on tenofovir containing therapy during pregnancy: report of two cases.
Topics: Adenine; Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Italy; Kidney; Male; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Tenofovir | 2007 |
Comparison of the induction of P-glycoprotein activity by nucleotide, nucleoside, and non-nucleoside reverse transcriptase inhibitors.
Topics: Adenine; Anti-HIV Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cell Proliferation; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; Nucleosides; Nucleotides; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Up-Regulation | 2008 |
Intracellular metabolism of the nucleotide prodrug GS-9131, a potent anti-human immunodeficiency virus agent.
Topics: Adenine; Anti-HIV Agents; Diphosphates; Guanosine; HIV Infections; HIV-1; Humans; Leukocytes, Mononuclear; Lymphocyte Activation; Organophosphonates; Prodrugs; Reverse Transcriptase Inhibitors; Tenofovir | 2008 |
Acute renal failure after initiation of tenofovir disoproxil fumarate.
Topics: Acute Kidney Injury; Adenine; Anti-HIV Agents; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Tenofovir | 2007 |
Tenofovir nephrotoxicity: focusing research questions and putting them into clinical context.
Topics: Adenine; HIV Infections; Humans; Kidney Diseases; Kidney Tubules; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2008 |
Tenofovir DF plus lamivudine or emtricitabine for nonoccupational postexposure prophylaxis (NPEP) in a Boston Community Health Center.
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Boston; Clinical Trials, Phase IV as Topic; Community Health Centers; Deoxycytidine; Disease Transmission, Infectious; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Tenofovir; Treatment Outcome | 2008 |
Tenofovir-based rescue therapy for advanced liver disease in 6 patients coinfected with HIV and hepatitis B virus and receiving lamivudine.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Infections; Homosexuality, Male; Humans; Lamivudine; Liver Diseases; Male; Organophosphonates; Tenofovir; Transaminases; Viral Load | 2008 |
Can the new humanized mouse model give HIV research a boost.
Topics: Adenine; Administration, Intravaginal; Animals; Deoxycytidine; Disease Models, Animal; Disease Susceptibility; Drug Evaluation, Preclinical; Emtricitabine; Female; Hematopoietic Stem Cell Transplantation; HIV Infections; HIV-1; Humans; Liver Transplantation; Macaca mulatta; Mice; Mice, Inbred NOD; Mice, Inbred Strains; Mice, SCID; Organophosphonates; Radiation Chimera; Species Specificity; Tenofovir; Thymus Gland; Transplantation, Heterologous | 2008 |
Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice.
Topics: Adenine; Administration, Intravaginal; Animals; Anti-HIV Agents; Deoxycytidine; Disease Models, Animal; Drug Evaluation, Preclinical; Emtricitabine; Female; Fetal Tissue Transplantation; Genitalia, Female; Hematopoietic Stem Cell Transplantation; HIV Infections; HIV-1; Humans; Immunity, Mucosal; Liver Transplantation; Mice; Mice, Inbred Strains; Mice, SCID; Organophosphonates; Radiation Chimera; Species Specificity; Tenofovir; Thymus Gland; Transplantation, Heterologous | 2008 |
Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Female; Glomerular Filtration Rate; HIV Infections; HIV-1; Humans; Kidney; Male; Organophosphonates; Switzerland; Tenofovir | 2007 |
Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system.
Topics: Adenine; Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Anti-HIV Agents; Child; Fanconi Syndrome; Female; HIV Infections; Humans; Incidence; Male; Middle Aged; Organophosphonates; Registries; Retrospective Studies; Risk Assessment; Survival Analysis; Tenofovir; United States; United States Food and Drug Administration | 2008 |
Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cost-Benefit Analysis; Cyclopropanes; Decision Trees; Deoxycytidine; Drug Costs; Emtricitabine; Health Care Costs; Health Resources; HIV Infections; HIV-1; Humans; Lamivudine; Models, Economic; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Time Factors; Treatment Outcome; Zidovudine | 2008 |
Urolithiasis under atazanavir boosted and tenofovir therapy: a case report.
Topics: Adenine; Adult; Anti-HIV Agents; Antiviral Agents; Atazanavir Sulfate; HIV Infections; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir; Urolithiasis; Viral Load | 2008 |
Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus.
Topics: Absorptiometry, Photon; Adenine; Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone Density; Child; Female; HIV; HIV Infections; Humans; Male; Organophosphonates; Tenofovir | 2008 |
Syncope as a probable side effect to combination antiretroviral therapy initiated during primary HIV-1 infection.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Emtricitabine; HIV Infections; Humans; Male; Nevirapine; Organophosphonates; Syncope; Tenofovir | 2008 |
Changing patterns in HIV reverse transcriptase resistance mutations after availability of tenofovir.
Topics: Adenine; Anti-HIV Agents; Didanosine; Drug Resistance, Multiple, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Organophosphonates; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir | 2008 |
Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Female; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Logistic Models; Male; Middle Aged; Organophosphonates; Point Mutation; Tenofovir | 2008 |
FDA grants tentative approval to first generic version of antiretroviral Viread.
Topics: Adenine; Anti-HIV Agents; Drug Approval; Drugs, Generic; HIV Infections; Humans; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; United States; United States Food and Drug Administration | 2008 |
European Commission approves Atripla.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Approval; Drug Combinations; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Emtricitabine; European Union; HIV Infections; Humans; Organophosphonates; Oxazines; Reverse Transcriptase Inhibitors; Tenofovir | 2008 |
Does tenofovir increase efavirenz hepatotoxicity?
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Chemical and Drug Induced Liver Injury; Cyclopropanes; Female; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Tenofovir | 2008 |
[Acute renal failure associated with the use of tenofovir combined with atazanavir in patients with HIV infection].
Topics: Acute Kidney Injury; Adenine; Anti-HIV Agents; Atazanavir Sulfate; Drug Therapy, Combination; HIV Infections; Humans; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Tenofovir | 2008 |
[Severe hypokalemia and tenofovir].
Topics: Adenine; Anti-HIV Agents; HIV Infections; Humans; Hypokalemia; Male; Middle Aged; Organophosphonates; Severity of Illness Index; Tenofovir | 2008 |
Targeting only reverse transcriptase with zidovudine/lamivudine/abacavir plus tenofovir in HIV-1-infected patients with multidrug-resistant virus: a multicentre pilot study.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Resistance, Multiple, Viral; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Pilot Projects; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Thymidine; Viral Load; Zidovudine | 2008 |
Partial immunological and mitochondrial recovery after reducing didanosine doses in patients on didanosine and tenofovir-based regimens.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Dose-Response Relationship, Drug; Drug Therapy, Combination; HIV Infections; Humans; Male; Mitochondria; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2008 |
AIDS research. New drug shows promise in monkeys.
Topics: Adenine; Animals; Antiviral Agents; HIV; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Macaca fascicularis; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Tenofovir | 1995 |
Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine.
Topics: Adenine; Animals; Antibodies, Viral; Antiviral Agents; Base Sequence; Cells, Cultured; HIV Infections; Humans; Injections, Subcutaneous; Leukocytes, Mononuclear; Lymph Nodes; Macaca fascicularis; Molecular Sequence Data; Organophosphonates; Organophosphorus Compounds; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Tenofovir | 1995 |
Administration of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) for prevention of perinatal simian immunodeficiency virus infection in rhesus macaques.
Topics: Adenine; Animals; Animals, Newborn; Anti-HIV Agents; Antibodies, Viral; Cesarean Section; Chimera; Drug Administration Schedule; Female; HIV; HIV Infections; Humans; Macaca mulatta; Organophosphonates; Organophosphorus Compounds; Pregnancy; RNA, Viral; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Tenofovir; Treatment Outcome | 1998 |
Compassionate use for tenofovir.
Topics: Adenine; Anti-HIV Agents; Clinical Trials as Topic; Drug Approval; HIV Infections; Humans; Organophosphonates; Patient Selection; Tenofovir | 2000 |
Early HIV infection in vivo: branching-process model for studying timing of immune responses and drug therapy.
Topics: Adenine; Animals; Anti-HIV Agents; Computer Simulation; Disease Progression; HIV; HIV Infections; Humans; Macaca; Macrophages; Models, Immunological; Organophosphonates; Organophosphorus Compounds; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Soman; Stochastic Processes; Tenofovir; Time Factors; Viral Load | 2000 |
Promising results for tenofovir.
Topics: Adenine; Clinical Trials, Phase II as Topic; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load | 2000 |
Post-exposure chemoprophylaxis (PECP) against SIV infection of macaques as a model for protection from HIV infection.
Topics: Adenine; Animals; Disease Models, Animal; DNA, Viral; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Macaca fascicularis; Organophosphonates; Organophosphorus Compounds; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Tenofovir | 2000 |
Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4+ T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): Implications for HIV-1 infections of humans.
Topics: Adenine; Animals; Anti-HIV Agents; CD4 Lymphocyte Count; Chimera; Digestive System; Disease Progression; Drug Resistance, Microbial; HIV Infections; HIV-1; Lentivirus Infections; Lymphoid Tissue; Macaca mulatta; Macrophages; Organ Specificity; Organophosphonates; Reverse Transcriptase Inhibitors; RNA, Viral; Simian Immunodeficiency Virus; Tenofovir; Viral Load; Virus Replication | 2001 |
Development of virus-specific immune responses in SHIV(KU)-infected macaques treated with PMPA.
Topics: Adenine; Animals; Anti-HIV Agents; Antibodies, Viral; Disease Models, Animal; HIV Antibodies; HIV Infections; HIV-1; Humans; Macaca mulatta; Neutralization Tests; Organophosphonates; Organophosphorus Compounds; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Helper-Inducer; Tenofovir; Virus Replication | 2001 |
Update on antivirals.
Topics: Adenine; Anti-HIV Agents; Brazil; CD4 Lymphocyte Count; Clinical Trials as Topic; Dosage Forms; Drug Resistance, Microbial; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Infusions, Intravenous; Organophosphonates; Organophosphorus Compounds; Saquinavir; Tenofovir; Viral Load | 1997 |
Scientific basis for PEP rests in animal trials.
Topics: Adenine; Animals; Anti-HIV Agents; Centers for Disease Control and Prevention, U.S.; Health Personnel; HIV; HIV Infections; Humans; Macaca; Nevirapine; Occupational Diseases; Organophosphonates; Organophosphorus Compounds; Pan troglodytes; Pyridines; Reverse Transcriptase Inhibitors; Simian Immunodeficiency Virus; Tenofovir; United States; Zidovudine | 1997 |
Looking down the drug pipeline.
Topics: Adenine; Animals; Anti-HIV Agents; Biological Availability; Chlorobenzenes; Clinical Trials as Topic; Codon; Dideoxyadenosine; Drug Resistance, Microbial; Drugs, Investigational; Granulocyte-Macrophage Colony-Stimulating Factor; HIV Infections; HIV Protease Inhibitors; Humans; Naphthalenes; Organophosphonates; Pyrimidinones; Receptors, CCR5; Receptors, CXCR4; Reverse Transcriptase Inhibitors; Tenofovir | 1998 |
Lower doses of adefovir dipivoxil (Preveon).
Topics: Adenine; Anti-HIV Agents; CD4 Lymphocyte Count; Dose-Response Relationship, Drug; Drug Therapy, Combination; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load | 1999 |
Upcoming compassionate use programs for two new antiretrovirals will begin this fall.
Topics: Adenine; Anti-HIV Agents; Clinical Trials as Topic; Drug Approval; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Organophosphonates; Organophosphorus Compounds; Patient Selection; Pyrimidinones; Reverse Transcriptase Inhibitors; Tenofovir | 1999 |
Expanded access.
Topics: Adenine; Anti-HIV Agents; Drug Approval; Drugs, Investigational; Health Services Accessibility; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Organophosphonates; Organophosphorus Compounds; Pyrimidinones; Reverse Transcriptase Inhibitors; Tenofovir | 1999 |
[Once daily administration improves therapy adherence in HAART. New substance class with more powerful reserves against virus resistance].
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Administration Schedule; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2001 |
Tenofovir ready for approval.
Topics: Adenine; Anti-HIV Agents; Drug Approval; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Tenofovir; United States; United States Food and Drug Administration | 2001 |
Tenofovir, adefovir, and zidovudine susceptibilities of primary human immunodeficiency virus type 1 isolates with non-B subtypes or nucleoside resistance.
Topics: Adenine; Anti-HIV Agents; Drug Resistance, Microbial; HIV Infections; HIV-1; Humans; Microbial Sensitivity Tests; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir; Zidovudine | 2001 |
Encouraging results for tenofovir.
Topics: Adenine; Clinical Trials, Phase III as Topic; HIV Infections; HIV-1; Humans; Organophosphonates; Organophosphorus Compounds; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load | 2001 |
Tenofovir: Gilead applies for approval; expanded access liberalized.
Topics: Adenine; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Approval; Drug Industry; Health Services Accessibility; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir; United States; United States Food and Drug Administration; Viral Load | 2001 |
Tenofovir: FDA hearing October 3, public comment deadlines September 26.
Topics: Adenine; Anti-HIV Agents; Drug Approval; Drug Resistance, Microbial; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Patient Compliance; Reverse Transcriptase Inhibitors; Tenofovir; United States; United States Food and Drug Administration | 2001 |
Tenofovir: FDA hearing on important new antiretroviral.
Topics: Adenine; Drug Approval; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir; United States; United States Food and Drug Administration | 2001 |
Tenacious tenofovir struts its stuff in a virtual ICAAC.
Topics: Adenine; Clinical Trials as Topic; Drug Interactions; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir | 2001 |
From the Food and Drug Administration.
Topics: Adenine; Administration, Oral; Anti-HIV Agents; Cathartics; Defibrillators, Implantable; HIV Infections; HIV-1; Humans; Monitoring, Ambulatory; Organophosphonates; Organophosphorus Compounds; Pacemaker, Artificial; Pharmaceutical Solutions; Phosphates; Tenofovir; United States; United States Food and Drug Administration; Viral Load; Water-Electrolyte Imbalance | 2001 |
Expanded access to tenofovir.
Topics: Adenine; Canada; Europe; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir; United States | 2001 |
Tenofovir approved: broad indication.
Topics: Adenine; Drug Approval; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir; United States; United States Food and Drug Administration | 2001 |
Prodrug of tenofovir diphosphate approved for combination HIV therapy.
Topics: Adenine; Anti-HIV Agents; Biological Availability; Drug Approval; Drug Therapy, Combination; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Prodrugs; Tenofovir; United States; United States Food and Drug Administration | 2002 |
More uses for tenofovir?
Topics: Adenine; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir | 2001 |
Nutrient deficiency associated with new HIV medication.
Topics: Adenine; HIV Infections; Humans; Nutrition Disorders; Organophosphonates; Organophosphorus Compounds; Phosphorus; Reverse Transcriptase Inhibitors; Tenofovir | 2002 |
Gilead sciences releases Viread.
Topics: Adenine; Drug Approval; Drug Industry; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir; United States; United States Food and Drug Administration | 2002 |
New antiretroviral for HIV infection.
Topics: Adenine; Anti-HIV Agents; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2002 |
[Tenofovir--a new option for combination therapy].
Topics: Adenine; Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2002 |
[No comparison with NRTI. Tenofovir is robust against resistance trouble].
Topics: Acquired Immunodeficiency Syndrome; Adenine; Anti-HIV Agents; Drug Resistance, Viral; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2002 |
[Nucleotide analog shows effectiveness in previously treated patients. The new kind of HAART].
Topics: Acquired Immunodeficiency Syndrome; Adenine; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Clinical Trials as Topic; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Tenofovir; Viral Load | 2002 |
[First nucleotide analog on the market. New drug for the pretreated patient].
Topics: Acquired Immunodeficiency Syndrome; Adenine; Anti-HIV Agents; Drug Approval; Drug Therapy, Combination; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2002 |
Drugs in development.
Topics: Adenine; Anti-HIV Agents; Clinical Trials as Topic; Cyclic N-Oxides; HIV Infections; Humans; Nitriles; Organophosphonates; Organophosphorus Compounds; Oximes; Piperidines; Pyridazines; Pyridines; Pyrimidines; Tenofovir | 2002 |
8th European Conference on Clinical Aspects and Treatment of HIV Infection, Athens, 28-31 October 2001.
Topics: Adenine; Anti-HIV Agents; Greece; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2002 |